



(51) International Patent Classification:

C12N 15/113 (2010.01) A61K 31/7088 (2006.01)

(21) International Application Number:

PCT/US2021/017276

(22) International Filing Date:

09 February 2021 (09.02.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/972,519	10 February 2020 (10.02.2020)	US
63/055,627	23 July 2020 (23.07.2020)	US
63/140,714	22 January 2021 (22.01.2021)	US

(71) Applicant: **ALNYLAM PHARMACEUTICALS, INC.**
[US/US]; 675 West Kendall Street, Henri A. Termeer
Square, Cambridge, MA 02142 (US).

(72) Inventor; and

(71) Applicant: **MCININCH, James D.** [US/US]; 675 West
Kendall Street, Henri A. Termeer Square, Cambridge, MA
02142 (US).

(72) Inventors: **KEATING, Mark**; 675 West Kendall Street,
Henri A. Termeer Square, Cambridge, MA 02142 (US).
SCHLEGEL, Mark K.; 675 West Kendall Street, Hen-
ri A. Termeer Square, Cambridge, MA 02142 (US). **CAS-
TORENO, Adam**; 675 West Kendall Street, Henri A. Ter-
meer Square, Cambridge, MA 02142 (US). **JADHAV, Vas-
ant R.**; 675 West Kendall Street, Henri A. Termeer Square,
Cambridge, MA 02142 (US). **KAITTANIS, Charalam-
bos**; 675 West Kendall Street, Henri A. Termeer Square,
Cambridge, MA 02142 (US). **CASTELLANOS-RIZAL-
DOS, Elena**; 675 West Kendall Street, Henri A. Termeer
Square, Cambridge, MA 02142 (US). **PANDYA, Bhaumik
A.**; 675 West Kendall Street, Henri A. Termeer Square,
Cambridge, MA 02142 (US).

(74) Agent: **KOYFMAN, Hannah, R.** et al.; Lando & Anastasi,
LLP, 60 State Street, 23rd Floor, Boston, MA 02109 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: COMPOSITIONS AND METHODS FOR SILENCING VEGF-A EXPRESSION

(57) Abstract: The disclosure relates to double-stranded ribonucleic acid (dsRNA) compositions targeting VEGF-A, and methods of
using such dsRNA compositions to alter (e.g., inhibit) expression of VEGF-A.



COMPOSITIONS AND METHODS FOR SILENCING VEGF-A EXPRESSION

Related Applications

This application claims priority to U.S. provisional application number 62/972,519, filed
5 on February 10, 2020, U.S. provisional application number 63/055,627, filed on July 23, 2020,
and U.S. provisional application number 63/140,714, filed on January 22, 2021. The entire
contents of the foregoing applications are hereby incorporated herein by reference.

Sequence Listing

The instant application contains a Sequence Listing which has been submitted
10 electronically in ASCII format and is hereby incorporated by reference in its entirety. Said
ASCII copy, created on February 4, 2021, is named A2038-7236WO_SL.txt and is 1,327,255
bytes in size.

Field of the Disclosure

The disclosure relates to the specific inhibition of the expression of the VEGF-A.

15

Background

Vascular eye diseases are the leading cause of vision loss in today's aging population,
including exudative age-related macular degeneration (exudative AMD), retinal vein occlusion
(RVO), retinopathy of prematurity (ROP), diabetic retinopathy (DR), and diabetic macular
20 edema (DME). Several of these ocular disorders are associated with pathological angiogenesis.
The release of vascular endothelial growth factors (VEGFs) contributes to increased vascular
permeability and inappropriate new vessel growth in the eye. New treatments for angiogenic
ocular disorders are needed.

25

SUMMARY

The present disclosure describes methods and iRNA compositions for modulating the
expression of VEGF-A. In certain embodiments, expression of VEGF-A is reduced or inhibited
using a VEGF-A-specific iRNA. Such inhibition can be useful in treating disorders related to
VEGF-A expression, such as ocular disorders (*e.g.*, age-related macular degeneration (AMD),
30 macular edema following retinal vein occlusion (MEfRVO) or central retinal vein occlusion

(CVO), retinopathy of prematurity (ROP), diabetic macular edema (DME), and diabetic retinopathy (DR)).

Accordingly, described herein are compositions and methods that effect the RNA-induced silencing complex (RISC)-mediated cleavage of RNA transcripts of VEGF-A, such as in a cell or in a subject (*e.g.*, in a mammal, such as a human subject). Also described are compositions and methods for treating a disorder related to expression of VEGF-A, such as an angiogenic ocular disorder (*e.g.*, AMD, RVO, MEfRVO, CVO, ROP, DME, mCNV, and DR)).

The iRNAs (*e.g.*, dsRNAs) included in the compositions featured herein include an RNA strand (the antisense strand) having a region, *e.g.*, a region that is 30 nucleotides or less, generally 19-24 nucleotides in length, that is substantially complementary to at least part of an mRNA transcript of VEGF-A (*e.g.*, a human VEGF-A) (also referred to herein as a “VEGF-A-specific iRNA”). In some embodiments, the VEGF-A mRNA transcript is a human VEGF-A mRNA transcript, *e.g.*, SEQ ID NO: 1 herein.

In some embodiments, the iRNA (*e.g.*, dsRNA) described herein comprises an antisense strand having a region that is substantially complementary to a region of a human VEGF-A mRNA. In some embodiments, the human VEGF-A mRNA has the sequence NM_001171623.1 (SEQ ID NO: 1). The sequence of NM_001171623.1 is also herein incorporated by reference in its entirety. The reverse complement of SEQ ID NO: 1 is provided as SEQ ID NO: 2 herein.

In some aspects, the present disclosure provides a double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of vascular endothelial growth factor A (VEGF-A), wherein the dsRNA agent comprises a sense strand and an antisense strand forming a double stranded region, wherein the sense strand comprises a nucleotide sequence comprising at least 15 contiguous nucleotides, with 0, 1, 2, or 3 mismatches, of a portion of a coding strand of human VEGF-A and the antisense strand comprises a nucleotide sequence comprising at least 15 contiguous nucleotides, with 0, 1, 2, or 3 mismatches, of the corresponding portion of a non-coding strand of human VEGF-A such that the sense strand is complementary to the at least 15 contiguous nucleotides in the antisense strand.

In some aspects, the present disclosure provides a double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of VEGF-A, wherein the dsRNA agent comprises a sense strand and an antisense strand forming a double stranded region, wherein the antisense strand comprises a nucleotide sequence comprising at least 15 contiguous nucleotides, with 0, 1,

2, or 3 mismatches, of a portion of nucleotide sequence of SEQ ID NO: 2 such that the sense strand is complementary to the at least 15 contiguous nucleotides in the antisense strand.

In some aspects, the present disclosure provides a human cell or tissue comprising a reduced level of VEGF-A mRNA or a level of VEGF-A protein as compared to an otherwise similar untreated cell or tissue, wherein optionally the cell or tissue is not genetically engineered (*e.g.*, wherein the cell or tissue comprises one or more naturally arising mutations, *e.g.*, VEGF-A), wherein optionally the level is reduced by at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%. In some embodiments, the human cell or tissue is a retinal pigment epithelium (RPE), a retinal tissue, an astrocyte, a pericyte, a Müller cell, a ganglion cell, an endothelial cell, a photoreceptor cell, a retinal blood vessel (*e.g.*, including endothelial cells and vascular smooth muscle cells), or choroid tissue, *e.g.*, a choroid vessel.

The present disclosure also provides, in some aspects, a cell containing the dsRNA agent described herein.

In another aspect, provided herein is a human ocular cell, *e.g.*, (an RPE cell, a retinal cell, an astrocyte, a pericyte, a Müller cell, a ganglion cell, an endothelial cell, or a photoreceptor cell) comprising a reduced level of VEGF-A mRNA or a level of VEGF-A protein as compared to an otherwise similar untreated cell. In some embodiments, the level is reduced by at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%.

In some aspects, the present disclosure also provides a pharmaceutical composition for inhibiting expression of a gene encoding VEGF-A, comprising a dsRNA agent described herein.

The present disclosure also provides, in some aspects, a method of inhibiting expression of VEGF-A in a cell, the method comprising:

(a) contacting the cell with the dsRNA agent described herein, or a pharmaceutical composition described herein; and

(b) maintaining the cell produced in step (a) for a time sufficient to obtain degradation of the mRNA transcript of VEGF-A, thereby inhibiting expression of the VEGF-A in the cell.

The present disclosure also provides, in some aspects, a method of inhibiting expression of VEGF-A in a cell, the method comprising:

(a) contacting the cell with the dsRNA agent described herein, or a pharmaceutical composition described herein; and

(b) maintaining the cell produced in step (a) for a time sufficient to reduce levels of VEGF-A mRNA, VEGF-A protein, or both of VEGF-A mRNA and protein, thereby inhibiting
5 expression of the VEGF-A in the cell.

The present disclosure also provides, in some aspects, a method of inhibiting expression of VEGF-A in an ocular cell or tissue, the method comprising:

(a) contacting the cell or tissue with a dsRNA agent that binds VEGF-A; and

(b) maintaining the cell or tissue produced in step (a) for a time sufficient to reduce
10 levels of VEGF-A mRNA, VEGF-A protein, or both of VEGF-A mRNA and protein, thereby inhibiting expression of VEGF-A in the cell or tissue.

The present disclosure also provides, in some aspects, a method of treating a subject diagnosed with VEGF-A-associated disorder comprising administering to the subject a therapeutically effective amount of the dsRNA agent described herein or a pharmaceutical
15 composition described herein, thereby treating the disorder.

In any of the aspects herein, *e.g.*, the compositions and methods above, any of the embodiments herein (*e.g.*, below) may apply.

In some embodiments, the coding strand of human VEGF-A has the sequence of SEQ ID NO: 1. In some embodiments, the non-coding strand of human VEGF-A has the sequence of
20 SEQ ID NO: 2.

In some embodiments, the sense strand comprises a nucleotide sequence comprising at least 15 contiguous nucleotides, with 0, or 1, 2, or 3 mismatches, of the corresponding portion of the nucleotide sequence of SEQ ID NO: 1.

In some embodiments, the dsRNA agent comprises a sense strand and an antisense strand, wherein the antisense strand comprises a nucleotide sequence comprising at least 17
25 contiguous nucleotides, with 0, 1, 2, or 3 mismatches, of a portion of nucleotide sequence of SEQ ID NO: 2 such that the sense strand is complementary to the at least 17 contiguous nucleotides in the antisense strand. In some embodiments, the sense strand comprises a nucleotide sequence comprising at least 17 contiguous nucleotides, with 0, or 1, 2, or 3
30 mismatches, of the corresponding portion of the nucleotide sequence of SEQ ID NO: 1.

In some embodiments, the dsRNA agent comprises a sense strand and an antisense strand, wherein the antisense strand comprises a nucleotide sequence comprising at least 19 contiguous nucleotides, with 0, 1, 2, or 3 mismatches, of a portion of nucleotide sequence of SEQ ID NO: 2 such that the sense strand is complementary to the at least 19 contiguous
5 nucleotides in the antisense strand. In some embodiments, the sense strand comprises a nucleotide sequence comprising at least 19 contiguous nucleotides, with 0, 1, 2, or 3 mismatches, of the corresponding portion of the nucleotide sequence of SEQ ID NO: 1.

In some embodiments, the dsRNA agent comprises a sense strand and an antisense strand, wherein the antisense strand comprises a nucleotide sequence comprising at least 21
10 contiguous nucleotides, with 0, 1, 2, or 3 mismatches, of a portion of nucleotide sequence of SEQ ID NO: 2 such that the sense strand is complementary to the at least 21 contiguous nucleotides in the antisense strand. In some embodiments, the sense strand comprises a nucleotide sequence comprising at least 21 contiguous nucleotides, with 0, or 1, 2, or 3 mismatches, of the corresponding portion of the nucleotide sequence of SEQ ID NO: 1.

15 In some embodiments, the portion of the sense strand is a portion within nucleotides 1855-1875, 1858-1878, 2178-2198, 2181-2201, 2944-2964, 2946-2966, 2952-2972, 3361-3381, or 3362-3382 of SEQ ID NO: 1. In some embodiments, the portion of the sense strand is a portion corresponding to SEQ ID NO: 4200, 4201, 4202, 4203, 4204, 4205, 4206, 4207, 4208, 4209, 4210, or 4211.

20 In some embodiments, the portion of the sense strand is a portion within a sense strand in any one of Tables 2A, 2B, 3A, 3B, 4A, 4B, 5A, 5B, 8A, 8B, 10A, 10B, 12, 13, 14, 18A and 18B.

In some embodiments, the portion of the antisense strand is a portion within an antisense strand in any one of Tables 2A, 2B, 3A, 3B, 4A, 4B, 5A, 5B, 8A, 8B, 10A, 10B, 12, 13, 14, 18A and 18B.

25 In some embodiments, the antisense strand comprises a nucleotide sequence comprising at least 15 contiguous nucleotides, with 0, 1, 2, or 3 mismatches, from one of the antisense sequences listed in any one of Tables 2A, 2B, 3A, 3B, 4A, 4B, 5A, 5B, 8A, 8B, 10A, 10B, 12, 13, 14, 18A and 18B. In some embodiments, the sense strand comprises a nucleotide sequence comprising at least 15 contiguous nucleotides, with 0, 1, 2, or 3 mismatches, from a sense
30 sequence listed in any one of Tables 2A, 2B, 3A, 3B, 4A, 4B, 5A, 5B, 8A, 8B, 10A, 10B, 12, 13, 14, 18A and 18B that corresponds to the antisense sequence.

In some embodiments, the antisense strand comprises a nucleotide sequence comprising at least 17 contiguous nucleotides, with 0, 1, 2, or 3 mismatches, from one of the antisense sequences listed in any one of Tables 2A, 2B, 3A, 3B, 4A, 4B, 5A, 5B, 8A, 8B, 10A, 10B, 12, 13, 14, 18A and 18B. In some embodiments, the sense strand comprises a nucleotide sequence comprising at least 17 contiguous nucleotides, with 0, 1, 2, or 3 mismatches, from a sense sequence listed in any one of Tables 2A, 2B, 3A, 3B, 4A, 4B, 5A, 5B, 8A, 8B, 10A, 10B, 12, 13, 14, 18A and 18B that corresponds to the antisense sequence.

In some embodiments, the antisense strand comprises a nucleotide sequence comprising at least 19 contiguous nucleotides, with 0, 1, 2, or 3 mismatches, from one of the antisense sequences listed in any one of Tables 2A, 2B, 3A, 3B, 4A, 4B, 5A, 5B, 8A, 8B, 10A, 10B, 12, 13, 14, 18A and 18B. In some embodiments, the sense strand comprises a nucleotide sequence comprising at least 19 contiguous nucleotides, with 0, 1, 2, or 3 mismatches, from a sense sequence listed in any one of Tables 2A, 2B, 3A, 3B, 4A, 4B, 5A, 5B, 8A, 8B, 10A, 10B, 12, 13, 14, 18A and 18B that corresponds to the antisense sequence.

In some embodiments, the antisense strand comprises a nucleotide sequence comprising at least 21 contiguous nucleotides, with 0, 1, 2, or 3 mismatches, from one of the antisense sequences listed in any one of Tables 2A, 2B, 3A, 3B, 4A, 4B, 5A, 5B, 8A, 8B, 10A, 10B, 12, 13, 14, 18A and 18B. In some embodiments, the sense strand comprises a nucleotide sequence comprising at least 21 contiguous nucleotides, with 0, 1, 2, or 3 mismatches, from a sense sequence listed in any one of Tables 2A, 2B, 3A, 3B, 4A, 4B, 5A, 5B, 8A, 8B, 10A, 10B, 12, 13, 14, 18A and 18B that corresponds to the antisense sequence.

In some embodiments, the sense strand of the dsRNA agent is at least 23 nucleotides in length, *e.g.*, 23-30 nucleotides in length.

In some embodiments, the portion of the sense strand is a portion within a sense strand from a duplex chosen from AD-1020574 (CGACAGAACAGUCCUAAUCA (SEQ ID NO: 4200)), AD-901094 (CAGAACAGUCCUAAUCCAGA (SEQ ID NO: 4201)), AD-1020575 (CAGAACAGUCCUAAUCCAGA (SEQ ID NO: 4202)), AD-901100 (AACAGUGCUAAUGUUAUUGGA (SEQ ID NO: 4203)), AD-901101 (AGUGCUAAUGUUAUUGGUGUA (SEQ ID NO: 4204)), AD-901113 (GAGAAAGUGUUUUAUAUACGA (SEQ ID NO: 4205)), AD-901123 (AAAAUAGACAUUGCUAUUCUA (SEQ ID NO: 4206)), AD-901124

(AAAUAGACAUUGCUAUUCUGA (SEQ ID NO: 4207)), AD-901158
 (GAAAGUGUUUUAUAUACGGUA (SEQ ID NO: 4208)), AD-901159
 (GUUUUAUAUACGGUACUUAUA (SEQ ID NO: 4209)), AD-1020573
 (AGUGCUAATGTUAUUGGUGUA (SEQ ID NO: 4210)), or AD-1023143

- 5 (AAAAUAGACATUGCUAUUCUA (SEQ ID NO: 4211)). In some embodiments, the portion is a portion of a corresponding chemically modified sequence provided in Tables 2A, 3A, 4A, or Table 18A.

In some embodiments, the portion of the sense strand is a sense strand chosen from the sense strands of AD-1020574 (CGACAGAACAGUCCUAAUCA (SEQ ID NO: 4200)), AD-
 10 901094 (CAGAACAGUCCUAAUCCAGA (SEQ ID NO: 4201)), AD-1020575
 (CAGAACAGUCCUAAUCCAGA (SEQ ID NO: 4202)), AD-901100
 (AACAGUGCUAAUGUUAUUGGA (SEQ ID NO: 4203)), AD-901101
 (AGUGCUAAUGUUAUUGGUGUA (SEQ ID NO: 4204)), AD-901113
 (GAGAAAGUGUUUUAUAUACGA (SEQ ID NO: 4205)), AD-901123
 15 (AAAAUAGACAUUGCUAUUCUA (SEQ ID NO: 4206)), AD-901124
 (AAAUAGACAUUGCUAUUCUGA (SEQ ID NO: 4207)), AD-901158
 (GAAAGUGUUUUAUAUACGGUA (SEQ ID NO: 4208)), AD-901159
 (GUUUUAUAUACGGUACUUAUA (SEQ ID NO: 4209)), AD-1020573
 (AGUGCUAATGTUAUUGGUGUA (SEQ ID NO: 4210)), or AD-1023143
 20 (AAAAUAGACATUGCUAUUCUA (SEQ ID NO: 4211)). In some embodiments, the portion is a portion of a corresponding chemically modified sequence provided in Tables 2A, 3A, 4A, or Table 18A.

In some embodiments, the portion of the sense strand is a portion within a sense strand from a duplex chosen from AD-953374 (SEQ ID NO: 813), AD-953504 (SEQ ID NO: 1297),
 25 AD-953481 (SEQ ID NO: 1298), AD-953351 (SEQ ID NO: 800), AD-901356 (SEQ ID NO: 261), AD-953344 (SEQ ID NO: 787), AD-901355 (SEQ ID NO: 262), AD-953410 (SEQ ID NO: 845), AD-953363 (SEQ ID NO: 779), AD-953411 (SEQ ID NO: 844), AD-953350 (SEQ ID NO: 784), or AD-953375 (SEQ ID NO: 790). In some embodiments, the portion is a portion of a corresponding chemically modified sequence provided in Tables 2A, 3A, 4A, or Table 18A.

30 In some embodiments, the portion of the sense strand is a sense strand chosen from the sense strands of AD-953374 (SEQ ID NO: 813), AD-953504 (SEQ ID NO: 1297), AD-953481

(SEQ ID NO: 1298), AD-953351 (SEQ ID NO: 800), AD-901356 (SEQ ID NO: 261), AD-953344 (SEQ ID NO: 787), AD-901355 (SEQ ID NO: 262), AD-953410 (SEQ ID NO: 845), AD-953363 (SEQ ID NO: 779), AD-953411 (SEQ ID NO: 844), AD-953350 (SEQ ID NO: 784), or AD-953375 (SEQ ID NO: 790). In some embodiments, the portion is a portion of a
 5 corresponding chemically modified sequence provided in Tables 2A, 3A, 4A, or Table 18A.

In some embodiments, the portion of the antisense strand is a portion within an antisense strand from a duplex chosen from AD-1020574 (UGAUUAAGGACUGUUCUGUCGAU (SEQ ID NO: 4212)), AD-901094 (UCUGGAUUAAGGACUGUUCUGUC (SEQ ID NO: 4213)), AD-1020575 (UCUGGATUAAGGACUGUUCUGUC (SEQ ID NO: 4214)), AD-901100
 10 (UCCAAUAACAUAUAGCACUGUAA (SEQ ID NO: 4215)), AD-901101 (UACACCAUAACAUAUAGCACUGU (SEQ ID NO: 4216)), AD-901113 (UCGUUAUAUAAAACACUUCUCUU (SEQ ID NO: 4217)), AD-901123 (UAGAAUAGCAAUGUCUAUUUUUAU (SEQ ID NO: 4218)), AD-901124 (UCAGAAUAGCAAUGUCUAUUUUUA (SEQ ID NO: 4219)), AD-901158
 15 (UACCGUAUAUAAAACACUUCUC (SEQ ID NO: 4220)), AD-901159 (UAUAAGUACCGUAUAUAAAACAC (SEQ ID NO: 4221)), AD-1020573 (UACACCAUAACATUAGCACUGU (SEQ ID NO: 4222)), or AD-1023143 (UAGAAUAGCAATGTCTAUUUUAU (SEQ ID NO: 4223)). In some embodiments, the portion is a portion of a corresponding chemically modified sequence provided in Tables 2A, 3A,
 20 4A, or Table 18A.

In some embodiments, the portion of the antisense strand is an antisense strand chosen from the antisense strands of AD-1020574 (UGAUUAAGGACUGUUCUGUCGAU (SEQ ID NO: 4212)), AD-901094 (UCUGGAUUAAGGACUGUUCUGUC (SEQ ID NO: 4213)), AD-1020575 (UCUGGATUAAGGACUGUUCUGUC (SEQ ID NO: 4214)), AD-901100
 25 (UCCAAUAACAUAUAGCACUGUAA (SEQ ID NO: 4215)), AD-901101 (UACACCAUAACAUAUAGCACUGU (SEQ ID NO: 4216)), AD-901113 (UCGUUAUAUAAAACACUUCUCUU (SEQ ID NO: 4217)), AD-901123 (UAGAAUAGCAAUGUCUAUUUUUAU (SEQ ID NO: 4218)), AD-901124 (UCAGAAUAGCAAUGUCUAUUUUUA (SEQ ID NO: 4219)), AD-901158
 30 (UACCGUAUAUAAAACACUUCUC (SEQ ID NO: 4220)), AD-901159 (UAUAAGUACCGUAUAUAAAACAC (SEQ ID NO: 4221)), AD-1020573

(UACACCAAUAACATUAGCACUGU (SEQ ID NO: 4222)), or AD-1023143 (UAGAAUAGCAATGTCTAUUUUAU (SEQ ID NO: 4223)). In some embodiments, the portion is a portion of a corresponding chemically modified sequence provided in Tables 2A, 3A, 4A, or Table 18A.

5 In some embodiments, the portion of the antisense strand is a portion within an antisense strand from a duplex chosen from AD-953374 (SEQ ID NO: 943), AD-953504 (SEQ ID NO: 1427), AD-953481 (SEQ ID NO: 1428), AD-953351 (SEQ ID NO: 930), AD-901356 (SEQ ID NO: 390), AD-953344 (SEQ ID NO: 917), AD-901355 (SEQ ID NO: 391), AD-953410 (SEQ ID NO: 975), AD-953363 (SEQ ID NO: 909), AD-953411 (SEQ ID NO: 974), AD-953350 (SEQ ID NO: 914), or AD-953375 (SEQ ID NO: 920). In some embodiments, the portion is a portion of a corresponding chemically modified sequence provided in Tables 2A, 3A, 4A, or Table 18A.

In some embodiments, the portion of the antisense strand is an antisense strand chosen from the antisense strands of AD-953374 (SEQ ID NO: 943), AD-953504 (SEQ ID NO: 1427), AD-953481 (SEQ ID NO: 1428), AD-953351 (SEQ ID NO: 930), AD-901356 (SEQ ID NO: 390), AD-953344 (SEQ ID NO: 917), AD-901355 (SEQ ID NO: 391), AD-953410 (SEQ ID NO: 975), AD-953363 (SEQ ID NO: 909), AD-953411 (SEQ ID NO: 974), AD-953350 (SEQ ID NO: 914), or AD-953375 (SEQ ID NO: 920). In some embodiments, the portion is a portion of a corresponding chemically modified sequence provided in Tables 2A, 3A, 4A, or Table 18A.

20 In some embodiments, the sense strand and the antisense strand of the dsRNA agent comprise nucleotide sequences of the paired sense strand and antisense strand of a duplex selected from AD-1020574 (SEQ ID NO: 4200 and 4212), AD-901094 (SEQ ID NO: 4201 and 4213), AD-1020575 (SEQ ID NO: 4202 and 4214), AD-901100 (SEQ ID NO: 4203 and 4215), AD-901101 (SEQ ID NO: 4204 and 4216), AD-901113 (SEQ ID NO: 4205 and 4217), AD-901123 (SEQ ID NO: 4206 and 4218), AD-901124 (SEQ ID NO: 4207 and 4219), AD-901158 (SEQ ID NO: 4208 and 4220), AD-901159 (SEQ ID NO: 4209 and 4221), AD-1020573 (SEQ ID NO: 4210 and 4222), or AD-1023143 (SEQ ID NO: 4211 and 4223). In some embodiments, the sense strand and antisense strand comprises the corresponding chemically modified sense sequence and antisense sequence provided in Tables 2A, 3A, 4A, or Table 18A.

30 In some embodiments, the sense strand and the antisense strand of the dsRNA agent comprise nucleotide sequences of the paired sense strand and antisense strand of a duplex

selected from AD-953374 (SEQ ID NO: 813 and 943), AD-953504 (SEQ ID NO: 1297 and 1427), AD-953481 (SEQ ID NO: 1298 and 1428), AD-953351 (SEQ ID NO: 800 and 930), AD-901356 (SEQ ID NO: 261 and 390), AD-953344 (SEQ ID NO: 787 and 917), AD-901355 (SEQ ID NO: 262 and 391), AD-953410 (SEQ ID NO: 845 and 975), AD-953363 (SEQ ID NO: 779 and 909), AD-953411 (SEQ ID NO: 844 and 974), AD-953350 (SEQ ID NO: 784 and 914), or AD-953375 (SEQ ID NO: 790 and 920). In some embodiments, the sense strand and antisense strand comprises the corresponding chemically modified sense sequence and antisense sequence provided in Tables 2A, 3A, 4A, or Table 18A.

In some embodiments, at least one of the sense strand and the antisense strand is conjugated to one or more lipophilic moieties. In some embodiments, the lipophilic moiety is conjugated to one or more positions in the double stranded region of the dsRNA agent. In some embodiments, the lipophilic moiety is conjugated via a linker or carrier. In some embodiments, lipophilicity of the lipophilic moiety, measured by logKow, exceeds 0. In some embodiments, In some embodiments, the hydrophobicity of the double-stranded RNAi agent, measured by the unbound fraction in a plasma protein binding assay of the double-stranded RNAi agent, exceeds 0.2. In some embodiments, the plasma protein binding assay is an electrophoretic mobility shift assay using human serum albumin protein.

In some embodiments, the dsRNA agent comprises at least one modified nucleotide. In some embodiments, no more than five of the sense strand nucleotides and not more than five of the nucleotides of the antisense strand are unmodified nucleotides. In some embodiments, all of the nucleotides of the sense strand and all of the nucleotides of the antisense strand comprise a modification.

In some embodiments, at least one of the modified nucleotides is selected from the group consisting of a deoxy-nucleotide, a 3'-terminal deoxy-thymine (dT) nucleotide, a 2'-O-methyl modified nucleotide, a 2'-fluoro modified nucleotide, a 2'-deoxy-modified nucleotide, a locked nucleotide, an unlocked nucleotide, a conformationally restricted nucleotide, a constrained ethyl nucleotide, an abasic nucleotide, a 2'-amino-modified nucleotide, a 2'-O-allyl-modified nucleotide, 2'-C-alkyl-modified nucleotide, a 2'-methoxyethyl modified nucleotide, a 2'-O-alkyl-modified nucleotide, a morpholino nucleotide, a phosphoramidate, a non-natural base comprising nucleotide, a tetrahydropyran modified nucleotide, a 1,5-anhydrohexitol modified nucleotide, a cyclohexenyl modified nucleotide, a nucleotide comprising a phosphorothioate

group, a nucleotide comprising a methylphosphonate group, a nucleotide comprising a 5'-phosphate, a nucleotide comprising a 5'-phosphate mimic, a glycol modified nucleotide, and a 2-O-(N-methylacetamide) modified nucleotide; and combinations thereof. In some embodiments, no more than five of the sense strand nucleotides and not more than five of the nucleotides of the antisense strand include modifications other than 2'-O-methyl modified nucleotide, a 2'-fluoro modified nucleotide, a 2'-deoxy-modified nucleotide, unlocked nucleic acids (UNA) or glycerol nucleic acid (GNA).

In some embodiments, the dsRNA comprises a non-nucleotide spacer (wherein optionally the non-nucleotide spacer comprises a C3-C6 alkyl) between two of the contiguous nucleotides of the sense strand or between two of the contiguous nucleotides of the antisense strand.

In some embodiments, each strand is no more than 30 nucleotides in length. In some embodiments, at least one strand comprises a 3' overhang of at least 1 nucleotide. In some embodiments, at least one strand comprises a 3' overhang of at least 2 nucleotides. In some embodiments, at least one strand comprises a 3' overhang of 2 nucleotides.

In some embodiments, the double stranded region is 15-30 nucleotide pairs in length. In some embodiments, the double stranded region is 17-23 nucleotide pairs in length. In some embodiments, the double stranded region is 17-25 nucleotide pairs in length. In some embodiments, the double stranded region is 23-27 nucleotide pairs in length. In some embodiments, the double stranded region is 19-21 nucleotide pairs in length. In some embodiments, the double stranded region is 21-23 nucleotide pairs in length. In some embodiments, each strand has 19-30 nucleotides. In some embodiments, each strand has 19-23 nucleotides. In some embodiments, each strand has 21-23 nucleotides.

In some embodiments, the agent comprises at least one phosphorothioate or methylphosphonate internucleotide linkage. In some embodiments, the phosphorothioate or methylphosphonate internucleotide linkage is at the 3'-terminus of one strand. In some embodiments, the strand is the antisense strand. In some embodiments, the strand is the sense strand.

In some embodiments, the phosphorothioate or methylphosphonate internucleotide linkage is at the 5'-terminus of one strand. In some embodiments, the strand is the antisense strand. In some embodiments, the strand is the sense strand.

In some embodiments, each of the 5'- and 3'-terminus of one strand comprises a phosphorothioate or methylphosphonate internucleotide linkage. In some embodiments, the strand is the antisense strand.

5 In some embodiments, the base pair at the 1 position of the 5'-end of the antisense strand of the duplex is an AU base pair.

In some embodiments, the sense strand has a total of 21 nucleotides and the antisense strand has a total of 23 nucleotides.

10 In some embodiments, one or more lipophilic moieties are conjugated to one or more internal positions on at least one strand. In some embodiments, the one or more lipophilic moieties are conjugated to one or more internal positions on at least one strand via a linker or carrier.

In some embodiments, the internal positions include all positions except the terminal two positions from each end of the at least one strand. In some embodiments, the internal positions include all positions except the terminal three positions from each end of the at least one strand.

15 In some embodiments, the internal positions exclude a cleavage site region of the sense strand. In some embodiments, the internal positions include all positions except positions 9-12, counting from the 5'-end of the sense strand. In some embodiments, the internal positions include all positions except positions 11-13, counting from the 3'-end of the sense strand. In some

20 In some embodiments, the internal positions exclude a cleavage site region of the antisense strand. In some embodiments, the internal positions include all positions except positions 12-14, counting from the 5'-end of the antisense strand. In some embodiments, the internal positions include all positions except positions 11-13 on the sense strand, counting from the 3'-end, and positions 12-14 on the antisense strand, counting from the 5'-end.

25 In some embodiments, the one or more lipophilic moieties are conjugated to one or more of the internal positions selected from the group consisting of positions 4-8 and 13-18 on the sense strand, and positions 6-10 and 15-18 on the antisense strand, counting from the 5'-end of each strand. In some embodiments, the one or more lipophilic moieties are conjugated to one or more of the internal positions selected from the group consisting of positions 5, 6, 7, 15, and 17 on the sense strand, and positions 15 and 17 on the antisense strand, counting from the 5'-end of

30 each strand.

In some embodiments, the positions in the double stranded region exclude a cleavage site region of the sense strand.

In some embodiments, the sense strand is 21 nucleotides in length, the antisense strand is 23 nucleotides in length, and the lipophilic moiety is conjugated to position 21, position 20, position 15, position 1, position 7, position 6, or position 2 of the sense strand or position 16 of the antisense strand. In some embodiments, the lipophilic moiety is conjugated to position 21, position 20, position 15, position 1, or position 7 of the sense strand. In some embodiments, the lipophilic moiety is conjugated to position 21, position 20, or position 15 of the sense strand. In some embodiments, the lipophilic moiety is conjugated to position 20 or position 15 of the sense strand. In some embodiments, the lipophilic moiety is conjugated to position 16 of the antisense strand. In some embodiments, the lipophilic moiety is conjugated to position 6, counting from the 5'-end of the sense strand.

In some embodiments, the lipophilic moiety is an aliphatic, alicyclic, or polyalicyclic compound. In some embodiments, the lipophilic moiety is selected from the group consisting of lipid, cholesterol, retinoic acid, cholic acid, adamantane acetic acid, 1-pyrene butyric acid, dihydrotestosterone, 1,3-bis-O(hexadecyl)glycerol, geranyloxyhexanol, hexadecylglycerol, borneol, menthol, 1,3-propanediol, heptadecyl group, palmitic acid, myristic acid, O3-(oleoyl)lithocholic acid, O3-(oleoyl)cholenic acid, dimethoxytrityl, or phenoxazine. In some embodiments, the lipophilic moiety contains a saturated or unsaturated C4-C30 hydrocarbon chain, and an optional functional group selected from the group consisting of hydroxyl, amine, carboxylic acid, sulfonate, phosphate, thiol, azide, and alkyne. In some embodiments, the lipophilic moiety contains a saturated or unsaturated C6-C18 hydrocarbon chain. In some embodiments, the lipophilic moiety contains a saturated or unsaturated C16 hydrocarbon chain.

In some embodiments, the lipophilic moiety is conjugated via a carrier that replaces one or more nucleotide(s) in the internal position(s) or the double stranded region. In some embodiments, the carrier is a cyclic group selected from the group consisting of pyrrolidinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, piperidinyl, piperazinyl, [1,3]dioxolanyl, oxazolidinyl, isoxazolidinyl, morpholinyl, thiazolidinyl, isothiazolidinyl, quinoxalinyl, pyridazinonyl, tetrahydrofuranyl, and decaliny; or is an acyclic moiety based on a serinol backbone or a diethanolamine backbone.

In some embodiments, the lipophilic moiety is conjugated to the double-stranded iRNA agent via a linker containing an ether, thioether, urea, carbonate, amine, amide, maleimide-thioether, disulfide, phosphodiester, sulfonamide linkage, a product of a click reaction, or carbamate.

5 In some embodiments, the lipophilic moiety is conjugated to a nucleobase, sugar moiety, or internucleosidic linkage.


In some embodiments, the lipophilic moiety or targeting ligand is conjugated via a bio-cleavable linker selected from the group consisting of DNA, RNA, disulfide, amide, functionalized monosaccharides or oligosaccharides of galactosamine, glucosamine, glucose,
10 galactose, mannose, and combinations thereof.

In some embodiments, the 3' end of the sense strand is protected via an end cap which is a cyclic group having an amine, said cyclic group being selected from the group consisting of pyrrolidinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, piperidinyl, piperazinyl, [1,3]dioxolanyl, oxazolidinyl, isoxazolidinyl, morpholinyl, thiazolidinyl, isothiazolidinyl,
15 quinoxalinyl, pyridazinonyl, tetrahydrofuranyl, and decalanyl.


In some embodiments, the dsRNA agent further comprises a targeting ligand, *e.g.*, a ligand that targets an ocular tissue or a liver tissue. In some embodiments, the ocular tissue is a retinal pigment epithelium (RPE) or choroid tissue, *e.g.*, a choroid vessel.

In some embodiments, the ligand is conjugated to the sense strand. In some
20 embodiments, the ligand is conjugated to the 3' end or the 5' end of the sense strand. In some embodiments, the ligand is conjugated to the 3' end of the sense strand.

In some embodiments, the ligand comprises N-acetylgalactosamine (GalNAc). In some embodiments, the targeting ligand comprises one or more GalNAc conjugates or one or more GalNAc derivatives. In some embodiments, the ligand is one or more GalNAc conjugates or one
25 or more GalNAc derivatives are attached through a monovalent linker, or a bivalent, trivalent, or tetravalent branched linker. In some embodiments, the ligand is



In some embodiments, the dsRNA agent is conjugated to the ligand as shown in the following schematic



wherein X is O or S. In some embodiments, the X is O.

In some embodiments, the dsRNA agent further comprises a terminal, chiral modification occurring at the first internucleotide linkage at the 3' end of the antisense strand, having the linkage phosphorus atom in Sp configuration, a terminal, chiral modification occurring at the first internucleotide linkage at the 5' end of the antisense strand, having the linkage phosphorus atom in Rp configuration, and a terminal, chiral modification occurring at the first internucleotide linkage at the 5' end of the sense strand, having the linkage phosphorus atom in either Rp configuration or Sp configuration.

In some embodiments, the dsRNA agent further comprises a terminal, chiral modification occurring at the first and second internucleotide linkages at the 3' end of the antisense strand, having the linkage phosphorus atom in Sp configuration, a terminal, chiral modification occurring at the first internucleotide linkage at the 5' end of the antisense strand, having the

linkage phosphorus atom in Rp configuration, and a terminal, chiral modification occurring at the first internucleotide linkage at the 5' end of the sense strand, having the linkage phosphorus atom in either Rp or Sp configuration.

In some embodiments, the dsRNA agent further comprises a terminal, chiral modification occurring at the first, second and third internucleotide linkages at the 3' end of the antisense strand, having the linkage phosphorus atom in Sp configuration, a terminal, chiral modification occurring at the first internucleotide linkage at the 5' end of the antisense strand, having the linkage phosphorus atom in Rp configuration, and a terminal, chiral modification occurring at the first internucleotide linkage at the 5' end of the sense strand, having the linkage phosphorus atom in either Rp or Sp configuration.

In some embodiments, the dsRNA agent further comprises a terminal, chiral modification occurring at the first, and second internucleotide linkages at the 3' end of the antisense strand, having the linkage phosphorus atom in Sp configuration, a terminal, chiral modification occurring at the third internucleotide linkages at the 3' end of the antisense strand, having the linkage phosphorus atom in Rp configuration, a terminal, chiral modification occurring at the first internucleotide linkage at the 5' end of the antisense strand, having the linkage phosphorus atom in Rp configuration, and a terminal, chiral modification occurring at the first internucleotide linkage at the 5' end of the sense strand, having the linkage phosphorus atom in either Rp or Sp configuration.

In some embodiments, the dsRNA agent further comprises a terminal, chiral modification occurring at the first, and second internucleotide linkages at the 3' end of the antisense strand, having the linkage phosphorus atom in Sp configuration, a terminal, chiral modification occurring at the first, and second internucleotide linkages at the 5' end of the antisense strand, having the linkage phosphorus atom in Rp configuration, and a terminal, chiral modification occurring at the first internucleotide linkage at the 5' end of the sense strand, having the linkage phosphorus atom in either Rp or Sp configuration.

In some embodiments, the dsRNA agent further comprises a phosphate or phosphate mimic at the 5'-end of the antisense strand. In some embodiments, the phosphate mimic is a 5'-vinyl phosphonate (VP).

In some embodiments, a cell described herein, *e.g.*, a human cell, was produced by a process comprising contacting a human cell with the dsRNA agent described herein.

In some embodiments, a pharmaceutical composition described herein comprises the dsRNA agent and a lipid formulation.

In some embodiments (*e.g.*, embodiments of the methods described herein), the cell is within a subject. In some embodiments, the subject is a human. In some embodiments, the level of VEGF-A mRNA is inhibited by at least 50%. In some embodiments, the level of VEGF-A protein is inhibited by at least 50%. In some embodiments, the expression of VEGF-A is inhibited by at least 50%. In some embodiments, inhibiting expression of VEGF-A decreases the VEGF-A protein level in a biological sample (*e.g.*, an aqueous ocular fluid sample) from the subject by at least 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95%. In some embodiments, inhibiting expression of VEGF-A gene decreases the VEGF-A mRNA level in a biological sample (*e.g.*, an aqueous ocular fluid sample) from the subject by at least 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95%.

In some embodiments, the subject has been diagnosed with a VEGF-A-associated disorder. In some embodiments, the subject meets at least one diagnostic criterion for a VEGF-A-associated disorder. In some embodiments, the VEGF-A associated disorder is wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR), diabetic macular edema (DME), retinal vein occlusion (RVO), macular edema following retinal vein occlusion (MEfRVO), retinopathy of prematurity (ROP), or myopic choroidal neovascularization (mCNV). In some embodiments, the VEGF-A associated disorder is macular edema, *e.g.*, diabetic macular edema.

In some embodiments, the ocular cell or tissue is RPE, a retinal cell, an astrocyte, a pericyte, a Müller cell, a ganglion cell, an endothelial cell, a photoreceptor cell, a retinal blood vessel (*e.g.*, including endothelial cells and vascular smooth muscle cells), or choroid tissue, *e.g.*, a choroid vessel.

In some embodiments, the VEGF-A-associated disorder is an angiogenic ocular disorder. In some embodiments, the angiogenic ocular disorder is caused by or associated with the growth or proliferation of blood vessels. In some embodiments, the angiogenic ocular disorder is caused by or associated with ocular neovascularization. In some embodiments, the angiogenic ocular disorder is AMD, DR, DME, RVO, MEfRVO, ROP, or mCNV.

In some embodiments, treating comprises amelioration of at least one sign or symptom of the disorder. In some embodiments, the at least one sign or symptom includes a measure of one or more of angiogenesis, choroidal neovascularization, ocular inflammation, visual acuity, or

presence, level, or activity of VEGF-A (*e.g.*, VEGF-A gene, VEGF-A mRNA, or VEGF-A protein).

In some embodiments, a level of the VEGF-A that is higher than a reference level is indicative that the subject has an angiogenic ocular disorder. In some embodiments, treating comprises prevention of progression of the disorder. In some embodiments, the treating comprises one or more of (a) inhibiting angiogenesis; (b) inhibiting or reducing the expression or activity of VEGF-A; (c) inhibiting choroidal neovascularization; (d) inhibiting growth of new blood vessels in the choriocapillaris; (e) reducing retinal thickness; (f) increasing visual acuity; or (g) reducing intraocular inflammation.

In some embodiments, the treating results in at least a 30% mean reduction from baseline of VEGF-A mRNA in the retina, RPE, a retinal blood vessel (*e.g.*, including endothelial cells and vascular smooth muscle cells), or choroid tissue, *e.g.*, a choroid vessel. In some embodiments, the treating results in at least a 60% mean reduction from baseline of VEGF-A mRNA in the retina, RPE, a retinal blood vessel (*e.g.*, including endothelial cells and vascular smooth muscle cells), or choroid tissue, *e.g.*, a choroid vessel. In some embodiments, the treating results in at least a 90% mean reduction from baseline of VEGF-A mRNA in the retina, RPE, a retinal blood vessel (*e.g.*, including endothelial cells and vascular smooth muscle cells), or choroid tissue, *e.g.*, a choroid vessel.

In some embodiments, after treatment the subject experiences at least an 8-week duration of knockdown following a single dose of dsRNA as assessed by VEGF-A protein in the retina. In some embodiments, treating results in at least a 12-week duration of knockdown following a single dose of dsRNA as assessed by VEGF-A protein in the retina. In some embodiments, treating results in at least a 16-week duration of knockdown following a single dose of dsRNA as assessed by VEGF-A protein in the retina.

In some embodiments, the subject is human.

In some embodiments, the dsRNA agent is administered at a dose of about 0.01 mg/kg to about 50 mg/kg.

In some embodiments, the dsRNA agent is administered to the subject intraocularly. In some embodiments, the intraocular administration comprises intravitreal administration, *e.g.*, intravitreal injection; transscleral administration, *e.g.*, transscleral injection; subconjunctival administration, *e.g.*, subconjunctival injection; retrobulbar administration, *e.g.*, retrobulbar

injection; intracameral administration, e.g., intracameral injection, or subretinal administration, e.g., subretinal injection.

In some embodiments, the dsRNA agent is administered to the subject intravenously. In some embodiments, the dsRNA agent is administered to the subject topically.

5 In some embodiments, a method described herein further comprises measuring a level of VEGF-A (*e.g.*, VEGF-A gene, VEGF-A mRNA, or VEGF-A protein) in the subject. In some embodiments, measuring the level of VEGF-A in the subject comprises measuring the level of VEGF-A protein in a biological sample from the subject (*e.g.*, an aqueous ocular fluid sample). In some embodiments, a method described herein further comprises performing a blood test, an
10 imaging test, or an aqueous ocular fluid biopsy (*e.g.*, an aqueous humor tap).

In some embodiments, a method described herein further measuring level of VEGF-A (*e.g.*, VEGF-A gene, VEGF-A mRNA, or VEGF-A protein) in the subject is performed prior to treatment with the dsRNA agent or the pharmaceutical composition. In some embodiments, upon determination that a subject has a level of VEGF-A that is greater than a reference level,
15 the dsRNA agent or the pharmaceutical composition is administered to the subject. In some embodiments, measuring level of VEGF-A in the subject is performed after treatment with the dsRNA agent or the pharmaceutical composition.

In some embodiments, a method described herein further comprises treating the subject with a therapy suitable for treatment or prevention of a VEGF-A-associated disorder, *e.g.*,
20 wherein the therapy comprises photodynamic therapy, photocoagulation therapy, or vitrectomy. In some embodiments, a method described herein further comprises administering to the subject an additional agent suitable for treatment or prevention of a VEGF-A-associated disorder. In some embodiments, the additional agent comprises a steroid, a non-steroidal anti-inflammatory agent, or an anti-VEGF-A agent.

25 In some embodiments, the anti-VEGF-A agent comprises a fusion protein or an anti-VEGF-A antibody or antigen-binding fragment thereof (*e.g.*, an anti-VEGF-A antibody molecule).

All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety.

The details of various embodiments of the disclosure are set forth in the description below. Other features, objects, and advantages of the disclosure will be apparent from the description and the drawings, and from the claims.

BRIEF DESCRIPTION OF THE DRAWINGS

5 **FIG. 1A** depicts the sequences and chemistry of the exemplary VEGF-A siRNAs including AD-64228 (SEQ ID NO: 4162 and 4163), AD-953374 (SEQ ID NO: 553 and 683), AD-953504 (SEQ ID NO: 1037 and 1167), AD-953336 (SEQ ID NO: 518 and 648), AD-953337 (SEQ ID NO: 522 and 652), AD-901376 (SEQ ID NO: 4157 and 131), AD-953364 (SEQ ID NO: 567 and 697). **FIG. 1B** depicts the sequences and chemistry of the exemplary VEGF-A
10 siRNAs including AD-953340 (SEQ ID NO: 517 and 647), AD-953351 (SEQ ID NO: 540 and 670), AD-953342 (SEQ ID NO: 523 and 653), AD-953308 (SEQ ID NO: 579 and 709), AD-953344 (SEQ ID NO: 527 and 657), AD-953339 (SEQ ID NO: 528 and 658), and AD-953363 (SEQ ID NO: 519 and 649). For each siRNA, “F” is the “2’-fluoro” modification, OMe is a methoxy group, GNA refers to a glycol nucleic acid, “DNA” refers to a DNA base, 2-C16 refers
15 to the targeting ligand, and PS refers to the phosphorothioate linkage.

FIG. 2 is a graph depicting the percent VEGF-A message remaining normalized to PBS in mice on day 14 post-treatment with the exemplary duplexes indicated on the X-axis (from left to right: PBS control, naïve control, AAV positive control (AD-64228), AD-901376.2, AD-953308.2, AD-953336.2, AD-953337.2, AD-953339.2, AD-953340.2, AD-953342.2, AD-
20 953344.2, AD-953351.2, AD-953363.2, AD-953364.2, AD-953374.2, AD-953504.2).

FIG. 3A depicts the sequences and chemistry of the exemplary VEGF-A siRNAs including AD-901349 (SEQ ID NO: 4156 and 130), AD-953481 (SEQ ID NO: 1038 and 1168), AD-901356 (SEQ ID NO: 3 and 132), AD-901355 (SEQ ID NO: 4 and 133), AD-953365 (SEQ ID NO: 552 and 682), AD-953410 (SEQ ID NO: 585 and 715), AD-953411 (SEQ ID NO: 584
25 and 714). **FIG. 3B** depicts the sequences and chemistry of the exemplary VEGF-A siRNAs including AD-953338 (SEQ ID NO: 520 and 650), AD-953350 (SEQ ID NO: 524 and 654), AD-953375 (SEQ ID NO: 530 and 660), AD-953341 (SEQ ID NO: 532 and 662), AD-953370 (SEQ ID NO: 533 and 663), AD-953386 (SEQ ID NO: 541 and 671), AD-64958 (SEQ ID NO: 5003 and 5004). For each siRNA, “F” is the “2’-fluoro” modification, OMe is a methoxy group, GNA
30 refers to a glycol nucleic acid, 2-C16 refers to the targeting ligand, and PS refers to the phosphorothioate linkage.

FIG. 4 is a graph depicting the percent VEGF-A message remaining normalized to PBS in mice on day 14 post-treatment with the exemplary duplexes indicated on the X-axis (from left to right: PBS control, naïve control, AD-901349.1, AD-953481.1, AD-901356.1, AD-901355.1, AD-953365.1, AD-953410.1, AD-953411.1, AD-953338.1, AD-953350.1, AD-953375.1, AD-953341.1, AD-953370.1, AD-953386.1, and AD-64958 (ELF8 TTR control)).

FIG. 5A depicts the sequences and chemistry of the exemplary VEGF-A siRNAs including AD-1397050 (SEQ ID NO: 5005 and 3936), AD-1397051 (SEQ ID NO: 5006 and 3918), AD-1397052 (SEQ ID NO: 10 and 3957), AD-1397053 (SEQ ID NO: 5007 and 3924), AD-1397054 (SEQ ID NO: 5008 and 2640), AD-1397055 (SEQ ID NO: 5009 and 2775). **FIG. 5B** depicts the sequences and chemistry of the exemplary VEGF-A siRNAs including AD-1397056 (SEQ ID NO: 5010 and 2776), AD-1397058 (SEQ ID NO: 5011 and 3953), AD-1397059 (SEQ ID NO: 5012 and 3889), AD-1397060 (SEQ ID NO: 5013 and 3902), AD-1397061 (SEQ ID NO: 5014 and 3932), and AD-1397062 (SEQ ID NO: 5015 and 3944). **FIG. 5C** depicts the sequences and chemistry of the exemplary VEGF-A siRNAs including AD-1397064 (SEQ ID NO: 5016 and 3938), AD-1397065 (SEQ ID NO: 5017 and 3965), AD-1397066 (SEQ ID NO: 5018 and 3962), AD-1397067 (SEQ ID NO: 5019 and 3971), AD-1397068 (SEQ ID NO: 1044 and 3901), AD-1397069 (SEQ ID NO: 5020 and 3928), and AD-64958 (SEQ ID NO: 5003 and 5004). For each siRNA, “F” is the “2’-fluoro” modification, OMe is a methoxy group, GNA refers to a glycol nucleic acid, “(A2p)” refers to adenosine 2’-phosphate, “(C2p)” refers to cytosine 2’-phosphate, “(U2p)” refers to uracil 2’-phosphate, “DNA” refers to a DNA base, 2-C16 refers to the targeting ligand, and PS refers to the phosphorothioate linkage.

FIG. 6 is a graph depicting the percent VEGF-A message remaining normalized to PBS in mice on day 14 post-treatment with the exemplary duplexes indicated on the X-axis (from left to right: PBS control, naïve control, AD-1397050.2, AD-1397051.2, AD-1397052.2, AD-1397053.2, AD-1397054.2, AD-1397055.2, AD-1397056.2, AD-1397058.2, AD-1397059.2, AD-1397060.2, AD-1397061.2, AD-1397062.2, AD-1397064.2, AD-1397065.2, AD-1397066.2, AD-1397067.2, AD-1397068.2, AD-1397069.2, and AD-64958.100).

DETAILED DESCRIPTION

iRNA directs the sequence-specific degradation of mRNA through a process known as RNA interference (RNAi). Described herein are iRNAs and methods of using them for modulating (*e.g.*, inhibiting) the expression of VEGF-A. Also provided are compositions and methods for treatment of disorders related to VEGF-A expression, such as an angiogenic ocular disorder (*e.g.*, wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR), diabetic macular edema (DME), retinal vein occlusion (RVO), macular edema following retinal vein occlusion (MEfRVO), retinopathy of prematurity (ROP), or myopic choroidal neovascularization (mCNV)).

Human VEGF-A is a dimeric glycoprotein of approximately 40 kDa and is a potent endothelial cell mitogen with a role in proliferation, migration, and tube formation leading to angiogenic growth of new blood vessels. VEGF-A is typically expressed and secreted by a variety of tissues including the retinal pigmented epithelium (RPE), retinal tissues, astrocytes, Müller cells, photoreceptor cells, endothelial cells (*e.g.*, vascular endothelial cells), retinal blood vessels (*e.g.*, including endothelial cells and vascular smooth muscle cells), choroid tissue, *e.g.*, a choroid vessel, and ganglion cells. Several angiogenic ocular disorders are associated with pathological angiogenesis, including wet AMD, DR, DME, RVO, MEfRVO, ROP, and mCNV. Without wishing to be bound by theory, VEGF-A may exacerbate the pathogenesis of angiogenic ocular disorders, *e.g.*, by increasing vascular permeability and promoting neovascularization.

The following description discloses how to make and use compositions containing iRNAs to modulate (*e.g.*, inhibit) the expression of VEGF-A, as well as compositions and methods for treating disorders related to expression of VEGF-A.

In some aspects, pharmaceutical compositions containing VEGF-A iRNA and a pharmaceutically acceptable carrier, methods of using the compositions to inhibit expression of VEGF-A, and methods of using the pharmaceutical compositions to treat disorders related to expression of VEGF-A (*e.g.*, angiogenic ocular disorders) are featured herein.

I. Definitions

For convenience, the meaning of certain terms and phrases used in the specification, examples, and appended claims, are provided below. If there is an apparent discrepancy between the usage of a term in other parts of this specification and its definition provided in this section, the definition in this section shall prevail.

The term “about” when referring to a number or a numerical range means that the number or numerical range referred to is an approximation within experimental variability (or within statistical experimental error), and thus the number or numerical range may vary from, for example, between 1% and 15% of the stated number or numerical range.

5 The term “at least” prior to a number or series of numbers is understood to include the number adjacent to the term “at least”, and all subsequent numbers or integers that could logically be included, as clear from context. For example, the number of nucleotides in a nucleic acid molecule must be an integer. For example, “at least 17 nucleotides of a 20-nucleotide nucleic acid molecule” means that 17, 18, 19, or 20 nucleotides have the
10 indicated property. When at least is present before a series of numbers or a range, it is understood that “at least” can modify each of the numbers in the series or range.

As used herein, “no more than” or “less than” is understood as the value adjacent to the phrase and logical lower values or integers, as logical from context, to zero. For example, a duplex with mismatches to a target site of “no more than 2 nucleotides” has a 2, 1, or 0
15 mismatches. When “no more than” is present before a series of numbers or a range, it is understood that “no more than” can modify each of the numbers in the series or range.

As used herein, “up to” as in “up to 10” is understood as up to and including 10, *i.e.*, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

Ranges provided herein are understood to include all individual integer values and all
20 subranges within the ranges.

The terms “activate,” “enhance,” “up-regulate the expression of,” “increase the expression of,” and the like, in so far as they refer to a VEGF-A gene, herein refer to the at least partial activation of the expression of a VEGF-A gene, as manifested by an increase in the amount of VEGF-A mRNA, which may be isolated from or detected in a first cell or group of
25 cells in which a VEGF-A gene is transcribed and which has or have been treated such that the expression of a VEGF-A gene is increased, as compared to a second cell or group of cells substantially identical to the first cell or group of cells but which has or have not been so treated (control cells).

In some embodiments, expression of a VEGF-A gene is activated by at least about 10%,
30 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% by administration of an iRNA as described herein. In some embodiments, a VEGF-A gene is activated by at least about 60%, 70%, or 80%

by administration of an iRNA featured in the disclosure. In some embodiments, expression of a VEGF-A gene is activated by at least about 85%, 90%, or 95% or more by administration of an iRNA as described herein. In some embodiments, the VEGF-A gene expression is increased by at least 1-fold, at least 2-fold, at least 5-fold, at least 10-fold, at least 50-fold, at least 100-fold, at least 500-fold, at least 1000-fold or more in cells treated with an iRNA as described herein compared to the expression in an untreated cell. Activation of expression by small dsRNAs is described, for example, in Li *et al.*, 2006 *Proc. Natl. Acad. Sci. U.S.A.* 103:17337-42, and in US2007/0111963 and US2005/226848, each of which is incorporated herein by reference.

The terms “silence,” “inhibit expression of,” “down-regulate expression of,” “suppress expression of,” and the like, in so far as they refer to VEGF-A, herein refer to the at least partial suppression of the expression of VEGF-A, as assessed, *e.g.*, based on VEGF-A mRNA expression, VEGF-A protein expression, or another parameter functionally linked to VEGF-A expression. For example, inhibition of VEGF-A expression may be manifested by a reduction of the amount of VEGF-A mRNA which may be isolated from or detected in a first cell or group of cells in which VEGF-A is transcribed and which has or have been treated such that the expression of VEGF-A is inhibited, as compared to a control. The control may be a second cell or group of cells substantially identical to the first cell or group of cells, except that the second cell or group of cells have not been so treated (control cells). The degree of inhibition is usually expressed as a percentage of a control level, *e.g.*,

$$\frac{(\text{mRNA in control cells}) - (\text{mRNA in treated cells})}{(\text{mRNA in control cells})} \bullet 100\%$$

Alternatively, the degree of inhibition may be given in terms of a reduction of a parameter that is functionally linked to VEGF-A expression, *e.g.*, the amount of protein encoded by a VEGF-A gene. The reduction of a parameter functionally linked to VEGF-A expression may similarly be expressed as a percentage of a control level. In principle, VEGF-A silencing may be determined in any cell expressing VEGF-A, either constitutively or by genomic engineering, and by any appropriate assay.

For example, in certain instances, expression of VEGF-A is suppressed by at least about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% by administration of an iRNA disclosed herein. In some embodiments, VEGF-A is suppressed by at least about 60%, 65%, 70%, 75%, or 80% by administration of an iRNA disclosed herein. In some embodiments, VEGF-A is

suppressed by at least about 85%, 90%, 95%, 98%, 99%, or more by administration of an iRNA as described herein.

The term “antisense strand” or “guide strand” refers to the strand of an iRNA, *e.g.*, a dsRNA, which includes a region that is substantially complementary to a target sequence.

5 As used herein, the term “region of complementarity” refers to the region on the antisense strand that is substantially complementary to a sequence, for example a target sequence, as defined herein. Where the region of complementarity is not fully complementary to the target sequence, the mismatches may be in the internal or terminal regions of the molecule. In some embodiments, the region of complementarity comprises 0, 1, or 2 mismatches.

10 The term “sense strand” or “passenger strand” as used herein, refers to the strand of an iRNA that includes a region that is substantially complementary to a region of the antisense strand as that term is defined herein.

The terms “blunt” or “blunt ended” as used herein in reference to a dsRNA mean that there are no unpaired nucleotides or nucleotide analogs at a given terminal end of a dsRNA, *i.e.*,
15 no nucleotide overhang. One or both ends of a dsRNA can be blunt. Where both ends of a dsRNA are blunt, the dsRNA is said to be blunt ended. To be clear, a “blunt ended” dsRNA is a dsRNA that is blunt at both ends, *i.e.*, no nucleotide overhang at either end of the molecule. Most often such a molecule will be double-stranded over its entire length.

As used herein, and unless otherwise indicated, the term “complementary,” when used to
20 describe a first nucleotide sequence in relation to a second nucleotide sequence, refers to the ability of an oligonucleotide or polynucleotide comprising the first nucleotide sequence to hybridize and form a duplex structure under certain conditions with an oligonucleotide or polynucleotide comprising the second nucleotide sequence, as will be understood by the skilled person. Such conditions can, for example, be stringent conditions, where stringent conditions
25 may include: 400 mM NaCl, 40 mM PIPES pH 6.4, 1 mM EDTA, 50°C or 70°C for 12-16 hours followed by washing. Other conditions, such as physiologically relevant conditions as may be encountered inside an organism, can apply. The skilled person will be able to determine the set of conditions most appropriate for a test of complementarity of two sequences in accordance with the ultimate application of the hybridized nucleotides.

30 Complementary sequences within an iRNA, *e.g.*, within a dsRNA as described herein, include base-pairing of the oligonucleotide or polynucleotide comprising a first nucleotide

sequence to an oligonucleotide or polynucleotide comprising a second nucleotide sequence over the entire length of one or both nucleotide sequences. Such sequences can be referred to as “fully complementary” with respect to each other herein. However, where a first sequence is referred to as “substantially complementary” with respect to a second sequence herein, the two sequences can be fully complementary, or they may form one or more, but generally not more than 5, 4, 3 or 2 mismatched base pairs upon hybridization for a duplex up to 30 base pairs, while retaining the ability to hybridize under the conditions most relevant to their ultimate application, *e.g.*, inhibition of gene expression via a RISC pathway. However, where two oligonucleotides are designed to form, upon hybridization, one or more single stranded overhangs, such overhangs shall not be regarded as mismatches with regard to the determination of complementarity. For example, a dsRNA comprising one oligonucleotide 21 nucleotides in length and another oligonucleotide 23 nucleotides in length, wherein the longer oligonucleotide comprises a sequence of 21 nucleotides that is fully complementary to the shorter oligonucleotide, may yet be referred to as “fully complementary” for the purposes described herein.

Complementary sequences, as used herein, may also include, or be formed entirely from, non-Watson-Crick base pairs and/or base pairs formed from non-natural and modified nucleotides, in as far as the above requirements with respect to their ability to hybridize are fulfilled. Such non-Watson-Crick base pairs includes, but are not limited to, G:U Wobble or Hoogsteen base pairing.

The terms “complementary,” “fully complementary” and “substantially complementary” herein may be used with respect to the base matching between the sense strand and the antisense strand of a dsRNA, or between the antisense strand of an iRNA agent and a target sequence, as will be understood from the context of their use.

As used herein, a polynucleotide that is “substantially complementary to at least part of” a messenger RNA (mRNA) refers to a polynucleotide that is substantially complementary to a contiguous portion of the mRNA of interest (*e.g.*, an mRNA encoding a VEGF-A protein). For example, a polynucleotide is complementary to at least a part of a VEGF-A mRNA if the sequence is substantially complementary to a non-interrupted portion of an mRNA encoding VEGF-A. The term “complementarity” refers to the capacity for pairing between nucleobases of a first nucleic acid and a second nucleic acid.

As used herein, the term “region of complementarity” refers to the region of one nucleotide sequence agent that is substantially complementary to another sequence, *e.g.*, the region of a sense sequence and corresponding antisense sequence of a dsRNA, or the antisense strand of an iRNA and a target sequence, *e.g.*, a VEGF-A nucleotide sequence, as defined herein.

5 Where the region of complementarity is not fully complementary to the target sequence, the mismatches can be in the internal or terminal regions of the antisense strand of the iRNA. Generally, the most tolerated mismatches are in the terminal regions, *e.g.*, within 5, 4, 3, or 2 nucleotides of the 5'- or 3'-terminus of the iRNA agent.

“Contacting,” as used herein, includes directly contacting a cell, as well as indirectly
10 contacting a cell. For example, a cell within a subject may be contacted when a composition comprising an iRNA is administered (*e.g.*, intraocularly, topically, or intravenously) to the subject.

“Introducing into a cell,” when referring to an iRNA, means facilitating or effecting uptake or absorption into the cell. Absorption or uptake of an iRNA can occur through unaided
15 diffusive or active cellular processes, or by auxiliary agents or devices. The meaning of this term is not limited to cells *in vitro*; an iRNA may also be “introduced into a cell,” wherein the cell is part of a living organism. In such an instance, introduction into the cell will include the delivery to the organism. For example, for *in vivo* delivery, iRNA can be injected into a tissue site or administered systemically. *In vivo* delivery can also be by a β -glucan delivery system, such as
20 those described in U.S. Patent Nos. 5,032,401 and 5,607,677, and U.S. Publication No. 2005/0281781, which are hereby incorporated by reference in their entirety. *In vitro* introduction into a cell includes methods known in the art such as electroporation and lipofection. Further approaches are described herein below or known in the art. As used herein, a “disorder related to VEGF-A expression,” a “disease related to VEGF-A expression,” a “pathological process
25 related to VEGF-A expression,” “a VEGF-A-associated disorder,” “a VEGF-A-associated disease,” or the like includes any condition, disorder, or disease in which VEGF-A expression is altered (*e.g.*, decreased or increased relative to a reference level, *e.g.*, a level characteristic of a non-diseased subject). In some embodiments, VEGF-A expression is decreased. In some
embodiments, VEGF-A expression is increased. In some embodiments, the decrease or increase
30 in VEGF-A expression is detectable in a tissue sample from the subject (*e.g.*, in an aqueous ocular fluid sample). The decrease or increase may be assessed relative the level observed in the

same individual prior to the development of the disorder or relative to other individual(s) who do not have the disorder. The decrease or increase may be limited to a particular organ, tissue, or region of the body (*e.g.*, the eye). VEGF-A-associated disorders include, but are not limited to, angiogenic ocular disorders.

5 The term “angiogenic ocular disorder,” as used herein, means any disease of the eye that is caused by or associated with the growth or proliferation of blood vessels or by blood vessel leakage. Non-limiting examples of angiogenic ocular disorders that are treatable using methods provided herein include age-related macular degeneration (*e.g.*, wet AMD, exudative AMD, etc.), retinal vein occlusion (RVO), central retinal vein occlusion (CRVO; *e.g.*, macular edema
10 following RVO (MEfRVO)), branch retinal vein occlusion (BRVO), retinopathy of prematurity (ROP), diabetic macular edema (DME), choroidal neovascularization (CNV; *e.g.*, myopic CNV), iris neovascularization, neovascular glaucoma, post-surgical fibrosis in glaucoma, proliferative retinopathy, proliferative vitreoretinopathy (PVR), optic disc neovascularization, corneal neovascularization, retinal neovascularization, vitreal neovascularization, pannus, pterygium,
15 vascular retinopathy, von Hippel-Lindau disease, histoplasmosis, and diabetic retinopathies.

 The term “double-stranded RNA,” “dsRNA,” or “siRNA” as used herein, refers to an iRNA that includes an RNA molecule or complex of molecules having a hybridized duplex region that comprises two anti-parallel and substantially complementary nucleic acid strands, which will be referred to as having “sense” and “antisense” orientations with respect to a target
20 RNA. The duplex region can be of any length that permits specific degradation of a desired target RNA, *e.g.*, through a RISC pathway, but will typically range from 9 to 36 base pairs in length, *e.g.*, 15-30 base pairs in length. Considering a duplex between 9 and 36 base pairs, the duplex can be any length in this range, for example, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, or 36 and any sub-range therein
25 between, including, but not limited to 15-30 base pairs, 15-26 base pairs, 15-23 base pairs, 15-22 base pairs, 15-21 base pairs, 15-20 base pairs, 15-19 base pairs, 15-18 base pairs, 15-17 base pairs, 18-30 base pairs, 18-26 base pairs, 18-23 base pairs, 18-22 base pairs, 18-21 base pairs, 18-20 base pairs, 19-30 base pairs, 19-26 base pairs, 19-23 base pairs, 19-22 base pairs, 19-21 base pairs, 19-20 base pairs, 20-30 base pairs, 20-26 base pairs, 20-25 base pairs, 20-24 base
30 pairs, 20-23 base pairs, 20-22 base pairs, 20-21 base pairs, 21-30 base pairs, 21-26 base pairs, 21-25 base pairs, 21-24 base pairs, 21-23 base pairs, or 21-22 base pairs. dsRNAs generated in

the cell by processing with Dicer and similar enzymes are generally in the range of 19-22 base pairs in length. One strand of the duplex region of a dsDNA comprises a sequence that is substantially complementary to a region of a target RNA. The two strands forming the duplex structure can be from a single RNA molecule having at least one self-complementary region, or
5 can be formed from two or more separate RNA molecules. Where the duplex region is formed from two strands of a single molecule, the molecule can have a duplex region separated by a single stranded chain of nucleotides (herein referred to as a "hairpin loop") between the 3'-end of one strand and the 5'-end of the respective other strand forming the duplex structure. The hairpin loop can comprise at least one unpaired nucleotide; in some embodiments the hairpin
10 loop can comprise at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 20, at least 23 or more unpaired nucleotides. Where the two substantially complementary strands of a dsRNA are comprised by separate RNA molecules, those molecules need not, but can be covalently connected. In some embodiments, the two strands are connected covalently by means other than a hairpin loop, and the connecting structure is a linker.

15 In some embodiments, the iRNA agent may be a "single-stranded siRNA" that is introduced into a cell or organism to inhibit a target mRNA. In some embodiments, single-stranded RNAi agents can bind to the RISC endonuclease Argonaute 2, which then cleaves the target mRNA. The single-stranded siRNAs are generally 15-30 nucleotides and are optionally chemically modified. The design and testing of single-stranded siRNAs are described in U.S.
20 Patent No. 8,101,348 and in Lima *et al.*, (2012) *Cell* 150: 883-894, the entire contents of each of which are hereby incorporated herein by reference. Any of the antisense nucleotide sequences described herein (*e.g.*, sequences provided in Tables 2A, 2B, 3A, 3B, 4A, 4B, 5A, 5B, 8A, 8B, 10A, 10B, 12, 13, 14, 18A or 18B) may be used as a single-stranded siRNA as described herein and optionally as chemically modified, *e.g.*, as described herein, *e.g.*, by the methods described
25 in Lima *et al.*, (2012) *Cell* 150:883-894.

In some embodiments, an RNA interference agent includes a single stranded RNA that interacts with a target RNA sequence to direct the cleavage of the target RNA. Without wishing to be bound by theory, long double stranded RNA introduced into cells is broken down into siRNA by a Type III endonuclease known as Dicer (Sharp *et al.*, *Genes Dev.* 2001, 15:485).
30 Dicer, a ribonuclease-III-like enzyme, processes the dsRNA into 19-23 base pair short interfering RNAs with characteristic two base 3' overhangs (Bernstein, *et al.*, (2001) *Nature* 409:363). The

siRNAs are then incorporated into an RNA-induced silencing complex (RISC) where one or more helicases unwind the siRNA duplex, enabling the complementary antisense strand to guide target recognition (Nykanen, *et al.*, (2001) *Cell* 107:309). Upon binding to the appropriate target mRNA, one or more endonucleases within the RISC cleaves the target to induce silencing
5 (Elbashir, *et al.*, (2001) *Genes Dev.* 15:188). Thus, in some embodiments, the disclosure relates to a single stranded RNA that promotes the formation of a RISC complex to effect silencing of the target gene.

“G,” “C,” “A,” “T” and “U” each generally stand for a nucleotide that contains guanine, cytosine, adenine, thymidine and uracil as a base, respectively. However, it will be understood
10 that the terms “deoxyribonucleotide,” “ribonucleotide,” or “nucleotide” can also refer to a modified nucleotide, as further detailed below, or a surrogate replacement moiety. The skilled person is well aware that guanine, cytosine, adenine, and uracil may be replaced by other moieties without substantially altering the base pairing properties of an oligonucleotide comprising a nucleotide bearing such replacement moiety. For example, without limitation, a
15 nucleotide comprising inosine as its base may base pair with nucleotides containing adenine, cytosine, or uracil. Hence, nucleotides containing uracil, guanine, or adenine may be replaced in the nucleotide sequences of dsRNA featured in the disclosure by a nucleotide containing, for example, inosine. In another example, adenine and cytosine anywhere in the oligonucleotide can be replaced with guanine and uracil, respectively to form G-U Wobble base pairing with the
20 target mRNA. Sequences containing such replacement moieties are suitable for the compositions and methods featured in the disclosure.

As used herein, the term “iRNA,” “RNAi,” “iRNA agent,” or “RNAi agent” or “RNAi molecule” refers to an agent that contains RNA as that term is defined herein, and which mediates the targeted cleavage of an RNA transcript, *e.g.*, via an RNA-induced silencing
25 complex (RISC) pathway. In some embodiments, an iRNA as described herein effects inhibition of VEGF-A expression, *e.g.*, in a cell or mammal. Inhibition of VEGF-A expression may be assessed based on a reduction in the level of VEGF-A mRNA or a reduction in the level of the VEGF-A protein.

The term “linker” or “linking group” means an organic moiety that connects two parts of
30 a compound, *e.g.*, covalently attaches two parts of a compound.

The term “lipophile” or “lipophilic moiety” broadly refers to any compound or chemical moiety having an affinity for lipids. One way to characterize the lipophilicity of the lipophilic moiety is by the octanol-water partition coefficient, $\log K_{ow}$, where K_{ow} is the ratio of a chemical's concentration in the octanol-phase to its concentration in the aqueous phase of a two-phase system at equilibrium. The octanol-water partition coefficient is a laboratory-measured property of a substance. However, it may also be predicted by using coefficients attributed to the structural components of a chemical which are calculated using first-principle or empirical methods (see, for example, Tetko et al., *J. Chem. Inf. Comput. Sci.* 41:1407-21 (2001), which is incorporated herein by reference in its entirety). It provides a thermodynamic measure of the tendency of the substance to prefer a non-aqueous or oily milieu rather than water (i.e. its hydrophilic/lipophilic balance). In principle, a chemical substance is lipophilic in character when its $\log K_{ow}$ exceeds 0. Typically, the lipophilic moiety possesses a $\log K_{ow}$ exceeding 1, exceeding 1.5, exceeding 2, exceeding 3, exceeding 4, exceeding 5, or exceeding 10. For instance, the $\log K_{ow}$ of 6-amino hexanol, for instance, is predicted to be approximately 0.7. Using the same method, the $\log K_{ow}$ of cholesteryl N-(hexan-6-ol) carbamate is predicted to be 10.7.

The lipophilicity of a molecule can change with respect to the functional group it carries. For instance, adding a hydroxyl group or amine group to the end of a lipophilic moiety can increase or decrease the partition coefficient (*e.g.*, $\log K_{ow}$) value of the lipophilic moiety.

Alternatively, the hydrophobicity of the double-stranded RNAi agent, conjugated to one or more lipophilic moieties, can be measured by its protein binding characteristics. For instance, in certain embodiments, the unbound fraction in the plasma protein binding assay of the double-stranded RNAi agent could be determined to positively correlate to the relative hydrophobicity of the double-stranded RNAi agent, which could then positively correlate to the silencing activity of the double-stranded RNAi agent.

In some embodiments, the plasma protein binding assay determined is an electrophoretic mobility shift assay (EMSA) using human serum albumin protein. An exemplary protocol of this binding assay is illustrated in detail in, *e.g.*, PCT/US2019/031170. The hydrophobicity of the double-stranded RNAi agent, measured by fraction of unbound siRNA in the binding assay, exceeds 0.15, exceeds 0.2, exceeds 0.25, exceeds 0.3, exceeds 0.35, exceeds 0.4, exceeds 0.45, or exceeds 0.5 for an enhanced *in vivo* delivery of siRNA.

Accordingly, conjugating the lipophilic moieties to the internal position(s) of the double-stranded RNAi agent provides optimal hydrophobicity for the enhanced *in vivo* delivery of siRNA.

The term “lipid nanoparticle” or “LNP” is a vesicle comprising a lipid layer encapsulating a pharmaceutically active molecule, such as a nucleic acid molecule, *e.g.*, a RNAi agent or a plasmid from which a RNAi agent is transcribed. LNPs are described in, for example, U.S. Patent Nos. 6,858,225, 6,815,432, 8,158,601, and 8,058,069, the entire contents of which are hereby incorporated herein by reference.

As used herein, the term “modulate the expression of,” refers to an at least partial “inhibition” or partial “activation” of a gene (*e.g.*, VEGF-A gene) expression in a cell treated with an iRNA composition as described herein compared to the expression of the corresponding gene in a control cell. A control cell includes an untreated cell, or a cell treated with a non-targeting control iRNA.

The skilled artisan will recognize that the term “RNA molecule” or “ribonucleic acid molecule” encompasses not only RNA molecules as expressed or found in nature, but also analogs and derivatives of RNA comprising one or more ribonucleotide/ribonucleoside analogs or derivatives as described herein or as known in the art. Strictly speaking, a “ribonucleoside” includes a nucleoside base and a ribose sugar, and a “ribonucleotide” is a ribonucleoside with one, two or three phosphate moieties or analogs thereof (*e.g.*, phosphorothioate). However, the terms “ribonucleoside” and “ribonucleotide” can be considered to be equivalent as used herein. The RNA can be modified in the nucleobase structure, in the ribose structure, or in the ribose-phosphate backbone structure, *e.g.*, as described herein below. However, the molecules comprising ribonucleoside analogs or derivatives must retain the ability to form a duplex. As non-limiting examples, an RNA molecule can also include at least one modified ribonucleoside including but not limited to a 2'-O-methyl modified nucleoside, a nucleoside comprising a 5' phosphorothioate group, a terminal nucleoside linked to a cholesteryl derivative or dodecanoic acid bisdecylamide group, a locked nucleoside, an abasic nucleoside, an acyclic nucleoside, a glycol nucleotide, a 2'-deoxy-2'-fluoro modified nucleoside, a 2'-amino-modified nucleoside, 2'-alkyl-modified nucleoside, morpholino nucleoside, a phosphoramidate or a non-natural base comprising nucleoside, or any combination thereof. Alternatively, or in combination, an RNA molecule can comprise at least two modified ribonucleosides, at least 3, at least 4, at least 5, at

least 6, at least 7, at least 8, at least 9, at least 10, at least 15, at least 20 or more, up to the entire length of the dsRNA molecule. The modifications need not be the same for each of such a plurality of modified ribonucleosides in an RNA molecule. In some embodiments, modified RNAs contemplated for use in methods and compositions described herein are peptide nucleic acids (PNAs) that have the ability to form the required duplex structure and that permit or
5 mediate the specific degradation of a target RNA, *e.g.*, via a RISC pathway. For clarity, it is understood that the term “iRNA” does not encompass a naturally occurring double stranded DNA molecule or a 100% deoxynucleoside-containing DNA molecule.

In some aspects, a modified ribonucleoside includes a deoxyribonucleoside. In such an
10 instance, an iRNA agent can comprise one or more deoxynucleosides, including, for example, a deoxynucleoside overhang(s), or one or more deoxynucleosides within the double stranded portion of a dsRNA. In certain embodiments, the RNA molecule comprises a percentage of deoxyribonucleosides of at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95% or higher (but not 100%) deoxyribonucleosides, *e.g.*, in one or both strands.

As used herein, the term “nucleotide overhang” refers to at least one unpaired nucleotide
15 that protrudes from the duplex structure of an iRNA, *e.g.*, a dsRNA. For example, when a 3’-end of one strand of a dsRNA extends beyond the 5’-end of the other strand, or vice versa, there is a nucleotide overhang. A dsRNA can comprise an overhang of at least one nucleotide; alternatively, the overhang can comprise at least two nucleotides, at least three nucleotides, at
20 least four nucleotides, or at least five nucleotides or more. A nucleotide overhang can comprise or consist of a nucleotide/nucleoside analog, including a deoxynucleotide/nucleoside. The overhang(s) may be on the sense strand, the antisense strand or any combination thereof. Furthermore, the nucleotide(s) of an overhang can be present on the 5’ end, 3’ end or both ends of either an antisense or sense strand of a dsRNA.

In some embodiments, the antisense strand of a dsRNA has a 1-10 nucleotide overhang at
25 the 3’ end and/or the 5’ end. In some embodiments, the sense strand of a dsRNA has a 1-10 nucleotide overhang at the 3’ end and/or the 5’ end. In some embodiments, one or more of the nucleotides in the overhang is replaced with a nucleoside thiophosphate.

As used herein, a “pharmaceutical composition” comprises a pharmacologically effective
30 amount of a therapeutic agent (*e.g.*, an iRNA) and a pharmaceutically acceptable carrier. As used herein, “pharmacologically effective amount,” “therapeutically effective amount” or simply

“effective amount” refers to that amount of an agent (*e.g.*, iRNA) effective to produce the intended pharmacological, therapeutic or preventive result. For example, in a method of treating a disorder related to VEGF-A expression (*e.g.*, an angiogenic ocular disorder), an effective amount includes an amount effective to reduce one or more symptoms associated with the disorder (*e.g.*, an amount effective to (a) inhibit angiogenesis; (b) inhibit or reduces the expression or activity of VEGF-A; (c) inhibit choroidal neovascularization; (d) inhibit growth of new blood vessels in the choriocapillaris; (e) reduce retinal thickness; (f) increase visual acuity; or (g) reduce intraocular inflammation) or an amount effective to reduce the risk of developing conditions associated with the disorder. For example, if a given clinical treatment is considered effective when there is at least a 10% reduction in a measurable parameter associated with a disease or disorder, a therapeutically effective amount of a drug for the treatment of that disease or disorder is the amount necessary to obtain at least a 10% reduction in that parameter. For example, a therapeutically effective amount of an iRNA targeting VEGF-A can reduce a level of VEGF-A mRNA or a level of VEGF-A protein by any measurable amount, *e.g.*, by at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%.

The term “pharmaceutically acceptable carrier” refers to a carrier for administration of a therapeutic agent. Such carriers include, but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof. The term specifically excludes cell culture medium. For drugs administered orally, pharmaceutically acceptable carriers include, but are not limited to pharmaceutically acceptable excipients such as inert diluents, disintegrating agents, binding agents, lubricating agents, sweetening agents, flavoring agents, coloring agents and preservatives. Suitable inert diluents include sodium and calcium carbonate, sodium and calcium phosphate, and lactose, while corn starch and alginic acid are suitable disintegrating agents. Binding agents may include starch and gelatin, while the lubricating agent, if present, will generally be magnesium stearate, stearic acid or talc. If desired, the tablets may be coated with a material such as glyceryl monostearate or glyceryl distearate, to delay absorption in the gastrointestinal tract. Agents included in drug formulations are described further herein below.

As used herein, the term “SNALP” refers to a stable nucleic acid-lipid particle. A SNALP represents a vesicle of lipids coating a reduced aqueous interior comprising a nucleic acid such as an iRNA or a plasmid from which an iRNA is transcribed. SNALPs are described,

e.g., in U.S. Patent Application Publication Nos. 2006/0240093, 2007/0135372, and in International Application No. WO 2009/082817. These applications are incorporated herein by reference in their entirety. In some embodiments, the SNALP is a SPLP. As used herein, the term “SPLP” refers to a nucleic acid-lipid particle comprising plasmid DNA encapsulated within
5 a lipid vesicle.

As used herein, the term “strand comprising a sequence” refers to an oligonucleotide comprising a chain of nucleotides that is described by the sequence referred to using the standard nucleotide nomenclature.

As used herein, a “subject” to be treated according to the methods described herein,
10 includes a human or non-human animal, *e.g.*, a mammal. The mammal may be, for example, a rodent (*e.g.*, a rat or mouse) or a primate (*e.g.*, a monkey). In some embodiments, the subject is a human.

A “subject in need thereof” includes a subject having, suspected of having, or at risk of developing a disorder related to VEGF-A expression, *e.g.*, overexpression (*e.g.*, an angiogenic
15 ocular disorder). In some embodiments, the subject has, or is suspected of having, a disorder related to VEGF-A expression or overexpression. In some embodiments, the subject is at risk of developing a disorder related to VEGF-A expression or overexpression.

As used herein, “target sequence” refers to a contiguous portion of the nucleotide sequence of an mRNA molecule formed during the transcription of a gene, *e.g.*, VEGF-A,
20 including mRNA that is a product of RNA processing of a primary transcription product. The target portion of the sequence will be at least long enough to serve as a substrate for iRNA-directed cleavage at or near that portion. For example, the target sequence will generally be from 9-36 nucleotides in length, *e.g.*, 15-30 nucleotides in length, including all sub-ranges therebetween. As non-limiting examples, the target sequence can be from 15-30 nucleotides, 15-
25 26 nucleotides, 15-23 nucleotides, 15-22 nucleotides, 15-21 nucleotides, 15-20 nucleotides, 15-19 nucleotides, 15-18 nucleotides, 15-17 nucleotides, 18-30 nucleotides, 18-26 nucleotides, 18-23 nucleotides, 18-22 nucleotides, 18-21 nucleotides, 18-20 nucleotides, 19-30 nucleotides, 19-26 nucleotides, 19-23 nucleotides, 19-22 nucleotides, 19-21 nucleotides, 19-20 nucleotides, 20-30 nucleotides, 20-26 nucleotides, 20-25 nucleotides, 20-24 nucleotides, 20-23 nucleotides, 20-
30 22 nucleotides, 20-21 nucleotides, 21-30 nucleotides, 21-26 nucleotides, 21-25 nucleotides, 21-24 nucleotides, 21-23 nucleotides, or 21-22 nucleotides.

As used herein, the phrases “therapeutically effective amount” and “prophylactically effective amount” and the like refer to an amount that provides a therapeutic benefit in the treatment, prevention, or management of any disorder or pathological process related to VEGF-A expression (*e.g.*, an angiogenic ocular disorder). The specific amount that is therapeutically effective may vary depending on factors known in the art, such as, for example, the type of disorder or pathological process, the patient’s history and age, the stage of the disorder or pathological process, and the administration of other therapies.

In the context of the present disclosure, the terms “treat,” “treatment,” and the like mean to prevent, delay, relieve or alleviate at least one symptom associated with a disorder related to VEGF-A expression, or to slow or reverse the progression or anticipated progression of such a disorder. For example, the methods featured herein, when employed to treat an angiogenic ocular disorder, may serve to reduce or prevent one or more symptoms of the angiogenic ocular disorder, as described herein, or to reduce the risk or severity of associated conditions. Thus, unless the context clearly indicates otherwise, the terms “treat,” “treatment,” and the like are intended to encompass prophylaxis, *e.g.*, prevention of disorders and/or symptoms of disorders related to VEGF-A expression. Treatment can also mean prolonging survival as compared to expected survival in the absence of treatment.

By “lower” in the context of a disease marker or symptom is meant any decrease, *e.g.*, a statistically or clinically significant decrease in such level. The decrease can be, for example, at least 10%, at least 20%, at least 30%, at least 40%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%. The decrease can be down to a level accepted as within the range of normal for an individual without such disorder.

As used herein, “VEGF-A” refers to “vascular endothelial growth factor A” the corresponding mRNA (“VEGF-A mRNA”), or the corresponding protein (“VEGF-A protein”). The sequence of a human VEGF-A mRNA transcript can be found at SEQ ID NO: 1.

II. iRNA Agents

Described herein are iRNA agents that modulate (*e.g.*, inhibit) the expression of VEGF-A.

In some embodiments, the iRNA agent activates the expression of VEGF-A in a cell or mammal.

In some embodiments, the iRNA agent includes double-stranded ribonucleic acid (dsRNA) molecules for inhibiting the expression of VEGF-A in a cell or in a subject (*e.g.*, in a mammal, *e.g.*, in a human), where the dsRNA includes an antisense strand having a region of complementarity which is complementary to at least a part of an mRNA formed in the expression of VEGF-A, and where the region of complementarity is 30 nucleotides or less in length, generally 19-24 nucleotides in length, and where the dsRNA, upon contact with a cell expressing VEGF-A, inhibits the expression of VEGF-A, *e.g.*, by at least 10%, 20%, 30%, 40%, or 50%.

The modulation (*e.g.*, inhibition) of expression of VEGF-A can be assayed by, for example, a PCR or branched DNA (bDNA)-based method, or by a protein-based method, such as by Western blot. Expression of VEGF-A in cell culture, such as in COS cells, ARPE-19 cells, hTERT RPE-1 cells, HeLa cells, primary hepatocytes, HepG2 cells, primary cultured cells or in a biological sample from a subject can be assayed by measuring VEGF-A mRNA levels, such as by bDNA or TaqMan assay, or by measuring protein levels, such as by immunofluorescence analysis, using, for example, Western Blotting or flow cytometric techniques.

A dsRNA typically includes two RNA strands that are sufficiently complementary to hybridize to form a duplex structure under conditions in which the dsRNA will be used. One strand of a dsRNA (the antisense strand) typically includes a region of complementarity that is substantially complementary, and generally fully complementary, to a target sequence, derived from the sequence of an mRNA formed during the expression of VEGF-A. The other strand (the sense strand) typically includes a region that is complementary to the antisense strand, such that the two strands hybridize and form a duplex structure when combined under suitable conditions. Generally, the duplex structure is between 15 and 30 inclusive, more generally between 18 and 25 inclusive, yet more generally between 19 and 24 inclusive, and most generally between 19 and 21 base pairs in length, inclusive. Similarly, the region of complementarity to the target sequence is between 15 and 30 inclusive, more generally between 18 and 25 inclusive, yet more generally between 19 and 24 inclusive, and most generally between 19 and 21 nucleotides in length, inclusive.

In some embodiments, the dsRNA is between 15 and 20 nucleotides in length, inclusive, and in other embodiments, the dsRNA is between 25 and 30 nucleotides in length, inclusive. As the ordinarily skilled person will recognize, the targeted region of an RNA targeted for cleavage

will most often be part of a larger RNA molecule, often an mRNA molecule. Where relevant, a “part” of an mRNA target is a contiguous sequence of an mRNA target of sufficient length to be a substrate for RNAi-directed cleavage (*i.e.*, cleavage through a RISC pathway). dsRNAs having duplexes as short as 9 base pairs can, under some circumstances, mediate RNAi-directed RNA cleavage. Most often a target will be at least 15 nucleotides in length, *e.g.*, 15-30 nucleotides in length.

One of skill in the art will also recognize that the duplex region is a primary functional portion of a dsRNA, *e.g.*, a duplex region of 9 to 36, *e.g.*, 15-30 base pairs. Thus, in some embodiments, to the extent that it becomes processed to a functional duplex of *e.g.*, 15-30 base pairs that targets a desired RNA for cleavage, an RNA molecule or complex of RNA molecules having a duplex region greater than 30 base pairs is a dsRNA. Thus, an ordinarily skilled artisan will recognize that in some embodiments, then, an miRNA is a dsRNA. In some embodiments, a dsRNA is not a naturally occurring miRNA. In some embodiments, an iRNA agent useful to target VEGF-A expression is not generated in the target cell by cleavage of a larger dsRNA.

A dsRNA as described herein may further include one or more single-stranded nucleotide overhangs. The dsRNA can be synthesized by standard methods known in the art as further discussed below, *e.g.*, by use of an automated DNA synthesizer, such as are commercially available from, for example, Biosearch, Applied Biosystems, Inc.

In some embodiments, VEGF-A is a human VEGF-A.

In specific embodiments, the dsRNA comprises a sense strand that comprises or consists of a sense sequence selected from the sense sequences provided in Tables 2A, 2B, 3A, 3B, 4A, 4B, 5A, 5B, 8A, 8B, 10A, 10B, 12, 13, 14, 18A or 18B and an antisense strand that comprises or consists of an antisense sequence selected from the antisense sequences provided in Tables 2A, 2B, 3A, 3B, 4A, 4B, 5A, 5B, 8A, 8B, 10A, 10B, 12, 13, 14, 18A or 18B.

In some aspects, a dsRNA will include at least sense and antisense nucleotide sequences, whereby the sense strand is selected from the sequences provided in Tables 2A, 2B, 3A, 3B, 4A, 4B, 5A, 5B, 8A, 8B, 10A, 10B, 12, 13, 14, 18A or 18B and the corresponding antisense strand is selected from the sequences provided in Tables 2A, 2B, 3A, 3B, 4A, 4B, 5A, 5B, 8A, 8B, 10A, 10B, 12, 13, 14, 18A or 18B.

In these aspects, one of the two sequences is complementary to the other of the two sequences, with one of the sequences being substantially complementary to a sequence of an

mRNA generated by the expression of VEGF-A. As such, a dsRNA will include two oligonucleotides, where one oligonucleotide is described as the sense strand, and the second oligonucleotide is described as the corresponding antisense strand. As described elsewhere herein and as known in the art, the complementary sequences of a dsRNA can also be contained
5 as self-complementary regions of a single nucleic acid molecule, as opposed to being on separate oligonucleotides.

The skilled person is well aware that dsRNAs having a duplex structure of between 20 and 23, but specifically 21, base pairs have been hailed as particularly effective in inducing RNA interference (Elbashir *et al.*, *EMBO* 2001, 20:6877-6888). However, others have found that
10 shorter or longer RNA duplex structures can be effective as well.

In the embodiments described above, by virtue of the nature of the oligonucleotide sequences provided in Tables 2A, 2B, 3A, 3B, 4A, 4B, 5A, 5B, 8A, 8B, 10A, 10B, 12, 13, 14, 18A and 18B, dsRNAs described herein can include at least one strand of a length of minimally 19 nucleotides. It can be reasonably expected that shorter duplexes having one of the sequences
15 of Tables 2A, 2B, 3A, 3B, 4A, 4B, 5A, 5B, 8A, 8B, 10A, 10B, 12, 13, 14, 18A and 18B minus only a few nucleotides on one or both ends will be similarly effective as compared to the dsRNAs described above.

In some embodiments, the dsRNA has a partial sequence of at least 15, 16, 17, 18, 19, 20, or more contiguous nucleotides from one of the sequences of Tables 2A, 2B, 3A, 3B, 4A, 4B,
20 5A, 5B, 8A, 8B, 10A, 10B, 12, 13, 14, 18A or 18B.

In some embodiments, the dsRNA has an antisense sequence that comprises at least 15, 16, 17, 18, or 19 contiguous nucleotides of an antisense sequence provided in Tables 2A, 2B, 3A, 3B, 4A, 4B, 5A, 5B, 8A, 8B, 10A, 10B, 12, 13, 14, 18A or 18B and a sense sequence that
25 comprises at least 15, 16, 17, 18, or 19 contiguous nucleotides of a corresponding sense sequence provided in Tables 2A, 2B, 3A, 3B, 4A, 4B, 5A, 5B, 8A, 8B, 10A, 10B, 12, 13, 14, 18A or 18B.

In some embodiments, the dsRNA comprises an antisense sequence that comprises at least 15, 16, 17, 18, 19, 20, 21, 22, or 23 contiguous nucleotides of an antisense sequence provided in Tables 2A, 2B, 3A, 3B, 4A, 4B, 5A, 5B, 8A, 8B, 10A, 10B, 12, 13, 14, 18A or 18B and a sense sequence that comprises at least 15, 16, 17, 18, 19, 20, or 21 contiguous nucleotides
30 of a corresponding sense sequence provided in Tables 2A, 2B, 3A, 3B, 4A, 4B, 5A, 5B, 8A, 8B, 10A, 10B, 12, 13, 14, 18A or 18B.

In some such embodiments, the dsRNA, although it comprises only a portion of the sequences provided in Tables 2A, 2B, 3A, 3B, 4A, 4B, 5A, 5B, 8A, 8B, 10A, 10B, 12, 13, 14, 18A or 18B is equally effective in inhibiting a level of VEGF-A expression as is a dsRNA that comprises the full-length sequences provided in Tables 2A, 2B, 3A, 3B, 4A, 4B, 5A, 5B, 8A, 8B, 10A, 10B, 12, 13, 14, 18A or 18B. In some embodiments, the dsRNA differs in its inhibition of a level of expression of VEGF-A by not more than 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50 % inhibition compared with a dsRNA comprising the full sequence disclosed herein.

The iRNAs of Tables 5A and 5B were designed based on rat VEGF-A sequence. Without wishing to be bound by theory, VEGF-A sequence is conserved sufficiently between species such that certain iRNAs designed based on a rodent sequence have activity against a primate VEGF-A. Working Example 2 herein gives evidence of iRNAs designed based on a rodent sequence having activity against cynomolgus monkey VEGF-A.

Consequently, in some embodiments, an iRNA of Table 5A or Table 5B decreases VEGF-A protein or VEGF-A mRNA levels in a cell. In some embodiments, the cell is a rodent cell (e.g., a rat cell), or a primate cell (e.g., a cynomolgus monkey cell or a human cell). In some embodiments, VEGF-A protein or VEGF-F mRNA levels are reduced by at least 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95%. In some embodiments, the iRNA of Table 5A or 5B that inhibits VEGF-A in a human cell has less than 5, 4, 3, 2, or 1 mismatches to the corresponding portion of human VEGF-A. In some embodiments, the iRNA of Table 5A or 5B that inhibits VEGF-A in a human cell has no mismatches to the corresponding portion of human VEGF-A.

iRNAs designed based on rodent sequences can have utility, e.g., for inhibiting VEGF-A in human cells, e.g., for therapeutic purposes, or for inhibiting VEGF-A in rodent cells, e.g., for research characterizing VEGF-A in a rodent model.

In some embodiments, an iRNA described herein comprises an antisense strand comprising at least 15 contiguous nucleotides, with 0, 1, 2, or 3 mismatches, of a portion of nucleotide sequence of SEQ ID NO: 2. In some embodiments, an iRNA described herein comprises a sense strand comprising at least 15 contiguous nucleotides, with 0, or 1, 2, or 3 mismatches, of the corresponding portion of the nucleotide sequence of SEQ ID NO: 1.

A human VEGF-A mRNA may have the sequence of SEQ ID NO: 1 provided herein.

Homo sapiens vascular endothelial growth factor A (VEGFA), transcript variant 1, mRNA

TCGCGGAGGCTTGGGGCAGCCGGGTAGCTCGGAGGTCGTGGCGCTGGGGGCTAGCACCAGCGCT
CTGTCTGGGAGGCGCAGCGGTAGGTGGACCGGTCAGCGGACTCACCGGCCAGGGCGCTCGGTGC
TGGAATTTGATATTCATTGATCCGGGTTTTATCCCTCTTCTTTTTTCTTAAACATTTTTTTTTTA
5 AAACGTGATTGTTTCTCGTTTTAATTTATTTTTTGCTTGCCATTCCCCACTTGAATCGGGCCGAC
GGCTTGGGGAGATTGCTCTACTTCCCCAAATCACTGTGGATTTTGGAACCAGCAGAAAGAGGA
AAGAGGTAGCAAGAGCTCCAGAGAGAAGTCGAGGAAGAGAGAGACGGGGTCAGAGAGAGCGCGC
GGGCGTGCGAGCAGCGAAAGCGACAGGGGCAAAGTGAGTGACCTGCTTTTGGGGGTGACCGCCG
GAGCGCGGCGTGAGCCCTCCCCCTTGGGATCCCGCAGCTGACCAGTCGCGCTGACGGACAGACA
10 GACAGACACCGCCCCCAGCCCCAGCTACCACCTCCTCCCCGGCCGGCGGCGGACAGTGGACGCG
GCGGCGAGCCGCGGGCAGGGGCCGAGCCCGCGCCCGGAGGCGGGGTGGAGGGGGTCGGGGCTC
GCGGCGTTCGCACTGAAACTTTTTCTGTTCAACTTCTGGGCTGTTCTCGCTTCGGAGGAGCCGTGGT
CCGCGCGGGGGAAGCCGAGCCGAGCGGAGCCGCGAGAAGTGCTAGCTCGGGCCGGGAGGAGCCG
CAGCCGGAGGAGGGGGAGGAGGAAGAAGAGAAGGAAGAGGAGAGGGGGCCGCACTGGCGACTCG
15 GCGCTCGGAAGCCGGGCTCATGGACGGGTGAGGCGGCGGTGTGCGCAGACAGTGCTCCAGCCGC
GCGCGCTCCCCAGGCCCTTGCCCCGGGCTCGGGCCGGGGAGGAAGAGTAGCTCGCCGAGGCGCC
GAGGAGAGCGGGCCGCCCCACAGCCCGAGCCGGAGAGGGAGCGCGAGCCGCGCCGGCCCCGGTC
GGGCTCCGAAACCATGAACTTTCTGCTGTCTTGGGTGCATTGGAGCCTTGCCCTGCTGCTCTA
CCTCCACCATGCCAAGTGGTCCCAGGCTGCACCCATGGCAGAAGGAGGAGGGCAGAATCATCAC
20 GAAGTGGTGAAGTTCATGGATGTCTATCAGCGCAGCTACTGCCATCCAATCGAGACCTGGTGG
ACATCTTCCAGGAGTACCCTGATGAGATCGAGTACATCTTCAAGCCATCCTGTGTGCCCTGAT
GCGATGCGGGGCTGCTGCAATGACGAGGGCCTGGAGTGTGTGCCCACTGAGGAGTCCAACATC
ACCATGCAGATTATGCGGATCAAACCTCACCAAGGCCAGCACATAGGAGAGATGAGCTTCCTAC
AGCACAACAAATGTGAATGCAGACCAAAGAAAGATAGAGCAAGACAAGAAAAAAATCAGTTTCG
25 AGGAAAGGGAAAGGGGCAAAAACGAAAGCGCAAGAAATCCCGGTATAAGTCTTGAGCGTGTAC
GTTGGTGCCCGCTGCTGTCTAATGCCCTGGAGCCTCCCTGGCCCCCATCCCTGTGGGCCTTGCT
CAGAGCGGAGAAAGCATTTGTTTGTACAAGATCCGCAGACGTGTAAATGTTCTGCAAAAACAC
AGACTCGCGTTGCAAGGCGAGGCAGCTTGAGTTAAACGAACGTACTTGCAATGTGACAAGCCG
AGGCGGTGAGCCGGGCAGGAGGAAGGAGCCTCCCTCAGGGTTTTCGGGAACCAGATCTCTACCA
30 GGAAAGACTGATACAGAACGATCGATACAGAAACCACGCTGCCGCCACCACACCATCACCATCG
ACAGAACAGTCCTTAATCCAGAAACCTGAAATGAAGGAAGAGGAGACTCTGCGCAGAGCACTTT
GGGTCCGGAGGGCGAGACTCCGGCGGAAGCATTCCCGGGCGGGTGACCCAGCACGGTCCCTCTT
GGAATTGGATTGCGCATTTTATTTTTCTTGCTGCTAAATCACCGAGCCCGGAAGATTAGAGAGT
TTTATTTCTGGGATTCTGTAGACACACCCACCCACATACATATATATATATATATTA
35 TATATATATAAAAATAAATATCTCTATTTTATATATATAAAATATATATATTCTTTTTTTAAAT
TAACAGTGCTAATGTTATTGGTGTCTTCACTGGATGTATTTGACTGCTGTGGACTTGAGTTGGG
AGGGGAATGTTCCCACTCAGATCCTGACAGGGAAGAGGAGAGATGAGAGACTCTGGCATGATC
TTTTTTTTTGTTCCCACTTGGTGGGGCCAGGGTCTCTCCCTGCCCAGGAATGTGCAAGGCCAGG
GCATGGGGGCAAATATGACCCAGTTTTGGGAACACCGACAAACCCAGCCCTGGCGCTGAGCCTC
40 TCTACCCCAGGTGAGACGGACAGAAAGACAGATCACAGGTACAGGGATGAGGACACCGGCTCTG
ACCAGGAGTTTGGGGAGCTTCAGGACATTGCTGTGCTTTGGGGATTCCCTCCACATGCTGCACG
CGCATCTCGCCCCCAGGGGCACTGCCTGGAAGATTAGGAGCCTGGGCGGCCTTCGCTTACTCT
CACCTGCTTCTGAGTTGCCAGGAGACCACTGGCAGATGTCCCGGCGAAGAGAAGAGACACATT
GTTGGAAGAAGCAGCCCATGACAGCTCCCTTTCCTGGGACTCGCCCTCATCCTCTTCCTGCTCC
45 CTTTCTGGGGTGAGCCTAAAAGGACCTATGTCTTCACACCATTGAAACCACTAGTTCTGTCC
CCCCAGGAGACCTGGTTGTGTGTGTGTGAGTGGTTGACCTTCTCCATCCCCTGGTCTTCCCT

TCCCTTCCCGAGGCACAGAGAGACAGGGCAGGATCCACGTGCCCATTTGTGGAGGCAGAGAAAAG
AGAAAGTGTTTTATATACGGTACTTATTTAATATCCCTTTTTAATTAGAAATTAAAACAGTTAA
TTTAATTAAAGAGTAGGGTTTTTTTTTCAGTATTCTTGGTTAATATTTAATTTCAACTATTTATG
AGATGTATCTTTTTGCTCTCTCTTGTCTCTCTTATTTGTACCGGTTTTTGTATATAAAATTCATGT
5 TTCCAATCTCTCTCTCCCTGATCGGTGACAGTCACTAGCTTATCTTGAACAGATATTTAATTTT
GCTAACACTCAGCTCTGCCCTCCCCGATCCCCTGGCTCCCCAGCACACATTCCCTTTGAAATAAG
GTTTCAATATACATCTACATACTATATATATATTTGGCAACTTGTATTTGTGTGTATATATATA
TATATATGTTTATGTATATATGTGATTCTGATAAAATAGACATTGCTATTCTGTTTTTTATATG
TAAAAACAAAACAAGAAAAAATAGAGAATTCTACATACTAAATCTCTCTCCTTTTTTAATTTTA
10 ATATTTGTTATCATTTATTTATTGGTGCTACTGTTTATCCGTAATAATTGTGGGGAAAAGATAT
TAACATCACGTCTTTGTCTCTAGTGCAGTTTTTCGAGATATTCCGTAGTACATATTTATTTTAA
ACAACGACAAAGAAATACAGATATATCTTAAAAAAGCATTTTGTATTAAAGAATTTA
ATTCTGATCTCAAAAAAAAAAAAAAAAAA (SEQ ID NO: 1)

15

The reverse complement of SEQ ID NO: 1 is provided as SEQ ID NO: 2 herein:

TTTTTTTTTTTTTTTTTTGAGATCAGAATTAAATCTTTAATACAAAATGCTTTTTTTTTTTTA
AGATATATCTGTATTTCTTTGTCGTTGTTTAAAAATAAATATGTACTACGGAATATCTCGAAAA
ACTGCACTAGAGACAAAGACGTGATGTTAATATCTTTTCCCCACAATTATTACGGATAAACAGT
20 AGCACCAATAAATAAATGATAACAAATATTTAAATTTAAAAAAGGAGAGAGATTTAGTATGTAGA
ATTCTCTATTTTTTTCTTGTTTTGTTTTTACATATAAAAAACAGAATAGCAATGTCTATTTTATC
AGAATCACATATATACATAAACATATATATATATATATACACACAAATACAAGTTGCCAAATAT
ATATATAGTATGTAGATGTATATTGAAACCTTATTTCAAAGGAATGTGTGCTGGGGAGCCAGGG
GATCGGGGAGGGCAGAGCTGAGTGTTAGCAAAATTAATATCTGTTCAAGATAAGCTAGTGACT
25 GTCACCGATCAGGGAGAGAGAGATTGGAACATGAATTTTATATACAAAACCGGTACAAATAA
GAGAGCAAGAGAGAGCAAAAGATACATCTCATAAATAGTTGAAATTAAATATTAACCAAGAATA
CTGAAAAAAAACCTACTCTTTAATTAATTAAGTGTTTTAAATTTCTAATTAAAAAGGGATATT
AAATAAGTACCGTATATAAAAACACTTTCTCTTTTCTCTGCCTCCACAATGGGCACGTGGATCCT
GCCCTGTCTCTCTGTGCCTCGGGAAGGGAAGGGAAGGACCAGGGGATGGAGGAAGGTCAACCAC
30 TCACACACACACAACCAGGTCTCCTGGGGGGACAGAACTAGTGGTTTCAATGGTGTGAGGACAT
AGGTCCTTTTAGGCTGCACCCCAAGGAGGAGCAGGAAGAGGATGAGGGCGAGTCCCAGGAAG
GGGAGCTGTGATGGGCTGCTTCTTCCAACAATGTGTCTCTTCTCTTCGCCGGGACATCTGCCAG
TGGTCTCCTGGGCAACTCAGAAGCAGGTGAGAGTAAGCGAAGGCCGCCAGGCTCCTGAATCTT
CCAGGCAGTGCCCCTGGGGGCGAGATGCGCGTGCAGCATGTGGAGGGAATCCCCAAAGCACAGC
35 AATGTCTTGAAGCTCCCCAACTCCTGGTCAGAGCCGGTGTCTCATCCCTGTACCTGTGATCT
GTCTTTCTGTCCGTCTGACCTGGGGTAGAGAGGCTCAGCGCCAGGGCTGGGTTTGTGCGGTGTTT
CCAAAACCTGGGTTCATATTTGCCCCCATGCCCTGGCCTTGACATTCCTGGGCAGGGGAGAGGAC
CCTGGCCCCACCAAGTGGGACAAAAAAGATCATGCCAGAGTCTCTCATCTCCTCCTCTTCCC
TGTCAGGATCTGAGTGGGAACATTCCCCTCCCAACTCAAGTCCACAGCAGTCAAATACATCCAG
40 TGAAGACACCAATAACATTAGCACTGTTAATTTAAAAAAGAATATATATATATATATATATA
AAATAGAGATATTTATTTTATATATATATAATATATATATATATAAATGTATGTATGTGGGTG
GGTGTGTCTACAGGAATCCCAGAAATAAACTCTCTAATCTTCCGGGCTCGGTGATTTAGCAGC
AAGAAAAATAAATGGCGAATCCAATTCCAAGAGGGACCGTGCTGGGTACCCGCCCGGGAATG
CTTCCGCCGGAGTCTCGCCCTCCGGACCCAAAGTGCTCTGCGCAGAGTCTCCTCTTCCCTTCAAT
45 TCAGGTTTCTGGATTAAGGACTGTTCTGTGATGGTGTGGTGGTGGCGGCAGCGTGGTTTC
TGTATCGATCGTTCTGTATCAGTCTTTCCTGGTGAGAGATCTGGTTCCCGAAACCCTGAGGGAG

GCTCCTTCCTCCTGCCCCGGCTCACCGCCTCGGCTTGTACATCTGCAAGTACGTTTCGTTTAACT
 CAAGCTGCCTCGCCTTGCAACGCGAGTCTGTGTTTTTGCAGGAACATTTACACGTCTGCGGATC
 TTGTACAAACAAATGCTTTCTCCGCTCTGAGCAAGGCCACAGGGATGGGGGCCAGGGAGGCTC
 CAGGGCATTAGACAGCAGCGGGCACCAACGTACACGCTCCAGGACTTATACCGGGATTTCCTTGC
 5 GCTTTTCGTTTTTGGCCCTTTCCCTTTCCTCGAAGTGAATTTTTTTCTTGTCTTGCTCTATCTTT
 CTTTGGTCTGCATTACATTTGTTGTGCTGTAGGAAGCTCATCTCTCCTATGTGCTGGCCTTGG
 TGAGGTTTGATCCGCATAATCTGCATGGTGATGTTGGACTCCTCAGTGGGCACACACTCCAGGC
 CCTCGTCATTGCAGCAGCCCCCGCATCGCATCAGGGGCACACAGGATGGCTTGAAGATGTACTC
 GATCTCATCAGGGTACTCCTGGAAGATGTCCACCAGGGTCTCGATTGGATGGCAGTAGCTGCGC
 10 TGATAGACATCCATGAAGTTACCACTTCGTGATGATTCTGCCCTCCTCCTTCTGCCATGGGTG
 CAGCCTGGGACCACTTGGCATGGTGGAGGTAGAGCAGCAAGGCAAGGCTCCAATGCACCCAAGA
 CAGCAGAAAGTTCATGGTTTTCGGAGGCCCGACCGGGGCCGGCGGGCTCGCGCTCCCTCTCCGG
 CTCGGGCTGTGGGGCGGCCCGCTCTCCTCGGCGCCTCGGCGAGCTACTCTTCCTCCCCGGCCCCG
 AGGCCCGGGCCAGGGCCTGGGGAGCGCGCGGGCTGGAGCACTGTCTGCGCACACCGCCGCCTC
 15 ACCCGTCCATGAGCCCGGCTTCCGAGCGCCGAGTCGCCACTGCGGCCCCCTCTCCTCTTCCTTC
 TCTTCTTCCTCCTCCCCCTCCTCCGGCTGCGGCTCCTCCCGGCCCGAGCTAGCACTTCTCGCGG
 CTCCGCTCGGCTCGGCTTCCCCCGCGCGGACCACGGCTCCTCCGAAGCGAGAACAGCCAGAAAG
 TTGGACGAAAAGTTTCAGTGCGACGCCGCGAGCCCCGACCCCCCTCCACCCCGCCTCCGGGCGCG
 GGCTCCGGCCCCCTGCCCGCGGCTCGCCGCGCGTCCACTGTCCGCCGCCGGCCGGGGAGGAGGT
 20 GGTAGCTGGGGCTGGGGGCGGTGTCTGTCTGTCTGTCCGTCAGCGCGACTGGTCAGCTGCGGGA
 TCCCAAGGGGGAGGGCTCACGCCGCGCTCCGGCGGTACCCCCAAAAGCAGGTCACTCACTTTG
 CCCCTGTGCTTTTCGCTGCTCGCACGCCGCGCGTCTCTCTGACCCCGTCTCTCTCTTCCTCG
 ACTTCTCTCTGGAGCTCTTGCTACCTCTTTCTCTTTCTGCTGGTTTTCCAAAATCCACAGTGAT
 TTGGGGAAGTAGAGCAATCTCCCCAAGCCGTCGGCCCGATTCAAGTGGGGAATGGCAAGCAAAA
 25 ATAAATTAAAACGAGAAACAATACAGTTTTTAAAAAAAATGTTTAAGAAAAAGAAGAGGGATA
 AAACCCGGATCAATGAATATCAAATTCAGCACCGAGCGCCCTGGCCGGTGAGTCCGCTGACCG
 GTCCACCTAACCGCTGCGCCTCCCGACAGAGCGCTGGTGCTAGCCCCCAGCGCCACGACCTCCG
 AGCTACCCGGCTGCCCCAAGCCTCCGCGA (SEQ ID NO: 2)

30 In some embodiments, an iRNA described herein includes at least 15 contiguous
 nucleotides from one of the sequences provided in Tables 2A, 2B, 3A, 3B, 4A, 4B, 5A, 5B, 8A,
 8B, 10A, 10B, 12, 13, 14, 18A and 18B, and may optionally be coupled to additional nucleotide
 sequences taken from the region contiguous to the selected sequence in VEGF-A.

While a target sequence is generally 15-30 nucleotides in length, there is wide variation
 35 in the suitability of particular sequences in this range for directing cleavage of any given target
 RNA. Various software packages and the guidelines set out herein provide guidance for the
 identification of optimal target sequences for any given gene target, but an empirical approach
 can also be taken in which a “window” or “mask” of a given size (as a non-limiting example, 21
 nucleotides) is literally or figuratively (including, *e.g.*, in silico) placed on the target RNA
 40 sequence to identify sequences in the size range that may serve as target sequences. By moving

the sequence “window” progressively one nucleotide upstream or downstream of an initial target sequence location, the next potential target sequence can be identified, until the complete set of possible sequences is identified for any given target size selected. This process, coupled with systematic synthesis and testing of the identified sequences (using assays described herein or known in the art) to identify those sequences that perform optimally can identify those RNA sequences that, when targeted with an iRNA agent, mediate the best inhibition of target gene expression. Thus, it is contemplated that further optimization of inhibition efficiency can be achieved by progressively “walking the window” one nucleotide upstream or downstream of the given sequences to identify sequences with equal or better inhibition characteristics.

Further, it is contemplated that for any sequence identified, *e.g.*, in Tables 2A, 2B, 3A, 3B, 4A, 4B, 5A, 5B, 8A, 8B, 10A, 10B, 12, 13, 14, 18A and 18B, further optimization can be achieved by systematically either adding or removing nucleotides to generate longer or shorter sequences and testing those and sequences generated by walking a window of the longer or shorter size up or down the target RNA from that point. Again, coupling this approach to generating new candidate targets with testing for effectiveness of iRNAs based on those target sequences in an inhibition assay as known in the art or as described herein can lead to further improvements in the efficiency of inhibition. Further still, such optimized sequences can be adjusted by, *e.g.*, the introduction of modified nucleotides as described herein or as known in the art, addition or changes in overhang, or other modifications as known in the art and/or discussed herein to further optimize the molecule (*e.g.*, increasing serum stability or circulating half-life, increasing thermal stability, enhancing transmembrane delivery, targeting to a particular location or cell type, increasing interaction with silencing pathway enzymes, increasing release from endosomes, *etc.*) as an expression inhibitor.

In some embodiments, the disclosure provides an iRNA of any of Tables 2B, 3B, 4B, 5B, 8B, 10B, 14, or 18B that un-modified or un-conjugated. In some embodiments, an RNAi agent of the disclosure has a nucleotide sequence as provided in any of Tables 2A, 3A, 4A, 5A, 8A, 10A, 12, 13 14, and 18A but lacks one or more ligand or moiety shown in the table. A ligand or moiety (*e.g.*, a lipophilic ligand or moiety) can be included in any of the positions provided in the instant application.

An iRNA as described herein can contain one or more mismatches to the target sequence. In some embodiments, an iRNA as described herein contains no more than 3 mismatches. In

some embodiments, when the antisense strand of the iRNA contains mismatches to a target sequence, the area of mismatch is not located in the center of the region of complementarity. In some embodiments, when the antisense strand of the iRNA contains mismatches to the target sequence, the mismatch is restricted to be within the last 5 nucleotides from either the 5' or 3' end of the region of complementarity. For example, for a 23 nucleotide iRNA agent RNA strand which is complementary to a region of VEGF-A, the RNA strand generally does not contain any mismatch within the central 13 nucleotides. The methods described herein, or methods known in the art can be used to determine whether an iRNA containing a mismatch to a target sequence is effective in inhibiting the expression of VEGF-A. Consideration of the efficacy of iRNAs with mismatches in inhibiting expression of VEGF-A is important, especially if the particular region of complementarity in a VEGF-A gene is known to have polymorphic sequence variation within the population.

In some embodiments, at least one end of a dsRNA has a single-stranded nucleotide overhang of 1 to 4, generally 1 or 2 nucleotides. In some embodiments, dsRNAs having at least one nucleotide overhang have superior inhibitory properties relative to their blunt-ended counterparts. In some embodiments, the RNA of an iRNA (*e.g.*, a dsRNA) is chemically modified to enhance stability or other beneficial characteristics. The nucleic acids featured in the disclosure may be synthesized and/or modified by methods well established in the art, such as those described in "Current protocols in nucleic acid chemistry," Beaucage, S.L. *et al.* (Edrs.), John Wiley & Sons, Inc., New York, NY, USA, which is hereby incorporated herein by reference. Modifications include, for example, (a) end modifications, *e.g.*, 5' end modifications (phosphorylation, conjugation, inverted linkages, *etc.*) 3' end modifications (conjugation, DNA nucleotides, inverted linkages, *etc.*), (b) base modifications, *e.g.*, replacement with stabilizing bases, destabilizing bases, or bases that base pair with an expanded repertoire of partners, removal of bases (abasic nucleotides), or conjugated bases, (c) sugar modifications (*e.g.*, at the 2' position or 4' position, or having an acyclic sugar) or replacement of the sugar, as well as (d) backbone modifications, including modification or replacement of the phosphodiester linkages. Specific examples of RNA compounds useful in this disclosure include, but are not limited to, RNAs containing modified backbones or no natural internucleoside linkages. RNAs having modified backbones include, among others, those that do not have a phosphorus atom in the backbone. For the purposes of this specification, and as sometimes referenced in the art,

modified RNAs that do not have a phosphorus atom in their internucleoside backbone can also be considered to be oligonucleosides. In particular embodiments, the modified RNA will have a phosphorus atom in its internucleoside backbone.

Modified RNA backbones include, for example, phosphorothioates, chiral
5 phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates including 3'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3'-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having normal 3'-5' linkages, 2'-5' linked
10 analogs of these, and those) having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3'-5' to 5'-3' or 2'-5' to 5'-2'. Various salts, mixed salts and free acid forms are also included.

Representative U.S. patents that teach the preparation of the above phosphorus-containing linkages include, but are not limited to, U.S. Pat. Nos. 3,687,808; 4,469,863;
15 4,476,301; 5,023,243; 5,177,195; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,316; 5,550,111; 5,563,253; 5,571,799; 5,587,361; 5,625,050; 6,028,188; 6,124,445; 6,160,109; 6,169,170; 6,172,209; 6, 239,265; 6,277,603; 6,326,199; 6,346,614; 6,444,423; 6,531,590; 6,534,639; 6,608,035; 6,683,167; 6,858,715; 6,867,294; 6,878,805;
20 7,015,315; 7,041,816; 7,273,933; 7,321,029; and US Pat RE39464, each of which is herein incorporated by reference.

Modified RNA backbones that do not include a phosphorus atom therein have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatoms and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or
25 heterocyclic internucleoside linkages. These include those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones;
30 and others having mixed N, O, S and CH₂ component parts.

Representative U.S. patents that teach the preparation of the above oligonucleosides include, but are not limited to, U.S. Pat. Nos. 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,64,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312; 5,633,360; 5,677,437; and, 5,677,439, each of which is herein incorporated by reference.

In other RNA mimetics suitable or contemplated for use in iRNAs, both the sugar and the internucleoside linkage, *i.e.*, the backbone, of the nucleotide units are replaced with novel groups. The base units are maintained for hybridization with an appropriate nucleic acid target compound. One such oligomeric compound, an RNA mimetic that has been shown to have excellent hybridization properties, is referred to as a peptide nucleic acid (PNA). In PNA compounds, the sugar backbone of an RNA is replaced with an amide containing backbone, in particular an aminoethylglycine backbone. The nucleobases are retained and are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone. Representative U.S. patents that teach the preparation of PNA compounds include, but are not limited to, U.S. Pat. Nos. 5,539,082; 5,714,331; and 5,719,262, each of which is herein incorporated by reference. Further teaching of PNA compounds can be found, for example, in Nielsen *et al.*, Science, 1991, 254, 1497-1500.

Some embodiments featured in the disclosure include RNAs with phosphorothioate backbones and oligonucleosides with heteroatom backbones, and in particular --CH₂--NH--CH₂--, --CH₂--N(CH₃)--O--CH₂--[known as a methylene (methylimino) or MMI backbone], --CH₂--O--N(CH₃)--CH₂--, --CH₂--N(CH₃)--N(CH₃)--CH₂-- and --N(CH₃)--CH₂--CH₂--[wherein the native phosphodiester backbone is represented as --O--P--O--CH₂--] of the above-referenced U.S. Pat. No. 5,489,677, and the amide backbones of the above-referenced U.S. Pat. No. 5,602,240. In some embodiments, the RNAs featured herein have morpholino backbone structures of the above-referenced U.S. Pat. No. 5,034,506.

Modified RNAs may also contain one or more substituted sugar moieties. The iRNAs, *e.g.*, dsRNAs, featured herein can include one of the following at the 2' position: OH; F; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S- or N-alkynyl; or O-alkyl-O-alkyl, wherein the alkyl, alkenyl and alkynyl may be substituted or unsubstituted C₁ to C₁₀ alkyl or C₂ to C₁₀ alkenyl and alkynyl. Exemplary suitable modifications include O[(CH₂)_nO]_mCH₃, O(CH₂)_nOCH₃,


$O(CH_2)_nNH_2$, $O(CH_2)_nCH_3$, $O(CH_2)_nONH_2$, and $O(CH_2)_nON[(CH_2)_nCH_3]_2$, where n and m are from 1 to about 10. In other embodiments, dsRNAs include one of the following at the 2' position: C_1 to C_{10} lower alkyl, substituted lower alkyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH₃, OCN, Cl, Br, CN, CF₃, OCF₃, SOCH₃, SO₂CH₃, ONO₂, NO₂, N₃, NH₂,

heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of an iRNA, or a group for improving the pharmacodynamic properties of an iRNA, and other substituents having similar properties. In some embodiments, the modification includes a 2'-methoxyethoxy (2'-O--CH₂CH₂OCH₃, also known as 2'-O-(2-methoxyethyl) or 2'-MOE) (Martin *et al.*, *Helv. Chim. Acta*, 1995, 78:486-504) *i.e.*, an alkoxy-alkoxy group. Another exemplary modification is 2'-dimethylaminoethoxyethoxy, *i.e.*, a $O(CH_2)_2ON(CH_3)_2$ group, also known as 2'-DMAOE, and 2'-dimethylaminoethoxyethoxy (also known in the art as 2'-O-dimethylaminoethoxyethyl or 2'-DMAEOE), *i.e.*, 2'-O--CH₂--O--CH₂--N(CH₂)₂.

In other embodiments, an iRNA agent comprises one or more (*e.g.*, about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) acyclic nucleotides (or nucleosides). In certain embodiments, the sense strand or the antisense strand, or both sense strand and antisense strand, include less than five acyclic nucleotides per strand (*e.g.*, four, three, two or one acyclic nucleotides per strand). The one or more acyclic nucleotides can be found, for example, in the double-stranded region, of the sense or antisense strand, or both strands; at the 5'-end, the 3'-end, both of the 5' and 3'-ends of the sense or antisense strand, or both strands, of the iRNA agent. In some embodiments, one or more acyclic nucleotides are present at positions 1 to 8 of the sense or antisense strand, or both. In some embodiments, one or more acyclic nucleotides are found in the antisense strand at positions 4 to 10 (*e.g.*, positions 6-8) from the 5'-end of the antisense strand. In some embodiments, the one or more acyclic nucleotides are found at one or both 3'-terminal overhangs of the iRNA agent.

The term "acyclic nucleotide" or "acyclic nucleoside" as used herein refers to any nucleotide or nucleoside having an acyclic sugar, *e.g.*, an acyclic ribose. An exemplary acyclic nucleotide or nucleoside can include a nucleobase, *e.g.*, a naturally occurring or a modified nucleobase (*e.g.*, a nucleobase as described herein). In certain embodiments, a bond between any of the ribose carbons (C1, C2, C3, C4, or C5), is independently or in combination absent

from the nucleotide. In some embodiments, the bond between C2-C3 carbons of the ribose ring is absent, *e.g.*, an acyclic 2'-3'-seco-nucleotide monomer. In other embodiments, the bond between C1-C2, C3-C4, or C4-C5 is absent (*e.g.*, a 1'-2', 3'-4' or 4'-5'-seco nucleotide monomer). Exemplary acyclic nucleotides are disclosed in US 8,314,227, incorporated herein by reference in its entirety. For example, an acyclic nucleotide can include any of monomers D-J in Figures 1-2 of US 8,314,227. In some embodiments, the acyclic nucleotide includes the following monomer:



wherein Base is a nucleobase, *e.g.*, a naturally occurring or a modified nucleobase (*e.g.*, a nucleobase as described herein).

In certain embodiments, the acyclic nucleotide can be modified or derivatized, *e.g.*, by coupling the acyclic nucleotide to another moiety, *e.g.*, a ligand (*e.g.*, a GalNAc, a cholesterol ligand), an alkyl, a polyamine, a sugar, a polypeptide, among others.

In other embodiments, the iRNA agent includes one or more acyclic nucleotides and one or more LNAs (*e.g.*, an LNA as described herein). For example, one or more acyclic nucleotides and/or one or more LNAs can be present in the sense strand, the antisense strand, or both. The number of acyclic nucleotides in one strand can be the same or different from the number of LNAs in the opposing strand. In certain embodiments, the sense strand and/or the antisense strand comprises less than five LNAs (*e.g.*, four, three, two or one LNAs) located in the double stranded region or a 3'-overhang. In other embodiments, one or two LNAs are located in the double stranded region or the 3'-overhang of the sense strand. Alternatively, or in combination, the sense strand and/or antisense strand comprises less than five acyclic nucleotides (*e.g.*, four, three, two or one acyclic nucleotides) in the double-stranded region or a 3'-overhang. In some embodiments, the sense strand of the iRNA agent comprises one or two LNAs in the 3'-overhang of the sense strand, and one or two acyclic nucleotides in the double-stranded region of the antisense strand (*e.g.*, at positions 4 to 10 (*e.g.*, positions 6-8) from the 5'-end of the antisense strand) of the iRNA agent.

In other embodiments, inclusion of one or more acyclic nucleotides (alone or in addition to one or more LNAs) in the iRNA agent results in one or more (or all) of: (i) a reduction in an off-target effect; (ii) a reduction in passenger strand participation in RNAi; (iii) an increase in specificity of the guide strand for its target mRNA; (iv) a reduction in a microRNA off-target effect; (v) an increase in stability; or (vi) an increase in resistance to degradation, of the iRNA molecule.

Other modifications include 2'-methoxy (2'-OCH₃), 2'-5 aminopropoxy (2'-OCH₂CH₂CH₂NH₂) and 2'-fluoro (2'-F). Similar modifications may also be made at other positions on the RNA of an iRNA, particularly the 3' position of the sugar on the 3' terminal nucleotide or in 2'-5' linked dsRNAs and the 5' position of 5' terminal nucleotide. iRNAs may also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar. Representative U.S. patents that teach the preparation of such modified sugar structures include, but are not limited to, U.S. Pat. Nos. 4,981,957; 5,118,800; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786; 5,514,785; 5,519,134; 5,567,811; 5,576,427; 5,591,722; 5,597,909; 5,610,300; 5,627,053; 5,639,873; 5,646,265; 5,658,873; 5,670,633; and 5,700,920, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference.

An iRNA may also include nucleobase (often referred to in the art simply as "base") modifications or substitutions. As used herein, "unmodified" or "natural" nucleobases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U). Modified nucleobases include other synthetic and natural nucleobases such as 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo, particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-daazaadenine and 3-deazaguanine and 3-deazaadenine.

Further nucleobases include those disclosed in U.S. Pat. No. 3,687,808, those disclosed in Modified Nucleosides in Biochemistry, Biotechnology and Medicine, Herdewijn, P. ed. Wiley-

VCH, 2008; those disclosed in The Concise Encyclopedia of Polymer Science and Engineering, pages 858-859, Kroschwitz, J. L, ed. John Wiley & Sons, 1990, these disclosed by Englisch *et al.*, *Angewandte Chemie*, International Edition, 1991, 30, 613, and those disclosed by Sanghvi, Y S., Chapter 15, *dsRNA Research and Applications*, pages 289-302, Crooke, S. T. and Lebleu, B.,
5 Ed., CRC Press, 1993. Certain of these nucleobases are particularly useful for increasing the binding affinity of the oligomeric compounds featured in the disclosure. These include 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and O-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine. 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2°C (Sanghvi, Y. S., Crooke, S. T. and Lebleu, B., Eds., *dsRNA Research and Applications*, CRC Press, Boca Raton, 1993,
10 pp. 276-278) and are exemplary base substitutions, even more particularly when combined with 2'-O-methoxyethyl sugar modifications.

Representative U.S. patents that teach the preparation of certain of the above noted modified nucleobases as well as other modified nucleobases include, but are not limited to, the
15 above noted U.S. Pat. No. 3,687,808, as well as U.S. Pat. Nos. 4,845,205; 5,130,30; 5,134,066; 5,175,273; 5,367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908; 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,594,121, 5,596,091; 5,614,617; 5,681,941; 6,015,886; 6,147,200; 6,166,197; 6,222,025; 6,235,887; 6,380,368; 6,528,640; 6,639,062; 6,617,438; 7,045,610; 7,427,672; and 7,495,088, each of which is herein incorporated by reference, and U.S. Pat. No.
20 5,750,692, also herein incorporated by reference.

The RNA of an iRNA can also be modified to include one or more (*e.g.*, about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) bicyclic sugar moieties. A “bicyclic sugar” is a furanosyl ring modified by the bridging of two atoms. A “bicyclic nucleoside” (“BNA”) is a nucleoside having a sugar moiety comprising a bridge connecting two carbon atoms of the sugar ring, thereby forming a
25 bicyclic ring system. In certain embodiments, the bridge connects the 4'-carbon and the 2'-carbon of the sugar ring. Thus, in some embodiments an agent of the disclosure may include one or more locked nucleic acids (LNAs) (also referred to herein as “locked nucleotides”). In some embodiments, a locked nucleic acid is a nucleotide having a modified ribose moiety in which the ribose moiety comprises an extra bridge connecting, *e.g.*, the 2' and 4' carbons. This structure
30 effectively “locks” the ribose in the 3'-endo structural conformation. The addition of locked nucleic acids to siRNAs has been shown to increase siRNA stability in serum, increase thermal

stability, and to reduce off-target effects (Elmen, J. *et al.*, (2005) *Nucleic Acids Research* 33(1):439-447; Mook, OR. *et al.*, (2007) *Mol Canc Ther* 6(3):833-843; Grunweller, A. *et al.*, (2003) *Nucleic Acids Research* 31(12):3185-3193).

Examples of bicyclic nucleosides for use in the polynucleotides of the disclosure include without limitation nucleosides comprising a bridge between the 4' and the 2' ribosyl ring atoms. In certain embodiments, the antisense polynucleotide agents of the disclosure include one or more bicyclic nucleosides comprising a 4' to 2' bridge. Examples of such 4' to 2' bridged bicyclic nucleosides, include but are not limited to 4'-(CH₂)—O-2' (LNA); 4'-(CH₂)—S-2'; 4'-(CH₂)₂—O-2' (ENA); 4'-CH(CH₃)—O-2' (also referred to as "constrained ethyl" or "cEt") and 4'-CH(CH₂OCH₃)—O-2' (and analogs thereof; see, *e.g.*, U.S. Pat. No. 7,399,845); 4'-C(CH₃)(CH₃)—O-2' (and analogs thereof; see *e.g.*, US Patent No. 8,278,283); 4'-CH₂—N(OCH₃)-2' (and analogs thereof; see *e.g.*, US Patent No. 8,278,425); 4'-CH₂—O—N(CH₃)-2' (see, *e.g.*, U.S. Patent Publication No. 2004/0171570); 4'-CH₂—N(R)—O-2', wherein R is H, C1-C12 alkyl, or a protecting group (see, *e.g.*, U.S. Pat. No. 7,427,672); 4'-CH₂—C(H)(CH₃)-2' (see, *e.g.*, Chattopadhyaya *et al.*, *J. Org. Chem.*, 2009, 74, 118-134); and 4'-CH₂—C(=CH₂)-2' (and analogs thereof; see, *e.g.*, US Patent No. 8,278,426). The contents of each of the foregoing are incorporated herein by reference for the methods provided therein. Representative U.S. Patents that teach the preparation of locked nucleic acids include, but are not limited to, the following: U.S. Pat. Nos. 6,268,490; 6,670,461; 6,794,499; 6,998,484; 7,053,207; 7,084,125; 7,399,845, and 8,314,227, each of which is herein incorporated by reference in its entirety. Exemplary LNAs include but are not limited to, a 2', 4'-C methylene bicyclo nucleotide (see for example Wengel *et al.*, International PCT 5 Publication No. WO 00/66604 and WO 99/14226).

Any of the foregoing bicyclic nucleosides can be prepared having one or more stereochemical sugar configurations including for example α -L-ribofuranose and β -D-ribofuranose (see WO 99/14226).

A RNAi agent of the disclosure can also be modified to include one or more constrained ethyl nucleotides. As used herein, a "constrained ethyl nucleotide" or "cEt" is a locked nucleic acid comprising a bicyclic sugar moiety comprising a 4'-CH(CH₃)-O-2' bridge. In some embodiments, a constrained ethyl nucleotide is in the S conformation referred to herein as "S-cEt."

A RNAi agent of the disclosure may also include one or more “conformationally restricted nucleotides” (“CRN”). CRN are nucleotide analogs with a linker connecting the C2’ and C4’ carbons of ribose or the C3 and -C5’ carbons of ribose. CRN lock the ribose ring into a stable conformation and increase the hybridization affinity to mRNA. The linker is of sufficient length to place the oxygen in an optimal position for stability and affinity resulting in less ribose ring puckering.

Representative publications that teach the preparation of certain of the above noted CRN include, but are not limited to, US 2013/0190383; and WO 2013/036868, the contents of each of which are hereby incorporated herein by reference for the methods provided therein.

In some embodiments, a RNAi agent of the disclosure comprises one or more monomers that are UNA (unlocked nucleic acid) nucleotides. UNA is unlocked acyclic nucleic acid, wherein any of the bonds of the sugar has been removed, forming an unlocked “sugar” residue. In one example, UNA also encompasses monomer with bonds between C1’-C4’ have been removed (i.e. the covalent carbon-oxygen-carbon bond between the C1’ and C4’ carbons). In another example, the C2’-C3’ bond (i.e. the covalent carbon-carbon bond between the C2’ and C3’ carbons) of the sugar has been removed (see *Nuc. Acids Symp. Series*, 52, 133-134 (2008) and Fluiter et al., *Mol. Biosyst.*, 2009, 10, 1039).

Representative U.S. publications that teach the preparation of UNA include, but are not limited to, US8,314,227; and US Patent Publication Nos. 2013/0096289; 2013/0011922; and 2011/0313020, the contents of each of which are hereby incorporated herein by reference for the methods provided therein.

In other embodiments, the iRNA agents include one or more (*e.g.*, about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) G-clamp nucleotides. A G-clamp nucleotide is a modified cytosine analog wherein the modifications confer the ability to hydrogen bond both Watson-Crick and Hoogsteen faces of a complementary guanine within a duplex, see for example Lin and Matteucci, 1998, *J. Am. Chem. Soc.*, 120, 8531-8532. A single G-clamp analog substitution within an oligonucleotide can result in substantially enhanced helical thermal stability and mismatch discrimination when hybridized to complementary oligonucleotides. The inclusion of such nucleotides in the iRNA molecules can result in enhanced affinity and specificity to nucleic acid targets, complementary sequences, or template strands.

Potentially stabilizing modifications to the ends of RNA molecules can include N-(acetylaminocaproyl)-4-hydroxyprolinol (Hyp-C6-NHAc), N-(caproyl-4-hydroxyprolinol (Hyp-C6), N-(acetyl-4-hydroxyprolinol (Hyp-NHAc), thymidine-2'-O-deoxythymidine (ether), N-(aminocaproyl)-4-hydroxyprolinol (Hyp-C6-amino), 2-docosanoyl-uridine-3"- phosphate,
 5 inverted base dT(idT) and others. Disclosure of this modification can be found in PCT Publication No. WO 2011/005861.

Other modifications of a RNAi agent of the disclosure include a 5' phosphate or 5' phosphate mimic, *e.g.*, a 5'-terminal phosphate or phosphate mimic on the antisense strand of a RNAi agent. Suitable phosphate mimics are disclosed in, for example US 2012/0157511, the
 10 contents of which are incorporated herein by reference for the methods provided therein.

iRNA Motifs

In certain aspects of the disclosure, the double-stranded RNAi agents of the disclosure include agents with chemical modifications as disclosed, for example, in WO 2013/075035, the contents of which are incorporated herein by reference for the methods provided therein. As
 15 shown herein and in WO 2013/075035, a superior result may be obtained by introducing one or more motifs of three identical modifications on three consecutive nucleotides into a sense strand or antisense strand of an RNAi agent, particularly at or near the cleavage site. In some embodiments, the sense strand and antisense strand of the RNAi agent may otherwise be completely modified. The introduction of these motifs interrupts the modification pattern, if
 20 present, of the sense or antisense strand. The RNAi agent may be optionally conjugated with a lipophilic moiety or ligand, *e.g.*, a C16 moiety or ligand, for instance on the sense strand. The RNAi agent may be optionally modified with a (S)-glycol nucleic acid (GNA) modification, for instance on one or more residues of the antisense strand. The resulting RNAi agents present superior gene silencing activity.

25 In some embodiments, the sense strand sequence may be represented by formula (I):



wherein:

i and j are each independently 0 or 1;

p and q are each independently 0-6;

30 each N_a independently represents an oligonucleotide sequence comprising 0-25 modified nucleotides, each sequence comprising at least two differently modified nucleotides;

each N_b independently represents an oligonucleotide sequence comprising 0-10 modified nucleotides;

each n_p and n_q independently represent an overhang nucleotide;

wherein N_b and Y do not have the same modification; and

5 XXX, YYY and ZZZ each independently represent one motif of three identical modifications on three consecutive nucleotides. In some embodiments, YYY is all 2'-F modified nucleotides.

In some embodiments, the N_a and/or N_b comprise modifications of alternating pattern.

10 In some embodiments, the YYY motif occurs at or near the cleavage site of the sense strand. For example, when the RNAi agent has a duplex region of 17-23 nucleotides in length, the YYY motif can occur at or the vicinity of the cleavage site (*e.g.*: can occur at positions 6, 7, 8; 7, 8, 9; 8, 9, 10; 9, 10, 11; 10, 11, 12 or 11, 12, 13) of the sense strand, the count starting from the 1st nucleotide, from the 5'-end; or optionally, the count starting at the 1st paired nucleotide within the duplex region, from the 5'-end.

15 In some embodiments, i is 1 and j is 0, or i is 0 and j is 1, or both i and j are 1. The sense strand can therefore be represented by the following formulas:

5' n_p - N_a -YYY- N_b -ZZZ- N_a - n_q 3' (Ib);

5' n_p - N_a -XXX- N_b -YYY- N_a - n_q 3' (Ic); or

5' n_p - N_a -XXX- N_b -YYY- N_b -ZZZ- N_a - n_q 3' (Id).


20 When the sense strand is represented by formula (Ib), N_b represents an oligonucleotide sequence comprising 0-10, 0-7, 0-5, 0-4, 0-2 or 0 modified nucleotides. Each N_a independently can represent an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides.

When the sense strand is represented as formula (Ic), N_b represents an oligonucleotide sequence comprising 0-10, 0-7, 0-5, 0-4, 0-2 or 0 modified nucleotides. Each N_a can
25 independently represent an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides.

When the sense strand is represented as formula (Id), each N_b independently represents an oligonucleotide sequence comprising 0-10, 0-7, 0-5, 0-4, 0-2 or 0 modified nucleotides. In some
30 embodiments, N_b is 0, 1, 2, 3, 4, 5 or 6. Each N_a can independently represent an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides.


Each of X, Y and Z may be the same or different from each other.

In other embodiments, i is 0 and j is 0, and the sense strand may be represented by the formula:



When the sense strand is represented by formula (Ia), each N_a independently can represent an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides.

In some embodiments, the antisense strand sequence of the RNAi may be represented by formula (II):



wherein:

k and l are each independently 0 or 1;

p' and q' are each independently 0-6;

each N_a' independently represents an oligonucleotide sequence comprising 0-25 modified nucleotides, each sequence comprising at least two differently modified nucleotides;

each N_b' independently represents an oligonucleotide sequence comprising 0-10 modified nucleotides;

each n_p' and n_q' independently represent an overhang nucleotide;

wherein N_b' and Y' do not have the same modification;

and

$X'X'X'$, $Y'Y'Y'$, and $Z'Z'Z'$ each independently represent one of three identical

modification on three consecutive nucleotides.

In some embodiments, the N_a' and/or N_b' comprise modification of alternating pattern.

The $Y'Y'Y'$ motif occurs at or near the cleavage site of the antisense strand. For example, when the RNAi agent has a duplex region of 17-23 nucleotides in length, the $Y'Y'Y'$ motif can occur at positions 9, 10, 11; 10, 11, 12; 11, 12, 13; 12, 13, 14 ; or 13, 14, 15 of the antisense strand, with the count starting from the 1st nucleotide, from the 5'-end; or optionally, the count starting at the 1st paired nucleotide within the duplex region, from the 5'- end. In some embodiments, the $Y'Y'Y'$ motif occurs at positions 11, 12, 13.

In some embodiments, $Y'Y'Y'$ motif is all 2'-Ome modified nucleotides.

In on embodiment, k is 1 and l is 0, or k is 0 and l is 1, or both k and l are 1.

The antisense strand can therefore be represented by the following formulas:



5' n_q'-N_a'-Y'Y'Y'-N_b'-X'X'X'-n_p' 3' (IIc); or

5' n_q'-N_a'-Z'Z'Z'-N_b'-Y'Y'Y'-N_b'-X'X'X'-N_a'-n_p' 3' (IId).

When the antisense strand is represented by formula (IIb), N_b' represents an oligonucleotide sequence comprising 0-10, 0-7, 0-5, 0-4, 0-2 or 0 modified nucleotides. Each N_a'
5 independently represents an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides.

When the antisense strand is represented as formula (IId), each N_b' independently represents an oligonucleotide sequence comprising 0-10, 0-7, 0-5, 0-4, 0-2 or 0 modified nucleotides. Each N_a' independently represents an oligonucleotide sequence comprising 2-20, 2-
10 15, or 2-10 modified nucleotides. In some embodiments, N_b is 0, 1, 2, 3, 4, 5 or 6.

In other embodiments, k is 0 and l is 0 and the antisense strand may be represented by the formula:

5' n_p'-N_a'-Y'Y'Y'-N_a'-n_q' 3' (Ia).

When the antisense strand is represented as formula (IIa), each N_a' independently
15 represents an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides.

Each of X', Y' and Z' may be the same or different from each other.

Each nucleotide of the sense strand and antisense strand may be independently modified with LNA, HNA, CeNA, GNA, 2'-methoxyethyl, 2'-O-methyl, 2'-O-allyl, 2'-C-allyl, 2'-hydroxyl, or 2'-fluoro. For example, each nucleotide of the sense strand and antisense strand is
20 independently modified with 2'-O-methyl or 2'-fluoro. Each X, Y, Z, X', Y' and Z', in particular, may represent a 2'-O-methyl modification or a 2'-fluoro modification.


In some embodiments, the sense strand of the RNAi agent may contain YYY motif occurring at 9, 10 and 11 positions of the strand when the duplex region is 21 nt, the count starting from the 1st nucleotide from the 5'-end, or optionally, the count starting at the 1st paired
25 nucleotide within the duplex region, from the 5'-end; and Y represents 2'-F modification. The sense strand may additionally contain XXX motif or ZZZ motifs as wing modifications at the opposite end of the duplex region; and XXX and ZZZ each independently represents a 2'-OMe modification or 2'-F modification.

In some embodiments the antisense strand may Y'Y'Y' motif occurring at positions 11,
30 12, 13 of the strand, the count starting from the 1st nucleotide from the 5'-end, or optionally, the count starting at the 1st paired nucleotide within the duplex region, from the 5'-end; and Y'

represents 2'-O-methyl modification. The antisense strand may additionally contain X'X'X' motif or Z'Z'Z' motifs as wing modifications at the opposite end of the duplex region; and X'X'X' and Z'Z'Z' each independently represents a 2'-OMe modification or 2'-F modification.

The sense strand represented by any one of the above formulas (Ia), (Ib), (Ic), and (Id) forms a duplex with an antisense strand being represented by any one of formulas (IIa), (IIb), (IIc), and (IId), respectively.

Accordingly, certain RNAi agents for use in the methods of the disclosure may comprise a sense strand and an antisense strand, each strand having 14 to 30 nucleotides, the RNAi duplex represented by formula (III):



wherein,

i, j, k, and l are each independently 0 or 1;

p, p', q, and q' are each independently 0-6;

each N_a and N_a' independently represents an oligonucleotide sequence comprising 0-25 modified nucleotides, each sequence comprising at least two differently modified nucleotides;

each N_b and N_b' independently represents an oligonucleotide sequence comprising 0-10 modified nucleotides;


wherein

each n_p , n_p , n_q , and n_q , each of which may or may not be present independently represents an overhang nucleotide; and


XXX, YYY, ZZZ, X'X'X', Y'Y'Y', and Z'Z'Z' each independently represent one motif of three identical modification on three consecutive nucleotides.

In some embodiments, i is 0 and j is 0; or i is 1 and j is 0; or i is 0 and j is 1; or both i and j are 0; or both i and j are 1. In some embodiments, k is 0 and l is 0; or k is 1 and l is 0; k is 0 and l is 1; or both k and l are 0; or both k and l are 1.


Exemplary combinations of the sense strand and antisense strand forming a RNAi duplex include the formulas below:




(IIIa)



(IIIb)



(IIIc)



10 (IIId)

When the RNAi agent is represented by formula (IIIa), each N_a independently represents an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides.

When the RNAi agent is represented by formula (IIIb), each N_b independently represents an oligonucleotide sequence comprising 1-10, 1-7, 1-5 or 1-4 modified nucleotides. Each N_a independently represents an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides.

When the RNAi agent is represented as formula (IIIc), each N_b , N_b' independently represents an oligonucleotide sequence comprising 0-10, 0-7, 0-5, 0-4, 0-2 or 0 modified nucleotides. Each N_a independently represents an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides.

When the RNAi agent is represented as formula (IIId), each N_b , N_b' independently represents an oligonucleotide sequence comprising 0-10, 0-7, 0-5, 0-4, 0-2 or 0 modified nucleotides. Each N_a , N_a' independently represents an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides. Each of N_a , N_a' , N_b and N_b' independently comprises modifications of alternating pattern.

Each of X, Y and Z in formulas (III), (IIIa), (IIIb), (IIIc), and (IIId) may be the same or different from each other.

When the RNAi agent is represented by formula (III), (IIIa), (IIIb), (IIIc), and (IIId), at least one of the Y nucleotides may form a base pair with one of the Y' nucleotides.

Alternatively, at least two of the Y nucleotides form base pairs with the corresponding Y'

nucleotides; or all three of the Y nucleotides all form base pairs with the corresponding Y' nucleotides.

When the RNAi agent is represented by formula (IIIb) or (IIIc), at least one of the Z nucleotides may form a base pair with one of the Z' nucleotides. Alternatively, at least two of the Z nucleotides form base pairs with the corresponding Z' nucleotides; or all three of the Z nucleotides all form base pairs with the corresponding Z' nucleotides.

When the RNAi agent is represented as formula (IIIc) or (IIId), at least one of the X nucleotides may form a base pair with one of the X' nucleotides. Alternatively, at least two of the X nucleotides form base pairs with the corresponding X' nucleotides; or all three of the X nucleotides all form base pairs with the corresponding X' nucleotides.

In some embodiments, the modification on the Y nucleotide is different than the modification on the Y' nucleotide, the modification on the Z nucleotide is different than the modification on the Z' nucleotide, and/or the modification on the X nucleotide is different than the modification on the X' nucleotide.

In some embodiments, when the RNAi agent is represented by formula (IIId), the N_a modifications are 2'-O-methyl or 2'-fluoro modifications. In some embodiments, when the RNAi agent is represented by formula (IIId), the N_a modifications are 2'-O-methyl or 2'-fluoro modifications and $n_p' > 0$ and at least one n_p' is linked to a neighboring nucleotide via a phosphorothioate linkage. In some embodiments, when the RNAi agent is represented by formula (IIId), the N_a modifications are 2'-O-methyl or 2'-fluoro modifications, $n_p' > 0$ and at least one n_p' is linked to a neighboring nucleotide via phosphorothioate linkage, and the sense strand is conjugated to one or more moieties or ligands (*e.g.*, one or more lipophilic moieties, optionally one or more C16 moieties, or one or more GalNAc moieties) attached through a bivalent or trivalent branched linker. In some embodiments, when the RNAi agent is represented by formula (IIId), the N_a modifications are 2'-O-methyl or 2'-fluoro modifications, $n_p' > 0$ and at least one n_p' is linked to a neighboring nucleotide via phosphorothioate linkage, the sense strand comprises at least one phosphorothioate linkage, and the sense strand is conjugated to one or more moieties or ligands (*e.g.*, one or more lipophilic moieties, optionally one or more C16 moieties, or one or more GalNAc moieties) attached through a bivalent or trivalent branched linker.

In some embodiments, when the RNAi agent is represented by formula (IIIa), the N_a modifications are 2'-O-methyl or 2'-fluoro modifications, n_p' > 0 and at least one n_p' is linked to a neighboring nucleotide via phosphorothioate linkage, the sense strand comprises at least one phosphorothioate linkage, and the sense strand is conjugated to one or more moieties or ligands (e.g., one or more lipophilic moieties, optionally one or more C16 moieties, or one or more GalNAc moieties) attached through a bivalent or trivalent branched linker.

In some embodiments, the RNAi agent is a multimer containing at least two duplexes represented by formula (III), (IIIa), (IIIb), (IIIc), and (IIId), wherein the duplexes are connected by a linker. The linker can be cleavable or non-cleavable. Optionally, the multimer further comprises a ligand. Each of the duplexes can target the same gene or two different genes; or each of the duplexes can target same gene at two different target sites.

In some embodiments, the RNAi agent is a multimer containing three, four, five, six or more duplexes represented by formula (III), (IIIa), (IIIb), (IIIc), and (IIId), wherein the duplexes are connected by a linker. The linker can be cleavable or non-cleavable. Optionally, the multimer further comprises a ligand. Each of the duplexes can target the same gene or two different genes; or each of the duplexes can target same gene at two different target sites.

In some embodiments, two RNAi agents represented by formula (III), (IIIa), (IIIb), (IIIc), and (IIId) are linked to each other at the 5' end, and one or both of the 3' ends and are optionally conjugated to a ligand. Each of the agents can target the same gene or two different genes; or each of the agents can target same gene at two different target sites.

Various publications describe multimeric RNAi agents that can be used in the methods of the disclosure. Such publications include WO2007/091269, WO2010/141511, WO2007/117686, WO2009/014887, and WO2011/031520; and US 7858769, the contents of each of which are hereby incorporated herein by reference for the methods provided therein. In certain embodiments, the RNAi agents of the disclosure may include GalNAc ligands.

As described in more detail below, the RNAi agent that contains conjugations of one or more carbohydrate moieties to a RNAi agent can optimize one or more properties of the RNAi agent. In many cases, the carbohydrate moiety will be attached to a modified subunit of the RNAi agent. For example, the ribose sugar of one or more ribonucleotide subunits of a dsRNA agent can be replaced with another moiety, e.g., a non-carbohydrate (preferably cyclic) carrier to which is attached a carbohydrate ligand. A ribonucleotide subunit in which the ribose sugar of

the subunit has been so replaced is referred to herein as a ribose replacement modification subunit (RRMS). A cyclic carrier may be a carbocyclic ring system, *i.e.*, all ring atoms are carbon atoms, or a heterocyclic ring system, *i.e.*, one or more ring atoms may be a heteroatom, *e.g.*, nitrogen, oxygen, sulfur. The cyclic carrier may be a monocyclic ring system, or may
5 contain two or more rings, *e.g.* fused rings. The cyclic carrier may be a fully saturated ring system, or it may contain one or more double bonds.

The ligand may be attached to the polynucleotide via a carrier. The carriers include (i) at least one “backbone attachment point,” preferably two “backbone attachment points” and (ii) at least one “tethering attachment point.” A “backbone attachment point” as used herein refers to a
10 functional group, *e.g.* a hydroxyl group, or generally, a bond available for, and that is suitable for incorporation of the carrier into the backbone, *e.g.*, the phosphate, or modified phosphate, *e.g.*, sulfur containing, backbone, of a ribonucleic acid. A “tethering attachment point” (TAP) in some embodiments refers to a constituent ring atom of the cyclic carrier, *e.g.*, a carbon atom or a heteroatom (distinct from an atom which provides a backbone attachment point), that connects a
15 selected moiety. The moiety can be, *e.g.*, a carbohydrate, *e.g.* monosaccharide, disaccharide, trisaccharide, tetrasaccharide, oligosaccharide, and polysaccharide. Optionally, the selected moiety is connected by an intervening tether to the cyclic carrier. Thus, the cyclic carrier will often include a functional group, *e.g.*, an amino group, or generally, provide a bond, that is suitable for incorporation or tethering of another chemical entity, *e.g.*, a ligand to the constituent
20 ring.

The RNAi agents may be conjugated to a ligand *via* a carrier, wherein the carrier can be cyclic group or acyclic group; preferably, the cyclic group is selected from pyrrolidinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, piperidinyl, piperazinyl, [1,3]dioxolane, oxazolidinyl, isoxazolidinyl, morpholinyl, thiazolidinyl, isothiazolidinyl, quinoxalinyl,
25 pyridazinonyl, tetrahydrofuryl and decalin; preferably, the acyclic group is selected from serinol backbone or diethanolamine backbone.

In certain specific embodiments, the RNAi agent for use in the methods of the disclosure is an agent selected from the group of agents listed in any one of Tables 2A, 2B, 3A, 3B, 4A, 4B, 5A, 5B, 8A, 8B, 10A, 10B, 12, 13, 14, 18A and 18B. These agents may further comprise a
30 ligand. The ligand can be attached to the sense strand, antisense strand or both strands, at the 3’-

end, 5'-end, or both ends. For instance, the ligand may be conjugated to the sense strand, in particular, the 3'-end of the sense strand.

iRNA Conjugates

The iRNA agents disclosed herein can be in the form of conjugates. The conjugate may be attached at any suitable location in the iRNA molecule, *e.g.*, at the 3' end or the 5' end of the sense or the antisense strand. The conjugates are optionally attached via a linker.

In some embodiments, an iRNA agent described herein is chemically linked to one or more ligands, moieties or conjugates, which may confer functionality, *e.g.*, by affecting (*e.g.*, enhancing) the activity, cellular distribution or cellular uptake of the iRNA. Such moieties include but are not limited to lipid moieties such as a cholesterol moiety (Letsinger *et al.*, *Proc. Natl. Acad. Sci. USA*, 1989, 86: 6553-6556), cholic acid (Manoharan *et al.*, *Biorg. Med. Chem. Lett.*, 1994, 4:1053-1060), a thioether, *e.g.*, beryl-S-tritylthiol (Manoharan *et al.*, *Ann. N.Y. Acad. Sci.*, 1992, 660:306-309; Manoharan *et al.*, *Biorg. Med. Chem. Lett.*, 1993, 3:2765-2770), a thiocholesterol (Oberhauser *et al.*, *Nucl. Acids Res.*, 1992, 20:533-538), an aliphatic chain, *e.g.*, dodecandiol or undecyl residues (Saison-Behmoaras *et al.*, *EMBO J*, 1991, 10:1111-1118; Kabanov *et al.*, *FEBS Lett.*, 1990, 259:327-330; Svinarchuk *et al.*, *Biochimie*, 1993, 75:49-54), a phospholipid, *e.g.*, di-hexadecyl-rac-glycerol or triethyl-ammonium 1,2-di-O-hexadecyl-rac-glycero-3-phosphonate (Manoharan *et al.*, *Tetrahedron Lett.*, 1995, 36:3651-3654; Shea *et al.*, *Nucl. Acids Res.*, 1990, 18:3777-3783), a polyamine or a polyethylene glycol chain (Manoharan *et al.*, *Nucleosides & Nucleotides*, 1995, 14:969-973), or adamantane acetic acid (Manoharan *et al.*, *Tetrahedron Lett.*, 1995, 36:3651-3654), a palmityl moiety (Mishra *et al.*, *Biochim. Biophys. Acta*, 1995, 1264:229-237), or an octadecylamine or hexylamino-carbonyloxycholesterol moiety (Crooke *et al.*, *J. Pharmacol. Exp. Ther.*, 1996, 277:923-937).

In some embodiments, a ligand alters the distribution, targeting or lifetime of an iRNA agent into which it is incorporated. In some embodiments, a ligand provides an enhanced affinity for a selected target, *e.g.*, molecule, cell or cell type, compartment, *e.g.*, a cellular or organ compartment, tissue, organ or region of the body, as, *e.g.*, compared to a species absent such a ligand. Typical ligands will not take part in duplex pairing in a duplexed nucleic acid.

Ligands can include a naturally occurring substance, such as a protein (*e.g.*, human serum albumin (HSA), low-density lipoprotein (LDL), or globulin); carbohydrate (*e.g.*, a dextran,

pullulan, chitin, chitosan, inulin, cyclodextrin or hyaluronic acid); or a lipid. The ligand may also be a recombinant or synthetic molecule, such as a synthetic polymer, *e.g.*, a synthetic polyamino acid. Examples of polyamino acids include polyamino acid is a polylysine (PLL), poly L-aspartic acid, poly L-glutamic acid, styrene-maleic acid anhydride copolymer, poly(L-lactide-co-glycolide) copolymer, divinyl ether-maleic anhydride copolymer, N-(2-hydroxypropyl)methacrylamide copolymer (HMPA), polyethylene glycol (PEG), polyvinyl alcohol (PVA), polyurethane, poly(2-ethylacrylic acid), N-isopropylacrylamide polymers, or polyphosphazine. Examples of polyamines include: polyethylenimine, polylysine (PLL), spermine, spermidine, polyamine, pseudopeptide-polyamine, peptidomimetic polyamine, dendrimer polyamine, arginine, amidine, protamine, cationic lipid, cationic porphyrin, quaternary salt of a polyamine, or an α helical peptide.

Ligands can also include targeting groups, *e.g.*, a cell or tissue targeting agent, *e.g.*, a lectin, glycoprotein, lipid or protein, *e.g.*, an antibody, that binds to a specified cell type such as a kidney cell. A targeting group can be a thyrotropin, melanotropin, lectin, glycoprotein, surfactant protein A, Mucin carbohydrate, multivalent lactose, multivalent galactose, N-acetyl-galactosamine, N-acetyl-gulucosamine multivalent mannose, multivalent fucose, glycosylated polyaminoacids, multivalent galactose, transferrin, bisphosphonate, polyglutamate, polyaspartate, a lipid, cholesterol, a steroid, bile acid, folate, vitamin B12, biotin, or an RGD peptide or RGD peptide mimetic.

Other examples of ligands include dyes, intercalating agents (*e.g.* acridines), cross-linkers (*e.g.* psoralene, mitomycin C), porphyrins (TPPC4, texaphyrin, Sapphyrin), polycyclic aromatic hydrocarbons (*e.g.*, phenazine, dihydrophenazine), artificial endonucleases (*e.g.* EDTA), lipophilic molecules, *e.g.* cholesterol, cholic acid, adamantane acetic acid, 1-pyrene butyric acid, dihydrotestosterone, 1,3-Bis-O(hexadecyl)glycerol, geranyloxyhexyl group, hexadecylglycerol, borneol, menthol, 1,3-propanediol, heptadecyl group, palmitic acid, myristic acid, O3-(oleoyl)lithocholic acid, O3-(oleoyl)cholenic acid, dimethoxytrityl, or phenoxazine) and peptide conjugates (*e.g.*, antennapedia peptide, Tat peptide), alkylating agents, phosphate, amino, mercapto, PEG (*e.g.*, PEG-40K), MPEG, [MPEG]₂, polyamino, alkyl, substituted alkyl, radiolabeled markers, enzymes, haptens (*e.g.* biotin), transport/absorption facilitators (*e.g.*, aspirin, vitamin E, folic acid), synthetic ribonucleases (*e.g.*, imidazole, bisimidazole, histamine,

imidazole clusters, acridine-imidazole conjugates, Eu³⁺ complexes of tetraazamacrocycles), dinitrophenyl, HRP, or AP.

Ligands can be proteins, *e.g.*, glycoproteins, or peptides, *e.g.*, molecules having a specific affinity for a co-ligand, or antibodies *e.g.*, an antibody, that binds to a specified cell type such as an ocular cell. Ligands may also include hormones and hormone receptors. They can also include non-peptidic species, such as lipids, lectins, carbohydrates, vitamins, cofactors, multivalent lactose, multivalent galactose, N-acetyl-galactosamine, N-acetyl-glucosamine multivalent mannose, or multivalent fucose. The ligand can be, for example, a lipopolysaccharide, an activator of p38 MAP kinase, or an activator of NF- κ B.

The ligand can be a substance, *e.g.*, a drug, which can increase the uptake of the iRNA agent into the cell, for example, by disrupting the cell's cytoskeleton, *e.g.*, by disrupting the cell's microtubules, microfilaments, and/or intermediate filaments. The drug can be, for example, taxon, vincristine, vinblastine, cytochalasin, nocodazole, japlakinolide, latrunculin A, phalloidin, swinholide A, indanocine, or myoservin.

In some embodiments, a ligand attached to an iRNA as described herein acts as a pharmacokinetic modulator (PK modulator). PK modulators include lipophiles, bile acids, steroids, phospholipid analogues, peptides, protein binding agents, PEG, vitamins *etc.* Exemplary PK modulators include, but are not limited to, cholesterol, fatty acids, cholic acid, lithocholic acid, dialkylglycerides, diacylglyceride, phospholipids, sphingolipids, naproxen, ibuprofen, vitamin E, biotin *etc.* Oligonucleotides that comprise a number of phosphorothioate linkages are also known to bind to serum protein, thus short oligonucleotides, *e.g.*, oligonucleotides of about 5 bases, 10 bases, 15 bases or 20 bases, comprising multiple of phosphorothioate linkages in the backbone are also amenable to the present disclosure as ligands (*e.g.* as PK modulating ligands). In addition, aptamers that bind serum components (*e.g.* serum proteins) are also suitable for use as PK modulating ligands in the embodiments described herein.

Ligand-conjugated oligonucleotides of the disclosure may be synthesized by the use of an oligonucleotide that bears a pendant reactive functionality, such as that derived from the attachment of a linking molecule onto the oligonucleotide (described below). This reactive oligonucleotide may be reacted directly with commercially available ligands, ligands that are synthesized bearing any of a variety of protecting groups, or ligands that have a linking moiety attached thereto.

The oligonucleotides used in the conjugates of the present disclosure may be conveniently and routinely made through the well-known technique of solid-phase synthesis. Equipment for such synthesis is sold by several vendors including, for example, Applied Biosystems (Foster City, Calif.). Any other means for such synthesis known in the art may additionally or alternatively be employed. It is also known to use similar techniques to prepare other oligonucleotides, such as the phosphorothioates and alkylated derivatives.

In the ligand-conjugated oligonucleotides and ligand-molecule bearing sequence-specific linked nucleosides of the present disclosure, the oligonucleotides and oligonucleosides may be assembled on a suitable DNA synthesizer utilizing standard nucleotide or nucleoside precursors, or nucleotide or nucleoside conjugate precursors that already bear the linking moiety, ligand-nucleotide or nucleoside-conjugate precursors that already bear the ligand molecule, or non-nucleoside ligand-bearing building blocks.

When using nucleotide-conjugate precursors that already bear a linking moiety, the synthesis of the sequence-specific linked nucleosides is typically completed, and the ligand molecule is then reacted with the linking moiety to form the ligand-conjugated oligonucleotide. In some embodiments, the oligonucleotides or linked nucleosides of the present disclosure are synthesized by an automated synthesizer using phosphoramidites derived from ligand-nucleoside conjugates in addition to the standard phosphoramidites and non-standard phosphoramidites that are commercially available and routinely used in oligonucleotide synthesis.

A. Lipophilic Moieties

In certain embodiments, the lipophilic moiety is an aliphatic, cyclic such as alicyclic, or polycyclic such as polyalicyclic compound, such as a steroid (*e.g.*, sterol) or a linear or branched aliphatic hydrocarbon. The lipophilic moiety may generally comprise a hydrocarbon chain, which may be cyclic or acyclic. The hydrocarbon chain may comprise various substituents or one or more heteroatoms, such as an oxygen or nitrogen atom. Such lipophilic aliphatic moieties include, without limitation, saturated or unsaturated C₄-C₃₀ hydrocarbon (*e.g.*, C₆-C₁₈ hydrocarbon), saturated or unsaturated fatty acids, waxes (*e.g.*, monohydric alcohol esters of fatty acids and fatty diamides), terpenes (*e.g.*, C₁₀ terpenes, C₁₅ sesquiterpenes, C₂₀ diterpenes, C₃₀ triterpenes, and C₄₀ tetraterpenes), and other polyalicyclic hydrocarbons. For instance, the lipophilic moiety may contain a C₄-C₃₀ hydrocarbon chain (*e.g.*, C₄-C₃₀ alkyl or alkenyl). In

some embodiments the lipophilic moiety contains a saturated or unsaturated C₆-C₁₈ hydrocarbon chain (*e.g.*, a linear C₆-C₁₈ alkyl or alkenyl). In some embodiments, the lipophilic moiety contains a saturated or unsaturated C₁₆ hydrocarbon chain (*e.g.*, a linear C₁₆ alkyl or alkenyl).

The lipophilic moiety may be attached to the RNAi agent by any method known in the art, including via a functional grouping already present in the lipophilic moiety or introduced into the RNAi agent, such as a hydroxy group (*e.g.*, —CO—CH₂—OH). The functional groups already present in the lipophilic moiety or introduced into the RNAi agent include, but are not limited to, hydroxyl, amine, carboxylic acid, sulfonate, phosphate, thiol, azide, and alkyne.

Conjugation of the RNAi agent and the lipophilic moiety may occur, for example, through formation of an ether or a carboxylic or carbamoyl ester linkage between the hydroxy and an alkyl group R—, an alkanoyl group RCO— or a substituted carbamoyl group RNHCO—. The alkyl group R may be cyclic (*e.g.*, cyclohexyl) or acyclic (*e.g.*, straight-chained or branched; and saturated or unsaturated). Alkyl group R may be a butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl or octadecyl group, or the like.

In some embodiments, the lipophilic moiety is conjugated to the double-stranded RNAi agent via a linker a linker containing an ether, thioether, urea, carbonate, amine, amide, maleimide-thioether, disulfide, phosphodiester, sulfonamide linkage, a product of a click reaction (*e.g.*, a triazole from the azide-alkyne cycloaddition), or carbamate.

In another embodiment, the lipophilic moiety is a steroid, such as sterol. Steroids are polycyclic compounds containing a perhydro-1,2-cyclopentanophenanthrene ring system. Steroids include, without limitation, bile acids (*e.g.*, cholic acid, deoxycholic acid and dehydrocholic acid), cortisone, digoxigenin, testosterone, cholesterol, and cationic steroids, such as cortisone. A “cholesterol derivative” refers to a compound derived from cholesterol, for example by substitution, addition or removal of substituents.


In another embodiment, the lipophilic moiety is an aromatic moiety. In this context, the term “aromatic” refers broadly to mono- and polyaromatic hydrocarbons. Aromatic groups include, without limitation, C₆-C₁₄ aryl moieties comprising one to three aromatic rings, which may be optionally substituted; “aralkyl” or “arylalkyl” groups comprising an aryl group covalently linked to an alkyl group, either of which may independently be optionally substituted or unsubstituted; and “heteroaryl” groups. As used herein, the term “heteroaryl” refers to groups

having 5 to 14 ring atoms, preferably 5, 6, 9, or 10 ring atoms; having 6, 10, or 14π electrons shared in a cyclic array, and having, in addition to carbon atoms, one to about three heteroatoms selected from the group consisting of nitrogen (N), oxygen (O), and sulfur (S).


As employed herein, a “substituted” alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclic group is one having one to about four, preferably one to about three, more preferably one or two, non-hydrogen substituents. Suitable substituents include, without limitation, halo, hydroxy, nitro, haloalkyl, alkyl, alkaryl, aryl, aralkyl, alkoxy, aryloxy, amino, acylamino, alkylcarbamoyl, arylcarbamoyl, aminoalkyl, alkoxycarbonyl, carboxy, hydroxyalkyl, alkanesulfonyl, arenesulfonyl, alkanesulfonamido, arenesulfonamido, aralkylsulfonamido, alkylcarbonyl, acyloxy, cyano, and ureido groups.

In some embodiments, the lipophilic moiety is an aralkyl group, *e.g.*, a 2-arylpropanoyl moiety. The structural features of the aralkyl group are selected so that the lipophilic moiety will bind to at least one protein *in vivo*. In certain embodiments, the structural features of the aralkyl group are selected so that the lipophilic moiety binds to serum, vascular, or cellular proteins. In certain embodiments, the structural features of the aralkyl group promote binding to albumin, an immunoglobulin, a lipoprotein, α -2-macroglobulin, or α -1-glycoprotein.

In certain embodiments, the ligand is naproxen or a structural derivative of naproxen. Procedures for the synthesis of naproxen can be found in U.S. Pat. No. 3,904,682 and U.S. Pat. No. 4,009,197, which are hereby incorporated by reference in their entirety. Naproxen has the chemical name (S)-6-Methoxy- α -methyl-2-naphthaleneacetic acid and the structure is



In certain embodiments, the ligand is ibuprofen or a structural derivative of ibuprofen. Procedures for the synthesis of ibuprofen can be found in US3,228,831, which is incorporated herein by reference for the methods provided therein. The structure of ibuprofen is



Additional exemplary aralkyl groups are illustrated in US 7,626,014, which is incorporated herein by reference for the methods provided therein.

In another embodiment, suitable lipophilic moieties include lipid, cholesterol, retinoic acid, cholic acid, adamantane acetic acid, 1-pyrene butyric acid, dihydrotestosterone, 1,3-bis-
5 O(hexadecyl)glycerol, geranyloxyhexanol, hexadecylglycerol, borneol, menthol, 1,3-propanediol, heptadecyl group, palmitic acid, myristic acid, O3-(oleoyl)lithocholic acid, O3-(oleoyl)cholenic acid, ibuprofen, naproxen, dimethoxytrityl, or phenoxazine.

In certain embodiments, more than one lipophilic moiety can be incorporated into the double-strand RNAi agent, particularly when the lipophilic moiety has a low lipophilicity or
10 hydrophobicity. In some embodiments, two or more lipophilic moieties are incorporated into the same strand of the double-strand RNAi agent. In some embodiments, each strand of the double-strand RNAi agent has one or more lipophilic moieties incorporated. In some embodiments, two or more lipophilic moieties are incorporated into the same position (i.e., the same nucleobase, same sugar moiety, or same internucleosidic linkage) of the double-strand RNAi agent. This can
15 be achieved by, *e.g.*, conjugating the two or more lipophilic moieties via a carrier, or conjugating the two or more lipophilic moieties via a branched linker, or conjugating the two or more lipophilic moieties via one or more linkers, with one or more linkers linking the lipophilic moieties consecutively.

The lipophilic moiety may be conjugated to the RNAi agent via a direct attachment to the
20 ribosugar of the RNAi agent. Alternatively, the lipophilic moiety may be conjugated to the double-strand RNAi agent via a linker or a carrier.

In certain embodiments, the lipophilic moiety may be conjugated to the RNAi agent via one or more linkers (tethers).

In some embodiments, the lipophilic moiety is conjugated to the double-stranded RNAi
25 agent via a linker containing an ether, thioether, urea, carbonate, amine, amide, maleimide-thioether, disulfide, phosphodiester, sulfonamide linkage, a product of a click reaction (*e.g.*, a triazole from the azide-alkyne cycloaddition), or carbamate.

B. Lipid Conjugates

In some embodiments, the ligand is a lipid or lipid-based molecule. Such a lipid or lipid-
30 based molecule can typically bind a serum protein, such as human serum albumin (HSA). An HSA binding ligand allows for vascular distribution of the conjugate to a target tissue. For

example, the target tissue can be the eye. Other molecules that can bind HSA can also be used as ligands. For example, neproxin or aspirin can be used. A lipid or lipid-based ligand can (a) increase resistance to degradation of the conjugate, (b) increase targeting or transport into a target cell or cell membrane, and/or (c) can be used to adjust binding to a serum protein, *e.g.*,
5 HSA.

A lipid-based ligand can be used to modulate, *e.g.*, control (*e.g.*, inhibit) the binding of the conjugate to a target tissue. For example, a lipid or lipid-based ligand that binds to HSA more strongly will be less likely to be targeted to the kidney and therefore less likely to be cleared from the body. A lipid or lipid-based ligand that binds to HSA less strongly can be used
10 to target the conjugate to the kidney.

In some embodiments, the lipid-based ligand binds HSA. For example, the ligand can bind HSA with a sufficient affinity such that distribution of the conjugate to a non-kidney tissue is enhanced. However, the affinity is typically not so strong that the HSA-ligand binding cannot be reversed.

15 In some embodiments, the lipid-based ligand binds HSA weakly or not at all, such that distribution of the conjugate to the kidney is enhanced. Other moieties that target to kidney cells can also be used in place of or in addition to the lipid-based ligand.

In another aspect, the ligand is a moiety, *e.g.*, a vitamin, which is taken up by a target cell, *e.g.*, a proliferating cell. These are particularly useful for treating disorders characterized by
20 unwanted cell proliferation, *e.g.*, of the malignant or non-malignant type, *e.g.*, cancer cells. Exemplary vitamins include vitamin A, E, and K. Other exemplary vitamins include are B vitamin, *e.g.*, folic acid, B12, riboflavin, biotin, pyridoxal or other vitamins or nutrients taken up by cancer cells. Also included are HSA and low-density lipoprotein (LDL).

25 Cell Permeation Agents

In another aspect, the ligand is a cell-permeation agent, such as a helical cell-permeation agent. In some embodiments, the agent is amphipathic. An exemplary agent is a peptide such as tat or antennopedia. If the agent is a peptide, it can be modified, including a peptidylmimetic, invertomers, non-peptide or pseudo-peptide linkages, and use of D-amino acids. The helical
30 agent is typically an α -helical agent, and can have a lipophilic and a lipophobic phase.

The ligand can be a peptide or peptidomimetic. A peptidomimetic (also referred to herein as an oligopeptidomimetic) is a molecule capable of folding into a defined three-dimensional structure similar to a natural peptide. The attachment of peptide and peptidomimetics to iRNA agents can affect pharmacokinetic distribution of the iRNA, such as by enhancing cellular recognition and absorption. The peptide or peptidomimetic moiety can be about 5-50 amino acids long, *e.g.*, about 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50 amino acids long.

A peptide or peptidomimetic can be, for example, a cell permeation peptide, cationic peptide, amphipathic peptide, or hydrophobic peptide (*e.g.*, consisting primarily of Tyr, Trp or Phe). The peptide moiety can be a dendrimer peptide, constrained peptide or crosslinked peptide. In another alternative, the peptide moiety can include a hydrophobic membrane translocation sequence (MTS). An exemplary hydrophobic MTS-containing peptide is RFGF having the amino acid sequence AAVALLPAVLLALLAP (SEQ ID NO: 4158). An RFGF analogue (*e.g.*, amino acid sequence AALLPVLLAAP (SEQ ID NO: 4159)) containing a hydrophobic MTS can also be a targeting moiety. The peptide moiety can be a “delivery” peptide, which can carry large polar molecules including peptides, oligonucleotides, and protein across cell membranes. For example, sequences from the HIV Tat protein (GRKKRRQRRRPPQ (SEQ ID NO: 4160)) and the *Drosophila Antennapedia* protein (RQIKIWFQNRRMKWKK (SEQ ID NO: 4161)) have been found to be capable of functioning as delivery peptides. A peptide or peptidomimetic can be encoded by a random sequence of DNA, such as a peptide identified from a phage-display library, or one-bead-one-compound (OBOC) combinatorial library (Lam *et al.*, *Nature*, 354:82-84, 1991). Typically, the peptide or peptidomimetic tethered to a dsRNA agent via an incorporated monomer unit is a cell targeting peptide such as an arginine-glycine-aspartic acid (RGD)-peptide, or RGD mimic. A peptide moiety can range in length from about 5 amino acids to about 40 amino acids. The peptide moieties can have a structural modification, such as to increase stability or direct conformational properties. Any of the structural modifications described below can be utilized.

An RGD peptide for use in the compositions and methods of the disclosure may be linear or cyclic, and may be modified, *e.g.*, glycosylated or methylated, to facilitate targeting to a specific tissue(s). RGD-containing peptides and peptidomimetics may include D-amino acids, as well as synthetic RGD mimics. In addition to RGD, one can use other moieties that target the integrin ligand. In some embodiments, conjugates of this ligand target PECAM-1 or VEGF.

An RGD peptide moiety can be used to target a particular cell type, *e.g.*, a tumor cell, such as an endothelial tumor cell or a breast cancer tumor cell (Zitzmann *et al.*, *Cancer Res.*, 62:5139-43, 2002). An RGD peptide can facilitate targeting of an dsRNA agent to tumors of a variety of other tissues, including the lung, kidney, spleen, or liver (Aoki *et al.*, *Cancer Gene Therapy* 8:783-787, 2001). Typically, the RGD peptide will facilitate targeting of an iRNA agent to the kidney. The RGD peptide can be linear or cyclic, and can be modified, *e.g.*, glycosylated or methylated to facilitate targeting to specific tissues. For example, a glycosylated RGD peptide can deliver a iRNA agent to a tumor cell expressing $\alpha_v\beta_3$ (Haubner *et al.*, *Jour. Nucl. Med.*, 42:326-336, 2001).


A “cell permeation peptide” is capable of permeating a cell, *e.g.*, a microbial cell, such as a bacterial or fungal cell, or a mammalian cell, such as a human cell. A microbial cell-permeating peptide can be, for example, an α -helical linear peptide (*e.g.*, LL-37 or Ceropin P1), a disulfide bond-containing peptide (*e.g.*, α -defensin, β -defensin or bactenecin), or a peptide containing only one or two dominating amino acids (*e.g.*, PR-39 or indolicidin). A cell permeation peptide can also include a nuclear localization signal (NLS). For example, a cell permeation peptide can be a bipartite amphipathic peptide, such as MPG, which is derived from the fusion peptide domain of HIV-1 gp41 and the NLS of SV40 large T antigen (Simeoni *et al.*, *Nucl. Acids Res.* 31:2717-2724, 2003).

Carbohydrate Conjugates and Ligands

In some embodiments of the compositions and methods of the disclosure, an iRNA oligonucleotide further comprises a carbohydrate. The carbohydrate conjugated iRNA are advantageous for the *in vivo* delivery of nucleic acids, as well as compositions suitable for *in vivo* therapeutic use, as described herein. As used herein, “carbohydrate” refers to a compound which is either a carbohydrate *per se* made up of one or more monosaccharide units having at least 6 carbon atoms (which can be linear, branched or cyclic) with an oxygen, nitrogen or sulfur atom bonded to each carbon atom; or a compound having as a part thereof a carbohydrate moiety made up of one or more monosaccharide units each having at least six carbon atoms (which can be linear, branched or cyclic), with an oxygen, nitrogen or sulfur atom bonded to each carbon atom. Representative carbohydrates include the sugars (mono-, di-, tri- and oligosaccharides containing from about 4, 5, 6, 7, 8, or 9 monosaccharide units), and polysaccharides such as

starches, glycogen, cellulose and polysaccharide gums. Specific monosaccharides include C5 and above (*e.g.*, C5, C6, C7, or C8) sugars; di- and trisaccharides include sugars having two or three monosaccharide units (*e.g.*, C5, C6, C7, or C8).

In certain embodiments, the compositions and methods of the disclosure include a C16 ligand. In exemplary embodiments, the C16 ligand of the disclosure has the following structure (exemplified here below for a uracil base, yet attachment of the C16 ligand is contemplated for a nucleotide presenting any base (C, G, A, etc.) or possessing any other modification as presented herein, provided that 2' ribo attachment is preserved) and is attached at the 2' position of the ribo within a residue that is so modified:



Chemical Formula: $C_{25}H_{43}N_2O_8P$

Exact Mass: 530.2757


Molecular Weight: 530.5913

As shown above, a C16 ligand-modified residue presents a straight chain alkyl at the 2'-ribo position of an exemplary residue (here, a Uracil) that is so modified.

In some embodiments, a carbohydrate conjugate of a RNAi agent of the instant disclosure further comprises one or more additional ligands as described above, such as, but not limited to, a PK modulator or a cell permeation peptide.


Additional carbohydrate conjugates (and linkers) suitable for use in the present disclosure include those described in WO 2014/179620 and WO 2014/179627, the entire contents of each of which are incorporated herein by reference.

In certain embodiments, the compositions and methods of the disclosure include a vinyl phosphonate (VP) modification of an RNAi agent as described herein. In exemplary embodiments, a vinyl phosphonate of the disclosure has the following structure:



A vinyl phosphonate of the instant disclosure may be attached to either the antisense or the sense strand of a dsRNA of the disclosure. In certain preferred embodiments, a vinyl phosphonate of the instant disclosure is attached to the antisense strand of a dsRNA, optionally at the 5' end of the antisense strand of the dsRNA.


Vinyl phosphate modifications are also contemplated for the compositions and methods of the instant disclosure. An exemplary vinyl phosphate structure is:



In some embodiments, a carbohydrate conjugate comprises a monosaccharide. In some embodiments, the monosaccharide is an N-acetylgalactosamine (GalNAc). GalNAc conjugates, which comprise one or more N-acetylgalactosamine (GalNAc) derivatives, are described, for example, in U.S. Patent No. 8,106,022, the entire content of which is hereby incorporated herein by reference. In some embodiments, the GalNAc conjugate serves as a ligand that targets the iRNA to particular cells. In some embodiments, the GalNAc conjugate targets the iRNA to liver cells, *e.g.*, by serving as a ligand for the asialoglycoprotein receptor of liver cells (*e.g.*, hepatocytes).


In some embodiments, the carbohydrate conjugate comprises one or more GalNAc derivatives. The GalNAc derivatives may be attached via a linker, *e.g.*, a bivalent or trivalent branched linker. In some embodiments the GalNAc conjugate is conjugated to the 3' end of the sense strand. In some embodiments, the GalNAc conjugate is conjugated to the iRNA agent (*e.g.*, to the 3' end of the sense strand) via a linker, *e.g.*, a linker as described herein.

In some embodiments, the GalNAc conjugate is




Formula II.


In some embodiments, the RNAi agent is attached to the carbohydrate conjugate via a linker as shown in the following schematic, wherein X is O or S:




- 5 In some embodiments, the RNAi agent is conjugated to L96 as defined in Table 1 and shown below:




- 10 In some embodiments, a carbohydrate conjugate for use in the compositions and methods of the disclosure is selected from the group consisting of:




Formula II,




Formula III,




Formula IV,




Formula V,




Formula VI,




Formula VII,




Formula VIII,




Formula IX,




Formula X,




Formula XI,




Formula XII,




Formula XIII,




Formula XIV,




Formula XV,




Formula XVI,






Formula XVII,



Formula XVIII,




Formula XIX,



Another representative carbohydrate conjugate for use in the embodiments described


5 herein includes, but is not limited to,




when one of X or Y is an oligonucleotide, the other is a hydrogen.

In some embodiments, the carbohydrate conjugate further comprises one or more additional ligands as described above, such as, but not limited to, a PK modulator and/or a cell permeation peptide.


In some embodiments, an iRNA of the disclosure is conjugated to a carbohydrate through a linker. Non-limiting examples of iRNA carbohydrate conjugates with linkers of the




(Formula XXIV),





(Formula XXV),




(Formula XXVI),



(Formula XXVII),



and



5 when one of X or Y is an oligonucleotide, the other is a hydrogen.


E. Thermally Destabilizing Modifications

In certain embodiments, a dsRNA molecule can be optimized for RNA interference by incorporating thermally destabilizing modifications in the seed region of the antisense strand (i.e., at positions 2-9 of the 5'-end of the antisense strand) to reduce or inhibit off-target gene silencing. It has been discovered that dsRNAs with an antisense strand comprising at least one thermally destabilizing modification of the duplex within the first 9 nucleotide positions, counting from the 5' end, of the antisense strand have reduced off-target gene silencing activity. Accordingly, in some embodiments, the antisense strand comprises at least one (e.g., one, two, three, four, five, or more) thermally destabilizing modification of the duplex within the first 9 nucleotide positions of the 5' region of the antisense strand. In some embodiments, one or more thermally destabilizing modification(s) of the duplex is/are located in positions 2-9, or preferably positions 4-8, from the 5'-end of the antisense strand. In some further embodiments, the


thermally destabilizing modification(s) of the duplex is/are located at position 6, 7, or 8 from the 5'-end of the antisense strand. In still some further embodiments, the thermally destabilizing modification of the duplex is located at position 7 from the 5'-end of the antisense strand. The term "thermally destabilizing modification(s)" includes modification(s) that would result with a dsRNA with a lower overall melting temperature (T_m) (preferably a T_m with one, two, three, or four degrees lower than the T_m of the dsRNA without having such modification(s). In some embodiments, the thermally destabilizing modification of the duplex is located at position 2, 3, 4, 5, or 9 from the 5'-end of the antisense strand.

The thermally destabilizing modifications can include, but are not limited to, abasic modification; mismatch with the opposing nucleotide in the opposing strand; and sugar modification such as 2'-deoxy modification or acyclic nucleotide, *e.g.*, unlocked nucleic acids (UNA) or glycol nucleic acid (GNA).

Exemplified abasic modifications include, but are not limited to, the following:




Wherein R = H, Me, Et or OMe; R' = H, Me, Et or OMe; R'' = H, Me, Et or OMe




wherein B is a modified or unmodified nucleobase.

Exemplified sugar modifications include, but are not limited to the following:



wherein B is a modified or unmodified nucleobase.


In some embodiments the thermally destabilizing modification of the duplex is selected from the group consisting of:



wherein B is a modified or unmodified nucleobase and the asterisk on each structure represents either *R*, *S* or *racemic*.

The term "acyclic nucleotide" refers to any nucleotide having an acyclic ribose sugar, for example, where any of bonds between the ribose carbons (*e.g.*, C1'-C2', C2'-C3', C3'-C4', C4'-O4', or C1'-O4') is absent or at least one of ribose carbons or oxygen (*e.g.*, C1', C2', C3', C4',


or O4') are independently or in combination absent from the nucleotide. In some embodiments,



- 5 The term “UNA” refers to unlocked acyclic nucleic acid, wherein any of the bonds of the sugar has been removed, forming an unlocked "sugar" residue. In one example, UNA also encompasses monomers with bonds between C1'-C4' being removed (i.e. the covalent carbon-oxygen-carbon bond between the C1' and C4' carbons). In another example, the C2'-C3' bond (i.e. the covalent carbon-carbon bond between the C2' and C3' carbons) of the sugar is removed
- 10 (see Mikhailov et. al., Tetrahedron Letters, 26 (17): 2059 (1985); and Fluiter et al., Mol. Biosyst., 10: 1039 (2009), which are hereby incorporated by reference in their entirety). The acyclic derivative provides greater backbone flexibility without affecting the Watson-Crick pairings. The acyclic nucleotide can be linked via 2'-5' or 3'-5' linkage.


The term ‘GNA’ refers to glycol nucleic acid which is a polymer similar to DNA or RNA but differing in the composition of its “backbone” in that is composed of repeating glycerol units linked by phosphodiester bonds:

15



The thermally destabilizing modification of the duplex can be mismatches (i.e., noncomplementary base pairs) between the thermally destabilizing nucleotide and the opposing nucleotide in the opposite strand within the dsRNA duplex. Exemplary mismatch base pairs include G:G, G:A, G:U, G:T, A:A, A:C, C:C, C:U, C:T, U:U, T:T, U:T, or a combination thereof. Other mismatch base pairings known in the art are also amenable to the present invention. A mismatch can occur between nucleotides that are either naturally occurring nucleotides or modified nucleotides, i.e., the mismatch base pairing can occur between the nucleobases from respective nucleotides independent of the modifications on the ribose sugars of the nucleotides. In certain embodiments, the dsRNA molecule contains at least one nucleobase in the mismatch pairing that is a 2'-deoxy nucleobase; *e.g.*, the 2'-deoxy nucleobase is in the sense strand.


In some embodiments, the thermally destabilizing modification of the duplex in the seed region of the antisense strand includes nucleotides with impaired W-C H-bonding to complementary base on the target mRNA, such as:




More examples of abasic nucleotide, acyclic nucleotide modifications (including UNA and GNA), and mismatch modifications have been described in detail in WO 2011/133876, which is herein incorporated by reference in its entirety.

The thermally destabilizing modifications may also include universal base with reduced or abolished capability to form hydrogen bonds with the opposing bases, and phosphate modifications.


In some embodiments, the thermally destabilizing modification of the duplex includes nucleotides with non-canonical bases such as, but not limited to, nucleobase modifications with impaired or completely abolished capability to form hydrogen bonds with bases in the opposite strand. These nucleobase modifications have been evaluated for destabilization of the central region of the dsRNA duplex as described in WO 2010/0011895, which is herein incorporated by reference in its entirety. Exemplary nucleobase modifications are:




inosine




nebularine




2-aminopurine




2,4-difluorotoluene




5-nitroindole



3-nitropyrrole




4-Fluoro-6-methylbenzimidazole




4-Methylbenzimidazole

In some embodiments, the thermally destabilizing modification of the duplex in the seed region of the antisense strand includes one or more α -nucleotide complementary to the base on the target mRNA, such as:



wherein R is H, OH, OCH₃, F, NH₂, NHMe, NMe₂ or O-alkyl.

Exemplary phosphate modifications known to decrease the thermal stability of dsRNA duplexes compared to natural phosphodiester linkages are:



R = alkyl

The alkyl for the R group can be a C₁-C₆alkyl. Specific alkyls for the R group include, but are not limited to methyl, ethyl, propyl, isopropyl, butyl, pentyl and hexyl.

As the skilled artisan will recognize, in view of the functional role of nucleobases is defining specificity of a RNAi agent of the disclosure, while nucleobase modifications can be performed in the various manners as described herein, *e.g.*, to introduce destabilizing modifications into a RNAi agent of the disclosure, *e.g.*, for purpose of enhancing on-target effect

relative to off-target effect, the range of modifications available and, in general, present upon RNAi agents of the disclosure tends to be much greater for non-nucleobase modifications, *e.g.*, modifications to sugar groups or phosphate backbones of polyribonucleotides. Such modifications are described in greater detail in other sections of the instant disclosure and are expressly contemplated for RNAi agents of the disclosure, either possessing native nucleobases or modified nucleobases as described above or elsewhere herein.

In addition to the antisense strand comprising a thermally destabilizing modification, the dsRNA can also comprise one or more stabilizing modifications. For example, the dsRNA can comprise at least two (*e.g.*, two, three, four, five, six, seven, eight, nine, ten, or more) stabilizing modifications. Without limitations, the stabilizing modifications all can be present in one strand. In some embodiments, both the sense and the antisense strands comprise at least two stabilizing modifications. The stabilizing modification can occur on any nucleotide of the sense strand or antisense strand. For instance, the stabilizing modification can occur on every nucleotide on the sense strand or antisense strand; each stabilizing modification can occur in an alternating pattern on the sense strand or antisense strand; or the sense strand or antisense strand comprises both stabilizing modification in an alternating pattern. The alternating pattern of the stabilizing modifications on the sense strand may be the same or different from the antisense strand, and the alternating pattern of the stabilizing modifications on the sense strand can have a shift relative to the alternating pattern of the stabilizing modifications on the antisense strand.

In some embodiments, the antisense strand comprises at least two (*e.g.*, two, three, four, five, six, seven, eight, nine, ten, or more) stabilizing modifications. Without limitations, a stabilizing modification in the antisense strand can be present at any positions.

In some embodiments, the antisense strand comprises stabilizing modifications at positions 2, 6, 8, 9, 14, and 16 from the 5'-end. In some other embodiments, the antisense strand comprises stabilizing modifications at positions 2, 6, 14, and 16 from the 5'-end. In still some other embodiments, the antisense strand comprises stabilizing modifications at positions 2, 14, and 16 from the 5'-end.

In some embodiments, the antisense strand comprises at least one stabilizing modification adjacent to the destabilizing modification. For example, the stabilizing modification can be the nucleotide at the 5'-end or the 3'-end of the destabilizing modification, *i.e.*, at position -1 or +1 from the position of the destabilizing modification. In some embodiments, the antisense strand

comprises a stabilizing modification at each of the 5'-end and the 3'-end of the destabilizing modification, *i.e.*, positions -1 and +1 from the position of the destabilizing modification.

In some embodiments, the antisense strand comprises at least two stabilizing modifications at the 3'-end of the destabilizing modification, *i.e.*, at positions +1 and +2 from the position of the destabilizing modification.

In some embodiments, the sense strand comprises at least two (*e.g.*, two, three, four, five, six, seven, eight, nine, ten or more) stabilizing modifications. Without limitations, a stabilizing modification in the sense strand can be present at any positions. In some embodiments, the sense strand comprises stabilizing modifications at positions 7, 10, and 11 from the 5'-end. In some other embodiments, the sense strand comprises stabilizing modifications at positions 7, 9, 10, and 11 from the 5'-end. In some embodiments, the sense strand comprises stabilizing modifications at positions opposite or complimentary to positions 11, 12, and 15 of the antisense strand, counting from the 5'-end of the antisense strand. In some other embodiments, the sense strand comprises stabilizing modifications at positions opposite or complimentary to positions 11, 12, 13, and 15 of the antisense strand, counting from the 5'-end of the antisense strand. In some embodiments, the sense strand comprises a block of two, three, or four stabilizing modifications.

In some embodiments, the sense strand does not comprise a stabilizing modification in position opposite or complimentary to the thermally destabilizing modification of the duplex in the antisense strand.

Exemplary thermally stabilizing modifications include, but are not limited to, 2'-fluoro modifications. Other thermally stabilizing modifications include, but are not limited to, LNA.

In some embodiments, the dsRNA of the disclosure comprises at least four (*e.g.*, four, five, six, seven, eight, nine, ten, or more) 2'-fluoro nucleotides. Without limitations, the 2'-fluoro nucleotides all can be present in one strand. In some embodiments, both the sense and the antisense strands comprise at least two 2'-fluoro nucleotides. The 2'-fluoro modification can occur on any nucleotide of the sense strand or antisense strand. For instance, the 2'-fluoro modification can occur on every nucleotide on the sense strand or antisense strand; each 2'-fluoro modification can occur in an alternating pattern on the sense strand or antisense strand; or the sense strand or antisense strand comprises both 2'-fluoro modifications in an alternating pattern. The alternating pattern of the 2'-fluoro modifications on the sense strand may be the

same or different from the antisense strand, and the alternating pattern of the 2'-fluoro modifications on the sense strand can have a shift relative to the alternating pattern of the 2'-fluoro modifications on the antisense strand.

In some embodiments, the antisense strand comprises at least two (*e.g.*, two, three, four, five, six, seven, eight, nine, ten, or more) 2'-fluoro nucleotides. Without limitations, a 2'-fluoro modification in the antisense strand can be present at any positions. In some embodiments, the antisense comprises 2'-fluoro nucleotides at positions 2, 6, 8, 9, 14, and 16 from the 5'-end. In some other embodiments, the antisense comprises 2'-fluoro nucleotides at positions 2, 6, 14, and 16 from the 5'-end. In still some other embodiments, the antisense comprises 2'-fluoro nucleotides at positions 2, 14, and 16 from the 5'-end.

In some embodiments, the antisense strand comprises at least one 2'-fluoro nucleotide adjacent to the destabilizing modification. For example, the 2'-fluoro nucleotide can be the nucleotide at the 5'-end or the 3'-end of the destabilizing modification, *i.e.*, at position -1 or +1 from the position of the destabilizing modification. In some embodiments, the antisense strand comprises a 2'-fluoro nucleotide at each of the 5'-end and the 3'-end of the destabilizing modification, *i.e.*, positions -1 and +1 from the position of the destabilizing modification.

In some embodiments, the antisense strand comprises at least two 2'-fluoro nucleotides at the 3'-end of the destabilizing modification, *i.e.*, at positions +1 and +2 from the position of the destabilizing modification.

In some embodiments, the sense strand comprises at least two (*e.g.*, two, three, four, five, six, seven, eight, nine, ten, or more) 2'-fluoro nucleotides. Without limitations, a 2'-fluoro modification in the sense strand can be present at any positions. In some embodiments, the antisense comprises 2'-fluoro nucleotides at positions 7, 10, and 11 from the 5'-end. In some other embodiments, the sense strand comprises 2'-fluoro nucleotides at positions 7, 9, 10, and 11 from the 5'-end. In some embodiments, the sense strand comprises 2'-fluoro nucleotides at positions opposite or complimentary to positions 11, 12, and 15 of the antisense strand, counting from the 5'-end of the antisense strand. In some other embodiments, the sense strand comprises 2'-fluoro nucleotides at positions opposite or complimentary to positions 11, 12, 13, and 15 of the antisense strand, counting from the 5'-end of the antisense strand. In some embodiments, the sense strand comprises a block of two, three, or four 2'-fluoro nucleotides.

In some embodiments, the sense strand does not comprise a 2'-fluoro nucleotide in position opposite or complementary to the thermally destabilizing modification of the duplex in the antisense strand.

In some embodiments, the dsRNA molecule of the disclosure comprises a 21 nucleotides (nt) sense strand and a 23 nucleotides (nt) antisense, wherein the antisense strand contains at least one thermally destabilizing nucleotide, where the at least one thermally destabilizing nucleotide occurs in the seed region of the antisense strand (*i.e.*, at position 2-9 of the 5'-end of the antisense strand), wherein one end of the dsRNA is blunt, while the other end is comprises a 2 nt overhang, and wherein the dsRNA optionally further has at least one (*e.g.*, one, two, three, four, five, six, or all seven) of the following characteristics: (i) the antisense comprises 2, 3, 4, 5, or 6 2'-fluoro modifications; (ii) the antisense comprises 1, 2, 3, 4, or 5 phosphorothioate internucleotide linkages; (iii) the sense strand is conjugated with a ligand; (iv) the sense strand comprises 2, 3, 4, or 5 2'-fluoro modifications; (v) the sense strand comprises 1, 2, 3, 4, or 5 phosphorothioate internucleotide linkages; (vi) the dsRNA comprises at least four 2'-fluoro modifications; and (vii) the dsRNA comprises a blunt end at 5'-end of the antisense strand. Preferably, the 2 nt overhang is at the 3'-end of the antisense.

In some embodiments, every nucleotide in the sense strand and antisense strand of the dsRNA molecule may be modified. Each nucleotide may be modified with the same or different modification which can include one or more alteration of one or both of the non-linking phosphate oxygens or of one or more of the linking phosphate oxygens; alteration of a constituent of the ribose sugar, *e.g.*, of the 2' hydroxyl on the ribose sugar; wholesale replacement of the phosphate moiety with "dephospho" linkers; modification or replacement of a naturally occurring base; and replacement or modification of the ribose-phosphate backbone.

As nucleic acids are polymers of subunits, many of the modifications occur at a position which is repeated within a nucleic acid, *e.g.*, a modification of a base, or a phosphate moiety, or a non-linking O of a phosphate moiety. In some cases, the modification will occur at all of the subject positions in the nucleic acid but in many cases it will not. By way of example, a modification may only occur at a 3' or 5' terminal position, may only occur in a terminal region, *e.g.*, at a position on a terminal nucleotide or in the last 2, 3, 4, 5, or 10 nucleotides of a strand. A modification may occur in a double strand region, a single strand region, or in both. A modification may occur only in the double strand region of an RNA or may only occur in a

single strand region of an RNA. *E.g.*, a phosphorothioate modification at a non-linking O position may only occur at one or both termini, may only occur in a terminal region, *e.g.*, at a position on a terminal nucleotide or in the last 2, 3, 4, 5, or 10 nucleotides of a strand, or may occur in double strand and single strand regions, particularly at termini. The 5' end or ends can be phosphorylated.

It may be possible, *e.g.*, to enhance stability, to include particular bases in overhangs, or to include modified nucleotides or nucleotide surrogates, in single strand overhangs, *e.g.*, in a 5' or 3' overhang, or in both. *E.g.*, it can be desirable to include purine nucleotides in overhangs. In some embodiments all or some of the bases in a 3' or 5' overhang may be modified, *e.g.*, with a modification described herein. Modifications can include, *e.g.*, the use of modifications at the 2' position of the ribose sugar with modifications that are known in the art, *e.g.*, the use of deoxyribonucleotides, 2'-deoxy-2'-fluoro (2'-F) or 2'-O-methyl modified instead of the ribosugar of the nucleobase, and modifications in the phosphate group, *e.g.*, phosphorothioate modifications. Overhangs need not be homologous with the target sequence.

In some embodiments, each residue of the sense strand and antisense strand is independently modified with LNA, HNA, CeNA, 2'-methoxyethyl, 2'-O-methyl, 2'-O-allyl, 2'-C-allyl, 2'-deoxy, or 2'-fluoro. The strands can contain more than one modification. In some embodiments, each residue of the sense strand and antisense strand is independently modified with 2'-O-methyl or 2'-fluoro. It is to be understood that these modifications are in addition to the at least one thermally destabilizing modification of the duplex present in the antisense strand.

At least two different modifications are typically present on the sense strand and antisense strand. Those two modifications may be the 2'-deoxy, 2'-O-methyl, or 2'-fluoro modifications, acyclic nucleotides or others. In some embodiments, the sense strand and antisense strand each comprises two differently modified nucleotides selected from 2'-O-methyl or 2'-deoxy. In some embodiments, each residue of the sense strand and antisense strand is independently modified with 2'-O-methyl nucleotide, 2'-deoxy nucleotide, 2'-deoxy-2'-fluoro nucleotide, 2'-O-N-methylacetamido (2'-O-NMA) nucleotide, a 2'-O-dimethylaminoethoxyethyl (2'-O-DMAEOE) nucleotide, 2'-O-aminopropyl (2'-O-AP) nucleotide, or 2'-ara-F nucleotide. Again, it is to be understood that these modifications are in addition to the at least one thermally destabilizing modification of the duplex present in the antisense strand.

In some embodiments, the dsRNA molecule of the disclosure comprises modifications of an alternating pattern, particular in the B1, B2, B3, B1', B2', B3', B4' regions. The term "alternating motif" or "alternative pattern" as used herein refers to a motif having one or more modifications, each modification occurring on alternating nucleotides of one strand. The alternating nucleotide may refer to one per every other nucleotide or one per every three nucleotides, or a similar pattern. For example, if A, B and C each represent one type of modification to the nucleotide, the alternating motif can be "ABABABABABAB...", "AABBAABBAABB...", "AABAABAABAAB...", "AAABAAABAAAB...", "AAABBBAAABBB...", or "ABCABCABCABC..." etc.

The type of modifications contained in the alternating motif may be the same or different. For example, if A, B, C, D each represent one type of modification on the nucleotide, the alternating pattern, i.e., modifications on every other nucleotide, may be the same, but each of the sense strand or antisense strand can be selected from several possibilities of modifications within the alternating motif such as "ABABAB...", "ACACAC..." "BDBDBD..." or "CDCDCD..." etc.

In some embodiments, the dsRNA molecule of the disclosure comprises the modification pattern for the alternating motif on the sense strand relative to the modification pattern for the alternating motif on the antisense strand is shifted. The shift may be such that the modified group of nucleotides of the sense strand corresponds to a differently modified group of nucleotides of the antisense strand and vice versa. For example, the sense strand when paired with the antisense strand in the dsRNA duplex, the alternating motif in the sense strand may start with "ABABAB" from 5'-3' of the strand and the alternating motif in the antisense strand may start with "BABABA" from 3'-5' of the strand within the duplex region. As another example, the alternating motif in the sense strand may start with "AABBAABB" from 5'-3' of the strand and the alternating motif in the antisense strand may start with "BBAABBAA" from 3'-5' of the strand within the duplex region, so that there is a complete or partial shift of the modification patterns between the sense strand and the antisense strand.

The dsRNA molecule of the disclosure may further comprise at least one phosphorothioate or methylphosphonate internucleotide linkage. The phosphorothioate or methylphosphonate internucleotide linkage modification may occur on any nucleotide of the sense strand or antisense strand or both in any position of the strand. For instance, the

internucleotide linkage modification may occur on every nucleotide on the sense strand or antisense strand; each internucleotide linkage modification may occur in an alternating pattern on the sense strand or antisense strand; or the sense strand or antisense strand comprises both internucleotide linkage modifications in an alternating pattern. The alternating pattern of the internucleotide linkage modification on the sense strand may be the same or different from the antisense strand, and the alternating pattern of the internucleotide linkage modification on the sense strand may have a shift relative to the alternating pattern of the internucleotide linkage modification on the antisense strand.

In some embodiments, the dsRNA molecule comprises the phosphorothioate or methylphosphonate internucleotide linkage modification in the overhang region. For example, the overhang region comprises two nucleotides having a phosphorothioate or methylphosphonate internucleotide linkage between the two nucleotides. Internucleotide linkage modifications also may be made to link the overhang nucleotides with the terminal paired nucleotides within duplex region. For example, at least 2, 3, 4, or all the overhang nucleotides may be linked through phosphorothioate or methylphosphonate internucleotide linkage, and optionally, there may be additional phosphorothioate or methylphosphonate internucleotide linkages linking the overhang nucleotide with a paired nucleotide that is next to the overhang nucleotide. For instance, there may be at least two phosphorothioate internucleotide linkages between the terminal three nucleotides, in which two of the three nucleotides are overhang nucleotides, and the third is a paired nucleotide next to the overhang nucleotide. Preferably, these terminal three nucleotides may be at the 3'-end of the antisense strand.

In some embodiments, the sense strand of the dsRNA molecule comprises 1-10 blocks of two to ten phosphorothioate or methylphosphonate internucleotide linkages separated by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 phosphate internucleotide linkages, wherein one of the phosphorothioate or methylphosphonate internucleotide linkages is placed at any position in the oligonucleotide sequence and the said sense strand is paired with an antisense strand comprising any combination of phosphorothioate, methylphosphonate, and phosphate internucleotide linkages or an antisense strand comprising either phosphorothioate or methylphosphonate or phosphate linkage.

In some embodiments, the antisense strand of the dsRNA molecule comprises two blocks of two phosphorothioate or methylphosphonate internucleotide linkages separated by 1, 2, 3, 4,

5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18 phosphate internucleotide linkages, wherein one of the phosphorothioate or methylphosphonate internucleotide linkages is placed at any position in the oligonucleotide sequence and the said antisense strand is paired with a sense strand comprising any combination of phosphorothioate, methylphosphonate, and phosphate internucleotide linkages or an antisense strand comprising either phosphorothioate or methylphosphonate or phosphate linkage.

In some embodiments, the antisense strand of the dsRNA molecule comprises two blocks of three phosphorothioate or methylphosphonate internucleotide linkages separated by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 phosphate internucleotide linkages, wherein one of the phosphorothioate or methylphosphonate internucleotide linkages is placed at any position in the oligonucleotide sequence and the said antisense strand is paired with a sense strand comprising any combination of phosphorothioate, methylphosphonate, and phosphate internucleotide linkages or an antisense strand comprising either phosphorothioate or methylphosphonate or phosphate linkage.

In some embodiments, the antisense strand of the dsRNA molecule comprises two blocks of four phosphorothioate or methylphosphonate internucleotide linkages separated by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 phosphate internucleotide linkages, wherein one of the phosphorothioate or methylphosphonate internucleotide linkages is placed at any position in the oligonucleotide sequence and the said antisense strand is paired with a sense strand comprising any combination of phosphorothioate, methylphosphonate, and phosphate internucleotide linkages or an antisense strand comprising either phosphorothioate or methylphosphonate or phosphate linkage.

In some embodiments, the antisense strand of the dsRNA molecule comprises two blocks of five phosphorothioate or methylphosphonate internucleotide linkages separated by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 phosphate internucleotide linkages, wherein one of the phosphorothioate or methylphosphonate internucleotide linkages is placed at any position in the oligonucleotide sequence and the said antisense strand is paired with a sense strand comprising any combination of phosphorothioate, methylphosphonate, and phosphate internucleotide linkages or an antisense strand comprising either phosphorothioate or methylphosphonate or phosphate linkage.

In some embodiments, the antisense strand of the dsRNA molecule comprises two blocks of six phosphorothioate or methylphosphonate internucleotide linkages separated by 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 phosphate internucleotide linkages, wherein one of the phosphorothioate or methylphosphonate internucleotide linkages is placed at any position in the oligonucleotide sequence and the said antisense strand is paired with a sense strand comprising any combination of phosphorothioate, methylphosphonate, and phosphate internucleotide linkages or an antisense strand comprising either phosphorothioate or methylphosphonate or phosphate linkage.

In some embodiments, the antisense strand of the dsRNA molecule comprises two blocks of seven phosphorothioate or methylphosphonate internucleotide linkages separated by 1, 2, 3, 4, 5, 6, 7, or 8 phosphate internucleotide linkages, wherein one of the phosphorothioate or methylphosphonate internucleotide linkages is placed at any position in the oligonucleotide sequence and the said antisense strand is paired with a sense strand comprising any combination of phosphorothioate, methylphosphonate, and phosphate internucleotide linkages or an antisense strand comprising either phosphorothioate or methylphosphonate or phosphate linkage.

In some embodiments, the antisense strand of the dsRNA molecule comprises two blocks of eight phosphorothioate or methylphosphonate internucleotide linkages separated by 1, 2, 3, 4, 5, or 6 phosphate internucleotide linkages, wherein one of the phosphorothioate or methylphosphonate internucleotide linkages is placed at any position in the oligonucleotide sequence and the said antisense strand is paired with a sense strand comprising any combination of phosphorothioate, methylphosphonate, and phosphate internucleotide linkages or an antisense strand comprising either phosphorothioate or methylphosphonate or phosphate linkage.

In some embodiments, the antisense strand of the dsRNA molecule comprises two blocks of nine phosphorothioate or methylphosphonate internucleotide linkages separated by 1, 2, 3, or 4 phosphate internucleotide linkages, wherein one of the phosphorothioate or methylphosphonate internucleotide linkages is placed at any position in the oligonucleotide sequence and the said antisense strand is paired with a sense strand comprising any combination of phosphorothioate, methylphosphonate, and phosphate internucleotide linkages or an antisense strand comprising either phosphorothioate or methylphosphonate or phosphate linkage.

In some embodiments, the dsRNA molecule of the disclosure further comprises one or more phosphorothioate or methylphosphonate internucleotide linkage modification within positions 1-10 of the termini position(s) of the sense or antisense strand. For example, at least 2,

3, 4, 5, 6, 7, 8, 9, or 10 nucleotides may be linked through phosphorothioate or methylphosphonate internucleotide linkage at one end or both ends of the sense or antisense strand.

In some embodiments, the dsRNA molecule of the disclosure further comprises one or more phosphorothioate or methylphosphonate internucleotide linkage modification within positions 1-10 of the internal region of the duplex of each of the sense or antisense strand. For example, at least 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides may be linked through phosphorothioate methylphosphonate internucleotide linkage at position 8-16 of the duplex region counting from the 5'-end of the sense strand; the dsRNA molecule can optionally further comprise one or more phosphorothioate or methylphosphonate internucleotide linkage modification within positions 1-10 of the termini position(s).

In some embodiments, the dsRNA molecule of the disclosure further comprises one to five phosphorothioate or methylphosphonate internucleotide linkage modification(s) within position 1-5 and one to five phosphorothioate or methylphosphonate internucleotide linkage modification(s) within position 18-23 of the sense strand (counting from the 5'-end), and one to five phosphorothioate or methylphosphonate internucleotide linkage modification at positions 1 and 2 and one to five within positions 18-23 of the antisense strand (counting from the 5'-end).

In some embodiments, the dsRNA molecule of the disclosure further comprises one phosphorothioate internucleotide linkage modification within position 1-5 and one phosphorothioate or methylphosphonate internucleotide linkage modification within position 18-23 of the sense strand (counting from the 5'-end), and one phosphorothioate internucleotide linkage modification at positions 1 and 2 and two phosphorothioate or methylphosphonate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5'-end).

In some embodiments, the dsRNA molecule of the disclosure further comprises two phosphorothioate internucleotide linkage modifications within position 1-5 and one phosphorothioate internucleotide linkage modification within position 18-23 of the sense strand (counting from the 5'-end), and one phosphorothioate internucleotide linkage modification at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5'-end).

In some embodiments, the dsRNA molecule of the disclosure further comprises two phosphorothioate internucleotide linkage modifications within position 1-5 and two phosphorothioate internucleotide linkage modifications within position 18-23 of the sense strand (counting from the 5'-end), and one phosphorothioate internucleotide linkage modification at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5'-end).

In some embodiments, the dsRNA molecule of the disclosure further comprises two phosphorothioate internucleotide linkage modifications within position 1-5 and two phosphorothioate internucleotide linkage modifications within position 18-23 of the sense strand (counting from the 5'-end), and one phosphorothioate internucleotide linkage modification at positions 1 and 2 and one phosphorothioate internucleotide linkage modification within positions 18-23 of the antisense strand (counting from the 5'-end).

In some embodiments, the dsRNA molecule of the disclosure further comprises one phosphorothioate internucleotide linkage modification within position 1-5 and one phosphorothioate internucleotide linkage modification within position 18-23 of the sense strand (counting from the 5'-end), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5'-end).

In some embodiments, the dsRNA molecule of the disclosure further comprises one phosphorothioate internucleotide linkage modification within position 1-5 and one within position 18-23 of the sense strand (counting from the 5'-end), and two phosphorothioate internucleotide linkage modification at positions 1 and 2 and one phosphorothioate internucleotide linkage modification within positions 18-23 of the antisense strand (counting from the 5'-end).

In some embodiments, the dsRNA molecule of the disclosure further comprises one phosphorothioate internucleotide linkage modification within position 1-5 (counting from the 5'-end) of the sense strand, and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and one phosphorothioate internucleotide linkage modification within positions 18-23 of the antisense strand (counting from the 5'-end).

In some embodiments, the dsRNA molecule of the disclosure further comprises two phosphorothioate internucleotide linkage modifications within position 1-5 (counting from the

5'-end) of the sense strand, and one phosphorothioate internucleotide linkage modification at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5'-end).

In some embodiments, the dsRNA molecule of the disclosure further comprises two phosphorothioate internucleotide linkage modifications within position 1-5 and one within position 18-23 of the sense strand (counting from the 5'-end), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and one phosphorothioate internucleotide linkage modification within positions 18-23 of the antisense strand (counting from the 5'-end).

In some embodiments, the dsRNA molecule of the disclosure further comprises two phosphorothioate internucleotide linkage modifications within position 1-5 and one phosphorothioate internucleotide linkage modification within position 18-23 of the sense strand (counting from the 5'-end), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5'-end).

In some embodiments, the dsRNA molecule of the disclosure further comprises two phosphorothioate internucleotide linkage modifications within position 1-5 and one phosphorothioate internucleotide linkage modification within position 18-23 of the sense strand (counting from the 5'-end), and one phosphorothioate internucleotide linkage modification at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5'-end).

In some embodiments, the dsRNA molecule of the disclosure further comprises two phosphorothioate internucleotide linkage modifications at position 1 and 2, and two phosphorothioate internucleotide linkage modifications at position 20 and 21 of the sense strand (counting from the 5'-end), and one phosphorothioate internucleotide linkage modification at positions 1 and one at position 21 of the antisense strand (counting from the 5'-end).

In some embodiments, the dsRNA molecule of the disclosure further comprises one phosphorothioate internucleotide linkage modification at position 1, and one phosphorothioate internucleotide linkage modification at position 21 of the sense strand (counting from the 5'-end), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and

two phosphorothioate internucleotide linkage modifications at positions 20 and 21 the antisense strand (counting from the 5'-end).

In some embodiments, the dsRNA molecule of the disclosure further comprises two phosphorothioate internucleotide linkage modifications at position 1 and 2, and two
5 phosphorothioate internucleotide linkage modifications at position 21 and 22 of the sense strand (counting from the 5'-end), and one phosphorothioate internucleotide linkage modification at positions 1 and one phosphorothioate internucleotide linkage modification at position 21 of the antisense strand (counting from the 5'-end).

In some embodiments, the dsRNA molecule of the disclosure further comprises one
10 phosphorothioate internucleotide linkage modification at position 1, and one phosphorothioate internucleotide linkage modification at position 21 of the sense strand (counting from the 5'-end), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications at positions 21 and 22 the antisense strand (counting from the 5'-end).

In some embodiments, the dsRNA molecule of the disclosure further comprises two
15 phosphorothioate internucleotide linkage modifications at position 1 and 2, and two phosphorothioate internucleotide linkage modifications at position 22 and 23 of the sense strand (counting from the 5'-end), and one phosphorothioate internucleotide linkage modification at positions 1 and one phosphorothioate internucleotide linkage modification at position 21 of the
20 antisense strand (counting from the 5'-end).

In some embodiments, the dsRNA molecule of the disclosure further comprises one phosphorothioate internucleotide linkage modification at position 1, and one phosphorothioate internucleotide linkage modification at position 21 of the sense strand (counting from the 5'-end), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and
25 two phosphorothioate internucleotide linkage modifications at positions 23 and 23 the antisense strand (counting from the 5'-end).

In some embodiments, compound of the disclosure comprises a pattern of backbone chiral centers. In some embodiments, a common pattern of backbone chiral centers comprises at least 5 internucleotidic linkages in the Sp configuration. In some embodiments, a common
30 pattern of backbone chiral centers comprises at least 6 internucleotidic linkages in the Sp configuration. In some embodiments, a common pattern of backbone chiral centers comprises at

least 7 internucleotidic linkages in the Sp configuration. In some embodiments, a common pattern of backbone chiral centers comprises at least 8 internucleotidic linkages in the Sp configuration. In some embodiments, a common pattern of backbone chiral centers comprises at least 9 internucleotidic linkages in the Sp configuration. In some embodiments, a common pattern of backbone chiral centers comprises at least 10 internucleotidic linkages in the Sp configuration. In some embodiments, a common pattern of backbone chiral centers comprises at least 11 internucleotidic linkages in the Sp configuration. In some embodiments, a common pattern of backbone chiral centers comprises at least 12 internucleotidic linkages in the Sp configuration. In some embodiments, a common pattern of backbone chiral centers comprises at least 13 internucleotidic linkages in the Sp configuration. In some embodiments, a common pattern of backbone chiral centers comprises at least 14 internucleotidic linkages in the Sp configuration. In some embodiments, a common pattern of backbone chiral centers comprises at least 15 internucleotidic linkages in the Sp configuration. In some embodiments, a common pattern of backbone chiral centers comprises at least 16 internucleotidic linkages in the Sp configuration. In some embodiments, a common pattern of backbone chiral centers comprises at least 17 internucleotidic linkages in the Sp configuration. In some embodiments, a common pattern of backbone chiral centers comprises at least 18 internucleotidic linkages in the Sp configuration. In some embodiments, a common pattern of backbone chiral centers comprises at least 19 internucleotidic linkages in the Sp configuration. In some embodiments, a common pattern of backbone chiral centers comprises no more than 8 internucleotidic linkages in the Rp configuration. In some embodiments, a common pattern of backbone chiral centers comprises no more than 7 internucleotidic linkages in the Rp configuration. In some embodiments, a common pattern of backbone chiral centers comprises no more than 6 internucleotidic linkages in the Rp configuration. In some embodiments, a common pattern of backbone chiral centers comprises no more than 5 internucleotidic linkages in the Rp configuration. In some embodiments, a common pattern of backbone chiral centers comprises no more than 4 internucleotidic linkages in the Rp configuration. In some embodiments, a common pattern of backbone chiral centers comprises no more than 3 internucleotidic linkages in the Rp configuration. In some embodiments, a common pattern of backbone chiral centers comprises no more than 2 internucleotidic linkages in the Rp configuration. In some embodiments, a common pattern of backbone chiral centers comprises no more than 1 internucleotidic linkages

in the Rp configuration. In some embodiments, a common pattern of backbone chiral centers comprises no more than 8 internucleotidic linkages which are not chiral (as a non-limiting example, a phosphodiester). In some embodiments, a common pattern of backbone chiral centers comprises no more than 7 internucleotidic linkages which are not chiral. In some
5 embodiments, a common pattern of backbone chiral centers comprises no more than 6 internucleotidic linkages which are not chiral. In some embodiments, a common pattern of backbone chiral centers comprises no more than 5 internucleotidic linkages which are not chiral. In some embodiments, a common pattern of backbone chiral centers comprises no more than 4 internucleotidic linkages which are not chiral. In some embodiments, a common pattern of
10 backbone chiral centers comprises no more than 3 internucleotidic linkages which are not chiral. In some embodiments, a common pattern of backbone chiral centers comprises no more than 2 internucleotidic linkages which are not chiral. In some embodiments, a common pattern of backbone chiral centers comprises no more than 1 internucleotidic linkages which are not chiral. In some embodiments, a common pattern of backbone chiral centers comprises at least 10
15 internucleotidic linkages in the Sp configuration, and no more than 8 internucleotidic linkages which are not chiral. In some embodiments, a common pattern of backbone chiral centers comprises at least 11 internucleotidic linkages in the Sp configuration, and no more than 7 internucleotidic linkages which are not chiral. In some embodiments, a common pattern of backbone chiral centers comprises at least 12 internucleotidic linkages in the Sp configuration,
20 and no more than 6 internucleotidic linkages which are not chiral. In some embodiments, a common pattern of backbone chiral centers comprises at least 13 internucleotidic linkages in the Sp configuration, and no more than 6 internucleotidic linkages which are not chiral. In some embodiments, a common pattern of backbone chiral centers comprises at least 14
25 internucleotidic linkages in the Sp configuration, and no more than 5 internucleotidic linkages which are not chiral. In some embodiments, a common pattern of backbone chiral centers comprises at least 15 internucleotidic linkages in the Sp configuration, and no more than 4 internucleotidic linkages which are not chiral. In some embodiments, the internucleotidic linkages in the Sp configuration are optionally contiguous or not contiguous. In some
30 embodiments, the internucleotidic linkages in the Rp configuration are optionally contiguous or not contiguous. In some embodiments, the internucleotidic linkages which are not chiral are optionally contiguous or not contiguous.

In some embodiments, compound of the disclosure comprises a block is a stereochemistry block. In some embodiments, a block is an Rp block in that each internucleotidic linkage of the block is Rp. In some embodiments, a 5'-block is an Rp block. In some embodiments, a 3'-block is an Rp block. In some embodiments, a block is an Sp block in that each internucleotidic linkage of the block is Sp. In some embodiments, a 5'-block is an Sp block. In some embodiments, a 3'-block is an Sp block. In some embodiments, provided oligonucleotides comprise both Rp and Sp blocks. In some embodiments, provided oligonucleotides comprise one or more Rp but no Sp blocks. In some embodiments, provided oligonucleotides comprise one or more Sp but no Rp blocks. In some embodiments, provided oligonucleotides comprise one or more PO blocks wherein each internucleotidic linkage in a natural phosphate linkage.

In some embodiments, compound of the disclosure comprises a 5'-block is an Sp block wherein each sugar moiety comprises a 2'-F modification. In some embodiments, a 5'-block is an Sp block wherein each of internucleotidic linkage is a modified internucleotidic linkage and each sugar moiety comprises a 2'-F modification. In some embodiments, a 5'-block is an Sp block wherein each of internucleotidic linkage is a phosphorothioate linkage and each sugar moiety comprises a 2'-F modification. In some embodiments, a 5'-block comprises 4 or more nucleoside units. In some embodiments, a 5'-block comprises 5 or more nucleoside units. In some embodiments, a 5'-block comprises 6 or more nucleoside units. In some embodiments, a 5'-block comprises 7 or more nucleoside units. In some embodiments, a 3'-block is an Sp block wherein each sugar moiety comprises a 2'-F modification. In some embodiments, a 3'-block is an Sp block wherein each of internucleotidic linkage is a modified internucleotidic linkage and each sugar moiety comprises a 2'-F modification. In some embodiments, a 3'-block is an Sp block wherein each of internucleotidic linkage is a phosphorothioate linkage and each sugar moiety comprises a 2'-F modification. In some embodiments, a 3'-block comprises 4 or more nucleoside units. In some embodiments, a 3'-block comprises 5 or more nucleoside units. In some embodiments, a 3'-block comprises 6 or more nucleoside units. In some embodiments, a 3'-block comprises 7 or more nucleoside units.

In some embodiments, compound of the disclosure comprises a type of nucleoside in a region or an oligonucleotide is followed by a specific type of internucleotidic linkage, *e.g.*, natural phosphate linkage, modified internucleotidic linkage, Rp chiral internucleotidic linkage,

Sp chiral internucleotidic linkage, etc. In some embodiments, A is followed by Sp. In some
embodiments, A is followed by Rp. In some embodiments, A is followed by natural phosphate
linkage (PO). In some embodiments, U is followed by Sp. In some embodiments, U is followed
by Rp. In some embodiments, U is followed by natural phosphate linkage (PO). In some
5 embodiments, C is followed by Sp. In some embodiments, C is followed by Rp. In some
embodiments, C is followed by natural phosphate linkage (PO). In some embodiments, G is
followed by Sp. In some embodiments, G is followed by Rp. In some embodiments, G is
followed by natural phosphate linkage (PO). In some embodiments, C and U are followed by
Sp. In some embodiments, C and U are followed by Rp. In some embodiments, C and U are
10 followed by natural phosphate linkage (PO). In some embodiments, A and G are followed by
Sp. In some embodiments, A and G are followed by Rp.

In some embodiments, the dsRNA molecule of the disclosure comprises mismatch(es)
with the target, within the duplex, or combinations thereof. The mismatch can occur in the
overhang region or the duplex region. The base pair can be ranked on the basis of their
15 propensity to promote dissociation or melting (*e.g.*, on the free energy of association or
dissociation of a particular pairing, the simplest approach is to examine the pairs on an individual
pair basis, though next neighbor or similar analysis can also be used). In terms of promoting
dissociation: A:U is preferred over G:C; G:U is preferred over G:C; and I:C is preferred over
G:C (I=inosine). Mismatches, *e.g.*, non-canonical or other than canonical pairings (as described
20 elsewhere herein) are preferred over canonical (A:T, A:U, G:C) pairings; and pairings which
include a universal base are preferred over canonical pairings.

In some embodiments, the dsRNA molecule of the disclosure comprises at least one of
the first 1, 2, 3, 4, or 5 base pairs within the duplex regions from the 5'-end of the antisense
strand can be chosen independently from the group of: A:U, G:U, I:C, and mismatched pairs,
25 *e.g.*, non-canonical or other than canonical pairings or pairings which include a universal base, to
promote the dissociation of the antisense strand at the 5'-end of the duplex.

In some embodiments, the nucleotide at the 1 position within the duplex region from the
5'-end in the antisense strand is selected from the group consisting of A, dA, dU, U, and dT.
Alternatively, at least one of the first 1, 2 or 3 base pair within the duplex region from the 5'-end
30 of the antisense strand is an AU base pair. For example, the first base pair within the duplex
region from the 5'-end of the antisense strand is an AU base pair.

It was found that introducing 4'-modified or 5'-modified nucleotide to the 3'-end of a phosphodiester (PO), phosphorothioate (PS), or phosphorodithioate (PS2) linkage of a dinucleotide at any position of single stranded or double stranded oligonucleotide can exert steric effect to the internucleotide linkage and, hence, protecting or stabilizing it against nucleases.

5 In some embodiments, 5'-modified nucleoside is introduced at the 3'-end of a dinucleotide at any position of single stranded or double stranded siRNA. For instance, a 5'-alkylated nucleoside may be introduced at the 3'-end of a dinucleotide at any position of single stranded or double stranded siRNA. The alkyl group at the 5' position of the ribose sugar can be racemic or chirally pure *R* or *S* isomer. An exemplary 5'-alkylated nucleoside is 5'-methyl
10 nucleoside. The 5'-methyl can be either racemic or chirally pure *R* or *S* isomer.

In some embodiments, 4'-modified nucleoside is introduced at the 3'-end of a dinucleotide at any position of single stranded or double stranded siRNA. For instance, a 4'-alkylated nucleoside may be introduced at the 3'-end of a dinucleotide at any position of single stranded or double stranded siRNA. The alkyl group at the 4' position of the ribose sugar can be
15 racemic or chirally pure *R* or *S* isomer. An exemplary 4'-alkylated nucleoside is 4'-methyl nucleoside. The 4'-methyl can be either racemic or chirally pure *R* or *S* isomer. Alternatively, a 4'-*O*-alkylated nucleoside may be introduced at the 3'-end of a dinucleotide at any position of single stranded or double stranded siRNA. The 4'-*O*-alkyl of the ribose sugar can be racemic or chirally pure *R* or *S* isomer. An exemplary 4'-*O*-alkylated nucleoside is 4'-*O*-methyl nucleoside.
20 The 4'-*O*-methyl can be either racemic or chirally pure *R* or *S* isomer.

In some embodiments, 5'-alkylated nucleoside is introduced at any position on the sense strand or antisense strand of a dsRNA, and such modification maintains or improves potency of the dsRNA. The 5'-alkyl can be either racemic or chirally pure *R* or *S* isomer. An exemplary 5'-alkylated nucleoside is 5'-methyl nucleoside. The 5'-methyl can be either racemic or chirally
25 pure *R* or *S* isomer.

In some embodiments, 4'-alkylated nucleoside is introduced at any position on the sense strand or antisense strand of a dsRNA, and such modification maintains or improves potency of the dsRNA. The 4'-alkyl can be either racemic or chirally pure *R* or *S* isomer. An exemplary 4'-alkylated nucleoside is 4'-methyl nucleoside. The 4'-methyl can be either racemic or chirally
30 pure *R* or *S* isomer.

In some embodiments, 4'-*O*-alkylated nucleoside is introduced at any position on the sense strand or antisense strand of a dsRNA, and such modification maintains or improves potency of the dsRNA. The 5'-alkyl can be either racemic or chirally pure *R* or *S* isomer. An exemplary 4'-*O*-alkylated nucleoside is 4'-*O*-methyl nucleoside. The 4'-*O*-methyl can be either
 5 racemic or chirally pure *R* or *S* isomer.

In some embodiments, the dsRNA molecule of the disclosure can comprise 2'-5' linkages (with 2'-H, 2'-OH, and 2'-OMe and with P=O or P=S). For example, the 2'-5' linkages modifications can be used to promote nuclease resistance or to inhibit binding of the sense to the antisense strand, or can be used at the 5' end of the sense strand to avoid sense strand activation
 10 by RISC.

In another embodiment, the dsRNA molecule of the disclosure can comprise L sugars (e.g., L ribose, L-arabinose with 2'-H, 2'-OH and 2'-OMe). For example, these L sugars modifications can be used to promote nuclease resistance or to inhibit binding of the sense to the antisense strand, or can be used at the 5' end of the sense strand to avoid sense strand activation
 15 by RISC.

Various publications describe multimeric siRNA which can all be used with the dsRNA of the disclosure. Such publications include WO2007/091269, US 7858769, WO2010/141511, WO2007/117686, WO2009/014887, and WO2011/031520 which are hereby incorporated by their entirety.

In some embodiments dsRNA molecules of the disclosure are 5' phosphorylated or include a phosphoryl analog at the 5' prime terminus. 5'-phosphate modifications include those which are compatible with RISC mediated gene silencing. Suitable modifications include: 5'-monophosphate ((HO)₂(O)P-O-5'); 5'-diphosphate ((HO)₂(O)P-O-P(HO)(O)-O-5'); 5'-triphosphate ((HO)₂(O)P-O-(HO)(O)P-O-P(HO)(O)-O-5'); 5'-guanosine cap (7-methylated or
 25 non-methylated) (7m-G-O-5'-(HO)(O)P-O-(HO)(O)P-O-P(HO)(O)-O-5'); 5'-adenosine cap (Appp), and any modified or unmodified nucleotide cap structure (N-O-5'-(HO)(O)P-O-(HO)(O)P-O-P(HO)(O)-O-5'); 5'-monothiophosphate (phosphorothioate; (HO)₂(S)P-O-5'); 5'-monodithiophosphate (phosphorodithioate; (HO)(HS)(S)P-O-5'), 5'-phosphorothiolate ((HO)₂(O)P-S-5'); any additional combination of oxygen/sulfur replaced monophosphate,
 30 diphosphate and triphosphates (e.g. 5'-alpha-thiotriphosphate, 5'-gamma-thiotriphosphate, etc.), 5'-phosphoramidates ((HO)₂(O)P-NH-5', (HO)(NH₂)(O)P-O-5'), 5'-alkylphosphonates

(R=alkyl=methyl, ethyl, isopropyl, propyl, etc., e.g. RP(OH)(O)-O-5' -, 5'-alkenylphosphonates (i.e. vinyl, substituted vinyl), $(\text{OH})_2(\text{O})\text{P-5'-CH}_2$ -), 5'-alkyletherphosphonates (R=alkylether=methoxymethyl (MeOCH_2 -), ethoxymethyl, etc., e.g. RP(OH)(O)-O-5' -). In one example, the modification can be placed in the antisense strand of a dsRNA molecule.

5

Linkers


In some embodiments, the conjugate or ligand described herein can be attached to an iRNA oligonucleotide with various linkers that can be cleavable or non-cleavable.

Linkers typically comprise a direct bond or an atom such as oxygen or sulfur, a unit such as NR_8 , C(O) , C(O)NH , SO , SO_2 , SO_2NH or a chain of atoms, such as, but not limited to, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, heterocyclalkyl, heterocyclalkenyl, heterocyclalkynyl, aryl, heteroaryl, heterocycl, cycloalkyl, cycloalkenyl, alkylarylalkyl, alkylarylalkenyl, alkylarylalkynyl, alkenylarylalkyl, alkenylarylalkenyl, alkenylarylalkynyl, alkynylarylalkyl, alkynylarylalkenyl, alkynylarylalkynyl, alkylheteroarylalkyl, alkylheteroarylalkenyl, alkylheteroarylalkynyl, alkenylheteroarylalkyl, alkenylheteroarylalkenyl, alkenylheteroarylalkynyl, alkynylheteroarylalkyl, alkynylheteroarylalkenyl, alkynylheteroarylalkynyl, alkylheterocyclalkyl, alkylheterocyclalkenyl, alkylheterocyclalkynyl, alkenylheterocyclalkyl, alkenylheterocyclalkenyl, alkenylheterocyclalkynyl, alkynylheterocyclalkyl, alkynylheterocyclalkenyl, alkynylheterocyclalkynyl, alkylaryl, alkenylaryl, alkynylaryl, alkylheteroaryl, alkenylheteroaryl, alkynylheteroaryl, which one or more methylenes can be interrupted or terminated by O, S, S(O) , SO_2 , $\text{N(R}_8)$, C(O) , substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclic; where R_8 is hydrogen, acyl, aliphatic or substituted aliphatic. In some embodiments, the linker is between about 1-24 atoms, 2-24, 3-24, 4-24, 5-24, 6-24, 6-18, 7-18, 8-18 atoms, 7-17, 8-17, 6-16, 7-16, or 8-16 atoms.

In some embodiments, a dsRNA of the disclosure is conjugated to a bivalent or trivalent branched linker selected from the group of structures shown in any of formula (XXXI) – (XXXIV):


30

Formula XXXI





(IV)

Formula XXXII



(V)



Formula XXXIII

Formula XXXIV

5


wherein:

q^{2A}, q^{2B}, q^{3A}, q^{3B}, q^{4A}, q^{4B}, q^{5A}, q^{5B} and q^{5C} represent independently for each occurrence 0-20 and wherein the repeating unit can be the same or different;

10 P^{2A}, P^{2B}, P^{3A}, P^{3B}, P^{4A}, P^{4B}, P^{5A}, P^{5B}, P^{5C}, T^{2A}, T^{2B}, T^{3A}, T^{3B}, T^{4A}, T^{4B}, T^{4A}, T^{5B}, T^{5C} are each independently for each occurrence absent, CO, NH, O, S, OC(O), NHC(O), CH₂, CH₂NH or CH₂O;

Q^{2A}, Q^{2B}, Q^{3A}, Q^{3B}, Q^{4A}, Q^{4B}, Q^{5A}, Q^{5B}, Q^{5C} are independently for each occurrence absent, alkylene, substituted alkylene wherein one or more methylenes can be interrupted or terminated by one or more of O, S, S(O), SO₂, N(R^N), C(R')=C(R''), C≡C or C(O);


15 R^{2A}, R^{2B}, R^{3A}, R^{3B}, R^{4A}, R^{4B}, R^{5A}, R^{5B}, R^{5C} are each independently for each occurrence absent, NH, O, S, CH₂, C(O)O, C(O)NH, NHCH(R^a)C(O), -C(O)-CH(R^a)-NH-, CO, CH=N-O,



L^{2A} , L^{2B} , L^{3A} , L^{3B} , L^{4A} , L^{4B} , L^{5A} , L^{5B} and L^{5C} represent the ligand; *i.e.* each independently for each occurrence a monosaccharide (such as GalNAc), disaccharide, trisaccharide, tetrasaccharide, oligosaccharide, or polysaccharide; and R^a is H or amino acid side chain. Trivalent conjugating GalNAc derivatives are particularly useful for use with RNAi agents for

5 inhibiting the expression of a target gene, such as those of formula (XXXV):

Formula XXXV



(VII)

wherein L^{5A} , L^{5B} and L^{5C} represent a monosaccharide, such as GalNAc derivative.

Examples of suitable bivalent and trivalent branched linker groups conjugating GalNAc

10 derivatives include, but are not limited to, the structures recited above as formulas II, VII, XI, X, and XIII.

A cleavable linking group is one which is sufficiently stable outside the cell, but which upon entry into a target cell is cleaved to release the two parts the linker is holding together. In some embodiments, the cleavable linking group is cleaved at least about 10 times, 20, times, 30

15 times, 40 times, 50 times, 60 times, 70 times, 80 times, 90 times or more, or at least about 100 times faster in a target cell or under a first reference condition (which can, *e.g.*, be selected to mimic or represent intracellular conditions) than in the blood of a subject, or under a second reference condition (which can, *e.g.*, be selected to mimic or represent conditions found in the blood or serum).

20 Cleavable linking groups are susceptible to cleavage agents, *e.g.*, pH, redox potential or the presence of degradative molecules. Generally, cleavage agents are more prevalent or found at higher levels or activities inside cells than in serum or blood. Examples of such degradative agents include: redox agents which are selected for particular substrates or which have no substrate specificity, including, *e.g.*, oxidative or reductive enzymes or reductive agents such as

25 mercaptans, present in cells, that can degrade a redox cleavable linking group by reduction; esterases; endosomes or agents that can create an acidic environment, *e.g.*, those that result in a

pH of five or lower; enzymes that can hydrolyze or degrade an acid cleavable linking group by acting as a general acid, peptidases (which can be substrate specific), and phosphatases.

A cleavable linkage group, such as a disulfide bond can be susceptible to pH. The pH of human serum is 7.4, while the average intracellular pH is slightly lower, ranging from about 7.1-7.3. Endosomes have a more acidic pH, in the range of 5.5-6.0, and lysosomes have an even more acidic pH at around 5.0. Some linkers will have a cleavable linking group that is cleaved at a suitable pH, thereby releasing a cationic lipid from the ligand inside the cell, or into the desired compartment of the cell.

A linker can include a cleavable linking group that is cleavable by a particular enzyme.

The type of cleavable linking group incorporated into a linker can depend on the cell to be targeted.

In general, the suitability of a candidate cleavable linking group can be evaluated by testing the ability of a degradative agent (or condition) to cleave the candidate linking group. It will also be desirable to also test the candidate cleavable linking group for the ability to resist cleavage in the blood or when in contact with other non-target tissue. Thus, one can determine the relative susceptibility to cleavage between a first and a second condition, where the first is selected to be indicative of cleavage in a target cell and the second is selected to be indicative of cleavage in other tissues or biological fluids, *e.g.*, blood or serum. The evaluations can be carried out in cell free systems, in cells, in cell culture, in organ or tissue culture, or in whole animals. It can be useful to make initial evaluations in cell-free or culture conditions and to confirm by further evaluations in whole animals. In some embodiments, useful candidate compounds are cleaved at least about 2, 4, 10, 20, 30, 40, 50, 60, 70, 80, 90, or about 100 times faster in the cell (or under *in vitro* conditions selected to mimic intracellular conditions) as compared to blood or serum (or under *in vitro* conditions selected to mimic extracellular conditions).

Redox cleavable linking groups

In some embodiments, a cleavable linking group is a redox cleavable linking group that is cleaved upon reduction or oxidation. An example of reductively cleavable linking group is a disulphide linking group (-S-S-). To determine if a candidate cleavable linking group is a suitable “reductively cleavable linking group,” or for example is suitable for use with a particular

iRNA moiety and particular targeting agent one can look to methods described herein. For example, a candidate can be evaluated by incubation with dithiothreitol (DTT), or other reducing agent using reagents known in the art, which mimic the rate of cleavage which would be observed in a cell, *e.g.*, a target cell. The candidates can also be evaluated under conditions which are selected to mimic blood or serum conditions. In one, candidate compounds are cleaved by at most about 10% in the blood. In other embodiments, useful candidate compounds are degraded at least about 2, 4, 10, 20, 30, 40, 50, 60, 70, 80, 90, or about 100 times faster in the cell (or under *in vitro* conditions selected to mimic intracellular conditions) as compared to blood (or under *in vitro* conditions selected to mimic extracellular conditions). The rate of cleavage of candidate compounds can be determined using standard enzyme kinetics assays under conditions chosen to mimic intracellular media and compared to conditions chosen to mimic extracellular media.

Phosphate-based cleavable linking groups

In some embodiments, a cleavable linker comprises a phosphate-based cleavable linking group. A phosphate-based cleavable linking group is cleaved by agents that degrade or hydrolyze the phosphate group. An example of an agent that cleaves phosphate groups in cells are enzymes such as phosphatases in cells. Examples of phosphate-based linking groups are -O-P(O)(OR_k)-O-, -O-P(S)(OR_k)-O-, -O-P(S)(SR_k)-O-, -S-P(O)(OR_k)-O-, -O-P(O)(OR_k)-S-, -S-P(O)(OR_k)-S-, -O-P(S)(OR_k)-S-, -S-P(S)(OR_k)-O-, -O-P(O)(R_k)-O-, -O-P(S)(R_k)-O-, -S-P(O)(R_k)-O-, -S-P(S)(R_k)-O-, -S-P(O)(R_k)-S-, -O-P(S)(R_k)-S-. In some embodiments, phosphate-based linking groups are -O-P(O)(OH)-O-, -O-P(S)(OH)-O-, -O-P(S)(SH)-O-, -S-P(O)(OH)-O-, -O-P(O)(OH)-S-, -S-P(O)(OH)-S-, -O-P(S)(OH)-S-, -S-P(S)(OH)-O-, -O-P(O)(H)-O-, -O-P(S)(H)-O-, -S-P(O)(H)-O-, -S-P(S)(H)-O-, -S-P(O)(H)-S-, -O-P(S)(H)-S-. In some embodiments, a phosphate-based linking group is -O-P(O)(OH)-O-. These candidates can be evaluated using methods analogous to those described above.

Acid cleavable linking groups

In some embodiments, a cleavable linker comprises an acid cleavable linking group. An acid cleavable linking group is a linking group that is cleaved under acidic conditions. In some embodiments acid cleavable linking groups are cleaved in an acidic environment with a pH of

about 6.5 or lower (*e.g.*, about 6.0, 5.75, 5.5, 5.25, 5.0, or lower), or by agents such as enzymes that can act as a general acid. In a cell, specific low pH organelles, such as endosomes and lysosomes can provide a cleaving environment for acid cleavable linking groups. Examples of acid cleavable linking groups include but are not limited to hydrazones, esters, and esters of amino acids. Acid cleavable groups can have the general formula $-C=NN-$, $C(O)O-$, or $-OC(O)-$. In some embodiments, the carbon attached to the oxygen of the ester (the alkoxy group) is an aryl group, substituted alkyl group, or tertiary alkyl group such as dimethyl pentyl or t-butyl. These candidates can be evaluated using methods analogous to those described above.

Ester-based cleavable linking groups

In some embodiments, a cleavable linker comprises an ester-based cleavable linking group. An ester-based cleavable linking group is cleaved by enzymes such as esterases and amidases in cells. Examples of ester-based cleavable linking groups include but are not limited to esters of alkylene, alkenylene and alkynylene groups. Ester cleavable linking groups have the general formula $-C(O)O-$, or $-OC(O)-$. These candidates can be evaluated using methods analogous to those described above.

Peptide-based cleavable linking groups

In some embodiments, a cleavable linker comprises a peptide-based cleavable linking group. A peptide-based cleavable linking group is cleaved by enzymes such as peptidases and proteases in cells. Peptide-based cleavable linking groups are peptide bonds formed between amino acids to yield oligopeptides (*e.g.*, dipeptides, tripeptides *etc.*) and polypeptides. Peptide-based cleavable groups do not include the amide group ($-C(O)NH-$). The amide group can be formed between any alkylene, alkenylene or alkynylene. A peptide bond is a special type of amide bond formed between amino acids to yield peptides and proteins. The peptide-based cleavage group is generally limited to the peptide bond (*i.e.*, the amide bond) formed between amino acids yielding peptides and proteins and does not include the entire amide functional group. Peptide-based cleavable linking groups have the general formula – $NHCHRAC(O)NHCHRBC(O)-$, where RA and RB are the R groups of the two adjacent amino acids. These candidates can be evaluated using methods analogous to those described above. Representative U.S. patents that teach the preparation of RNA conjugates include, but are not

limited to, U.S. Pat. Nos. 4,828,979; 4,948,882; 5,218,105; 5,525,465; 5,541,313; 5,545,730; 5,552,538; 5,578,717; 5,580,731; 5,591,584; 5,109,124; 5,118,802; 5,138,045; 5,414,077; 5,486,603; 5,512,439; 5,578,718; 5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762,779; 4,789,737; 4,824,941; 4,835,263; 4,876,335; 4,904,582; 4,958,013; 5,082,830; 5,112,963; 5,214,136; 5,082,830; 5,112,963; 5,214,136; 5,245,022; 5,254,469; 5,258,506; 5,262,536; 5,272,250; 5,292,873; 5,317,098; 5,371,241; 5,391,723; 5,416,203; 5,451,463; 5,510,475; 5,512,667; 5,514,785; 5,565,552; 5,567,810; 5,574,142; 5,585,481; 5,587,371; 5,595,726; 5,597,696; 5,599,923; 5,599,928 and 5,688,941; 6,294,664; 6,320,017; 6,576,752; 6,783,931; 6,900,297; 7,037,646; 8,106,022, the entire contents of each of which is herein incorporated by reference.

It is not necessary for all positions in a given compound to be uniformly modified, and in fact more than one of the aforementioned modifications may be incorporated in a single compound or even at a single nucleoside within an iRNA. The present disclosure also includes iRNA compounds that are chimeric compounds.

“Chimeric” iRNA compounds, or “chimeras,” in the context of the present disclosure, are iRNA compounds, *e.g.*, dsRNAs, that contain two or more chemically distinct regions, each made up of at least one monomer unit, *i.e.*, a nucleotide in the case of a dsRNA compound. These iRNAs typically contain at least one region wherein the RNA is modified so as to confer upon the iRNA increased resistance to nuclease degradation, increased cellular uptake, and/or increased binding affinity for the target nucleic acid. An additional region of the iRNA may serve as a substrate for enzymes capable of cleaving RNA:DNA or RNA:RNA hybrids. By way of example, RNase H is a cellular endonuclease which cleaves the RNA strand of an RNA:DNA duplex. Activation of RNase H, therefore, results in cleavage of the RNA target, thereby greatly enhancing the efficiency of iRNA inhibition of gene expression. Consequently, comparable results can often be obtained with shorter iRNAs when chimeric dsRNAs are used, compared to phosphorothioate deoxy dsRNAs hybridizing to the same target region. Cleavage of the RNA target can be routinely detected by gel electrophoresis and, if necessary, associated nucleic acid hybridization techniques known in the art.

In certain instances, the RNA of an iRNA can be modified by a non-ligand group. A number of non-ligand molecules have been conjugated to iRNAs in order to enhance the activity, cellular distribution or cellular uptake of the iRNA, and procedures for performing such

conjugations are available in the scientific literature. Such non-ligand moieties have included lipid moieties, such as cholesterol (Kubo, T. *et al.*, *Biochem. Biophys. Res. Comm.*, 2007, 365(1):54-61; Letsinger *et al.*, *Proc. Natl. Acad. Sci. USA*, 1989, 86:6553), cholic acid (Manoharan *et al.*, *Bioorg. Med. Chem. Lett.*, 1994, 4:1053), a thioether, *e.g.*, hexyl-S-tritylthiol (Manoharan *et al.*, *Ann. N.Y. Acad. Sci.*, 1992, 660:306; Manoharan *et al.*, *Bioorg. Med. Chem. Lett.*, 1993, 3:2765), a thiocholesterol (Oberhauser *et al.*, *Nucl. Acids Res.*, 1992, 20:533), an aliphatic chain, *e.g.*, dodecandiol or undecyl residues (Saison-Behmoaras *et al.*, *EMBO J.*, 1991, 10:111; Kabanov *et al.*, *FEBS Lett.*, 1990, 259:327; Svinarchuk *et al.*, *Biochimie*, 1993, 75:49), a phospholipid, *e.g.*, di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan *et al.*, *Tetrahedron Lett.*, 1995, 36:3651; Shea *et al.*, *Nucl. Acids Res.*, 1990, 18:3777), a polyamine or a polyethylene glycol chain (Manoharan *et al.*, *Nucleosides & Nucleotides*, 1995, 14:969), or adamantane acetic acid (Manoharan *et al.*, *Tetrahedron Lett.*, 1995, 36:3651), a palmityl moiety (Mishra *et al.*, *Biochim. Biophys. Acta*, 1995, 1264:229), or an octadecylamine or hexylamino-carbonyl-oxysterol moiety (Crooke *et al.*, *J. Pharmacol. Exp. Ther.*, 1996, 277:923). Representative United States patents that teach the preparation of such RNA conjugates have been listed above. Typical conjugation protocols involve the synthesis of an RNAs bearing an aminolinker at one or more positions of the sequence. The amino group is then reacted with the molecule being conjugated using appropriate coupling or activating reagents. The conjugation reaction may be performed either with the RNA still bound to the solid support or following cleavage of the RNA, in solution phase. Purification of the RNA conjugate by HPLC typically affords the pure conjugate.

Delivery of iRNA

The delivery of an iRNA to a subject in need thereof can be achieved in a number of different ways. *In vivo* delivery can be performed directly by administering a composition comprising an iRNA, *e.g.* a dsRNA, to a subject. Alternatively, delivery can be performed indirectly by administering one or more vectors that encode and direct the expression of the iRNA. These alternatives are discussed further below.

Direct delivery

In general, any method of delivering a nucleic acid molecule can be adapted for use with an iRNA (*see e.g.*, Akhtar S. and Julian RL. (1992) *Trends Cell. Biol.* 2(5):139-144 and WO94/02595, which are incorporated herein by reference in their entireties). However, there are three factors that are important to consider in order to successfully deliver an iRNA molecule *in vivo*: (a) biological stability of the delivered molecule, (2) preventing non-specific effects, and (3) accumulation of the delivered molecule in the target tissue. The non-specific effects of an iRNA can be minimized by local administration, for example by direct injection or implantation into a tissue (as a non-limiting example, the eye) or topically administering the preparation.

Local administration to a treatment site maximizes local concentration of the agent, limits the exposure of the agent to systemic tissues that may otherwise be harmed by the agent or that may degrade the agent, and permits a lower total dose of the iRNA molecule to be administered. Several studies have shown successful knockdown of gene products when an iRNA is administered locally. For example, intraocular delivery of a VEGF dsRNA by intravitreal injection in cynomolgus monkeys (Tolentino, MJ., *et al* (2004) *Retina* 24:132-138) and subretinal injections in mice (Reich, SJ., *et al* (2003) *Mol. Vis.* 9:210-216) were both shown to prevent neovascularization in an experimental model of age-related macular degeneration. In addition, direct intratumoral injection of a dsRNA in mice reduces tumor volume (Pille, J., *et al* (2005) *Mol. Ther.* 11:267-274) and can prolong survival of tumor-bearing mice (Kim, WJ., *et al* (2006) *Mol. Ther.* 14:343-350; Li, S., *et al* (2007) *Mol. Ther.* 15:515-523). RNA interference has also shown success with local delivery to the CNS by direct injection (Dorn, G., *et al.* (2004) *Nucleic Acids* 32:e49; Tan, PH., *et al* (2005) *Gene Ther.* 12:59-66; Makimura, H., *et al* (2002) *BMC Neurosci.* 3:18; Shishkina, GT., *et al* (2004) *Neuroscience* 129:521-528; Thakker, ER., *et al* (2004) *Proc. Natl. Acad. Sci. U.S.A.* 101:17270-17275; Akaneya, Y., *et al* (2005) *J. Neurophysiol.* 93:594-602) and to the lungs by intranasal administration (Howard, KA., *et al* (2006) *Mol. Ther.* 14:476-484; Zhang, X., *et al* (2004) *J. Biol. Chem.* 279:10677-10684; Bitko, V., *et al* (2005) *Nat. Med.* 11:50-55). For administering an iRNA systemically for the treatment of a disease, the RNA can be modified or alternatively delivered using a drug delivery system; both methods act to prevent the rapid degradation of the dsRNA by endo- and exo-nucleases *in vivo*.

Modification of the RNA or the pharmaceutical carrier can also permit targeting of the iRNA composition to the target tissue and avoid undesirable off-target effects. iRNA molecules can be modified by chemical conjugation to other groups, *e.g.*, a lipid or carbohydrate group as described herein. Such conjugates can be used to target iRNA to particular cells, *e.g.*, liver cells, *e.g.*, hepatocytes. For example, GalNAc conjugates or lipid (*e.g.*, LNP) formulations can be used to target iRNA to particular cells, *e.g.*, liver cells, *e.g.*, hepatocytes.

iRNA molecules can also be modified by chemical conjugation to lipophilic groups such as cholesterol to enhance cellular uptake and prevent degradation. For example, an iRNA directed against ApoB conjugated to a lipophilic cholesterol moiety was injected systemically into mice and resulted in knockdown of apoB mRNA in both the liver and jejunum (Soutschek, J., *et al* (2004) *Nature* 432:173-178). Conjugation of an iRNA to an aptamer has been shown to inhibit tumor growth and mediate tumor regression in a mouse model of prostate cancer (McNamara, JO., *et al* (2006) *Nat. Biotechnol.* 24:1005-1015). In an alternative embodiment, the iRNA can be delivered using drug delivery systems such as a nanoparticle, a dendrimer, a polymer, liposomes, or a cationic delivery system. Positively charged cationic delivery systems facilitate binding of an iRNA molecule (negatively charged) and also enhance interactions at the negatively charged cell membrane to permit efficient uptake of an iRNA by the cell. Cationic lipids, dendrimers, or polymers can either be bound to an iRNA, or induced to form a vesicle or micelle (*see e.g.*, Kim SH., *et al* (2008) *Journal of Controlled Release* 129(2):107-116) that encases an iRNA. The formation of vesicles or micelles further prevents degradation of the iRNA when administered systemically. Methods for making and administering cationic- iRNA complexes are well within the abilities of one skilled in the art (*see e.g.*, Sorensen, DR., *et al* (2003) *J. Mol. Biol* 327:761-766; Verma, UN., *et al* (2003) *Clin. Cancer Res.* 9:1291-1300; Arnold, AS *et al* (2007) *J. Hypertens.* 25:197-205, which are incorporated herein by reference in their entirety). Some non-limiting examples of drug delivery systems useful for systemic delivery of iRNAs include DOTAP (Sorensen, DR., *et al* (2003), *supra*; Verma, UN., *et al* (2003), *supra*), Oligofectamine, "solid nucleic acid lipid particles" (Zimmermann, TS., *et al* (2006) *Nature* 441:111-114), cardiolipin (Chien, PY., *et al* (2005) *Cancer Gene Ther.* 12:321-328; Pal, A., *et al* (2005) *Int J. Oncol.* 26:1087-1091), polyethyleneimine (Bonnet ME., *et al* (2008) *Pharm. Res.* Aug 16 Epub ahead of print; Aigner, A. (2006) *J. Biomed. Biotechnol.* 71659), Arg-Gly-Asp (RGD) peptides (Liu, S. (2006) *Mol. Pharm.* 3:472-487), and

polyamidoamines (Tomalia, DA., *et al* (2007) *Biochem. Soc. Trans.* 35:61-67; Yoo, H., *et al* (1999) *Pharm. Res.* 16:1799-1804). In some embodiments, an iRNA forms a complex with cyclodextrin for systemic administration. Methods for administration and pharmaceutical compositions of iRNAs and cyclodextrins can be found in U.S. Patent No. 7,427,605, which is
5 herein incorporated by reference in its entirety.

Vector encoded iRNAs

In another aspect, iRNA targeting VEGF-A can be expressed from transcription units inserted into DNA or RNA vectors (*see, e.g.*, Couture, A, *et al.*, *TIG.* (1996), 12:5-10; Skillern, A., *et al.*, International PCT Publication No. WO 00/22113, Conrad, International PCT
10 Publication No. WO 00/22114, and Conrad, U.S. Pat. No. 6,054,299). Expression can be transient (on the order of hours to weeks) or sustained (weeks to months or longer), depending upon the specific construct used and the target tissue or cell type. These transgenes can be introduced as a linear construct, a circular plasmid, or a viral vector, which can be an integrating
15 or non-integrating vector. The transgene can also be constructed to permit it to be inherited as an extrachromosomal plasmid (Gassmann, *et al.*, *Proc. Natl. Acad. Sci. USA* (1995) 92:1292).

The individual strand or strands of an iRNA can be transcribed from a promoter on an expression vector. Where two separate strands are to be expressed to generate, for example, a dsRNA, two separate expression vectors can be co-introduced (*e.g.*, by transfection or infection)
20 into a target cell. Alternatively, each individual strand of a dsRNA can be transcribed by promoters both of which are located on the same expression plasmid. In some embodiments, a dsRNA is expressed as an inverted repeat joined by a linker polynucleotide sequence such that the dsRNA has a stem and loop structure.

An iRNA expression vector is typically a DNA plasmid or viral vector. An expression
25 vector compatible with eukaryotic cells, *e.g.*, with vertebrate cells, can be used to produce recombinant constructs for the expression of an iRNA as described herein. Eukaryotic cell expression vectors are well known in the art and are available from a number of commercial sources. Typically, such vectors contain convenient restriction sites for insertion of the desired nucleic acid segment. Delivery of iRNA expressing vectors can be systemic, such as by
30 intravenous or intramuscular administration, by administration to target cells ex-planted from the

patient followed by reintroduction into the patient, or by any other means that allows for introduction into a desired target cell.

An iRNA expression plasmid can be transfected into a target cell as a complex with a cationic lipid carrier (*e.g.*, Oligofectamine) or a non-cationic lipid-based carrier (*e.g.*, Transit-TKO™). Multiple lipid transfections for iRNA-mediated knockdowns targeting different regions of a target RNA over a period of a week or more are also contemplated by the disclosure. Successful introduction of vectors into host cells can be monitored using various known methods. For example, transient transfection can be signaled with a reporter, such as a fluorescent marker, such as Green Fluorescent Protein (GFP). Stable transfection of cells *ex vivo* can be ensured using markers that provide the transfected cell with resistance to specific environmental factors (*e.g.*, antibiotics and drugs), such as hygromycin B resistance.

Viral vector systems which can be utilized with the methods and compositions described herein include, but are not limited to, (a) adenovirus vectors; (b) retrovirus vectors, including but not limited to lentiviral vectors, moloney murine leukemia virus, *etc.*; (c) adeno- associated virus vectors; (d) herpes simplex virus vectors; (e) SV40 vectors; (f) polyoma virus vectors; (g) papilloma virus vectors; (h) picornavirus vectors; (i) pox virus vectors such as an orthopox, *e.g.*, vaccinia virus vectors or avipox, *e.g.* canary pox or fowl pox; and (j) a helper-dependent or gutless adenovirus. Replication-defective viruses can also be advantageous. Different vectors will or will not become incorporated into the cells' genome. The constructs can include viral sequences for transfection, if desired. Alternatively, the construct may be incorporated into vectors capable of episomal replication, *e.g.* EPV and EBV vectors. Constructs for the recombinant expression of an iRNA will generally require regulatory elements, *e.g.*, promoters, enhancers, *etc.*, to ensure the expression of the iRNA in target cells. Other aspects to consider for vectors and constructs are further described below.

Vectors useful for the delivery of an iRNA will include regulatory elements (promoter, enhancer, *etc.*) sufficient for expression of the iRNA in the desired target cell or tissue. The regulatory elements can be chosen to provide either constitutive or regulated/inducible expression.

Expression of the iRNA can be precisely regulated, for example, by using an inducible regulatory sequence that is sensitive to certain physiological regulators, *e.g.*, circulating glucose levels, or hormones (Docherty *et al.*, 1994, *FASEB J.* 8:20-24). Such inducible expression

systems, suitable for the control of dsRNA expression in cells or in mammals include, for example, regulation by ecdysone, by estrogen, progesterone, tetracycline, chemical inducers of dimerization, and isopropyl- β -D1-thiogalactopyranoside (IPTG). A person skilled in the art would be able to choose the appropriate regulatory/promoter sequence based on the intended use of the iRNA transgene.

In a specific embodiment, viral vectors that contain nucleic acid sequences encoding an iRNA can be used. For example, a retroviral vector can be used (see Miller *et al.*, *Meth. Enzymol.* 217:581-599 (1993)). These retroviral vectors contain the components necessary for the correct packaging of the viral genome and integration into the host cell DNA. The nucleic acid sequences encoding an iRNA are cloned into one or more vectors, which facilitates delivery of the nucleic acid into a patient. More detail about retroviral vectors can be found, for example, in Boesen *et al.*, *Biotherapy* 6:291-302 (1994), which describes the use of a retroviral vector to deliver the *mdr1* gene to hematopoietic stem cells in order to make the stem cells more resistant to chemotherapy. Other references illustrating the use of retroviral vectors in gene therapy are: Clowes *et al.*, *J. Clin. Invest.* 93:644-651 (1994); Kiem *et al.*, *Blood* 83:1467-1473 (1994); Salmons and Gunzberg, *Human Gene Therapy* 4:129-141 (1993); and Grossman and Wilson, *Curr. Opin. in Genetics and Devel.* 3:110-114 (1993). Lentiviral vectors contemplated for use include, for example, the HIV based vectors described in U.S. Patent Nos. 6,143,520; 5,665,557; and 5,981,276, which are herein incorporated by reference.

Adenoviruses are also contemplated for use in delivery of iRNAs. Adenoviruses are especially attractive vehicles, *e.g.*, for delivering genes to respiratory epithelia. Adenoviruses naturally infect respiratory epithelia where they cause a mild disease. Other targets for adenovirus-based delivery systems are liver, the central nervous system, endothelial cells, and muscle. Adenoviruses have the advantage of being capable of infecting non-dividing cells. Kozarsky and Wilson, *Current Opinion in Genetics and Development* 3:499-503 (1993) present a review of adenovirus-based gene therapy. Bout *et al.*, *Human Gene Therapy* 5:3-10 (1994) demonstrated the use of adenovirus vectors to transfer genes to the respiratory epithelia of rhesus monkeys. Other instances of the use of adenoviruses in gene therapy can be found in Rosenfeld *et al.*, *Science* 252:431-434 (1991); Rosenfeld *et al.*, *Cell* 68:143-155 (1992); Mastrangeli *et al.*, *J. Clin. Invest.* 91:225-234 (1993); PCT Publication WO94/12649; and Wang, *et al.*, *Gene Therapy* 2:775-783 (1995). A suitable AV vector for expressing an iRNA featured in the

disclosure, a method for constructing the recombinant AV vector, and a method for delivering the vector into target cells, are described in Xia H *et al.* (2002), *Nat. Biotech.* 20: 1006-1010.

Use of Adeno-associated virus (AAV) vectors is also contemplated (Walsh *et al.*, *Proc. Soc. Exp. Biol. Med.* 204:289-300 (1993); U.S. Pat. No. 5,436,146). In some embodiments, the
5 iRNA can be expressed as two separate, complementary single-stranded RNA molecules from a recombinant AAV vector having, for example, either the U6 or H1 RNA promoters, or the cytomegalovirus (CMV) promoter. Suitable AAV vectors for expressing the dsRNA featured in the disclosure, methods for constructing the recombinant AV vector, and methods for delivering the vectors into target cells are described in Samulski R *et al.* (1987), *J. Virol.* 61: 3096-3101;
10 Fisher K J *et al.* (1996), *J. Virol.*, 70: 520-532; Samulski R *et al.* (1989), *J. Virol.* 63: 3822-3826; U.S. Pat. No. 5,252,479; U.S. Pat. No. 5,139,941; International Patent Application No. WO 94/13788; and International Patent Application No. WO 93/24641, the entire disclosures of which are herein incorporated by reference.

Another typical viral vector is a pox virus such as a vaccinia virus, for example an
15 attenuated vaccinia such as Modified Virus Ankara (MVA) or NYVAC, an avipox such as fowl pox or canary pox.

The tropism of viral vectors can be modified by pseudotyping the vectors with envelope proteins or other surface antigens from other viruses, or by substituting different viral capsid proteins, as appropriate. For example, lentiviral vectors can be pseudotyped with surface proteins
20 from vesicular stomatitis virus (VSV), rabies, Ebola, Mokola, and the like. AAV vectors can be made to target different cells by engineering the vectors to express different capsid protein serotypes; *see, e.g.*, Rabinowitz J E *et al.* (2002), *J Virol* 76:791-801, the entire disclosure of which is herein incorporated by reference.

The pharmaceutical preparation of a vector can include the vector in an acceptable
25 diluent, or can include a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery vector can be produced intact from recombinant cells, *e.g.*, retroviral vectors, the pharmaceutical preparation can include one or more cells which produce the gene delivery system.

III. Pharmaceutical compositions containing iRNA

In some embodiments, the disclosure provides pharmaceutical compositions containing an iRNA, as described herein, and a pharmaceutically acceptable carrier. The pharmaceutical composition containing the iRNA is useful for treating a disease or disorder related to the expression or activity of VEGF-A (*e.g.*, an angiogenic ocular disorder). Such pharmaceutical compositions are formulated based on the mode of delivery. In some embodiments, compositions can be formulated for localized delivery, *e.g.*, by intraocular delivery (*e.g.*, intravitreal administration, *e.g.*, intravitreal injection; transscleral administration, *e.g.*, transscleral injection; subconjunctival administration, *e.g.*, subconjunctival injection; retrobulbar administration, *e.g.*, retrobulbar injection; intracameral administration, *e.g.*, intracameral injection; or subretinal administration, *e.g.*, subretinal injection). In other embodiments, compositions can be formulated for topical delivery. In another example, compositions can be formulated for systemic administration via parenteral delivery, *e.g.*, by intravenous (IV) delivery. In some embodiments, a composition provided herein (*e.g.*, a composition comprising a GalNAc conjugate or an LNP formulation) is formulated for intravenous delivery.

The pharmaceutical compositions featured herein are administered in a dosage sufficient to inhibit expression of VEGF-A. In general, a suitable dose of iRNA will be in the range of 0.01 to 200.0 milligrams per kilogram body weight of the recipient per day. The pharmaceutical composition may be administered once daily, or the iRNA may be administered as two, three, or more sub-doses at appropriate intervals throughout the day or even using continuous infusion or delivery through a controlled release formulation. In that case, the iRNA contained in each sub-dose must be correspondingly smaller in order to achieve the total daily dosage. The dosage unit can also be compounded for delivery over several days, *e.g.*, using a conventional sustained release formulation which provides sustained release of the iRNA over a several day period. Sustained release formulations are well known in the art and are particularly useful for delivery of agents at a particular site, such as can be used with the agents of the present disclosure. In this embodiment, the dosage unit contains a corresponding multiple of the daily dose.

The effect of a single dose on VEGF-A levels can be long lasting, such that subsequent doses are administered at not more than 3, 4, or 5-day intervals, or at not more than 1, 2, 3, 4, 12, 24, or 36-week intervals.

The skilled artisan will appreciate that certain factors may influence the dosage and timing required to effectively treat a subject, including but not limited to the severity of the disease or disorder, previous treatments, the general health and/or age of the subject, and other diseases present. Moreover, treatment of a subject with a therapeutically effective amount of a composition can include a single treatment or a series of treatments. Estimates of effective dosages and *in vivo* half-lives for the individual iRNAs encompassed by the disclosure can be made using conventional methodologies or on the basis of *in vivo* testing using a suitable animal model.

A suitable animal model, *e.g.*, a mouse or a cynomolgus monkey, *e.g.*, an animal containing a transgene expressing human VEGF-A, can be used to determine the therapeutically effective dose and/or an effective dosage regimen administration of VEGF-A siRNA.

The present disclosure also includes pharmaceutical compositions and formulations that include the iRNA compounds featured herein. The pharmaceutical compositions of the present disclosure may be administered in a number of ways depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be local (*e.g.*, by intraocular injection), topical (*e.g.*, by an eye drop solution), or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; subdermal, *e.g.*, via an implanted device; or intracranial, *e.g.*, by intraparenchymal, intrathecal, or intraventricular administration.

Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable. Coated condoms, gloves and the like may also be useful. Suitable topical formulations include those in which the iRNAs featured in the disclosure are in admixture with a topical delivery agent such as lipids, liposomes, fatty acids, fatty acid esters, steroids, chelating agents and surfactants. Suitable lipids and liposomes include neutral (*e.g.*, dioleoylphosphatidyl DOPE ethanolamine, dimyristoylphosphatidyl choline DMPC, distearoylphosphatidyl choline) negative (*e.g.*, dimyristoylphosphatidyl glycerol DMPG) and cationic (*e.g.*, dioleoyltetramethylaminopropyl DOTAP and dioleoylphosphatidyl ethanolamine DOTMA). iRNAs featured in the disclosure may be encapsulated within liposomes or may form complexes thereto, in particular to cationic liposomes. Alternatively, iRNAs may be complexed

to lipids, in particular to cationic lipids. Suitable fatty acids and esters include but are not limited to arachidonic acid, oleic acid, eicosanoic acid, lauric acid, caprylic acid, capric acid, myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprate, tricaprate, monoolein, dilaurin, glyceryl 1-monocaprate, 1-dodecylazacycloheptan-2-one, an acylcarnitine, an
5 acylcholine, or a C₁₋₂₀ alkyl ester (*e.g.*, isopropylmyristate IPM), monoglyceride, diglyceride or pharmaceutically acceptable salt thereof. Topical formulations are described in detail in U.S. Patent No. 6,747,014, which is incorporated herein by reference.

Liposomal formulations

10 There are many organized surfactant structures besides microemulsions that have been studied and used for the formulation of drugs. These include monolayers, micelles, bilayers and vesicles. Vesicles, such as liposomes, have attracted great interest because of their specificity and the duration of action they offer from the standpoint of drug delivery. As used in the present disclosure, the term "liposome" means a vesicle composed of amphiphilic lipids arranged in a
15 spherical bilayer or bilayers.

Liposomes are unilamellar or multilamellar vesicles which have a membrane formed from a lipophilic material and an aqueous interior. The aqueous portion contains the composition to be delivered. Cationic liposomes possess the advantage of being able to fuse to the cell wall. Non-cationic liposomes, although not able to fuse as efficiently with the cell wall,
20 are taken up by macrophages *in vivo*.

In order to traverse intact mammalian skin, lipid vesicles must pass through a series of fine pores, each with a diameter less than 50 nm, under the influence of a suitable transdermal gradient. Therefore, it is desirable to use a liposome which is highly deformable and able to pass through such fine pores.

25 Further advantages of liposomes include; liposomes obtained from natural phospholipids are biocompatible and biodegradable; liposomes can incorporate a wide range of water and lipid soluble drugs; liposomes can protect encapsulated drugs in their internal compartments from metabolism and degradation (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245). Important
30 considerations in the preparation of liposome formulations are the lipid surface charge, vesicle size and the aqueous volume of the liposomes.

Liposomes are useful for the transfer and delivery of active ingredients to the site of action. Because the liposomal membrane is structurally similar to biological membranes, when liposomes are applied to a tissue, the liposomes start to merge with the cellular membranes and as the merging of the liposome and cell progresses, the liposomal contents are emptied into the cell where the active agent may act.

Liposomal formulations have been the focus of extensive investigation as the mode of delivery for many drugs. There is growing evidence that for topical administration, liposomes present several advantages over other formulations. Such advantages include reduced side-effects related to high systemic absorption of the administered drug, increased accumulation of the administered drug at the desired target, and the ability to administer a wide variety of drugs, both hydrophilic and hydrophobic, into the skin.

Several reports have detailed the ability of liposomes to deliver agents including high-molecular weight DNA into the skin. Compounds including analgesics, antibodies, hormones and high-molecular weight DNAs have been administered to the skin. The majority of applications resulted in the targeting of the upper epidermis

Liposomes fall into two broad classes. Cationic liposomes are positively charged liposomes which interact with the negatively charged DNA molecules to form a stable complex. The positively charged DNA/liposome complex binds to the negatively charged cell surface and is internalized in an endosome. Due to the acidic pH within the endosome, the liposomes are ruptured, releasing their contents into the cell cytoplasm (Wang *et al.*, *Biochem. Biophys. Res. Commun.*, 1987, 147, 980-985).

Liposomes which are pH-sensitive or negatively charged, entrap DNA rather than complex with it. Since both the DNA and the lipid are similarly charged, repulsion rather than complex formation occurs. Nevertheless, some DNA is entrapped within the aqueous interior of these liposomes. pH-sensitive liposomes have been used to deliver DNA encoding the thymidine kinase gene to cell monolayers in culture. Expression of the exogenous gene was detected in the target cells (Zhou *et al.*, *Journal of Controlled Release*, 1992, 19, 269-274).

One major type of liposomal composition includes phospholipids other than naturally derived phosphatidylcholine. Neutral liposome compositions, for example, can be formed from dimyristoyl phosphatidylcholine (DMPC) or dipalmitoyl phosphatidylcholine (DPPC). Anionic liposome compositions generally are formed from dimyristoyl phosphatidylglycerol, while

anionic fusogenic liposomes are formed primarily from dioleoyl phosphatidylethanolamine (DOPE). Another type of liposomal composition is formed from phosphatidylcholine (PC) such as, for example, soybean PC, and egg PC. Another type is formed from mixtures of phospholipid and/or phosphatidylcholine and/or cholesterol.

5 Several studies have assessed the topical delivery of liposomal drug formulations to the skin. Application of liposomes containing interferon to guinea pig skin resulted in a reduction of skin herpes sores while delivery of interferon via other means (*e.g.*, as a solution or as an emulsion) were ineffective (Weiner *et al.*, *Journal of Drug Targeting*, 1992, 2, 405-410). Further, an additional study tested the efficacy of interferon administered as part of a liposomal
10 formulation to the administration of interferon using an aqueous system, and concluded that the liposomal formulation was superior to aqueous administration (du Plessis *et al.*, *Antiviral Research*, 1992, 18, 259-265).

Non-ionic liposomal systems have also been examined to determine their utility in the delivery of drugs to the skin, in particular systems comprising non-ionic surfactant and
15 cholesterol. Non-ionic liposomal formulations comprising Novasome™ I (glyceryl dilaurate/cholesterol/polyoxyethylene-10-stearyl ether) and Novasome™ II (glyceryl distearate/cholesterol/polyoxyethylene-10-stearyl ether) were used to deliver cyclosporin-A into the dermis of mouse skin. Results indicated that such non-ionic liposomal systems were effective in facilitating the deposition of cyclosporin-A into different layers of the skin (Hu *et al.*
20 S.T.P. *Pharma. Sci.*, 1994, 4, 6, 466).

Liposomes also include “sterically stabilized” liposomes, a term which, as used herein, refers to liposomes comprising one or more specialized lipids that, when incorporated into liposomes, result in enhanced circulation lifetimes relative to liposomes lacking such specialized lipids. Examples of sterically stabilized liposomes are those in which part of the vesicle-forming
25 lipid portion of the liposome (A) comprises one or more glycolipids, such as monosialoganglioside G_{M1}, or (B) is derivatized with one or more hydrophilic polymers, such as a polyethylene glycol (PEG) moiety. While not wishing to be bound by any particular theory, it is thought in the art that, at least for sterically stabilized liposomes containing gangliosides, sphingomyelin, or PEG-derivatized lipids, the enhanced circulation half-life of these sterically
30 stabilized liposomes derives from a reduced uptake into cells of the reticuloendothelial system (RES) (Allen *et al.*, *FEBS Letters*, 1987, 223, 42; Wu *et al.*, *Cancer Research*, 1993, 53, 3765).

Various liposomes comprising one or more glycolipids are known in the art. Papahadjopoulos *et al.* (*Ann. N.Y. Acad. Sci.*, 1987, 507, 64) reported the ability of monosialoganglioside G_{M1}, galactocerebroside sulfate and phosphatidylinositol to improve blood half-lives of liposomes. These findings were expounded upon by Gabizon *et al.* (*Proc. Natl. Acad. Sci. U.S.A.*, 1988, 85, 6949). U.S. Pat. No. 4,837,028 and WO 88/04924, both to Allen *et al.*, disclose liposomes comprising (1) sphingomyelin and (2) the ganglioside G_{M1} or a galactocerebroside sulfate ester. U.S. Pat. No. 5,543,152 (Webb *et al.*) discloses liposomes comprising sphingomyelin. Liposomes comprising 1,2-sn-dimyristoylphosphatidylcholine are disclosed in WO 97/13499 (Lim *et al.*).

Many liposomes comprising lipids derivatized with one or more hydrophilic polymers, and methods of preparation thereof, are known in the art. Sunamoto *et al.* (*Bull. Chem. Soc. Jpn.*, 1980, 53, 2778) described liposomes comprising a nonionic detergent, 2C₁₂15G, that contains a PEG moiety. Illum *et al.* (*FEBS Lett.*, 1984, 167, 79) noted that hydrophilic coating of polystyrene particles with polymeric glycols results in significantly enhanced blood half-lives. Synthetic phospholipids modified by the attachment of carboxylic groups of polyalkylene glycols (*e.g.*, PEG) are described by Sears (U.S. Pat. Nos. 4,426,330 and 4,534,899). Klibanov *et al.* (*FEBS Lett.*, 1990, 268, 235) described experiments demonstrating that liposomes comprising phosphatidylethanolamine (PE) derivatized with PEG or PEG stearate have significant increases in blood circulation half-lives. Blume *et al.* (*Biochimica et Biophysica Acta*, 1990, 1029, 91) extended such observations to other PEG-derivatized phospholipids, *e.g.*, DSPE-PEG, formed from the combination of distearoylphosphatidylethanolamine (DSPE) and PEG. Liposomes having covalently bound PEG moieties on their external surface are described in European Patent No. EP 0 445 131 B1 and WO 90/04384 to Fisher. Liposome compositions containing 1-20 mole percent of PE derivatized with PEG, and methods of use thereof, are described by Woodle *et al.* (U.S. Pat. Nos. 5,013,556 and 5,356,633) and Martin *et al.* (U.S. Pat. No. 5,213,804 and European Patent No. EP 0 496 813 B1). Liposomes comprising a number of other lipid-polymer conjugates are disclosed in WO 91/05545 and U.S. Pat. No. 5,225,212 (both to Martin *et al.*) and in WO 94/20073 (Zalipsky *et al.*). Liposomes comprising PEG-modified ceramide lipids are described in WO 96/10391 (Choi *et al.*). U.S. Pat. No. 5,540,935 (Miyazaki *et al.*) and U.S. Pat. No. 5,556,948 (Tagawa *et al.*) describe PEG-containing liposomes that can be further derivatized with functional moieties on their surfaces.

A number of liposomes comprising nucleic acids are known in the art. WO 96/40062 to Thierry *et al.* discloses methods for encapsulating high molecular weight nucleic acids in liposomes. U.S. Pat. No. 5,264,221 to Tagawa *et al.* discloses protein-bonded liposomes and asserts that the contents of such liposomes may include a dsRNA. U.S. Pat. No. 5,665,710 to Rahman *et al.* describes certain methods of encapsulating oligodeoxynucleotides in liposomes. WO 97/04787 to Love *et al.* discloses liposomes comprising dsRNAs targeted to the raf gene.

Transfersomes are yet another type of liposomes, and are highly deformable lipid aggregates which are attractive candidates for drug delivery vehicles. Transfersomes may be described as lipid droplets which are so highly deformable that they are easily able to penetrate through pores which are smaller than the droplet. Transfersomes are adaptable to the environment in which they are used, *e.g.*, they are self-optimizing (adaptive to the shape of pores in the skin), self-repairing, frequently reach their targets without fragmenting, and often self-loading. To make transfersomes it is possible to add surface edge-activators, usually surfactants, to a standard liposomal composition. Transfersomes have been used to deliver serum albumin to the skin. The transfersome-mediated delivery of serum albumin has been shown to be as effective as subcutaneous injection of a solution containing serum albumin.

Surfactants find wide application in formulations such as emulsions (including microemulsions) and liposomes. The most common way of classifying and ranking the properties of the many different types of surfactants, both natural and synthetic, is by the use of the hydrophile/lipophile balance (HLB). The nature of the hydrophilic group (also known as the "head") provides the most useful means for categorizing the different surfactants used in formulations (Rieger, in *Pharmaceutical Dosage Forms*, Marcel Dekker, Inc., New York, N.Y., 1988, p. 285).

If the surfactant molecule is not ionized, it is classified as a nonionic surfactant. Nonionic surfactants find wide application in pharmaceutical and cosmetic products and are usable over a wide range of pH values. In general, their HLB values range from 2 to about 18 depending on their structure. Nonionic surfactants include nonionic esters such as ethylene glycol esters, propylene glycol esters, glyceryl esters, polyglyceryl esters, sorbitan esters, sucrose esters, and ethoxylated esters. Nonionic alkanolamides and ethers such as fatty alcohol ethoxylates, propoxylated alcohols, and ethoxylated/propoxylated block polymers are also included in this

class. The polyoxyethylene surfactants are the most popular members of the nonionic surfactant class.

If the surfactant molecule carries a negative charge when it is dissolved or dispersed in water, the surfactant is classified as anionic. Anionic surfactants include carboxylates such as soaps, acyl lactylates, acyl amides of amino acids, esters of sulfuric acid such as alkyl sulfates and ethoxylated alkyl sulfates, sulfonates such as alkyl benzene sulfonates, acyl isethionates, acyl taurates and sulfosuccinates, and phosphates. The most important members of the anionic surfactant class are the alkyl sulfates and the soaps.

If the surfactant molecule carries a positive charge when it is dissolved or dispersed in water, the surfactant is classified as cationic. Cationic surfactants include quaternary ammonium salts and ethoxylated amines. The quaternary ammonium salts are the most used members of this class.

If the surfactant molecule has the ability to carry either a positive or negative charge, the surfactant is classified as amphoteric. Amphoteric surfactants include acrylic acid derivatives, substituted alkylamides, N-alkylbetaines and phosphatides.

The use of surfactants in drug products, formulations and in emulsions has been reviewed (Rieger, in *Pharmaceutical Dosage Forms*, Marcel Dekker, Inc., New York, N.Y., 1988, p. 285).

Nucleic acid lipid particles

In some embodiments, a VEGF-A dsRNA featured in the disclosure is fully encapsulated in the lipid formulation, *e.g.*, to form a SPLP, pSPLP, SNALP, or other nucleic acid-lipid particle. SNALPs and SPLPs typically contain a cationic lipid, a non-cationic lipid, and a lipid that prevents aggregation of the particle (*e.g.*, a PEG-lipid conjugate). SNALPs and SPLPs are extremely useful for systemic applications, as they exhibit extended circulation lifetimes following intravenous (i.v.) injection and accumulate at distal sites (*e.g.*, sites physically separated from the administration site). SPLPs include “pSPLP,” which include an encapsulated condensing agent-nucleic acid complex as set forth in PCT Publication No. WO 00/03683. The particles of the present disclosure typically have a mean diameter of about 50 nm to about 150 nm, more typically about 60 nm to about 130 nm, more typically about 70 nm to about 110 nm, most typically about 70 nm to about 90 nm, and are substantially nontoxic. In addition, the nucleic acids when present in the nucleic acid-lipid particles of the present disclosure are

resistant in aqueous solution to degradation with a nuclease. Nucleic acid-lipid particles and their method of preparation are disclosed in, *e.g.*, U.S. Patent Nos. 5,976,567; 5,981,501; 6,534,484; 6,586,410; 6,815,432; and PCT Publication No. WO 96/40964.

In some embodiments, the lipid to drug ratio (mass/mass ratio) (*e.g.*, lipid to dsRNA ratio) will be in the range of from about 1:1 to about 50:1, from about 1:1 to about 25:1, from about 3:1 to about 15:1, from about 4:1 to about 10:1, from about 5:1 to about 9:1, or about 6:1 to about 9:1.

The cationic lipid may be, for example, N,N-dioleoyl-N,N-dimethylammonium chloride (DODAC), N,N-distearyl-N,N-dimethylammonium bromide (DDAB), N-(1-(2,3-dioleoyloxy)propyl)-N,N,N-trimethylammonium chloride (DOTAP), N-(1-(2,3-dioleoyloxy)propyl)-N,N,N-trimethylammonium chloride (DOTMA), N,N-dimethyl-2,3-dioleoyloxypropylamine (DODMA), 1,2-DiLinoleoyloxy-N,N-dimethylaminopropane (DLinDMA), 1,2-Dilinolenyloxy-N,N-dimethylaminopropane (DLinDMA), 1,2-Dilinoleylcarbamoyloxy-3-dimethylaminopropane (DLin-C-DAP), 1,2-Dilinoleoyloxy-3-(dimethylamino)acetoxyp propane (DLin-DAC), 1,2-Dilinoleoyloxy-3-morpholinopropane (DLin-MA), 1,2-Dilinoleoyl-3-dimethylaminopropane (DLinDAP), 1,2-Dilinoleylthio-3-dimethylaminopropane (DLin-S-DMA), 1-Linoleoyl-2-linoleoyloxy-3-dimethylaminopropane (DLin-2-DMA), 1,2-Dilinoleoyloxy-3-trimethylaminopropane chloride salt (DLin-TMA.Cl), 1,2-Dilinoleoyl-3-trimethylaminopropane chloride salt (DLin-TAP.Cl), 1,2-Dilinoleoyloxy-3-(N-methylpiperazino)propane (DLin-MPZ), or 3-(N,N-Dilinoleylamino)-1,2-propanediol (DLinAP), 3-(N,N-Dioleylamino)-1,2-propanedio (DOAP), 1,2-Dilinoleoyloxy-3-(2-N,N-dimethylamino)ethoxypropane (DLin-EG-DMA), 1,2-Dilinolenyloxy-N,N-dimethylaminopropane (DLinDMA), 2,2-Dilinoleyl-4-dimethylaminomethyl-[1,3]-dioxolane (DLin-K-DMA) or analogs thereof, (3aR,5s,6aS)-N,N-dimethyl-2,2-di((9Z,12Z)-octadeca-9,12-dienyl)tetrahydro-3aH-cyclopenta[d][1,3]dioxol-5-amine (ALN100), (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate (MC3), 1,1'-(2-(4-(2-((2-(bis(2-hydroxydodecyl)amino)ethyl)(2-hydroxydodecyl)amino)ethyl)piperazin-1-yl)ethylazanediyldidodecan-2-ol (Tech G1), or a mixture thereof. The cationic lipid may comprise from about 20 mol % to about 50 mol % or about 40 mol % of the total lipid present in the particle.

In some embodiments, the compound 2,2-Dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane can be used to prepare lipid-siRNA nanoparticles. Synthesis of 2,2-Dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane is described in United States provisional patent application number 61/107,998 filed on October 23, 2008, which is herein incorporated by reference.

5 In some embodiments, the lipid-siRNA particle includes 40% 2, 2-Dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane: 10% DSPC: 40% Cholesterol: 10% PEG-C-DOMG (mole percent) with a particle size of 63.0 ± 20 nm and a 0.027 siRNA/Lipid Ratio.

The non-cationic lipid may be an anionic lipid or a neutral lipid including, but not limited to, distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC),
 10 dipalmitoylphosphatidylcholine (DPPC), dioleoylphosphatidylglycerol (DOPG), dipalmitoylphosphatidylglycerol (DPPG), dioleoyl-phosphatidylethanolamine (DOPE), palmitoyloleoylphosphatidylcholine (POPC), palmitoyloleoylphosphatidylethanolamine (POPE), dioleoyl- phosphatidylethanolamine 4-(N-maleimidomethyl)-cyclohexane-1- carboxylate (DOPE-mal), dipalmitoyl phosphatidyl ethanolamine (DPPE), dimyristoylphosphoethanolamine
 15 (DMPE), distearoyl-phosphatidyl-ethanolamine (DSPE), 16-O-monomethyl PE, 16-O-dimethyl PE, 18-1 -trans PE, 1 -stearoyl-2-oleoyl- phosphatidylethanolamine (SOPE), cholesterol, or a mixture thereof. The non-cationic lipid may be from about 5 mol % to about 90 mol %, about 10 mol %, or about 58 mol % if cholesterol is included, of the total lipid present in the particle.


The conjugated lipid that inhibits aggregation of particles may be, for example, a
 20 polyethyleneglycol (PEG)-lipid including, without limitation, a PEG-diacylglycerol (DAG), a PEG-dialkylloxypropyl (DAA), a PEG-phospholipid, a PEG-ceramide (Cer), or a mixture thereof. The PEG-DAA conjugate may be, for example, a PEG-dilauryloxypropyl (C₁₂), a PEG-dimyristyloxypropyl (C₁₄), a PEG-dipalmitoyloxypropyl (C₁₆), or a PEG- distearyloxypropyl (C₁₈). The conjugated lipid that prevents aggregation of particles may be from 0 mol % to about
 25 20 mol % or about 2 mol % of the total lipid present in the particle.

In some embodiments, the nucleic acid-lipid particle further includes cholesterol at, *e.g.*, about 10 mol % to about 60 mol % or about 48 mol % of the total lipid present in the particle.

In some embodiments, the iRNA is formulated in a lipid nanoparticle (LNP).

LNP01

In some embodiments, the lipidoid ND98·4HCl (MW 1487) (see U.S. Patent Application No. 12/056,230, filed 3/26/2008, which is herein incorporated by reference), Cholesterol (Sigma-Aldrich), and PEG-Ceramide C16 (Avanti Polar Lipids) can be used to prepare lipid-dsRNA nanoparticles (*e.g.*, LNP01 particles). Stock solutions of each in ethanol can be prepared as follows: ND98, 133 mg/ml; Cholesterol, 25 mg/ml, PEG-Ceramide C16, 100 mg/ml. The ND98, Cholesterol, and PEG-Ceramide C16 stock solutions can then be combined in a, *e.g.*, 42:48:10 molar ratio. The combined lipid solution can be mixed with aqueous dsRNA (*e.g.*, in sodium acetate pH 5) such that the final ethanol concentration is about 35-45% and the final sodium acetate concentration is about 100-300 mM. Lipid-dsRNA nanoparticles typically form spontaneously upon mixing. Depending on the desired particle size distribution, the resultant nanoparticle mixture can be extruded through a polycarbonate membrane (*e.g.*, 100 nm cut-off) using, for example, a thermobarrel extruder, such as Lipex Extruder (Northern Lipids, Inc). In some cases, the extrusion step can be omitted. Ethanol removal and simultaneous buffer exchange can be accomplished by, for example, dialysis or tangential flow filtration. Buffer can be exchanged with, for example, phosphate buffered saline (PBS) at about pH 7, *e.g.*, about pH 6.9, about pH 7.0, about pH 7.1, about pH 7.2, about pH 7.3, or about pH 7.4.



Formula 1

LNP01 formulations are described, *e.g.*, in International Application Publication No. WO 2008/042973, which is hereby incorporated by reference.

Additional exemplary lipid-dsRNA formulations are provided in the following table.

Table 6: Exemplary lipid formulations

	Cationic Lipid	cationic lipid/non-cationic lipid/cholesterol/PEG-lipid conjugate Lipid:siRNA ratio
SNALP	1,2-Dilinolenyloxy-N,N-dimethylaminopropane (DLinDMA)	DLinDMA/DPPC/Cholesterol/PEG-cDMA (57.1/7.1/34.4/1.4) lipid:siRNA ~ 7:1
S-XTC	2,2-Dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (XTC)	XTC/DPPC/Cholesterol/PEG-cDMA 57.1/7.1/34.4/1.4 lipid:siRNA ~ 7:1
LNP05	2,2-Dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (XTC)	XTC/DSPC/Cholesterol/PEG-DMG 57.5/7.5/31.5/3.5 lipid:siRNA ~ 6:1
LNP06	2,2-Dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (XTC)	XTC/DSPC/Cholesterol/PEG-DMG 57.5/7.5/31.5/3.5 lipid:siRNA ~ 11:1
LNP07	2,2-Dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (XTC)	XTC/DSPC/Cholesterol/PEG-DMG 60/7.5/31/1.5, lipid:siRNA ~ 6:1
LNP08	2,2-Dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (XTC)	XTC/DSPC/Cholesterol/PEG-DMG 60/7.5/31/1.5, lipid:siRNA ~ 11:1
LNP09	2,2-Dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (XTC)	XTC/DSPC/Cholesterol/PEG-DMG 50/10/38.5/1.5 Lipid:siRNA 10:1
LNP10	(3aR,5s,6aS)-N,N-dimethyl-2,2-di((9Z,12Z)-octadeca-9,12-dienyl)tetrahydro-3aH-cyclopenta[d][1,3]dioxol-5-amine (ALN100)	ALN100/DSPC/Cholesterol/PEG-DMG 50/10/38.5/1.5 Lipid:siRNA 10:1
LNP11	(6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate (MC3)	MC-3/DSPC/Cholesterol/PEG-DMG 50/10/38.5/1.5 Lipid:siRNA 10:1

LNP12	1,1'-(2-(4-(2-((2-(bis(2-hydroxydodecyl)amino)ethyl)(2-hydroxydodecyl)amino)ethyl)piperazin-1-yl)ethylazanediy)didodecan-2-ol (C12-200)	C12-200/DSPC/Cholesterol/PEG-DMG 50/10/38.5/1.5 Lipid:siRNA 10:1
LNP13	XTC	XTC/DSPC/Chol/PEG-DMG 50/10/38.5/1.5 Lipid:siRNA: 33:1
LNP14	MC3	MC3/DSPC/Chol/PEG-DMG 40/15/40/5 Lipid:siRNA: 11:1
LNP15	MC3	MC3/DSPC/Chol/PEG-DSG/GalNAc-PEG-DSG 50/10/35/4.5/0.5 Lipid:siRNA: 11:1
LNP16	MC3	MC3/DSPC/Chol/PEG-DMG 50/10/38.5/1.5 Lipid:siRNA: 7:1
LNP17	MC3	MC3/DSPC/Chol/PEG-DSG 50/10/38.5/1.5 Lipid:siRNA: 10:1
LNP18	MC3	MC3/DSPC/Chol/PEG-DMG 50/10/38.5/1.5 Lipid:siRNA: 12:1
LNP19	MC3	MC3/DSPC/Chol/PEG-DMG 50/10/35/5 Lipid:siRNA: 8:1
LNP20	MC3	MC3/DSPC/Chol/PEG-DPG 50/10/38.5/1.5 Lipid:siRNA: 10:1
LNP21	C12-200	C12-200/DSPC/Chol/PEG-DSG 50/10/38.5/1.5 Lipid:siRNA: 7:1
LNP22	XTC	XTC/DSPC/Chol/PEG-DSG 50/10/38.5/1.5 Lipid:siRNA: 10:1

DSPC: distearoylphosphatidylcholine

DPPC: dipalmitoylphosphatidylcholine

PEG-DMG: PEG-didimyristoyl glycerol (C14-PEG, or PEG-C14) (PEG with avg mol wt of 2000)

5 PEG-DSG: PEG-distyryl glycerol (C18-PEG, or PEG-C18) (PEG with avg mol wt of 2000)

PEG-cDMA: PEG-carbamoyl-1,2-dimyristyloxypropylamine (PEG with avg mol wt of 2000)

SNALP (1,2-Dilinolenyloxy-N,N-dimethylaminopropane (DLinDMA)) comprising formulations are described in International Publication No. WO2009/127060, filed April 15,
10 2009, which is hereby incorporated by reference.

XTC comprising formulations are described, *e.g.*, in U.S. Provisional Serial No. 61/148,366, filed January 29, 2009; U.S. Provisional Serial No. 61/156,851, filed March 2, 2009; U.S. Provisional Serial No. 61/185,712, filed June 10, 2009; U.S. Provisional Serial No. 61/228,373, filed July 24, 2009; U.S. Provisional Serial No. 61/239,686, filed September 3,
15 2009, and International Application No. PCT/US2010/022614, filed January 29, 2010, which are hereby incorporated by reference.

MC3 comprising formulations are described, *e.g.*, in U.S. Provisional Serial No. 61/244,834, filed September 22, 2009, U.S. Provisional Serial No. 61/185,800, filed June 10, 2009, and International Application No. PCT/US10/28224, filed June 10, 2010, which are hereby
20 incorporated by reference.

ALNY-100 comprising formulations are described, *e.g.*, International patent application number PCT/US09/63933, filed on November 10, 2009, which is hereby incorporated by reference.

C12-200 comprising formulations are described in U.S. Provisional Serial No. 61/175,770, filed May 5, 2009 and International Application No. PCT/US10/33777, filed May 5,
25 2010, which are hereby incorporated by reference.

Synthesis of cationic lipids

Any of the compounds, *e.g.*, cationic lipids and the like, used in the nucleic acid-lipid particles featured in the disclosure may be prepared by known organic synthesis techniques. All substituents are as defined below unless indicated otherwise.

5 “Alkyl” means a straight chain or branched, noncyclic or cyclic, saturated aliphatic hydrocarbon containing from 1 to 24 carbon atoms. Representative saturated straight chain alkyls include methyl, ethyl, *n*-propyl, *n*-butyl, *n*-pentyl, *n*-hexyl, and the like; while saturated branched alkyls include isopropyl, *sec*-butyl, isobutyl, *tert*-butyl, isopentyl, and the like. Representative saturated cyclic alkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like; while unsaturated cyclic alkyls include cyclopentenyl and cyclohexenyl, and the like.

10 “Alkenyl” means an alkyl, as defined above, containing at least one double bond between adjacent carbon atoms. Alkenyls include both *cis* and *trans* isomers. Representative straight chain and branched alkenyls include ethylenyl, propylenyl, 1-butenyl, 2-butenyl, isobutylenyl, 1-pentenyl, 2-pentenyl, 3-methyl-1-butenyl, 2-methyl-2-butenyl, 2,3-dimethyl-2-butenyl, and the like.

20 “Alkynyl” means any alkyl or alkenyl, as defined above, which additionally contains at least one triple bond between adjacent carbons. Representative straight chain and branched alkynyls include acetylenyl, propynyl, 1-butylnyl, 2-butylnyl, 1-pentylnyl, 2-pentylnyl, 3-methyl-1-butylnyl, and the like.

“Acyl” means any alkyl, alkenyl, or alkynyl wherein the carbon at the point of attachment is substituted with an oxo group, as defined below. For example, -C(=O)alkyl, -C(=O)alkenyl, and -C(=O)alkynyl are acyl groups.

25 “Heterocycle” means a 5- to 7-membered monocyclic, or 7- to 10-membered bicyclic, heterocyclic ring which is either saturated, unsaturated, or aromatic, and which contains from 1 or 2 heteroatoms independently selected from nitrogen, oxygen and sulfur, and wherein the nitrogen and sulfur heteroatoms may be optionally oxidized, and the nitrogen heteroatom may be optionally quaternized, including bicyclic rings in which any of the above heterocycles are fused to a benzene ring. The heterocycle may be attached via any heteroatom or carbon atom.

30 Heterocycles include heteroaryls as defined below. Heterocycles include morpholinyl, pyrrolidinonyl, pyrrolidinyl, piperidinyl, piperizynyl, hydantoinyl, valerolactamyl, oxiranyl,

oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyridinyl, tetrahydroprimidinyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, tetrahydropyrimidinyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, and the like.

The terms “optionally substituted alkyl”, “optionally substituted alkenyl”, “optionally substituted alkynyl”, “optionally substituted acyl”, and “optionally substituted heterocycle” means that, when substituted, at least one hydrogen atom is replaced with a substituent. In the case of an oxo substituent (=O) two hydrogen atoms are replaced. In this regard, substituents include oxo, halogen, heterocycle, -CN, -

OR^x , $-\text{NR}^x\text{R}^y$, $-\text{NR}^x\text{C}(=\text{O})\text{R}^y$, $-\text{NR}^x\text{SO}_2\text{R}^y$, $-\text{C}(=\text{O})\text{R}^x$, $-\text{C}(=\text{O})\text{OR}^x$, $-\text{C}(=\text{O})\text{NR}^x\text{R}^y$, $-\text{SO}_n\text{R}^x$


and $-\text{SO}_n\text{NR}^x\text{R}^y$, wherein n is 0, 1 or 2, R^x and R^y are the same or different and independently hydrogen, alkyl or heterocycle, and each of said alkyl and heterocycle substituents may be further substituted with one or more of oxo, halogen, -OH, -CN, alkyl, $-\text{OR}^x$, heterocycle, $-\text{NR}^x\text{R}^y$, $-\text{NR}^x\text{C}(=\text{O})\text{R}^y$, $-\text{NR}^x\text{SO}_2\text{R}^y$, $-\text{C}(=\text{O})\text{R}^x$, $-\text{C}(=\text{O})\text{OR}^x$, $-\text{C}(=\text{O})\text{NR}^x\text{R}^y$, $-\text{SO}_n\text{R}^x$ and $-\text{SO}_n\text{NR}^x\text{R}^y$.

“Halogen” means fluoro, chloro, bromo and iodo.

In some embodiments, the methods featured in the disclosure may require the use of protecting groups. Protecting group methodology is well known to those skilled in the art (*see, for example*, PROTECTIVE GROUPS IN ORGANIC SYNTHESIS, Green, T.W. *et al.*, Wiley-Interscience, New York City, 1999). Briefly, protecting groups within the context of this disclosure are any group that reduces or eliminates unwanted reactivity of a functional group. A protecting group can be added to a functional group to mask its reactivity during certain reactions and then removed to reveal the original functional group. In some embodiments an “alcohol protecting group” is used. An “alcohol protecting group” is any group which decreases or eliminates unwanted reactivity of an alcohol functional group. Protecting groups can be added and removed using techniques well known in the art.


Synthesis of Formula A

In some embodiments, nucleic acid-lipid particles featured in the disclosure are formulated using a cationic lipid of formula A:



where R1 and R2 are independently alkyl, alkenyl or alkynyl, each can be optionally substituted, and R3 and R4 are independently lower alkyl or R3 and R4 can be taken together to form an optionally substituted heterocyclic ring. In some embodiments, the cationic lipid is XTC (2,2-Dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane). In general, the lipid of formula A above may be made by the following Reaction Schemes 1 or 2, wherein all substituents are as defined above unless indicated otherwise.


10 Scheme 1



Lipid A, where R₁ and R₂ are independently alkyl, alkenyl or alkynyl, each can be optionally substituted, and R₃ and R₄ are independently lower alkyl or R₃ and R₄ can be taken together to form an optionally substituted heterocyclic ring, can be prepared according to Scheme 1. Ketone 1 and bromide 2 can be purchased or prepared according to methods known to those of ordinary skill in the art. Reaction of 1 and 2 yields ketal 3. Treatment of ketal 3 with amine 4 yields lipids of formula A. The lipids of formula A can be converted to the

corresponding ammonium salt with an organic salt of formula 5, where X is anion counter ion selected from halogen, hydroxide, phosphate, sulfate, or the like.

Scheme 2



- 5 Alternatively, the ketone 1 starting material can be prepared according to Scheme 2. Grignard reagent 6 and cyanide 7 can be purchased or prepared according to methods known to those of ordinary skill in the art. Reaction of 6 and 7 yields ketone 1. Conversion of ketone 1 to the corresponding lipids of formula A is as described in Scheme 1.


10 Synthesis of MC3

- Preparation of DLin-M-C3-DMA (*i.e.*, (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate) was as follows. A solution of (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-ol (0.53 g), 4-N,N-dimethylaminobutyric acid hydrochloride (0.51 g), 4-N,N-dimethylaminopyridine (0.61g) and 1-ethyl-3-(3-
- 15 dimethylaminopropyl)carbodiimide hydrochloride (0.53 g) in dichloromethane (5 mL) was stirred at room temperature overnight. The solution was washed with dilute hydrochloric acid followed by dilute aqueous sodium bicarbonate. The organic fractions were dried over anhydrous magnesium sulphate, filtered and the solvent removed on a rotovap. The residue was passed down a silica gel column (20 g) using a 1-5% methanol/dichloromethane elution gradient.

Fractions containing the purified product were combined and the solvent removed, yielding a colorless oil (0.54 g).

Synthesis of ALNY-100

Synthesis of ketal 519 [ALNY-100] was performed using the following scheme 3:



Synthesis of 515:

To a stirred suspension of LiAlH_4 (3.74 g, 0.09852 mol) in 200 ml anhydrous THF in a two neck RBF (1L), was added a solution of 514 (10g, 0.04926mol) in 70 mL of THF slowly at 0°C under nitrogen atmosphere. After complete addition, reaction mixture was warmed to room temperature and then heated to reflux for 4 h. Progress of the reaction was monitored by TLC. After completion of reaction (by TLC) the mixture was cooled to 0°C and quenched with careful addition of saturated Na_2SO_4 solution. Reaction mixture was stirred for 4 h at room temperature and filtered off. Residue was washed well with THF. The filtrate and washings were mixed and diluted with 400 mL dioxane and 26 mL conc. HCl and stirred for 20 minutes at room temperature. The volatilities were stripped off under vacuum to furnish the hydrochloride salt of 515 as a white solid. Yield: 7.12 g 1H-NMR (DMSO, 400MHz): δ = 9.34 (broad, 2H), 5.68 (s, 2H), 3.74 (m, 1H), 2.66-2.60 (m, 2H), 2.50-2.45 (m, 5H).

Synthesis of 516:

To a stirred solution of compound 515 in 100 mL dry DCM in a 250 mL two neck RBF, was added NEt_3 (37.2 mL, 0.2669 mol) and cooled to 0°C under nitrogen atmosphere. After a slow addition of N-(benzyloxy-carbonyloxy)-succinimide (20 g, 0.08007 mol) in 50 mL dry DCM, reaction mixture was allowed to warm to room temperature. After completion of the

reaction (2-3 h by TLC) mixture was washed successively with 1N HCl solution (1 x 100 mL) and saturated NaHCO₃ solution (1 x 50 mL). The organic layer was then dried over anhyd. Na₂SO₄ and the solvent was evaporated to give crude material which was purified by silica gel column chromatography to get 516 as sticky mass. Yield: 11g (89%). ¹H-NMR (CDCl₃, 400MHz): δ = 7.36-7.27(m, 5H), 5.69 (s, 2H), 5.12 (s, 2H), 4.96 (br., 1H) 2.74 (s, 3H), 2.60(m, 2H), 2.30-2.25(m, 2H). LC-MS [M+H]⁺ -232.3 (96.94%).

Synthesis of 517A and 517B:

The cyclopentene 516 (5 g, 0.02164 mol) was dissolved in a solution of 220 mL acetone and water (10:1) in a single neck 500 mL RBF and to it was added N-methyl morpholine-N-oxide (7.6 g, 0.06492 mol) followed by 4.2 mL of 7.6% solution of OsO₄ (0.275 g, 0.00108 mol) in tert-butanol at room temperature. After completion of the reaction (~ 3 h), the mixture was quenched with addition of solid Na₂SO₃ and resulting mixture was stirred for 1.5 h at room temperature. Reaction mixture was diluted with DCM (300 mL) and washed with water (2 x 100 mL) followed by saturated NaHCO₃ (1 x 50 mL) solution, water (1 x 30 mL) and finally with brine (1x 50 mL). Organic phase was dried over an. Na₂SO₄ and solvent was removed in vacuum. Silica gel column chromatographic purification of the crude material was afforded a mixture of diastereomers, which were separated by prep HPLC. Yield: - 6 g crude

517A - Peak-1 (white solid), 5.13 g (96%). ¹H-NMR (DMSO, 400MHz): δ = 7.39-7.31(m, 5H), 5.04(s, 2H), 4.78-4.73 (m, 1H), 4.48-4.47(d, 2H), 3.94-3.93(m, 2H), 2.71(s, 3H), 1.72- 1.67(m, 4H). LC-MS - [M+H]⁺-266.3, [M+NH₄]⁺-283.5 present, HPLC-97.86%. Stereochemistry confirmed by X-ray.

Synthesis of 518:

Using a procedure analogous to that described for the synthesis of compound 505, compound 518 (1.2 g, 41%) was obtained as a colorless oil. ¹H-NMR (CDCl₃, 400MHz): δ = 7.35-7.33(m, 4H), 7.30-7.27(m, 1H), 5.37-5.27(m, 8H), 5.12(s, 2H), 4.75(m, 1H), 4.58-4.57(m, 2H), 2.78-2.74(m, 7H), 2.06-2.00(m, 8H), 1.96-1.91(m, 2H), 1.62(m, 4H), 1.48(m, 2H), 1.37-1.25(br m, 36H), 0.87(m, 6H). HPLC-98.65%.

General Procedure for the Synthesis of Compound 519:

A solution of compound 518 (1 eq) in hexane (15 mL) was added in a drop-wise fashion to an ice-cold solution of LAH in THF (1 M, 2 eq). After complete addition, the mixture was heated at 40°C over 0.5 h then cooled again on an ice bath. The mixture was carefully hydrolyzed with saturated aqueous Na₂SO₄ then filtered through celite and reduced to an oil.

5 Column chromatography provided the pure 519 (1.3 g, 68%) which was obtained as a colorless oil. ¹³C NMR = 130.2, 130.1 (x2), 127.9 (x3), 112.3, 79.3, 64.4, 44.7, 38.3, 35.4, 31.5, 29.9 (x2), 29.7, 29.6 (x2), 29.5 (x3), 29.3 (x2), 27.2 (x3), 25.6, 24.5, 23.3, 226, 14.1; Electrospray MS (+ve): Molecular weight for C₄₄H₈₀NO₂ (M + H)⁺ Calc. 654.6, Found 654.6.

Formulations prepared by either the standard or extrusion-free method can be
10 characterized in similar manners. For example, formulations are typically characterized by visual inspection. They should be whitish translucent solutions free from aggregates or sediment. Particle size and particle size distribution of lipid-nanoparticles can be measured by light scattering using, for example, a Malvern Zetasizer Nano ZS (Malvern, USA). Particles should be about 20-300 nm, such as 40-100 nm in size. The particle size distribution should be
15 unimodal. The total dsRNA concentration in the formulation, as well as the entrapped fraction, is estimated using a dye exclusion assay. A sample of the formulated dsRNA can be incubated with an RNA-binding dye, such as Ribogreen (Molecular Probes) in the presence or absence of a formulation disrupting surfactant, *e.g.*, 0.5% Triton-X100. The total dsRNA in the formulation can be determined by the signal from the sample containing the surfactant, relative to a standard
20 curve. The entrapped fraction is determined by subtracting the “free” dsRNA content (as measured by the signal in the absence of surfactant) from the total dsRNA content. Percent entrapped dsRNA is typically >85%. For SNALP formulation, the particle size is at least 30 nm, at least 40 nm, at least 50 nm, at least 60 nm, at least 70 nm, at least 80 nm, at least 90 nm, at least 100 nm, at least 110 nm, and at least 120 nm. The suitable range is typically about at least
25 50 nm to about at least 110 nm, about at least 60 nm to about at least 100 nm, or about at least 80 nm to about at least 90 nm.

Compositions and formulations for oral administration include powders or granules, microparticulates, nanoparticulates, suspensions or solutions in water or non-aqueous media, capsules, gel capsules, sachets, tablets or minitables. Thickeners, flavoring agents, diluents,
30 emulsifiers, dispersing aids or binders may be desirable. In some embodiments, oral formulations are those in which dsRNAs featured in the disclosure are administered in

conjunction with one or more penetration enhancers surfactants and chelators. Suitable surfactants include fatty acids and/or esters or salts thereof, bile acids and/or salts thereof. Suitable bile acids/salts include chenodeoxycholic acid (CDCA) and ursodeoxychenodeoxycholic acid (UDCA), cholic acid, dehydrocholic acid, deoxycholic acid, glucolic acid, glycholic acid, glycodeoxycholic acid, taurocholic acid, taurodeoxycholic acid, sodium tauro-24,25-dihydro-fusidate and sodium glycodihydrofusidate. Suitable fatty acids include arachidonic acid, undecanoic acid, oleic acid, lauric acid, caprylic acid, capric acid, myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprate, tricaprate, monoolein, dilaurin, glyceryl 1-monocaprate, 1-dodecylazacycloheptan-2-one, an acylcarnitine, an acylcholine, or a monoglyceride, a diglyceride or a pharmaceutically acceptable salt thereof (*e.g.*, sodium). In some embodiments, combinations of penetration enhancers are used, for example, fatty acids/salts in combination with bile acids/salts. One exemplary combination is the sodium salt of lauric acid, capric acid and UDCA. Further penetration enhancers include polyoxyethylene-9-lauryl ether, polyoxyethylene-20-cetyl ether. DsRNAs featured in the disclosure may be delivered orally, in granular form including sprayed dried particles, or complexed to form micro or nanoparticles. DsRNA complexing agents include poly-amino acids; polyimines; polyacrylates; polyalkylacrylates, polyoxethanes, polyalkylcyanoacrylates; cationized gelatins, albumins, starches, acrylates, polyethyleneglycols (PEG) and starches; polyalkylcyanoacrylates; DEAE-derivatized polyimines, pullulans, celluloses and starches. Suitable complexing agents include chitosan, N-trimethylchitosan, poly-L-lysine, polyhistidine, polyornithine, polyspermines, protamine, polyvinylpyridine, polythiodiethylaminomethylethylene P(TDAE), polyaminostyrene (*e.g.*, p-amino), poly(methylcyanoacrylate), poly(ethylcyanoacrylate), poly(butylcyanoacrylate), poly(isobutylcyanoacrylate), poly(isohexylcyanoacrylate), DEAE-methacrylate, DEAE-hexylacrylate, DEAE-acrylamide, DEAE-albumin and DEAE-dextran, polymethylacrylate, polyhexylacrylate, poly(D,L-lactic acid), poly(DL-lactic-co-glycolic acid (PLGA), alginate, and polyethyleneglycol (PEG). Oral formulations for dsRNAs and their preparation are described in detail in U.S. Patent 6,887,906, US Publn. No. 20030027780, and U.S. Patent No. 6,747,014, each of which is incorporated herein by reference.

Compositions and formulations for parenteral, intraparenchymal (into the brain), intrathecal, intravitreal, subretinal, transscleral, subconjunctival, retrobulbar, intracameral,

intraventricular, or intrahepatic administration may include sterile aqueous solutions which may also contain buffers, diluents and other suitable additives such as, but not limited to, penetration enhancers, carrier compounds and other pharmaceutically acceptable carriers or excipients.

Pharmaceutical compositions of the present disclosure include, but are not limited to, solutions, emulsions, and liposome-containing formulations. These compositions may be generated from a variety of components that include, but are not limited to, preformed liquids, self-emulsifying solids and self-emulsifying semisolids.

The pharmaceutical formulations featured in the present disclosure, which may conveniently be presented in unit dosage form, may be prepared according to conventional techniques well known in the pharmaceutical industry. Such techniques include the step of bringing into association the active ingredients with the pharmaceutical carrier(s) or excipient(s). In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.

The compositions featured in the present disclosure may be formulated into any of many possible dosage forms such as, but not limited to, tablets, capsules, gel capsules, liquid syrups, soft gels, suppositories, and enemas. The compositions may also be formulated as suspensions in aqueous, non-aqueous or mixed media. Aqueous suspensions may further contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension may also contain stabilizers.

Additional Formulations

Emulsions

The compositions of the present disclosure may be prepared and formulated as emulsions. Emulsions are typically heterogeneous systems of one liquid dispersed in another in the form of droplets usually exceeding 0.1µm in diameter (*see e.g.*, Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems, Allen, LV., Popovich NG., and Ansel HC., 2004, Lippincott Williams & Wilkins (8th ed.), New York, NY; Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199; Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., Volume 1, p. 245; Block in *Pharmaceutical*

Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 2, p. 335; Higuchi *et al.*, in Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pa., 1985, p. 301). Emulsions are often biphasic systems comprising two immiscible liquid phases intimately mixed and dispersed with each other. In general, emulsions may be of either the water-in-oil (w/o) or the oil-in-water (o/w) variety. When an aqueous phase is finely divided into and dispersed as minute droplets into a bulk oily phase, the resulting composition is called a water-in-oil (w/o) emulsion. Alternatively, when an oily phase is finely divided into and dispersed as minute droplets into a bulk aqueous phase, the resulting composition is called an oil-in-water (o/w) emulsion. Emulsions may contain additional components in addition to the dispersed phases, and the active drug which may be present as a solution in either the aqueous phase, oily phase or itself as a separate phase. Pharmaceutical excipients such as emulsifiers, stabilizers, dyes, and anti-oxidants may also be present in emulsions as needed. Pharmaceutical emulsions may also be multiple emulsions that are comprised of more than two phases such as, for example, in the case of oil-in-water-in-oil (o/w/o) and water-in-oil-in-water (w/o/w) emulsions. Such complex formulations often provide certain advantages that simple binary emulsions do not. Multiple emulsions in which individual oil droplets of an o/w emulsion enclose small water droplets constitute a w/o/w emulsion. Likewise, a system of oil droplets enclosed in globules of water stabilized in an oily continuous phase provides an o/w/o emulsion.

Emulsions are characterized by little or no thermodynamic stability. Often, the dispersed or discontinuous phase of the emulsion is well dispersed into the external or continuous phase and maintained in this form through the means of emulsifiers or the viscosity of the formulation. Either of the phases of the emulsion may be a semisolid or a solid, as is the case of emulsion-style ointment bases and creams. Other means of stabilizing emulsions entail the use of emulsifiers that may be incorporated into either phase of the emulsion. Emulsifiers may broadly be classified into four categories: synthetic surfactants, naturally occurring emulsifiers, absorption bases, and finely dispersed solids (*see e.g.*, Ansel's *Pharmaceutical Dosage Forms and Drug Delivery Systems*, Allen, LV., Popovich NG., and Ansel HC., 2004, Lippincott Williams & Wilkins (8th ed.), New York, NY; Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199).

Synthetic surfactants, also known as surface active agents, have found wide applicability in the formulation of emulsions and have been reviewed in the literature (*see e.g.*, Ansel's *Pharmaceutical Dosage Forms and Drug Delivery Systems*, Allen, LV., Popovich NG., and Ansel HC., 2004, Lippincott Williams & Wilkins (8th ed.), New York, NY; Rieger, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 285; Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), Marcel Dekker, Inc., New York, N.Y., 1988, volume 1, p. 199). Surfactants are typically amphiphilic and comprise a hydrophilic and a hydrophobic portion. The ratio of the hydrophilic to the hydrophobic nature of the surfactant has been termed the hydrophile/lipophile balance (HLB) and is a valuable tool in categorizing and selecting surfactants in the preparation of formulations. Surfactants may be classified into different classes based on the nature of the hydrophilic group: nonionic, anionic, cationic and amphoteric (*see e.g.*, Ansel's *Pharmaceutical Dosage Forms and Drug Delivery Systems*, Allen, LV., Popovich NG., and Ansel HC., 2004, Lippincott Williams & Wilkins (8th ed.), New York, NY Rieger, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 285).

Naturally occurring emulsifiers used in emulsion formulations include lanolin, beeswax, phosphatides, lecithin and acacia. Absorption bases possess hydrophilic properties such that they can soak up water to form w/o emulsions yet retain their semisolid consistencies, such as anhydrous lanolin and hydrophilic petrolatum. Finely divided solids have also been used as good emulsifiers especially in combination with surfactants and in viscous preparations. These include polar inorganic solids, such as heavy metal hydroxides, nonswelling clays such as bentonite, attapulgite, hectorite, kaolin, montmorillonite, colloidal aluminum silicate and colloidal magnesium aluminum silicate, pigments and nonpolar solids such as carbon or glyceryl tristearate.

A large variety of non-emulsifying materials are also included in emulsion formulations and contribute to the properties of emulsions. These include fats, oils, waxes, fatty acids, fatty alcohols, fatty esters, humectants, hydrophilic colloids, preservatives and antioxidants (Block, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 335; Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199).

Hydrophilic colloids or hydrocolloids include naturally occurring gums and synthetic polymers such as polysaccharides (for example, acacia, agar, alginic acid, carrageenan, guar gum, karaya gum, and tragacanth), cellulose derivatives (for example, carboxymethylcellulose and carboxypropylcellulose), and synthetic polymers (for example, carbomers, cellulose ethers, and carboxyvinyl polymers). These disperse or swell in water to form colloidal solutions that stabilize emulsions by forming strong interfacial films around the dispersed-phase droplets and by increasing the viscosity of the external phase.

Since emulsions often contain a number of ingredients such as carbohydrates, proteins, sterols and phosphatides that may readily support the growth of microbes, these formulations often incorporate preservatives. Commonly used preservatives included in emulsion formulations include methyl paraben, propyl paraben, quaternary ammonium salts, benzalkonium chloride, esters of p-hydroxybenzoic acid, and boric acid. Antioxidants are also commonly added to emulsion formulations to prevent deterioration of the formulation. Antioxidants used may be free radical scavengers such as tocopherols, alkyl gallates, butylated hydroxyanisole, butylated hydroxytoluene, or reducing agents such as ascorbic acid and sodium metabisulfite, and antioxidant synergists such as citric acid, tartaric acid, and lecithin.

The application of emulsion formulations via dermatological, oral and parenteral routes and methods for their manufacture have been reviewed in the literature (*see e.g.*, Ansel's *Pharmaceutical Dosage Forms and Drug Delivery Systems*, Allen, LV., Popovich NG., and Ansel HC., 2004, Lippincott Williams & Wilkins (8th ed.), New York, NY; Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199). Emulsion formulations for oral delivery have been very widely used because of ease of formulation, as well as efficacy from an absorption and bioavailability standpoint (*see e.g.*, Ansel's *Pharmaceutical Dosage Forms and Drug Delivery Systems*, Allen, LV., Popovich NG., and Ansel HC., 2004, Lippincott Williams & Wilkins (8th ed.), New York, NY; Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245; Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199). Mineral-oil base laxatives, oil-soluble vitamins and high fat nutritive preparations are among the materials that have commonly been administered orally as o/w emulsions.

In some embodiments of the present disclosure, the compositions of iRNAs and nucleic acids are formulated as microemulsions. A microemulsion may be defined as a system of water, oil and amphiphile which is a single optically isotropic and thermodynamically stable liquid solution (*see e.g.*, Ansel's *Pharmaceutical Dosage Forms and Drug Delivery Systems*, Allen, LV., Popovich NG., and Ansel HC., 2004, Lippincott Williams & Wilkins (8th ed.), New York, NY; Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245). Typically, microemulsions are systems that are prepared by first dispersing an oil in an aqueous surfactant solution and then adding a sufficient amount of a fourth component, generally an intermediate chain-length alcohol to form a transparent system. Therefore, microemulsions have also been described as thermodynamically stable, isotopically clear dispersions of two immiscible liquids that are stabilized by interfacial films of surface-active molecules (Leung and Shah, in: *Controlled Release of Drugs: Polymers and Aggregate Systems*, Rosoff, M., Ed., 1989, VCH Publishers, New York, pages 185-215). Microemulsions commonly are prepared via a combination of three to five components that include oil, water, surfactant, cosurfactant and electrolyte. Whether the microemulsion is of the water-in-oil (w/o) or an oil-in-water (o/w) type is dependent on the properties of the oil and surfactant used and on the structure and geometric packing of the polar heads and hydrocarbon tails of the surfactant molecules (Schott, in Remington's *Pharmaceutical Sciences*, Mack Publishing Co., Easton, Pa., 1985, p. 271).

The phenomenological approach utilizing phase diagrams has been extensively studied and has yielded a comprehensive knowledge, to one skilled in the art, of how to formulate microemulsions (*see e.g.*, Ansel's *Pharmaceutical Dosage Forms and Drug Delivery Systems*, Allen, LV., Popovich NG., and Ansel HC., 2004, Lippincott Williams & Wilkins (8th ed.), New York, NY; Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245; Block, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 335). Compared to conventional emulsions, microemulsions offer the advantage of solubilizing water-insoluble drugs in a formulation of thermodynamically stable droplets that are formed spontaneously.

Surfactants used in the preparation of microemulsions include, but are not limited to, ionic surfactants, non-ionic surfactants, Brij 96, polyoxyethylene oleyl ethers, polyglycerol fatty

acid esters, tetraglycerol monolaurate (ML310), tetraglycerol monooleate (MO310), hexaglycerol monooleate (PO310), hexaglycerol pentaoleate (PO500), decaglycerol monocaprate (MCA750), decaglycerol monooleate (MO750), decaglycerol sequioleate (SO750), decaglycerol decaoleate (DAO750), alone or in combination with cosurfactants. The cosurfactant, usually a short-chain alcohol such as ethanol, 1-propanol, and 1-butanol, serves to increase the interfacial fluidity by penetrating into the surfactant film and consequently creating a disordered film because of the void space generated among surfactant molecules. Microemulsions may, however, be prepared without the use of cosurfactants and alcohol-free self-emulsifying microemulsion systems are known in the art. The aqueous phase may typically be, but is not limited to, water, an aqueous solution of the drug, glycerol, PEG300, PEG400, polyglycerols, propylene glycols, and derivatives of ethylene glycol. The oil phase may include, but is not limited to, materials such as Captex 300, Captex 355, Capmul MCM, fatty acid esters, medium chain (C8-C12) mono, di, and tri-glycerides, polyoxyethylated glyceryl fatty acid esters, fatty alcohols, polyglycolized glycerides, saturated polyglycolized C8-C10 glycerides, vegetable oils and silicone oil.

Microemulsions are particularly of interest from the standpoint of drug solubilization and the enhanced absorption of drugs. Lipid based microemulsions (both o/w and w/o) have been proposed to enhance the oral bioavailability of drugs, including peptides (*see e.g.*, U.S. Patent Nos. 6,191,105; 7,063,860; 7,070,802; 7,157,099; Constantinides *et al.*, *Pharmaceutical Research*, 1994, 11, 1385-1390; Ritschel, *Meth. Find. Exp. Clin. Pharmacol.*, 1993, 13, 205). Microemulsions afford advantages of improved drug solubilization, protection of drug from enzymatic hydrolysis, possible enhancement of drug absorption due to surfactant-induced alterations in membrane fluidity and permeability, ease of preparation, ease of oral administration over solid dosage forms, improved clinical potency, and decreased toxicity (*see e.g.*, U.S. Patent Nos. 6,191,105; 7,063,860; 7,070,802; 7,157,099; Constantinides *et al.*, *Pharmaceutical Research*, 1994, 11, 1385; Ho *et al.*, *J. Pharm. Sci.*, 1996, 85, 138-143). Often microemulsions may form spontaneously when their components are brought together at ambient temperature. This may be particularly advantageous when formulating thermolabile drugs, peptides or iRNAs. Microemulsions have also been effective in the transdermal delivery of active components in both cosmetic and pharmaceutical applications. It is expected that the microemulsion compositions and formulations of the present disclosure will facilitate the

increased systemic absorption of iRNAs and nucleic acids from the gastrointestinal tract, as well as improve the local cellular uptake of iRNAs and nucleic acids.

Microemulsions of the present disclosure may also contain additional components and additives such as sorbitan monostearate (Grill 3), Labrasol, and penetration enhancers to improve the properties of the formulation and to enhance the absorption of the iRNAs and nucleic acids of the present disclosure. Penetration enhancers used in the microemulsions of the present disclosure may be classified as belonging to one of five broad categories--surfactants, fatty acids, bile salts, chelating agents, and non-chelating non-surfactants (Lee *et al.*, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, p. 92). Each of these classes has been discussed above.

Penetration Enhancers

In some embodiments, the present disclosure employs various penetration enhancers to effect the efficient delivery of nucleic acids, particularly iRNAs, to the skin of animals. Most drugs are present in solution in both ionized and nonionized forms. However, usually only lipid soluble or lipophilic drugs readily cross cell membranes. It has been discovered that even non-lipophilic drugs may cross cell membranes if the membrane to be crossed is treated with a penetration enhancer. In addition to aiding the diffusion of non-lipophilic drugs across cell membranes, penetration enhancers also enhance the permeability of lipophilic drugs.

Penetration enhancers may be classified as belonging to one of five broad categories, *i.e.*, surfactants, fatty acids, bile salts, chelating agents, and non-chelating non-surfactants (*see e.g.*, Malmsten, M. Surfactants and polymers in drug delivery, *Informa Health Care*, New York, NY, 2002; Lee *et al.*, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, p.92). Each of the above-mentioned classes of penetration enhancers are described below in greater detail.

Surfactants: In connection with the present disclosure, surfactants (or "surface-active agents") are chemical entities which, when dissolved in an aqueous solution, reduce the surface tension of the solution or the interfacial tension between the aqueous solution and another liquid, with the result that absorption of iRNAs through the mucosa is enhanced. In addition to bile salts and fatty acids, these penetration enhancers include, for example, sodium lauryl sulfate, polyoxyethylene-9-lauryl ether and polyoxyethylene-20-cetyl ether) (*see e.g.*, Malmsten, M. Surfactants and polymers in drug delivery, *Informa Health Care*, New York, NY, 2002; Lee *et*

al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, p.92); and perfluorochemical emulsions, such as FC-43. Takahashi *et al.*, *J. Pharm. Pharmacol.*, 1988, 40, 252).

Fatty acids: Various fatty acids and their derivatives which act as penetration enhancers include, for example, oleic acid, lauric acid, capric acid (n-decanoic acid), myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprinate, tricaprinate, monoolein (1-monooleoyl-rac-glycerol), dilaurin, caprylic acid, arachidonic acid, glycerol 1-monocaprate, 1-dodecylazacycloheptan-2-one, acylcarnitines, acylcholines, C₁₋₂₀ alkyl esters thereof (*e.g.*, methyl, isopropyl and t-butyl), and mono- and di-glycerides thereof (*i.e.*, oleate, laurate, caprate, myristate, palmitate, stearate, linoleate, *etc.*) (*see e.g.*, Touitou, E., *et al. Enhancement in Drug Delivery*, CRC Press, Danvers, MA, 2006; Lee *et al.*, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, p.92; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1990, 7, 1-33; El Hariri *et al.*, *J. Pharm. Pharmacol.*, 1992, 44, 651-654).

Bile salts: The physiological role of bile includes the facilitation of dispersion and absorption of lipids and fat-soluble vitamins (*see e.g.*, Malmsten, M. Surfactants and polymers in drug delivery, *Informa Health Care*, New York, NY, 2002; Brunton, Chapter 38 in: Goodman & Gilman's *The Pharmacological Basis of Therapeutics*, 9th Ed., Hardman *et al.* Eds., McGraw-Hill, New York, 1996, pp. 934-935). Various natural bile salts, and their synthetic derivatives, act as penetration enhancers. Thus, the term "bile salts" includes any of the naturally occurring components of bile as well as any of their synthetic derivatives. Suitable bile salts include, for example, cholic acid (or its pharmaceutically acceptable sodium salt, sodium cholate), dehydrocholic acid (sodium dehydrocholate), deoxycholic acid (sodium deoxycholate), glucolic acid (sodium glucolate), glycholic acid (sodium glycocholate), glycodeoxycholic acid (sodium glycodeoxycholate), taurocholic acid (sodium taurocholate), taurodeoxycholic acid (sodium taurodeoxycholate), chenodeoxycholic acid (sodium chenodeoxycholate), ursodeoxycholic acid (UDCA), sodium tauro-24,25-dihydro-fusidate (STDHF), sodium glycodihydrofusidate and polyoxyethylene-9-lauryl ether (POE) (*see e.g.*, Malmsten, M. Surfactants and polymers in drug delivery, *Informa Health Care*, New York, NY, 2002; Lee *et al.*, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, page 92; Swinyard, Chapter 39 In: *Remington's Pharmaceutical Sciences*, 18th Ed., Gennaro, ed., Mack Publishing Co., Easton, Pa., 1990, pages 782-783; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1990, 7, 1-33; Yamamoto *et al.*, *J. Pharm. Exp. Ther.*, 1992, 263, 25; Yamashita *et al.*, *J. Pharm. Sci.*, 1990, 79, 579-583).

Chelating Agents: Chelating agents, as used in connection with the present disclosure, can be defined as compounds that remove metallic ions from solution by forming complexes therewith, with the result that absorption of iRNAs through the mucosa is enhanced. With regards to their use as penetration enhancers in the present disclosure, chelating agents have the added advantage of also serving as DNase inhibitors, as most characterized DNA nucleases require a divalent metal ion for catalysis and are thus inhibited by chelating agents (Jarrett, *J. Chromatogr.*, 1993, 618, 315-339). Suitable chelating agents include but are not limited to disodium ethylenediaminetetraacetate (EDTA), citric acid, salicylates (*e.g.*, sodium salicylate, 5-methoxysalicylate and homovanilate), N-acyl derivatives of collagen, laureth-9 and N-amino acyl derivatives of β -diketones (enamines)(*see e.g.*, Katdare, A. *et al.*, *Excipient development for pharmaceutical, biotechnology, and drug delivery*, CRC Press, Danvers, MA, 2006; Lee *et al.*, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, page 92; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1990, 7, 1-33; Buur *et al.*, *J. Control Rel.*, 1990, 14, 43-51).

Non-chelating non-surfactants: As used herein, non-chelating non-surfactant penetration enhancing compounds can be defined as compounds that demonstrate insignificant activity as chelating agents or as surfactants but that nonetheless enhance absorption of iRNAs through the alimentary mucosa (*see e.g.*, Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1990, 7, 1-33). This class of penetration enhancers include, for example, unsaturated cyclic ureas, 1-alkyl- and 1-alkenylazacyclo-alkanone derivatives (Lee *et al.*, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, page 92); and non-steroidal anti-inflammatory agents such as diclofenac sodium, indomethacin and phenylbutazone (Yamashita *et al.*, *J. Pharm. Pharmacol.*, 1987, 39, 621-626).

Agents that enhance uptake of iRNAs at the cellular level may also be added to the pharmaceutical and other compositions of the present disclosure. For example, cationic lipids, such as lipofectin (Junichi *et al.*, U.S. Pat. No. 5,705,188), cationic glycerol derivatives, and polycationic molecules, such as polylysine (Lollo *et al.*, PCT Application WO 97/30731), are also known to enhance the cellular uptake of dsRNAs. Examples of commercially available transfection reagents include, for example Lipofectamine™ (Invitrogen; Carlsbad, CA), Lipofectamine 2000™ (Invitrogen; Carlsbad, CA), 293fectin™ (Invitrogen; Carlsbad, CA), Cellfectin™ (Invitrogen; Carlsbad, CA), DMRIE-C™ (Invitrogen; Carlsbad, CA), FreeStyle™

MAX (Invitrogen; Carlsbad, CA), Lipofectamine™ 2000 CD (Invitrogen; Carlsbad, CA), Lipofectamine™ (Invitrogen; Carlsbad, CA), RNAiMAX (Invitrogen; Carlsbad, CA), Oligofectamine™ (Invitrogen; Carlsbad, CA), Optifect™ (Invitrogen; Carlsbad, CA), X-tremeGENE Q2 Transfection Reagent (Roche; Grenzacherstrasse, Switzerland), DOTAP
 5 Liposomal Transfection Reagent (Grenzacherstrasse, Switzerland), DOSPER Liposomal Transfection Reagent (Grenzacherstrasse, Switzerland), or Eugene (Grenzacherstrasse, Switzerland), Transfectam® Reagent (Promega; Madison, WI), TransFast™ Transfection Reagent (Promega; Madison, WI), Tfx™-20 Reagent (Promega; Madison, WI), Tfx™-50 Reagent (Promega; Madison, WI), DreamFect™ (OZ Biosciences; Marseille, France),
 10 EcoTransfect (OZ Biosciences; Marseille, France), TransPass^a D1 Transfection Reagent (New England Biolabs; Ipswich, MA, USA), LyoVec™/LipoGen™ (Invivogen; San Diego, CA, USA), PerFectin Transfection Reagent (Genlantis; San Diego, CA, USA), NeuroPORTER Transfection Reagent (Genlantis; San Diego, CA, USA), GenePORTER Transfection reagent (Genlantis; San Diego, CA, USA), GenePORTER 2 Transfection reagent (Genlantis; San Diego,
 15 CA, USA), Cytofectin Transfection Reagent (Genlantis; San Diego, CA, USA), BaculoPORTER Transfection Reagent (Genlantis; San Diego, CA, USA), TroganPORTER™ transfection Reagent (Genlantis; San Diego, CA, USA), RiboFect (Bioline; Taunton, MA, USA), PlasFect (Bioline; Taunton, MA, USA), UniFECTOR (B-Bridge International; Mountain View, CA, USA), SureFECTOR (B-Bridge International; Mountain View, CA, USA), or HiFect™ (B-
 20 Bridge International, Mountain View, CA, USA), among others.

Other agents may be utilized to enhance the penetration of the administered nucleic acids, including glycols such as ethylene glycol and propylene glycol, pyrrols such as 2-pyrrol, azones, and terpenes such as limonene and menthone.

25 Carriers

Certain compositions of the present disclosure also incorporate carrier compounds in the formulation. As used herein, “carrier compound” can refer to a nucleic acid, or analog thereof, which is inert (*i.e.*, does not possess biological activity per se) but is recognized as a nucleic acid by *in vivo* processes that reduce the bioavailability of a nucleic acid having biological activity by,
 30 for example, degrading the biologically active nucleic acid or promoting its removal from circulation. The coadministration of a nucleic acid and a carrier compound, typically with an

excess of the latter substance, can result in a substantial reduction of the amount of nucleic acid recovered in the liver, kidney or other extracirculatory reservoirs, presumably due to competition between the carrier compound and the nucleic acid for a common receptor. For example, the recovery of a partially phosphorothioate dsRNA in hepatic tissue can be reduced when it is coadministered with polyinosinic acid, dextran sulfate, polycytidic acid or 4-acetamido-4'-isothiocyano-stilbene-2,2'-disulfonic acid (Miyao *et al.*, *DsRNA Res. Dev.*, 1995, 5, 115-121; Takakura *et al.*, *DsRNA & Nucl. Acid Drug Dev.*, 1996, 6, 177-183).

Excipients

In contrast to a carrier compound, a pharmaceutical carrier or excipient may comprise, *e.g.*, a pharmaceutically acceptable solvent, suspending agent or any other pharmacologically inert vehicle for delivering one or more nucleic acids to an animal. The excipient may be liquid or solid and is selected, with the planned manner of administration in mind, so as to provide for the desired bulk, consistency, *etc.*, when combined with a nucleic acid and the other components of a given pharmaceutical composition. Typical pharmaceutical carriers include, but are not limited to, binding agents (*e.g.*, pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose, *etc.*); fillers (*e.g.*, lactose and other sugars, microcrystalline cellulose, pectin, gelatin, calcium sulfate, ethyl cellulose, polyacrylates or calcium hydrogen phosphate, *etc.*); lubricants (*e.g.*, magnesium stearate, talc, silica, colloidal silicon dioxide, stearic acid, metallic stearates, hydrogenated vegetable oils, corn starch, polyethylene glycols, sodium benzoate, sodium acetate, *etc.*); disintegrants (*e.g.*, starch, sodium starch glycolate, *etc.*); and wetting agents (*e.g.*, sodium lauryl sulphate, *etc.*).

Pharmaceutically acceptable organic or inorganic excipients suitable for non-parenteral administration which do not deleteriously react with nucleic acids can also be used to formulate the compositions of the present disclosure. Suitable pharmaceutically acceptable carriers include, but are not limited to, water, salt solutions, alcohols, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose, polyvinylpyrrolidone and the like.

Formulations for topical administration of nucleic acids may include sterile and non-sterile aqueous solutions, non-aqueous solutions in common solvents such as alcohols, or solutions of the nucleic acids in liquid or solid oil bases. The solutions may also contain buffers,

diluents and other suitable additives. Pharmaceutically acceptable organic or inorganic excipients suitable for non-parenteral administration which do not deleteriously react with nucleic acids can be used.

Suitable pharmaceutically acceptable excipients include, but are not limited to, water, salt solutions, alcohol, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose, polyvinylpyrrolidone and the like.

Other Components

The compositions of the present disclosure may additionally contain other adjunct components conventionally found in pharmaceutical compositions, *e.g.*, at their art-established usage levels. Thus, for example, the compositions may contain additional, compatible, pharmaceutically-active materials such as, for example, antipruritics, astringents, local anesthetics or anti-inflammatory agents, or may contain additional materials useful in physically formulating various dosage forms of the compositions of the present disclosure, such as dyes, flavoring agents, preservatives, antioxidants, opacifiers, thickening agents and stabilizers. However, such materials, when added, should not unduly interfere with the biological activities of the components of the compositions of the present disclosure. The formulations can be sterilized and, if desired, mixed with auxiliary agents, *e.g.*, lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorings, flavorings and/or aromatic substances and the like which do not deleteriously interact with the nucleic acid(s) of the formulation.

Aqueous suspensions may contain substances that increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension may also contain stabilizers.

In some embodiments, pharmaceutical compositions featured in the disclosure include (a) one or more iRNA compounds and (b) one or more biologic agents which function by a non-RNAi mechanism. Examples of such biologic agents include agents that interfere with an interaction of VEGF-A and at least one VEGF-A binding partner.

Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, *e.g.*, for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective

in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD₅₀/ED₅₀. Compounds that exhibit high therapeutic indices are typical.

The data obtained from cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of compositions featured in the disclosure lies generally within a range of circulating concentrations that include the ED₅₀ with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For any compound used in the methods featured in the disclosure, the therapeutically effective dose can be estimated initially from cell culture assays.

A dose may be formulated in animal models to achieve a circulating plasma concentration range of the compound or, when appropriate, of the polypeptide product of a target sequence (*e.g.*, achieving a decreased concentration of the polypeptide) that includes the IC₅₀ (*i.e.*, the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma may be measured, for example, by high performance liquid chromatography.

In addition to their administration, as discussed above, the iRNAs featured in the disclosure can be administered in combination with other known agents effective in treatment of diseases or disorders related to VEGF-A expression (*e.g.*, an angiogenic ocular disorder). In any event, the administering physician can adjust the amount and timing of iRNA administration on the basis of results observed using standard measures of efficacy known in the art or described herein.

Methods of treating disorders related to expression of VEGF-A

The present disclosure relates to the use of an iRNA targeting VEGF-A to inhibit VEGF-A expression and/or to treat a disease, disorder, or pathological process that is related to VEGF-A expression (*e.g.*, an angiogenic ocular disorder).

In some aspects, a method of treatment of a disorder related to expression of VEGF-A is provided, the method comprising administering an iRNA (*e.g.*, a dsRNA) disclosed herein to a subject in need thereof. In some embodiments, the iRNA inhibits (decreases) VEGF-A expression.

In some embodiments, the subject is an animal that serves as a model for a disorder related to VEGF-A expression, *e.g.*, an angiogenic ocular disorder, *e.g.*, AMD, DR, DME, RVO, MEfRVO, CVO, ROP, or mCNV.

5 Angiogenic Ocular Disorders

In some embodiments, the disorder related to VEGF-A expression is an angiogenic ocular disorder. Non-limiting examples of angiogenic ocular disorders that are treatable using the methods described herein include AMD (including wet AMD, exudative AMD, etc.), RVO (e.g., CRVO, MEfRVO, retinopathy of prematurity (ROP), or branch retinal vein occlusion (BRVO), DME, CNV (*e.g.*, myopic CNV), iris neovascularization, neovascular glaucoma, post-surgical fibrosis in glaucoma, proliferative retinopathy, proliferative vitreoretinopathy (PVR),
10 optical disc neovascularization, corneal neovascularization, retinal neovascularization, vitreal neovascularization, pannus, pterygium, vascular retinopathy, von Hippel-Lindau disease, histoplasmosis, and diabetic retinopathies.

15 Clinical and pathological features of angiogenic ocular disorders include, but are not limited to, a reduction in visual acuity (*e.g.*, characterized by floating spots, blurriness around the edges or center of field of vision (*e.g.*, scotoma), metamorphopsia, and impaired color vision), increased leakage from the CNV, increased vascular permeability in the eye, collection of fluid or blood beneath the macula, abnormal ocular angiogenesis, and intraretinal hemorrhage.

20 In some embodiments, the subject with the angiogenic ocular disorder is less than 18 years old. In some embodiments, the subject with the angiogenic ocular disorder is an adult. In some embodiments, the subject has, or is identified as having, elevated levels of VEGF-A mRNA or protein relative to a reference level (*e.g.*, a level of VEGF-A that is greater than a reference level).

25 In some embodiments, the angiogenic ocular disorder is diagnosed using analysis of a sample from the subject (*e.g.*, an aqueous ocular fluid sample). In some embodiments, the sample is analyzed using a method selected from one or more of: fluorescent in situ hybridization (FISH), immunohistochemistry, VEGF-A immunoassay, electron microscopy, laser microdissection, and mass spectrometry. In some embodiments, angiogenic ocular disorder
30 is diagnosed using any suitable diagnostic test or technique, *e.g.*, angiography (*e.g.*, fluorescein angiography or indocyanine green angiography), electroretinography, ultrasonography,

pachymetry, optical coherence tomography (OCT), computed tomography (CT) and magnetic resonance imaging (MRI), tonometry, color vision testing, visual field testing, slit-lamp examination, ophthalmoscopy, and physical examination (*e.g.*, to assess visual acuity (*e.g.*, by funduscopy or optical coherence tomography (OCT))).

5

Combination Therapies

In some embodiments, an iRNA (*e.g.*, a dsRNA) disclosed herein is administered in combination with a second therapy (*e.g.*, one or more additional therapies) known to be effective in treating a disorder related to VEGF-A expression (*e.g.*, an angiogenic ocular disorder) or a symptom of such a disorder. The iRNA may be administered before, after, or concurrent with the second therapy. In some embodiments, the iRNA is administered before the second therapy. In some embodiments, the iRNA is administered after the second therapy. In some embodiments, the iRNA is administered concurrent with the second therapy.

The second therapy may be an additional therapeutic agent. The iRNA and the additional therapeutic agent can be administered in combination in the same composition or the additional therapeutic agent can be administered as part of a separate composition.

In some embodiments, the second therapy is a non-iRNA therapeutic agent that is effective to treat the disorder or symptoms of the disorder.

In some embodiments, the iRNA is administered in conjunction with a therapy.

Exemplary combination therapies include, but are not limited to, photodynamic therapy, photocoagulation therapy, a steroid, a non-steroidal anti-inflammatory agent, an anti-VEGF agent, and a vitrectomy.

In some embodiments, the anti-VEGF-A agent comprises a fusion protein. Exemplary anti-VEGF fusion proteins include, but are not limited to, aflibercept (EYLEA®). In some embodiments, the anti-VEGF-A fusion protein has the amino acid sequence of

SDTGRPFVEMYSEIPEIIHMTGRELVIPCRVTSPNITVTLKKFPLDTLIPDGKRIIWDSRKG
FIISNATYKEIGLLTCEATVNGHLYKTNYLTHRQTNTIIDVVLSPSHGIELSVGEKLVVLC
TARTELVGIDFNWEYPSSKHQHKLVNRDLKTQSGSEMKKFLSTLTIDGVTRSDQGLY
TCAASSGLMTKKNSTFVRVHEKDKTHTCPPCPAPPELLGGPSVFLFPPKPKDTLMISRTPE
VTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWL
NGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYP

SDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEAL
HNHYTQKSLSLSPG (SEQ ID NO: 1905), or a variant thereof having at least about 80%, 85%,
90%, 95%, or 99% sequence identity thereto.

In some embodiments, the anti-VEGF-A agent is an antibody or antigen-binding
5 fragment thereof (e.g., an anti-VEGF-A antibody molecule). Exemplary anti-VEGF-A antibody
molecules include, but are not limited to, ranibizumab (LUCENTIS®) and brolucizumab
(BEOVU®). In some embodiments, an anti-VEGF-A antibody molecule competes for binding
to VEGF-A with ranibizumab or brolucizumab.

In some embodiments, the anti-VEGF-A antibody molecules comprises one or more
10 (e.g., all three) of a heavy chain complementarity determining region 1 (HCDR1), a heavy chain
complementarity determining region 2 (HCDR2) and a heavy chain complementarity
determining region 3 (HCDR3). In some embodiments, the anti-VEGF-A antibody molecules
comprises one or more (e.g., all three) of a light chain complementarity determining region 1
(LCDR1), a light chain complementarity determining region 2 (LCDR2) and a light chain
15 complementarity determining region 3 (LCDR3).

In some embodiments, the anti-VEGF-A antibody molecule comprises a VH comprising
one or more (e.g., all three) of a heavy chain complementarity determining region 1 (HCDR1) of
an anti-VEGF-A antibody molecule described herein, e.g., in Table 7, (or a sequence with no
more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions), a HCDR2 of an
20 anti-VEGF-A antibody or antibody fragment thereof described herein, e.g., in Table 7, (or a
sequence with no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions),
and a HCDR3 of an anti-VEGF-A antibody molecule described herein, e.g., in Table 7, (or a
sequence with no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions).

In some embodiments, the anti-VEGF-A antibody molecule comprises a VL comprising
25 one or more (e.g., all three) of a light chain complementarity determining region 1 (LCDR1) of
an anti-VEGF-A antibody molecule described herein, e.g., in Table 7, (or a sequence with no
more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions), a LCDR2 of an anti-
VEGF-A antibody molecule described herein, e.g., in Table 7, (or a sequence with no more than
1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions), and a LCDR3 of an anti-
30 VEGF-A antibody molecule described herein, e.g., in Table 7, (or a sequence with no more than
1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions).

In some embodiments, the anti-VEGF-A antibody molecule comprises a VH comprising an amino acid sequence of an anti-VEGF-A antibody molecule described herein, e.g., in Table 7, or an amino acid sequence having at least about 80%, 85%, 90%, 95%, or 99% sequence identity thereto. In some embodiments, the anti-VEGF-A antibody molecule comprises a VL comprising the amino acid sequence of an anti-VEGF-A antibody molecule described herein, e.g., in Table 7, or an amino acid sequence having at least about 80%, 85%, 90%, 95%, or 99% sequence identity thereto.

In some embodiments, the anti-VEGF-A antibody molecule comprises a VH comprising the amino acid sequence of an anti-VEGF-A antibody molecule described herein, e.g., in Table 7, (or an amino acid sequence having at least about 80%, 85%, 90%, 95%, or 99% sequence identity thereto) and a VL comprising the amino acid sequence of an anti-VEGF-A antibody molecule described herein, e.g., in Table 7, (or an amino acid sequence having at least about 80%, 85%, 90%, 95%, or 99% sequence identity thereto).

In one embodiment, the anti-VEGF-A antibody molecule comprises a scFv comprising a light chain and a heavy chain of an amino acid sequence of anti-VEGF-A antibody molecule described herein, e.g., in Table 7. In one embodiment, the anti-VEGF-A antibody molecule (e.g., an scFv) comprises: a light chain variable region comprising an amino acid sequence having at least one, two, or three modifications (e.g., substitutions) but not more than 30, 20, or 10 modifications (e.g., substitutions) of an amino acid sequence of a light chain variable region of an anti-VEGF-A antibody molecule described herein, e.g., in Table 7, or a sequence with 95-99% identity with an amino acid sequence of an anti-VEGF-A antibody molecule described herein, e.g., in Table 7; and/or a heavy chain variable region comprising an amino acid sequence having at least one, two, or three modifications (e.g., substitutions) but not more than 30, 20, or 10 modifications (e.g., substitutions) of an amino acid sequence of a heavy chain variable region of an anti-VEGF-A antibody molecule described herein, e.g., in Table 7, or a sequence with 95-99% identity to an amino acid sequence of an anti-VEGF-A antibody molecule described herein, e.g., in Table 7.

In one embodiment, the anti-VEGF-A antibody molecule is a scFv, and a light chain variable region comprising an amino acid sequence of anti-VEGF-A antibody molecule described herein, e.g., in Table 7, is attached to a heavy chain variable region comprising an amino acid sequence of an anti-VEGF-A antibody molecule described herein, via a linker, e.g., a

linker described herein. In one embodiment, the anti-VEGF-A antibody molecule includes a (Gly₄-Ser)_n linker, wherein n is 1, 2, 3, 4, 5, or 6, preferably 3 or 4 (SEQ ID NO:1951). The light chain variable region and heavy chain variable region of a scFv can be, e.g., in any of the following orientations: light chain variable region-linker-heavy chain variable region or heavy chain variable region-linker-light chain variable region.

Table 7: Exemplary Anti-VEGF Antibody Molecule Sequences

Description	SEQ ID NO.	Sequence
Brolucizumab Sequence	1906	MEIVMTQSPSTLSASVGDRVIITCQASEIIHSWLA WYQQKPGKAPKLLIYLASTLASGVPSRFSGSGG AEFTLTISLQPDFFATYYCQNVYLASTNGANIG QGTKLTVLGGGGGSGGGGSGGGGSGGGGSEVQ LVESGGGLVQPGGSLRLSCTASGFSLTDDYYM WVRQAPGKGLEWVGFDIPDDDPYYATWAKGIF TISRDN SKNTLYLQMNSLRAEDTAVYYCAGGIH NSGWGLDIWGQGTLLTVSS
Brolucizumab VH	1907	EVQLVESGGGLVQPGGSLRLSCTASGFSLTDDYY MTWVRQAPGKGLEWVGFDIPDDDPYYATWAI GRFTISRDN SKNTLYLQMNSLRAEDTAVYYCA GDHNSGWGLDIWGQGTLLTVSS
Brolucizumab VL	1908	MEIVMTQSPSTLSASVGDRVIITCQASEIIHSWLA WYQQKPGKAPKLLIYLASTLASGVPSRFSGSGG AEFTLTISLQPDFFATYYCQNVYLASTNGANIG QGTKLTVLG
Brolucizumab Linker	1909	GGGGSGGGGSGGGGSGGGGS
Ranibizumab Heavy Chain	1910	EVQLVESGGGLVQPGGSLRLSCAASGYDFTHYG MNWVRQAPGKGLEWVGWINTYTGEPTYAAIF KRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCA KYPYYGTSHWYFDVWGQGTLLTVSSASTKIP SVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVTVPS SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTH L
Ranibizumab Light Chain	1911	DIQLTQSPSSLSASVGDRVTITCSASQDISNYLNW YQQKPGKAPKVLIIYFTSSLHSGVPSRFSGSGSCF DFTLTISLQPEDFATYYCQQYSTVPWTFGQG KVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLIN NFYPREAKVQWKVDNALQSGNSQESVTEQDS DSTYLSSTLTLSKADYEKHKVYACEVTHQGLS PVTKSFNRGEC
Ranibizumab VH	1912	EVQLVESGGGLVQPGGSLRLSCAASGYDFTHYG MNWVRQAPGKGLEWVGWINTYTGEPTYAAIF

		<u>KRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCA</u> <u>KYPYYYGTSHWYFDV</u> WGQGLVT VSS
Ranibizumab VL	1913	DIQLTQSPSSLSASVGDRVTITC <u>SASQDISNYLNW</u> YQQKPGKAPKVLII <u>FTSSLHSGVPSRFSGSGSGT</u> DFTLTISLQPEDFATYYC <u>QQYSTVPWTF</u> GQGT KVEIK

Note: CDR sequences are bolded and underlined.

Administration dosages, routes, and timing

A subject (*e.g.*, a human subject, *e.g.*, a patient) can be administered a therapeutic amount of iRNA. The therapeutic amount can be, *e.g.*, 0.05-50 mg/kg.

5 In some embodiments, the iRNA is formulated for delivery to a target organ, *e.g.*, to the eye.

In some embodiments, the iRNA is formulated as a lipid formulation, *e.g.*, an LNP formulation as described herein. In some such embodiments, the therapeutic amount is 0.05-5 mg/kg dsRNA. In some embodiments, the lipid formulation, *e.g.*, LNP formulation, is
10 administered intravenously.

In some embodiments, the iRNA is in the form of a GalNAc conjugate *e.g.*, as described herein. In some such embodiments, the therapeutic amount is 0.5-50 mg dsRNA. In some embodiments, the *e.g.*, GalNAc conjugate is administered subcutaneously.

In some embodiments, the administration is repeated, for example, on a regular basis,
15 such as, daily, biweekly (*i.e.*, every two weeks) for one month, two months, three months, four months, six months or longer. After an initial treatment regimen, the treatments can be administered on a less frequent basis. For example, after administration biweekly for three months, administration can be repeated once per month, for six months or a year or longer.

In some embodiments, the iRNA agent is administered in two or more doses. In some
20 embodiments, the number or amount of subsequent doses is dependent on the achievement of a desired effect, *e.g.*, to (a) inhibit angiogenesis; (b) inhibit or reduce the expression or activity of VEGF A; (c) inhibit choroidal neovascularization; (d) inhibit growth of new blood vessels in the choriocapillaris; (e) reduce retinal thickness; (f) increase visual acuity; or (g) reduce intraocular inflammation, or the achievement of a therapeutic or prophylactic effect, *e.g.*, reduction or
25 prevention of one or more symptoms associated with the disorder.

In some embodiments, the iRNA agent is administered according to a schedule. For example, the iRNA agent may be administered once per week, twice per week, three times per week, four times per week, or five times per week. In some embodiments, the schedule involves regularly spaced administrations, *e.g.*, hourly, every four hours, every six hours, every eight
5 hours, every twelve hours, daily, every 2 days, every 3 days, every 4 days, every 5 days, weekly, biweekly, or monthly. In some embodiments, the iRNA agent is administered at the frequency required to achieve a desired effect.

In some embodiments, the schedule involves closely spaced administrations followed by a longer period of time during which the agent is not administered. For example, the schedule
10 may involve an initial set of doses that are administered in a relatively short period of time (*e.g.*, about every 6 hours, about every 12 hours, about every 24 hours, about every 48 hours, or about every 72 hours) followed by a longer time period (*e.g.*, about 1 week, about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, or about 8 weeks) during which the iRNA agent is not administered. In some embodiments, the iRNA agent is initially
15 administered hourly and is later administered at a longer interval (*e.g.*, daily, weekly, biweekly, or monthly). In some embodiments, the iRNA agent is initially administered daily and is later administered at a longer interval (*e.g.*, weekly, biweekly, or monthly). In certain embodiments, the longer interval increases over time or is determined based on the achievement of a desired effect.

20 Before administration of a full dose of the iRNA, patients can be administered a smaller dose, such as a 5% infusion dose, and monitored for adverse effects, such as an allergic reaction, or for elevated lipid levels or blood pressure. In another example, the patient can be monitored for unwanted effects.

25 **Methods for modulating expression of VEGF-A**

In some aspects, the disclosure provides a method for modulating (*e.g.*, inhibiting or activating) the expression of VEGF-A, *e.g.*, in a cell, in a tissue, or in a subject. In some
embodiments, the cell or tissue is *ex vivo*, *in vitro*, or *in vivo*. In some embodiments, the cell or tissue is in the eye (*e.g.*, retinal pigment epithelium (RPE), a retinal tissue, an astrocyte, a
30 pericyte, a Müller cell, a ganglion cell, an endothelial cell, a photoreceptor cell, a retinal blood vessel (*e.g.*, including endothelial cells and vascular smooth muscle cells), or choroid tissue, *e.g.*,

a choroid vessel). In some embodiments, the cell or tissue is in a subject (*e.g.*, a mammal, such as, for example, a human). In some embodiments, the subject (*e.g.*, the human) is at risk, or is diagnosed with a disorder related to expression of VEGF-A expression, as described herein.

In some embodiments, the method includes contacting the cell with an iRNA as described herein, in an amount effective to decrease the expression of VEGF-A in the cell. In some embodiments, contacting a cell with an RNAi agent includes contacting a cell *in vitro* with the RNAi agent or contacting a cell *in vivo* with the RNAi agent. In some embodiments, the RNAi agent is put into physical contact with the cell by the individual performing the method, or the RNAi agent may be put into a situation that will permit or cause it to subsequently come into contact with the cell. Contacting a cell *in vitro* may be done, for example, by incubating the cell with the RNAi agent. Contacting a cell *in vivo* may be done, for example, by injecting the RNAi agent into or near the tissue where the cell is located, or by injecting the RNAi agent into another area, *e.g.*, ocular tissue. For example, the RNAi agent may contain or be coupled to a ligand, *e.g.*, a lipophilic moiety or moieties as described below and further detailed, *e.g.*, in PCT/US2019/031170 which is incorporated herein by reference in its entirety, including the passages therein describing lipophilic moieties, that directs or otherwise stabilizes the RNAi agent at a site of interest. Combinations of *in vitro* and *in vivo* methods of contacting are also possible. For example, a cell may also be contacted *in vitro* with an RNAi agent and subsequently transplanted into a subject.

The expression of VEGF-A may be assessed based on the level of expression of VEGF-A mRNA, VEGF-A protein, or the level of another parameter functionally linked to the level of expression of VEGF-A. In some embodiments, the expression of VEGF-A is inhibited by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95%. In some embodiments, the iRNA has an IC₅₀ in the range of 0.001-0.01 nM, 0.001-0.10 nM, 0.001-1.0 nM, 0.001-10 nM, 0.01-0.05 nM, 0.01-0.50 nM, 0.02-0.60 nM, 0.01-1.0 nM, 0.01-1.5 nM, 0.01-10 nM. The IC₅₀ value may be normalized relative to an appropriate control value, *e.g.*, the IC₅₀ of a non-targeting iRNA.

In some embodiments, the method includes introducing into the cell or tissue an iRNA as described herein and maintaining the cell or tissue for a time sufficient to obtain degradation of

the mRNA transcript of VEGF-A, thereby inhibiting the expression of VEGF-A in the cell or tissue.

In some embodiments, the method includes administering a composition described herein, *e.g.*, a composition comprising an iRNA that binds VEGF-A, to the mammal such that expression of the target VEGF-A is decreased, such as for an extended duration, *e.g.*, at least two, three, four days or more, *e.g.*, one week, two weeks, three weeks, or four weeks or longer. In some embodiments, the decrease in expression of VEGF-A is detectable within 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, or 24 hours of the first administration.

In some embodiments, the method includes administering a composition as described herein to a mammal such that expression of the target VEGF-A is increased by *e.g.*, at least 10% compared to an untreated animal. In some embodiments, the activation of VEGF-A occurs over an extended duration, *e.g.*, at least two, three, four days or more, *e.g.*, one week, two weeks, three weeks, four weeks, or more. Without wishing to be bound by theory, an iRNA can activate VEGF-A expression by stabilizing the VEGF-A mRNA transcript, interacting with a promoter in the genome, or inhibiting an inhibitor of VEGF-A expression.

The iRNAs useful for the methods and compositions featured in the disclosure specifically target RNAs (primary or processed) of VEGF-A. Compositions and methods for inhibiting the expression of VEGF-A using iRNAs can be prepared and performed as described elsewhere herein.

In some embodiments, the method includes administering a composition containing an iRNA, where the iRNA includes a nucleotide sequence that is complementary to at least a part of an RNA transcript of VEGF-A of the subject, *e.g.*, the mammal, *e.g.*, the human, to be treated. The composition may be administered by any appropriate means known in the art including, but not limited to ocular (*e.g.*, intraocular), topical, and intravenous administration.

In certain embodiments, the composition is administered intraocularly (*e.g.*, by intravitreal administration, *e.g.*, intravitreal injection; transscleral administration, *e.g.*, transscleral injection; subconjunctival administration, *e.g.*, subconjunctival injection; retrobulbar administration, *e.g.*, retrobulbar injection; intracameral administration, *e.g.*, intracameral injection; or subretinal administration, *e.g.*, subretinal injection. In other embodiments, the composition is administered topically. In other embodiments, the composition is administered by intravenous infusion or injection.

In certain embodiments, the composition is administered by intravenous infusion or injection. In some such embodiments, the composition comprises a lipid formulated siRNA (*e.g.*, an LNP formulation, such as an LNP11 formulation) for intravenous infusion.

5 Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the iRNAs and methods featured in the disclosure, suitable methods and materials are described below. All publications, patent applications, patents, and
10 other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In the event of a discrepancy between the recited positions of the duplexes presented herein and the alignment of the duplexes to the recited sequences, the alignment of the duplexes to the recited sequence will govern. In addition, the materials, methods, and examples are illustrative only and not intended
15 to be limiting.

Specific Embodiments

1. A double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of vascular endothelial growth factor A (VEGF-A), wherein the dsRNA agent comprises a sense strand and an antisense strand forming a double stranded region, wherein the sense strand comprises a nucleotide sequence comprising at least 15 contiguous nucleotides, with 0, 1, 2, or 3 mismatches, of a portion of a coding strand of human VEGF-A and the antisense strand comprises a nucleotide sequence comprising at least 15 contiguous nucleotides, with 0, 1, 2, or 3 mismatches, of the corresponding portion of a non-coding strand of human VEGF-A such that the sense strand is complementary to the at least 15 contiguous nucleotides in the antisense strand.

2. The dsRNA agent of embodiment 1, wherein the coding strand of human VEGF-A comprises the sequence SEQ ID NO: 1.

3. The dsRNA agent of embodiment 1 or 2, wherein the non-coding strand of human VEGF-A comprises the sequence of SEQ ID NO: 2.

4. A double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of VEGF-A, wherein the dsRNA agent comprises a sense strand and an antisense strand forming a double stranded region, wherein the antisense strand comprises a nucleotide sequence comprising at least 15 contiguous nucleotides, with 0, 1, 2, or 3 mismatches, of a portion of nucleotide sequence of SEQ ID NO: 2 such that the sense strand is complementary to the at least 15 contiguous nucleotides in the antisense strand.

5. The dsRNA agent of embodiment 4, wherein the sense strand comprises a nucleotide sequence comprising at least 15 contiguous nucleotides, with 0, or 1, 2, or 3 mismatches, of the corresponding portion of the nucleotide sequence of SEQ ID NO: 1.

6. The dsRNA of any of the preceding embodiments, wherein the dsRNA agent comprises a sense strand and an antisense strand, wherein the antisense strand comprises a nucleotide sequence comprising at least 17 contiguous nucleotides, with 0, 1, 2, or 3 mismatches, of a

portion of nucleotide sequence of SEQ ID NO: 2 such that the sense strand is complementary to the at least 17 contiguous nucleotides in the antisense strand.

7. The dsRNA of embodiment 6, wherein the sense strand comprises a nucleotide sequence comprising at least 17 contiguous nucleotides, with 0, or 1, 2, or 3 mismatches, of the corresponding portion of the nucleotide sequence of SEQ ID NO: 1.

8. The dsRNA of any of the preceding embodiments, wherein the dsRNA agent comprises a sense strand and an antisense strand, wherein the antisense strand comprises a nucleotide sequence comprising at least 19 contiguous nucleotides, with 0, 1, 2, or 3 mismatches, of a portion of nucleotide sequence of SEQ ID NO: 2 such that the sense strand is complementary to the at least 19 contiguous nucleotides in the antisense strand.

9. The dsRNA of embodiment 8, wherein the sense strand comprises a nucleotide sequence comprising at least 19 contiguous nucleotides, with 0, 1, 2, or 3 mismatches, of the corresponding portion of the nucleotide sequence of SEQ ID NO: 1.

10. The dsRNA of any of the preceding embodiments, wherein the dsRNA agent comprises a sense strand and an antisense strand, wherein the antisense strand comprises a nucleotide sequence comprising at least 21 contiguous nucleotides, with 0, 1, 2, or 3 mismatches, of a portion of nucleotide sequence of SEQ ID NO: 2 such that the sense strand is complementary to the at least 21 contiguous nucleotides in the antisense strand.

11. The dsRNA of embodiment 10, wherein the sense strand comprises a nucleotide sequence comprising at least 21 contiguous nucleotides, with 0, or 1, 2, or 3 mismatches, of the corresponding portion of the nucleotide sequence of SEQ ID NO: 1.

12. The dsRNA agent of any one of embodiments 1-11, wherein the portion of the sense strand is a portion within nucleotides 1855-1875, 1858-1878, 2178-2198, 2181-2201, 2944-2964, 2946-2966, 2952-2972, 3361-3381, or 3362-3382 of SEQ ID NO: 1.

13. The dsRNA agent of any one of embodiments 1-12, wherein the portion of the sense strand is a portion within a sense strand from a duplex chosen from AD-1020574

(CGACAGAACAGUCCUUAUAUCA (SEQ ID NO: 4200)), AD-901094

(CAGAACAGUCCUUAUCCAGA (SEQ ID NO: 4201)), AD-1020575

5 (CAGAACAGUCCUUAUCCAGA (SEQ ID NO: 4202)), AD-901100

(AACAGUGCUAAUGUUUUAUUGGA (SEQ ID NO: 4203)), AD-901101

(AGUGCUAAUGUUUUAUUGGUGUA (SEQ ID NO: 4204)), AD-901113

(GAGAAAGUGUUUUUAUUAUACGA (SEQ ID NO: 4205)), AD-901123

(AAAAUAGACAUUGCUAUUCUA (SEQ ID NO: 4206)), AD-901124

10 (AAAUAGACAUUGCUAUUCUGA (SEQ ID NO: 4207)), AD-901158

(GAAAGUGUUUUUAUUAUACGGUA (SEQ ID NO: 4208)), AD-901159

(GUUUUAUUAUACGGUACUUAUA (SEQ ID NO: 4209)), AD-1020573

(AGUGCUAATGTUAUUGGUGUA (SEQ ID NO: 4210)), or AD-1023143

(AAAAUAGACATUGCUAUUCUA (SEQ ID NO: 4211)).

15

14. The dsRNA agent of any one of embodiments 1-13, wherein the portion of the sense strand is a sense strand chosen from the sense strands of AD-1020574

(CGACAGAACAGUCCUUAUAUCA (SEQ ID NO: 4200)), AD-901094

(CAGAACAGUCCUUAUCCAGA (SEQ ID NO: 4201)), AD-1020575

20 (CAGAACAGUCCUUAUCCAGA (SEQ ID NO: 4202)), AD-901100

(AACAGUGCUAAUGUUUUAUUGGA (SEQ ID NO: 4203)), AD-901101

(AGUGCUAAUGUUUUAUUGGUGUA (SEQ ID NO: 4204)), AD-901113

(GAGAAAGUGUUUUUAUUAUACGA (SEQ ID NO: 4205)), AD-901123

(AAAAUAGACAUUGCUAUUCUA (SEQ ID NO: 4206)), AD-901124

25 (AAAUAGACAUUGCUAUUCUGA (SEQ ID NO: 4207)), AD-901158

(GAAAGUGUUUUUAUUAUACGGUA (SEQ ID NO: 4208)), AD-901159

(GUUUUAUUAUACGGUACUUAUA (SEQ ID NO: 4209)), AD-1020573

(AGUGCUAATGTUAUUGGUGUA (SEQ ID NO: 4210)), or AD-1023143

(AAAAUAGACATUGCUAUUCUA (SEQ ID NO: 4211)).

30

15. The dsRNA of any one of embodiments 1-14, wherein the portion of the antisense strand is a portion within an antisense strand from a duplex chosen from AD-1020574

(UGAUUAAGGACUGUUCUGUCGAU (SEQ ID NO: 4212)), AD-901094

(UCUGGAUUAAGGACUGUUCUGUC (SEQ ID NO: 4213)), AD-1020575

5 (UCUGGATUAAGGACUGUUCUGUC (SEQ ID NO: 4214)), AD-901100

(UCCAAUAACAUUAGCACUGUUA (SEQ ID NO: 4215)), AD-901101

(UACACCAUAACAUUAGCACUGU (SEQ ID NO: 4216)), AD-901113

(UCGUUAUUAACACUUCUCUU (SEQ ID NO: 4217)), AD-901123

(UAGAAUAGCAAUGUCUAUUUUAU (SEQ ID NO: 4218)), AD-901124

10 (UCAGAAUAGCAAUGUCUAUUUUA (SEQ ID NO: 4219)), AD-901158

(UACCGUAUAUAAACACUUCUC (SEQ ID NO: 4220)), AD-901159

(UAUAAGUACCGUAUAUAAACAC (SEQ ID NO: 4221)), AD-1020573

(UACACCAUAACATUAGCACUGU (SEQ ID NO: 4222)), or AD-1023143

(UAGAAUAGCAATGTCTAUUUUAU (SEQ ID NO: 4223)).

15

16. The dsRNA of any one of embodiments 1-15, wherein the portion of the antisense strand is an antisense strand chosen the antisense strands of AD-1020574

(UGAUUAAGGACUGUUCUGUCGAU (SEQ ID NO: 4212)), AD-901094

(UCUGGAUUAAGGACUGUUCUGUC (SEQ ID NO: 4213)), AD-1020575

20 (UCUGGATUAAGGACUGUUCUGUC (SEQ ID NO: 4214)), AD-901100

(UCCAAUAACAUUAGCACUGUUA (SEQ ID NO: 4215)), AD-901101

(UACACCAUAACAUUAGCACUGU (SEQ ID NO: 4216)), AD-901113

(UCGUUAUUAACACUUCUCUU (SEQ ID NO: 4217)), AD-901123

(UAGAAUAGCAAUGUCUAUUUUAU (SEQ ID NO: 4218)), AD-901124

25 (UCAGAAUAGCAAUGUCUAUUUUA (SEQ ID NO: 4219)), AD-901158

(UACCGUAUAUAAACACUUCUC (SEQ ID NO: 4220)), AD-901159

(UAUAAGUACCGUAUAUAAACAC (SEQ ID NO: 4221)), AD-1020573

(UACACCAUAACATUAGCACUGU (SEQ ID NO: 4222)), or AD-1023143

(UAGAAUAGCAATGTCTAUUUUAU (SEQ ID NO: 4223)).

30

17. The dsRNA of any one of embodiments 1-16, wherein the sense strand and the antisense strand comprise nucleotide sequences of the paired sense strand and antisense strand of a duplex selected from AD-1020574 (SEQ ID NO: 4200 and 4212), AD-901094 (SEQ ID NO: 4201 and 4213), AD-1020575 (SEQ ID NO: 4202 and 4214), AD-901100 (SEQ ID NO: 4203 and 4215),
5 AD-901101 (SEQ ID NO: 4204 and 4216), AD-901113 (SEQ ID NO: 4205 and 4217), AD-901123 (SEQ ID NO: 4206 and 4218), AD-901124 (SEQ ID NO: 4207 and 4219), AD-901158 (SEQ ID NO: 4208 and 4220), AD-901159 (SEQ ID NO: 4209 and 4221), AD-1020573 (SEQ ID NO: 4210 and 4222), or AD-1023143 (SEQ ID NO: 4211 and 4223).

10 18. The dsRNA agent of any one of embodiments 1-11, wherein the portion of the sense strand is a portion within a sense strand from a duplex chosen from AD-953374 (SEQ ID NO: 813), AD-953504 (SEQ ID NO: 1297), AD-953481 (SEQ ID NO: 1298), AD-953351 (SEQ ID NO: 800), AD-901356 (SEQ ID NO: 261), AD-953344 (SEQ ID NO: 787), AD-901355 (SEQ ID NO: 262), AD-953410 (SEQ ID NO: 845), AD-953363 (SEQ ID NO: 779), AD-953411
15 (SEQ ID NO: 844), AD-953350 (SEQ ID NO: 784), or AD-953375 (SEQ ID NO: 790).

19. The dsRNA agent of any one of embodiments 1-11 or 18, wherein the portion of the sense strand is a sense strand chosen from the sense strands of AD-953374 (SEQ ID NO: 813), AD-953504 (SEQ ID NO: 1297), AD-953481 (SEQ ID NO: 1298), AD-953351 (SEQ ID NO: 800), AD-901356 (SEQ ID NO: 261), AD-953344 (SEQ ID NO: 787), AD-901355 (SEQ ID NO: 262), AD-953410 (SEQ ID NO: 845), AD-953363 (SEQ ID NO: 779), AD-953411 (SEQ ID NO: 844), AD-953350 (SEQ ID NO: 784), or AD-953375 (SEQ ID NO: 790).

20. The dsRNA of any one of embodiments 1-11 or 18-19, wherein the portion of the antisense strand is a portion within an antisense strand from a duplex chosen from AD-953374 (SEQ ID NO: 943), AD-953504 (SEQ ID NO: 1427), AD-953481 (SEQ ID NO: 1428), AD-953351 (SEQ ID NO: 930), AD-901356 (SEQ ID NO: 390), AD-953344 (SEQ ID NO: 917), AD-901355 (SEQ ID NO: 391), AD-953410 (SEQ ID NO: 975), AD-953363 (SEQ ID NO: 909), AD-953411 (SEQ ID NO: 974), AD-953350 (SEQ ID NO: 914), or AD-953375 (SEQ ID NO: 920).
30

21. The dsRNA of any one of embodiments 1-11 or 18-20, wherein the portion of the antisense strand is an antisense strand chosen from AD-953374 (SEQ ID NO: 943), AD-953504 (SEQ ID NO: 1427), AD-953481 (SEQ ID NO: 1428), AD-953351 (SEQ ID NO: 930), AD-901356 (SEQ ID NO: 390), AD-953344 (SEQ ID NO: 917), AD-901355 (SEQ ID NO: 391),
5 AD-953410 (SEQ ID NO: 975), AD-953363 (SEQ ID NO: 909), AD-953411 (SEQ ID NO: 974), AD-953350 (SEQ ID NO: 914), or AD-953375 (SEQ ID NO: 920).

22. The dsRNA of any one of embodiments 1-11, or 18-21 wherein the sense strand and the antisense strand of comprise the nucleotide sequences of the paired sense strand and antisense
10 strand of a duplex selected from AD-953374 (SEQ ID NO: 813 and 943), AD-953504 (SEQ ID NO: 1297 and 1427), AD-953481 (SEQ ID NO: 1298 and 1428), AD-953351 (SEQ ID NO: 800 and 930), AD-901356 (SEQ ID NO: 261 and 390), AD-953344 (SEQ ID NO: 787 and 917), AD-901355 (SEQ ID NO: 262 and 391), AD-953410 (SEQ ID NO: 845 and 975), AD-953363 (SEQ ID NO: 779 and 909), AD-953411 (SEQ ID NO: 844 and 974), AD-953350 (SEQ ID NO: 784
15 and 914), or AD-953375 (SEQ ID NO: 790 and 920).

23. The dsRNA agent of any one of the preceding embodiments, wherein the portion of the sense strand is a portion within a sense strand in any one of Tables 2A, 2B, 3A, 3B, 4A, 4B, 5A, 5B, 8A, 8B, 10A, 10B, 12, 13, 14, 18A and 18B.

24. The dsRNA agent of any one of the preceding embodiments, wherein the portion of the antisense strand is a portion within an antisense strand in any one of Tables 2A, 2B, 3A, 3B, 4A, 4B, 5A, 5B, 8A, 8B, 10A, 10B, 12, 13, 14, 18A and 18B.

25. The dsRNA agent of any of the preceding embodiments, wherein the antisense strand comprises a nucleotide sequence comprising at least 15 contiguous nucleotides, with 0, 1, 2, or 3 mismatches, from one of the antisense sequences listed in any one of Tables 2A, 2B, 3A, 3B, 4A, 4B, 5A, 5B, 8A, 8B, 10A, 10B, 12, 13, 14, 18A and 18B.

26. The dsRNA agent of any of the preceding embodiments, wherein the sense strand comprises a nucleotide sequence comprising at least 15 contiguous nucleotides, with 0, 1, 2, or 3

mismatches, from a sense sequence listed in any one of Tables 2A, 2B, 3A, 3B, 4A, 4B, 5A, 5B, 8A, 8B, 10A, 10B, 12, 13, 14, 18A and 18B that corresponds to the antisense sequence.

27. The dsRNA agent of any of the preceding embodiments, wherein the antisense strand
5 comprises a nucleotide sequence comprising at least 17 contiguous nucleotides, with 0, 1, 2, or 3 mismatches, from one of the antisense sequences listed in any one of Tables 2A, 2B, 3A, 3B, 4A, 4B, 5A, 5B, 8A, 8B, 10A, 10B, 12, 13, 14, 18A and 18B.

28. The dsRNA agent of any of the preceding embodiments, wherein the sense strand
10 comprises a nucleotide sequence comprising at least 17 contiguous nucleotides, with 0, 1, 2, or 3 mismatches, from a sense sequence listed in any one of Tables 2A, 2B, 3A, 3B, 4A, 4B, 5A, 5B, 8A, 8B, 10A, 10B, 12, 13, 14, 18A and 18B that corresponds to the antisense sequence.

29. The dsRNA agent of any of the preceding embodiments, wherein the antisense strand
15 comprises a nucleotide sequence comprising at least 19 contiguous nucleotides, with 0, 1, 2, or 3 mismatches, from one of the antisense sequences listed in any one of Tables 2A, 2B, 3A, 3B, 4A, 4B, 5A, 5B, 8A, 8B, 10A, 10B, 12, 13, 14, 18A and 18B.

30. The dsRNA agent of any of the preceding embodiments, wherein the sense strand
20 comprises a nucleotide sequence comprising at least 19 contiguous nucleotides, with 0, 1, 2, or 3 mismatches, from a sense sequence listed in any one of Tables 2A, 2B, 3A, 3B, 4A, 4B, 5A, 5B, 8A, 8B, 10A, 10B, 12, 13, 14, 18A and 18B that corresponds to the antisense sequence.

31. The dsRNA agent of any of the preceding embodiments, wherein the antisense strand
25 comprises a nucleotide sequence comprising at least 21 contiguous nucleotides, with 0, 1, 2, or 3 mismatches, from one of the antisense sequences listed in any one of Tables 2A, 2B, 3A, 3B, 4A, 4B, 5A, 5B, 8A, 8B, 10A, 10B, 12, 13, 14, 18A and 18B.

32. The dsRNA agent of any of the preceding embodiments, wherein the sense strand
30 comprises a nucleotide sequence comprising at least 21 contiguous nucleotides, with 0, 1, 2, or 3

mismatches, from a sense sequence listed in any one of Tables 2A, 2B, 3A, 3B, 4A, 4B, 5A, 5B, 8A, 8B, 10A, 10B, 12, 13, 14, 18A and 18B that corresponds to the antisense sequence.

33. A double-stranded ribonucleic acid (dsRNA) agent for inhibiting expression of VEGF-A,
5 wherein the dsRNA agent comprises a sense strand and an antisense strand forming a double-stranded region, wherein the antisense strand comprises a nucleotide sequence of an antisense sequence listed in any one of Tables 2A, 2B, 3A, 3B, 4A, 4B, 5A, 5B, 8A, 8B, 10A, 10B, 12, 13, 14, 18A and 18B, and the sense strand comprises a nucleotide sequence of a sense sequence listed in any one of Tables 2A, 2B, 3A, 3B, 4A, 4B, 5A, 5B, 8A, 8B, 10A, 10B, 12, 13, 14, 18A
10 and 18B that corresponds to the antisense sequence.

34. The dsRNA agent of embodiment 33, wherein the antisense strand comprises a nucleotide sequence of an antisense sequence listed in Table 2A, and the sense strand comprises a nucleotide sequence of a sense sequence listed in Table 2A that corresponds to the antisense
15 sequence.

35. The dsRNA agent of embodiment 33, wherein the antisense strand comprises a nucleotide sequence of an antisense sequence listed in Table 3A, and the sense strand comprises a nucleotide sequence of a sense sequence listed in Table 3A that corresponds to the antisense
20 sequence.

36. The dsRNA agent of embodiment 33, wherein the antisense strand comprises a nucleotide sequence of an antisense sequence listed in Table 4A, and the sense strand comprises a nucleotide sequence of a sense sequence listed in Table 4A that corresponds to the antisense
25 sequence.

37. The dsRNA agent of embodiment 33, wherein the antisense strand comprises a nucleotide sequence of an antisense sequence listed in Table 18A, and the sense strand comprises a nucleotide sequence of a sense sequence listed in Table 18A that corresponds to the antisense
30 sequence.

38. The dsRNA agent of any one of embodiments 33 or 37, wherein the dsRNA agent is AD-1020574, AD-901094, AD-1020575, AD-901100, AD-901101, AD-901113, AD-901123, AD-901124, AD-901158, AD-901159, AD-1020573, or AD-1023143.

39. The dsRNA agent of any one of embodiments 33 or 37-38, comprising:

(i) the sense strand comprises the sequence and all the modifications of SEQ ID NO: 4164, and the antisense strand comprises the sequence and all the modifications of SEQ ID NO: 4176;

(ii) the sense strand comprises the sequence and all the modifications of SEQ ID NO: 1465, and the antisense strand comprises the sequence and all the modifications of SEQ ID NO: 4177;

(iii) the sense strand comprises the sequence and all the modifications of SEQ ID NO: 1466, and the antisense strand comprises the sequence and all the modifications of SEQ ID NO: 4178;

(iv) the sense strand comprises the sequence and all the modifications of SEQ ID NO: 1467, and the antisense strand comprises the sequence and all the modifications of SEQ ID NO: 4179;

(v) the sense strand comprises the sequence and all the modifications of SEQ ID NO: 1468, and the antisense strand comprises the sequence and all the modifications of SEQ ID NO: 4180;

(vi) the sense strand comprises the sequence and all the modifications of SEQ ID NO: 1469, and the antisense strand comprises the sequence and all the modifications of SEQ ID NO: 4181;

(vii) the sense strand comprises the sequence and all the modifications of SEQ ID NO: 1470, and the antisense strand comprises the sequence and all the modifications of SEQ ID NO: 4182;

(viii) the sense strand comprises the sequence and all the modifications of SEQ ID NO: 1471, and the antisense strand comprises the sequence and all the modifications of SEQ ID NO: 4183;

(ix) the sense strand comprises the sequence and all the modifications of SEQ ID NO: 1472, and the antisense strand comprises the sequence and all the modifications of SEQ ID NO: 4184;

(x) the sense strand comprises the sequence and all the modifications of SEQ ID NO: 1473, and the antisense strand comprises the sequence and all the modifications of SEQ ID NO: 4185;

(xi) the sense strand comprises the sequence and all the modifications of SEQ ID NO: 1474, and the antisense strand comprises the sequence and all the modifications of SEQ ID NO: 4186;

or

(xii) the sense strand comprises the sequence and all the modifications of SEQ ID NO: 1475, and the antisense strand comprises the sequence and all the modifications of SEQ ID NO: 4187.

40. The dsRNA agent of any one of embodiments 33-36, wherein the dsRNA agent is AD-953374, AD-953504, AD-953481, AD-953351, AD-901356, AD-953344, AD-901355, AD-953410, AD-953363, AD-953411, AD-953350, or AD-953375.

- 5 41. The dsRNA agent of any one of embodiments 33-36 or 40, comprising:
- (i) the sense strand comprises the sequence and all the modifications of SEQ ID NO: 553, and the antisense strand comprises the sequence and all the modifications of SEQ ID NO: 683;
 - (ii) the sense strand comprises the sequence and all the modifications of SEQ ID NO: 1037, and the antisense strand comprises the sequence and all the modifications of SEQ ID NO: 1167;
 - 10 (iii) the sense strand comprises the sequence and all the modifications of SEQ ID NO: 1038, and the antisense strand comprises the sequence and all the modifications of SEQ ID NO: 1168;
 - (iv) the sense strand comprises the sequence and all the modifications of SEQ ID NO: 540, and the antisense strand comprises the sequence and all the modifications of SEQ ID NO: 670;
 - (v) the sense strand comprises the sequence and all the modifications of SEQ ID NO: 3, and
15 the antisense strand comprises the sequence and all the modifications of SEQ ID NO: 132;
 - (vi) the sense strand comprises the sequence and all the modifications of SEQ ID NO: 527, and the antisense strand comprises the sequence and all the modifications of SEQ ID NO: 657;
 - (vii) the sense strand comprises the sequence and all the modifications of SEQ ID NO: 4, and the antisense strand comprises the sequence and all the modifications of SEQ ID NO: 133;
 - 20 (viii) the sense strand comprises the sequence and all the modifications of SEQ ID NO: 585, and the antisense strand comprises the sequence and all the modifications of SEQ ID NO: 715;
 - (ix) the sense strand comprises the sequence and all the modifications of SEQ ID NO: 519, and the antisense strand comprises the sequence and all the modifications of SEQ ID NO: 649;
 - (x) the sense strand comprises the sequence and all the modifications of SEQ ID NO: 584,
25 and the antisense strand comprises the sequence and all the modifications of SEQ ID NO: 714;
 - (xi) the sense strand comprises the sequence and all the modifications of SEQ ID NO: 524, and the antisense strand comprises the sequence and all the modifications of SEQ ID NO: 654;
 - or
 - (xii) the sense strand comprises the sequence and all the modifications of SEQ ID NO: 530,
30 and the antisense strand comprises the sequence and all the modifications of SEQ ID NO: 660.

42. The dsRNA agent of any of the preceding embodiments, wherein the sense strand is at least 23 nucleotides in length, e.g., 23-30 nucleotides in length.

43. The dsRNA agent of any of the preceding embodiments, wherein at least one of the sense strand and the antisense strand is conjugated to one or more lipophilic moieties.

44. The dsRNA agent of embodiment 43, wherein the lipophilic moiety is conjugated to one or more positions in the double stranded region of the dsRNA agent.

45. The dsRNA agent of embodiment 43 or 44, wherein the lipophilic moiety is conjugated via a linker or carrier.

46. The dsRNA agent of any one of embodiments 43-45, wherein lipophilicity of the lipophilic moiety, measured by logKow, exceeds 0.

47. The dsRNA agent of any one of the preceding embodiments, wherein the hydrophobicity of the double-stranded RNAi agent, measured by the unbound fraction in a plasma protein binding assay of the double-stranded RNAi agent, exceeds 0.2.

48. The dsRNA agent of embodiment 47, wherein the plasma protein binding assay is an electrophoretic mobility shift assay using human serum albumin protein.

49. The dsRNA agent of any of the preceding embodiments, wherein the dsRNA agent comprises at least one modified nucleotide.

50. The dsRNA agent of embodiment 49, wherein no more than five of the sense strand nucleotides and not more than five of the nucleotides of the antisense strand are unmodified nucleotides.

51. The dsRNA agent of embodiment 50, wherein all of the nucleotides of the sense strand and all of the nucleotides of the antisense strand comprise a modification.

52. The dsRNA agent of any one of embodiments 49-51, wherein at least one of the modified nucleotides is selected from the group consisting of a deoxy-nucleotide, a 3'-terminal deoxy-thymine (dT) nucleotide, a 2'-O-methyl modified nucleotide, a 2'-fluoro modified nucleotide, a 2'-deoxy-modified nucleotide, a locked nucleotide, an unlocked nucleotide, a conformationally restricted nucleotide, a constrained ethyl nucleotide, an abasic nucleotide, a 2'-amino-modified nucleotide, a 2'-O-allyl-modified nucleotide, 2'-C-alkyl-modified nucleotide, a 2'-methoxyethyl modified nucleotide, a 2'-O-alkyl-modified nucleotide, a morpholino nucleotide, a phosphoramidate, a non-natural base comprising nucleotide, a tetrahydropyran modified nucleotide, a 1,5-anhydrohexitol modified nucleotide, a cyclohexenyl modified nucleotide, a nucleotide comprising a phosphorothioate group, a nucleotide comprising a methylphosphonate group, a nucleotide comprising a 5'-phosphate, a nucleotide comprising a 5'-phosphate mimic, a glycol modified nucleotide, and a 2-O-(N-methylacetamide) modified nucleotide; and combinations thereof.

53. The dsRNA agent of any of embodiments 49-51, wherein no more than five of the sense strand nucleotides and not more than five of the nucleotides of the antisense strand include modifications other than 2'-O-methyl modified nucleotide, a 2'-fluoro modified nucleotide, a 2'-deoxy-modified nucleotide, unlocked nucleic acids (UNA) or glycerol nucleic acid (GNA).

54. The dsRNA agent of any of the preceding embodiments, which comprises a non-nucleotide spacer (wherein optionally the non-nucleotide spacer comprises a C3-C6 alkyl) between two of the contiguous nucleotides of the sense strand or between two of the contiguous nucleotides of the antisense strand.

55. The dsRNA agent of any of the preceding embodiments, wherein each strand is no more than 30 nucleotides in length.

56. The dsRNA agent of any of the preceding embodiments, wherein at least one strand comprises a 3' overhang of at least 1 nucleotide.

57. The dsRNA agent of any of the preceding embodiments, wherein at least one strand comprises a 3' overhang of at least 2 nucleotides.

58. The dsRNA agent of any of the preceding embodiments, wherein the double stranded
5 region is 15-30 nucleotide pairs in length.

59. The dsRNA agent of embodiment 58, wherein the double stranded region is 17-23 nucleotide pairs in length.

10 60. The dsRNA agent of embodiment 58, wherein the double stranded region is 17-25 nucleotide pairs in length.

61. The dsRNA agent of embodiment 58, wherein the double stranded region is 23-27 nucleotide pairs in length.

15 62. The dsRNA agent of embodiment 58, wherein the double stranded region is 19-21 nucleotide pairs in length.

63. The dsRNA agent of embodiment 58, wherein the double stranded region is 21-23
20 nucleotide pairs in length.

64. The dsRNA agent of any of the preceding embodiments, wherein each strand has 19-30 nucleotides.

25 65. The dsRNA agent of any of the preceding embodiments, wherein each strand has 19-23 nucleotides.

66. The dsRNA agent of any of the preceding embodiments, wherein each strand has 21-23 nucleotides.

30

67. The dsRNA agent of any of the preceding embodiments, wherein the agent comprises at least one phosphorothioate or methylphosphonate internucleotide linkage.

68. The dsRNA agent of embodiment 67, wherein the phosphorothioate or methylphosphonate internucleotide linkage is at the 3'-terminus of one strand.

69. The dsRNA agent of embodiment 68, wherein the strand is the antisense strand.

70. The dsRNA agent of embodiment 68, wherein the strand is the sense strand.

71. The dsRNA agent of embodiment 67, wherein the phosphorothioate or methylphosphonate internucleotide linkage is at the 5'-terminus of one strand.

72. The dsRNA agent of embodiment 71, wherein the strand is the antisense strand.

73. The dsRNA agent of embodiment 71, wherein the strand is the sense strand.

74. The dsRNA agent of embodiment 67, wherein each of the 5'- and 3'-terminus of one strand comprises a phosphorothioate or methylphosphonate internucleotide linkage.

75. The dsRNA agent of embodiment 74, wherein the strand is the antisense strand.

76. The dsRNA agent of any of the preceding embodiments, wherein the base pair at the 1 position of the 5'-end of the antisense strand of the duplex is an AU base pair.

77. The dsRNA agent of embodiment 74, wherein the sense strand has a total of 21 nucleotides and the antisense strand has a total of 23 nucleotides.

78. The dsRNA agent of any one of embodiments 43-77, wherein one or more lipophilic moieties are conjugated to one or more internal positions on at least one strand.

79. The dsRNA agent of embodiment 78, wherein the one or more lipophilic moieties are conjugated to one or more internal positions on at least one strand via a linker or carrier.

80. The dsRNA agent of embodiment 79, wherein the internal positions include all positions except the terminal two positions from each end of the at least one strand.

81. The dsRNA agent of embodiment 79, wherein the internal positions include all positions except the terminal three positions from each end of the at least one strand.

82. The dsRNA agent of any one of embodiments 79-61, wherein the internal positions exclude a cleavage site region of the sense strand.

83. The dsRNA agent of embodiment 82, wherein the internal positions include all positions except positions 9-12, counting from the 5'-end of the sense strand.

84. The dsRNA agent of embodiment 82, wherein the internal positions include all positions except positions 11-13, counting from the 3'-end of the sense strand.

85. The dsRNA agent of any one of embodiments 79-81, wherein the internal positions exclude a cleavage site region of the antisense strand.

86. The dsRNA agent of embodiment 85, wherein the internal positions include all positions except positions 12-14, counting from the 5'-end of the antisense strand.

87. The dsRNA agent of any one of embodiments 79-81, wherein the internal positions include all positions except positions 11-13 on the sense strand, counting from the 3'-end, and positions 12-14 on the antisense strand, counting from the 5'-end.

88. The dsRNA agent of any one of embodiments 43-87, wherein the one or more lipophilic moieties are conjugated to one or more of the internal positions selected from the group

consisting of positions 4-8 and 13-18 on the sense strand, and positions 6-10 and 15-18 on the antisense strand, counting from the 5' end of each strand.

89. The dsRNA agent of embodiment 88, wherein the one or more lipophilic moieties are conjugated to one or more of the internal positions selected from the group consisting of positions 5, 6, 7, 15, and 17 on the sense strand, and positions 15 and 17 on the antisense strand, counting from the 5'-end of each strand.

90. The dsRNA agent of embodiment 44, wherein the positions in the double stranded region exclude a cleavage site region of the sense strand.

91. The dsRNA agent of any one of embodiments 43-90, wherein the sense strand is 21 nucleotides in length, the antisense strand is 23 nucleotides in length, and the lipophilic moiety is conjugated to position 21, position 20, position 15, position 1, position 7, position 6, or position 2 of the sense strand or position 16 of the antisense strand.

92. The dsRNA agent of embodiment 91, wherein the lipophilic moiety is conjugated to position 21, position 20, position 15, position 1, or position 7 of the sense strand.

93. The dsRNA agent of embodiment 91, wherein the lipophilic moiety is conjugated to position 21, position 20, or position 15 of the sense strand.

94. The dsRNA agent of embodiment 91, wherein the lipophilic moiety is conjugated to position 20 or position 15 of the sense strand.

95. The dsRNA agent of embodiment 91, wherein the lipophilic moiety is conjugated to position 16 of the antisense strand.

96. The dsRNA agent of embodiment 91, wherein the lipophilic moiety is conjugated to position 6, counting from the 5'-end of the sense strand.

97. The dsRNA agent of any one of embodiments 43-96, wherein the lipophilic moiety is an aliphatic, alicyclic, or polyalicyclic compound.

98. The dsRNA agent of embodiment 98, wherein the lipophilic moiety is selected from the group consisting of lipid, cholesterol, retinoic acid, cholic acid, adamantane acetic acid, 1-pyrene butyric acid, dihydrotestosterone, 1,3-bis-O(hexadecyl)glycerol, geranyloxyhexanol, hexadecylglycerol, borneol, menthol, 1,3-propanediol, heptadecyl group, palmitic acid, myristic acid, O3-(oleoyl)lithocholic acid, O3-(oleoyl)cholenic acid, dimethoxytrityl, or phenoxazine.

99. The dsRNA agent of embodiment 98, wherein the lipophilic moiety contains a saturated or unsaturated C4-C30 hydrocarbon chain, and an optional functional group selected from the group consisting of hydroxyl, amine, carboxylic acid, sulfonate, phosphate, thiol, azide, and alkyne.

100. The dsRNA agent of embodiment 99, wherein the lipophilic moiety contains a saturated or unsaturated C6-C18 hydrocarbon chain.

101. The dsRNA agent of embodiment 99, wherein the lipophilic moiety contains a saturated or unsaturated C16 hydrocarbon chain.

102. The dsRNA agent of any one of embodiments 43-101, wherein the lipophilic moiety is conjugated via a carrier that replaces one or more nucleotide(s) in the internal position(s) or the double stranded region.

103. The dsRNA agent of embodiment 102, wherein the carrier is a cyclic group selected from the group consisting of pyrrolidinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, piperidinyl, piperazinyl, [1,3]dioxolanyl, oxazolidinyl, isoxazolidinyl, morpholinyl, thiazolidinyl, isothiazolidinyl, quinoxalinyl, pyridazinonyl, tetrahydrofuranyl, and decalinyl; or is an acyclic moiety based on a serinol backbone or a diethanolamine backbone.

104. The dsRNA agent of any one of embodiments 43-101, wherein the lipophilic moiety is conjugated to the double-stranded iRNA agent via a linker containing an ether, thioether, urea, carbonate, amine, amide, maleimide-thioether, disulfide, phosphodiester, sulfonamide linkage, a product of a click reaction, or carbamate.

5

105. The double-stranded iRNA agent of any one of embodiments 43-104, wherein the lipophilic moiety is conjugated to a nucleobase, sugar moiety, or internucleosidic linkage.

106. The dsRNA agent of any one of embodiments 43-105, wherein the lipophilic moiety is conjugated via a bio-cleavable linker selected from the group consisting of DNA, RNA, disulfide, amide, functionalized monosaccharides or oligosaccharides of galactosamine, glucosamine, glucose, galactose, mannose, and combinations thereof.

107. The dsRNA agent of any one of embodiments 43-106, wherein the 3' end of the sense strand is protected via an end cap which is a cyclic group having an amine, said cyclic group being selected from the group consisting of pyrrolidinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, piperidinyl, piperazinyl, [1,3]dioxolanyl, oxazolidinyl, isoxazolidinyl, morpholinyl, thiazolidinyl, isothiazolidinyl, quinoxalinyl, pyridazinonyl, tetrahydrofuranyl, and decalinyl.

20

108. The dsRNA agent of any one of embodiments 43-107, further comprising a targeting ligand, e.g., a ligand that targets an ocular tissue or a liver tissue.

109. The dsRNA agent of embodiment 108, wherein the ligand is conjugated to the sense strand.

25

110. The dsRNA agent of embodiment 108 or 109, wherein the ligand is conjugated to the 3' end or the 5' end of the sense strand.

111. The dsRNA agent of embodiment 108 or 109, wherein the ligand is conjugated to the 3' end of the sense strand.

30


112. The dsRNA agent of any one of embodiments 108-111, wherein the ocular tissue is a retinal pigment epithelium (RPE) or choroid tissue, e.g., a choroid vessel.

113. The dsRNA agent of any one of embodiments 108-111, wherein the targeting ligand comprises N-acetylgalactosamine (GalNAc).


114. The dsRNA agent of any one of embodiments 108-111, wherein the targeting ligand is one or more GalNAc conjugates or one or more GalNAc derivatives.

115. The dsRNA agent of embodiment 114, wherein the one or more GalNAc conjugates or one or more GalNAc derivatives are attached through a monovalent linker, or a bivalent, trivalent, or tetravalent branched linker.

116. The dsRNA agent of embodiment 114, wherein the ligand is



117. The dsRNA agent of embodiment 116, wherein the dsRNA agent is conjugated to the ligand as shown in the following schematic



wherein X is O or S.

5

118. The dsRNA agent of embodiment 117, wherein the X is O.

119. The dsRNA agent of any one of embodiments 1-118, further comprising a terminal, chiral modification occurring at the first internucleotide linkage at the 3' end of the antisense strand, having the linkage phosphorus atom in Sp configuration,

10

a terminal, chiral modification occurring at the first internucleotide linkage at the 5' end of the antisense strand, having the linkage phosphorus atom in Rp configuration, and

a terminal, chiral modification occurring at the first internucleotide linkage at the 5' end of the sense strand, having the linkage phosphorus atom in either Rp configuration or Sp configuration.

15

120. The dsRNA agent of any one of embodiments 1-118, further comprising a terminal, chiral modification occurring at the first and second internucleotide linkages at the 3' end of the antisense strand, having the linkage phosphorus atom in Sp configuration,

20

a terminal, chiral modification occurring at the first internucleotide linkage at the 5' end of the antisense strand, having the linkage phosphorus atom in Rp configuration, and

a terminal, chiral modification occurring at the first internucleotide linkage at the 5' end of the sense strand, having the linkage phosphorus atom in either Rp or Sp configuration.

121. The dsRNA agent of any one of embodiments 1-118, further comprising
a terminal, chiral modification occurring at the first, second and third internucleotide linkages
at the 3' end of the antisense strand, having the linkage phosphorus atom in Sp configuration,
a terminal, chiral modification occurring at the first internucleotide linkage at the 5' end of
5 the antisense strand, having the linkage phosphorus atom in Rp configuration, and
a terminal, chiral modification occurring at the first internucleotide linkage at the 5' end of
the sense strand, having the linkage phosphorus atom in either Rp or Sp configuration.

122. The dsRNA agent of any one of embodiments 1-118, further comprising
10 a terminal, chiral modification occurring at the first, and second internucleotide linkages at
the 3' end of the antisense strand, having the linkage phosphorus atom in Sp configuration,
a terminal, chiral modification occurring at the third internucleotide linkages at the 3' end of
the antisense strand, having the linkage phosphorus atom in Rp configuration,
a terminal, chiral modification occurring at the first internucleotide linkage at the 5' end of
15 the antisense strand, having the linkage phosphorus atom in Rp configuration, and
a terminal, chiral modification occurring at the first internucleotide linkage at the 5' end of
the sense strand, having the linkage phosphorus atom in either Rp or Sp configuration.

123. The dsRNA agent of any one of embodiments 1-118, further comprising
20 a terminal, chiral modification occurring at the first, and second internucleotide linkages at
the 3' end of the antisense strand, having the linkage phosphorus atom in Sp configuration,
a terminal, chiral modification occurring at the first, and second internucleotide linkages at
the 5' end of the antisense strand, having the linkage phosphorus atom in Rp configuration, and
a terminal, chiral modification occurring at the first internucleotide linkage at the 5' end of
25 the sense strand, having the linkage phosphorus atom in either Rp or Sp configuration.

124. The dsRNA agent of any one of embodiments 1-123, further comprising a
phosphate or phosphate mimic at the 5'-end of the antisense strand.

30 125. The dsRNA agent of embodiment 104, wherein the phosphate mimic is a 5'-vinyl
phosphonate (VP).

126. A cell containing the dsRNA agent of any one of embodiments 1-125.

127. A human ocular cell, e.g., (an RPE cell, an astrocyte, a pericyte, a Müller cell, a ganglion cell, an endothelial cell, or a photoreceptor cell) comprising a reduced level of VEGF-A mRNA or a level of VEGF-A protein as compared to an otherwise similar untreated cell, wherein optionally the level is reduced by at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%.

128. The human cell of embodiment 127, which was produced by a process comprising contacting a human cell with the dsRNA agent of any one of embodiments 1-125.

129. A pharmaceutical composition for inhibiting expression of VEGF-A, comprising the dsRNA agent of any one of embodiments 1-125.

130. A pharmaceutical composition comprising the dsRNA agent of any one of embodiments 1-125 and a lipid formulation.

131. A method of inhibiting expression of VEGF-A in a cell, the method comprising:

(a) contacting the cell with the dsRNA agent of any one of embodiments 1-125, or a pharmaceutical composition of embodiment 129 or 130; and
(b) maintaining the cell produced in step (a) for a time sufficient to obtain degradation of the mRNA transcript of VEGF-A, thereby inhibiting expression of VEGF-A in the cell.

132. A method of inhibiting expression of VEGF-A in a cell, the method comprising:

(a) contacting the cell with the dsRNA agent of any one of embodiments 1-125, or a pharmaceutical composition of embodiment 129 or 130; and
(b) maintaining the cell produced in step (a) for a time sufficient to reduce levels of VEGF-A mRNA, VEGF-A protein, or both of VEGF-A mRNA and protein, thereby inhibiting expression of VEGF-A in the cell.

133. The method of embodiment 131 or 132, wherein the cell is within a subject.

134. The method of embodiment 133, wherein the subject is a human.

135. The method of any one of embodiments 131-134, wherein the level of VEGF-A mRNA
5 is inhibited by at least 50%.

136. The method of any one of embodiments 131-134, wherein the level of VEGF-A protein
is inhibited by at least 50%.

10 137. The method of embodiment 134-136, wherein inhibiting expression of VEGF-A
decreases a VEGF-A protein level in a biological sample (*e.g.*, an aqueous ocular fluid sample)
from the subject by at least 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95%.

138. The method of any one of embodiments 134-137, wherein the subject has been
15 diagnosed with a VEGF-A-associated disorder, *e.g.*, wet age-related macular degeneration (wet
AMD), diabetic retinopathy (DR), diabetic macular edema (DME), retinal vein occlusion (RVO),
macular edema following retinal vein occlusion (MEfRVO), retinopathy of prematurity (ROP),
or myopic choroidal neovascularization (mCNP).

20 139. A method of inhibiting expression of VEGF-A in an ocular cell or tissue, the method
comprising:

- (a) contacting the cell or tissue with a dsRNA agent that binds VEGF-A; and
- (b) maintaining the cell or tissue produced in step (a) for a time sufficient to reduce levels of
VEGF-A mRNA, VEGF-A protein, or both of VEGF-A mRNA and protein, thereby
25 inhibiting expression of VEGF-A in the cell or tissue.

140. The method of embodiment 139, wherein the ocular cell or tissue comprises an RPE
cell, a retinal tissue, an astrocyte, a pericyte, a Müller cell, a ganglion cell, an endothelial cell, a
photoreceptor cell, a retinal blood vessel (*e.g.*, including endothelial cells and vascular smooth
30 muscle cells), or choroid tissue, *e.g.*, a choroid vessel.

141. A method of treating a subject diagnosed with a VEGF-A-associated disorder comprising administering to the subject a therapeutically effective amount of the dsRNA agent of any one of embodiments 1-125 or a pharmaceutical composition of embodiment 129 or 130, thereby treating the disorder.

5

142. The method of embodiment 138 or 141, wherein the VEGF-A-associated disorder is an angiogenic ocular disorder.

143. The method of embodiment 142, wherein the angiogenic ocular disorder is selected from the group consisting of AMD, DR, DME, RVO, CVO, MEfRVO, ROP, or mCNV.

10

144. The method of any one of embodiments 141-143, wherein treating comprises amelioration of at least one sign or symptom of the disorder .

15

145. The method of embodiment 144, wherein at least one sign or symptom of the angiogenic ocular disorder comprises a measure of one or more of angiogenesis, choroidal neovascularization, ocular inflammation, visual acuity, or presence, level, or activity of VEGF-A (*e.g.*, VEGF-A gene, VEGF-A mRNA, or VEGF-A protein).

20

146. The method of any one of embodiments 141-143, where treating comprises prevention of progression of the disorder.

147. The method of any one of embodiments 144-146, wherein the treating comprises one or more of (a) inhibiting angiogenesis; (b) inhibiting or reducing the expression or activity of VEGF-A; (c) inhibiting choroidal neovascularization; (d) inhibiting growth of new blood vessels in the choriocapillaris; (e) reducing retinal thickness; (f) increasing visual acuity; or (g) reducing intraocular inflammation.

25

148. The method of embodiment 147, wherein the treating results in at least a 30% mean reduction from baseline of VEGF mRNA in the retina, RPE, a retinal blood vessel (*e.g.*, including endothelial cells and vascular smooth muscle cells), or choroid tissue, *e.g.*, a choroid vessel.

30

149. The method of embodiment 148 wherein the treating results in at least a 60% mean reduction from baseline of VEGF mRNA in the retina, RPE, a retinal blood vessel (e.g., including endothelial cells and vascular smooth muscle cells), or choroid tissue, e.g., a choroid vessel.

5

150. The method of embodiment 149, wherein the treating results in at least a 90% mean reduction from baseline of VEGF mRNA in the retina, RPE, a retinal blood vessel (e.g., including endothelial cells and vascular smooth muscle cells), or choroid tissue, e.g., a choroid vessel.

10

151. The method of any one of embodiments 144-149, wherein after treatment the subject experiences at least an 8-week duration of knockdown following a single dose of dsRNA as assessed by VEGF-A protein in the retina.

15

152. The method of embodiment 151, wherein treating results in at least a 12-week duration of knockdown following a single dose of dsRNA as assessed by VEGF-A protein in the retina.

153. The method of embodiment 152, wherein treating results in at least a 16-week duration of knockdown following a single dose of dsRNA as assessed by VEGF-A protein in the retina.

20

154. The method of any of embodiments 133-153, wherein the subject is human.

155. The method of any one of embodiments 134-154, wherein the dsRNA agent is administered at a dose of about 0.01 mg/kg to about 50 mg/kg.

25

156. The method of any one of embodiments 134-155, wherein the dsRNA agent is administered to the subject intraocularly, intravenously, or topically.

157. The method of embodiment 156, wherein the intraocular administration comprises intravitreal administration (e.g., intravitreal injection), transscleral administration (e.g., transscleral injection), subconjunctival administration (e.g., subconjunctival injection), retrobulbar administration (e.g., retrobulbar injection), intracameral administration (e.g., intracameral injection), or subretinal administration (e.g., subretinal injection).

30

158. The method of any one of embodiments 134-157, further comprising measuring level of VEGF-A (*e.g.*, VEGF-A gene, VEGF-A mRNA, or VEGF-A protein) in the subject.

5 159. The method of embodiment 158, where measuring the level of VEGF-A in the subject comprises measuring the level of VEGF-A gene, VEGF-A protein or VEGF-A mRNA in a biological sample from the subject (*e.g.*, an aqueous ocular fluid sample).

10 160. The method of any one of embodiments 134-159, further comprising performing a blood test, an imaging test, or an aqueous ocular fluid biopsy.

161. The method of any one of embodiments 158-160, wherein measuring level of VEGF-A (*e.g.*, VEGF-A gene, VEGF-A mRNA, or VEGF-A protein) in the subject is performed prior to treatment with the dsRNA agent or the pharmaceutical composition.

15 162. The method of embodiment 161, wherein, upon determination that a subject has a level of VEGF-A (*e.g.*, VEGF-A gene, VEGF-A mRNA, or VEGF-A protein) that is greater than a reference level, the dsRNA agent or the pharmaceutical composition is administered to the subject.

20 163. The method of any one of embodiments 159-162, wherein measuring level of VEGF-A (*e.g.*, VEGF-A gene, VEGF-A mRNA, or VEGF-A protein) in the subject is performed after treatment with the dsRNA agent or the pharmaceutical composition.

25 164. The method of any one of embodiments 141-163, further comprising administering to the subject an additional agent and/or therapy suitable for treatment or prevention of a VEGF-A-associated disorder.

30 165. The method of embodiment 164, wherein the additional agent and/or therapy comprises one or more of a photodynamic therapy, photocoagulation therapy, a steroid, a non-steroidal anti-inflammatory agent, an anti-VEGF-A agent, and/or a vitrectomy.

166. The method of embodiment 165, wherein the anti-VEGF-A agent is a fusion protein or an anti-VEGF-A antibody or antigen-binding fragment thereof (e.g., an anti-VEGF-A antibody molecule).

EXAMPLES

Example 1. VEGF-A siRNA

Nucleic acid sequences provided herein are represented using standard nomenclature. See the abbreviations of Table 1.

5 **Table 1. Abbreviations of nucleotide monomers used in nucleic acid sequence** representation


It will be understood that these monomers, when present in an oligonucleotide, are mutually linked by 5'-3'-phosphodiester bonds.

Abbreviation	Nucleotide(s)
A	Adenosine-3'-phosphate
Ab	beta-L-adenosine-3'-phosphate
Abs	beta-L-adenosine-3'-phosphorothioate
Af	2'-fluoroadenosine-3'-phosphate
Afs	2'-fluoroadenosine-3'-phosphorothioate
(Ahd)	2'-O-hexadecyl-adenosine-3'-phosphate
(Ahds)	2'-O-hexadecyl-adenosine-3'-phosphorothioate
As	adenosine-3'-phosphorothioate
(A2p)	adenosine 2'-phosphate
C	cytidine-3'-phosphate
Cb	beta-L-cytidine-3'-phosphate
Cbs	beta-L-cytidine-3'-phosphorothioate
Cf	2'-fluorocytidine-3'-phosphate
Cfs	2'-fluorocytidine-3'-phosphorothioate
(Chd)	2'-O-hexadecyl-cytidine-3'-phosphate
(Chds)	2'-O-hexadecyl-cytidine-3'-phosphorothioate
Cs	cytidine-3'-phosphorothioate
(C2p)	cytosine 2'-phosphate
G	guanosine-3'-phosphate
Gb	beta-L-guanosine-3'-phosphate
Gbs	beta-L-guanosine-3'-phosphorothioate
Gf	2'-fluoroguanosine-3'-phosphate
Gfs	2'-fluoroguanosine-3'-phosphorothioate
(Ghd)	2'-O-hexadecyl-guanosine-3'-phosphate
(Ghds)	2'-O-hexadecyl-guanosine-3'-phosphorothioate
Gs	guanosine-3'-phosphorothioate
T	5'-methyluridine-3'-phosphate
Tb	beta-L-thymidine-3'-phosphate
Tbs	beta-L-thymidine-3'-phosphorothioate
Tf	2'-fluoro-5-methyluridine-3'-phosphate
Tfs	2'-fluoro-5-methyluridine-3'-phosphorothioate

Tgn	thymidine-glycol nucleic acid (GNA) S-Isomer
Agn	adenosine- glycol nucleic acid (GNA) S-Isomer
Cgn	cytidine-glycol nucleic acid (GNA) S-Isomer
Ggn	guanosine-glycol nucleic acid (GNA) S-Isomer
Ts	5-methyluridine-3'-phosphorothioate
U	Uridine-3'-phosphate
Ub	beta-L-uridine-3'-phosphate
Ubs	beta-L-uridine-3'-phosphorothioate
Uf	2'-fluorouridine-3'-phosphate
Ufs	2'-fluorouridine -3'-phosphorothioate
(Uhd)	2'-O-hexadecyl-uridine-3'-phosphate
(Uhds)	2'-O-hexadecyl-uridine-3'-phosphorothioate
Us	uridine -3'-phosphorothioate
(U2p)	uracil 2'-phosphate
N	any nucleotide (G, A, C, T or U)
VP	Vinyl phosphonate
a	2'-O-methyladenosine-3'-phosphate
as	2'-O-methyladenosine-3'- phosphorothioate
c	2'-O-methylcytidine-3'-phosphate
cs	2'-O-methylcytidine-3'- phosphorothioate
g	2'-O-methylguanosine-3'-phosphate
gs	2'-O-methylguanosine-3'- phosphorothioate
t	2'-O-methyl-5-methyluridine-3'-phosphate
ts	2'-O-methyl-5-methyluridine-3'-phosphorothioate
u	2'-O-methyluridine-3'-phosphate
us	2'-O-methyluridine-3'-phosphorothioate
dA	2'-deoxyadenosine-3'-phosphate
dAs	2'-deoxyadenosine-3'-phosphorothioate
dC	2'-deoxycytidine-3'-phosphate
dCs	2'-deoxycytidine-3'-phosphorothioate
dG	2'-deoxyguanosine-3'-phosphate
dGs	2'-deoxyguanosine-3'-phosphorothioate
dT	2'-deoxythymidine
dTs	2'-deoxythymidine-3'-phosphorothioate
dU	2'-deoxyuridine
s	phosphorothioate linkage
L96 ¹	N-[tris(GalNAc-alkyl)-amidodecanoyl]-4-hydroxyprolinol Hyp-(GalNAc-alkyl) ₃
(Aeo)	2'-O-methoxyethyladenosine-3'-phosphate
(Aeos)	2'-O-methoxyethyladenosine-3'-phosphorothioate
(Geo)	2'-O-methoxyethylguanosine-3'-phosphate
(Geos)	2'-O-methoxyethylguanosine-3'- phosphorothioate
(Teo)	2'-O-methoxyethyl-5-methyluridine-3'-phosphate
(Teos)	2'-O-methoxyethyl-5-methyluridine-3'- phosphorothioate

(m5Ceo)	2'-O-methoxyethyl-5-methylcytidine-3'-phosphate
(m5Ceos)	2'-O-methoxyethyl-5-methylcytidine-3'-phosphorothioate

¹The chemical structure of L96 is as follows:



Experimental Methods

Bioinformatics

Transcripts

Three sets of siRNAs targeting the human VEGF-A, “vascular endothelial growth factor A” (human: NCBI refseqID NM_001171623; NCBI GeneID: 7422) were generated. The human NM_001171623 REFSEQ mRNA, version 1, has a length of 3677 bases. Pairs of oligos were generated using bioinformatic methods and ranked, and exemplary pairs of oligos are shown in Table 2A, Table 2B, Table 3A, Table 3B, Table 4A, Table 4B, Table 8A, Table 8B, Table 10A, Table 10B, Table 18A, and Table 18B. Modified sequences are presented in Table 2A, Table 3A, Table 4A, Table 8A, Table 10A, Table 18A. Unmodified sequences are presented in Table 2B, Table 3B, Table 4B, Table 8B, Table 10B, Table 18B.

Similarly, a set of siRNAs targeting rat VEGF-A (rat: NCBI refseqID NM_001110333; NCBI GeneID 83785) were generated. The rat NM_001110333.2REFSEQ mRNA, version 2, has a length of 3474 base pairs. Pairs of oligos were generated using bioinformatic methods and ranked, and exemplary pairs of oligos are shown in Table 5A and Table 5B. Modified sequences are presented in Table 5A. Unmodified sequences are presented in Table 5B.

Table 2A. Exemplary Human VEGF-A siRNA Modified Single Strands and Duplex Sequences

Duplex Name	Sense Oligo Name	SEQ ID NO: (Sense)	Sense Sequence	Anti-sense Oligo Name	SEQ ID NO: (Anti-sense)	Antisense Sequence	mRNA target sequence	SEQ ID NO: (mRNA target)
AD-901349.1	A-1701255.1	4156	asagac(Uhd)GfaUfAfCfag aacgaucal96	A-1701256.1	130	VPusGfsaucg(Tgn)ucuguaUfcAfgucuuusc	GAAAAGACUGAUA CAGAACGAUCG	4224
AD-901376.1	A-1701309.1	4157	ascsggu(Ahd)CfuUfAfUfu aaauccal96	A-1701310.1	131	VPusGfsauga(Tgn)uaa auaAfgUfaacgusasu	AUACGGUACUUA UUUAAUAUCCCC	4225
AD-901356.1	A-1701269.1	3	csasgaa(Chd)AfgUfCfuu aauccagaL96	A-1701270.1	132	VPusCfsugga(Tgn)uaa ggaCfuGfuucgusc	GACAGAACAGUCC UUAAUCCAGA	4226
AD-901355.1	A-1701267.1	4	csgsaca(Ghd)AfaCfAfGfuc cuuaucal96	A-1701268.1	133	VPusGfsauua(Agn)gg acugUfuCfugucgsasu	AUCGACAGAACAG UCCUUAAUCC	4227
AD-901407.1	A-1701371.1	5	gscsaau(Uhd)GfuUfUfGfua caagaucal96	A-1701372.1	134	VPusGfsaucu(Tgn)gua caaAfcAfaaugcsusu	AAGCAUUUGUUU GUACAAAGAUC	4228
AD-901367.1	A-1701291.1	6	usasuug(Ghd)UfgUfCfUfuc acuggauaL96	A-1701292.1	135	VPusAfsucca(Ggn)ug aagaCfaCfcauasasc	GUUAUUGGUGUC UUCACUGGAUG	4229
AD-901352.1	A-1701261.1	7	ascsuga(Uhd)AfcAfGfAfac gaucgaual96	A-1701262.1	136	VPusAfsucga(Tgn)cgu ucuGfuAfuacguscu	AGACUGAUACAG AACGAUCGAUA	4230
AD-901348.1	A-1701253.1	8	asasaga(Chd)UfgAfUfAfca gaacgaual96	A-1701254.1	137	VPusAfsucgu(Tgn)cu guauCfaGfucuuusc	GGAAAAGACUGAU ACAGAACGAUC	4231
AD-901354.1	A-1701265.1	9	asusaca(Ghd)AfaCfGfAfuc gauacagaL96	A-1701266.1	138	VPusCfsugua(Tgn)cga ucgUfuCfuguausca	UGAUACAGAACG AUCGAUACAGA	4232

AD-901353.1	A-1701263.1	10	csusgau(Ahd)CfaGfAfAfcg aucgaualL96	A-170126 4.1	139	VPusUfsauc(Agn)uc guucUfgUfaucagsusc	GACUGAUACAGA ACGAUCGAUAC	4233
AD-901375.1	A-1701307.1	11	gsasgaa(Ahd)GfuGfUfUfu auauacgaL96	A-170130 8.1	140	VPusCfsguau(Agn)ua aaacAfcUfuucgsusu	AAGAGAAAAGUGU UUUAUAUACGG	4234
AD-901345.1	A-1701247.1	12	ascsgaa(Chd)GfuAfCfUfug cagauguaL96	A-170124 8.1	141	VPusAfiscauc(Tgn)gca aguAfcGfuucgsusu	AAACGAACGUACU UGCAGAUGUG	4235
AD-901357.1	A-1701271.1	13	csusugg(Ahd)AfuUfGfGfa uuegccauL96	A-170127 2.1	142	VPusAfsuggc(Ggn)aa uccaAfuUfccaagsasg	CUCUUUGGAAUUG GAUUCGCCAUU	4236
AD-901334.1	A-1701225.1	14	gsgscag(Chd)UfuGfAfGfu aaacgaalL96	A-170122 6.1	143	VPusUfsucgu(Tgn)uaa cucAfaGfuegccsusc	GAGGCAGCUUGA GUUAAACGAAC	4237
AD-901313.1	A-1701183.1	15	gsgsgca(Ghd)AfaUfCfAfuc acgaagualL96	A-170118 4.1	144	VPusAfsuuc(Ggn)ug augaUfuCfugcccsusc	GAGGGCAGAAUC AUCACGAAAGUG	4238
AD-901344.1	A-1701245.1	16	ususaaa(Chd)GfaAfCfGfua cuugcagaL96	A-170124 6.1	145	VPusCfsugca(Agn)gu acguUfcGfuuaacsu	AGUUAACGAAC GUACUUGCAGA	4239
AD-901366.1	A-1701289.1	17	gsusuau(Uhd)GfgUfGfUfc uucacuggaL96	A-170129 0.1	146	VPusCfscagu(Ggn)aag acaCfcAfauaacsu	AUGUUAUUGGUG UCUUCACUGGA	4240
AD-901337.1	A-1701231.1	18	asgscuu(Ghd)AfgUfUfAfaa cgaacgualL96	A-170123 2.1	147	VPusAfsccgu(Cgn)gu uuaaCfuCfaagcusc	GCAGCUUGAGUU AAACGAACGUA	4241
AD-901335.1	A-1701227.1	19	gscsagc(Uhd)UfgAfGfUfua aacgaacalL96	A-170122 8.1	148	VPusGfsuuc(Tgn)uu aacuCfaAfcugcscsu	AGGCAGCUUGAG UUAAACGAACG	4242
AD-901398.1	A-1701353.1	20	csgsaag(Uhd)GfgUfGfAfag uucacuggaL96	A-170135 4.1	149	VPusCfscagu(Agn)acu ucaCfcAfcuucgsug	CACGAAUGGGUG AAGUUCAUUGGA	4243
AD-901314.1	A-1701185.1	21	csasgaa(Uhd)CfaUfCfAfcg aaguggualL96	A-170118 6.1	150	VPusAfsccac(Tgn)ucg ugaUfgAfuucgscsc	GGCAGAAUCAUCA CGAAGUGGUG	4244

AD-901386.1	A-1701329.1	22	asasaau(Ahd)GfaCfAfUfug cuaucuaL96	A-1701330.1	151	VPusAfsgaau(Agn)gc aaugUfcUfauuusasu	AUAAAUAAGACA UUGCUAUUCUG	4245
AD-901336.1	A-1701229.1	23	csasgau(Uhd)GfaGfUfuaa acgaacgaL96	A-1701230.1	152	VPusCfsguuc(Ggn)uu uaacUfcAfagcugscsc	GGCAGCUUGAGU UAAACGAACGU	4246
AD-901310.1	A-1701177.1	24	csgscac(Uhd)GfaAfCfuu uucguccaL96	A-1701178.1	153	VPusGfsgacg(Agn)aaa guuUfcAfugcgsasc	GUCGCACUGAAAC UUUUUGGUCCA	4247
AD-901321.1	A-1701199.1	25	asgsauu(Ahd)UfgCfGfGfau caaaccuaL96	A-1701200.1	154	VPusAfsgguu(Tgn)ga uucgCfaUfaucugsc	GCAGAUUAUGCG GAUCAAAACCUC	4248
AD-901382.1	A-1701321.1	26	gscsucu(Chd)UfuAfUfUfug uaccgguaL96	A-1701322.1	155	VPusAfsccg(Tgn)aca aaUfaGfagagsasa	UUGCUCUCUUAUU UGUACCGGUU	4249
AD-901384.1	A-1701325.1	27	usgsaca(Ghd)UfcAfCfUfag cuuaucuaL96	A-1701326.1	156	VPusAfsgaau(Agn)gc uaguGfaCfugucascsc	GGUGACAGUCACU AGCUUAUCUU	4250
AD-901339.1	A-1701235.1	28	csusuga(Ghd)UfuAfAfAfeg aacguacaL96	A-1701237.1	157	VPusGfsuacg(Tgn)ucg uuuAfaCfucaagsesu	AGCUUGAGUUA ACGAAACGUACU	4251
AD-901363.1	A-1701283.1	29	asgsugc(Uhd)AfaUfGfUfua uugguguaL96	A-1701284.1	158	VPusAfsccg(Agn)aaa acaUfuAfgcacusgu	ACAGUGCUAAUG UUUUUGGUGUC	4252
AD-901325.1	A-1701207.1	30	asusccg(Chd)AfgAfCfGfug uaaauquaL96	A-1701208.1	159	VPusAfscauu(Tgn)aca cguCfuGfcggausesu	AGAUCGCGACAGC UGUAAAUGUU	4253
AD-901350.1	A-1701257.1	31	asgsacu(Ghd)AfuAfCfAfga acgaucgaL96	A-1701258.1	160	VPusCfsgauc(Ggn)uu cuguAfuCfagucusus	AAAGACUGAUAC AGAACGAUCCGA	4254
AD-901365.1	A-1701287.1	32	usgsuua(Uhd)UfgGfUfGfu cuucacugaL96	A-1701288.1	161	VPusCfsagug(Agn)ag aacCfaAfuacacusu	AAUGUUUUUGGU GUCUUCACUGG	4255
AD-901306.1	A-1701169.1	33	gsusgcu(Ghd)GfaAfUfUfu gauauucaL96	A-1701170.1	162	VPusUfsgaau(Agn)uc aaaUfcCfagcacscsg	CGGUGCUGGAAU UUGAUUUUCAU	4256

AD-901361.1	A-1701279.1	34	ususgc(Ghd)CfuAfAfAfuacaggcaL96	A-1701280.1	163	V PusGfscug(Ggn)ugauuAfgCfagcaagsa	UCUUGCUGCUAAAUCACCGAGCC	4257
AD-901320.1	A-1701197.1	35	csascca(Uhd)GfcAfGfAfuuaugcggaalL96	A-1701198.1	164	V PusUfscgc(Agn)uaa ucuGfcAfuggugsasu	AUCACCAUUGCAGAUUAUGCGGAU	4258
AD-901405.1	A-1701367.1	36	gsasaag(Chd)AfuUfGfuuuguacaaaL96	A-1701368.1	165	V PusUfsugua(Cgn)aaacaaAfuGfcuuuusc	GAGAAAGCAUUUGUUUGUACAAG	4259
AD-901338.1	A-1701233.1	37	gscsuug(Ahd)GfuUfAfAfuagaacguaalL96	A-1701234.1	166	V PusUfsacgu(Tgn)cguaaAfcUfcaagcsug	CAGCUUGAGUUAACGAACGUAC	4260
AD-901383.1	A-1701323.1	38	uscsngu(Ghd)AfcAfGfUfca cuagcuuaL96	A-1701324.1	167	V PusAfsaguu(Agn)gugacuGfuCfaccgasusc	GAUCGGUGACAGUCACUAGCUUA	4261
AD-901333.1	A-1701223.1	39	asgsnga(Ghd)CfuUfGfAfguaaacgaalL96	A-1701224.1	168	V PusUfscgu(Tgn)aaucuaAfgCfugccscsg	CGAGGCAGCUUGAGUUAAACGAA	4262
AD-901330.1	A-1701217.1	40	csusnga(Ahd)AfaAfCfAfcagacgcaL96	A-1701218.1	169	V PusGfscgag(Tgn)cuuguUfuUfugcaggsa	UCCUGCAAAAACA CAGACUCGCG	4263
AD-901360.1	A-1701277.1	41	csusngc(Uhd)GfcUfAfAfaucaccgaalL96	A-1701278.1	170	V PusCfsucgg(Tgn)gaauuaGfcAfgeaagsasa	UUCUUGCUGCUAAUACACCGAGC	4264
AD-901358.1	A-1701273.1	42	ususcuu(Ghd)CfuGfCfUfaa aucaccgaL96	A-1701274.1	171	V PusCfsggug(Agn)uuuagcAfgCfaagaasasa	UUUUCUUGCUGCUAAAUCACCGA	4265
AD-901406.1	A-1701369.1	43	asasagc(Ahd)UfuUfGfUfuu guacaaalL96	A-1701370.1	172	V PusCfsuugu(Agn)ca aacaAfaUfgeuuusc	AGAAAAGCAUUUGUUUGUACAAGA	4266
AD-901326.1	A-1701209.1	44	uscsngc(Ahd)GfaCfGfUfgu aauguuuaL96	A-1701210.1	173	V PusAfsacuu(Tgn)uacacgUfcUfgeggasusc	GAUCCGCAGACGUGUAAAUGUUC	4267
AD-901377.1	A-1701311.1	45	csngsgua(Chd)UfuAfUfuaaaucccaL96	A-1701312.1	174	V PusGfsggag(Agn)uu aaauAfaGfuaccgsusa	UACGGUACUUAUUUAAUAUCCCU	4268

AD-901351.1	A-1701259.1	46	gsascug(Ahd)UfaCfAfGfaa cgauccgaal96	A-1701260.1	175	VpusUfscgau(Cgn)gu ucugUfaUfcagucsusu	AAGACUGAUACA GAACGAUCGAU	4269
AD-901415.1	A-1701387.1	47	asasaac(Ahd)CfaGfAfCfuc gcuugcaal96	A-1701388.1	176	VpusGfscac(Ggn)cga gucUfgUfguuuusg	CAAAAACACAGAC UCGCGUUGCA	4270
AD-901342.1	A-1701241.1	48	gsasguu(Ahd)AfaCfGfAfac guacuugaal96	A-1701242.1	177	VpusCfsaagu(Agn)cg uucgUfuUfaacucsasa	UUGAGUUAAACG AACGUACUUGC	4271
AD-901420.1	A-1701397.1	49	uscsacu(Ghd)GfaUfGfUfau uugacuugaal96	A-1701398.1	178	VpusCfsaguc(Agn)aa acaUfcCfagugasag	CUUCACUGGAUGU AUUUGACUGC	4272
AD-901312.1	A-1701181.1	50	csesucc(Ghd)AfaAfCfCfau gaacuuaal96	A-1701182.1	179	VpusAfsaagu(Tgn)cau ggUfuCfaggagcsc	GGCCUCCGAAACC AUGAACUUUC	4273
AD-901340.1	A-1701237.1	51	ususgag(Uhd)UfaAfAfCfga acguacuuaal96	A-1701238.1	180	VpusAfsuac(Ggn)uu cguUfaAfcucaasgsc	GCUUGAGUUAAA CGAACGUACUU	4274
AD-901392.1	A-1701341.1	52	usgsuca(Chd)UfgUfUfUfau ccguuaal96	A-1701342.1	181	VpusAfsuac(Ggn)ga uaaaCfaGfuagcascsc	GGUGCUACUGUU UAUCCGUAAUA	4275
AD-901327.1	A-1701211.1	53	csesgca(Ghd)AfcGfUfGfua aanguuuaal96	A-1701212.1	182	VpusGfsaaca(Tgn)uua cacGfuCfugcggsasu	AUCCGCAGACGUG UAAAUGUUUCC	4276
AD-901328.1	A-1701213.1	54	csesgca(Ahd)CfGfUfGfUfau aanguuuaal96	A-1701214.1	183	VpusGfsgaac(Agn)uu uacaCfGfUfcggsasa	UCCGCAGACGUGU AAAUUUUCCU	4277
AD-901370.1	A-1701297.1	55	asgsaga(Ahd)GfaGfAfCfuc aanguugaal96	A-1701298.1	184	VpusCfsaaca(Agn)ugu gucUfcUfucucusc	GAAGAGAAAGAGA CACAUUGUUGG	4278
AD-901399.1	A-1701355.1	56	ascsaga(Ahd)CfaAfCfAfaa ugugaauuaal96	A-1701356.1	185	VpusAfsuua(Cgn)au uuguUfgUfgucgusasg	CUACAGCACAAACA AAUGUGAAUG	4279
AD-901359.1	A-1701275.1	57	uscsuug(Chd)UfgCfUfAfaa ucaccgaal96	A-1701276.1	186	VpusUfscggg(Ggn)au uuagCfaGfcaagasasa	UUUCUUGCUGCUA AAUACCCGAG	4280

AD-901373.1	A-1701303.1	58	ascsacc(Ahd)UfuGfAfAfaccacuaaL96	A-1701304.1	187	VpusAfsuag(Tgn)gguuucAfaUfggugusgsa	UCACACCAUUGAAACCACUAGUU	4281
AD-901332.1	A-1701221.1	59	gsasggc(Ahd)GfcUfUfGfaguuuaacgaL96	A-1701222.1	188	VpusCfsguuu(Agn)acucaaGfcUfgccucsgsc	GCGAGGCAGCUUGAGUUAAACGA	4282
AD-901311.1	A-1701179.1	60	gscsacu(Ghd)AfaAfCfUfuucgucacaaL96	A-1701180.1	189	VpusUfsggac(Ggn)aaaguUfuCfagugcgsa	UCGCACUGAAACUUUUCGUCCAA	4283
AD-901423.1	A-1701403.1	61	gsusuuu(Ahd)UfaUfAfCfaguacuuuaL96	A-1701404.1	190	VpusAfsuaag(Tgn)accguaUfaUfaaaacsasc	GUGUUUUUAUAACGGUACUUUAU	4284
AD-901374.1	A-1701305.1	62	csascca(Uhd)UfgAfAfAfccacuaguuL96	A-1701306.1	191	VpusAfsacua(Ggn)uguuuUfaUfaaacsasc	CACACCAUUGAAACACUAGUUC	4285
AD-901319.1	A-1701195.1	63	asuscac(CHd)AfuGfCfAfgaauuagcgaL96	A-1701196.1	192	VpusCfsgcau(Agn)aucugcAfuGfugausgsu	ACAUCACCAUGCAGAUUUUGCGG	4286
AD-901341.1	A-1701239.1	64	usgsagu(Uhd)AfaAfCfGfaacguacuuL96	A-1701240.1	193	VpusAfsagua(Cgn)guucguUfuAfacucasag	CUUGAGUUAAACGAACGUACUUG	4287
AD-901422.1	A-1701401.1	65	gsasaag(Uhd)GfuUfUfUfaauuacgguaL96	A-1701402.1	194	VpusAfsccgu(Agn)uaaaaaAfcAfcuuucusc	GAGAAAGUGUUUUUAUAUACGGUA	4288
AD-901385.1	A-1701327.1	66	ascsagu(CHd)AfcUfAfGfcuuaucuuL96	A-1701328.1	195	VpusCfsaaga(Tgn)aagcuaGfuGfacuguscsa	UGACAGUCACUAGCUUAUCUUGA	4289
AD-901391.1	A-1701339.1	67	gsusgcu(Ahd)CfuGfUfUfuaucguaaaL96	A-1701340.1	196	VpusUfsuacg(Ggn)auaaacAfgUfagcacscsa	UGGUGCUACUGUUUAUCCGUAAU	4290
AD-901329.1	A-1701215.1	68	cscsugc(Ahd)AfaAfAfCfagacucgaL96	A-1701216.1	197	VpusCfsgagu(Cgn)uguuuUfuUfgcaggsasa	UUCUUGCAAAACACAGACUCGC	4291
AD-901331.1	A-1701219.1	69	csasaaa(Ahd)CfaCfAfGfagucgguuaL96	A-1701220.1	198	VpusAfsacgc(Ggn)agucugUfgUfuuuugscsa	UGCAAAAACACAGACUCGCUUG	4292

AD-901368.1	A-1701293.1	70	usgscug(Uhd)GfgAfCfUfu gaguuggaL96	A-1701294.1	199	VpUsCfscac(Cgn)uca aguCfcAfcagcagsu	ACUGCUGUGGACU UGAGUUGGGA	4293
AD-901364.1	A-1701285.1	71	gsusgcu(Ahd)AfuGfUfUfa uugguguaL96	A-1701286.1	200	VpUsGfsacac(Cgn)aa aacAfuUfagcacsug	CAGUGCUA AUGU UAUUGGUGUCU	4294
AD-901389.1	A-1701335.1	72	usgsgug(Chd)UfaCfUfGfu uaucggaL96	A-1701336.1	201	VpUsAfsccga(Tgn)aaa cagUfaGfcaccasau	AUUGGUGCUACU GUUU AUCCGUA	4295
AD-901421.1	A-1701399.1	73	asgsaaa(Chd)UfgUfUfUfa uaucggaL96	A-1701400.1	202	VpUsCfscga(Tgn)aaa aaaCfaCfuucscsu	AGAGAAAAGUGU UUUAUAUACGGU	4296
AD-901380.1	A-1701317.1	74	asascua(Uhd)UfuAfUfGfg auguaL96	A-1701318.1	203	VpUsGfsauac(Agn)uc ucauAfaAfuagugsa	UCAACUAUUUAU GAGAUGUAUCU	4297
AD-901343.1	A-1701243.1	75	asgsuua(Ahd)AfcGfAfAfcg uaucggaL96	A-1701244.1	204	VpUsGfscag(Tgn)acg uucGfuUfuaucscsa	UGAGUUAACGA ACGUACUUGCA	4298
AD-901317.1	A-1701191.1	76	csasucu(Uhd)CfaAfGfCfca uccuggaL96	A-1701192.1	205	VpUsCfsacag(Ggn)aug gcuUfgAfagausa	UACAUCUUAACG CAUCCUGUGU	4299
AD-901424.1	A-1701405.1	77	ususuuu(Uhd)UfuCfAfGfu auucuggaL96	A-1701406.1	206	VpUsCfscag(Agn)aaa cugAfaAfaaaascsc	GGUUUUUUUUA GUUUUUUUUGU	4300
AD-901431.1	A-1701419.1	78	ususauu(Chd)GfuAfAfUfaa uuguggaL96	A-1701420.1	207	VpUsCfscac(Agn)aaa auuAfcGfgauaasc	GUUU AUCCGUA UAAUUGUGGGG	4301
AD-901378.1	A-1701313.1	79	gsusuac(Uhd)UfaUfUfUfaa uaucggaL96	A-1701314.1	208	VpUsAfsccga(Tgn)au uaaaUfaAfguaccsu	ACGGUACUUAU UAAUAUCCCUU	4302
AD-901434.1	A-1701425.1	80	csascgu(Chd)UfuUfGfUfcu cuaguggaL96	A-1701426.1	209	VpUsGfscacu(Agn)ga gacaAfaGfagcagsu	AUCACGUCUUUG CUCUAGUGCA	4303
AD-901412.1	A-1701381.1	81	usgscaa(Ahd)AfaCfAfCfag acucggaL96	A-1701382.1	210	VpUsCfscga(Ggn)uc ugugUfuUfuagcsgg	CCUGCAAAAACAC AGACUCGCGU	4304

AD-901426.1	A-1701409.1	82	ascsuau(Uhd)UfaUfGfAfga uguaucaL96	A-1701410.1	211	VpUsAfsgau(Cgn)auc ucaUfaAfaugusug	CAACUAAUUAUG AGAUGUAUCUU	4305
AD-901322.1	A-1701201.1	83	asgsagg(Chd)AfaAfAfAfg aaagcgcaL96	A-1701202.1	212	VpUsGfscgu(Tgn)ucg uuUfuGfcccusu	AAAGGGGCAAAA ACGAAAGCGCA	4306
AD-901381.1	A-1701319.1	84	ususgu(Chd)UfcUfUfAfu uguaccgaL96	A-1701320.1	213	VpUsCfsggua(Cgn)aaa uaaGfaGfagcaasgsa	UCUUGCUCUCUUA UUUGUACCGG	4307
AD-901324.1	A-1701205.1	85	asusuug(Uhd)UfuGfUfAfa agaucgcaL96	A-1701206.1	214	VpUsCfsggu(Cgn)uu guacAfaAfaaasgsc	GCAUUUGUUUGU ACAAGAUCCGC	4308
AD-901347.1	A-1701251.1	86	ususgca(Ghd)AfuGfUfGfac aagccgaaL96	A-1701252.1	215	VpUsUfscggc(Tgn)ug ucacAfuCfugcaasgsu	ACUUGCAGAUUGU GACAAAGCCGAG	4309
AD-901379.1	A-1701315.1	87	csasacu(Ahd)UfuUfAfUfga gauguaaL96	A-1701316.1	216	VpUsAfsuaca(Tgn)cuc aauAfaUfaguugsasa	UUCAACUAUUUA UGAGAUGUAUC	4310
AD-901428.1	A-1701413.1	88	asasuuc(Uhd)AfcAfUfAfcu aaaucaL96	A-1701414.1	217	VpUsGfsagau(Tgn)uag uauGfuAfgaauscsu	AGAAUUCUACAU ACUAAAUUCUCU	4311
AD-901371.1	A-1701299.1	89	asusguc(Chd)UfcAfCfAfcc auugaaaaL96	A-1701300.1	218	VpUsUfsuaca(Agn)ug guguGfaGfgacaasag	CUAUGUCCUCACA CCAUUUGAAAC	4312
AD-901408.1	A-1701373.1	90	ususguu(Uhd)GfuAfCfAfa gaucgcaL96	A-1701374.1	219	VpUsUfsgcgg(Agn)uc uuguAfcAfaacaasu	AUUUGUUUGUAC AAGAUCCGCAG	4313
AD-901417.1	A-1701391.1	91	usasauc(Chd)AfgAfAfAfcc ugaauaL96	A-1701392.1	220	VpUsCfsauu(Cgn)ag guuuCfuGfgauuasag	CUUAAUCCAGAAA CCUGAAAUAGA	4314
AD-901400.1	A-1701357.1	92	gsasaaa(Ahd)AfaAfUfCfag uucgaggaL96	A-1701358.1	221	VpUsCfscuc(Agn)acu gauUfuUfuuuususu	AAGAAAAAAAU CAGUUCGAGGA	4315
AD-901323.1	A-1701203.1	93	gsgsgca(Ahd)AfaAfCfGfaa agcgcaaaL96	A-1701204.1	222	VpUsUfsugcg(Cgn)uu ucguUfuUfugccscsu	AGGGGCAAAAAC GAAAGCGCAAG	4316

AD-901316.1	A-1701189.1	94	usgsaag(Uhd)UfcAfUfGfga ugucuaaL96	A-1701190.1	223	VPusAfsuaga(Cgn)auc cauGfaAfcuacscsc	GGUGAAGUUCAU GGAUGUCUAUC	4317
AD-901315.1	A-1701187.1	95	csascga(Ahd)GfuGfGfUfga aguucuaaL96	A-1701188.1	224	VPusAfsugaa(Cgn)uu caccAfcUfucgugsasu	AUCACGAAAGUGG UGAAGUUCUAUG	4318
AD-901395.1	A-1701347.1	96	ascsguc(Uhd)UfuGfUfCfuc uagugcaL96	A-1701348.1	225	VPusUfsgcac(Tgn)aga gacAfaAfgacgusgsa	UCACGUCUUUGUC UCUAGUGCAG	4319
AD-901318.1	A-1701193.1	97	asascga(Uhd)AfcCfAfUfgc agaauuaaL96	A-1701194.1	226	VPusAfsuaau(Cgn)ug caugGfuGfauguusgs	CCAACAUCACCAU GCAGAUUAUG	4320
AD-901390.1	A-1701337.1	98	gsugsug(Uhd)AfcUfGfUfu uaucggaL96	A-1701338.1	227	VPusUfsacgg(Agn)ua aacaGfuAfgcaccsasa	UUGGUGCUACUG UUUAUCCGUAA	4321
AD-901387.1	A-1701331.1	99	asasaua(Ghd)AfcAfUfUfgc uaucugaL96	A-1701332.1	228	VPusCfsagaa(Tgn)agc aaUGfuCfuuuusasa	UAAAAUAGACAU UGCUAUUCUGU	4322
AD-901307.1	A-1701171.1	100	ususccc(Ghd)AfaAfUfCfuc uguggaL96	A-1701172.1	229	VPusAfsucca(Cgn)agu gauUfuGfgggaagsu	ACUUCCCCAAUUC ACUGUGGAU	4323
AD-901410.1	A-1701377.1	101	gsasucc(Ghd)CfaGfAfCfug guuaaL96	A-1701378.1	230	VPusCfsauuu(Agn)cac gucUfgCfggauususu	AAGAUCGCGCAGAC GUGUAAAUGU	4324
AD-901433.1	A-1701423.1	102	ususaac(Ahd)UfcAfCfGfuc uuugucuaL96	A-1701424.1	231	VPusAfsagaa(Cgn)aga cguGfaUfguuuasasa	UAUUAAACAUCACG UCUUUGUCUC	4325
AD-901308.1	A-1701173.1	103	asasagu(Ghd)AfgUfGfAfcc ugcuuuuaL96	A-1701174.1	232	VPusAfsaaag(Cgn)agg ucaCfuCfauuuusgs	GCAAAAGUGAGUG ACCUGCUUUUG	4326
AD-901414.1	A-1701385.1	104	asasaaa(Ghd)AfcAfGfAfcu cgcuuugaL96	A-1701386.1	233	VPusCfsaacg(Cgn)gag ucuGfuGfuuuusgs	GCAAAAACACACAGA CUCGCGUUUGC	4327
AD-901309.1	A-1701175.1	105	cgsugc(Ghd)AfcUfGfAfua cuuucgaL96	A-1701176.1	234	VPusCfsgaaa(Agn)gu uucaGfuGfagacgsc	GGCGUCGCACUGA AACUUUUCGU	4328

AD-901362.1	A-1701281.1	106	asascag(Uhd)GfcUfAfAfug uuauuggaL96	A-1701282.1	235	V PusCfscuu(Agn)aca uuuGfcAfcguusasa	UUAACAGUGCUA AUGUUUUUGGU	4329
AD-901397.1	A-1701351.1	107	ususcgu(Chd)CfaAfCfUfuc ugggcugaL96	A-1701352.1	236	V PusCfsagcc(Cgn)aga aguUfgGfacgaasasa	UUUUCGUCCAACU UCUGGGCUGU	4330
AD-901419.1	A-1701395.1	108	asusugg(Uhd)GfuCfUfUfca cuggaugaL96	A-1701396.1	237	V PusCfsaucc(Agn)gu gaagAfcAfccaasasa	UUAUUGGUGUCU UCACUGGAUGU	4331
AD-901413.1	A-1701383.1	109	gscsaaa(Ahd)AfcAfCfAfga cucgcgual96	A-1701384.1	238	V PusAfsagcc(Agn)gu cuguGfuUfuugcsag	CUGCAAAAACACA GACUCGCGUU	4332
AD-901401.1	A-1701359.1	110	asasaaa(Uhd)CfaGfUfUfcg aggaagaL96	A-1701360.1	239	V PusCfsuuuc(Cgn)uc gaacUfgAfuuuusuu	AAAAAAAUUCAGU UCGAGGAAAGG	4333
AD-901411.1	A-1701379.1	111	csasgac(Ghd)UfgUfAfAfau guuccugaL96	A-1701380.1	240	V PusCfsagga(Agn)cau uuuAfcAfcgucgscg	CGCAGACGUGUAA AUGUUCCUGC	4334
AD-901372.1	A-1701301.1	112	usgsucc(Uhd)CfaCfAfCfca uuuagaacaL96	A-1701302.1	241	V PusGfsuuuc(Agn)au ggugUfgAfggacasa	UAUGUCCUCACAC CAUUGAAACC	4335
AD-901425.1	A-1701407.1	113	ususuuu(Uhd)UfcAfGfUfa uuuugguaL96	A-1701408.1	242	V PusAfsccaa(Ggn)aa acuGfaAfaaaasasc	GUUUUUUUUCAG UAUUUUUGGUU	4336
AD-901409.1	A-1701375.1	114	asgsauc(Chd)GfcAfGfAfca uguuaaual96	A-1701376.1	243	V PusAfsuuua(Cgn)ac gucuGfcGfgaucusug	CAAGAUCCGCAGA CGUGUAAUUG	4337
AD-901418.1	A-1701393.1	115	csescuc(Uhd)UfgGfAfAfuu ggauucgaL96	A-1701394.1	244	V PusCfsgaa(Cgn)caa uucCfaAfgagggsasc	GUCCCUUUUGGAA UUGGAUUUCGC	4338
AD-901393.1	A-1701343.1	116	gsasuau(Uhd)AfaCfAfUfca cgucuuuaL96	A-1701344.1	245	V PusAfsaaga(Cgn)gu gaugUfuAfaauusuu	AAGAUUUUAACA UCACGUCUUUG	4339
AD-901388.1	A-1701333.1	117	ususggg(Ghd)CfuAfCfUfg uuuauccgaL96	A-1701334.1	246	V PusCfsgga(Agn)aac aguAfcCfaccasasa	UAUUGGUGCUAC UGUUUAUCCGU	4340

AD-901404.1	A-1701365.1	118	asasggg(Ghd)CfaAfAfAfac gaaagcgaL96	A-170136 6.1	247	V PusCfsgcuu(Tgn)cgu uuuUfgCfcccususc	GAAAAGGGGCAAA AACGAAAGCGC	4341
AD-901346.1	A-1701249.1	119	csusugc(Ahd)GfaUfGfUfga caagccgaL96	A-170125 0.1	248	V PusCfsgcuu(Tgn)guc acaUfcUfgcaagsusa	UACUUGCAGAUG UGACAAAGCCGA	4342
AD-901403.1	A-1701363.1	120	asasauc(Ahd)GfuUfCfGfag gaaaggggaL96	A-170136 4.1	249	V PusCfsgcuu(Tgn)ccu cgaAfcUfgauuususu	AAAAAUCAGUUC GAGGAAAGGGA	4343
AD-901396.1	A-1701349.1	121	ascsuuu(Uhd)CfGfUfCfCfaa cuucuggaL96	A-170135 0.1	250	V PusCfsgcuu(Tgn)gu uggaCfGfAfaaagsusu	AAACUUUUUCGUCC AACUUUCUGGG	4344
AD-901432.1	A-1701421.1	122	asusuaa(Chd)AfuCfAfCfGu cuuugucaL96	A-170142 2.1	251	V PusGfsacaa(Agn)gac gugAfuGfuuaausasu	AUAUUAACAUCAC GUCUUUGUCU	4345
AD-901435.1	A-1701427.1	123	csgsucu(Uhd)UfgUfCfUfcu agugcagaL96	A-170142 8.1	252	V PusCfsgcuu(Tgn)uag agaCfaAfagacgsusg	CACGUCUUUGUCU CUAGUGCAGU	4346
AD-901416.1	A-1701389.1	124	asascac(Ahd)GfaCfUfCfGc guugcaaaL96	A-170139 0.1	253	V PusUfsugca(Agn)cg cgagUfcUfguguususu	AAACACACAGACUC GCGUUUGCAAG	4347
AD-901394.1	A-1701345.1	125	asusauu(Ahd)AfcAfUfCfCf gucuuugaL96	A-170134 6.1	254	V PusCfsaaag(Agn)cgu gauGfuUfaauauscsu	AGAUUUUAACAUC CACGUCUUUGU	4348
AD-901429.1	A-1701415.1	126	gsusuua(Uhd)CfcGfUfAfau aaugugaL96	A-170141 6.1	255	V PusCfsacaa(Tgn)uau uacGfgAfuaaacsasg	CUGUUUAUCCGUA AUAAUUUGUGG	4349
AD-901402.1	A-1701361.1	127	asasaau(Chd)AfgUfUfCfG ggaaggaL96	A-170136 2.1	256	V PusCfscuuu(Cgn)cuc gaaCfuGfauuuususu	AAAAAAUUCAGUU CGAGGAAAGGG	4350
AD-901430.1	A-1701417.1	128	ususuaa(Chd)CfGfUfAfAfa auuguggaL96	A-170141 8.1	257	V PusCfscacaa(Agn)uua uuaCfGfGfauaaacsca	UGUUUAUCCGUA AUAAUUUGUGG	4351
AD-901369.1	A-1701295.1	129	asgsgac(Ahd)UfuGfCfUfgu gcuuuggaL96	A-170129 6.1	258	V PusCfscacaa(Ggn)cac agcAfaUfguccusgsa	UCAGGACAUCUCU GUGCUUUUGGG	4352

Table 2B. Exemplary Human VEGF-A siRNA Unmodified Single Strands and Duplex Sequences

Duplex Name	Sense Oligo Name	SEQ ID NO: (Sense)	Sense Sequence	mRNA Target Range	Antisense Oligo Name	SEQ ID NO: (Antisense)	Antisense Sequence	mRNA Target Range
AD-901349.1	A-170125 5.1	259	AAGACUGAUACAGAA CGAUC	1796-1816	A-170125 6.1	388	UGAUCGTUCUGUAUCAGU CUUUC	1794-1816
AD-901376.1	A-170130 9.1	260	ACGGUACUUAUUUA UAUCCA	2961-2981	A-170131 0.1	389	UGGAUATUAAAUAAGUAC CGUAU	2959-2981
AD-901356.1	A-170126 9.1	261	CAGAACAGUCCUUA UCCAGA	1858-1878	A-170127 0.1	390	UCUGGATUAAGGACUGUU CUGUC	1856-1878
AD-901355.1	A-170126 7.1	262	CGACAGAACAGUCCU UAAUCA	1855-1875	A-170126 8.1	391	UGAUUAAGGACUGUUCU GUCGAU	1853-1875
AD-901407.1	A-170137 1.1	263	GCAUUUGUUUGUACA AGAUA	1614-1634	A-170137 2.1	392	UGAUCUTGUACAAACAAA UGCUC	1612-1634
AD-901367.1	A-170129 1.1	264	UAUUGGUGUCUUCAC UGGAUA	2192-2212	A-170129 2.1	393	UAUCCAGUGAAGACACCA AUAAC	2190-2212
AD-901352.1	A-170126 1.1	265	ACUGAUACAGAACGA UCGAUA	1799-1819	A-170126 2.1	394	UAUCGATCGUUCUGUAUC AGUCU	1797-1819
AD-901348.1	A-170125 3.1	266	AAAGACUGAUACAGA ACGAUA	1795-1815	A-170125 4.1	395	UAUCGUTCUGUAUCAGUC UUUCC	1793-1815
AD-901354.1	A-170126 5.1	267	AUACAGAACGAUCGA UACAGA	1803-1823	A-170126 6.1	396	UCUGUATCGAUCGUUCUG UAUCA	1801-1823
AD-901353.1	A-170126 3.1	268	CUGAUACAGAACGAU CGAUAA	1800-1820	A-170126 4.1	397	UUAUCGAUCGUUCUGUAU CAGUC	1798-1820

AD-901375.1	A-170130 7.1	269	GAGAAAGUGUUUUA UAUACGA	2944-2964	A-170130 8.1	398	UCGUUAUAAAACACUUU CUCUU	2942-2964
AD-901345.1	A-170124 7.1	270	ACGAACGUACUUGCA GAUGUA	1700-1720	A-170124 8.1	399	UACAUCTGCAAGUACGUU CGUUU	1698-1720
AD-901357.1	A-170127 1.1	271	CUUGGAAUUGGAUUC GCCAUA	1982-2002	A-170127 2.1	400	UAUGGCGAAUCCAAUUC AAGAG	1980-2002
AD-901334.1	A-170122 5.1	272	GGCAGCUUGAGUUAA ACGAAA	1685-1705	A-170122 6.1	401	UUUCGUTUAAACUCAAGCU GCCUC	1683-1705
AD-901313.1	A-170118 3.1	273	GGCAGAAUCAUCAC GAAGUA	1138-1158	A-170118 4.1	402	UACUUCGUGAUGAUUCUG CCCUC	1136-1158
AD-901344.1	A-170124 5.1	274	UUAAACGAACGUACU UGCAGA	1696-1716	A-170124 6.1	403	UCUGCAAGUACGUUCGUU UAACU	1694-1716
AD-901366.1	A-170128 9.1	275	GUUAUUGGUGUCUUC ACUGGA	2190-2210	A-170129 0.1	404	UCCAGUGAAGACACCAAU AACAU	2188-2210
AD-901337.1	A-170123 1.1	276	AGCUUGAGUUAAAACG AACGUA	1688-1708	A-170123 2.1	405	UACGUUCGUUUUAAACUCA GCUGC	1686-1708
AD-901335.1	A-170122 7.1	277	GCAGCUUGAGUUAAA CGAACA	1686-1706	A-170122 8.1	406	UGUUCGTUUAAACUCAAGC UGCCU	1684-1706
AD-901398.1	A-170135 3.1	278	CGAAGUGGUGAAGUU CAUGGA	1152-1172	A-170135 4.1	407	UCCAUGAACUUCACCACU UCGUG	1150-1172
AD-901314.1	A-170118 5.1	279	CAGAAUCAUCACGAA GUGGUA	1141-1161	A-170118 6.1	408	UACCACTUCGUGAUGAUU CUGCC	1139-1161
AD-901386.1	A-170132 9.1	280	AAAAUAGACAUUGCU AUUCUA	3361-3381	A-170133 0.1	409	UAGAAUAGCAAUGUCUA UUUUU	3359-3381

AD-901336.1	A-170122.9.1	281	CAGCUUGAGUUAACGAACGA	1687-1707	A-170123.0.1	410	UCGUUCGUUUAACUCAAGCUGCC	1685-1707
AD-901310.1	A-170117.7.1	282	CGCACUGAAACUUUUCGUCCA	648-668	A-170117.8.1	411	UGGACGAAAGUUUUCAGUGCGAC	646-668
AD-901321.1	A-170119.9.1	283	AGAUUAUGCGGAUCAAACCUA	1352-1372	A-170120.0.1	412	UAGGUUTGAUCCGCAUAAUCUGC	1350-1372
AD-901382.1	A-170132.1.1	284	GCUCUCUUUUUUGUACCGGUA	3096-3116	A-170132.2.1	413	UACCGGTACAAAUAAGAGAGCAA	3094-3116
AD-901384.1	A-170132.5.1	285	UGACAGUCACUAGCUUAUCUA	3162-3182	A-170132.6.1	414	UAGAUAAAGCUAGUGACUGUCACC	3160-3182
AD-901339.1	A-170123.5.1	286	CUUGAGUUAAACGAAACGUACA	1690-1710	A-170123.6.1	415	UGUACGTUCGUUUUAACUCAGCU	1688-1710
AD-901363.1	A-170128.3.1	287	AGUGCUAUGUUUAUUGGUGUA	2181-2201	A-170128.4.1	416	UACACCAAUAACAUAUAGCACUGU	2179-2201
AD-901325.1	A-170120.7.1	288	AUCCGCAGACGUGUAAUGUA	1631-1651	A-170120.8.1	417	UACAUUTACACGUCUGCGGAUCU	1629-1651
AD-901350.1	A-170125.7.1	289	AGACUGAUACAGAACAACGA	1797-1817	A-170125.8.1	418	UCGAUCGUUCUGUAUCAGUCUUU	1795-1817
AD-901365.1	A-170128.7.1	290	UGUUAUUGGUGUCUUCACUGA	2189-2209	A-170128.8.1	419	UCAGUGAAGACACCAUAACAUA	2187-2209
AD-901306.1	A-170116.9.1	291	GUGCUGGAAUUUGAUUUUCA	125-145	A-170117.0.1	420	UUGAAUAUCAAUUUCCAGCACCG	123-145
AD-901361.1	A-170127.9.1	292	UUGCUGCUAAAUCACCGAGCA	2012-2032	A-170128.0.1	421	UGCUCGGUGAUUUUAGCAGCAAGA	2010-2032

AD-901320.1	A-170119 7.1	293	CACCAUGCAGAUUAU GCGGAA	1344-1364	A-170119 8.1	422	UUCCGCAUAAUCUGCAUG GUGAU	1342-1364
AD-901405.1	A-170136 7.1	294	GAAAGCAUUUGUUUG UACAAA	1610-1630	A-170136 8.1	423	UUUGUACAAACAAUAGCU UUCUC	1608-1630
AD-901338.1	A-170123 3.1	295	GCUUGAGUUAACGA ACGUAA	1689-1709	A-170123 4.1	424	UUACGUTCGUUUAAACUCA AGCUG	1687-1709
AD-901383.1	A-170132 3.1	296	UCGGUGACAGUCACU AGCUUA	3158-3178	A-170132 4.1	425	UAAGCUAGUGACUGUCAC CGAUC	3156-3178
AD-901333.1	A-170122 3.1	297	AGCAGCUUGAGUUA AACGAA	1684-1704	A-170122 4.1	426	UUCGUUTAACUCAAGCUG CCUCG	1682-1704
AD-901330.1	A-170121 7.1	298	CUGCAAAAACACAGAG CUCGCA	1653-1673	A-170121 8.1	427	UGCGAGTCUGUGUUUUUG CAGGA	1651-1673
AD-901360.1	A-170127 7.1	299	CUUGCUGCUAAAUCA CCGAGA	2011-2031	A-170127 8.1	428	UCUCGGTGAAUUAAGCAGC AAGAA	2009-2031
AD-901358.1	A-170127 3.1	300	UUCUUGCUGCUAAA CACCGA	2009-2029	A-170127 4.1	429	UCGGUGAUUUAGCAGCAA GAAAA	2007-2029
AD-901406.1	A-170136 9.1	301	AAAGCAUUUGUUUGU ACAAAG	1611-1631	A-170137 0.1	430	UCUUGUACAAACAAUAGC UUUCU	1609-1631
AD-901326.1	A-170120 9.1	302	UCCGCAGACGUGUAA AUGUUA	1632-1652	A-170121 0.1	431	UAACAUTUACACGUCUGC GGAUC	1630-1652
AD-901377.1	A-170131 1.1	303	CGGUACUUUUUAAU AUCCCA	2962-2982	A-170131 2.1	432	UGGGAUUAUAAUAAUAGU ACCGUA	2960-2982
AD-901351.1	A-170125 9.1	304	GACUGAUACAGAACG AUCGAA	1798-1818	A-170126 0.1	433	UUCGAUCGUUCUGUAUCA GUCUU	1796-1818

AD-901415.1	A-170138 7.1	305	AAACACAGACUCGC GUUGCA	1658-1678	A-170138 8.1	434	UGCAACGCGAGUCUGUGU UUUUG	1656-1678
AD-901342.1	A-170124 1.1	306	GAGUAAACGAACGU ACUUGA	1693-1713	A-170124 2.1	435	UCAAGUACGUUCGUUAA CUCAA	1691-1713
AD-901420.1	A-170139 7.1	307	UCACUGGAUGUAUUU GACUGA	2203-2223	A-170139 8.1	436	UCAGUCAAUAUACAUCAG UGAAG	2201-2223
AD-901312.1	A-170118 1.1	308	CCUCCGAAACCAUGA ACUUUA	1028-1048	A-170118 2.1	437	UAAAGUTCAUGGUUUUCGG AGGCC	1026-1048
AD-901340.1	A-170123 7.1	309	UUGAGUUAAACGAAC GUACUA	1691-1711	A-170123 8.1	438	UAGUACGUUCGUUUUAACU CAAGC	1689-1711
AD-901392.1	A-170134 1.1	310	UGCUCUGUUUAUCC GUAAUA	3482-3502	A-170134 2.1	439	UAUUACGGAUAAACAGU AGCACC	3480-3502
AD-901327.1	A-170121 1.1	311	CGCAGACGUGUAAA UGUUCA	1633-1653	A-170121 2.1	440	UGAACATUUACACGUCUG CGGAU	1631-1653
AD-901328.1	A-170121 3.1	312	CGCAGACGUGUAAA GUUCCA	1634-1654	A-170121 4.1	441	UGGAACAUUUACACGUCU GCGGA	1632-1654
AD-901370.1	A-170129 7.1	313	AGAGAAGAGACACAU UGUUUA	2673-2693	A-170129 8.1	442	UCAACAAGUGUCUCUCUUC UCUUC	2671-2693
AD-901399.1	A-170135 5.1	314	ACAGCACACAACAAUG UGAAUA	1407-1427	A-170135 6.1	443	UAUUACAUUUGUUUGUGC UGUAG	1405-1427
AD-901359.1	A-170127 5.1	315	UCUUGCUGCUAAAUC ACCGAA	2010-2030	A-170127 6.1	444	UUCGGUGAUUUAGCAGCA AGAAA	2008-2030
AD-901373.1	A-170130 3.1	316	ACACCAUUGAAACCA CUAGUA	2790-2810	A-170130 4.1	445	UACUAGTGGUUUCAAUGG UGUGA	2788-2810

AD-901332.1	A-170122.1.1	317	GAGCAGCUUGAGUU AAACGA	1683-1703	A-170122.2.1	446	UCGUUUAACUCAAGCUGC CUCGC	1681-1703
AD-901311.1	A-170117.9.1	318	GCACUGAAACUUUUC GUCCAA	649-669	A-170118.0.1	447	UUGGACGAAAAGUUUCA GUGCGA	647-669
AD-901423.1	A-170140.3.1	319	GUUUUAUAUACGGUA CUUAUA	2952-2972	A-170140.4.1	448	UAUAAGTACCGUAUAUAA AACAC	2950-2972
AD-901374.1	A-170130.5.1	320	CACCAUUUGAAACCAC UAGUUA	2791-2811	A-170130.6.1	449	UAACUAGUGGUUUCAAU GGUGUG	2789-2811
AD-901319.1	A-170119.5.1	321	AUCACCAUGCAGAUU AUGCGA	1342-1362	A-170119.6.1	450	UCGCAUAAUCUGCAUGGU GAUGU	1340-1362
AD-901341.1	A-170123.9.1	322	UGAGUUAAACGAACG UACUUA	1692-1712	A-170124.0.1	451	UAAGUACGUUCGUUUUAA UCAAG	1690-1712
AD-901422.1	A-170140.1.1	323	GAAAGUGUUUUUAUA UACGGUA	2946-2966	A-170140.2.1	452	UACCGUAUAUAAAACACU UUCUC	2944-2966
AD-901385.1	A-170132.7.1	324	ACAGUCACUAGCUUA UCUUUA	3164-3184	A-170132.8.1	453	UCAAGATAAGCUAGUGAC UGUCA	3162-3184
AD-901391.1	A-170133.9.1	325	GUGCUACUGUUUAUC CGUAAA	3481-3501	A-170134.0.1	454	UUUACGGUAUAAACAGUA GCACCA	3479-3501
AD-901329.1	A-170121.5.1	326	CCUGCAAAAACACACAG ACUCGA	1652-1672	A-170121.6.1	455	UCGAGUCUGUGUUUUUUGC AGGAA	1650-1672
AD-901331.1	A-170121.9.1	327	CAAAAACACACAGACUC GCGUUA	1656-1676	A-170122.0.1	456	UAACGCGAGUCUGUGUUU UUGCA	1654-1676
AD-901368.1	A-170129.3.1	328	UGCUGUGGACUUGAG UUUGGA	2221-2241	A-170129.4.1	457	UCCCAACUCAAGUCCACA GCAGU	2219-2241

AD-901364.1	A-170128 5.1	329	GUGCUAAUGUUUAUUG GUGUCA	2182-2202	A-170128 6.1	458	UGACACCAUAACAUAUAG CACUG	2180-2202
AD-901389.1	A-170133 5.1	330	UGGUGCUACUGUUUA UCCGUA	3479-3499	A-170133 6.1	459	UACGGATAAACAGUAGCA CCAAU	3477-3499
AD-901421.1	A-170139 9.1	331	AGAAAGUGUUUUUAU AUACGGA	2945-2965	A-170140 0.1	460	UCCGUATAUAAAACACUU UCUCU	2943-2965
AD-901380.1	A-170131 7.1	332	AACUAAUUUAUGAGAU GUAUCA	3062-3082	A-170131 8.1	461	UGAUACAUCUCAUAAUA GUUGA	3060-3082
AD-901343.1	A-170124 3.1	333	AGUUAACGAAACGUA CUUGCA	1694-1714	A-170124 4.1	462	UGCAAAGTACGUUCGUUUA ACUCA	1692-1714
AD-901317.1	A-170119 1.1	334	CAUCUUCAAGCCAUC CUGUGA	1251-1271	A-170119 2.1	463	UCACAGGAUGGCUUGAAG AUGUA	1249-1271
AD-901424.1	A-170140 5.1	335	UUUUUUUUCAGUAUU CUUGGA	3027-3047	A-170140 6.1	464	UCCAAAGAAUACUGAAAA AAACC	3025-3047
AD-901431.1	A-170141 9.1	336	UUAUCCGUAUAAAUU GUGGGA	3491-3511	A-170142 0.1	465	UCCCAAAUUAUUAACGGA UAAAC	3489-3511
AD-901378.1	A-170131 3.1	337	GGUACUUUUUAAUA UCCCUA	2963-2983	A-170131 4.1	466	UAGGGATAUUAAAUAAAG UACCGU	2961-2983
AD-901434.1	A-170142 5.1	338	CACGUCUUUGUCUCU AGUGCA	3527-3547	A-170142 6.1	467	UGCACUAGAGACAAAGAC GUGAU	3525-3547
AD-901412.1	A-170138 1.1	339	UGCAAAAACACAGAC UCGCGA	1654-1674	A-170138 2.1	468	UCGCGAGUCUGUUUUUU GCAGG	1652-1674
AD-901426.1	A-170140 9.1	340	ACUAAUUUAUGAGAU UAUCUA	3063-3083	A-170141 0.1	469	UAGAUACAUCUCAUAAU AGUUG	3061-3083

AD-901322.1	A-170120 1.1	341	AGGGGCAAAAACGAA AGCGCA	1484-1504	A-170120 2.1	470	UGCGCUTUCGUUUUUUGCC CCUUU	1482-1504
AD-901381.1	A-170131 9.1	342	UUGCUCUCUUUUUG UACCGA	3094-3114	A-170132 0.1	471	UCGGUACAAAUAAAGAGA GCAAGA	3092-3114
AD-901324.1	A-170120 5.1	343	AUUUGUUUGUACAAG AUCCGA	1616-1636	A-170120 6.1	472	UCGGAUCUUUGUACAACA AAUGC	1614-1636
AD-901347.1	A-170125 1.1	344	UUGCAGAUUGUGACAA GCCGAA	1710-1730	A-170125 2.1	473	UUCGGCTUGUCACAUCUG CAAGU	1708-1730
AD-901379.1	A-170131 5.1	345	CAACUAAUUUAUGAGA UGUAUA	3061-3081	A-170131 6.1	474	UAUACATCUCAUAAAUAAG UUGAA	3059-3081
AD-901428.1	A-170141 3.1	346	AAUUCUACAUACUAA AUCUCA	3419-3439	A-170141 4.1	475	UGAGAUTUAGUAUGUAG AAUUCU	3417-3439
AD-901371.1	A-170129 9.1	347	AUGUCCUCACACCAU UGAAAA	2782-2802	A-170130 0.1	476	UUUCAAUGGUGUGAGG ACAUAG	2780-2802
AD-901408.1	A-170137 3.1	348	UUGUUUGUACAAGAU CCGCAA	1618-1638	A-170137 4.1	477	UUGCGGAUCUUUGUACAAA CAAAU	1616-1638
AD-901417.1	A-170139 1.1	349	UAAUCCAGAAACCUG AAAUAGA	1870-1890	A-170139 2.1	478	UCAUUUCAGGUUUCUGGA UUAAG	1868-1890
AD-901400.1	A-170135 7.1	350	GAAAAAAAUCAGUU CGAGGA	1456-1476	A-170135 8.1	479	UCCUCGAAACUGAUUUUUU UUCUU	1454-1476
AD-901323.1	A-170120 3.1	351	GGGCAAAAACGAAAG CGCAAA	1486-1506	A-170120 4.1	480	UUUGCGCUUUCGUUUUUUG CCCCU	1484-1506
AD-901316.1	A-170118 9.1	352	UGAAGUUCAUGGAUG UCUAUA	1160-1180	A-170119 0.1	481	UAUAGACAUCCAUGAACU UCACC	1158-1180

AD-901315.1	A-170118 7.1	353	CACGAAGUGGUGAAG UUCAUA	1150-1170	A-170118 8.1	482	UAUGAACUUCACCAUUC GUGAU	1148-1170
AD-901395.1	A-170134 7.1	354	ACGUCUUUGUCUCUA GUGCAA	3528-3548	A-170134 8.1	483	UUGCACCTAGAGACAAAGA CGUGA	3526-3548
AD-901318.1	A-170119 3.1	355	AACAUCACCAUGCAG AUUAUA	1339-1359	A-170119 4.1	484	UAUAAUCUGCAUGGUGA UGUUGG	1337-1359
AD-901390.1	A-170133 7.1	356	GGUGCUACUGUUUAU CCGUAA	3480-3500	A-170133 8.1	485	UUACGGAUAAACAGUAGC ACCAA	3478-3500
AD-901387.1	A-170133 1.1	357	AAAUAGACAUUGCUA UUCUGA	3362-3382	A-170133 2.1	486	UCAGAAATAGCAAUGUCUA UUUUA	3360-3382
AD-901307.1	A-170117 1.1	358	UUCGCCAAAUACACUG UGGAUA	278-298	A-170117 2.1	487	UAUCCACAGUGAUUUUGGG GAAGU	276-298
AD-901410.1	A-170137 7.1	359	GAUCCGCAGACGUGU AAAUUA	1630-1650	A-170137 8.1	488	UCAUUUACACGUCUGCGG AUCUU	1628-1650
AD-901433.1	A-170142 3.1	360	UUAACAUCACGUCUU UGUCUA	3520-3540	A-170142 4.1	489	UAGACAAAAGACGUGAUG UUAAUA	3518-3540
AD-901308.1	A-170117 3.1	361	AAAGUGAGUGACCUG CUUUUA	415-435	A-170117 4.1	490	UAAAAGCAGGUCACUCAC UUUGC	413-435
AD-901414.1	A-170138 5.1	362	AAAAACACAGACUCG CGUUGA	1657-1677	A-170138 6.1	491	UCAACGCGAGUCUGUGUU UUUGC	1655-1677
AD-901309.1	A-170117 5.1	363	CGUCGCACUGAAACU UUUCGA	645-665	A-170117 6.1	492	UCGAAAAGUUUCAGUGCG ACGCC	643-665
AD-901362.1	A-170128 1.1	364	AACAGUGCUAAUGUU AUUGGA	2178-2198	A-170128 2.1	493	UCCAAUAACAUUAAGCACU GUUAA	2176-2198

AD-901397.1	A-170135 1.1	365	UUCGUCCAACUUCUG GGCUGA	661-681	A-170135 2.1	494	UCAGCCCAGAAAGUUGGAC GAAAA	659-681
AD-901419.1	A-170139 5.1	366	AUUGGUGUCUUCACU GGAUGA	2193-2213	A-170139 6.1	495	UCAUCCAGUGAAGACACC AAUAA	2191-2213
AD-901413.1	A-170138 3.1	367	GCAAAAACACAGACU CGCGUA	1655-1675	A-170138 4.1	496	UACGCGAGUCUGUGUUUU UGCAG	1653-1675
AD-901401.1	A-170135 9.1	368	AAAAAUCAGUUCGAG GAAAGA	1460-1480	A-170136 0.1	497	UCUUUCCUCGAAACUGAUU UUUUU	1458-1480
AD-901411.1	A-170137 9.1	369	CAGACGUGUAAAUUGU UCCUGA	1636-1656	A-170138 0.1	498	UCAGGAACAUAUUACACGU CUGCG	1634-1656
AD-901372.1	A-170130 1.1	370	UGUCCUCACACCAUU GAAACA	2783-2803	A-170130 2.1	499	UGUUUCAAUGGUGUGAG GACAU	2781-2803
AD-901425.1	A-170140 7.1	371	UUUUUUUUCAGUAUUC UUGGUA	3028-3048	A-170140 8.1	500	UACCAAGAAUACUGAAAA AAAC	3026-3048
AD-901409.1	A-170137 5.1	372	AGAUCCGCAGACGUG UAAUA	1629-1649	A-170137 6.1	501	UAUUUACACGUCUGCGGA UCUUG	1627-1649
AD-901418.1	A-170139 3.1	373	CCCUCUUGGAAUUGG AUUCGA	1978-1998	A-170139 4.1	502	UCGAAUCCAAUUCCAAGA GGGAC	1976-1998
AD-901393.1	A-170134 3.1	374	GAUUAUUAACAUCACG UCUUUA	3516-3536	A-170134 4.1	503	UAAAAGACGUGAUGUUA UAUCUU	3514-3536
AD-901388.1	A-170133 3.1	375	UUGGUGCUACUGUUU AUCCGA	3478-3498	A-170133 4.1	504	UCGGAUAAACAGUAGCAC CAAUA	3476-3498
AD-901404.1	A-170136 5.1	376	AAGGGGCAAAAACGA AAGCGA	1483-1503	A-170136 6.1	505	UCGCUUTCUGUUUUUGCCC CUUUC	1481-1503

AD-901346.1	A-170124 9.1	377	CUUGCAGAUUGUGACA AGCCGA	1709-1729	A-170125 0.1	506	UCGGCUTGUCACAUCUGC AAGUA	1707-1729
AD-901403.1	A-170136 3.1	378	AAAUACAGUUCGAGGA AAGGA	1462-1482	A-170136 4.1	507	UCCCUUUTCCUCGAAACUGA UUUUU	1460-1482
AD-901396.1	A-170134 9.1	379	ACUUUUCGUGCCAAACU UCUGGA	657-677	A-170135 0.1	508	UCCAGAAGUUUGACGAAA AGUUU	655-677
AD-901432.1	A-170142 1.1	380	AUUAAACAUCACGUCU UUGUCA	3519-3539	A-170142 2.1	509	UGACAAAAGACGUGAUGU UAAUAU	3517-3539
AD-901435.1	A-170142 7.1	381	CGUCUUUGUCUCUAG UGCAGA	3529-3549	A-170142 8.1	510	UCUGCACUAGAGACAAAG ACGUG	3527-3549
AD-901416.1	A-170138 9.1	382	AACACAGACUCGCGU UGC AAA	1660-1680	A-170139 0.1	511	UUUGCAACGCGAGUCUGU GUUUU	1658-1680
AD-901394.1	A-170134 5.1	383	AUAUUAACAUCACGU CUUUGA	3517-3537	A-170134 6.1	512	UCAAAGACGUGAUGUUA AUAUCU	3515-3537
AD-901429.1	A-170141 5.1	384	GUUUAUCCGUAUAUA UUGUGA	3489-3509	A-170141 6.1	513	UCACAATUAUACGGAUA AACAG	3487-3509
AD-901402.1	A-170136 1.1	385	AAAUCAGUUCGAGG AAAGGA	1461-1481	A-170136 2.1	514	UCCUUUCCUCGAAACUGAU UUUUU	1459-1481
AD-901430.1	A-170141 7.1	386	UUUAUCCGUAUAUAU UGUGGA	3490-3510	A-170141 8.1	515	UCCACAAUUAUUACGGAU AAACA	3488-3510
AD-901369.1	A-170129 5.1	387	AGGACAUUGCUGUGC UUUGGA	2518-2538	A-170129 6.1	516	UCCAAAGCACAGCAAUGU CCUGA	2516-2538

Table 3A. Exemplary Human VEGF-A siRNA Modified Single Strands and Duplex Sequences

Duplex Name	Sense Oligo Name	SEQ ID NO: (Sense)	Sense Sequence	Anti-sense Oligo Name	SEQ ID NO: (Anti-sense)	Antisense Sequence	mRNA target sequence	SEQ ID NO: (mRNA target)
AD-953340.1	A-17012 61.1	517	ascsgaa(Uhd)AfcAfGfAfac gaucgauaL96	A-10688 04.1	647	VPusAfsuegAfuCfGfu ucuGfuAfucaguscusu	AGACUGAUACAG AACGAUCGAUA	4353
AD-953336.1	A-17012 53.1	518	asasaga(Chd)UfgAfUfAfa gaacgauaL96	A-10687 96.1	648	VPusAfsuegUfuCfUfg uauCfaGfucuuusc	GGAAAGACUGAU ACAGAACGAUC	4354
AD-953363.1	A-17013 07.1	519	gsasgaa(Ahd)GfuGfUfUfu auauacgaL96	A-10702 90.1	649	VPusCfsguaUfaUfAfa acAfcUfuucuscusu	AAGAGAAAGUGU UUUAUAUACGG	4355
AD-953338.1	A-17012 57.1	520	asgsacu(Ghd)AfuAfcAfga acgaucgaL96	A-10688 00.1	650	VPusCfsgauCfGUfUfcu guAfuCfagucuscusu	AAAGACUGAUAC AGAACGAUCGA	4356
AD-953367.1	A-17013 15.1	521	csasacu(Ahd)UfuUfAfUfga gaugauaL96	A-10703 76.1	651	VPusAfsuacAfuCfUfca uaAfaUfaguugsasa	TUCAACUAUUUA UGAGAUGUAUC	4357
AD-953337.1	A-17012 55.1	522	asasgac(Uhd)GfaUfAfCfag aacgaucal96	A-10687 98.1	652	VPusGfsaucGfuUfCfug uaUfcAfgucuuusc	GAAAGACUGAU CAGAACGAUCG	4358
AD-953342.1	A-17012 65.1	523	asusaca(Ghd)AfaCfGfAfac gauacagaL96	A-10688 12.1	653	VPusCfsuguAfuCfGfau cgUfuCfuguauusasa	UGAUACAGAACG AUCGAUACAGA	4359
AD-953350.1	A-17012 81.1	524	asascag(Uhd)GfcUfAfAfug uuauuggaL96	A-10693 42.1	654	VPusCfscuaUfaAfCfau uaGfcAfcuguusasa	UUAAACAGUGCUA AUGUUAUUUGGU	4360
AD-953352.1	A-17012 85.1	525	gsusgeu(Ahd)AfuGfUfUfau uggugucaL96	A-10693 50.1	655	VPusGfsacaCfcAfAfua acAfuUfagacuscsg	CAGUGCUAAUGU UAUUGGUGUCU	4361
AD-953368.1	A-17013 17.1	526	asascua(Uhd)UfuAfuGfGfag augaucaL96	A-10703 78.1	656	VPusGfsauaCfaUfCfuc auAfaAfuaguusgsa	UCAACUAUUUAU GAGAUGUAUCU	4362

AD-953344.1	A-17012 69.1	527	csasgaa(Chd)AfgUfCfCfu aauccagaL96	A-10689 18.1	657	VPusCfsuggAfuUfAfa ggaCfuGfuucugsusc	GACAGAACAGUCC UUAUCCAGA	4363
AD-953339.1	A-17012 59.1	528	gsascug(Ahd)UfaCfAfGfaa cgaucgaal96	A-10688 02.1	658	VPusUfscgaUfcGfUfuc ugUfaUfcagucsusu	AAGACUGAUACA GAACGAUCGAU	4364
AD-953387.1	A-17013 55.1	529	ascsgc(Ahd)CfaAfCfAfaa ugugaauaL96	A-10681 70.1	659	VPusAfsuucAfcAfUfu uguUfgUfgcugusag	CUACAGCACACA AAUGUGAAUG	4365
AD-953375.1	A-17013 31.1	530	asasaua(Ghd)AfcAfUfUfgc uaucugaaL96	A-10707 92.1	660	VPusCfsagaAfuAfGfca auGfuCfuauususa	UAAAAUAGACAU UGCUAUUCUGU	4366
AD-953355.1	A-17012 91.1	531	usasuug(Ghd)UfgUfCfUfuc acuggaual96	A-10693 70.1	661	VPusAfsuccAfgUfGfaa gaCfaCfcauasasc	GUUAUUGGUGUC UUCACUGGAUG	4367
AD-953341.1	A-17012 63.1	532	csusgau(Ahd)CfaGfAfAfGc aucgaual96	A-10688 06.1	662	VPusUfsaucGfaUfCfGu ucUfgUfaucagsusc	GACUGAUACAGA ACGAUCGAUAC	4368
AD-953370.1	A-17013 21.1	533	gscsucu(Chd)UfuAfUfUfug uaccgguaL96	A-10704 46.1	663	VPusAfsccgGfuAfCfaa auAfaGfagagsasa	UUGCUCUCUUAUU UGUACCGGUU	4369
AD-953362.1	A-17013 05.1	534	csascca(Uhd)UfgAfAfAfcc acuaguuaL96	A-10700 96.1	664	VPusAfsacuAfgUfGfg uuuCfaAfuggugsug	CACACCAUUGAAA CCACUAGUUC	4370
AD-953322.1	A-17012 25.1	535	gsgscag(Chd)UfuGfAfGfu aaacgaaal96	A-10685 96.1	665	VPusUfsucgUfuUfAfac ucAfaGfegccsusc	GAGGCAGCUUGA GUUAAACGAAC	4371
AD-953332.1	A-17012 45.1	536	ususaaa(Chd)GfaAfCfGfua cuugcagaL96	A-10686 18.1	666	VPusCfsugcAfaGfUfac guUfcGfuuaascsu	AGUUAACGAAC GUACUUGCAGA	4372
AD-953371.1	A-17013 23.1	537	uscsggu(Ghd)AfcAfGfUfca cuagcuuaL96	A-10705 50.1	667	VPusAfsageUfaGfUfga cuGfuCfaccgasusc	GAUCGGUGACAG UCACUAGCUUA	4373
AD-953331.1	A-17012 43.1	538	asgsuua(Ahd)AfcGfAfAfGc uacuugcaL96	A-10686 14.1	668	VPusGfscgaGfuAfCfGu ucGfuUfuuaacscsa	UGAGUUAACGA ACGUACUUGCA	4374

AD-953323.1	A-17012 27.1	539	gscsagc(Uhd)UfgAfGfUfua aacgaacaL96	A-10685 98.1	669	VpusGfsuucGfuUfUfaa cuCfaAfgcugscsu	AGCAGCUUGAG UUAACGAACG	4375
AD-953351.1	A-17012 83.1	540	asgsugc(Uhd)AfaUfGfUfua uugguguaL96	A-10693 48.1	670	VpusAfsacCfaAfUfaa caUfuAfgcacusgu	ACAGUGCUAUG UUAUUGGUGUC	4376
AD-953386.1	A-17013 53.1	541	csgsaag(Uhd)GfgUfGfAfag uucauggaL96	A-10677 28.1	671	VpusCfscauGfaAfCfu caCfcAfcuucgsug	CACGAAGUGGUG AAGUUCAUGGA	4377
AD-953394.1	A-17013 69.1	542	asasagc(Ahd)UfuUfGfUfu guacaagaL96	A-10684 48.1	672	VpusCfsuugUfaCfAfaa caAfaUfgcuuucsu	AGAAAAGCAUUUG UUUGUACAAAG	4378
AD-953359.1	A-17012 99.1	543	asusguc(Chd)UfcAfCfAfcc auugaaaaL96	A-10700 78.1	673	VpusUfsuucAfaUfGfg uguGfaGfgacaasag	CUAUGUCCUCACA CCAUUGAAAC	4379
AD-953329.1	A-17012 39.1	544	usgsagu(Uhd)AfaAfCfGfaa cguacuuaL96	A-10686 10.1	674	VpusAfsaguAfcGfUfuc guUfuAfaeucasag	CUUGAGUUAAAC GAACGUACUUG	4380
AD-953361.1	A-17013 03.1	545	ascsaec(Ahd)UfuGfAfAfac cacuagual96	A-10700 94.1	675	VpusAfsucaGfuGfGfu uucAfaUfggugusga	UCACACCAUUGAA ACCACUAGUU	4381
AD-953319.1	A-17012 19.1	546	csasaaa(Ahd)CfaCfAfGfac ucgcguuaL96	A-10685 38.1	676	VpusAfsacgCfGfAfGfuc ugUfgUfuuuugscsa	UGCAAAAACACAG ACUCGCGUUG	4382
AD-953360.1	A-17013 01.1	547	usgsuuc(Uhd)CfaCfAfCfca uugaaacaL96	A-10700 80.1	677	VpusGfsuuuCfaAfUfg gugUfgAfggacasusa	UAUGUCCUCACAC CAUUGAAACC	4383
AD-953324.1	A-17012 29.1	548	csasgcu(Uhd)GfaGfUfUfaa acgaacgaL96	A-10686 00.1	678	VpusCfsguuCfGfUfua acUfcAfgcugscsc	GGCAGCUUGAGU UAAACGAACGU	4384
AD-953378.1	A-17013 37.1	549	gsgsugc(Uhd)AfcUfGfUfu auccguuaL96	A-10708 74.1	679	VpusUfsacgGfaUfAfaa caGfuAfgcaccsasa	UUGGUGCUACUG UUUAUCCGUAA	4385
AD-953369.1	A-17013 19.1	550	ususgcu(Chd)UfcUfUfAfuu uguaccgaL96	A-10704 42.1	680	VpusCfsgguAfcAfAfau aaGfaGfagcaasga	UCUUGCUCUCUUA UUUGUACCGG	4386

AD-953347.1	A-17012 75.1	551	uscsuug(Chd)UfgCfUfAfaa ucaccgaL96	A-10691 88.1	681	VpusUfscggUfgAfUfu uagCfaGfcaagasasa	UUUCUUUGCUGCUA AAUCACCGAG	4387
AD-953365.1	A-17013 11.1	552	csgsgua(Chd)UfuAfUfUfua auaucccaL96	A-10703 26.1	682	VpusGfsggaUfaUfUfaa auAfaGfuaaccgsusa	UACGGUACUUAU UUAAUAUCCCU	4388
AD-953374.1	A-17013 29.1	553	asasaau(Ahd)GfaCfAfUfug cuauucuaL96	A-10707 90.1	683	VpusAfsigaaUfaGfCfaa ugUfcUfaunuusasu	AUAAAAUAGACA UUGCUAUUUCUG	4389
AD-953384.1	A-17013 49.1	554	ascsuuu(Uhd)CfGfUfCfCfaa cuucuggaL96	A-10672 66.1	684	VpusCfscagAfaGfUfug gaCfGfAfaagususu	AAACUUUUUCGUCC AACUUCUGGG	4390
AD-953376.1	A-17013 33.1	555	ususggu(Chd)CfuAfCfUfugu uuauccgaL96	A-10708 70.1	685	VpusCfsggaUfaAfafca guAfgCfaccasusa	UAUUGGUGUCUAC UGUUUAUCCGU	4391
AD-953354.1	A-17012 89.1	556	gsusuau(Uhd)GfgUfGfUfcu ucacuggaL96	A-10693 66.1	686	VpusCfscagUfgAfafga caCfcAfauaacsasu	AUGUUUUUGGUG UCUUCACUGGA	4392
AD-953385.1	A-17013 51.1	557	ususegu(Chd)CfaAfCfUfuc ugggcugaL96	A-10672 74.1	687	VpusCfsageCfcAfGfaa guUfgGfaccgaasasa	UUUUCGUCCAACU UCUGGGCUGU	4393
AD-953346.1	A-17012 73.1	558	ususuu(Chd)CfuGfCfUfaa aucaccgaL96	A-10691 86.1	688	VpusCfsgguGfaUfUfua gcAfgCfaagaasasa	UUUUCUUUGCUGCU AAAUCACCGA	4394
AD-953366.1	A-17013 13.1	559	gsgsuac(Uhd)UfaUfUfUfaa uaucuccuaL96	A-10703 28.1	689	VpusAfsiggaUfaUfUfu aaaUfaAfguaccgsu	ACGGUACUUAUU UAAUAUCCCUU	4395
AD-953382.1	A-17013 45.1	560	asusaau(Ahd)AfcAfUfCfac guucuuugaL96	A-10709 12.1	690	VpusCfsaaaGfaCfGfug auGfuUfaauauscu	AGAUUAUAACA CACGUCUUUGU	4396
AD-953320.1	A-17012 21.1	561	gsasggc(Ahd)GfcUfUfGfag uuuaaacgaL96	A-10685 92.1	691	VpusCfsguuUfaAfCfuc aaGfcUfgccucgsc	GCGAGGCAGCUUG AGUUAACGA	4397
AD-953379.1	A-17013 39.1	562	gsusgcu(Ahd)CfuGfUfUfua uccguaaaL96	A-10708 76.1	692	VpusUfsuacGfgAfUfaa acAfgUfagacscsa	UGGUGCUACUGU UUAUCCGUAAU	4398

AD-953321.1	A-17012 23.1	563	asgsgca(Ghd)CfuUfGfAfgu uaaacgaL96	A-10685 94.1	693	VPusUfscguUfuAfAfc ucaAfgCfugccuscs	CGAGGCAGCUUGA GUUAAACGAA	4399
AD-953377.1	A-17013 35.1	564	usgsug(Chd)UfaCfUfGfuu uauccgaL96	A-10708 72.1	694	VPusAfscggAfuAfAfac agUfaGfcaccasasu	AUUGGUGCUACU GUUUAUCCGUA	4400
AD-953392.1	A-17013 65.1	565	asasgg(Ghd)CfaAfAfAfac gaagcgL96	A-17008 76.1	695	VPusCfsgcuUfuCfGfuu uuUfgCfcccususc	GAAAGGGGCAAA AACGAAAGCGC	4401
AD-953373.1	A-17013 27.1	566	ascsgu(Chd)AfcUfaGfGfu uauccuL96	A-10705 62.1	696	VPusCfsaagAfuAfAfgc uaGfuGfacugusasa	UGACAGUCACUAG CUUAUCUUGA	4402
AD-953364.1	A-17013 09.1	567	ascsgu(Ahd)CfuUfaUfuu aaauccaL96	A-10703 24.1	697	VPusGfsgauAfuUfAfaa uaAfgUfacgusasu	AUACGGUACUUA UUUAAUAUCCCC	4403
AD-953330.1	A-17012 41.1	568	gsasgu(Ahd)AfaCfGfAfac guacuL96	A-10686 12.1	698	VPusCfsaagUfaCfGfuu cgUfuUfaacucsasa	UUAGAGUUAAACG AACGUACUUGC	4404
AD-953353.1	A-17012 87.1	569	usgsuu(Uhd)UfgGfUfGfuc uuacugaL96	A-10693 64.1	699	VPusCfsaguGfaAfGfac acCfaAfuacacasu	AAUGUUUUUGGU GUCUUACUUGG	4405
AD-953343.1	A-17012 67.1	570	csgsaca(Ghd)AfaCfAfGfuc cuuaucL96	A-10689 12.1	700	VPusGfsauAfaGfGfac ugUfuCfugcgsasu	AUCGACAGAACAG UCCUUAAUCC	4406
AD-953390.1	A-17013 61.1	571	asasaau(Chd)AfgUfUfCfga ggaaagL96	A-17008 73.1	701	VPusCfscuuUfcCfUfcg aaCfuGfauuususu	AAAAAUACAGUU CGAGGAAAGGG	4407
AD-953345.1	A-17012 71.1	572	csusugg(Ahd)AfuUfGfGfau ucgccaL96	A-10691 32.1	702	VPusAfsuggCfGfAfu ccaAfuUfccaagsasg	CUCUUGGAAUUG GAUUCGCCAUU	4408
AD-953358.1	A-17012 97.1	573	asgsaga(Ahd)GfaGfAfCfuc auuguL96	A-10699 54.1	703	VPusCfsaacAfaUfGfug ucUfcUfucucusc	GAAGAGAAAGAGA CACAUUGUUGG	4409
AD-953383.1	A-17013 47.1	574	ascsguc(Uhd)UfuGfUfCfuc uagugcaL96	A-10709 34.1	704	VPusUfsgcaCfuAfGfag acAfaAfgacgusasa	UCACGUCUUUGUC UCUAGUGCAG	4410

AD-953372.1	A-17013 25.1	575	usgsaca(Ghd)UfcAfCfUfag cuuaucaL96	A-10705 58.1	705	VpusAfsgauAfaGfCfua guGfaCfugucascsc	GGUGACAGUCACU AGCUUAUCUU	4411
AD-953328.1	A-17012 37.1	576	ususgag(Uhd)UfaAfAfCfga acguacuL96	A-10686 08.1	706	VpusAfsguaCfGfUfUfcg uuUfaAfcuacascsc	GCUUGAGUUAAA CGAACGUACUU	4412
AD-953393.1	A-17013 67.1	577	gsasaag(Chd)AfuUfUfGfu uguuacaaL96	A-10684 46.1	707	VpusUfsuguAfcAfAfac aaAfuGfcuuuscsc	GAGAAAAGCAUUU GUUUGUACAAG	4413
AD-953307.1	A-17011 95.1	578	asuscac(Chd)AfuGfCfAfga uuuugcgaL96	A-10680 40.1	708	VpusCfsgcaUfaAfUfcu gcAfuGfugausgsu	ACAUCACCAUGCA GAUUAUGCGG	4414
AD-953308.1	A-17011 97.1	579	csasca(Uhd)GfcAfGfAfu auugcgaaL96	A-10680 44.1	709	VpusUfscgcCfaUfAfau cuGfcAfugugsasu	AUCACCAUGCAGA UUUUGCGGAU	4415
AD-953327.1	A-17012 35.1	580	csusuga(Ghd)UfuAfAfAfCg aacguacuL96	A-10686 06.1	710	VpusGfsuacGfuUfCfGu uuAfaCfucagascsc	AGCUUGAGUUAA ACGAACGUACU	4416
AD-953335.1	A-17012 51.1	581	ususgea(Ghd)AfuGfUfGfac aagccgaL96	A-10686 46.1	711	VpusUfscgcCfuUfGfuc acAfuCfugcaagsu	ACUUGCAGAUUG GACAAGCCGAG	4417
AD-953414.1	A-17014 09.1	582	ascsuau(Uhd)UfuUfGfAfga uguuaucaL96	A-10703 80.1	712	VpusAfsgauAfcAfUfcu caUfaAfauagusug	CAACUAUUUAUG AGAUGUAUCUU	4418
AD-953412.1	A-17014 05.1	583	ususuuu(Uhd)UfuCfAfGfua uuuuggaL96	A-17008 97.1	713	VpusCfscgaGfaAfUfac ugAfaAfaaaascsc	GGUUUUUUUUA GUUUUUUUUGU	4419
AD-953411.1	A-17014 03.1	584	gsusuuu(Ahd)UfuUfAfCfGg uacuuauL96	A-10703 06.1	714	VpusAfsuaaGfuAfCfCg uaUfaUfaaaascsc	GUGUUUUUAUA CGGUACUUAU	4420
AD-953410.1	A-17014 01.1	585	gsasaag(Uhd)GfuUfUfUfau auacgguaL96	A-10702 94.1	715	VpusAfscegUfaUfAfua aaAfcAfcuuuscsc	GAGAAAAGUGUUU UAUAUACGGUA	4421
AD-953408.1	A-17013 97.1	586	uscsacu(Ghd)GfuUfGfUfau uuugacugaL96	A-10693 92.1	716	VpusCfsaguCfaAfAfua caUfcCfagugasag	CUUCACUGGAUGU AUUUGACUGC	4422

AD-953326.1	A-17012 33.1	587	gscsuug(Ahd)GfuUfAfAfacc gaacgual96	A-10686 04.1	717	VPusUfsacgUfuCfGfuuaAfcUfcaagcsusg	CAGCUUGAGUUA AACGAACGUAC	4423
AD-953300.1	A-17011 81.1	588	cscsucc(Ghd)AfaAfcCfau gaacuuaL96	A-10674 82.1	718	VPusAfsaagUfuCfAfug guUfuCfaggagcscc	GGCCUCCGAAACC AUGAACUUUC	4424
AD-953389.1	A-17013 59.1	589	asasaaa(Uhd)CfaGfUfUfcg aggaaagaL96	A-17008 71.1	719	VPusCfsuuuCfCfCfga acUfgAfuuuususu	AAAAAAUUCAGU UCGAGGAAAGG	4425
AD-953415.1	A-17014 11.1	590	gsasgaa(Uhd)UfcUfAfCfau acuuaaL96	A-10708 16.1	720	VPusAfsuuuAfgUfAfua guaGfaAfuucucusa	UAGAGAAUUCUA CAUACUAAAUC	4426
AD-953309.1	A-17011 99.1	591	asgsauu(Ahd)UfgCfGfGfau caaaccuaL96	A-10680 60.1	721	VPusAfsuggUfuGfAfua ccgCfaUfaucuscsc	GCAGAUUUAUGCG GAUCAAACCUC	4427
AD-953391.1	A-17013 63.1	592	asasauc(Ahd)GfuUfCfGfag gaagggaL96	A-10682 40.1	722	VPusCfscuuUfuCfCfuc gaAfcUfgauuususu	AAAAAUCAGUUC GAGGAAAGGGA	4428
AD-953395.1	A-17013 71.1	593	gscsaau(Uhd)GfuUfUfGfua caagaucuaL96	A-10684 54.1	723	VPusGfsaucUfuGfUfua aaAfcAfaagcsusu	AAGCAUUUGUUU GUACAAAGAUCC	4429
AD-953303.1	A-17011 87.1	594	csascga(Ahd)GfuGfGfUfga aguucuaL96	A-10677 24.1	724	VPusAfsugaAfcUfUfca ccAfcUfucgugsasu	AUCACGAAGUGG UGAAGUUC AUG	4430
AD-953405.1	A-17013 91.1	595	usasauc(Chd)AfgAfAfAfacc ugaauaL96	A-10689 42.1	725	VPusCfsauuUfcAfGfgu uuCfuGfgauuasag	CUUAAUCCAGAAA CCUGAAAUAGA	4431
AD-953305.1	A-17011 91.1	596	csasucu(Uhd)CfaAfgCfca uccugugaL96	A-10679 26.1	726	VPusCfsacaGfgAfUfgg cuUfgAfagaugsusa	UACAUCUUC AAGC CAUCCUGUGU	4432
AD-953380.1	A-17013 41.1	597	usgsuca(Chd)UfgUfUfUfau ccguuaaL96	A-10708 78.1	727	VPusAfsuuaCfGfAfua aaCfaGfuagcascsc	GGUGCUACUGUU UAUCCGUAAUA	4433
AD-953349.1	A-17012 79.1	598	ususgcu(Ghd)CfuAfAfAfuc accgagaL96	A-10691 92.1	728	VPusGfscucGfgUfGfau uuAfgCfagaasgsa	UCUUGCUGCUAAA UCACCGAGCC	4434

AD-953381.1	A-17013 43.1	599	gsasau(Uhd)AfaCfAfUfca cgucuuuaL96	A-10709 10.1	729	VpusAfsaagAfcGfUfga ugUfuAfaauucsusu	AAGAUAUUAACA UCACGUCUUUG	4435
AD-953318.1	A-17012 17.1	600	csusgca(Ahd)AfaCfAfca gacucgeaL96	A-10685 32.1	730	VpusGfscgaGfuCfUfgu guUfuUfugcagsgsa	UCCUGCAAAAACA CAGACUCGCG	4436
AD-953348.1	A-17012 77.1	601	csusugc(Uhd)GfcUfAfAfau caccgagaL96	A-10691 90.1	731	VpusCfsucgGfuGfAfua uuuGfcAfgeaagsasa	UUCUUGCUGCUAA AUCACCGAGC	4437
AD-953409.1	A-17013 99.1	602	asgsaaa(Ghd)UfgUfUfua uuuacggaL96	A-10702 92.1	732	VpusCfscguAfuUfUfaa aaCfaCfuuuucscsu	AGAGAAAAGUGUU UUUAUAUACGGU	4438
AD-953306.1	A-17011 93.1	603	asascuu(Chd)AfcCfAfUfgc agaauuaaL96	A-10680 34.1	733	VpusAfsuaaUfcUfGfca ugGfuGfauguusgsg	CCAAACAUCACCAU GCAGAUUAUG	4439
AD-953316.1	A-17012 13.1	604	csgscag(Ahd)CfGfUfUfua auguuccaL96	A-10684 94.1	734	VpusGfsgaaCfaUfUfua caCfGfUfcugcsgsa	UCCGCAGACGUGU AAUGUUCU	4440
AD-953325.1	A-17012 31.1	605	asgsuu(Ghd)AfgUfUfAfaa cgaacgaaL96	A-10686 02.1	735	VpusAfsuguUfcGfUfu uaaCfuCfaagcsgsc	GCAGCUUGAGUU AAACGAACGUA	4441
AD-953299.1	A-17011 79.1	606	gscsacu(Ghd)AfaCfUfuu ucguccaaL96	A-10672 50.1	736	VpusUfsggaCfGfAfAfaa guUfuCfagucsgsa	UCGCACUGAAACU UUUCGUCCAA	4442
AD-953416.1	A-17014 13.1	607	asasuuc(Uhd)AfcAfUfAfcu aaauccaaL96	A-10708 22.1	737	VpusGfsagaUfuUfAfg uuuGfuAfgaaucscsu	AGAAUUCUACAU ACUAAAUCUCU	4443
AD-953315.1	A-17012 11.1	608	cscsgca(Ghd)AfcGfUfGfua aauguuccaL96	A-10684 92.1	738	VpusGfsaacAfuUfUfac acGfuCfugcgsasu	AUCCGCAGACGUG UAAAUGUUC	4444
AD-953314.1	A-17012 09.1	609	uscscgc(Ahd)GfaCfGfUfgu aaauuuuaL96	A-10684 90.1	739	VpusAfsacaUfuUfAfaa cgUfcUfgecgasusc	GAUCCGCAGACGU GUAAAUGUUC	4445
AD-953298.1	A-17011 77.1	610	csgscac(Uhd)GfaAfAfCfu uuuguccaL96	A-10672 48.1	740	VpusGfsgacGfaAfAfag uuUfcAfugcgsasc	GUCGCACUGAAAC UUUUCGUCCA	4446

AD-953406.1	A-17013 93.1	611	cscscuc(Uhd)UfgGfAfAfuu ggauucgaL96	A-10691 24.1	741	VpusCfsgaaUfcCfAfau ucCfaAfgaggsasc	GUCCUCUUGGAA UUGGAUUCGC	4447
AD-953399.1	A-17013 79.1	612	csasgac(Ghd)UfgUfAfAfau guuccugaL96	A-10684 98.1	742	VpusCfsgaggAfaCfAfuu uaCfaCfugucgscsg	CGCAGACGUGUAA AUGUCCUGC	4448
AD-953333.1	A-17012 47.1	613	ascsgaa(Chd)GfuAfCfUfug cagauguaL96	A-10686 26.1	743	VpusAfiscauCfuGfCfaa guAfcGfuucgususu	AAACGAACGUACU UGCAGAUGUG	4449
AD-953313.1	A-17012 07.1	614	asusceg(Chd)AfgAfCfGfug uaaagualL96	A-10684 88.1	744	VpusAfiscauUfuAfCfac guCfuGfeggauscsu	AGAUCCGCAGACG UGUAAAUGUU	4450
AD-953302.1	A-17011 85.1	615	csasgaa(Uhd)CfaUfCfAfcg aagugguaL96	A-10677 06.1	745	VpusAfiscauCfuUfCfgu gaUfgAfuucgscsc	GGCAGAAUCAUCA CGAAGUGGUG	4451
AD-953317.1	A-17012 15.1	616	cscsugc(Ahd)AfaAfAfCfac agacuegaL96	A-10685 30.1	746	VpusCfsgagUfcUfGfug uuUfuUfgeaggsasa	UUCCUGCAA AAC ACAGACUCGC	4452
AD-953357.1	A-17012 95.1	617	asgsaac(Ahd)UfuGfCfUfgu gcuuuggaL96	A-10697 40.1	747	VpusCfscsaaAfgCfAfa gcAfaUfguccgsa	UCAGGACAUUGCU GUGCUUUUGG	4453
AD-953301.1	A-17011 83.1	618	gssgca(Ghd)AfaUfCfAfuc acgaagualL96	A-10677 00.1	748	VpusAfscuuCfugUfGfau gaUfuCfugcccsusc	GAGGGCAGAAUC AUCACGAAGUG	4454
AD-953304.1	A-17011 89.1	619	usgsaag(Uhd)UfcAfUfGfga ugucuaualL96	A-10677 44.1	749	VpusAfsuagAfcAfUfcc auGfaAfcuucascsc	GGUGAAGUUCAU GGAUGUCUAUC	4455
AD-953297.1	A-17011 75.1	620	csgsucg(Chd)AfcUfGfAfaa cuuucgaL96	A-10672 42.1	750	VpusCfsgaaAfaGfUfu caGfuGfegagcsusc	GGCGUCGCACUGA AACUUUUCGU	4456
AD-953388.1	A-17013 57.1	621	gsasaaa(Ahd)AfaAfUfCfag uucgaggaL96	A-17008 69.1	751	VpusCfscuacGfaAfCfug auUfuUfuuuucsusu	AAGAAAAAAAU CAGUUCGAGGA	4457
AD-953407.1	A-17013 95.1	622	asusugg(Uhd)GfuCfUfUfca cuggaualaL96	A-10693 72.1	752	VpusCfsaucCfaGfUfga agAfcAfccaausasa	UUUUUGGUGUCU UCACUGGAUGU	4458

AD-953397.1	A-17013 75.1	623	asgsauc(Chd)GfcAfGfAfcg uguuaauaL96	A-10684 84.1	753	VPusAfsuuuAfcAfCfgu ucuGfcGfgaucusug	CAAGAUCCGCAGA CGUGUAAAUG	4459
AD-953398.1	A-17013 77.1	624	gsasucc(Ghd)CfaGfAfCfgu guaaaugaL96	A-10684 86.1	754	VPusCfsauuUfaCfAfcg ucUfgCfsgaucusu	AAGAUCCGCAGAC GUGUAAAUGU	4460
AD-953396.1	A-17013 73.1	625	ususguu(Uhd)GfuAfCfAfag auccgcaal96	A-10684 62.1	755	VPusUfsgcgGfaUfCfuu guAfcAfaacaasasu	AUUUUUUUUGUAC AAGAUCCGCAG	4461
AD-953356.1	A-17012 93.1	626	usgsuug(Uhd)GfgAfCfUfug aguugggaL96	A-10694 28.1	756	VPusCfsecaAfcUfCfaa guCfcAfcagcasgu	ACUGCUGUGGACU UGAGUUUGGA	4462
AD-953422.1	A-17014 25.1	627	csasguu(Chd)UfuUfGfUfcu cuagugcaL96	A-10709 32.1	757	VPusGfscacUfaGfAfga caAfaGfacgugsasu	AUCACGUCUUUGU CUCUAGUGCA	4463
AD-953413.1	A-17014 07.1	628	ususuuu(Uhd)UfcAfGfUfau ucuugguaL96	A-17008 99.1	758	VPusAfsccaAfgAfAfua cuGfaAfaaaasasc	GUUUUUUUUUCAG UAUUUUUGGUU	4464
AD-953294.1	A-17011 69.1	629	gsusgeu(Chd)GfaAfUfUfug auauucaal96	A-10668 84.1	759	VPusUfsgaaUfaUfCfaa auUfcCfagcacscsg	CGGUGCUGGAAU UUGAUUUUCAU	4465
AD-953421.1	A-17014 23.1	630	ususaac(Ahd)UfcAfCfGfuc uuugucuaL96	A-10709 18.1	760	VPusAfsagacAfaAfGfac guGfaUfguuuasa	UAUUAAACAUCACG UCUUUGUCUC	4466
AD-953310.1	A-17012 01.1	631	asgsugg(Chd)AfaAfAfAfcg aaagcgcaL96	A-17007 93.1	761	VPusGfscgcUfuUfCfgu uuUfuGfccccusu	AAAGGGGCAAAA ACGAAAAGCGCA	4467
AD-953296.1	A-17011 73.1	632	asasagu(Ghd)AfgUfGfAfcc ugcuuuuaL96	A-10671 46.1	762	VPusAfsaaaGfcAfGfgu caCfuCfacuuusgc	GCAAAAGUGAGUG ACCUGCUUUUG	4468
AD-953402.1	A-17013 85.1	633	asasaaa(Chd)AfcAfGfAfcu cgcgguugaL96	A-10685 40.1	763	VPusCfsaacGfcGfAfgu cuGfuGfuuuuusgc	GCAAAAACACAGA CUCGCGUUUG	4469
AD-953312.1	A-17012 05.1	634	asusuug(Uhd)UfuGfUfAfca agaucgcaL96	A-10684 58.1	764	VPusCfsggaUfcUfUfgu acAfaAfaaausgc	GCAUUUGUUUGU ACAAGAUCCGC	4470

AD-953295.1	A-17011 71.1	635	ususccc(Chd)AfaAfUfCfac uguggaaL96	A-17007 78.1	765	VPusAfsuccAfcAfGfug auUfuGfggaagsu	ACUCCCCCAAUC ACUGUGGAU	4471
AD-953420.1	A-17014 21.1	636	asusuaa(Chd)AfuCfAfCfug cuuugucal96	A-10709 16.1	766	VPusGfsacaAfaGfAfeg ugAfuGfuaaasasu	AUAUUAAACAC GUCUUUGUCU	4472
AD-953423.1	A-17014 27.1	637	csgsuc(Uhd)UfgUfCfUfcu agugcagaL96	A-10709 36.1	767	VPusCfsugcAfcUfAfga gaCfaAfagacgsug	CACGUCUUUGUCU CUAGUGCAGU	4473
AD-953403.1	A-17013 87.1	638	asasaac(Ahd)CfaGfAfCfuc gcuugcal96	A-10685 42.1	768	VPusGfscaaCfGfCfGfag ucUfgUfguuuusug	CAAAAAACACAGAC UCGCGUUGCA	4474
AD-953400.1	A-17013 81.1	639	usgscaa(Ahd)AfaCfAfCfag acucgcgaL96	A-10685 34.1	769	VPusCfsgcgAfgUfCfug ugUfuUfuugcasgsg	CCUGCAAAAACAC AGACUCGCGU	4475
AD-953404.1	A-17013 89.1	640	asascac(Ahd)GfaCfUfCfgc guugcaaaL96	A-10685 46.1	770	VPusUfsugcAfaCfGfeg agUfcUfguguusuu	AAAACACAGACUC GCGUUGCAAAG	4476
AD-953334.1	A-17012 49.1	641	csusugc(Ahd)GfaUfGfUfga caagccgaL96	A-10686 44.1	771	VPusCfsggcUfuGfUfca caUfcUfgcaagsusa	UACUUGCAGAGUG UGACAAAGCCGA	4477
AD-953418.1	A-17014 17.1	642	ususuu(Chd)CfGfUfAfAfua auuguggaL96	A-10708 94.1	772	VPusCfscacAfaUfUfau uaCfGfGfuaaacsca	UGUUUAUCCGUA AUAAUUUGUGGG	4478
AD-953401.1	A-17013 83.1	643	gscaaaa(Ahd)AfcAfCfAfga cucgcgual96	A-10685 36.1	773	VPusAfsccgGfaGfUfca guGfuUfuugcsasg	CUGCAAAAACACA GACUCGCGUU	4479
AD-953417.1	A-17014 15.1	644	gsusuua(Uhd)CfcGfUfAfau aaugugaL96	A-10708 92.1	774	VPusCfsacaAfuUfAfua acGfgAfuaacsasg	CUGUUUAUCCGUA AUAAUUUGUGGG	4480
AD-953311.1	A-17012 03.1	645	gsgsgca(Ahd)AfaCfGfGfaa agcgcaaaL96	A-10682 52.1	775	VPusUfsugcGfcUfUfuc guUfuUfugccscsu	AGGGGCAAAAAC GAAAGCGCAAG	4481
AD-953419.1	A-17014 19.1	646	ususauc(Chd)GfuAfAfUfaa uuuggggaL96	A-17009 05.1	776	VPusCfsccaCfaAfUfua uuAfcGfgauaasasc	GUUUAUCCGUAA UAAUUUGUGGGG	4482

Table 3B. Exemplary Human VEGF-A siRNA Unmodified Single Strands and Duplex Sequences

Duplex Name	Sense Oligo Name	SEQ ID NO: (Sense)	Sense Sequence	mRNA Target Range	Antisense Oligo Name	SEQ ID NO: (Antisense)	Antisense Sequence	mRNA Target Range
AD-953340.1	A-170126 1.1	777	ACUGAUACAGAACG AUCGAUA	1799-1819	A-1068804.1	907	UAUCGAUCGUUCUGUAUC AGUCU	1797-1819
AD-953336.1	A-170125 3.1	778	AAAGACUGAUACAG AACGAUA	1795-1815	A-1068796.1	908	UAUCGUUCUGUAUCAGUC UUUCC	1793-1815
AD-953363.1	A-170130 7.1	779	GAGAAAGUGUUUU AUUAACGA	2944-2964	A-1070290.1	909	UCGUUAUAAACACUUU CUCUU	2942-2964
AD-953338.1	A-170125 7.1	780	AGACUGAUACAGAA CGAUCCA	1797-1817	A-1068800.1	910	UCGAUCGUUCUGUAUCAG UCUUU	1795-1817
AD-953367.1	A-170131 5.1	781	CAACUAAUUUAUGAG AUGUAUA	3061-3081	A-1070376.1	911	UAUACAUCUCAUAAUAG UUGAA	3059-3081
AD-953337.1	A-170125 5.1	782	AAGACUGAUACAGAA ACGAUCA	1796-1816	A-1068798.1	912	UGAUCGUUCUGUAUCAGU CUUUC	1794-1816
AD-953342.1	A-170126 5.1	783	AUACAGAACGAUCG AUACAGA	1803-1823	A-1068812.1	913	UCUGUAUCGAUCGUUCUG UAUCA	1801-1823
AD-953350.1	A-170128 1.1	784	AACAGUGCUAAUGU UAUUUGGA	2178-2198	A-1069342.1	914	UCCAAUAACAUAUAGCACU GUUAA	2176-2198
AD-953352.1	A-170128 5.1	785	GUGCUAAUGUUUAUU GGUGUCA	2182-2202	A-1069350.1	915	UGACACCAUAUACAUAUAG CACUG	2180-2202

AD-953368.1	A-170131 7.1	786	AACUAAUUUAUGAGA UGUAUCA	3062-3082	A-1070378. 1	916	UGAUACAUCUCAAAUA GUUGA	3060-3082
AD-953344.1	A-170126 9.1	787	CAGAACAGUCCUUA AUCCAGA	1858-1878	A-1068918. 1	917	UCUGGAUUAAGGACUGUU CUGUC	1856-1878
AD-953339.1	A-170125 9.1	788	GACUGAUACAGAAC GAUCGAA	1798-1818	A-1068802. 1	918	UUCGAUCGUUCUGUAUCA GUCUU	1796-1818
AD-953387.1	A-170135 5.1	789	ACAGCACAAACAAU GUGAAUA	1407-1427	A-1068170. 1	919	UAUUCACAUUUUGUUGGC UGUAG	1405-1427
AD-953375.1	A-170133 1.1	790	AAAUAGACAUUUGCU AUUCUGA	3362-3382	A-1070792. 1	920	UCAGAAUAGCAUUGUCUA UUUUA	3360-3382
AD-953355.1	A-170129 1.1	791	UAUUGGUGUCUUCA CUGGAUA	2192-2212	A-1069370. 1	921	UAUCCAGUGAAGACACCA AUAAC	2190-2212
AD-953341.1	A-170126 3.1	792	CUGAUACAGAACGA UCGAUAA	1800-1820	A-1068806. 1	922	UUAUCGAUCGUUCUGUAU CAGUC	1798-1820
AD-953370.1	A-170132 1.1	793	GCUCUCUUAUUUGU ACCGGUA	3096-3116	A-1070446. 1	923	UACCGGUACAAUAAGAG AGCAA	3094-3116
AD-953362.1	A-170130 5.1	794	CACCAUUGAAACCA CUAGUUA	2791-2811	A-1070096. 1	924	UAACUAGUGGUUUUCAAUG GUGUG	2789-2811
AD-953322.1	A-170122 5.1	795	GGCAGCUUGAGUUA AACGAAA	1685-1705	A-1068596. 1	925	UUUCGUUUAAACUCAAGCU GCCUC	1683-1705
AD-953332.1	A-170124 5.1	796	UUAACGAACGUAC UUGCAGA	1696-1716	A-1068618. 1	926	UCUGCAAGUACGUUCGUU UAACU	1694-1716
AD-953371.1	A-170132 3.1	797	UCGGUGACAGUCAC UAGCUUA	3158-3178	A-1070550. 1	927	UAAGCUAGUGACUGUCAC CGAUC	3156-3178

AD-953331.1	A-170124 3.1	798	AGUUAACGAAACGU ACUUGCA	1694-1714	A-1068614. 1	928	UGCAAGUACGUUCGUUUA ACUCA	1692-1714
AD-953323.1	A-170122 7.1	799	GCAGCUUGAGUUAA ACGAACA	1686-1706	A-1068598. 1	929	UGUUCGUUUAACUCAAGC UGCCU	1684-1706
AD-953351.1	A-170128 3.1	800	AGUGCUAUGUUUAU UGGUGUA	2181-2201	A-1069348. 1	930	UACACCAUAACAUAUAGC ACUGU	2179-2201
AD-953386.1	A-170135 3.1	801	CGAAGUGGUGAAGU UCAUGGA	1152-1172	A-1067728. 1	931	UCCAUGAACUUCACCCACU UCGUG	1150-1172
AD-953394.1	A-170136 9.1	802	AAAGCAUUUGUUUG UACAAGA	1611-1631	A-1068448. 1	932	UCUUGUACAAACAUAUAGC UUUCU	1609-1631
AD-953359.1	A-170129 9.1	803	AUGUCCUCACACCA UUGAAAA	2782-2802	A-1070078. 1	933	UUUUCAAUGGUGUGAGG ACAUAG	2780-2802
AD-953329.1	A-170123 9.1	804	UGAGUUAAACGAAC GUACUUA	1692-1712	A-1068610. 1	934	UAAGUACGUUCGUUUAAC UCAAG	1690-1712
AD-953361.1	A-170130 3.1	805	ACACCAUUUGAAACC ACUAGUA	2790-2810	A-1070094. 1	935	UACUAGUGGUUUCAAUGG UGUGA	2788-2810
AD-953319.1	A-170121 9.1	806	CAAAACACACAGACU CGCGUUA	1656-1676	A-1068538. 1	936	UAACGCGAGUCUGUGUUU UUGCA	1654-1676
AD-953360.1	A-170130 1.1	807	UGUCCUCACACCAU UGAAACA	2783-2803	A-1070080. 1	937	UGUUUCAUUGGUGUGAG GACAU	2781-2803
AD-953324.1	A-170122 9.1	808	CAGCUUGAGUUAAA CGAACGA	1687-1707	A-1068600. 1	938	UCGUUCGUUUAACUCAAG CUGCC	1685-1707
AD-953378.1	A-170133 7.1	809	GGUGCUCUGUUUA UCCGUAA	3480-3500	A-1070874. 1	939	UUACGGUAACACAGUAGC ACCAA	3478-3500

AD-953369. 1	A-170131 9.1	810	UUGCUCUCUUAUUU GUACCGA	3094-3114	A-1070442. 1	940	UCGGUACAAAUAAGAGAG CAAGA	3092-3114
AD-953347. 1	A-170127 5.1	811	UCUUGCUGCUAAA CACCGAA	2010-2030	A-1069188. 1	941	UUCGGUGAUUUAGCAGCA AGAAA	2008-2030
AD-953365. 1	A-170131 1.1	812	CGGUACUUAUUUAA UAUCCCA	2962-2982	A-1070326. 1	942	UGGGAUAUUAUUAAAGU ACCGUA	2960-2982
AD-953374. 1	A-170132 9.1	813	AAAAUAGACAUUGC UAUUCUA	3361-3381	A-1070790. 1	943	UAGAAUAGCAAUGUCUAU UUUAU	3359-3381
AD-953384. 1	A-170134 9.1	814	ACUUUUCGUGCCAAC UUCUGGA	657-677	A-1067266. 1	944	UCCAGAAAGUUUGGACGAAA AGUUU	655-677
AD-953376. 1	A-170133 3.1	815	UUGGUGCUACUGUU UAUCCGA	3478-3498	A-1070870. 1	945	UCGGAUAAACAGUAGCAC CAAUA	3476-3498
AD-953354. 1	A-170128 9.1	816	GUUAUUGGUGUCUU CACUGGA	2190-2210	A-1069366. 1	946	UCCAGUGAAGACACCAAU AACAU	2188-2210
AD-953385. 1	A-170135 1.1	817	UUCGUCCAACUUCU GGGCUGA	661-681	A-1067274. 1	947	UCAGCCCAGAAUUUGGAC GAAA	659-681
AD-953346. 1	A-170127 3.1	818	UUCUUGCUGCUAAA UCACCGA	2009-2029	A-1069186. 1	948	UCGGUGAUUUAGCAGCAA GAAA	2007-2029
AD-953366. 1	A-170131 3.1	819	GGUACUUAUUUAAU AUCCCUA	2963-2983	A-1070328. 1	949	UAGGGAUAUUAAAUAAG UACCGU	2961-2983
AD-953382. 1	A-170134 5.1	820	AUAUAAACAUACAG UCUUUGA	3517-3537	A-1070912. 1	950	UCAAAGACGUGAUGUUA UAUCU	3515-3537
AD-953320. 1	A-170122 1.1	821	GAGGCAGCUUGAGU UAAACGA	1683-1703	A-1068592. 1	951	UCGUUUAACUCAAGCUGC CUCGC	1681-1703

AD-953379.1	A-170133 9.1	822	GUGCACUGUUUAU CCGUAAA	3481-3501	A-1070876. 1	952	UUACGGAUAAACAGUAG CACCA	3479-3501
AD-953321.1	A-170122 3.1	823	AGGCAGCUUGAGUU AAACGAA	1684-1704	A-1068594. 1	953	UUCGUUUUAAACUCAAGCUG CCUCG	1682-1704
AD-953377.1	A-170133 5.1	824	UGGUGCUACUGUUU AUCCGUA	3479-3499	A-1070872. 1	954	UACGGAUAAAACAGUAGCA CCAAU	3477-3499
AD-953392.1	A-170136 5.1	825	AAGGGGCAAAAACG AAAGCGA	1483-1503	A-1700876. 1	955	UCGCUUUUCGUUUUUUGCCC CUUUC	1481-1503
AD-953373.1	A-170132 7.1	826	ACAGUCACUAGCUU AUCUUGA	3164-3184	A-1070562. 1	956	UCAAGAUAAAGCUAGUGAC UGUCA	3162-3184
AD-953364.1	A-170130 9.1	827	ACGGUACUUAUUUA AUAUCCA	2961-2981	A-1070324. 1	957	UGGAUUAUAAAUAAAGUA CCGUAU	2959-2981
AD-953330.1	A-170124 1.1	828	GAGUUAACGAACG UACUUGA	1693-1713	A-1068612. 1	958	UCAAGUACGUUCGUUUA CUCAA	1691-1713
AD-953353.1	A-170128 7.1	829	UGUUAUUGGUGUCU UCACUGA	2189-2209	A-1069364. 1	959	UCAGUGAAGACACCAAUA ACAUU	2187-2209
AD-953343.1	A-170126 7.1	830	CGACAGAACAGUCC UUAUAUA	1855-1875	A-1068912. 1	960	UGAUUAAGGACUGUUCUG UCGAU	1853-1875
AD-953390.1	A-170136 1.1	831	AAAAUCAGUUCGAG GAAAGGA	1461-1481	A-1700873. 1	961	UCCUUUCCUCGAACUGAU UUUUU	1459-1481
AD-953345.1	A-170127 1.1	832	CUUGGAAUUGGAUU CGCCAU	1982-2002	A-1069132. 1	962	UAUGGCGAAUCCAAUUC AAGAG	1980-2002
AD-953358.1	A-170129 7.1	833	AGAGAAGAGACACA UUGUUGA	2673-2693	A-1069954. 1	963	UCAACAAUGUGUCUCUUC UCUUC	2671-2693

AD-953383.1	A-170134 7.1	834	ACGUCUUUGUCUCU AGUGCAA	3528-3548	A-1070934. 1	964	UUGCACUAGAGACAAAGA CGUGA	3526-3548
AD-953372.1	A-170132 5.1	835	UGACAGUCACUAGC UUAUCUA	3162-3182	A-1070558. 1	965	UAGAUAAAGCUAGUGACUG UCACC	3160-3182
AD-953328.1	A-170123 7.1	836	UUGAGUUAAACGAA CGUACUA	1691-1711	A-1068608. 1	966	UAGUACGUUCGUUUUAACU CAAGC	1689-1711
AD-953393.1	A-170136 7.1	837	GAAAGCAUUUGUUU GUACAAA	1610-1630	A-1068446. 1	967	UUUGUACAAAACAAUUGCU UUCUC	1608-1630
AD-953307.1	A-170119 5.1	838	AUCACCAUGCAGAU UAUGCGA	1342-1362	A-1068040. 1	968	UCGCAUAAUCUGCAUGGU GAUGU	1340-1362
AD-953308.1	A-170119 7.1	839	CACCAUGCAGAUUA UGCGGAA	1344-1364	A-1068044. 1	969	UUCCGCAUAAUCUGCAUG GUGAU	1342-1364
AD-953327.1	A-170123 5.1	840	CUUGAGUUAAACGA ACGUACA	1690-1710	A-1068606. 1	970	UGUACGUUCGUUUUAACUC AAGCU	1688-1710
AD-953335.1	A-170125 1.1	841	UUGCAGAUUGAGACA AGCCGAA	1710-1730	A-1068646. 1	971	UUCGGCUUGUCACAUCUG CAAGU	1708-1730
AD-953414.1	A-170140 9.1	842	ACUAAUUUAUGAGAU GUAUCUA	3063-3083	A-1070380. 1	972	UAGAUACAUCUCAUAAAU AGUUG	3061-3083
AD-953412.1	A-170140 5.1	843	UUUUUUUUCAGUAU UCUUUGGA	3027-3047	A-1700897. 1	973	UCCAAGAAUACUGAAAAA AAACC	3025-3047
AD-953411.1	A-170140 3.1	844	GUUUUAUUAUACGGU ACUUUAU	2952-2972	A-1070306. 1	974	UAUAAGUACCGUAUAUA AACAC	2950-2972
AD-953410.1	A-170140 1.1	845	GAAAGUGUUUUUAU AUACGGUA	2946-2966	A-1070294. 1	975	UACCGUAUAUAAACACU UUCUC	2944-2966

AD-953408. 1	A-170139 7.1	846	UCACUGGAUGUAUU UGACUGA	2203-2223	A-1069392. 1	976	UCAGUCAAAUACAUCAG UGAAG	2201-2223
AD-953326. 1	A-170123 3.1	847	GCUUGAGUUAACG AACGUAA	1689-1709	A-1068604. 1	977	UUACGUUCGUUUAACUCA AGCUG	1687-1709
AD-953300. 1	A-170118 1.1	848	CCUCCGAAACCAUG AACUUUA	1028-1048	A-1067482. 1	978	UAAAGUUCAUGGUUUCGG AGGCC	1026-1048
AD-953389. 1	A-170135 9.1	849	AAAAUUCAGUUCGA GGAAAGA	1460-1480	A-1700871. 1	979	UCUUUCCUCGAACUGAUU UUUUU	1458-1480
AD-953415. 1	A-170141 1.1	850	GAGAAUUCUACAUA CUAAUA	3416-3436	A-1070816. 1	980	UAUUUAGUAUGUAGAAU UCUCUA	3414-3436
AD-953309. 1	A-170119 9.1	851	AGAUUAUGCGGAUC AAACCUA	1352-1372	A-1068060. 1	981	UAGGUUUGAUCCGCAUAA UCUGC	1350-1372
AD-953391. 1	A-170136 3.1	852	AAUUCAGUUCGAGG AAAGGGA	1462-1482	A-1068240. 1	982	UCCUUUCCUCGAACUGA UUUUU	1460-1482
AD-953395. 1	A-170137 1.1	853	GCAUUUGUUUGUAC AAGAUA	1614-1634	A-1068454. 1	983	UGAUCUUUGUACAAACAAA UGC UU	1612-1634
AD-953303. 1	A-170118 7.1	854	CACGAAGUGGUGAA GUUCAUA	1150-1170	A-1067724. 1	984	UAUGAACUUACACCACUUC GUGAU	1148-1170
AD-953405. 1	A-170139 1.1	855	UAAUCCAGAAACCU GAAAUUA	1870-1890	A-1068942. 1	985	UCAUUUCAGGUUUCUGGA UUAAAG	1868-1890
AD-953305. 1	A-170119 1.1	856	CAUCUUCAGCCAU CCUGUGA	1251-1271	A-1067926. 1	986	UCACAGGAUGGCUUGAAG AUGUA	1249-1271
AD-953380. 1	A-170134 1.1	857	UGCUCUGUUUAUC CGUAAUA	3482-3502	A-1070878. 1	987	UAUUACGGAUAAACAGUA GCACC	3480-3502

AD-953349.1	A-170127 9.1	858	UUGCUGCUAAAUCA CCGAGCA	2012-2032	A-1069192. 1	988	UGCUCGGUGAUUUAGCAG CAAGA	2010-2032
AD-953381.1	A-170134 3.1	859	GAUUAUUAAACAUCAC GUCUUUA	3516-3536	A-1070910. 1	989	UAAAGACGUGAUGUUAA UAUCUU	3514-3536
AD-953318.1	A-170121 7.1	860	CUGCAAAAACACACAG ACUCGCA	1653-1673	A-1068532. 1	990	UGCAGUCUGUGUUUUUG CAGGA	1651-1673
AD-953348.1	A-170127 7.1	861	CUUGCUGCUAAAUC ACCGAGA	2011-2031	A-1069190. 1	991	UCUCGGUGAUUUAGCAGC AAGAA	2009-2031
AD-953409.1	A-170139 9.1	862	AGAAAGUGUUUUUA UAUACGGA	2945-2965	A-1070292. 1	992	UCCGUAAUAAAACACUU UCUCU	2943-2965
AD-953306.1	A-170119 3.1	863	AACAUCACCAUGCA GAUUUAU	1339-1359	A-1068034. 1	993	UAUAAUCUGCAUGGUGAU GUUGG	1337-1359
AD-953316.1	A-170121 3.1	864	CGCAGACGUGUAAA UGUUCOA	1634-1654	A-1068494. 1	994	UGGAACAUUUACACGUCU GCGGA	1632-1654
AD-953325.1	A-170123 1.1	865	AGCUUGAGUUAAAC GAACGUA	1688-1708	A-1068602. 1	995	UACGUUCGUUUAAACUCAA GCUGC	1686-1708
AD-953299.1	A-170117 9.1	866	GCACUGAAACUUUU CGUCCAA	649-669	A-1067250. 1	996	UUGGACGAAAAGUUUUCAG UGCGA	647-669
AD-953416.1	A-170141 3.1	867	AAUUCUACAUACUA AAUCUCA	3419-3439	A-1070822. 1	997	UGAGAUUUAGUAUGUAG AAUUCU	3417-3439
AD-953315.1	A-170121 1.1	868	CCGCAGACGUGUAA AUGUUA	1633-1653	A-1068492. 1	998	UGAACAUUUACACGUCUG CGGAU	1631-1653
AD-953314.1	A-170120 9.1	869	UCCGCAGACGUGUA AAUGUUA	1632-1652	A-1068490. 1	999	UAACAUAUUACACGUCUCG GGAUC	1630-1652

AD-953298.1	A-170117 7.1	870	CGCACUGAAACUUU UCGUCCA	648-668	A-1067248. 1	1000	UGGACGAAAAAGUUUCAGU GCGAC	646-668
AD-953406.1	A-170139 3.1	871	CCCUCUUGGAAUUG GAUUCGA	1978-1998	A-1069124. 1	1001	UCGAAUCCAAUUCCAAGA GGGAC	1976-1998
AD-953399.1	A-170137 9.1	872	CAGACGUGUAA AUG UUCCUGA	1636-1656	A-1068498. 1	1002	UCAGGAACA UUAACACGU CUGCG	1634-1656
AD-953333.1	A-170124 7.1	873	ACGAACGUACUUGC AGAUGUA	1700-1720	A-1068626. 1	1003	UACAUCUGCAAGUACGUU CGUUU	1698-1720
AD-953313.1	A-170120 7.1	874	AUCCGCAGACGUGU AAAUGUA	1631-1651	A-1068488. 1	1004	UACAUUUACACGUCUGCG GAUCU	1629-1651
AD-953302.1	A-170118 5.1	875	CAGAAUCAUCACGA AGUGGUA	1141-1161	A-1067706. 1	1005	UACCACUUCGUGAUGAUU CUGCC	1139-1161
AD-953317.1	A-170121 5.1	876	CCUGCAAAAACACA GACUCGA	1652-1672	A-1068530. 1	1006	UCGAGUCUGUGUUUUUUGC AGGAA	1650-1672
AD-953357.1	A-170129 5.1	877	AGGACAUUGCUGUG CUUUUGGA	2518-2538	A-1069740. 1	1007	UCCAAAGCACAGCAAUGU CCUGA	2516-2538
AD-953301.1	A-170118 3.1	878	GGGCAGAAUCAUCA CGAAGUA	1138-1158	A-1067700. 1	1008	UACUUCGUGAUGAUUCUG CCCUC	1136-1158
AD-953304.1	A-170118 9.1	879	UGAAGUUCAUGGGAU GUCUAUA	1160-1180	A-1067744. 1	1009	UAUAGACA UCCAUGAACU UCACC	1158-1180
AD-953297.1	A-170117 5.1	880	CGUCGCACUGAAAC UUUUCGA	645-665	A-1067242. 1	1010	UCGAAAAAGUUUCAGUGCG ACGCC	643-665
AD-953388.1	A-170135 7.1	881	GAAAAAAAUCAGU UCGAGGA	1456-1476	A-1700869. 1	1011	UCCUCGAACUGAUUUUUU UUCUU	1454-1476

AD-953407.1	A-170139 5.1	882	AUUGGUGUCUUCAC UGGAUGA	2193-2213	A-1069372.1	1012	UCAUCCAGUGAAGACACC AAUAA	2191-2213
AD-953397.1	A-170137 5.1	883	AGAUCCGCAGACGU GUAAAU	1629-1649	A-1068484.1	1013	UAUUUACACGUCUGCGGA UCUUG	1627-1649
AD-953398.1	A-170137 7.1	884	GAUCCGCAGACGUG UAAAUGA	1630-1650	A-1068486.1	1014	UCAUUUACACGUCUGCGG AUCUU	1628-1650
AD-953396.1	A-170137 3.1	885	UUGUUUGUACAAGA UCCGCAA	1618-1638	A-1068462.1	1015	UUGCGGAUCUUUGUACAAA CAAAU	1616-1638
AD-953356.1	A-170129 3.1	886	UGCUGUGGACUUGA GUUGGGA	2221-2241	A-1069428.1	1016	UCCCAACUCAAGUCCACA GCAGU	2219-2241
AD-953422.1	A-170142 5.1	887	CACGUCUUUGUCUC UAGUGCA	3527-3547	A-1070932.1	1017	UGCACUAGAGACAAAAGAC GUGAU	3525-3547
AD-953413.1	A-170140 7.1	888	UUUUUUUUCAGUAUU CUUGGUA	3028-3048	A-1700899.1	1018	UACCAAGAAUACUGAAAA AAAC	3026-3048
AD-953294.1	A-170116 9.1	889	GUGCUGGAAUUUGA UAUUCAA	125-145	A-1066884.1	1019	UUGAAUAUCAAUUUCCAG CACCG	123-145
AD-953421.1	A-170142 3.1	890	UUAACAUCACGUCU UUGUCUA	3520-3540	A-1070918.1	1020	UAGACAAAGACGUGAUGU UAAUA	3518-3540
AD-953310.1	A-170120 1.1	891	AGGGGCAAAAACGA AAGCGCA	1484-1504	A-1700793.1	1021	UGCGCUUUCGUUUUUUGCC CCUUU	1482-1504
AD-953296.1	A-170117 3.1	892	AAAGUGAGUGACCU GCUUUUA	415-435	A-1067146.1	1022	UAAAAGCAGGUCACUCAC UUUGC	413-435
AD-953402.1	A-170138 5.1	893	AAAAACACAGACUC GCGUUGA	1657-1677	A-1068540.1	1023	UCAACGCGAGUCUGUGUU UUUGC	1655-1677

AD-953312.1	A-170120 5.1	894	AUUUGUUUGUACAA GAUCCGA	1616-1636	A-1068458. 1	1024	UCGGAUCUUGUACAAACA AAUGC	1614-1636
AD-953295.1	A-170117 1.1	895	UUCGCCAAAUACUCU GUGGAUA	278-298	A-1700778. 1	1025	UAUCCACAGUGAUUUUGGG GAAGU	276-298
AD-953420.1	A-170142 1.1	896	AUUAACAUCACGUC UUUGUCA	3519-3539	A-1070916. 1	1026	UGACAAAAGACGUGAUGUU AAUAU	3517-3539
AD-953423.1	A-170142 7.1	897	CGUCUUUGUCUCUA GUGCAGA	3529-3549	A-1070936. 1	1027	UCUGCACUAGAGACAAAG ACGUG	3527-3549
AD-953403.1	A-170138 7.1	898	AAAAACACAGACUCG CGUUGCA	1658-1678	A-1068542. 1	1028	UGCAACGCGAGUCUGUGU UUUUG	1656-1678
AD-953400.1	A-170138 1.1	899	UGCAAAAACACAGAGA CUCGCCA	1654-1674	A-1068534. 1	1029	UCGCGAGUCUGUGUUUU GCAGG	1652-1674
AD-953404.1	A-170138 9.1	900	AACACAGACUCGCG UUGCAAA	1660-1680	A-1068546. 1	1030	UUUGCAACGCGAGUCUGU GUUUU	1658-1680
AD-953334.1	A-170124 9.1	901	CUUGCAGAUUGAGC AAGCCGA	1709-1729	A-1068644. 1	1031	UCGGCUUGUCACAUCUCG AAGUA	1707-1729
AD-953418.1	A-170141 7.1	902	UUUAUCCGUAAUAA UUGUGGA	3490-3510	A-1070894. 1	1032	UCCACAAUUAUUACGGAU AAACA	3488-3510
AD-953401.1	A-170138 3.1	903	GCAAAAACACAGAC UCGCGUA	1655-1675	A-1068536. 1	1033	UACGCGAGUCUGUGUUUU UGCAG	1653-1675
AD-953417.1	A-170141 5.1	904	GUUUAUCCGUAAUA AUUGUGA	3489-3509	A-1070892. 1	1034	UCACAAUUAUUACGGUA AACAG	3487-3509
AD-953311.1	A-170120 3.1	905	GGGCAAAAACGAAA GCGCAAA	1486-1506	A-1068252. 1	1035	UUUGCGCUUUCGUUUUUG CCCCU	1484-1506

AD-953419.1	A-1701419.1	906	UUAUCCGUAUAUAAUUGUGGGA	3491-3511	A-1700905.1	1036	UCCACAAUUAUACGGAUAAAC	3489-3511
-------------	-------------	-----	------------------------	-----------	-------------	------	-----------------------	-----------

Table 4A. Exemplary Human VEGF-A siRNA Modified Single Strands and Duplex Sequences

Duplex Name	Sense Oligo Name	SEQ ID NO: (Sense)	Sense Sequence	Antisense Oligo Name	SEQ ID NO: (Antisense)	Antisense Sequence	mRNA target sequence	SEQ ID NO: (mRNA target)
AD-953504.1	A-1701069.1	1037	asasaau(Ahd)gadCadTugeuaucuaL96	A-1800407.1	1167	VPusdAsgadAudAgcaadTgdTcdTaaunuas	AUAAAUAAGACAUUGCUAUUCUG	4483
AD-953481.1	A-1701023.1	1038	asgsugc(Uhd)aadTgdTuaunguguL96	A-1800384.1	1168	VPusdAsgadCcdAuaadCadTudAgeacusg	ACAGUGCUAAUGUUAUUGGUGUC	4484
AD-953472.1	A-1701005.1	1039	asusaca(Ghd)aadCgdAucgaucagaL96	A-1800375.1	1169	VPusdCsugdTadTcgaudCgdTudCugauascs	UGAUACAGAACGACGGAUACAGA	4485
AD-953517.1	A-1701095.1	1040	ascsagc(Ahd)cadAcdAaunguaaL96	A-1800420.1	1170	VPusdAsuudCadCauuudGudTgdTgcugusa	CUACAGCACACAACA AUGUGAAUG	4486
AD-953471.1	A-1701003.1	1041	csusgau(Ahd)cadGadAcgaucgaaL96	A-1800374.1	1171	VPusdTsaudCgdAucgudTcdTgdTaucagsu	GACUGAUACAGAACGUAUCGUAUC	4487
AD-953493.1	A-1701047.1	1042	gsasgaa(Ahd)gudGudTuaauaacaL96	A-1800396.1	1172	VPusdCsugdAudAuaadAcdAcdTuucucu	AAGAGAAAAGUGUUUUAUAUACGG	4488
AD-953498.1	A-1701057.1	1043	asascua(Uhd)uudAudGagaugaucaL96	A-1800401.1	1173	VPusdGsaudAcdAucucdAudAadAuaguus	UCAACUAUUUAUGAGAUGUAUCU	4489
AD-953467.1	A-1700995.1	1044	asasgac(Uhd)gadTadCagaacgaucL96	A-1800370.1	1174	VPusdGsaudCgdTucugdTadTcdAgucuuu	GAAAGACUGAUACAGAACGAUCG	4490

AD-95354 5.1	A-1701151 .1	1045	gsasgaa(Uhd)ucd TadCauaauaaua L96	A-1800448.1	1175	VPusdAsuudTadGua ugdTadGadAuucucs sa	UAGAGAAUUCUAC AUACUAAAUC	4491
AD-95346 6.1	A-1700993 .1	1046	asasaga(Chd)ugd AudAcagaaagaa L96	A-1800369.1	1176	VPusdAsucdGudTeu gudAudCadGucuuusc sc	GGAAAAGACUGAUA CAGAAACGAUC	4492
AD-95349 4.1	A-1701049 .1	1047	ascsggu(Ahd)jud TadTuuauauacca L96	A-1800397.1	1177	VPusdGsgadTadTuua adTadAgdTaccgusas u	AUACGGUACUUAU UUAAUAUCCCC	4493
AD-95347 0.1	A-1701001 .1	1048	ascsgga(Uhd)acd AgdAacgaucgaa L96	A-1800373.1	1178	VPusdAsucdGadTeg uudCudGudAucagusc su	AGACUGAUACAGA ACGAUCGAUA	4494
AD-95347 3.1	A-1701007 .1	1049	csgsaga(Chd)aad CadGuccuuaauca L96	A-1800376.1	1179	VPusdGsaudTadAgg acdTgdTudCugucgsa su	AUCGACAGAACAG UCCUUAAUCC	4495
AD-95347 4.1	A-1701009 .1	1050	csasgaa(Chd)agd TedCuuaauaccaga L96	A-1800377.1	1180	VPusdCsugdGadTua agdGadCudGuucugsu sc	GACAGAACAGUCC UUAAUCCAGA	4496
AD-95348 0.1	A-1701021 .1	1051	asascag(Uhd)gcd TadAuguuaugg aL96	A-1800383.1	1181	VPusdCsadAudAac audTadGcdAcuguusa sa	UUAAACAGUGCUAA UGUUAUUUGGU	4497
AD-95350 3.1	A-1701067 .1	1052	ascsgu(Chd)acd TadGcuuaucuga L96	A-1800406.1	1182	VPusdCsadGadTaag cdTadGudGacugscs a	UGACAGUCACUAG CUUAUCUUGA	4498
AD-95347 8.1	A-1701017 .1	1053	csusuge(Uhd)gcd TadAaucaccgaga L96	A-1800381.1	1183	VPusdCsucdGgdTga uudTadGcdAgeaagsa sa	UUCUUGCUGCUAA AUCACCCGAGC	4499
AD-95354 0.1	A-1701141 .1	1054	gsasaag(Uhd)jud TudTauauaccgaa L96	A-1800443.1	1184	VPusdAscddGudAua uadAadAcdAcuuucs sc	GAGAAAAGUGUUUU AUUAACGGUA	4500
AD-95350 0.1	A-1701061 .1	1055	gscsueu(Chd)uud AudTuguaaccgaa L96	A-1800403.1	1185	VPusdAscddGgdTaca adAudAadGagagcsas a	UUGCUCUCUUAUU UGUACCCGGUU	4501
AD-95347 6.1	A-1701013 .1	1056	ususcuu(Chd)jud GcdTaaauaccaga L96	A-1800379.1	1186	VPusdCsggdTgdAu uadGcdAgdCaagaasa sa	UUUUCUUGCUGCU AAAUACCCGA	4502

AD-95349 2.1	A-1701045 .1	1057	csascca(Uhd)ugd AadAccacuagua L96	A-1800395.1	1187	VPusdAsacdTadGug gudTudCadAuggusg sg	CACACCAUUGAAA CCACUAGUUC	4503
AD-95349 5.1	A-1701051 .1	1058	cssgsua(Chd)uud AudTuaauauccca L96	A-1800398.1	1188	VPusdGsggdAudAu aadAudAadGuacg sa	UACGGUACUUAU UAAUAUCCCU	4504
AD-95349 7.1	A-1701055 .1	1059	csasacu(Ahd)uud TadTgagauua L96	A-1800400.1	1189	VPusdAsuadCadTc adTadAadTagu a	UUCAACUUAUUA GAGAUGUAUC	4505
AD-95353 5.1	A-1701131 .1	1060	usasau(Chd)agd AadAccuaga L96	A-1800438.1	1190	VPusdCsaudTudCag gudTudCudGga sg	CUUAAUCCAGAA CCUGAAUAGA	4506
AD-95350 5.1	A-1701071 .1	1061	asasaua(Ghd)acd AudTgcuauucga L96	A-1800408.1	1191	VPusdCsagdAadTagc adAudGudCuau a	UAAAAUAGACAU GCUAUUCUGU	4507
AD-95352 4.1	A-1701109 .1	1062	asasagc(Ahd)uud TgdTuuguacaaga L96	A-1800427.1	1192	VPusdCsudGudAca aadCadAadTgc su	AGAAAGCAUUUG UUGUACAAAGA	4508
AD-95347 5.1	A-1701011 .1	1063	csusugg(Ahd)aud TgdGauugccaua L96	A-1800378.1	1193	VPusdAsugdGcdGaa ucdCadAudTcca sg	CUCUUGGAAUUG AUUCGCCAUU	4509
AD-95349 1.1	A-1701043 .1	1064	ascsacc(Ahd)uud GadAaccacuagua L96	A-1800394.1	1194	VPusdAscudAgdTgg uudTcdAadTgg sa	UCACACCAUUGAA ACCACUAGUU	4510
AD-95343 6.1	A-1700933 .1	1065	asascu(Chd)acd CadTgagauua L96	A-1800339.1	1195	VPusdAsuadAudCug cadTgdGudGaug sg	CCAACAUCACCAU GCAGAUUAUG	4511
AD-95350 2.1	A-1701065 .1	1066	usgsaca(Ghd)ucd AcdTagcuauca L96	A-1800405.1	1196	VPusdAsgadTadAgc uadGudGadCug sc	GGUGACAGUCACU AGCUUAUCUU	4512
AD-95346 1.1	A-1700983 .1	1067	asgsuua(Ahd)acd GadAcguacuagca L96	A-1800364.1	1197	VPusdGscadAgdTac gudTcdGudTua sa	UGAGUUAACGAA CGUACUUGCA	4513
AD-95354 4.1	A-1701149 .1	1068	ascsuau(Uhd)uad TgdAgaugauca L96	A-1800447.1	1198	VPusdAsgadTadCauc udCadTadAua g	CAACUUAUUAUGA GAUGUAUCUU	4514

AD-95346 2.1	A-1700985 .1	1069	ususaaa(Chd)gad AcdGuacungcaga L96	A-1800365.1	1199	VPusdCsugdCadAgu acdGudTcdGuuaasc su	AGUUAACGAACG UACUUGCAGA	4515
AD-95349 6.1	A-1701053 .1	1070	gsgsuac(Uhd)uad TudTaauaucceua L96	A-1800399.1	1200	VPusdAsggdGadTau uadAadTadAguaccsg su	ACGGUACUUAUUU AAUAUCCCUU	4516
AD-95351 6.1	A-1701093 .1	1071	csgsaag(Uhd)ggd TgdAaguucaggga L96	A-1800419.1	1201	VPusdCscadTgdAacu udCadCcdAcuucgsus g	CACGAAGUGGUGA AGUUC AUGGA	4517
AD-95348 3.1	A-1701027 .1	1072	usgsuua(Uhd)ug dGudGucuucacu gaL96	A-1800386.1	1202	VPusdCsagdTgdAag acdAcdCadAuaacasu su	AAUGUUAUUGGUG UCUUCACUGG	4518
AD-95349 9.1	A-1701059 .1	1073	ususgeu(Chd)ucd TudAuunguaccga L96	A-1800402.1	1203	VPusdCsaggdTadCaaa udAadGadGagcaasgs a	UCUUGCUCUCUUA UUUGUACCGG	4519
AD-95354 1.1	A-1701143 .1	1074	gsusuua(Ahd)ua dTadCgguacuua aL96	A-1800444.1	1204	VPusdAsuadAgdTac egdTadTadTaaaacsas c	GUGUUUUUAUAC GGUACUUAUU	4520
AD-95353 8.1	A-1701137 .1	1075	uscsacu(Ghd)gad TgdTaanuagacuga L96	A-1800441.1	1205	VPusdCsagdTcdAaau adCadTcdCagugasas g	CUUCACUGGAUGU AUUUGACUGC	4521
AD-95343 0.1	A-1700921 .1	1076	cscsucc(Ghd)aad AcdCaugaacuua L96	A-1800333.1	1206	VPusdAsaadGudTca ugdGudTudCggaggsc sc	GGCCUCCGAAACC AUGAACUUUC	4522
AD-95348 5.1	A-1701031 .1	1077	usasuug(Ghd)ug dTcdTucacuggau aL96	A-1800388.1	1207	VPusdAsuedCadGug aadGadCadCcaauasas c	GUUAUUGGUGUCU UCACUGGAUG	4523
AD-95346 8.1	A-1700997 .1	1078	asgsacu(Ghd)aud AcdAgaacgaucga L96	A-1800371.1	1208	VPusdCsagdTcdGuu cudGudAudCagucusu su	AAAGACUGAUACA GAACGAUCGA	4524
AD-95344 4.1	A-1700949 .1	1079	uscscgc(Ahd)gad CgdTgaaauugua L96	A-1800347.1	1209	VPusdAsacdAudTua cadCgdTcdTgcggasu sc	GAUCCGCAGACGU GUAAAUGUUC	4525
AD-95346 0.1	A-1700981 .1	1080	gsasguu(Ahd)aad CgdAacguacuuga L96	A-1800363.1	1210	VPusdCsaadGudAag uudCgdTudTaaucsa sa	UUGAGUUAAACGA ACGUACUUGC	4526

AD-95353 9.1	A-1701139 .1	1081	asgsaaa(Ghd)ugd TudTuaauacgga L96	A-1800442.1	1211	VPusdCscgdTadTaa adAadCadCuucusc u	AGAGAAAGUGUU UAUAUACGGU	4527
AD-95348 4.1	A-1701029 .1	1082	gsusuau(Uhd)gg dTgdTeuucacugg aL96	A-1800387.1	1212	VPusdCscadGudGaa gadCadCedAauacsa su	AUGUUAUUGGUGU CUUCACUGGA	4528
AD-95345 7.1	A-1700975 .1	1083	csusuga(Ghd)uud AadAcgaacguaca L96	A-1800360.1	1213	VPusdGsuadCgdTuc gudTudAadCucagsc su	AGCUUGAGUUAAA CGAACGUACU	4529
AD-95345 9.1	A-1700979 .1	1084	usgsagu(Uhd)aad AcdGaagcuacua L96	A-1800362.1	1214	VPusdAsagdTadCgu ucdGudTudAaucasa sg	CUUGAGUUAAAACG AACGUACUUG	4530
AD-95343 7.1	A-1700935 .1	1085	asuscac(Ghd)aud GcdAgaauaugcg aL96	A-1800340.1	1215	VPusdCsgcdAudAau cudGcdAudGgugaus gsu	ACAUCACCAUGCA GAUUAUGCGG	4531
AD-95345 8.1	A-1700977 .1	1086	ususgag(Uhd)uad AadCgaacguacua L96	A-1800361.1	1216	VPusdAsgudAcdGuu egdTudTadAucuaasg sc	GCUUGAGUUAAAAC GAACGUACUU	4532
AD-95345 3.1	A-1700967 .1	1087	gscsage(Uhd)ugd AgtTuaaacgaaca L96	A-1800356.1	1217	VPusdGsuudCgdTu aadCudCadAgeugcsc su	AGGCAGCUUGAGU UAAACGAACG	4533
AD-95342 8.1	A-1700917 .1	1088	csgscac(Uhd)gad AadCuuuugucca L96	A-1800331.1	1218	VPusdGsgadCgdAaa agdTudTcdAguugcgsa sc	GUCGCACUGAAAC UUUUCGUCCA	4534
AD-95350 1.1	A-1701063 .1	1089	uscsggu(Ghd)acd AgtTcaacguacua L96	A-1800404.1	1219	VPusdAsagdCudAgu gadCudGudCaccgasu sc	GAUCGGUGACAGU CACUAGCUUA	4535
AD-95348 2.1	A-1701025 .1	1090	gsusgcu(Ahd)aud GudTauugguguc aL96	A-1800385.1	1220	VPusdGsacdAcdCaa uadAcdAudTagcacsu sg	CAGUGCUAAUGUU AUUGGUGUCU	4536
AD-95344 6.1	A-1700953 .1	1091	csgscag(Ahd)egd TgdTaauguucca L96	A-1800349.1	1221	VPusdGsgadAcdAuu uadCadCgdTeugcsgs sa	UCCGCAGACGUGU AAAUUUUCCU	4537
AD-95348 8.1	A-1701037 .1	1092	asgsaga(Ahd)gad GadCacauguuga L96	A-1800391.1	1222	VPusdCsaadCadAug ugdTcdTcdTucucsu sc	GAAGAGAAAGAGAC ACAUUGUUGG	4538

AD-95343 4.1	A-1700929 .1	1093	usgsaag(Uhd)ucd AudGgaugucuaa aL96	A-1800337.1	1223	VPusdAsuadGadCau ccdAudGadAcuucasc sc	GGUGAAGUUC AUG GAUGUCUAUC	4539
AD-95354 6.1	A-1701153 .1	1094	asasuuc(Uhd)acd AudAcuaaauca L96	A-1800449.1	1224	VPusdGsagdAudTua gudAudGudAgaauus csu	AGAAUUCUACAUA CUAAAUCUCU	4540
AD-95352 9.1	A-1701119 .1	1095	csasgac(Ghd)ugd TadAaanguuccga L96	A-1800432.1	1225	VPusdCsagdGadAca uudTadCadCgucugsc sg	CGCAGACGUGUAA AUGUUCUCCUGC	4541
AD-95343 3.1	A-1700927 .1	1096	csasgca(Ahd)gud GgdTgaagucaua L96	A-1800336.1	1226	VPusdAsugdAadCuu cadCcdAcdTucgugsa su	AUCACGAAAGUGGU GAAGUUCUAUG	4542
AD-95345 6.1	A-1700973 .1	1097	gscsuug(Ahd)gu dTadAacgaacgua aL96	A-1800359.1	1227	VPusdTsaadGudTcgu udTadAcdTcaagcsus g	CAGCUUGAGUUAA ACGAAACGUAC	4543
AD-95343 5.1	A-1700931 .1	1098	csasuc(Uhd)cad AgdCcaucuguga L96	A-1800338.1	1228	VPusdCsacdAgdGau ggdCudTgdAagaugsu sa	UACAUCUUAACAGC CAUCCUGUGU	4544
AD-95343 8.1	A-1700937 .1	1099	csascca(Uhd)gcd AgdAuuaugcgga aL96	A-1800341.1	1229	VPusdTscddGcdAuua udCudGcdAuggugsas u	AUCACCAUGCAGA UU AUGCGGAU	4545
AD-95345 2.1	A-1700965 .1	1100	gsgscag(Chd)uud GadGuuaaagaaa L96	A-1800355.1	1230	VPusdTsuadGudTuua cdTcdAadGcugccsus c	GAGGCAGCUUGAG UUAAAACGAAC	4546
AD-95348 9.1	A-1701039 .1	1101	asusguc(Chd)ucd AcdAccaungaaa L96	A-1800392.1	1231	VPusdTsuudCadAug gudGudGadGgacausa sg	CUAUGUCCUCACA CCAUUUGAAAC	4547
AD-95344 5.1	A-1700951 .1	1102	cscsgca(Ghd)acd GudGuuaaunguc aL96	A-1800348.1	1232	VPusdGsaadCadTuua cdAcdGudCugcggsas u	AUCCGCAGACGUG UAAAUGUUUCC	4548
AD-95343 2.1	A-1700925 .1	1103	csasgaa(Uhd)cad TcdAcgaugggua L96	A-1800335.1	1233	VPusdAsccdAcdTuc gudGadTgdAuueugsc sc	GGCAGAAUACAUA CGAAGUGGUG	4549
AD-95350 9.1	A-1701079 .1	1104	gsusgcu(Ahd)ucd GudTuuaucguaaa L96	A-1800412.1	1234	VPusdTsuadCgdGau aadAcdAgdTagcasc sa	UGGUGCUACUGUU UAUCCGUAAU	4550

AD-95349 0.1	A-1701041 .1	1105	usgsucc(Uhd)cad CadCcauugaacaa L96	A-1800393.1	1235	VPusdGsuudTcdAau ggdTgdTgdAggacasu sa	UAUGUCCUCACAC CAUUGAAACC	4551
AD-95344 8.1	A-1700957 .1	1106	csusgca(Ahd)aad AcdAcagacucgca L96	A-1800351.1	1236	VPusdGsgcdAgdTcu gudGudTudTugcagsg sa	UCCUGCAAAAACA CAGACUCGCG	4552
AD-95345 0.1	A-1700961 .1	1107	gsasggc(Ahd)gcd TudGaguuaaacga L96	A-1800353.1	1237	VPusdCsudTudAac ucdAadGcdTgcucsg sc	GCGAGGCAGCUUG AGUUAACGA	4553
AD-95344 3.1	A-1700947 .1	1108	asusccg(Chd)agd AcdGuguaaangu aL96	A-1800346.1	1238	VPusdAscudTudTaca cdGudCudGcggaucsc u	AGAUCGCGCAGACG UGUAAAUGUU	4554
AD-95352 5.1	A-1701111 .1	1109	gscauu(Uhd)gud TudGuacaagauc aL96	A-1800428.1	1239	VPusdGsaudCudTgu acdAadAcdAaagcsu su	AAGCAUUUGUUUG UACAAAGAUCC	4555
AD-95352 3.1	A-1701107 .1	1110	gsasaag(Chd)aud TudGuuuguaacaa L96	A-1800426.1	1240	VPusdTsugdTadCaaa cdAadAudGcuuucsc c	GAGAAAAGCAUUUG UUUGUACAAAG	4556
AD-95350 7.1	A-1701075 .1	1111	usgsug(Chd)uad CudGuuuaucgu aL96	A-1800410.1	1241	VPusdAsegdGadTaaa cdAgdTadGcaccas u	AUUGGUGCUACUG UUUAUCCGUA	4557
AD-95345 1.1	A-1700963 .1	1112	asgsgea(Chd)cud TgdAguuaaacgaa L96	A-1800354.1	1242	VPusdTsugdTudTaac udCadAgdCugccusc g	CGAGGCAGCUUGA GUUAAAACGAA	4558
AD-95342 9.1	A-1700919 .1	1113	gscaacu(Chd)aad AcdTuucguccaa L96	A-1800332.1	1243	VPusdTsgdAcdGaa aadGudTudCagucsg sa	UCGCACUGAAACU UUUCGUCCAA	4559
AD-95346 9.1	A-1700999 .1	1114	gsascug(Ahd)uad CadGaacgaucgaa L96	A-1800372.1	1244	VPusdTsgdAudCgu ucdTgdTadTcagusc u	AAGACUGAUACAG AACGAUCGAU	4560
AD-95346 3.1	A-1700987 .1	1115	ascsgaa(Chd)gud AcdTugcagaugaa L96	A-1800366.1	1245	VPusdAscudTcdTgca adGudAcdGuucgusc u	AAACGAACGUACU UGCAGAUGUG	4561
AD-95345 4.1	A-1700969 .1	1116	csasgcu(Uhd)gad GudTaaacgaacga L96	A-1800357.1	1246	VPusdCsudTcdGuu uadAcdTcdAagcusc sc	GGCAGCUUGAGUU AAACGAACGU	4562

AD-95345 5.1	A-1700971 .1	1117	asgscuu(Ghd)agd TudAaacgaacgua L96	A-1800358.1	1247	VPusdAscgdTudCgu uudAadCudCaagcug sc	GCAGCUUGAGUUA AACGAACGUA	4563
AD-95351 1.1	A-1701083 .1	1118	gsasuan(Uhd)aad CadTeacgucuuua L96	A-1800414.1	1248	VPusdAsaadGadCgu gadTgdTudAauaucsu su	AAGAUUUUAAACAU CACGUCUUUG	4564
AD-95344 7.1	A-1700955 .1	1119	cscsugc(Ahd)aad AadCacagacuega L96	A-1800350.1	1249	VPusdCsgadGudCug ugdTudTudTgcaggsa sa	UUCUUGCAAAAAC ACAGACUCGC	4565
AD-95342 4.1	A-1700909 .1	1120	gsusgeu(Ghd)gad AudTugauaucaaa L96	A-1800327.1	1250	VPusdTsgadAudAuc aadAudTcdCagcacs g	CGGUGCUGGAAUU UGAUUUUCAU	4566
AD-95350 6.1	A-1701073 .1	1121	ususgu(Ghd)cu dAcdTguuauccg aL96	A-1800409.1	1251	VPusdCsggdAudAaa cadGudAgdCaccaasu sa	UAUUGGUGCUACU GUUUAUCCGU	4567
AD-95353 7.1	A-1701135 .1	1122	asusugg(Uhd)gu dCudTeacuggaug aL96	A-1800440.1	1252	VPusdCsaudCcdAgu gadAgdAcdAccaausa sa	UUUUUGGUGUCUU CACUGGAUGU	4568
AD-95347 7.1	A-1701015 .1	1123	uscsuug(Chd)ugd CudAaaucaccgaa L96	A-1800380.1	1253	VPusdTsggdGudGau uudAgdCadGcaagasa sa	UUUCUUGCUGCUA AAUCACCGAG	4569
AD-95347 9.1	A-1701019 .1	1124	ususgeu(Ghd)cud AadAucaccagca L96	A-1800382.1	1254	VPusdGscudCgdGug audTudAgdCageaasg sa	UCUUGCUGCUAAA UCACCGAGCC	4570
AD-95343 9.1	A-1700939 .1	1125	asgsauu(Ahd)ugd CgdGaucacaacua L96	A-1800342.1	1255	VPusdAsggdTudTga ucdCgdCadTaaucug sc	GCAGAUUAUGCGG AUCAAAACCCUC	4571
AD-95343 1.1	A-1700923 .1	1126	gsgsgca(Ghd)aad TcdAucacgaagua L96	A-1800334.1	1256	VPusdAscudTcdGug audGadTudCugcccsu sc	GAGGGCAGAAUCA UCACGAAGUG	4572
AD-95344 2.1	A-1700945 .1	1127	asusuug(Uhd)uu dGudAcaagaucgg aL96	A-1800345.1	1257	VPusdCsggdAudCuu gudAcdAadAcaausg sc	GCAUUUGUUUUGUA CAAGAUCCGC	4573
AD-95344 9.1	A-1700959 .1	1128	csasaaa(Ahd)cad CadGacucgcuua L96	A-1800352.1	1258	VPusdAsacdGcdGag ucdTgdTgdTuuungsc sa	UGCAAAAACACAG ACUCGCGUUG	4574

AD-95351 0.1	A-1701081 .1	1129	usgsuca(Chd)ugd TudTaucgguaua L96	A-1800413.1	1259	VPusdAsuudAcdGga uadAadCadGuagcasc sc	GGUGCUACUGUUU AUCCGUAAUA	4575
AD-95351 4.1	A-1701089 .1	1130	ascsuu(Uhd)egd TcdCaacucugga L96	A-1800417.1	1260	VPusdCscadGadAgu ugdGadCgdAaaagusu su	AAACUUUUCGUCC AACUUUCUGGG	4576
AD-95350 8.1	A-1701077 .1	1131	gsgsugc(Uhd)acd TgdTuuauccguua L96	A-1800411.1	1261	VPusdTsacdGgdAua aadCadGudAgcaccsa sa	UUGGUGCUACUGU UUAUCCGUAA	4577
AD-95353 1.1	A-1701123 .1	1132	gscsaaa(Ahd)acd AcdAgacucgguua L96	A-1800434.1	1262	VPusdAscgdCgdAgu cudGudGudTuuugcsa sg	CUGCAAAAACACA GACUCGCGUU	4578
AD-95342 7.1	A-1700915 .1	1133	csugsuc(Chd)acd TgdAaacuuucga L96	A-1800330.1	1263	VPusdCsgadAadAgu uudCadGudGcgagcsc sc	GGCGUCGCACUGA AACUUUUCGU	4579
AD-95351 2.1	A-1701085 .1	1134	asusaau(Ahd)acd AudCacgucuuug aL96	A-1800415.1	1264	VPusdCsaadAgdAcd ugdAudGudTaaauusc su	AGAUAUUAACAUC ACGUCUUUGU	4580
AD-95353 3.1	A-1701127 .1	1135	asasaac(Ahd)cad GadCucgguugca L96	A-1800436.1	1265	VPusdGscadAcdGcg agdTcdTgdTguuuusu sg	CAAAAACACAGAC UCGCGUUUGCA	4581
AD-95346 4.1	A-1700989 .1	1136	csusugc(Ahd)gad TgdTgacaagcga L96	A-1800367.1	1266	VPusdCsggdCudTgu cadCadTcdTgcaagsus a	UACUUUGCAGAUU GACAAAGCCGA	4582
AD-95354 2.1	A-1701145 .1	1137	ususuuu(Uhd)uu dCadGuanuucug gaL96	A-1800445.1	1267	VPusdCscadAgdAau acdTgdAadAaaaaacs c	GGUUUUUUUUCAG UAUUCUUUGU	4583
AD-95342 6.1	A-1700913 .1	1138	asasagu(Ghd)agd TgdAccugcuuuua L96	A-1800329.1	1268	VPusdAsaadAgdCag gudCadCudCacuunsg sc	GCAAAAGUGAGUGA CCUGCUUUUG	4584
AD-95351 5.1	A-1701091 .1	1139	ususcgu(Chd)cad AcdTucugggcuga L96	A-1800418.1	1269	VPusdCsagdCcdCaga adGudTgdGacgaasas a	UUUUCGUCCAACU UCUGGGCUGU	4585
AD-95348 7.1	A-1701035 .1	1140	asgsgac(Ahd)uud GcdTgucguuug aL96	A-1800390.1	1270	VPusdCscadAadGcac adGcdAadTguccusgs a	UCAGGACAUUGCU GUGCUUUUGG	4586

AD-95352 1.1	A-1701103 .1	1141	asasauc(Ahd)gud TcdGaggaaaggga L96	A-1800424.1	1271	VPusdCscddTudTccu cdGadAcdTgaunus u	AAAAAUCAGUUCG AGGAAAGGGA	4587
AD-95342 5.1	A-1700911 .1	1142	ususccc(Chd)aad AudCacuguggau aL96	A-1800328.1	1272	VPusdAsucdCadCag ugdAudTudGgggaasg su	ACUUCGCCCAAUC ACUGUGGAUU	4588
AD-95353 6.1	A-1701133 .1	1143	cscscuc(Uhd)ugd GadAuuggaucg aL96	A-1800439.1	1273	VPusdCsgadAudCca audTcdCadAgagggsa sc	GUCCCUUCUUGGAA UUGGAUUCGC	4589
AD-95346 5.1	A-1700991 .1	1144	ususgca(Ghd)aud GudGacaagccgaa L96	A-1800368.1	1274	VPusdTscgdGcdTug uedAcdAudCugcaasg su	ACUUGCAGAUGUG ACAAGCCCGAG	4590
AD-95355 2.1	A-1701165 .1	1145	csascgu(Chd)uud TgdTeucuaugca L96	A-1800455.1	1275	VPusdGscadCudAga gadCadAadGacugsa su	AUCACGUCUUUGU CUCUAGUGCA	4591
AD-95352 8.1	A-1701117 .1	1146	gsasucc(Ghd)cad GadCguguaaanga L96	A-1800431.1	1276	VPusdCsaudTudAcac gdTcdTgdCggaucsus u	AAGAUCGCGCAGAC GUGUAAAUGU	4592
AD-95351 9.1	A-1701099 .1	1147	asasaaa(Uhd)cad GudTcgaggaanga L96	A-1800422.1	1277	VPusdCsundTcdCuc gadAcdTgdAuunuuu su	AAAAAAUUCAGUU CGAGGAAAAGG	4593
AD-95348 6.1	A-1701033 .1	1148	usgscug(Uhd)gg dAcdTugaguugg gaL96	A-1800389.1	1278	VPusdCscddAadCuca adGudCcdAcagcasgs u	ACUGCUUGUGGACU UGAGUUUGGA	4594
AD-95352 2.1	A-1701105 .1	1149	asasggg(Ghd)cad AadAacgaagcga L96	A-1800425.1	1279	VPusdCsgcdTudTcgu udTudTgdCccuunus c	GAAAGGGGCAAAA ACGAAAAGCGC	4595
AD-95353 0.1	A-1701121 .1	1150	usgscaa(Ahd)aad CadCagacucgcga L96	A-1800433.1	1280	VPusdCsgcdGadGuc ugdTgdTudTungcasg sg	CCUGCAAAAACAC AGACUCGCGU	4596
AD-95351 3.1	A-1701087 .1	1151	ascsugc(Uhd)uud GudCucuagugcaa L96	A-1800416.1	1281	VPusdTsgcdAcdTaga gdAcdAadAgacugsgs a	UCACGUCUUUGUC UCUAGUGCAG	4597
AD-95344 1.1	A-1700943 .1	1152	gsrgsca(Ahd)aad AcdGaaagcgcaaa L96	A-1800344.1	1282	VPusdTsgcdCgdCuu uedGudTudTugccsc su	AGGGGCAAAAACG AAAGCGCAAG	4598

AD-95344 0.1	A-1700941 .1	1153	asgsggg(Chd)aad AadAcgaaagcgca L96	A-1800343.1	1283	VPusdGsgcdCudTuc gudTudTudGccccu su	AAAGGGGCAAAA CGAAAGCGCA	4599
AD-95351 8.1	A-1701097 .1	1154	gsasaaa(Ahd)aad AudCaguucgagg aL96	A-1800421.1	1284	VPusdCseudCgdAac ugdAudTudTuuuusu su	AAGAAAAAUAUC AGUUCGAGGA	4600
AD-95352 0.1	A-1701101 .1	1155	asasaau(Chd)agd TudCgaggaagga L96	A-1800423.1	1285	VPusdCseudTudCuc gdAadCudGauuuus u	AAAAAUACAGUUC GAGGAAAGGG	4601
AD-95353 2.1	A-1701125 .1	1156	asasaaa(Chd)acd AgdAcucgcuug aL96	A-1800435.1	1286	VPusdCsaadCgdCga gudCudGudGuuuus gsc	GCAAAACACAGA CUCGCGUUGC	4602
AD-95354 8.1	A-1701157 .1	1157	ususau(Chd)cgd TadAuaauugga L96	A-1800451.1	1287	VPusdCseadCadAuu audTadCgdGauaaac sa	UGUUUAUCCGUAA UAAUUGUGGG	4603
AD-95352 7.1	A-1701115 .1	1158	asgsauc(Chd)gcd AgdAcguguaau aL96	A-1800430.1	1288	VPusdAsuudTadCac gudCudGcdGgaucsu sg	CAAGAUCCGCAGA CGUGUAAAUG	4604
AD-95355 1.1	A-1701163 .1	1159	ususaac(Ahd)ucd AcdGucuuugucu aL96	A-1800454.1	1289	VPusdAsgadCadAag acdGudGadTguuaasu sa	UAUUACAUCACAG UCUUUGUCUC	4605
AD-95355 3.1	A-1701167 .1	1160	csgsuc(Uhd)ugd TedTeuagucgaga L96	A-1800456.1	1290	VPusdCsugdCadCua gadGadCadAagacgsu sg	CACGUCUUUGUCU CUAGUGCAGU	4606
AD-95354 7.1	A-1701155 .1	1161	gsusuua(Uhd)ccd GudAuaauugug aL96	A-1800450.1	1291	VPusdCsacdAadTuau udAcdGgdAuaaacsas g	CUGUUUAUCCGUA AUAAUUGUGG	4607
AD-95352 6.1	A-1701113 .1	1162	ususguu(Uhd)gu dAcdAagaucgca aL96	A-1800429.1	1292	VPusdTsugdGgdAuc uudGudAcdAaacaasa su	AUUUGUUUGUACA AGAUCGCGCAG	4608
AD-95354 9.1	A-1701159 .1	1163	ususauc(Chd)gud AadTaauguggga L96	A-1800452.1	1293	VPusdCsacdAcdAau uadTudAcdGgaauasa sc	GUUUUAUCCGUAAU AAUUGUGGGG	4609
AD-95353 4.1	A-1701129 .1	1164	asascac(Ahd)gad CudCgcguugcaaa L96	A-1800437.1	1294	VPusdTsugdCadAag cgdAgdTcdTguuuusu su	AAAAACACAGACUC GCGUUGCAAG	4610

AD-95354 3.1	A-1701147 .1	1165	ususuu(Uhd)uc dAgdTauucugg uaL96	A-1800446.1	1295	VPusdAsccdAadGaa uadCudGadAaaaaasa sc	GUUUUUUUUCAGU AUUCUUGGUU	4611
AD-95355 0.1	A-1701161 .1	1166	asusuaa(Chd)aud CadCgucuuuguc aL96	A-1800453.1	1296	VPusdGsacdAadAga cgdTgdAudGuuaaaisa su	AUAUUAAACAUCAC GUCUUUGUCU	4612

Table 4B. Exemplary Human VEGF-A siRNA Unmodified Single Strands and Duplex Sequences

Duplex Name	Sense Oligo Name	SEQ ID NO: (Sense)	Sense Sequence	mRNA Target Range	Antisense Oligo Name	SEQ ID NO: (Antisense)	Antisense Sequence	mRNA Target Range
AD-953504.1	A-170106 9.1	1297	AAAUAAGACATUGCU AUUCUA	3361-3381	A-1800407. 1	1427	UAGAAUAGCAATGTCTA UUUUUAU	3359-3381
AD-953481.1	A-170102 3.1	1298	AGUGCUAATGTUAAU GGUGUA	2181-2201	A-1800384. 1	1428	UACACCAAUAAACATUAG CACUGU	2179-2201
AD-953472.1	A-170100 5.1	1299	AUACAGAACGAUCGA UACAGA	1803-1823	A-1800375. 1	1429	UCUGTATCGAUCGTUCU GUAUCA	1801-1823
AD-953517.1	A-170109 5.1	1300	ACAGCACAACAAAUG UGAAUA	1407-1427	A-1800420. 1	1430	UAUUCACAUUUUGUTGTG CUGUAG	1405-1427
AD-953471.1	A-170100 3.1	1301	CUGAUACAGAACGAU CGAUAA	1800-1820	A-1800374. 1	1431	UTAUCGAUCGUTCTGTA UCAGUC	1798-1820
AD-953493.1	A-170104 7.1	1302	GAGAAAAGUGUTUUA UAUACGA	2944-2964	A-1800396. 1	1432	UCGUAAUAAAACACTU UCUCUU	2942-2964
AD-953498.1	A-170105 7.1	1303	AACUAAUUUAUGAGA UGUAUCA	3062-3082	A-1800401. 1	1433	UGAUACAUCUCAUAAA UAGUUGA	3060-3082
AD-953467.1	A-170099 5.1	1304	AAGACUGATACAGAA CGAUCA	1796-1816	A-1800370. 1	1434	UGAUCGTUCUGTATCAG UCUUUC	1794-1816
AD-953545.1	A-170115 1.1	1305	GAGAAUUCTACAUAC UAAAUAA	3416-3436	A-1800448. 1	1435	UAUUTAGUAUGTAGAA UUCUCUA	3414-3436

AD-953466.1	A-1700993.1	1306	AAAGACUGAUACAG AACGAUA	1795-1815	A-1800369.1	1436	UAUCGUTCUGUAUCAGU CUUUC	1793-1815
AD-953494.1	A-1701049.1	1307	ACGGUACUTATUUA UAUCCA	2961-2981	A-1800397.1	1437	UGGATATUAAATAAGTA CCGUUAU	2959-2981
AD-953470.1	A-1701001.1	1308	ACUGAUACAGAACGA UCGAUA	1799-1819	A-1800373.1	1438	UAUCGATCGUUCUGUAU CAGUCU	1797-1819
AD-953473.1	A-1701007.1	1309	CGACAGAACAGUCCU UAAUCA	1855-1875	A-1800376.1	1439	UGAUTAAGGACTGTUCU GUCGAU	1853-1875
AD-953474.1	A-1701009.1	1310	CAGAACAGTCCUUA UCCAGA	1858-1878	A-1800377.1	1440	UCUGGATUAAGGACUG UUCUGUC	1856-1878
AD-953480.1	A-1701021.1	1311	AACAGUGCTAAUGUU AUUGGA	2178-2198	A-1800383.1	1441	UCCAAUAACAUTAGCAC UGUUA	2176-2198
AD-953503.1	A-1701067.1	1312	ACAGUCACTAGCUUA UCUUGA	3164-3184	A-1800406.1	1442	UCAAGATAAGCTAGUGA CUGUCA	3162-3184
AD-953478.1	A-1701017.1	1313	CUUGCUGCTAAAUCA CCGAGA	2011-2031	A-1800381.1	1443	UCUCGGTGAUUTAGCAG CAAGAA	2009-2031
AD-953540.1	A-1701141.1	1314	GAAAGUGUTUTAUUAU ACGGUA	2946-2966	A-1800443.1	1444	UACCGUAUAUAAAACA CUUUCUC	2944-2966
AD-953500.1	A-1701061.1	1315	GCUCUCUUAUTUGUA CCGGUA	3096-3116	A-1800403.1	1445	UACCGGTACAAAUAAGA GAGCAA	3094-3116
AD-953476.1	A-1701013.1	1316	UUCUUGCUGCTAAAU CACCGA	2009-2029	A-1800379.1	1446	UCGGTGAUUUAGCAGCA AGAAA	2007-2029
AD-953492.1	A-1701045.1	1317	CACCAUUGAAACCAC UAGUUA	2791-2811	A-1800395.1	1447	UAACTAGUGGUTUCAAU GGUGUG	2789-2811

AD-953495.1	A-170105.1.1	1318	CGGUACUUUAUTUAAU AUCCCA	2962-2982	A-1800398.1	1448	UGGGAUAUAAUAAG UACCGUA	2960-2982
AD-953497.1	A-170105.5.1	1319	CAACUAUUTATGAGA UGUAUA	3061-3081	A-1800400.1	1449	UAUACATCUCATAAATA GUUGAA	3059-3081
AD-953535.1	A-170113.1.1	1320	UAAUCCAGAAACCUG AAAUGA	1870-1890	A-1800438.1	1450	UCAUTUCAGGUTUCUGG AUUAAG	1868-1890
AD-953505.1	A-170107.1.1	1321	AAAUAGACAUTGCUA UUCUGA	3362-3382	A-1800408.1	1451	UCAGAATAGCAAUGUCU AUUUUA	3360-3382
AD-953524.1	A-170110.9.1	1322	AAAGCAUUTGTUUGU ACAAGA	1611-1631	A-1800427.1	1452	UCUUGUACAAACAAATG CUUUUCU	1609-1631
AD-953475.1	A-170101.1.1	1323	CUUGGAAUTGGAUUC GCCAUA	1982-2002	A-1800378.1	1453	UAUGGCGAAUCCAAATC CAAGAG	1980-2002
AD-953491.1	A-170104.3.1	1324	ACACCAUUGAAACCA CUAGUA	2790-2810	A-1800394.1	1454	UACUAGTGGUUTCAATG GUGUGA	2788-2810
AD-953436.1	A-170093.3.1	1325	AACAUCACCATGCAG AUUAUA	1339-1359	A-1800339.1	1455	UAUAAUCUCGATGGUG AUGUUGG	1337-1359
AD-953502.1	A-170106.5.1	1326	UGACAGUCACTAGCU UAUCUA	3162-3182	A-1800405.1	1456	UAGATAAGCUAGUGAC UGUCACC	3160-3182
AD-953461.1	A-170098.3.1	1327	AGUUAACGAACGU ACUUGCA	1694-1714	A-1800364.1	1457	UGCAAGTACGUTCUTU AACUCA	1692-1714
AD-953544.1	A-170114.9.1	1328	ACUAUUUATGAGAUG UAUCUA	3063-3083	A-1800447.1	1458	UAGATACAUCUCATAAA UAGUUG	3061-3083
AD-953462.1	A-170098.5.1	1329	UUAACGAACGUACU UGCAGA	1696-1716	A-1800365.1	1459	UCUGCAAGUACGUTCUGU UUAACU	1694-1716

AD-953496. 1	A-170105 3.1	1330	GGUACUUATUTAAUA UCCCUA	2963- 2983	A-1800399. 1	1460	UAGGGATAUUAATAA GUACCGU	2961- 2983
AD-953516. 1	A-170109 3.1	1331	CGAAGUGGTGAAGUU CAUGGA	1152- 1172	A-1800419. 1	1461	UCCATGAACUUCACCCAC UUCGUG	1150- 1172
AD-953483. 1	A-170102 7.1	1332	UGUUAUUGGUGUCU UCACUGA	2189- 2209	A-1800386. 1	1462	UCAGTGAAGACACCAAU AACAUU	2187- 2209
AD-953499. 1	A-170105 9.1	1333	UUGCUCUCTUAUUUG UACCGA	3094- 3114	A-1800402. 1	1463	UCGGTACAAAUAAAGAG AGCAAGA	3092- 3114
AD-953541. 1	A-170114 3.1	1334	GUUUUAUATACGGUA CUUAUA	2952- 2972	A-1800444. 1	1464	UAUAAGTACCGTATATA AAACAC	2950- 2972
AD-953538. 1	A-170113 7.1	1335	UCACUGGATGTAUUU GACUGA	2203- 2223	A-1800441. 1	1465	UCAGTCAAAUACATCCA GUGAAG	2201- 2223
AD-953430. 1	A-170092 1.1	1336	CCUCCGAAACCAUGA ACUUUA	1028- 1048	A-1800333. 1	1466	UAAAGUTCAUGGUTUCG GAGGCC	1026- 1048
AD-953485. 1	A-170103 1.1	1337	UAUUGGUGTCTUCAC UGGAUA	2192- 2212	A-1800388. 1	1467	UAUCCAGUGAAGACACC AAUAAAC	2190- 2212
AD-953468. 1	A-170099 7.1	1338	AGACUGAUACAGAAC GAUCGA	1797- 1817	A-1800371. 1	1468	UCGATCGUUCUGUAUCA GUCUUU	1795- 1817
AD-953444. 1	A-170094 9.1	1339	UCCGCAGACGTGUA AUGUUA	1632- 1652	A-1800347. 1	1469	UAACAUTUACACGTCTG CGGAUC	1630- 1652
AD-953460. 1	A-170098 1.1	1340	GAGUUAACGAACG UACUUGA	1693- 1713	A-1800363. 1	1470	UCAAGUACGUUCGTUTA ACUCA	1691- 1713
AD-953539. 1	A-170113 9.1	1341	AGAAAGUGTUTUAUA UACGGA	2945- 2965	A-1800442. 1	1471	UCCGTATAUAAAACACU UUCUCU	2943- 2965

AD-953484.1	A-170102 9.1	1342	GUUAUUGGTGTCUUC ACUGGA	2190-2210	A-1800387. 1	1472	UCCAGUGAAGACACCAA UAACAU	2188-2210
AD-953457.1	A-170097 5.1	1343	CUUGAGUUAAACGA ACGUACA	1690-1710	A-1800360. 1	1473	UGUACGTUCGUTUAA CAAGCU	1688-1710
AD-953459.1	A-170097 9.1	1344	UGAGUUAAACGAAC GUACUUA	1692-1712	A-1800362. 1	1474	UAAGTACGUUCGUTUAA CUCAAG	1690-1712
AD-953437.1	A-170093 5.1	1345	AUCACCAUGCAGAUU AUGCGA	1342-1362	A-1800340. 1	1475	UCGCAUAAUCUGCAUG GUGAUGU	1340-1362
AD-953458.1	A-170097 7.1	1346	UUGAGUUAAACGAA CGUACUA	1691-1711	A-1800361. 1	1476	UAGUACGUUCGTUTAAC UCAAGC	1689-1711
AD-953453.1	A-170096 7.1	1347	GCAGCUUGAGTUAAA CGAACA	1686-1706	A-1800356. 1	1477	UGUUCGTUUAACUCAAG CUGCCU	1684-1706
AD-953428.1	A-170091 7.1	1348	CGCACUGAAACUUUU CGUCCA	648-668	A-1800331. 1	1478	UGGACGAAAAGTUTCAG UGCGAC	646-668
AD-953501.1	A-170106 3.1	1349	UCGGUGACAGTCACU AGCUUA	3158-3178	A-1800404. 1	1479	UAAGCUAGUGACUGUC ACCGAUC	3156-3178
AD-953482.1	A-170102 5.1	1350	GUGCUAAUGUTAUUG GUGUCA	2182-2202	A-1800385. 1	1480	UGACACCAAUAACAUTA GCACUG	2180-2202
AD-953446.1	A-170095 3.1	1351	CGCAGACGTGTAAAU GUUCCA	1634-1654	A-1800349. 1	1481	UGGAACAUAUACACGTC UGCGGA	1632-1654
AD-953488.1	A-170103 7.1	1352	AGAGAAGAGACACA UUGUUGA	2673-2693	A-1800391. 1	1482	UCAACAAUGUGTCTCTU CUCUUC	2671-2693
AD-953434.1	A-170092 9.1	1353	UGAAGUUCAUUGGAU GUCUAUA	1160-1180	A-1800337. 1	1483	UAUAGACAUCCAUGAA CUUCACC	1158-1180

AD-953546.1	A-170115 3.1	1354	AAUUCUACAUACUAA AUCUCA	3419-3439	A-1800449. 1	1484	UGAGAUTUAGUAUGUA GAAUUCU	3417-3439
AD-953529.1	A-170111 9.1	1355	CAGACGUGTAAAUUGU UCCUGA	1636-1656	A-1800432. 1	1485	UCAGGAACAUAUACACG UCUGCG	1634-1656
AD-953433.1	A-170092 7.1	1356	CACGAAGUGGTGAAG UUCAUA	1150-1170	A-1800336. 1	1486	UAUGAACUUCACCACTU CGUGAU	1148-1170
AD-953456.1	A-170097 3.1	1357	GCUUGAGUTAAACGA ACGUAA	1689-1709	A-1800359. 1	1487	UTACGUTCGUUTAACTC AAGCUG	1687-1709
AD-953435.1	A-170093 1.1	1358	CAUCUUCAGCCCAUC CUGUGA	1251-1271	A-1800338. 1	1488	UCACAGGAUGGCUTGAA GAUGUA	1249-1271
AD-953438.1	A-170093 7.1	1359	CACCAUGCAGAUUAU GCGGAA	1344-1364	A-1800341. 1	1489	UTCCGCAUAAUCUGCAU GGUGAU	1342-1364
AD-953452.1	A-170096 5.1	1360	GGCAGCUUGAGUUA AACGAAA	1685-1705	A-1800355. 1	1490	UTUCGUTUAACTCAAGC UGCCUC	1683-1705
AD-953489.1	A-170103 9.1	1361	AUGUCCUCACACCAU UGAAAA	2782-2802	A-1800392. 1	1491	UTUUCAAUGGUGUGAG GACAUAG	2780-2802
AD-953445.1	A-170095 1.1	1362	CCGCAGACGUGUAAA UGUUCA	1633-1653	A-1800348. 1	1492	UGAACATUUACACGUCU GCGGAU	1631-1653
AD-953432.1	A-170092 5.1	1363	CAGAAUCATCACGAA GUGGUA	1141-1161	A-1800335. 1	1493	UACCACTUCGUGATGAU UCUGCC	1139-1161
AD-953509.1	A-170107 9.1	1364	GUGCUACUGUTUAUC CGUAAA	3481-3501	A-1800412. 1	1494	UTUACGGAUAAACAGTA GCACCA	3479-3501
AD-953490.1	A-170104 1.1	1365	UGUCCUCACACCAU GAAACA	2783-2803	A-1800393. 1	1495	UGUUTCAAUGGTGTGAG GACAU	2781-2803

AD-953448. 1	A-170095 7.1	1366	CUGCAAAAACACAGA CUCGCA	1653- 1673	A-1800351. 1	1496	UGCGAGTCUGUGUTUTU GCAGGA	1651- 1673
AD-953450. 1	A-170096 1.1	1367	GAGCAGCTUGAGUU AAACGA	1683- 1703	A-1800353. 1	1497	UCGUTUAAACUCAAAGCTG CCUCGC	1681- 1703
AD-953443. 1	A-170094 7.1	1368	AUCCGCAGACGUGUA AAUGUA	1631- 1651	A-1800346. 1	1498	UACATUTACACGUCUCG GGAUCU	1629- 1651
AD-953525. 1	A-170111 1.1	1369	GCAUUUGUTUGUACA AGAUA	1614- 1634	A-1800428. 1	1499	UGAUCUTGUACAAACAA AUGCUU	1612- 1634
AD-953523. 1	A-170110 7.1	1370	GAAAGCAUTUGUUUG UACAAA	1610- 1630	A-1800426. 1	1500	UTUGTACAAACAAAUAGC UUUCUC	1608- 1630
AD-953507. 1	A-170107 5.1	1371	UGGUGCUACUGUUU AUCCGUA	3479- 3499	A-1800410. 1	1501	UACGGATAAACAGTAGC ACCAAU	3477- 3499
AD-953451. 1	A-170096 3.1	1372	AGCAGCUTGAGUUA AACGAA	1684- 1704	A-1800354. 1	1502	UTC GTU TAA CUC AAGCU GCCUCG	1682- 1704
AD-953429. 1	A-170091 9.1	1373	GCACUGAAACTUUUC GUCCAA	649- 669	A-1800332. 1	1503	UTGGACGAAAAGUTUCA GUGCGA	647- 669
AD-953469. 1	A-170099 9.1	1374	GACUGAUACAGAAACG AUCGAA	1798- 1818	A-1800372. 1	1504	UTC GAUCGUUCTGTATC AGUCUU	1796- 1818
AD-953463. 1	A-170098 7.1	1375	ACGAACGUACTUGCA GAUGUA	1700- 1720	A-1800366. 1	1505	UACATCTGCAAGUACGU UCGUUU	1698- 1720
AD-953454. 1	A-170096 9.1	1376	CAGCUUGAGUTAAAC GAACGA	1687- 1707	A-1800357. 1	1506	UCGUTC GUUUA AACTCAA GCUGCC	1685- 1707
AD-953455. 1	A-170097 1.1	1377	AGCUUGAGTUAACG AACGUA	1688- 1708	A-1800358. 1	1507	UACGTUCGUUUAACUCA AGCUCG	1686- 1708

AD-953511.1	A-170108 3.1	1378	GAUUAUAAACATCAG UCUUUA	3516-3536	A-1800414. 1	1508	UAAAGACGUGATGTUAA UAUCUU	3514-3536
AD-953447.1	A-170095 5.1	1379	CCUGCAAAAACACAG ACUCGA	1652-1672	A-1800350. 1	1509	UCGAGUCUGUGTUTG CAGGAA	1650-1672
AD-953424.1	A-170090 9.1	1380	GUGCUGGAAUTUGAU AUUCAA	125-145	A-1800327. 1	1510	UTGAAUAUCAAUAUTCCA GCACCG	123-145
AD-953506.1	A-170107 3.1	1381	UUGGUGCUACTGUUU AUCCGA	3478-3498	A-1800409. 1	1511	UCGGAUAAACAGUAGC ACCAAUA	3476-3498
AD-953537.1	A-170113 5.1	1382	AUUGGUGUCUTCACU GGAUGA	2193-2213	A-1800440. 1	1512	UCAUCCAGUGAAGACAC CAAUAA	2191-2213
AD-953477.1	A-170101 5.1	1383	UCUUGCUGCUAAAUC ACCGAA	2010-2030	A-1800380. 1	1513	UTC GGUGAUUUAGCAGC AAGAAA	2008-2030
AD-953479.1	A-170101 9.1	1384	UUGCUGCUAAAUCAC CGAGCA	2012-2032	A-1800382. 1	1514	UGCUCGGUGAUTUAGCA GCAAGA	2010-2032
AD-953439.1	A-170093 9.1	1385	AGAUUAUGCGGAUC AAACCUA	1352-1372	A-1800342. 1	1515	UAGGTUTGAUCCGCATA AUCUGC	1350-1372
AD-953431.1	A-170092 3.1	1386	GGCAGAAATCAUCAC GAAGUA	1138-1158	A-1800334. 1	1516	UACUTCUGAUGATUCU GCCCCUC	1136-1158
AD-953442.1	A-170094 5.1	1387	AUUUGUUUGUACAA GAUCCGA	1616-1636	A-1800345. 1	1517	UCGGAUCUUGUACAAA CAAAUGC	1614-1636
AD-953449.1	A-170095 9.1	1388	CAAAAACACAGACUC GCGUUA	1656-1676	A-1800352. 1	1518	UAACGCGAGUCTGTGTU UUUGCA	1654-1676
AD-953510.1	A-170108 1.1	1389	UGCACUGTUTAUC GUAAUA	3482-3502	A-1800413. 1	1519	UAUUACGGAUAAACAG UAGCACC	3480-3502

AD-953514.1	A-170108 9.1	1390	ACUUUUCGTCCAACU UCUGGA	657-677	A-1800417. 1	1520	UCCAGAAAGUUGGACGA AAAGUUU	655-677
AD-953508.1	A-170107 7.1	1391	GGUGCUACTGTUUUAU CCGUAA	3480-3500	A-1800411. 1	1521	UTACGGGAUAAACAGUA GCACCAA	3478-3500
AD-953531.1	A-170112 3.1	1392	GCAAAAACACAGACU CGCGUA	1655-1675	A-1800434. 1	1522	UACGCGAGUCUGUGUTU UUGCAG	1653-1675
AD-953427.1	A-170091 5.1	1393	CGUCGCACTGAAACU UUUCGA	645-665	A-1800330. 1	1523	UCGAAAAGUUUCAGUG CGACGCC	643-665
AD-953512.1	A-170108 5.1	1394	AUAUUAACAUCACGU CUUUGA	3517-3537	A-1800415. 1	1524	UCAAAGACGUGAUGUT AAUAUCU	3515-3537
AD-953533.1	A-170112 7.1	1395	AAAACACAGACUCGC GUUGCA	1658-1678	A-1800436. 1	1525	UGCAAACGCGAGTCTGTG UUUUUG	1656-1678
AD-953464.1	A-170098 9.1	1396	CUUGCAGATGTGACA AGCCGA	1709-1729	A-1800367. 1	1526	UCGGCUTGUCACATCTG CAAGUA	1707-1729
AD-953542.1	A-170114 5.1	1397	UUUUUUUCAGUAU UCUUGGA	3027-3047	A-1800445. 1	1527	UCCAAGAAUACTGAAA AAAACC	3025-3047
AD-953426.1	A-170091 3.1	1398	AAAGUGAGTGACCUG CUUUUA	415-435	A-1800329. 1	1528	UAAAAGCAGGUCACUC ACUUUGC	413-435
AD-953515.1	A-170109 1.1	1399	UUCGUCCAACUUCUG GGCUGA	661-681	A-1800418. 1	1529	UCAGCCCCAGAAGUTGGA CGAAAA	659-681
AD-953487.1	A-170103 5.1	1400	AGGACAUUGCTGUGC UUUGGA	2518-2538	A-1800390. 1	1530	UCCAAAGCACAGCAATG UCCUGA	2516-2538
AD-953521.1	A-170110 3.1	1401	AAAUACAGUTCAGGA AAGGGA	1462-1482	A-1800424. 1	1531	UCCCTUTCCUCGAACTG AUUUUU	1460-1482

AD-953425.1	A-1700911.1	1402	UCCCCAAAUACACUGUGGAUA	278-298	A-1800328.1	1532	UAUCCACAGUGAUTUGGGAAAGU	276-298
AD-953536.1	A-1701133.1	1403	CCCUUUUGGAAUUUGGAUUCGA	1978-1998	A-1800439.1	1533	UCGAAUCCAAUTCCAAGAGGGAC	1976-1998
AD-953465.1	A-1700991.1	1404	UUGCAGAUUGUGACAAGCCGAA	1710-1730	A-1800368.1	1534	UTC GGCTUGUCACAUCUGCAAAGU	1708-1730
AD-953552.1	A-1701165.1	1405	CAGUCUUUTGTCUCUAGUGCA	3527-3547	A-1800455.1	1535	UGCACUAGAGACAAAAGACGUGAU	3525-3547
AD-953528.1	A-1701117.1	1406	GAUCCGCAGACGUGUAAAUGA	1630-1650	A-1800431.1	1536	UCAUTUACACGTCTGCGGAUCUU	1628-1650
AD-953519.1	A-1701099.1	1407	AAAAAUCAGUTCAGAGAAAGA	1460-1480	A-1800422.1	1537	UCUUTCCUCGAACTGAUUUUUUU	1458-1480
AD-953486.1	A-1701033.1	1408	UGCUGUGGACTUGAGUUGGGA	2221-2241	A-1800389.1	1538	UCCCAACUCAAGUCCACAGCAGU	2219-2241
AD-953522.1	A-1701105.1	1409	AAGGGGCAAAAACGAAAGCGA	1483-1503	A-1800425.1	1539	UCGCTUTCGUUTUTGCCCCUUUC	1481-1503
AD-953530.1	A-1701121.1	1410	UGCAAAAACACAGACUCGCGA	1654-1674	A-1800433.1	1540	UCGCGAGUCUGTGTUTUUGCAGG	1652-1674
AD-953513.1	A-1701087.1	1411	ACGUCUUUGUCUCUAGUGCAA	3528-3548	A-1800416.1	1541	UTGCACTAGAGACAAAAGACGUGA	3526-3548
AD-953441.1	A-1700943.1	1412	GGGCAAAAACGAAAGCGCAA	1486-1506	A-1800344.1	1542	UTUGCGCUUUCGUTUTUUGCCCUU	1484-1506
AD-953440.1	A-1700941.1	1413	AGGGGCAAAAACGAAGCGCA	1484-1504	A-1800343.1	1543	UGCGCUTUCGUTUTUUGCCCUU	1482-1504

AD-953518.1	A-170109 7.1	1414	GAAAAAAAUACAGU UCGAGGA	1456-1476	A-1800421. 1	1544	UCCUCGAAACUGAUTUTU UUUCUU	1454-1476
AD-953520.1	A-170110 1.1	1415	AAAUCAGTUCGAGG AAAGGA	1461-1481	A-1800423. 1	1545	UCCUTUCCUCGAAACUGA UUUUUU	1459-1481
AD-953532.1	A-170112 5.1	1416	AAAACACAGACUCG CGUUGA	1657-1677	A-1800435. 1	1546	UCAACGCGAGUCUGUG UUUUUUGC	1655-1677
AD-953548.1	A-170115 7.1	1417	UUUAUCCGTAAUAAU UGUGGA	3490-3510	A-1800451. 1	1547	UCCACAAUUUAUTACGGA UAAACA	3488-3510
AD-953527.1	A-170111 5.1	1418	AGAUCCGCAGACGUG UAAAUAA	1629-1649	A-1800430. 1	1548	UAUUTACACGUCUGCGG AUCUUG	1627-1649
AD-953551.1	A-170116 3.1	1419	UUAACAUCACGUCUU UGUCUA	3520-3540	A-1800454. 1	1549	UAGACAAAAGACGUGAT GUUAAUA	3518-3540
AD-953553.1	A-170116 7.1	1420	CGUCUUUGTCTCUAG UGCAGA	3529-3549	A-1800456. 1	1550	UCUGCACUAGAGACAA AGACGUG	3527-3549
AD-953547.1	A-170115 5.1	1421	GUUUAUCCGUAAUA AUUGUGA	3489-3509	A-1800450. 1	1551	UCACAAUUAUACGGAU AAACAG	3487-3509
AD-953526.1	A-170111 3.1	1422	UGUUUGUACAAGA UCCGCAA	1618-1638	A-1800429. 1	1552	UTGCGGAUCUUGUACAA ACAAAU	1616-1638
AD-953549.1	A-170115 9.1	1423	UUAUCCGUAAATAAUU GUGGGA	3491-3511	A-1800452. 1	1553	UCCACAAUUAUACGG AUAAAC	3489-3511
AD-953534.1	A-170112 9.1	1424	AACACAGACUCGCGU UGCAAA	1660-1680	A-1800437. 1	1554	UTUGCAACGCGAGTCTG UGUUUU	1658-1680
AD-953543.1	A-170114 7.1	1425	UUUUUUCAGTAUUC UUGGUA	3028-3048	A-1800446. 1	1555	UACCAAGAAUACUGAA AAAAAAC	3026-3048

AD-953550.1	A-170116 1.1	1426	AUUAACAUCACGUCU UUGUCA	3519-3539	A-1800453.1	1556	UGACAAAGACGTGAUG UUAAUUAU	3517-3539
-------------	-----------------	------	---------------------------	-----------	-------------	------	------------------------------	-----------

Table 5A. Exemplary Rat VEGF-A siRNA Modified Single Strands and Duplex Sequences. The mRNA target sequence refers to the target sequence in rat; the corresponding human target sequence may differ.

Duplex Name	Sense Oligo Name	SEQ ID NO: (Sense)	Sense Sequence	Antisense Oligo Name	SEQ ID NO: (Antisense)	Antisense Sequence	mRNA target sequence	SEQ ID NO: (mRNA target)
AD-579911.1	A-1110768.1	1557	csgsgaa(Ahd)CfuUfUfUfcguccaacsusa	A-1100967.1	1644	VPusAfsuuGfgAfCf gaaaAfgUfuuccgsug	CACGGAAACUU UUCGUCCAACU U	4613
AD-579912.1	A-1110769.1	1558	gsgsaaa(Chd)UfuUfUfCfguccaacsusa	A-1100969.1	1645	VPusAfsaguUfgGfAfcgaaAfaGfuuccgsu	ACGGAAACUUU UCGUCCAACUU C	4614
AD-579913.1	A-1110770.1	1559	csgsaga(Ghd)AfaCfa fGfuuccuaauscsa	A-1102172.1	1646	VPusGfsauuAfaGfGf acugUfuCfugucgsasc	GUCGACAGAAC AGUCCUUAAUC C	4615
AD-579914.1	A-1110771.1	1560	csusgcu(Ahd)AfuGfUfUfauugguguscsa	A-1102638.1	1647	VPusGfsacaCfcAfAfu aacAfuUfagcagsasg	CUCUGCUAAUG UUAUUGGUGUC U	4616
AD-579915.1	A-1110772.1	1561	uscscga(Ghd)AfuAfUfUfccguaguascsa	A-1103944.1	1648	VPusGfsuacUfaCfGf gaauAfuCfucggsasa	UUUCCGAGAU UUCCGUAGUAC A	4617
AD-579916.1	A-1110773.1	1562	csgsaga(Uhd)AfuUfCfCfuguaguacacsusa	A-1103888.1	1649	VPusAfsuguAfcUfAfcggaAfuAfuucucgsa	UCCGAGAUUU CCGUAGUACAU A	4618
AD-579917.1	A-1110774.1	1563	gscsacg(Ghd)AfaAfCfUfuuccguccsasa	A-1100961.1	1650	VPusUfsggaCfGfAfaaaguUfuCfucggsasa	UUGCACGGAAA CUUUUCGUCCA A	4619
AD-579918.1	A-1110775.1	1564	csascgg(Ahd)AfaCfUfUfuuccguccasasa	A-1100963.1	1651	VPusUfsggAfcGfAfaaagUfuUfccggsasa	UGCACGGAAAC UUUUCGUCCA C	4620

AD-579919.1	A-1110776.1	1565	gsasgau(Ahd)UfuCfCfGfuaguacausasa	A-1103889.1	1652	VPusUfsaugUfaCfUfacggAfaUfaucucsgsg	CCGAGAUUAUUC CGUAGUACAUA U	4621
AD-579921.1	A-1110778.1	1566	ususgu(Uhd)GfuCfCfAfagaucgcsasa	A-1101976.1	1653	VPusUfsgegGfaUfCfuuaggAfcAfaacaasasu	AUUUGUUUGUC CAAGAUCGCGA G	4622
AD-579922.1	A-1110779.1	1567	ascsgga(Ahd)AfcUfUfUfucguccaasasa	A-1100965.1	1654	VPusGfsuugGfaCfGfaaaaGfuUfuccgsgsc	GCACGGAAACU UUUCGUCCAAC U	4623
AD-579923.1	A-1110780.1	1568	asuscuu(Ghd)CfGfGfAfUfcaaacucgsasa	A-1101742.1	1655	VPusUfsaggGfuUfUfgaucCfGcfgaugauscu	AGAUCAUUGCG AUCAAAACCUCA C	4624
AD-579924.1	A-1110781.1	1569	asusgag(Ghd)AfuCfAfAfaccuaccsasa	A-1101659.1	1656	VPusUfsagguGfaGfGfuuuagAfuCfegcausgsa	UCAUGCGGAUC AAACCUCACCA A	4625
AD-579925.1	A-1110782.1	1570	gsasuca(Uhd)GfcGfGfAfucuaaacucgsasa	A-1101740.1	1657	VPusGfsaggUfuUfGfaucceGfcAfugaucsusg	CAGAUCAUGCG GAUCAAAACCUC A	4626
AD-579926.1	A-1110783.1	1571	ususgu(Uhd)UfgUfCfCfaagaucgcsasa	A-1101974.1	1658	VPusGfscggAfuCfUfuggaCfaAfacaasusg	CAUUUGUUUGU CCAAAGAUCCGC A	4627
AD-579927.1	A-1110784.1	1572	gsasucg(Ghd)UfgAfCfAfagucacuagcsasa	A-1103783.1	1659	VPusGfscuaGfuGfAfucuguCfaCfegaucsusg	CAGAUCCGUGA CAGUCACUAGC U	4628
AD-579929.1	A-1110786.1	1573	asasgau(Chd)CfGfCfAfGfagcuguuaasasa	A-1101968.1	1660	VPusUfsuuaCfaCfGfucugCfGfauucucsgsg	CCAAGAUCCGC AGACGUGUAAA U	4629
AD-579930.1	A-1110787.1	1574	usgsucc(Ahd)AfgAfUfCfegcagacgsusa	A-1101986.1	1661	VPusAfsccuGfuGfCfggauCfuUfggacasa	UUUGUCCAAGA UCCGCAGACGU G	4630
AD-579931.1	A-1110788.1	1575	asuscac(Ghd)UfcUfUfUfgucucuaasasa	A-1103887.1	1662	VPusUfscuaGfaGfAfcacaaGfaCfegaugusgu	ACAUACACGUCU UUGUCUCUAGA G	4631
AD-579932.1	A-1110789.1	1576	usgsaaa(Chd)CfaUfGfAfacuucugcsasa	A-1101283.1	1663	VPusGfscagAfaAfGfuucaUfgGfuucuasgsa	UCUGAAACCAU GAACUUUCUGC U	4632

AD-579933.1	A-1110790.1	1577	ususgu(Uhd)CfuAfGfAfgcaguuscsa	A-1103908.1	1664	VPusGfsaaaAfcUfGfcucuAfgAfgacaasag	CUUUGUCUCUA GAGCAGUUUUC C	4633
AD-579934.1	A-1110791.1	1578	csasuu(Chd)CfaGfAfAfacagacasasa	A-1102962.1	1665	VPusUfsuguCfGfUfGfuucUfgGfaagugsag	CUCACUUCCAG AAACACGACAA A	4634
AD-579935.1	A-1110792.1	1579	usgsaaa(Uhd)CfuGfUfgfuuccaauuscsa	A-1103728.1	1666	VPusGfsauuGfgAfAfacacAfgAfuucasusa	UAUGAAAUCUG UGUUUCCAAUC U	4635
AD-579936.1	A-1110793.1	1580	gsasaau(Chd)UfgUfGfUfuuccaauuscsa	A-1103730.1	1667	VPusAfsgauUfgGfAfaaCfaGfaauucasu	AUGAAAUCUGU GUUUCCAUCU C	4636
AD-579937.1	A-1110794.1	1581	ususgu(Uhd)UfcUfAfGfagcaguususa	A-1103906.1	1668	VPusAfsaaaCfuGfCfucuaGfaGfaaasgsa	UCUUUGUCUCU AGAGCAGUUUU C	4637
AD-579938.1	A-1110795.1	1582	usgsuu(Chd)UfaGfAfGfagcaguuscsa	A-1103910.1	1669	VPusGfsaaaAfaCfUfgcucUfaGfagacasasa	UUUGUCUCUAG AGCAGUUUUC G	4638
AD-579939.1	A-1110796.1	1583	asascug(Uhd)AfuUfGfUfuuaacguususa	A-1100541.1	1670	VPusAfsageGfuAfaaAfaAfcaguususa	UAAACUGUAUU GUUUUACGCUU U	4639
AD-579940.1	A-1110797.1	1584	ascsugu(Ahd)UfuGfUfuuaacguususa	A-1100543.1	1671	VPusAfsaagCfGfUfaaAfaUfacagususu	AAACUGUAUUG UUUUACGCUU A	4640
AD-579941.1	A-1110798.1	1585	csusgua(Uhd)UfgUfUfuacguusasa	A-1100545.1	1672	VPusUfsaaaGfcGfUfaaaaCfaAfuacagusu	AACUGUAUUGU UUUACGCUUUA A	4641
AD-579942.1	A-1110799.1	1586	usgsuau(Uhd)GfuUfUfuacguuuaasasa	A-1100547.1	1673	VPusUfsuaaAfgCfGfuuaaAfaAfuacagusu	ACUGUAUUGUU UUACGCUUUA U	4642
AD-579943.1	A-1110800.1	1587	asusuga(Ahd)AfcCfAfCfuuaucguusasa	A-1103504.1	1674	VPusAfsacagAfaUfUfagugGfuUfucaausgs	CCAUUGAAACC ACUAAUUCUGU C	4643
AD-579944.1	A-1110801.1	1588	ascsuua(Uhd)UfuAfAfUfagcccuususa	A-1103594.1	1675	VPusAfsaaaGfgGfCfuuaaAfaAfuacagusasc	GUACUUAUUUA AUAGCCCUUUU U	4644

AD-579945.1	A-1110802.1	1589	uscsuc(Ahd)GfaGfCfAfguuuuccgsasa	A-1103914.1	1676	VPusUfscggAfaAfaFfcugcUfcUfagagascsa	UGUCUCUAGAGCAGUUUUCCGA _G	4645
AD-579946.1	A-1110803.1	1590	csccgag(Ahd)UfaUfUfCfcgguaguacsasa	A-1103946.1	1677	VPusUfsguaCfuAfaCf ggaaUfaUfcuggsasa	UUCCGAGAUU UCCGUAGUACA _U	4646
AD-579947.1	A-1110804.1	1591	uscsugg(Ghd)AfuUfUfGfauuuaaasasa	A-1100511.1	1678	VPusUfsuugAfaUfaFfcuaaAfuCfccagasc	GCUCUGGGAUUUGAUUUUCAAA _C	4647
AD-579948.1	A-1110805.1	1592	ususcac(Uhd)GfaGfUfAfuuguuacsasa	A-1102658.1	1679	VPusAfsugcAfaAfaCf auauCfcAfgugaasgsa	UCUUCACUGGAUAUGUUUGACU _G	4648
AD-579949.1	A-1110806.1	1593	gsgscuc(Ahd)CfuUfCfCfagaacacsasa	A-1102954.1	1680	VPusCfsgugUfuUfCf uggaAfgUfgagccsasa	UUGGCUCACUUCCAGAAACACG _A	4649
AD-579950.1	A-1110807.1	1594	csusucc(Ahd)GfaAfaCfCfagcaaaacsasa	A-1102966.1	1681	VPusGfsuuGfuCfGf uguuUfcUfggaagsug	CACUUCACAGAAACACGACAAAC _C	4650
AD-579951.1	A-1110808.1	1595	gsasca(Uhd)UfgAfAfAfcacuaaasasa	A-1103496.1	1682	VPusAfsauuAfgUfgGf guuuCfaAfggucsug	CAGACCAUUGAAACACACUAAU _C	4651
AD-579953.1	A-1110810.1	1596	agsuca(Chd)UfaGfCfUfuguccugasasa	A-1103805.1	1683	VPusCfsucaGfgAfaCf aagcUfaGfugacussu	ACAGUCACUAGCUUGUCCUGAG _A	4652
AD-579954.1	A-1110811.1	1597	ascscac(Ahd)CfaUfUfCfcuuugaasasa	A-1103837.1	1684	VPusAfsuuuCfaAfaFfggaaUfgUfggusgsg	CCACCACACAUUCCUUUGAAA _A	4653
AD-579955.1	A-1110812.1	1598	ascscgg(Ahd)AfaGfAfCfcgaauaacsasa	A-1102128.1	1685	VPusGfsguuAfaUfCf ggucUfuUfcggusgsa	UCACCCGGAAGACCGAUUAACC _A	4654
AD-579956.1	A-1110813.1	1599	agsacc(Ghd)AfuUfAfAfcgaugacsasa	A-1102142.1	1686	VPusGfsugaCfaUfGf guuaAfuCfugucussu	AAAGACCGAUUAAACAUUCAC _C	4655
AD-579957.1	A-1110814.1	1600	csusuca(Chd)UfgGfAfUfanguuacsasa	A-1102656.1	1687	VPusGfsucaAfaCfaFfuauCfaGfugaasasc	GUCUUCACUGGAUAUGUUUGAC _U	4656

AD-579958.1	A-1110815.1	1601	ususggc(Uhd)CfaCfUfUfccagaaacsasa	A-1102950.1	1688	VPusUfsuuUfcUfGf gaagUfgAfgccaacs g	CGUUGGCUCACUCCAGAAACA	4657
AD-579959.1	A-1110816.1	1602	csuscac(Uhd)UfcCfAfGfaaacacgascsa	A-1102958.1	1689	VPusGfsuugUfgUfUf ucugGfaAfgugagsc	GGCUCACUUCAGAAACACGAC	4658
AD-579960.1	A-1110817.1	1603	gsusgac(Ahd)GfuCfAfCfuagcuugscsa	A-1103795.1	1690	VPusGfsacaAfgCfUf agugAfcUfgucacs g	CGGUGACAGUCACUAGCUUGUC	4659
AD-579961.1	A-1110818.1	1604	gsuscuc(Uhd)AfgAfGfCfaguuuccsgsa	A-1103912.1	1691	VPusCfsuggaAfaAfcf ugcuCfuAfgagacs a	UUGUCUCUAGAGCAGUUUUUCCG	4660
AD-579962.1	A-1110819.1	1605	csuscua(Ghd)AfgCfAfGfuuuuuccgasa	A-1103916.1	1692	VPusCfsucgGfaAfa f acugCfuCfuagags a	GUCUCUAGAGCAGUUUUUCCGAG	4661
AD-579963.1	A-1110820.1	1606	gsuuuu(Chd)CfGfAfGfAfuaauccgusa	A-1103936.1	1693	VPusUfsacgGfaAfa f aucuCfGfGfaaaacs g	CAGUUUUUCCGAGAUUUUCCGUA	4662
AD-579964.1	A-1110821.1	1607	ususccg(Ahd)GfaUfAfUfuccguagusa	A-1103942.1	1694	VPusUfsacuAfcGfGf aaauUfcUfcggaasa	UUUCCCGAGAUUUCCCGUAGUA	4663
AD-579965.1	A-1110822.1	1608	usuaaa(Chd)UfgUfAfUfuguuuuacs gsa	A-1100535.1	1695	VPusCfsguaAfaAfcf aaauCfaGfuuuaacs gsa	UCUUAACUCUGAUUUGUUUUUACG	4664
AD-579966.1	A-1110823.1	1609	asasacu(Ghd)UfaUfUfGfuuuuuacsusa	A-1100539.1	1696	VPusAfsgecUfaAfa f acaaUfaCfaguuaasa	UUAAACUGUAUUGUUUUUACGCU	4665
AD-579967.1	A-1110824.1	1610	gsasuuc(Ghd)CfcAfUfUfuuuuuauas a	A-1102468.1	1697	VPusAfsuauAfaGfAf aaauGfGfGaaacs a	UGGAUUUCGCCAUUUUCUUAUAU	4666
AD-579968.1	A-1110825.1	1611	usacu(Ghd)GfaUfAfUfuguuugacusa	A-1102660.1	1698	VPusCfsaguCfaAfa f caauUfcCfagugas g	CUUCACUGGAUUGUUUUGACUG	4667
AD-579969.1	A-1110826.1	1612	gsusugg(Chd)UfcAfCfUfuccagaaacs a	A-1102948.1	1699	VPusGfsuuCfuGfGf aaauGfaGfccaacs gsu	ACGUUGGCUCAUUCCAGAAAC	4668

AD-579970.1	A-1110827.1	1613	ascsuuc(Chd)AfgAfAfaAfcagacaasasa	A-1102964.1	1700	VPusUfsuugUfcGfUfguuCfuGfgaugsasa	UCACUUCAGAACACGACAAA	4669
AD-579971.1	A-1110828.1	1614	usascuu(Ahd)UfuUfAfaAfuagccuusasa	A-1103592.1	1701	VPusAfsaagGfgCfUfaauaAfaUfaaguascsc	GGUACUUUAUUAAUAGCCCUUU	4670
AD-579972.1	A-1110829.1	1615	asgsagc(Ahd)GfuUfUfUfccgagauasasa	A-1103924.1	1702	VPusAfsuauCfuCfGfgaaaAfcUfgcucusasg	CUAGAGCAGUUUCCCGAGAUAU	4671
AD-579973.1	A-1110830.1	1616	usgsaga(Uhd)UfuGfAfaUfaucacaacsasa	A-1100515.1	1703	VPusGfsguuUfgAfAfaauaCfaAfucccascsc	UCUGGGAUUUUAUAUCAAACC	4672
AD-579974.1	A-1110831.1	1617	gsgsgau(Uhd)UfgAfUfaAfucaaacscasa	A-1100517.1	1704	VPusAfsagguUfuGfAfaauaCfaAfucccascsc	CUGGGAUUUUGAUUCAAACCU	4673
AD-579975.1	A-1110832.1	1618	gsasuuu(Ghd)AfuUfUfUfcaaacscusa	A-1100521.1	1705	VPusAfsagGfuUfUfgaauAfuCfaaauascsc	GGGAUUUGAUUAUCAAACCU	4674
AD-579976.1	A-1110833.1	1619	usasaac(Uhd)GfuUfUfUfguuuacscasa	A-1100537.1	1706	VPusGfscguAfaAfaaauAfcAfguuuascsc	CUUAAACUGUAUUGUUUUAACGC	4675
AD-579977.1	A-1110834.1	1620	uscsacc(Ghd)GfaAfAfgfaccgaauasasa	A-1102124.1	1707	VPusUfsuuaUfcGfUfguuUfcCfaggugasasa	UCUCACCCGGAAAGACCGAUUAA	4676
AD-579978.1	A-1110835.1	1621	csascgg(Ghd)AfaUfGfAfccgaauaacsasa	A-1102126.1	1708	VPusGfsuuaAfuCfGfguuUfcCfaggugasasa	CUCACCCGGAAGACCGAUUAAAC	4677
AD-579979.1	A-1110836.1	1622	cscsaga(Ahd)AfgAfCfCfgaauaacsasa	A-1102130.1	1709	VPusUfsgguUfaAfuUfcgguCfuUfuccggsusg	CACCCGGAAGA CCGAUUAAACCA	4678
AD-579980.1	A-1110837.1	1623	gsasacu(Ghd)GfaUfUfCfCfccaauuacsasa	A-1102456.1	1710	VPusGfsaaaAfuGfGfgaaUfcCfaguascsc	UGGAACUGGAUUCGCCAUUUUC	4679
AD-579981.1	A-1110838.1	1624	csascug(Ghd)AfuUfUfGfuungacugscasa	A-1102662.1	1711	VPusGfscagUfcAfaaauAfuCfagugasasa	UUCACUGGAUUGUUUGACUGC	4680

AD-579982.1	A-1110839.1	1625	gsgsacc(Uhd)UfgUfGfUfgaucagacsca	A-1103464.1	1712	VPusGfsgucUfgAfUfcacaCfaAfgguccusc	GAGGACCUUGUGUGAUCAGACC A	4681
AD-579983.1	A-1110840.1	1626	uscaga(Chd)CfaUfUfGfaaaccacusasa	A-1103490.1	1713	VPusUfsaguGfgUfUfucuaUfgGfucugasc	GAUCAGACCAUUGAAACCACUA A	4682
AD-579984.1	A-1110841.1	1627	csasuug(Ahd)AfaCfCfAfcuaauucgsa	A-1103502.1	1714	VPusCfsagaAfuUfAfguggUfuUfcaaugsgu	ACCAUUGAAAC CACUAAUUCUG U	4683
AD-579985.1	A-1110842.1	1628	csusaga(Ghd)CfaGfUfUfucccgagasusa	A-1103920.1	1715	VPusAfsucUcGfgGfAfaaacUfgCfucuaagsag	CUCUAGAGCAG UUUCCGAGAU A	4684
AD-579986.1	A-1110843.1	1629	usasgag(Chd)AfgUfUfUfucccgagasusa	A-1103922.1	1716	VPusUfsaucUfcGfgGfaaaaCfuGfcuacgsa	UCUAGAGCAGU UUUCCGAGAU U	4685
AD-579987.1	A-1110844.1	1630	asgsuuu(Uhd)CfcGfAfGfauauucgsusa	A-1103934.1	1717	VPusAfscegAfaUfAfuucGfgAfaacugsc	GCAGUUUUCCG AGAUUUUCCGU A	4686
AD-579988.1	A-1110845.1	1631	gscsgga(Uhd)CfaAfAfCfucaccaasasa	A-1101748.1	1718	VPusUfsuugGfuGfAfgguuUfgAfuccgsasu	AUGCGGAUCAA ACCUACCCAAA G	4687
AD-579989.1	A-1110846.1	1632	asgscau(Uhd)UfgUfUfUfguccaagasusa	A-1101962.1	1719	VPusAfsucUfgGfAfcacaCfaAfaugcusus	AAAGCAUUUGU UUGUCCAAAGAU C	4688
AD-579990.1	A-1110847.1	1633	uscucu(Chd)CfGfAfAfagaccagasusa	A-1102120.1	1720	VPusAfsaucGfgUfCfuuucCfGfugagagsg	CCUCUCACCGG AAAGACCGAUU A	4689
AD-579992.1	A-1110849.1	1634	uscuaug(Ahd)GfcAfGfUfuuuccgagasusa	A-1103918.1	1721	VPusUfscucGfgAfAfaacuGfcUfcuagagsga	UCUCUAGAGCA GUUUUCCGAGA U	4690
AD-579993.1	A-1110850.1	1635	asusugc(Ahd)CfGfAfAfacuauucgsusa	A-1100955.1	1722	VPusAfscegAfaUfAfuucCfGfUfgcauucsc	GGAUUGCACCG AAACUUUUUCGU C	4691
AD-579995.1	A-1110852.1	1636	gscsucU(Chd)GfgAfUfUfugauauucgsa	A-1100507.1	1723	VPusUfsgaaUfaUfCfaaauCfcCfagagcsasc	GUGCUCUGGGA UUUGAUUUUCA A	4692

AD-579996.1	A-1110853.1	1637	usgsagc(Chd)UfuGfUfUfcagagcgsasa	A-1101930.1	1724	VPusUfscgcCfuCfUf gaacAfaGfgcucscsa	UGUGAGCCUUG UUCAGAGCGGA G	4693
AD-579997.1	A-1110854.1	1638	asgsccu(Uhd)GfuUfCfAfgagcgsasa	A-1101934.1	1725	VPusUfscucCfGcCfUf cugaAfcAfgagcscsa	UGAGCCCUUGUU CAGAGCGGAGA A	4694
AD-579998.1	A-1110855.1	1639	csasuuu(Ghd)UfuUfGfUfccagaucscsa	A-1101966.1	1726	VPusGfsgauCfuUfGf gacaAfaCfaaagcscu	AGCAUUUUGUUU GUCCAAGAUCC G	4695
AD-579999.1	A-1110856.1	1640	ggsaaa(Ghd)AfcCfGfAfuuaaccgsasa	A-1102134.1	1727	VPusCfsgauGfuUfAf aucGfuCfuuuccsg	CCGGAAGAGACC GAUUAACCAUG U	4696
AD-580000.1	A-1110857.1	1641	gsasaag(Ahd)CfcGfAfUfuaaccgsasa	A-1102136.1	1728	VPusAfscuGfgUfUf aaucGfgUfcuuucscg	CGGAAAGACCG AUUAACCAUGU C	4697
AD-580001.1	A-1110858.1	1642	asasgac(Chd)GfaUfUfAfaccagcsasa	A-1102140.1	1729	VPusUfsgacAfUfGfGf uuuaUfcGfgucuuusc	GAAAGACCGAU UAACCAUGUCA C	4698
AD-580002.1	A-1110859.1	1643	gsasccg(Ahd)UfuAfAfCfcaugcacsasa	A-1102144.1	1730	VPusGfsgugAfcAfUf gguuAfaUfcgucscsu	AAGACCGAUUA ACCAUGUCACC A	4699

Table 5B. Exemplary Rat VEGF-A siRNA Unmodified Single Strands and Duplex Sequences

Duplex Name	Sense Oligo Name	SEQ ID NO: (Sense)	Sense Sequence	mRNA Target Range	Antisense Oligo Name	SEQ ID NO: (Antisense)	Antisense Sequence	mRNA Target Range
AD-57991 1.1	A-11107 68.1	1731	CGGAAACUUUUCGUC CAACUA	631-651	A-1100967.1	1818	UAGUUUGACGAAA AGUUUCCGUG	629-651
AD-57991 2.1	A-11107 69.1	1732	GGAAACUUUUCGUCC AACUUA	632-652	A-1100969.1	1819	UAAGUUUGACGAA AAGUUUCCGU	630-652

AD-57991 3.1	A-11107 70.1	1733	CGACAGAACAGUCCU UAAUCA	1689-1709	A-1102172.1	1820	UGAUUAAAGGACUG UUCUGUCGAC	1687-1709
AD-57991 4.1	A-11107 71.1	1734	CUGCUAAUGUUUUAUUG GUGUCA	2020-2040	A-1102638.1	1821	UGACACCAAUAAC AUUAGCAGAG	2018-2040
AD-57991 5.1	A-11107 72.1	1735	UCCGAGAUUUUCCGU AGUACA	3364-3384	A-1103944.1	1822	UGUACUACGGAAU AUCUCGGAAA	3362-3384
AD-57991 6.1	A-11107 73.1	1736	CGAGAUUUUCCGUAG UACAUA	3366-3386	A-1103888.1	1823	UAUGUACUACGGA AUUUCUCGGA	3364-3386
AD-57991 7.1	A-11107 74.1	1737	GCACGGAAACUUUUUC GUCCAA	628-648	A-1100961.1	1824	UUGGACGAAAAGU UUCCGUGCAA	626-648
AD-57991 8.1	A-11107 75.1	1738	CACGGAAACUUUUUCG UCCAAA	629-649	A-1100963.1	1825	UUUGGACGAAAAG UUUCCGUGCA	627-649
AD-57991 9.1	A-11107 76.1	1739	GAGAUUUUCCGUAGU ACAUAA	3367-3387	A-1103889.1	1826	UUUUGUACUACGG AAUAUCUCGG	3365-3387
AD-57992 1.1	A-11107 78.1	1740	UUUUUUGUCCAAAGAU CCGCAA	1468-1488	A-1101976.1	1827	UUGCGGAUCUUUG ACAAACAAGU	1466-1488
AD-57992 2.1	A-11107 79.1	1741	ACGGAAACUUUUUCGU CCAACA	630-650	A-1100965.1	1828	UGUUGGACGAAA GUUUCGUGC	628-650
AD-57992 3.1	A-11107 80.1	1742	AUCAUGCGGAUCAAA CCUCAA	1327-1347	A-1101742.1	1829	UUGAGGUUUGAUC CGCAUGAUCU	1325-1347
AD-57992 4.1	A-11107 81.1	1743	AUGCGGAUCAAAACCU CACCAA	1330-1350	A-1101659.1	1830	UUGGUGAGGUUUG AUCCGCAUGA	1328-1350
AD-57992 5.1	A-11107 82.1	1744	GAUCAUGCGGAUCAA ACCUC	1326-1346	A-1101740.1	1831	UGAGGUUUGAUCC GCAUGAUCUG	1324-1346

AD-57992 6.1	A-11107 83.1	1745	UUUUUUUGUCCAAGA UCCGCA	1467-1487	A-1101974.1	1832	UGCGGAUCUUGGA CAAAACAAUG	1465-1487
AD-57992 7.1	A-11107 84.1	1746	GAUCGGUGACAGUCA CUAGCA	2972-2992	A-1103783.1	1833	UGCUGAGACUGU CACCGAUCUG	2970-2992
AD-57992 9.1	A-11107 86.1	1747	AAGAUCCGCAGACGU GUAAAA	1478-1498	A-1101968.1	1834	UUUACACGUCUG CGGAUCUUGG	1476-1498
AD-57993 0.1	A-11107 87.1	1748	UGUCCAAAGAUCCGCA GACGUA	1473-1493	A-1101986.1	1835	UACGUCUGCGGAU CUUGGACAAA	1471-1493
AD-57993 1.1	A-11107 88.1	1749	AUCACGUCUUUGUCU CUAGAA	3337-3357	A-1103887.1	1836	UUCUAGAGACAAA GACGUGAUGU	3335-3357
AD-57993 2.1	A-11107 89.1	1750	UGAAACCAUGAACUU UCUGCA	1008-1028	A-1101283.1	1837	UGCAGAAAAGUUCA UGGUUUCAGA	1006-1028
AD-57993 3.1	A-11107 90.1	1751	UUUGUCUCUAGAGCAG UUUUCA	3346-3366	A-1103908.1	1838	UGAAAACUGCUCU AGAGACAAAG	3344-3366
AD-57993 4.1	A-11107 91.1	1752	CACUCCAGAAAACACG ACAAA	2222-2242	A-1102962.1	1839	UUUGUCGUGUUUC UGGAAUGAG	2220-2242
AD-57993 5.1	A-11107 92.1	1753	UGAAAUCUGUGUUUC CAAUCA	2941-2961	A-1103728.1	1840	UGAUUGGAAACAC AGAUUUCUA	2939-2961
AD-57993 6.1	A-11107 93.1	1754	GAAAUCUGUGUUUCC AAUCUA	2942-2962	A-1103730.1	1841	UAGAUUGGAAACA CAGAUUUCAU	2940-2962
AD-57993 7.1	A-11107 94.1	1755	UUUGUCUCUAGAGCA GUUUUA	3345-3365	A-1103906.1	1842	UAAAACUGCUCUA GAGACAAAGA	3343-3365
AD-57993 8.1	A-11107 95.1	1756	UGUCUCUAGAGCAGU UUUCCA	3347-3367	A-1103910.1	1843	UGGAAAACUGCUC UAGAGACAAA	3345-3367

AD-57993 9.1	A-11107 96.1	1757	AACUGUAUUGUUUUA CGCUA	167-187	A-1100541.1	1844	UAGCGUAAAACA AUACAGUUUA	165-187
AD-57994 0.1	A-11107 97.1	1758	ACUGUAUUGUUUUA GCUUA	168-188	A-1100543.1	1845	UAAAGCGUAAAAC AAUACAGUUU	166-188
AD-57994 1.1	A-11107 98.1	1759	CUGUAUUGUUUUA CUUUA	169-189	A-1100545.1	1846	UAAAAGCGUAAA CAAUACAGUU	167-189
AD-57994 2.1	A-11107 99.1	1760	UGUAUUGUUUUA UUUAA	170-190	A-1100547.1	1847	UUUAAAGCGUAAA ACAAUACAGU	168-190
AD-57994 3.1	A-11108 00.1	1761	AUUGAAACCACUAAU UCUGUA	2611-2631	A-1103504.1	1848	UACAGAAUUAGUG GUUUCAAUGG	2609-2631
AD-57994 4.1	A-11108 01.1	1762	ACUUAUUUAAUAGCC CUUUUA	2764-2784	A-1103594.1	1849	UAAAAGGGCUAUU AAUUAAGUAC	2762-2784
AD-57994 5.1	A-11108 02.1	1763	UCUCUAGAGCAGUUU UCCGAA	3349-3369	A-1103914.1	1850	UUCGGAAAACUGC UCUAGAGACA	3347-3369
AD-57994 6.1	A-11108 03.1	1764	CCGAGAUUUCGUA GUACAA	3365-3385	A-1103946.1	1851	UUGUACUACGGAA UAUCUCGGAA	3363-3385
AD-57994 7.1	A-11108 04.1	1765	UCUGGGAUUUGAUUAU UCAAAA	129-149	A-1100511.1	1852	UUUUGAAUAUCAA AUCCCAGAGC	127-149
AD-57994 8.1	A-11108 05.1	1766	UUCACUGGAUAUGUU UGACUA	2040-2060	A-1102658.1	1853	UAGUCAAAACAUU CCAGUGAAGA	2038-2060
AD-57994 9.1	A-11108 06.1	1767	GGCUCACUUCGAGAA ACACGA	2218-2238	A-1102954.1	1854	UCGUGUUUCUGGA AGUGAGCCAA	2216-2238
AD-57995 0.1	A-11108 07.1	1768	CUUCCAGAAACACGAC AAACA	2224-2244	A-1102966.1	1855	UGUUUGUCGUGUU UCUGGAAGUG	2222-2244

AD-57995 1.1	A-11108 08.1	1769	GACCAUUGAAACCAC UAAUUA	2607- 2627	A- 1103496.1	1856	UAAUUAGUGGUUU CAAUGGUCUG	2605- 2627
AD-57995 3.1	A-11108 10.1	1770	AGUCACUAGCUUGUC CUGAGA	2982- 3002	A- 1103805.1	1857	UCUCAGGACAAGC UAGUGACUGU	2980- 3002
AD-57995 4.1	A-11108 11.1	1771	ACCACACAUUCCUUUG AAAUUA	3049- 3069	A- 1103837.1	1858	UAUUUCAAAGGAA UGUGUGGGUGG	3047- 3069
AD-57995 5.1	A-11108 12.1	1772	ACCGGAAAGACCGAU UAACCA	1639- 1659	A- 1102128.1	1859	UGGUUAAUCGGUC UUUCCGGUGA	1637- 1659
AD-57995 6.1	A-11108 13.1	1773	AGACCGAUUAACCAU GUCACA	1646- 1666	A- 1102142.1	1860	UGUGACAUGGUUA AUCGGUCUUU	1644- 1666
AD-57995 7.1	A-11108 14.1	1774	CUUCACUGGAUAUGU UUGACA	2039- 2059	A- 1102656.1	1861	UGUCAAAACAUAUC CAGUGAAGAC	2037- 2059
AD-57995 8.1	A-11108 15.1	1775	UUGGCUCACUUC CAG AAACAA	2216- 2236	A- 1102950.1	1862	UUGUUUCUGGAAG UGAGCCAACG	2214- 2236
AD-57995 9.1	A-11108 16.1	1776	CUCACUUC CAGAAACA CGACA	2220- 2240	A- 1102958.1	1863	UGUCGUGUUUCUG GAAGUGAGCC	2218- 2240
AD-57996 0.1	A-11108 17.1	1777	GUGACAGUCACUAGC UUUGUA	2977- 2997	A- 1103795.1	1864	UGACAAGCUAGUG ACUGUCACCG	2975- 2997
AD-57996 1.1	A-11108 18.1	1778	GUCUCUAGAGCAGUU UUCCGA	3348- 3368	A- 1103912.1	1865	UCGGAAAAACUGCU CUAGAGACAA	3346- 3368
AD-57996 2.1	A-11108 19.1	1779	CUCUAGAGCAGUUUU CCGAGA	3350- 3370	A- 1103916.1	1866	UCUCGGAAAAACUG CUCUAGAGAC	3348- 3370
AD-57996 3.1	A-11108 20.1	1780	GUUUUCCGAGUAUU CCGUAA	3360- 3380	A- 1103936.1	1867	UUACGGAAUAUCU CGGAAAAACUG	3358- 3380

AD-57996 4.1	A-11108 21.1	1781	UUCCGAGAUUUUCCG UAGUAA	3363-3383	A-1103942.1	1868	UUACUACGGAAUA UCUCGGAAA	3361-3383
AD-57996 5.1	A-11108 22.1	1782	UUAAACUGAUUUGUU UUACGA	164-184	A-1100535.1	1869	UCGUAAAAACAUA CAGUUUAGA	162-184
AD-57996 6.1	A-11108 23.1	1783	AAACUGAUUUGUUUU ACGCUA	166-186	A-1100539.1	1870	UAGCGUAAAAACAA UACAGUUUAA	164-186
AD-57996 7.1	A-11108 24.1	1784	GAUUCGCCAUUUUCU UAUAUA	1830-1850	A-1102468.1	1871	UAUAUAAAGAAAAU GGCGAAUCCA	1828-1850
AD-57996 8.1	A-11108 25.1	1785	UCACUGGAUAUGUUU GACUGA	2041-2061	A-1102660.1	1872	UCAGUCAAAACAUA UCCAGUGAAG	2039-2061
AD-57996 9.1	A-11108 26.1	1786	GUUGGCUCACUUCCA GAAACA	2215-2235	A-1102948.1	1873	UGUUUCUGGGAAGU GAGCCAACGU	2213-2235
AD-57997 0.1	A-11108 27.1	1787	ACUCCAGAAACACG ACAAA	2223-2243	A-1102964.1	1874	UUUUGUCGUGUUU CUGGAAGUGA	2221-2243
AD-57997 1.1	A-11108 28.1	1788	UACUUAUUUAAUAGC CCUUUA	2763-2783	A-1103592.1	1875	UAAAGGGCUAUUA AAUAGUACC	2761-2783
AD-57997 2.1	A-11108 29.1	1789	AGAGCAGUUUUCCGA GAUAUA	3354-3374	A-1103924.1	1876	UAUAUCUCGGAAA ACUGCUCUAG	3352-3374
AD-57997 3.1	A-11108 30.1	1790	UGGGAUUUGAUUUC AAACCA	131-151	A-1100515.1	1877	UGGUUUGAAUAUC AAAUCCCAGA	129-151
AD-57997 4.1	A-11108 31.1	1791	GGGAUUUGAUUUA AACCUA	132-152	A-1100517.1	1878	UAGGUUUGAAUAU CAAAUCCCAG	130-152
AD-57997 5.1	A-11108 32.1	1792	GAUUUGAUUUAUCAA CCUCUA	134-154	A-1100521.1	1879	UAGAGGUUUGAAU AUCAAAUCCC	132-154

AD-57997 6.1	A-11108 33.1	1793	UAAACUGUAUUGUUU UACGCA	165-185	A-1100537.1	1880	UGCGUAAACAAU ACAGUUUAAAG	163-185
AD-57997 7.1	A-11108 34.1	1794	UCACCGGAAAGACCG AUUAAA	1637-1657	A-1102124.1	1881	UUUAAUCGGUCUU UCCGGUGAGA	1635-1657
AD-57997 8.1	A-11108 35.1	1795	CACCGGAAAGACCGA UUAAACA	1638-1658	A-1102126.1	1882	UGUUAAUCGGUCU UUCCGGUGAG	1636-1658
AD-57997 9.1	A-11108 36.1	1796	CCGGAAAGACCGAUU AACCAA	1640-1660	A-1102130.1	1883	UUGGUUAAUCGGU CUUUCGGUG	1638-1660
AD-57998 0.1	A-11108 37.1	1797	GAACUGGAUUCGCCA UUUUCA	1824-1844	A-1102456.1	1884	UGAAAUUGGCGAA UCCAGUUCCA	1822-1844
AD-57998 1.1	A-11108 38.1	1798	CACUGGAUAUGUUUG ACUGCA	2042-2062	A-1102662.1	1885	UGCAGUCAAAACAU AUCCAGUGAA	2040-2062
AD-57998 2.1	A-11108 39.1	1799	GGACCUUGUGUGAUC AGACCA	2591-2611	A-1103464.1	1886	UGGUCUGAUCACA CAAGGUCCUC	2589-2611
AD-57998 3.1	A-11108 40.1	1800	UCAGACCAUUGAAAC CACUAA	2604-2624	A-1103490.1	1887	UUAGUGGUUUCAA UGGUCUGAUC	2602-2624
AD-57998 4.1	A-11108 41.1	1801	CAUUGAAACACACUAA UUUCUGA	2610-2630	A-1103502.1	1888	UCAGAAUUAGUGG UUUCAAUUGGU	2608-2630
AD-57998 5.1	A-11108 42.1	1802	CUAGAGCAGUUUUUCC GAGAU	3352-3372	A-1103920.1	1889	UAUCUCGGAAAAC UGCUCUAGAG	3350-3372
AD-57998 6.1	A-11108 43.1	1803	UAGAGCAGUUUUUCCG AGAUAA	3353-3373	A-1103922.1	1890	UUUUCUCGGAAA CUGCUCUAGA	3351-3373
AD-57998 7.1	A-11108 44.1	1804	AGUUUUCGAGAUU UCCGUA	3359-3379	A-1103934.1	1891	UACGGAAUAUCUC GGAAAACUGC	3357-3379

AD-57998 8.1	A-11108 45.1	1805	GCGGAUCAAACCCUCAC CAAAA	1332-1352	A-1101748.1	1892	UUUUGGUGAGGUU UGAUCCGCAU	1330-1352
AD-57998 9.1	A-11108 46.1	1806	AGCAUUUGUUUGUCC AAGAU	1463-1483	A-1101962.1	1893	UAUCUUUGGACAAA CAAUUGCUUU	1461-1483
AD-57999 0.1	A-11108 47.1	1807	UCUCACCGGAAAGACC GAUUA	1635-1655	A-1102120.1	1894	UAAUCGGUCUUUC CGGUGAGAGG	1633-1655
AD-57999 2.1	A-11108 49.1	1808	UCUAGAGCAGUUUUC CGAGAA	3351-3371	A-1103918.1	1895	UUCUCGGAAAAACU GCUCUAGAGA	3349-3371
AD-57999 3.1	A-11108 50.1	1809	AUUGCACGGAAACUU UUCGUA	625-645	A-1100955.1	1896	UACGAAAAAGUUUC CGUGCAAUCC	623-645
AD-57999 5.1	A-11108 52.1	1810	GCUCUGGGAUUUUGAU AUCAA	127-147	A-1100507.1	1897	UUGAAUAUCAAAU CCCAGAGCAC	125-147
AD-57999 6.1	A-11108 53.1	1811	UGAGCCUUUGUUCAGAA GCGGAA	1440-1460	A-1101930.1	1898	UUCCGCUCUGAAC AAGGCUCACA	1438-1460
AD-57999 7.1	A-11108 54.1	1812	AGCCUUUGUUCAGAGC GGAGAA	1442-1462	A-1101934.1	1899	UUCUCCGCUCUGA ACAAGGCUCA	1440-1462
AD-57999 8.1	A-11108 55.1	1813	CAUUUGUUUGUCCAA GAUCCA	1465-1485	A-1101966.1	1900	UGGAUCUUUGGACA AACAAUUGCU	1463-1485
AD-57999 9.1	A-11108 56.1	1814	GGAAAAGACCGAUUAA CCAUGA	1642-1662	A-1102134.1	1901	UCAUGGUUAAUUCG GUCUUUCCGG	1640-1662
AD-58000 0.1	A-11108 57.1	1815	GAAAGACCGAUUAAC CAUGUA	1643-1663	A-1102136.1	1902	UACAUGGUUAAUUC GGUCUUUCCG	1641-1663
AD-58000 1.1	A-11108 58.1	1816	AAGACCGAUUAACCA UGUCA	1645-1665	A-1102140.1	1903	UUGACAUGGUUAA UCGGUCUUUC	1643-1665

AD- 58000 2.1	A- 111108 59.1	1817	GACCGAUUAACCAUG UCACCA	1647- 1667	A- 1102144.1	1904	UGGUGACAUGGUU AAUCGGUCUU	1645- 1667
---------------------	----------------------	------	---------------------------	---------------	-----------------	------	-----------------------------	---------------

Table 8A. Exemplary Human VEGF-A siRNA Modified Single Strands and Duplex Sequences

Duplex Name	Sense Oligo Name	SEQ ID NO: (Sense)	Sense Sequence	Anti-sense Oligo Name	SEQ ID NO: (Anti-sense)	Antisense Sequence	mRNA Target Sequence	SEQ ID NO: (mRNA target)
AD-1228 66.1	A-22821 11.1	2000	csgsgugcUfgGfAfufuuga uauaL96	A-228211 2.1	2449	VPusAfsauaUfcaaaauuC faGfcaccgsag	CUCGGUGCUGGAAU UUGAUUUC	4700
AD-1228 67.1	A-22821 13.1	2001	gsgsugcuGfgAfAfufuuga auucaL96	A-228211 4.1	2450	VPusGfsaauAfuaaaauuC fcAfgcaccgsa	UCGGUGCUGGAAU UGAUUUAU	4701
AD-1228 68.1	A-22821 15.1	2002	usgscuggAfaUfUfufuuga cauaL96	A-228211 6.1	2451	VPusAfsugaAfuaaaauU fuCfcagcasc	GGUGCUGGAAU UAUUAU	4702
AD-1228 69.1	A-22821 17.1	2003	gscsuggaAfuUfUfGfuaauC auuaL96	A-228211 8.1	2452	VPusAfsaugAfuaaaauA fuUfcagcasc	GUGCUGGAAU UAUUAU	4703
AD-1228 70.1	A-22821 19.1	2004	usgsgaauUfuGfAfufuauC ugaL96	A-228212 0.1	2453	VPusUfscAaUfgaaauaC faAfuuccagsc	GCUGGAAU UUAUUA	4704
AD-1228 71.1	A-22821 21.1	2005	gsgsaauUfgAfUfAfuaauC gauaL96	A-228212 2.1	2454	VPusAfsucaAfuaaaauC faAfaauccsag	CUGGAAU UCAUUA	4705
AD-1228 72.1	A-22821 23.1	2006	gsasauuuGfaUfAfufuauC aucaL96	A-228212 4.1	2455	VPusGfsaucAfuaaaauU fcAfaauccsa	UGGAAU UCAUUA	4706
AD-1228 73.1	A-22821 25.1	2007	asasuugAfuAfUfUfuaauC uccaL96	A-228212 6.1	2456	VPusGfsgauCfaaaauA fuCfaaauscs	GGAAU AUUAU	4707
AD-1228 74.1	A-22821 27.1	2008	asusuugaUfaUfUfCfaauC ccgaL96	A-228212 8.1	2457	VPusCfsggaUfcaaaauU faUfcaaauscs	GAAU UUAUUA	4708

AD-12228 75.1	A-22821 29.1	2009	ususauAfuUfCfAfuugauc cgaL96	A-228213 0.1	2458	VPusCfscggAfucaagaA fuAfucaasusu	AAUUUGAUUAUCAU UGAUCCGGG	4709
AD-12228 76.1	A-22821 31.1	2010	ususauuUfuUfGfCfuugcca uucal96	A-228213 2.1	2459	VPusGfsaaUGfgcaagcaA faAfauaasusu	AAUUUAUUUUUGCU UGCCAUUCC	4710
AD-12228 77.1	A-22821 33.1	2011	ususauuuUfuGfCfUfugccau uccal96	A-228213 4.1	2460	VPusGfsgaaUfggaagcaA faAfauaasusu	AUUUAUUUUUGCUU GCCAUUCCC	4711
AD-12228 78.1	A-22821 35.1	2012	csasaauCfUfGfUfggaauu uggaL96	A-228213 6.1	2461	VPusCfscgaAfauccacaG fuGfaauugsgsg	CCCAAAUCACUGUG GAUUUUGGA	4712
AD-12228 79.1	A-22821 37.1	2013	asasaucCfuGfUfGfgaauuu ggaaL96	A-228213 8.1	2462	VPusUfscgaAfaauccacA fgUfgaauugsgsg	CCAAAUACACUGUG AUUUUGGAA	4713
AD-12228 80.1	A-22821 39.1	2014	asasucacUfgUfGfGfgaauuug gaal96	A-228214 0.1	2463	VPusUfsuccAfaaaucacC faGfugaauusug	CAAAUCACUGUGGA UUUUGGAAA	4714
AD-12228 81.1	A-22821 41.1	2015	asuscacuGfuGfGfAfuuuugg aaaal96	A-228214 2.1	2464	VPusUfsuucCfaaaauccA fcAfgugaususu	AAAUACACUGUGGAU UUUGGAAAC	4715
AD-12228 82.1	A-22821 43.1	2016	uscsacugUfgGfAfuuuugga aacaL96	A-228214 4.1	2465	VPusGfsuuuCfcaaaaucC faCfagugasusu	AAUCACUGUGGAUU UUGGAAACC	4716
AD-12228 83.1	A-22821 45.1	2017	csascuguGfgAfUfuuggaa accaL96	A-228214 6.1	2466	VPusGfsguuUfcaaaaucC fcAfcagugsasu	AUCACUGUGGAUUU UGGAAACCA	4717
AD-12228 84.1	A-22821 47.1	2018	ascugugGfaUfUfUfggaaa ccaaL96	A-228214 8.1	2467	VPusUfsgguUfucaaaaU fcCfacagusga	UCACUGUGGAUUUU GGAAACCAG	4718
AD-12228 85.1	A-22821 49.1	2019	csusgugGfaUfUfUfggaac cagaL96	A-228215 0.1	2468	VPusCfsuggUfuuccaaaA fuCfcacagusg	CACUGUGGAUUUUG GAAACCAGC	4719
AD-12228 86.1	A-22821 51.1	2020	usgsugGfaUfUfGfgaaacc agcaL96	A-228215 2.1	2469	VPusGfscugGfuuccaaa AfaUfccacagsu	ACUGUGGAUUUUGG AAACCAGCA	4720

AD-12228 87.1	A-22821 53.1	2021	gsusggauUfuUfGfGfaaacca gcaal96	A-228215 4.1	2470	VpusUfsgcuGfguuucca AfaAfuaccasag	CUGUGGAUUUUGGA AACCAGCAG	4721
AD-12228 88.1	A-22821 55.1	2022	gsasuuuuGfgAfAfAfcagca gaaal96	A-228215 6.1	2471	VpusUfsucuGfcgguuu CfcAfaaauccsa	UGGAUUUUGGAAAC CAGCAGAAA	4722
AD-12228 89.1	A-22821 57.1	2023	asusuungGfaAfAfCfcagcag aaaal96	A-228215 8.1	2472	VpusUfsuucUfcgguuu UfcCfaaauscsc	GGAUUUUGGAAACC AGCAGAAAG	4723
AD-12228 90.1	A-22821 59.1	2024	ususuungAfaCfCfagcaga aagal96	A-228216 0.1	2473	VpusCfsuuuUfcgguuu UfuCfcaaausc	GAUUUUGGAAACCA GCAGAAAGA	4724
AD-12228 91.1	A-22821 61.1	2025	ususuggaAfaCfCfagcaga agaal96	A-228216 2.1	2474	VpusUfscuuUfcgguuu UfuUfcaaaasu	AUUUUGGAAACCAG CAGAAAGAG	4725
AD-12228 92.1	A-22821 63.1	2026	gsasaaacCfaCfCfagcaga ggaal96	A-228216 4.1	2475	VpusUfscuuUfcgguuu UfgGfuuuuscasa	UUGGAAACCAGCAG AAAGAGGAA	4726
AD-12228 93.1	A-22821 65.1	2027	asasaccaGfcAfAfagagg aaaal96	A-228216 6.1	2476	VpusUfsuucUfcuuccu GfcUfgguuuuscsc	GGAAACCAGCAGAA AGAGGAAAG	4727
AD-12228 94.1	A-22821 67.1	2028	asasccagCfaGfAfagagg aagal96	A-228216 8.1	2477	VpusCfsuuuUfcuuccu UfgCfugguususc	GAAACCAGCAGAAA GAGGAAAGA	4728
AD-12228 95.1	A-22821 69.1	2029	asccagCfaGfAfagagg agaal96	A-228217 0.1	2478	VpusUfscuuUfcuuccu CfuGfcgguususu	AAACCAGCAGAAAG AGGAAAGAG	4729
AD-12228 96.1	A-22821 71.1	2030	cscsagcaGfaAfAfagagg gagal96	A-228217 2.1	2479	VpusCfsucuUfuuccu UfcUfgcuggsusu	AACCAGCAGAAAGA GGAAAGAGG	4730
AD-12228 97.1	A-22821 73.1	2031	csasgcagAfaAfAfagagg aggal96	A-228217 4.1	2480	VpusCfsuucUfuuccu fuCfugcuggsu	ACCAGCAGAAAGAG GAAAGAGGU	4731
AD-12228 98.1	A-22821 75.1	2032	asgscagaAfaGfAfagagg ggual96	A-228217 6.1	2481	VpusAfscuuUfuuccu fuUfcugcuggsu	CCAGCAGAAAGAG AAAGAGGUA	4732

AD-12228 99.1	A-22821 77.1	2033	gscsagaaAfgAfGfGfaagag gaaL96	A-228217 8.1	2482	V PusUfsaceUfcuuuccu fuUfucgcsusg	CAGCAGAAAGAGGA AAGAGGUAG	4733
AD-12229 00.1	A-22821 79.1	2034	csasgaaaGfaGfAfaagagg uagaL96	A-228218 0.1	2483	V PusCfsuacCfucuuuccU fcUfucugscsu	AGCAGAAAGAGGAA AGAGGUAGC	4734
AD-12229 01.1	A-22821 81.1	2035	asasagagGfaAfGfAgguag caaaL96	A-228218 2.1	2484	V PusUfsugcUfaccucuu UfcCfucuuuscsu	AGAAAGAGGAAAG AGGUAGCAAG	4735
AD-12229 02.1	A-22821 83.1	2036	asasgaggAfaAfGfAfgguagc aagaL96	A-228218 4.1	2485	V PusCfsuugCfuaccucuu fuCfucuuususc	GAAAGAGGAAAGA GGUAGCAAGA	4736
AD-12229 03.1	A-22821 85.1	2037	asgsaggaAfaGfAfGfuguagca agaL96	A-228218 6.1	2486	V PusUfscuuGfucacucU fuUfcucucusu	AAAGAGGAAAGAG GUAGCAAGAG	4737
AD-12229 04.1	A-22821 87.1	2038	gsasggaAfgAfGfGfuagcaa gagaL96	A-228218 8.1	2487	V PusCfsucuUfgucacuuC fuUfucucusu	AAGAGGAAAGAGG UAGCAAGAGC	4738
AD-12229 05.1	A-22821 89.1	2039	gsasaaagAfgGfUfAfgcaaga gcuaL96	A-228219 0.1	2488	V PusAfsgeuCfuugcuaC fuCfuuuccsusc	GAGGAAAGAGGUA GCAAGAGCUC	4739
AD-12229 06.1	A-22821 91.1	2040	asgsuagCfaAfGfAfgcucca gagaL96	A-228219 2.1	2489	V PusCfsucuGfgagcucu UfgCfuaccuscu	AGAGGUAGCAAGAG CUCCAGAGA	4740
AD-12229 07.1	A-22821 93.1	2041	uscsagaGfaAfAfgucgag gaaL96	A-228219 4.1	2490	V PusUfsuceUfcgacuuC fcUfcuggasgsc	GUCCAGAGAGAAAG UCGAGGAAG	4741
AD-12229 08.1	A-22821 95.1	2042	cscsagagAfgAfAfgfucgagg aagaL96	A-228219 6.1	2491	V PusCfsuucCfucgacuuC fuCfucuggsag	CUCCAGAGAGAAAGU CGAGGAAGA	4742
AD-12229 09.1	A-22821 97.1	2043	csasgagaGfaAfGfUfcgagga agaL96	A-228219 8.1	2492	V PusUfscuuCfucgacuuC fcUfcucuggsa	UCCAGAGAGAGUC GAGGAAGAG	4743
AD-12229 10.1	A-22821 99.1	2044	asgsagaaGfuCfGfAfggaaga gagaL96	A-228220 0.1	2493	V PusCfsucuCfuuccuA fuUfucucusu	AGAGAGAAAGUCGAG GAAAGAGAGA	4744

AD-12229 11.1	A-22822 01.1	2045	gsasgaagUfcGfAfGfagaag agaal96	A-228220 2.1	2494	VpUsUfscueUfcuuccueG faCfuucuscusc	GAGAGAAAGUCGAGG AAGAGAGAG	4745
AD-12229 12.1	A-22822 03.1	2046	gsasagucGfaGfGfAfagagag agaal96	A-228220 4.1	2495	VpUsUfscueUfcuuccueU fcGfaucucuscusc	GAGAAAGUCGAGGAA GAGAGAGAC	4746
AD-12229 13.1	A-22822 05.1	2047	asgsugagUfgAfCfCfugcuuu uggaal96	A-228220 6.1	2496	VpUsCfscaaAfagcagguC faCfucacuscusc	AAAGUGAGUGACCU GCUUUUUGG	4747
AD-12229 14.1	A-22822 07.1	2048	gsagcagGfcAfCfUfgaaacu uuual96	A-228220 8.1	2497	VpUsAfsaaaGfuucagu GfcGfagccscgsc	GCGGCGUCGACACUG AAACUUUUC	4748
AD-12229 15.1	A-22822 09.1	2049	gsuscgaCfuGfAfafacuuiu cgual96	A-228221 0.1	2498	VpUsAfscaAfaaguuc AfgUfgcagcscgsc	GCGUCGCACUGAAA CUUUUUCGUC	4749
AD-12229 16.1	A-22822 11.1	2050	uscscgacUfgAfAfafacuuc gucaal96	A-228221 2.1	2499	VpUsGfsagAfaaguuc faGfugcagcscgsc	CGUCGCACUGAAAC UUUUCGUCC	4750
AD-12229 17.1	A-22822 13.1	2051	csascugaAfaCfUfufuucguc caaal96	A-228221 4.1	2500	VpUsUfsuggAfgaaag UfuUfcagugscgsc	CGCACUGAAACUUU UCGUCCAAC	4751
AD-12229 18.1	A-22822 15.1	2052	ascsgaaAfcUfUfufuucguc aacaal96	A-228221 6.1	2501	VpUsGfsugGfagaaaaG fuUfucagugscsc	GCACUGAAACUUU CGUCCAAACU	4752
AD-12229 20.1	A-22822 19.1	2053	usgsaaacUfuUfUfCfuguccaa cuual96	A-228222 0.1	2502	VpUsAfsaguUfgagcaa AfaGfuucacgsc	ACUGAAACUUUUCG UCCAAACUUC	4753
AD-12229 21.1	A-22822 21.1	2054	asascuuUfcGfUfCfcaacu cugaal96	A-228222 2.1	2503	VpUsCfsagaAfguggac GfaAfaaguuscusc	GAAACUUUUCGUCC AACUUUCUGG	4754
AD-12229 22.1	A-22822 23.1	2055	csusgggcUfgUfUfCfugcuu cggaal96	A-228222 4.1	2504	VpUsCfscgaAfgcagaaC faGfcccagasa	UUCUGGCGUGUUCU CGCUUCGGA	4755
AD-12229 23.1	A-22822 25.1	2056	usgsggcuGfuUfCfUfugcuuc gggaal96	A-228222 6.1	2505	VpUsUfscgAfaagcagaA fcAfgccagasa	UCUGGCGUGUUCUC GCUUCGGAG	4756

AD-12229 24.1	A-22822 27.1	2057	gsgscgUfuCfUfCfguucg gagaL96	A-228222 8.1	2506	VPusCfsuccGfaagcgagA faCfagcccsasg	CUGGGCUGUUCUCG CUUCGGAGG	4757
AD-12229 25.1	A-22822 29.1	2058	gsesuguuCfuCfGfCfuucgga ggaal96	A-228223 0.1	2507	VPusUfsccuCfegaagcgA fgAfacagcscc	GGGCUGUUCUCGCU UCGGAGGAG	4758
AD-12229 26.1	A-22822 31.1	2059	gscscgcgAfgAfAfGfugcuag cucal96	A-228223 2.1	2508	VPusGfsagcUfagcacuuC fuCfgcggcsusc	GAGCCGCGAGAAAGU GCUAGCUCG	4759
AD-12229 27.1	A-22822 33.1	2060	csesgcgaGfaAfGfUfgcuagc uegal96	A-228223 4.1	2509	VPusCfsgagCfuagcacuU fcUfcgcgscsu	AGCCGCGAGAAAGUG CUAGCUCGG	4760
AD-12229 28.1	A-22822 35.1	2061	gscscuccGfaAfAfCfcaugaa cuual96	A-228223 6.1	2510	VPusAfsaguUfcaugguu UfcGfgaggcscc	GGGCCUCCGAAACC AUGAACUUU	4761
AD-12229 29.1	A-22822 37.1	2062	asagsgagGfaGfGfGfcagaau caual96	A-228223 8.1	2511	VPusAfsugaUfueugccc UfcCfuccuucsu	AGAAGGAGGAGGGC AGAAUCAUC	4762
AD-12229 30.1	A-22822 39.1	2063	gsgscagaAfuCfAfUfcacgaa gugaL96	A-228224 0.1	2512	VPusCfsacuUfegugaug AfuUfcugccscsu	AGGCGAGAAUCAUC ACGAAAGUGG	4763
AD-12229 31.1	A-22822 41.1	2064	asasucauCfaCfGfAfaguggu gaaal96	A-228224 2.1	2513	VPusUfsucaCfcacuucgU fgAfugauucsu	AGAAUCAUCACGAA GUGGUGAAG	4764
AD-12229 32.1	A-22822 43.1	2065	asuscaucAfcGfAfAfguggug aagaL96	A-228224 4.1	2514	VPusCfsuucAfcacacuucG fuGfaugaususc	GAAUCAUCACGAAG UGGUGAAGU	4765
AD-12229 33.1	A-22822 45.1	2066	uscsaucaCfgAfAfGfugguga aguaL96	A-228224 6.1	2515	VPusAfsccuCfaccacuuc fgUfgaugasusu	AAUCAUCACGAAGU GGUGAAGUU	4766
AD-12229 34.1	A-22822 47.1	2067	csasucacGfaAfGfUfggugaa guual96	A-228224 8.1	2516	VPusAfsacuUfaccacuU fcGfugaugsasu	AUCAUCACGAAGUG GUGAAGUUC	4767
AD-12229 35.1	A-22822 49.1	2068	uscsacgaAfgUfGfGfugaagu ucaal96	A-228225 0.1	2517	VPusUfsgaaCfuaccacC fuUfcgugasusg	CAUCACGAAGUGGU GAAGUUCAU	4768

AD-12229 36.1	A-22822 51.1	2069	asasguggUfgAfAfGfuucaug gaaL96	A-228225 2.1	2518	VpusAfsuccAfuagaacuC faCfcauucscg	CGAAGUGGUGAAGU UCAUGGAUG	4769
AD-12229 37.1	A-22822 53.1	2070	asgsugguGfaAfGfUfugaugg augaL96	A-228225 4.1	2519	VpusCfsaucCfagaacuU fcAfcacusc	GAAUGUGGUGAAGU UCAUGGAUGU	4770
AD-12229 38.1	A-22822 55.1	2071	gsusggugAfaGfUfUfugaugga uguaL96	A-228225 6.1	2520	VpusAfscauCfagaacuU fuCfaccacsu	AAGUGGUGAAGUUC AUGGAUGUC	4771
AD-12229 39.1	A-22822 57.1	2072	gsusgaaGfuUfCfAfugaugg ucuaL96	A-228225 8.1	2521	VpusAfsagAcfaucagaA fcUfucacsasc	GUGGUGAAGUUCAU GGAUGUCUA	4772
AD-12229 40.1	A-22822 59.1	2073	gsusgaagUfuCfAfUfugauggu cuuaL96	A-228226 0.1	2522	VpusUfsagaCfaucagaA faCfuucacsca	UGGUGAAGUUCAU GAUGUCUAU	4773
AD-12229 41.1	A-22822 61.1	2074	usgsaaguUfcAfUfGfugaugg uuaL96	A-228226 2.1	2523	VpusAfsuagAfcuacauG faAfcuucacscc	GGUGAAGUUCAU AUGUCUAUC	4774
AD-12229 42.1	A-22822 63.1	2075	asasguucAfuGfGfAfugucua ucaL96	A-228226 4.1	2524	VpusUfsaguAfgacaucA fuGfaacuucsa	UGAAGUUCAUUGGAU GUCUAUCAG	4775
AD-12229 43.1	A-22822 65.1	2076	asgsuuaUfgGfAfUfugucua cagaL96	A-228226 6.1	2525	VpusCfsugaUfagaucC faUfgaacusc	GAAGUUCAUUGGAU UCUAUCAGC	4776
AD-12229 44.1	A-22822 67.1	2077	ususcaugGfaUfGfUfucua gcgaL96	A-228226 8.1	2526	VpusCfsguGfauagacuU fcCfagaacsu	AGUUCAUUGGAUGUC UAUCAGCGC	4777
AD-12229 45.1	A-22822 69.1	2078	gsusggacAfuCfUfUfuccagga guuaL96	A-228227 0.1	2527	VpusUfsacuCfcuggagaA fuGfuccacsca	UGGUGGACAUCUUC CAGGAGUAC	4778
AD-12229 46.1	A-22822 71.1	2079	uscsaguAfcAfUfCfuucaag ccaaL96	A-228227 2.1	2528	VpusUfsggeUfugaagu GfuAfcuegasusc	GAUCGAGUACAUCU UCAAGCCAU	4779
AD-12229 47.1	A-22822 73.1	2080	csgsaguaCfaUfCfUfucaagc cauaL96	A-228227 4.1	2529	VpusAfsuggCfugaaga UfgUfucacsasu	AUCGAGUACAUCU CAAGCCAU	4780

AD-12229 48.1	A-22822 75.1	2081	gsasguacAfuCfUfUfcaagcc aucaL96	A-228227 6.1	2530	VpusGfsaugGfueuagaag AfuGfuacugsga	UCGAGUACAUCUUC AAGCCAUC	4781
AD-12229 49.1	A-22822 77.1	2082	gsusacauCfuUfCfAfagccau ccuaL96	A-228227 8.1	2531	VpusAfsaggaUfggcuuga AfgAfuguaucusc	GAGUACAUCUUCAA GCCAUCCUG	4782
AD-12229 50.1	A-22822 79.1	2083	cscsaacaUfcAfcCfcaagcaga uuuL96	A-228228 0.1	2532	VpusAfsaucUfgcauggu GfaUfguugsgasc	GUCCAACAUCACCA UGCAGAUUA	4783
AD-12229 51.1	A-22822 81.1	2084	csasacauCfaCfCfAfugcaga uuuL96	A-228228 2.1	2533	VpusUfsaauCfugcaugg UfgAfugugsgsa	UCCAACAUCACCAU GCAGAUUAU	4784
AD-12229 52.1	A-22822 83.1	2085	ascsaucaCfcAfuGfcaagauu augaL96	A-228228 4.1	2534	VpusCfsauaAfucugcauG fgUfgaugusug	CAACAUCACCAUGC AGAUUAUGC	4785
AD-12229 53.1	A-22822 85.1	2086	csasucacCfaUfGfCfagaaua ugeL96	A-228228 6.1	2535	VpusGfscauAfaucugcaU fgGfugaugsusu	AACAUCACCAUGCA GAUUAUGCG	4786
AD-12229 54.1	A-22822 87.1	2087	ascsaugCfaGfaUfuaugcg gauL96	A-228228 8.1	2536	VpusAfsuceGfcauaucU fgCfugaugsusa	UCACCAUGCAGAUU AUGCGGAUC	4787
AD-12229 55.1	A-22822 89.1	2088	asusgcagAfuUfAfUfgcgga caaL96	A-228229 0.1	2537	VpusUfsugaUfccgcauaA fuCfugaugsug	CCAUGCAGAUUAUG CGGAUCAA	4788
AD-12229 56.1	A-22822 91.1	2089	usgscagaUfuAfUfGfcaagc aaaL96	A-228229 2.1	2538	VpusUfsuugAfuccgcau AfaUfcugcasug	CAUGCAGAUUAUGC GGAUCAAAC	4789
AD-12229 57.1	A-22822 93.1	2090	gscsagauUfaUfGfCfagauc aacaL96	A-228229 4.1	2539	VpusGfsuuuGfauccgca UfaAfucugcasu	AUGCAGAUUAUGCG GAUCAAACC	4790
AD-12229 58.1	A-22822 95.1	2091	gsasuuuGfcGfGfAfuaaac cucaL96	A-228229 6.1	2540	VpusGfsaggUfuagauc GfcAfuaucugsg	CAGAUUAUGCGGAU CAAACCUCA	4791
AD-12229 59.1	A-22822 97.1	2092	asusuaugCfGfAfUfcaaac ucaL96	A-228229 8.1	2541	VpusUfsgagGfuugauc CfGfauaauuscu	AGAUUAUGCGGAUC AAACCUCAC	4792

AD-12229 60.1	A-22822 99.1	2093	csgsgaucAfaAfCfCfucacca aggal96	A-228230 0.1	2542	VPusCfscuuGfgugaggu UfuGfauccgscsa	UGCGGAUCAAACCU CACCAAGGC	4793
AD-12229 61.1	A-22823 01.1	2094	gsgsagagAfuGfAfGfucuccu acaaL96	A-228230 2.1	2543	VPusUfsguaGfgaagcuc AfuCfucuccsusa	UAGGAGAGAUGAGC UUCUACAG	4794
AD-12229 62.1	A-22823 03.1	2095	gsasgaugAfgCfUfUfccuaca gcaal96	A-228230 4.1	2544	VPusUfsgcuGfuaggaag CfuCfauccusc	GAGAGAUAGGCUUC CUACAGCAC	4795
AD-12229 63.1	A-22823 05.1	2096	gsasugagCfuUfCfCfucacgc acaaL96	A-228230 6.1	2545	VPusUfsgugCfuguagga AfgCfucacsusc	GAGAUAGGCUUCCU ACAGCACAA	4796
AD-12229 64.1	A-22823 07.1	2097	asusgagCfuUfCfCfUfacagca caaaL96	A-228230 8.1	2546	VPusUfsguGfeguagga AfaGfcaucscsu	AGAUGAGCUUCCUA CAGCACAAAC	4797
AD-12229 65.1	A-22823 09.1	2098	gsasgcuuCfcUfAfCfagcaca acaaL96	A-228231 0.1	2547	VPusUfsguuGfugcugua GfgAfagcucsasu	AUGAGCUUCCUACA GCACAACAA	4798
AD-12229 66.1	A-22823 11.1	2099	asgscuucCfuAfCfAfgcaca caaaL96	A-228231 2.1	2548	VPusUfsguUfgugcugu AfgGfagcucsca	UGAGCUUCCUACAG CACAAACAA	4799
AD-12229 67.1	A-22823 13.1	2100	gscsuuccUfaCfAfGfcaaac aaaaL96	A-228231 4.1	2549	VPusUfsuugUfugugcug UfaGfgaagcsusc	GAGCUUCCUACAGC ACAACAAAU	4800
AD-12229 68.1	A-22823 15.1	2101	csusuccuAfcAfGfCfacaaca aaual96	A-228231 6.1	2550	VPusAfsuuuGfuugugcu GfuAfggaagcsu	AGCUUCCUACAGCA CAACAAAUUG	4801
AD-12229 69.1	A-22823 17.1	2102	uscscuacAfgCfAfCfaacaaa ugual96	A-228231 8.1	2551	VPusAfscauUfuguugug CfuGfuaggasag	CUUCCUACAGCACA ACAAAUUGUG	4802
AD-12229 70.1	A-22823 19.1	2103	csusacagCfaCfAfAfcfaaang ugaaL96	A-228232 0.1	2552	VPusUfscacAfuunguug UfgCfuguagsa	UCCUACAGCACAAC AAAUUGUGAA	4803
AD-12229 71.1	A-22823 21.1	2104	usascagAfcAfAfCfaaangu gaaal96	A-228232 2.1	2553	VPusUfsucaCfaunguu GfuGfuguagsg	CCUACAGCACAACA AAUGUGAAU	4804

AD-12229 72.1	A-22823 23.1	2105	asgsacaAfcAfAfAfugaa ugcaL96	A-228232 4.1	2554	VpusGfscuUfcacuuuG fuUfgucgsu	ACAGCACAAACAAU GUGAAUGCA	4805
AD-12229 73.1	A-22823 25.1	2106	gsacaaCfaAfAfUfguaa gcaal96	A-228232 6.1	2555	VpusUfsgaUfucacuuU fgUfugucsg	CAGCACAAACAAUG UGAAUGCAG	4806
AD-12229 74.1	A-22823 27.1	2107	csuscaccAfgGfAfafagacug auaal96	A-228232 8.1	2556	VpusUfsaucAfgucuuuc CfuGfgugagsag	CUCUACCAGGAAA GACUGAUAC	4807
AD-12229 75.1	A-22823 29.1	2108	uscsaccaGfgAfAfafagacuga uacal96	A-228233 0.1	2557	VpusGfsuauCfagucuuu CfcUfggugagsa	UCUCACCAGGAAAG ACUGAUACA	4808
AD-12229 76.1	A-22823 31.1	2109	csascaggGfaAfAfGfagacugau acaaL96	A-228233 2.1	2558	VpusUfsguaUfcagucuu UfcCfugugagsag	CUCACCAGGAAAGA CUGAUACAG	4809
AD-12229 77.1	A-22823 33.1	2110	ascscaggAfaAfGfAfcagaua cagaL96	A-228233 4.1	2559	VpusCfsuguAfcagucuu UfuCfcugugagsa	UCACCAGGAAAGAC UGAUACAGA	4810
AD-12229 78.1	A-22823 35.1	2111	csesaggAfaGfAfcfagacugau agaaL96	A-228233 6.1	2560	VpusUfscugUfaucaguc UfuUfcugugagsg	CACCAGGAAAGACU GAUACAGAA	4811
AD-12229 79.1	A-22823 37.1	2112	csasggaaAfgAfcUfagacua gaaal96	A-228233 8.1	2561	VpusUfsucuGfuaucagu CfuUfucugsgu	ACCAGGAAAGACUG AUACAGAAC	4812
AD-12229 80.1	A-22823 39.1	2113	asgsaaaGfaCfUfGfuaucag aacaL96	A-228234 0.1	2562	VpusGfsuucUfguaucag UfcUfuucugsg	CCAGGAAAGACUGA UACAGAACG	4813
AD-12229 81.1	A-22823 41.1	2114	gsaaaagAfcUfGfAfuacaga acgaL96	A-228234 2.1	2563	VpusCfsguuCfuguauc GfuCfuucugsg	CAGGAAAGACUGAU ACAGAACGA	4814
AD-12229 82.1	A-22823 43.1	2115	gsaaaagaCfuGfAfUfacagaa cgaaL96	A-228234 4.1	2564	VpusUfscguUfcuguauc AfgUfcuucscu	AGGAAAGACUGAUA CAGAACGAU	4815
AD-12229 83.1	A-22823 45.1	2116	asasagacUfgAfUfAfcagac gaual96	A-228234 6.1	2565	VpusAfsuegUfucuguan CfaGfucuuusc	GGAAAGACUGAUAC AGAACGAUC	4816

AD-12229 84.1	A-22823 47.1	2117	asasgacuGfaUfAfCfagaacg aucaL96	A-228234 8.1	2566	VpusGfsaucGfuucugua UfcAfgucuuusc	GAAAGACUGAUACA GAACGAUCG	4817
AD-12229 85.1	A-22823 49.1	2118	asgsacugAfuAfCfAfgaaga uegaL96	A-228235 0.1	2567	VpusCfsgauCfguucugu AfuCfagucusu	AAAGACUGAUACAG AACGAUCGA	4818
AD-12229 86.1	A-22823 51.1	2119	gsascugaUfaCfAfGfaacgau cgaal96	A-228235 2.1	2568	VpusUfscgaUfcguucug UfaUfcagucsu	AAGACUGAUACAGA ACGAUCGAU	4819
AD-12229 87.1	A-22823 53.1	2120	ascugauAfcAfGfAfaacgau gaual96	A-228235 4.1	2569	VpusAfsuagAfuucugu GfuAfuacugsu	AGACUGAUACAGAA CGAUCGAUA	4820
AD-12229 88.1	A-22823 55.1	2121	csusgaucCfaGfAfAfcgaucg auaal96	A-228235 6.1	2570	VpusUfsaucGfaucguuc UfgUfaucagsuc	GACUGAUACAGAAC GAUCGAUAC	4821
AD-12229 89.1	A-22823 57.1	2122	usgsauacAfgAfAfcfagaucg uacal96	A-228235 8.1	2571	VpusGfsuauCfgaucgu CfuGfuacagsu	ACUGAUACAGAACG AUCGAUACA	4822
AD-12229 90.1	A-22823 59.1	2123	gsasuacaGfaAfCfGfaucgau acaaL96	A-228236 0.1	2572	VpusUfsguaUfcgaucgu UfcUfguacagsag	CUGAUACAGAACGA UCGAUACAG	4823
AD-12229 91.1	A-22823 61.1	2124	asusacagAfaCfGfAfuacgau cagaL96	A-228236 2.1	2573	VpusCfsuguAfuacgaucg UfuCfugaucscsa	UGAUACAGAACGAU CGAUACAGA	4824
AD-12229 92.1	A-22823 63.1	2125	usascagaAfcGfAfUfcgauc agaal96	A-228236 4.1	2574	VpusUfscugUfaucgauc GfuUfcuguausc	GAUACAGAACGAUC GAUACAGAA	4825
AD-12229 93.1	A-22823 65.1	2126	ascsgaaCfGfAfUfcfagauc gaal96	A-228236 6.1	2575	VpusUfsucuGfuacgau CfGfugaucsu	AUACAGAACGAUCG AUACAGAAA	4826
AD-12229 94.1	A-22823 67.1	2127	csasgaacGfaUfCfGfaucag aaaal96	A-228236 8.1	2576	VpusUfsuucUfguacga UfcGfuucugsua	UACAGAACGAUCGA UACAGAAAC	4827
AD-12229 95.1	A-22823 69.1	2128	asgsaacgAfuCfGfAfuacaga aacaL96	A-228237 0.1	2577	VpusGfsuuuUfuacgaucg AfuCfugaucgsu	ACAGAACGAUCGAU ACAGAAACC	4828

AD-12229 96.1	A-22823 71.1	2129	gsasacgaUfcGfAfUfacagaa accaL96	A-228237 2.1	2578	VpusGfsguUfucguau GfaUfcguusug	CAGAACGAUCGAUA CAGAAACCA	4829
AD-12229 97.1	A-22823 73.1	2130	asascgauCfGfAfUfcagaaa ccaaL96	A-228237 4.1	2579	VpusUfsgguUfucguau CfGfAfcguuscsu	AGAACGAUCGAUAC AGAAACCAC	4830
AD-12229 98.1	A-22823 75.1	2131	ascsgaucGfAfUfcfagaac cacaL96	A-228237 6.1	2580	VpusGfsuggUfucugua UfcGfauususc	GAAACGAUCGAUACA GAAACCACG	4831
AD-12229 99.1	A-22823 77.1	2132	csgsaucgAfuAfCfAfgaacc acgaL96	A-228237 8.1	2581	VpusCfsgugGfuucugu AfuCfgaucgsusu	AACGAUCGAUACAG AAACCACGC	4832
AD-12230 00.1	A-22823 79.1	2133	csasccauCfaCfCfAfcagacag aaalL96	A-228238 0.1	2582	VpusUfsucuGfucgagg UfgAfcguggsug	CACACCAUCACCAU CGACAGAAC	4833
AD-12230 01.1	A-22823 81.1	2134	csasucacCfaUfCfGfacagaa agaL96	A-228238 2.1	2583	VpusCfsuguUfcugcga UfgGfugaugsgsu	ACCAUCACCAUCGA CAGAACAGU	4834
AD-12230 02.1	A-22823 83.1	2135	uscsaccaUfcGfAfCfagaaca gucaL96	A-228238 4.1	2584	VpusGfsacuGfuucuguc GfaUfcgugasug	CAUCACCAUCGACA GAACAGUCC	4835
AD-12230 03.1	A-22823 85.1	2136	csasccauCfGfAfCfagaacag uccaL96	A-228238 6.1	2585	VpusGfsagUfcuucugu CfGfAfcguggsasu	AUCACCAUCGACAG AACAGUCCU	4836
AD-12230 04.1	A-22823 87.1	2137	ascsgaucGfAfCfGfaacagu ccuaL96	A-228238 8.1	2586	VpusAfsaggCfuguucug UfcGfauuggsa	UCACCAUCGACAGA ACAGUCCUU	4837
AD-12230 05.1	A-22823 89.1	2138	cscsaucgAfcAfGfAfagacug cuuaL96	A-228239 0.1	2587	VpusAfsaggAfcuguucu GfuCfgauggsug	CACCAUCGACAGAA CAGUCCUUA	4838
AD-12230 06.1	A-22823 91.1	2139	csasucgaCfGfAfAfcagucc uuuaL96	A-228239 2.1	2588	VpusUfsaagGfaguguc UfgUfcgaugsgsu	ACCAUCGACAGAAC AGUCCUUA	4839
AD-12230 07.1	A-22823 93.1	2140	asuscgacAfgAfAfcfaguccu uuaaL96	A-228239 4.1	2589	VpusUfsuaaGfgacugu CfuGfucgaugsg	CCAUCGACAGAAC GUCCUUAU	4840

AD-12230 08.1	A-22823 95.1	2141	uscsagacaGfaAfCfAfguccuu aaual96	A-228239 6.1	2590	VpusAfsuuaAfggacugu UfcUfgucgasusg	CAUCGACAGAACAG UCCUUAUCC	4841
AD-12230 09.1	A-22823 97.1	2142	csagsacagAfaCfAfguccuu aucaL96	A-228239 8.1	2591	VpusGfsauuAfggacug UfuCfugucgsasu	AUCGACAGAACAGU CCUUAUCC	4842
AD-12230 10.1	A-22823 99.1	2143	gsascagAfcAfGfuccuu uccaL96	A-228240 0.1	2592	VpusGfsgauUfaaggacu GfuUfcugucgsa	UCGACAGAACAGUC CUUAAUCCA	4843
AD-12230 11.1	A-22824 01.1	2144	ascsagaaCfaGfUfCfcuu ccaaL96	A-228240 2.1	2593	VpusUfsggaUfuaggac UfgUfucuguscsg	CGACAGAACAGUCC UUAAUCCAG	4844
AD-12230 12.1	A-22824 03.1	2145	asgsaacaGfuCfCfUfu agaaL96	A-228240 4.1	2594	VpusUfscugGfaauaagg AfcUfgucgusu	ACAGAACAGUCCUU AAUCCAGAA	4845
AD-12230 13.1	A-22824 05.1	2146	gsasacagUfcCfUfua gaaL96	A-228240 6.1	2595	VpusUfsucuGfgauaag GfaCfugucsusg	CAGAACAGUCCUUA AUCCAGAAA	4846
AD-12230 14.1	A-22824 07.1	2147	asascaguCfcUfUfa aaaL96	A-228240 8.1	2596	VpusUfsuucUfgauuaa GfgAfcugucscu	AGAACAGUCCUUA UCCAGAAAC	4847
AD-12230 15.1	A-22824 09.1	2148	ascsagucCfuUfAf aacaL96	A-228241 0.1	2597	VpusGfsuuuUfugauua AfgGfagucsusg	GAACAGUCCUUAU CCAGAAAACC	4848
AD-12230 16.1	A-22824 11.1	2149	csasgucUfuAfUf accaL96	A-228241 2.1	2598	VpusGfsguuUfugauu AfaGfagucgsu	AACAGUCCUUAUCC CAGAAAACCU	4849
AD-12230 17.1	A-22824 13.1	2150	asgsuccuUfaUfCf ccuaL96	A-228241 4.1	2599	VpusAfsggUfucuggau UfaAfggacgsu	ACAGUCCUUAUCC AGAAAACCU	4850
AD-12230 18.1	A-22824 15.1	2151	gsusccuuAfaUfCf cugaL96	A-228241 6.1	2600	VpusCfsaggUfuucugga UfuAfggacgsu	CAGUCCUUAUCCA GAAAACCU	4851
AD-12230 19.1	A-22824 17.1	2152	uscsuuuAfuCfCf ugaL96	A-228241 8.1	2601	VpusUfscagGfuucugg AfuUfaaggacscu	AGUCCUUAUCCAG AAACCUGAA	4852

AD-12230 20.1	A-22824 19.1	2153	cscsuuaaUfcCfAfGfaaaccu gaaal96	A-228242 0.1	2602	VpusUfsucaGfguuuucug GfaUfuaaggsasc	GUCCUUAUCCAGAA AACCUGAAA	4853
AD-12230 21.1	A-22824 21.1	2154	csusuauuCfcAfGfAfaaccug aaaal96	A-228242 2.1	2603	VpusUfsuucAfghuuuuc GfgAfuaaggsa	UCCUUAUCCAGAA ACCUGAAAU	4854
AD-12230 22.1	A-22824 23.1	2155	ususaauCfAfGfAfaaccuga aaual96	A-228242 4.1	2604	VpusAfsuuuCfagguuuc UfgGfaauaagsg	CCUUAUCCAGAAA CCUGAAAUG	4855
AD-12230 23.1	A-22824 25.1	2156	csasgaaaCfcUfGfAfaugaa ggaal96	A-228242 6.1	2605	VpusUfscuuUfcauuucaG fgUfuucgsgsa	UCCAGAAACCUGAA AUGAAGGAA	4856
AD-12230 24.1	A-22824 27.1	2157	asgsaaacCfuGfAfAfaugaag gaaal96	A-228242 8.1	2606	VpusUfsuccUfcauuuc AfgGfuucugsg	CCAGAAAACCUGAAA UGAAGGAAG	4857
AD-12230 25.1	A-22824 29.1	2158	gsasaaccUfgAfAfAfugaagg aagal96	A-228243 0.1	2607	VpusCfsuucCfucauuuC faGfguuucsg	CAGAAAACCUGAAAU GAAGGAAGA	4858
AD-12230 26.1	A-22824 31.1	2159	asasaccuGfaAfAfUfgaagga agaal96	A-228243 2.1	2608	VpusUfscuuCfcauuu UfcAfghuuucsu	AGAAACCUGAAAUUG AAGGAAGAG	4859
AD-12230 27.1	A-22824 33.1	2160	asaccugAfAfUfGfaagga gagal96	A-228243 4.1	2609	VpusCfsuccUfcauuuU fuCfagguusuc	GAAACCUGAAAUUGA AGGAAGAGG	4860
AD-12230 28.1	A-22824 35.1	2161	cscsugaaAfUfGfAfAfggaaga ggaal96	A-228243 6.1	2610	VpusUfscuuCfuuccuucA fuUfucaggsusu	AACCUGAAAUUGAAG GAAGAGGAG	4861
AD-12230 29.1	A-22824 37.1	2162	asusgaagGfaAfGfAfggagac ucual96	A-228243 8.1	2611	VpusAfsgagUfuccuuc UfcCfucaususu	AAAUGAAGGAAGA GGAGACUCUG	4862
AD-12230 30.1	A-22824 39.1	2163	uscscuccUfuGfGfAfaugga uuual96	A-228244 0.1	2612	VpusGfsaauCfcauuuucA faGfagggasasc	GGUCCCUUUGGAA UUGGAUUCG	4863
AD-12230 31.1	A-22824 41.1	2164	cscsucuuGfgAfAfUfuggauu cgcal96	A-228244 2.1	2613	VpusGfscgaAfuccaauuC fcAfagagsgsa	UCCUCUUGGAUUU GGAUUCGCC	4864

AD-12230 32.1	A-22824 43.1	2165	csuscuugGfaAfUfUfggauc gccal96	A-228244 4.1	2614	VPusGfsgeGfAfaucgauU fcCfaagagsgsg	CCCUCUUGGAUUUG GAUUCGCCA	4865
AD-12230 33.1	A-22824 45.1	2166	ususggaaUfuGfGfAfuuegc auual96	A-228244 6.1	2615	VPusAfsaugGfgegaucA faUfuccaasgsa	UCUUGGAAUUGGAU UCGCCAUUU	4866
AD-12230 34.1	A-22824 47.1	2167	usgsaaUfGfAfuugcca uuual96	A-228244 8.1	2616	VPusAfsaaUGfgegaucC faAfuuccasasg	CUUGGAAUUGGAUU CGCCAUUUU	4867
AD-12230 35.1	A-22824 49.1	2168	gsasaaUfGfAfuufcgccau uuual96	A-228245 0.1	2617	VPusAfsaaaUfgegaucC fcAfauccsasa	UUGGAAUUGGAUUC GCCAUUUUA	4868
AD-12230 36.1	A-22824 51.1	2169	gsasaaUfGfAfuufcgccau uuual96	A-228245 2.1	2618	VPusUfsaaaAfuugcgaaU fcCfaauuccesa	UGGAAUUGGAUUCG CCAUUUUUAU	4869
AD-12230 37.1	A-22824 53.1	2170	asasuuggAfuUfCfGfccaauu uual96	A-228245 4.1	2619	VPusAfsuaaAfaugcgga AfuCfcaauuscsc	GGAUUUGGAUUCGC CAUUUUUUU	4870
AD-12230 38.1	A-22824 55.1	2171	asusuggaUfuCfGfCfcauuu auual96	A-228245 6.1	2620	VPusAfsaaAfaauggcg AfaUfccaususc	GAAUUGGAUUCGCC AUUUUAUUU	4871
AD-12230 39.1	A-22824 57.1	2172	ususggauUfcGfCfCfcauuua uuual96	A-228245 8.1	2621	VPusAfsaaUfaaauggcG faAfuccaasusu	AAUUGGAUUCGCCA UUUUUUUUU	4872
AD-12230 40.1	A-22824 59.1	2173	usgsaaUfGfCfCfAfuuuuau uuual96	A-228246 0.1	2622	VPusAfsaaaUfaaauggC fgAfauccasasu	AUUGGAUUCGCCAU UUUAUUUUU	4873
AD-12230 41.1	A-22824 61.1	2174	gsasaaUfGfCfAfuuuuau uuual96	A-228246 2.1	2623	VPusAfsaaaAfuuaauggG fcGfauccsasa	UUGGAUUCGCCAUU UUUUUUUUC	4874
AD-12230 42.1	A-22824 63.1	2175	gsasaaUfGfCfAfuuuuau uuual96	A-228246 4.1	2624	VPusGfsaaaAfauaauggG fgCfgaauccesa	UGGAUUCGCCAUUU UAUUUUUCU	4875
AD-12230 43.1	A-22824 65.1	2176	uscsaaUfuUfAfuuuuuc uuual96	A-228246 6.1	2625	VPusCfsaagAfaaaauaaA faUfgecgasasu	AUUCGCCAUUUUAU UUUUCUUGC	4876

AD-12230 44.1	A-22824 67.1	2177	csgscgauUfuUfAfUfuuuuuu ugcaL96	A-228246 8.1	2626	VPusGfscaaGfaaaaaaA faAfuggcgsasa	UUCGCCAUUUUAUU UUUCUUGCU	4877
AD-12230 45.1	A-22824 69.1	2178	gscscauuUfuAfUfUfuuuuu gcuaL96	A-228247 0.1	2627	VPusAfsgeAfgaaaaaA faAfauggcgsa	UCGCCAUUUUAUU UUCUUGCUG	4878
AD-12230 46.1	A-22824 71.1	2179	cscsaauUfaUfUfUfuuuuug cugaL96	A-228247 2.1	2628	VPusCfsagcAfagaaaaU faAfaaugscsg	CGCCAUUUUAUUU UCUUGCUGC	4879
AD-12230 47.1	A-22824 73.1	2180	csasuuiuAfuUfUfUfuuuug ugcaL96	A-228247 4.1	2629	VPusGfsagcCfaagaaaaA fuAfaaungsgc	GCCAUUUUAUUUU CUUGCUGCU	4880
AD-12230 48.1	A-22824 75.1	2181	asusuuiuUfuUfUfUfuuuug gcuaL96	A-228247 6.1	2630	VPusAfsgeAfgcaagaaaA faUfaaaungsg	CCAUUUUAUUUUU UUGCUGCUA	4881
AD-12230 49.1	A-22824 77.1	2182	ususuuuUfuUfUfUfuuuug gcuaL96	A-228247 8.1	2631	VPusUfsagcAfgcaagaaaA faAfuaaaungsg	CAUUUUUAUUUUU UGCUGCUAA	4882
AD-12230 50.1	A-22824 79.1	2183	ususuuuGfcUfGfCfuuaaau accaL96	A-228248 0.1	2632	VPusGfsugAfuuaagca GfcAfagaasasa	UUUUUUUUGCUGCU AAAUACCCG	4883
AD-12230 51.1	A-22824 81.1	2184	uscaccgAfgCfCfCfugaaga uuuaL96	A-228248 2.1	2633	VPusUfsaauCfuuccgggC fuCfggugasusu	AAUCACCGAGCCCG GAAGAUUAG	4884
AD-12230 52.1	A-22824 83.1	2185	gscscggAfaGfAfUfuagaga guuaL96	A-228248 4.1	2634	VPusAfsacuCfuuaaauC fuCfcgggesusc	GAGCCCGGAAGAUA AGAGAUUU	4885
AD-12230 53.1	A-22824 85.1	2186	cscscggaAfgAfUfUfagagag uuuaL96	A-228248 6.1	2635	VPusAfsaacUfcuuaauC fuUfccgggscsu	AGCCCGGAAGAUA GAGAUUUU	4886
AD-12230 54.1	A-22824 87.1	2187	csgsgaagAfuUfAfGfagaguu uuuaL96	A-228248 8.1	2636	VPusUfsaaaAfcucuaaA fuCfuuccggsgg	CCCGGAAGAUUAGA GAGUUUAU	4887
AD-12230 55.1	A-22824 89.1	2188	gsgsaagaUfuAfGfAfgaguuu uuaaL96	A-228249 0.1	2637	VPusAfsuaaAfacucuaA faUfcuuccsgg	CCGGAAGAUUAGAG AGUUUUUAU	4888

AD-12230 56.1	A-22824 91.1	2189	gsasagauUfaGfAfGfaguuu auuaL96	A-228249 2.1	2638	VPusAfsauAfaacucU faAfcuucscsg	CGAAGAUUAGAGA GUUUUAUUU	4889
AD-12230 57.1	A-22824 93.1	2190	asasgauAfgAfGfAfguuua uuuaL96	A-228249 4.1	2639	VPusAfsauAfaacucU fuAfaucuuusc	GGAAGAUUAGAGA GUUUUAUUUC	4890
AD-12230 58.1	A-22824 95.1	2191	asgsauuaGfaGfAfGfuuuuu uuccaL96	A-228249 6.1	2640	VPusGfsaaaUfaaaacU fcUfaaucususc	GAAGAUUAGAGAG UUUUUAUUUCU	4891
AD-12230 59.1	A-22824 97.1	2192	asusuagaGfaGfUfufuuuuu cugaL96	A-228249 8.1	2641	VPusCfsagaAfaaaaaaC fcUfcauausc	AGAUUAGAGAGUU UUUUUUUCUGG	4892
AD-12230 60.1	A-22824 99.1	2193	ususagagAfgUfUfufuuuuu uggaL96	A-228250 0.1	2642	VPusCfscagAfaaaaaaC fuCfucuausc	GAUUAGAGAGUUU UAUUUCUGGG	4893
AD-12230 61.1	A-22825 01.1	2194	usagagaGfuUfUfufuuuuu gggaL96	A-228250 2.1	2643	VPusCfscgaGfaaaaaaA fcUfcuuaas	AUUAGAGAGUUUU AUUUCUGGGA	4894
AD-12230 62.1	A-22825 03.1	2195	asgsagagUfuUfUfufuuucg gggaL96	A-228250 4.1	2644	VPusUfscgcAfgaaauaA faCfucucusa	UUAGAGAGUUUUA UUUCUGGGAU	4895
AD-12230 63.1	A-22825 05.1	2196	gsasagauUfuUfAfufuucg ggauaL96	A-228250 6.1	2645	VPusAfsuccCfagaaauA faAfcuucusa	UAGAGAGUUUUUA UUCUGGGAUU	4896
AD-12230 64.1	A-22825 07.1	2197	asgsagauUfuAfUfufucgg gauuaL96	A-228250 8.1	2646	VPusAfsaucCfcagaaauA faAfaucusc	AGAGAGUUUUUAU UCUGGGAUUC	4897
AD-12230 65.1	A-22825 09.1	2198	gsasguuuUfaUfUfufucggga uuccaL96	A-228251 0.1	2647	VPusGfsauCfcagaaauA faAfaucusc	GAGAGUUUUUAUUC UGGGAUUC	4898
AD-12230 66.1	A-22825 11.1	2199	asgsuuuuAfuUfUfCfucggga uuccaL96	A-228251 2.1	2648	VPusGfsgaaUfccagaaA fuAfaaacusc	AGAGUUUUUAUUCU GGGAUUCU	4899
AD-12230 67.1	A-22825 13.1	2200	gsusuuuaUfuUfCfufggga uccuaL96	A-228251 4.1	2649	VPusAfsagaAfuuccagA faUfaaacusc	GAGUUUUUAUUCUG GGAUUCUG	4900

AD-12230 68.1	A-22825 15.1	2201	ususuuUfuCfUfGfggauc cugaL96	A-228251 6.1	2650	VpusCfsaggAfaucaggA faAfaaaacsu	AGUUUAUUUCUGG GAUCCUGU	4901
AD-12230 69.1	A-22825 17.1	2202	ususuuUfcUfGfggauc uguaL96	A-228251 8.1	2651	VpusAfsaggGfaucaggA faAfaaaacsu	GUUUUAUUUCUGG AUUCCUGA	4902
AD-12230 70.1	A-22825 19.1	2203	ususuuUfcUfGfggauc guuaL96	A-228252 0.1	2652	VpusUfsaggGfaucaggA fgAfaaaacsu	UUUAUUUCUGGGA UCCUGUAG	4903
AD-12230 71.1	A-22825 21.1	2204	ususuuUfcUfGfggauc uagaL96	A-228252 2.1	2653	VpusCfsuagAfggaucC faGfaaaacsu	UUUAUUUCUGGGA UCCUGUAGA	4904
AD-12230 72.1	A-22825 23.1	2205	asusuucUfcUfGfggauc agaL96	A-228252 4.1	2654	VpusUfsuagCfaggauC fcAfgaaacsu	UUUAUUUCUGGGA CCUGUAGAC	4905
AD-12230 73.1	A-22825 25.1	2206	ususucUfcUfGfggauc gacaL96	A-228252 6.1	2655	VpusGfsuagAfggaucC fcCfagaacsu	UUUAUUUCUGGGA CUGUAGACA	4906
AD-12230 74.1	A-22825 27.1	2207	usugggUfcUfGfggauc cacaL96	A-228252 8.1	2656	VpusGfsuagCfaggauC AfuCfcagacsu	UUUAUUUCUGGGA GUAGACACA	4907
AD-12230 75.1	A-22825 29.1	2208	usugggUfcUfGfggauc acaL96	A-228253 0.1	2657	VpusUfsuagUfcuagC AfaUfcagacsu	UUUAUUUCUGGGA UAGACACAC	4908
AD-12230 76.1	A-22825 31.1	2209	usugggUfcUfGfggauc cacaL96	A-228253 2.1	2658	VpusGfsuagUfcuagC GfaAfuagacsu	UUUAUUUCUGGGA AGACACACC	4909
AD-12230 77.1	A-22825 33.1	2210	gsggaUfcUfGfggauc accaL96	A-228253 4.1	2659	VpusGfsuagUfcuagC GfgAfuagacsu	UUUAUUUCUGGGA GACACACC	4910
AD-12230 78.1	A-22825 35.1	2211	ascsacCfcAfcCfagauc auaL96	A-228253 6.1	2660	VpusAfsuagUfcuagC GfgGfugagacsu	UUUAUUUCUGGGA ACAUACAUA	4911
AD-12230 79.1	A-22825 37.1	2212	ascsacCfcAfcCfagauc auaL96	A-228253 8.1	2661	VpusAfsuagUfcuagC GfgGfugagacsu	UUUAUUUCUGGGA ACAUACAUA	4912

AD-12230 80.1	A-22825 39.1	2213	cscsaccCfaCfAfUfauaaca uuaaL96	A-228254 0.1	2662	VPusAfsaugUfauaug UfgGfgggsgsg	CACCCACCCACAUA CAUACAUUU	4913
AD-12230 81.1	A-22825 41.1	2214	cscsaccAfcAfUfAfcuaca uuaaL96	A-228254 2.1	2663	VPusAfsauUGfauaugu GfuGfgggsgsgsu	ACCCACCCACAUA AUACAUAUA	4914
AD-12230 82.1	A-22825 43.1	2215	csascccaCfaUfAfCfauaau uuaaL96	A-228254 4.1	2664	VPusUfsaaaUfguaua UfgUfgggsgsgsg	CCCACCCACAUA UACAUAUAU	4915
AD-12230 83.1	A-22825 45.1	2216	cscsacauAfcAfUfAfcuaua uuaaL96	A-228254 6.1	2665	VPusAfsuauAfaugau GfuAfgggsgsgsu	ACCCACAUAUA AUUAUAUA	4916
AD-12230 84.1	A-22825 47.1	2217	csascauaCfaUfAfCfauuau auaaL96	A-228254 8.1	2666	VPusUfsauUfaaangua fgUfaugsgsgsg	CCCACAUAUA UUAUAUAU	4917
AD-12230 85.1	A-22825 49.1	2218	ususaaauUfaAfCfAfgucua augaL96	A-228255 0.1	2667	VPusCfsauAfgcacu UfaAfuuaasasa	UUUAAAUAUA UUAUAUAU	4918
AD-12230 86.1	A-22825 51.1	2219	usasaauAfaCfAfgucua uguaL96	A-228255 2.1	2668	VPusAfscauUfagcacu fuAfauuasasa	UUUAAAUAUA GCUAAUGUU	4919
AD-12230 87.1	A-22825 53.1	2220	asasaauAfaCfUfgucua guuaL96	A-228255 4.1	2669	VPusAfsacaUfuagcacu fuUfauuasasa	UUAAAUAUA CUAAUGUUA	4920
AD-12230 88.1	A-22825 55.1	2221	asasuuaaCfaGfUfGfuaaag uuaaL96	A-228255 6.1	2670	VPusUfsaacAfuagcacu fgUfuuaausasa	UAAUAUAUA UAAUGUUAU	4921
AD-12230 89.1	A-22825 57.1	2222	asusuaacAfgUfgCfuaangu uuaaL96	A-228255 8.1	2671	VPusAfsuaaCfaauagca fuGfuuaausasu	AAAUAUAUA AAUGUUAU	4922
AD-12230 90.1	A-22825 59.1	2223	ususaacaGfuGfCfuaangu auuaL96	A-228256 0.1	2672	VPusAfsauAfaauagca fcUfguaaasasu	AAUAUAUA AUGUUAUUG	4923
AD-12230 91.1	A-22825 61.1	2224	usasacagUfgCfUfAfaangu uugaL96	A-228256 2.1	2673	VPusCfsauAfaauagC faCfugaasasu	AUUAUAUA UGUUAUUGG	4924

AD-12230 92.1	A-22825 63.1	2225	asascaguGfcUfAfAfuguuau uggaL96	A-228256 4.1	2674	VPusCfscaaUfaacaauaG fcAfcuguusasa	UUAACAGUGCUAU GUUAUUGGU	4925
AD-12230 93.1	A-22825 65.1	2226	asesagugCfuAfAfUfguuauu gguaL96	A-228256 6.1	2675	VPusAfsccaAfuacaauaA fgCfcacugususa	UAACAGUGCUAU GUUAUUGGU	4926
AD-12230 94.1	A-22825 67.1	2227	csasgugcUfaAfUfGfuuaug gugaL96	A-228256 8.1	2676	VPusCfsaccAfauaacauU faGfcacugsusu	AACAGUGCUAU GUUAUUGGU	4927
AD-12230 95.1	A-22825 69.1	2228	gsusgcuafGfUfUfaugg uguaL96	A-228257 0.1	2677	VPusGfsacaCfcauaaacA fuUfagcacsug	CAGUGCUAU GUUAUUGGU	4928
AD-12230 96.1	A-22825 71.1	2229	usgsucauUfgUfUfAfuuggu gucuaL96	A-228257 2.1	2678	VPusAfsagcAfcacaauaC faUfuagcascu	AGUGCUAU GUUAUUGGU	4929
AD-12230 97.1	A-22825 73.1	2230	gsucauauGfuUfAfUfuggug ucuuaL96	A-228257 4.1	2679	VPusAfsagaCfaccacaauA fcAfuuaagsasc	GUGCUAU GUUAUUGGU	4930
AD-12230 98.1	A-22825 75.1	2231	csusaauGfuUfUfUfguguc uucuaL96	A-228257 6.1	2680	VPusGfsaagAfcacaauaA faCfaauuagcsa	UGCUAU GUUAUUGGU	4931
AD-12230 99.1	A-22825 77.1	2232	usasauguUfaUfUfGfgugucu ucaalL96	A-228257 8.1	2681	VPusUfsgaaGfacaccaaU faAfcacaauagsc	GCUAAUGUUAU GUUGUUCAC	4932
AD-12231 00.1	A-22825 79.1	2233	asasuguuAfuUfGfGfgugucu ucacaL96	A-228258 0.1	2682	VPusGfsugaAfgacaccaaA fuAfaacaauasag	CUAAUGUUAU GUUGGU	4933
AD-12231 01.1	A-22825 81.1	2234	asusguuaUfuGfGfUfgucuu acuuaL96	A-228258 2.1	2683	VPusAfsugAfgacaccaaA faUfaacaauasusa	UAAUGUUAU GUUGGU	4934
AD-12231 02.1	A-22825 83.1	2235	usgsuuaUfgGfUfGfucuuca cugaL96	A-228258 4.1	2684	VPusCfsaguGfaagacacC faAfuacaauasusu	AAUGUUAU GUUGGU	4935
AD-12231 03.1	A-22825 85.1	2236	gsusuuaUGfgUfGfUfucucac uggaL96	A-228258 6.1	2685	VPusCfsagUfgaagacacC faAfuacaauasusu	AUGUUAU GUUGGU	4936

AD-1223104.1	A-2282587.1	2237	ususauugGfuGfUfCfuucacu ggaal96	A-2282588.1	2686	VpusUfscacGfugaagacA fcCfaauaacsca	UGUUAUUGGUGUCU UCACUGGAU	4937
AD-1223105.1	A-2282589.1	2238	usgsugugCfuUfCfAfcuggau guaal96	A-2282590.1	2687	VpusUfsacaUfccagugacA fgAfcaccasasu	AUUGGUGUCUUCAC UGGAUGUAU	4938
AD-1223106.1	A-2282591.1	2239	usgsucuuCfaCfUfGfangua uuual96	A-2282592.1	2688	VpusAfsaauAfaucacagU fgAfaagacasc	GGUGUCUUCACUGG AUGUAUUUG	4939
AD-1223107.1	A-2282593.1	2240	csascuggAfuGfUfAfuugac ugcaal96	A-2282594.1	2689	VpusGfscagUfcaauaacA fuCfcagugsasa	UUCACUGGAUGUAU UUGACUGCU	4940
AD-1223108.1	A-2282595.1	2241	ascsgugaUfgUfAfUfuugacu gcuaal96	A-2282596.1	2690	VpusAfsagaGfuaaauaC faUfccagugsa	UCACUGGAUGUAU UAGACUGCU	4941
AD-1223109.1	A-2282597.1	2242	usgsaugUfaUfUfUfgacugc ugual96	A-2282598.1	2691	VpusAfsacagCfagucacaaU faCfauccagsu	ACUGGAUGUAUUUG ACUGCUGUG	4942
AD-1223110.1	A-2282599.1	2243	usasuugAfcUfGfCfuguga cuual96	A-2282600.1	2692	VpusAfsaguCfcacagacG fuCfaauaacsca	UGUAUUUGACUGCU GUGGACUUG	4943
AD-1223111.1	A-2282601.1	2244	ususugacUfgCfUfGfuggacu ugaaal96	A-2282602.1	2693	VpusUfscacGfuccacagC faGfuaaasusa	UAUUUGACUGCUGU GGACUUGAG	4944
AD-1223112.1	A-2282603.1	2245	gscsugugGfaCfUfUfgaguug ggaal96	A-2282604.1	2694	VpusUfscacAfacuacagU fcCfacagcsasg	CUGCUGUGGACUUG AGUUGGGAG	4945
AD-1223113.1	A-2282605.1	2246	uscscacUfcAfGfAfuccuga cagaal96	A-2282606.1	2695	VpusCfsuguCfaggacu GfaGfugggsasac	GUUCCACUCACAGU CCUGACAGG	4946
AD-1223114.1	A-2282607.1	2247	csccscacuCfaGfAfUfcugac aggaaal96	A-2282608.1	2696	VpusCfsengUfcaggacuU fgAfgugggsasa	UUCACUCACAGU CUGACAGG	4947
AD-1223115.1	A-2282609.1	2248	gsgsaggaGfaUfGfAfgagacu cugaal96	A-2282610.1	2697	VpusCfsagaGfucucuaU fcUfcuccusc	GAGGAGGAGUA GAGACUCUGG	4948

AD-12231 16.1	A-22826 11.1	2249	gsasggagAfuGfAfGfagacuc uggal96	A-228261 2.1	2698	VpusCfscagAfgucucucA fuCfuccucscsu	AGGAGGAGAUGAG AGACUCUGGC	4949
AD-12231 17.1	A-22826 13.1	2250	gsgsagauGfaGfAfGfagucug gcaal96	A-228261 4.1	2699	VpusUfsgccAfgagucuc UfcAfucucscsu	GAGGAGAUGAGAG ACUCUGGCAU	4950
AD-12231 18.1	A-22826 15.1	2251	gsasgacuCfuGfGfCfagauca uuual96	A-228261 6.1	2700	VpusAfsaagAfucaugccA fgAfucucscsu	GAGAGACUCUGGCA UGAUCUUUU	4951
AD-12231 19.1	A-22826 17.1	2252	asgsacucUfgGfCfAfugauc uuual96	A-228261 8.1	2701	VpusAfsaaaGfaucagccC faGfagucscsu	AGAGACUCUGGCAU GAUCUUUUU	4952
AD-12231 20.1	A-22826 19.1	2253	ususuuggGfaAfCfAfccgaca aacaL96	A-228262 0.1	2702	VpusGfsuuuGfucggugu UfcCfcaaaascsu	AGUUUUUGGGAACAC CGACAAAACC	4953
AD-12231 21.1	A-22826 21.1	2254	gsasgcuuCfaGfGfAfcauugc ugual96	A-228262 2.1	2703	VpusAfsagCfauguccU fgAfagucscsc	GGGAGCUUCAGGAC AUUGCUGUG	4954
AD-12231 22.1	A-22826 23.1	2255	gscsuucaGfgAfCfAfugcug ugcaL96	A-228262 4.1	2704	VpusGfscacAfgaauuG fcUfgaagcsuc	GAGCUUCAGGACAU UGCUGUGCU	4955
AD-12231 23.1	A-22826 25.1	2256	csusucagGfaCfAfUfugcugu gcuaL96	A-228262 6.1	2705	VpusAfsagCfagcaauG fcCfugaagcsu	AGCUUCAGGACAUU GCUGUGCUU	4956
AD-12231 24.1	A-22826 27.1	2257	ususcaggAfcAfUfUfugcug cuual96	A-228262 8.1	2706	VpusAfsagCfagcaauG fuCfugaagsc	GCUUCAGGACAUUG CUGUGCUUU	4957
AD-12231 25.1	A-22826 29.1	2258	uscsaggaCfaUfUfGfugcug uuual96	A-228263 0.1	2707	VpusAfsaagCfagcaauU fgUfugcugasg	CUUCAGGACAUUGC UGUGCUUUUG	4958
AD-12231 26.1	A-22826 31.1	2259	csasggacAfuUfGfGfugcugu uugal96	A-228263 2.1	2708	VpusCfsaaaGfcaagcaA fuGfuccugsasa	UUCAGGACAUUGCU GUGCUUUUG	4959
AD-12231 27.1	A-22826 33.1	2260	csgscuuaCfuCfUfCfaccug uucaL96	A-228263 4.1	2709	VpusGfsaagCfaggugag AfgUfaagcsasa	UUCGCUUACUCUCA CCUGCUUUCU	4960

AD-12231 28.1	A-22826 35.1	2261	gscsuuacUfcUfCfAfcuengu ucuaL96	A-228263 6.1	2710	VpusAfskaaGfcaggaga GfaGfuaagsga	UCGCUUACUCUCAC CUGCUUCUG	4961
AD-12231 29.1	A-22826 37.1	2262	ususacueUfcAfcCfucueuuc ugaaL96	A-228263 8.1	2711	VpusUfscagAfcaggagu GfaGfuaagsga	GCUUACUCUCACCU GCUUCUGAG	4962
AD-12231 30.1	A-22826 39.1	2263	csuscucaCfcUfGfCfucuega guuaL96	A-228264 0.1	2712	VpusAfsacuCfagaagcaG fgUfgagagsusa	UACUCUCACCUUCU UCUGAGUUG	4963
AD-12231 31.1	A-22826 41.1	2264	uscsuacCfuGfCfUfucugag uugaL96	A-228264 2.1	2713	VpusCfsaacUfcagaagca fgGfugagagsu	ACUCUCACCUUCU CUGAGUUGC	4964
AD-12231 32.1	A-22826 43.1	2265	csuscaccUfgCfUfUfcuagu ugcaL96	A-228264 4.1	2714	VpusGfscacCfucagaagC faGfugagagsa	CUCUCACCUUCU UGAGUUGCC	4965
AD-12231 33.1	A-22826 45.1	2266	uscsaccGfcUfUfCfugagu gecaL96	A-228264 6.1	2715	VpusGfsgcaAfcucagaG fcAfgugagsa	UCUCACCUUCU GAGUUGCCC	4966
AD-12231 34.1	A-22826 47.1	2267	csascuugCfuUfCfUfgagu cccaL96	A-228264 8.1	2716	VpusGfsggcAfcucagaA fgCfagugagsa	CUCACCUUCUUCUG AGUUGCCCA	4967
AD-12231 35.1	A-22826 49.1	2268	ascscugCfuUfCfUfgagu cccaL96	A-228265 0.1	2717	VpusUfsgggCfucucaga faGfcaggagsa	UCACCUUCUUCUGA GUUGCCCAG	4968
AD-12231 36.1	A-22826 51.1	2269	cscsugeuUfcUfGfAfgu cagaL96	A-228265 2.1	2718	VpusCfsuggGfcaacucaG faAfgcaggagsu	CACCUUCUUCUGAG UUGCCCAGG	4969
AD-12231 37.1	A-22826 53.1	2270	csgsgcgaAfgAfcAfcagac accaL96	A-228265 4.1	2719	VpusUfsgugUfcuucuu CfuUfcgcsags	CCCGCGAAGAGAA GAGACACAU	4970
AD-12231 38.1	A-22826 55.1	2271	gsgsgcaaGfaGfAfcagac cauaL96	A-228265 6.1	2720	VpusAfsuguGfucucuu UfcUfcgcsags	CCGCGAAGAGAG AGACACAUU	4971
AD-12231 39.1	A-22826 57.1	2272	gscsgaagAfgAfcAfcagac auuaL96	A-228265 8.1	2721	VpusAfsaugUfcuucuu CfuCfucags	CGGCGAAGAGAG GACACAUUG	4972

AD-12231 40.1	A-22826 59.1	2273	csgsaagaGfaAfGfAfgacaca uugaL96	A-228266 0.1	2722	VPusCfsaauGfugucucu UfcUfcuucgscsc	GCGAAGAGAGAGAG ACACAUUGU	4973
AD-12231 41.1	A-22826 61.1	2274	gsasagagAfaGfAfgacacau uguaL96	A-228266 2.1	2723	VPusAfscaaUfgugucuc UfuCfucuuucgsc	GCGAAGAGAGAGAG CACAUUGUU	4974
AD-12231 42.1	A-22826 63.1	2275	asasgagaAfgAfGfAfcacauu guuaL96	A-228266 4.1	2724	VPusAfsacaAfugugucu CfuUfcuucuscg	CGAAGAGAGAGAGAC ACAUUGUUG	4975
AD-12231 43.1	A-22826 65.1	2276	asgsagaaGfaGfAfcacauug uugaL96	A-228266 6.1	2725	VPusCfsaacAfaugugucU fcUfucucusc	GAAAGAGAGAGACA CAUUGUUGG	4976
AD-12231 44.1	A-22826 67.1	2277	gsasgaagAfgAfCfAfcacauu uggaL96	A-228266 8.1	2726	VPusCfscaaCfauguguc fuCfucucuscusu	AAGAGAGAGAGACAC AUUGUUGGA	4977
AD-12231 45.1	A-22826 69.1	2278	asgsaagaGfaCfAfcacauuu ggaal96	A-228267 0.1	2727	VPusUfsccaAfcaauguU fcUfcuucuscusu	AGAGAGAGAGACACA UUGUUGGAA	4978
AD-12231 46.1	A-22826 71.1	2279	gsasagagAfcAfCfAfcuug gaaal96	A-228267 2.1	2728	VPusUfsuccAfacaauG fuCfucucusc	GAGAGAGAGACACAU UGUUGGAAG	4979
AD-12231 47.1	A-22826 73.1	2280	asasgagaCfaCfAfUfugug aagaL96	A-228267 4.1	2729	VPusCfsuucCfaacaauG fgUfcuucuscusu	AGAAGAGAGACACAU GUUGGAAGA	4980
AD-12231 48.1	A-22826 75.1	2281	asgsagacAfcAfUfUfguuga agaal96	A-228267 6.1	2730	VPusUfscuuCfcaacaauG fuGfucucusc	GAAAGAGACACAUUG UUGGAAGAA	4981
AD-12231 49.1	A-22826 77.1	2282	gsasgacaCfaUfUfGfuuga gaaal96	A-228267 8.1	2731	VPusUfsucuUfcaacaau fgUfugucuscusu	AAGAGACACAUUGU UGGAAGAAG	4982
AD-12231 50.1	A-22826 79.1	2283	asgsacacAfUfGfUfuggaag aagaL96	A-228268 0.1	2732	VPusCfsuucUfucaacaA fuGfugucuscusu	AGAGACACAUUGUU GGAGAAGC	4983
AD-12231 51.1	A-22826 81.1	2284	gsascacaUfuGfUfUfggaaga agcaL96	A-228268 2.1	2733	VPusGfscuuCfuccaacaA faUfugucusc	GAGACACAUUGUUG GAAGAAGCA	4984

AD-12231 52.1	A-22826 83.1	2285	ascsaauUfgUfGfgaagaa gcaal96	A-228268 4.1	2734	VpusUfsgcuUfuucaaC faAfguguscu	AGACACAUGUUGG AAGAACGAG	4985
AD-12231 53.1	A-22826 85.1	2286	csascauGfuUfGfgaagaag cagaL96	A-228268 6.1	2735	VpusCfsugeUfuucaaA fcAfaugususc	GACACAUGUUGGA AGAAGCAGC	4986
AD-12231 54.1	A-22826 87.1	2287	usasugucCfuCfAfccauu gaaal96	A-228268 8.1	2736	VpusUfsucaAfuggugug AfgGfacauasgsg	CCUAUGUCCUCACA CCAUGGAAA	4987
AD-12231 55.1	A-22826 89.1	2288	uscscucaCfCfCfAfuaga ccaaL96	A-228269 0.1	2737	VpusUfsgguUfuaaugg UfgUfgagascsa	UGUCCUCACACCAU UGAAACCAC	4988
AD-12231 56.1	A-22826 91.1	2289	cscsucacAfcCfAfUfugaac cacaL96	A-228269 2.1	2738	VpusGfsugUfuaaugg GfuGfugaggsasc	GUCCUCACACCAU GAAACCACU	4989
AD-12231 57.1	A-22826 93.1	2290	csuscacaCfcAfUfUfgaa cuaL96	A-228269 4.1	2739	VpusAfsugGfuuaau GfgUfgugaggsa	UCCUCACACCAUUG AAACCACUA	4990
AD-12231 58.1	A-22826 95.1	2291	uscacacCfaUfUfgfaaac uaal96	A-228269 6.1	2740	VpusUfsaguGfguucaa UfgGfugaggsag	CCUCACACCAUUGA AACCACUAG	4991
AD-12231 59.1	A-22826 97.1	2292	csascaccAfUfGfAfaaccac uagaL96	A-228269 8.1	2741	VpusCfsuagUfguuu AfuGfgugagsag	CUCACACCAUUGAA ACCACUAGU	4992
AD-12231 60.1	A-22826 99.1	2293	cscsaungAfaAfCfCfaugu ucuaL96	A-228270 0.1	2742	VpusAfsagaCfuagugu UfuCfauggsug	CACCAUUGAAACCA CUAGUUCUG	4993
AD-12231 61.1	A-22827 01.1	2294	csasuugaAfaCfCfAfuagu cugaL96	A-228270 2.1	2743	VpusCfsagaAfcuagug UfuUfcauggsu	ACCAUUGAAACCAC UAGUUCUGU	4994
AD-12231 62.1	A-22827 03.1	2295	asusugaaAfcCfAfCfuagu uguaL96	A-228270 4.1	2744	VpusAfsagAfcuagug GfuUfuauggs	CCAUGAAACCACU AGUUCUGUC	4995
AD-12231 63.1	A-22827 05.1	2296	ususgaaaCfcAfCfUfagu gucaL96	A-228270 6.1	2745	VpusGfsacaGfaacuag fgUfuaaugs	CAUUGAAACCACUA GUUCUGUCC	4996

AD-12231 64.1	A-22827 07.1	2297	usgsaaacCfaCfUfAfgnuucug uccaL96	A-228270 8.1	2746	VPusGfsgacAfgaacuagU fgGfuucacasu	AUUGAAACCAUAG UUCUGUCCC	4997
AD-12231 65.1	A-22827 09.1	2298	gsasccugGfuUfGfUfgugug ugugaL96	A-228271 0.1	2747	VPusCfsacaCfacacacaAf cCfaggucusc	GAGACCUGGUUGUG UGUGUGUGA	4998
AD-12231 66.1	A-22827 11.1	2299	ascscuggUfuGfUfGfugugu gugaaL96	A-228271 2.1	2748	VPusUfscacAfcacacacA faCfcaggusc	AGACCUGGUUGUGU GUGUGUGAG	4999
AD-12231 67.1	A-22827 13.1	2300	cscsuggUfGfUfGfUfgugug ugagaL96	A-228271 4.1	2749	VPusCfsucaCfacacacaCf aAfcaggusc	GACCUGGUUGUGUG UGUGUGAGU	5000
AD-12231 68.1	A-22827 15.1	2301	csusgguuGfuGfUfGfugugu gaguaL96	A-228271 6.1	2750	VPusAfsucAfcacacacA fcAfcaggsgu	ACCUGGUUGUGUGU GUGUGAGUG	5001
AD-12231 69.1	A-22827 17.1	2302	usgsuugUfGfUfGfUfgugug agugaL96	A-228271 8.1	2751	VPusCfsacuCfacacacaCf aCfaaccasg	CCUGGUUGUGUGUG UGUGAGUGG	5002
AD-12231 70.1	A-22827 19.1	2303	gsusuuGfuGfUfGfuguga guggaL96	A-228272 0.1	2752	VPusCfscacUfcacacacA fcAfaaccasg	CUGGUUGUGUGUGU GUGAGUGGU	1914
AD-12231 71.1	A-22827 21.1	2304	gsusugugGfuGfUfGfugugg uugaaL96	A-228272 2.1	2753	VPusUfscacCfcacacacA fcAfcacacsasa	UUGUGUGUGUGUG AGUGGUUGAC	1915
AD-12231 72.1	A-22827 23.1	2305	usgsugugUfgUfGfAfguggu ugacaL96	A-228272 4.1	2754	VPusGfsucaAfcacacacA faCfacacacsca	UGUGUGUGUGUGA GUGGUUGACC	1916
AD-12231 73.1	A-22827 25.1	2306	usgsugugUfgAfgUfgugug accuaL96	A-228272 6.1	2755	VPusAfsuggCfaaccacuC faCfacacacsca	UGUGUGUGUGAGU GGUUGACCUU	1917
AD-12231 74.1	A-22827 27.1	2307	usgsugugAfgUfGfGfugac cuucaL96	A-228272 8.1	2756	VPusGfsaagGfuaaccaC fuCfacacacsca	UGUGUGUGAGUGG UUGACCUUCC	1918
AD-12231 75.1	A-22827 29.1	2308	gsusugugaGfuGfUfugaccu uccaL96	A-228273 0.1	2757	VPusGfsgaaGfugaaccaA fcUfcacacsasc	GUGUGUGAGUGGU UGACCUUCCU	1919

AD-12231 76.1	A-22827 31.1	2309	usgsugagUfgGfUfUfgaccuu ccuaL96	A-228273 2.1	2758	VpusAfsfgaAfggucaacC faCfucacascsa	UGUGUGAGUGGUU GACCUUCCUC	1920
AD-12231 77.1	A-22827 33.1	2310	usgsagugGfuUfGfAfcuucc uccaL96	A-228273 4.1	2759	VpusGfsfgagGfaagguca AfcCfaucacscsa	UGUGAGUGGUUGAC CUUCCUCCA	1921
AD-12231 78.1	A-22827 35.1	2311	gsusgguuGfaCfCfUfuccucc aucaL96	A-228273 6.1	2760	VpusGfsaugGfaggaagg UfcAfacacscusc	GAGUGGUUGACCUU CCUCCAUC	1922
AD-12231 79.1	A-22827 37.1	2312	ususguggAfgGfCfAfgagaaa agaal96	A-228273 8.1	2761	VpusUfscuuUfucucugc CfuCfcaacasug	CAUUGUGGAGGCAG AGAAAAGAG	1923
AD-12231 80.1	A-22827 39.1	2313	usgsuggaGfgCfAfGfagaaaa gagal96	A-228274 0.1	2762	VpusCfsucuUfucucug CfcUfccacasa	AUUGUGGAGGCAGA GAAAAGAGA	1924
AD-12231 81.1	A-22827 41.1	2314	gsusggagGfcAfGfAfgaaaag agaal96	A-228274 2.1	2763	VpusUfscueUfuuucucu GfcCfuccacsasa	UUGUGGAGGCAGAG AAAAGAGAA	1925
AD-12231 82.1	A-22827 43.1	2315	usgsaggcCfaGfAfGfaaaaga gaaal96	A-228274 4.1	2764	VpusUfsucuCfuuuucuc UfgCfuccacsasa	UGUGGAGGCAGAGA AAAAGAGAAA	1926
AD-12231 83.1	A-22827 45.1	2316	gsagsagcAfgAfGfAfaagag aaaaL96	A-228274 6.1	2765	VpusUfsuucUfuuuuucu CfuGfucccsasc	GUGGAGGCAGAGAA AAGAGAAAG	1927
AD-12231 84.1	A-22827 47.1	2317	gsasggcaGfaGfAfAfaagaga aagal96	A-228274 8.1	2766	VpusCfsuuuUfuuuuuc UfcUfgccscsa	UGGAGGCAGAGAAA AGAGAAAGU	1928
AD-12231 85.1	A-22827 49.1	2318	asgsagcAfgAfAfaagaga agual96	A-228275 0.1	2767	VpusAfsucuUfuuuuuu CfuCfucccsusc	GGAGGCAGAGAAAA GAGAAAAGUG	1929
AD-12231 86.1	A-22827 51.1	2319	gsagsagaGfaAfAfaagaaaa gugal96	A-228275 2.1	2768	VpusCfsacuUfucuuuu UfcUfucccsusc	GAGGCAGAGAAAAAG AGAAAAGUGU	1930
AD-12231 87.1	A-22827 53.1	2320	gscsagagAfaAfAfgagaaa ugual96	A-228275 4.1	2769	VpusAfscacUfuuucucu UfuCfucccsusu	AGGCAGAGAAAAAG GAAAAGUGU	1931

AD-12231 88.1	A-22827 55.1	2321	csasgagaAfaAfGfAfgaagu guuaL96	A-228275 6.1	2770	VPusAfsacaCfuucucuU fuUfcucugscsc	GGCAGAGAAAAGAG AAAAGUGUUU	1932
AD-12231 89.1	A-22827 57.1	2322	asgsagaaAfaGfAfgaagug uuuaL96	A-228275 8.1	2771	VPusAfsaacAfcuucucuU fuUfcucugsc	GCAGAGAAAAGAGA AAGUGUUUU	1933
AD-12231 90.1	A-22827 59.1	2323	gsasgaaaAfgAfGfAfaagugu uuuaL96	A-228276 0.1	2772	VPusAfsaaaCfauuucuC fuUfcucuscsg	CAGAGAAAAGAGAA AGUGUUUUUA	1934
AD-12231 91.1	A-22827 61.1	2324	asgsaaaaGfaGfAfafagugu uuuaL96	A-228276 2.1	2773	VPusUfsaaaAfcacuucuU fcUfcuucusc	AGAGAAAAGAGAA AGUGUUUUUAU	1935
AD-12231 92.1	A-22827 63.1	2325	gsasaaagAfgAfAfafguguuu uuaaL96	A-228276 4.1	2774	VPusAfsuaaAfacacuucuC fuCfuuuuscsc	GAGAAAAGAGAAA GUGUUUUUAUA	1936
AD-12231 93.1	A-22827 65.1	2326	asasaaagAfaAfAfGfuguuuu auaaL96	A-228276 6.1	2775	VPusUfsauaAfaacacuU fcUfcuuusc	AGAAAAGAGAAAAG UGUUUUUAUAU	1937
AD-12231 94.1	A-22827 67.1	2327	asasagAfaAfGfUfguuuaa uuaaL96	A-228276 8.1	2776	VPusAfsuaaAfaaacacuU fuCfcuuusc	GAAAAGAGAAAAGU GUUUUAUAUA	1938
AD-12231 95.1	A-22827 69.1	2328	asasgagaAfaGfUfguuuaa auaaL96	A-228277 0.1	2777	VPusUfsauaUfaaaacacU fuUfcuucusu	AAAAGAGAAAAGUG UUUAUAUAAC	1939
AD-12231 96.1	A-22827 71.1	2329	asgsagaaAfgUfgUfuuaa uacaL96	A-228277 2.1	2778	VPusGfsuaaUfuaaaacaC fuUfcucusu	AAAAGAGAAAAGUGU UUUAUAUAACG	1940
AD-12231 97.1	A-22827 73.1	2330	gsasgaaaGfuGfUfuuaa acgaL96	A-228277 4.1	2779	VPusCfsguaUfaaaaaaC fcUfcuucusu	AAGAGAAAAGUGUU UUUAUAUAACGG	1941
AD-12231 98.1	A-22827 75.1	2331	asgsaaagUfgUfuUfuuaa cggalL96	A-228277 6.1	2780	VPusCfsguAfuuaaaaaC faCfuucusc	AGAGAAAAGUGUUU UAUAUAUAACGGU	1942
AD-12231 99.1	A-22827 77.1	2332	asasagugUfuUfuUfuuaacg guuaL96	A-228277 8.1	2781	VPusUfsaccGfuuaaA faCfauuusc	AGAAAAGUGUUUA UAUAUAUAACGGUAC	1943

AD-1223200.1	A-2282779.1	2333	asasguguUfuUfAfUfaucagg uacaL96	A-2282780.1	2782	VPusGfsuacCfguauauaA faAfcacuusc	GAAAGUGUUUUAU AUACGGUACU	1944
AD-1223201.1	A-2282781.1	2334	asgsuguuUfuUfAfuaucagg uacuL96	A-2282782.1	2783	VPusAfsguaCfsguauau AfaAfaacusus	AAAGUGUUUUAUA UACGGUACUU	1945
AD-1223202.1	A-2282783.1	2335	gsusguuuUfaUfAfUfaucagg cuuaL96	A-2282784.1	2784	VPusAfsaguAfcguaua UfaAfaacacusu	AAGUGUUUUAUAU ACGGUACUUA	1946
AD-1223203.1	A-2282785.1	2336	usgsuuuuAfuUfAfUfaucagg cuuaL96	A-2282786.1	2785	VPusUfsaagUfaccguauA fuAfaaacacsu	AGUGUUUUAUAUAC GGUACUUUAU	1947
AD-1223204.1	A-2282787.1	2337	gsusuuaUfaUfAfCfGfguauc uaual96	A-2282788.1	2786	VPusAfsuaaGfuaccguauU faUfaaaacsasc	GUGUUUUAUAUACG GUACUUUAU	1948
AD-1223205.1	A-2282789.1	2338	ususuuuAfuUfAfCfGfguauc auuaL96	A-2282790.1	2787	VPusAfsuaaAfguaccgu AfuAfuuaaacsca	UGUUUUAUAUACGG UACUUUAUU	1949
AD-1223206.1	A-2282791.1	2339	ususuaaUfaUfAfCfGfguauc uuuaL96	A-2282792.1	2788	VPusAfsaauAfguaccguU faUfauaaacsasc	GUUUUAUAUACGGU ACUUUAUUUA	1950
AD-1223207.1	A-2282793.1	2340	ususauuAfcGfGfUfaucuu uuuaL96	A-2282794.1	2789	VPusUfsaaaUfaaguaccG fuAfuuaaasasa	UUUUAUAUACGGUA CUUAUUUUA	5040
AD-1223208.1	A-2282795.1	2341	usasuuaCfGfUfAfcuuuu uaaaL96	A-2282796.1	2790	VPusUfsuaaAfuaguacC fgUfauaaasasa	UUUAUAUACGGUAC UUUAUUUAAU	5041
AD-1223209.1	A-2282797.1	2342	gsusacuAfuUfUfAfuauc cuuaL96	A-2282798.1	2791	VPusAfsaggGfaauuaa AfuAfguacscsg	CGGUACUUUAUUUA UAUCCCCUU	5042
AD-1223210.1	A-2282799.1	2343	usascuuUfuUfAfAfuauc uuuaL96	A-2282800.1	2792	VPusAfsaagGfgauuaa AfaUfaaguacsc	GGUACUUUAUUUAU AUCCCCUUU	5043
AD-1223211.1	A-2282801.1	2344	ususaugaGfaUfGfUfaucuu ugcaL96	A-2282802.1	2793	VPusGfscAAfaguacaU fcUfcauaasasu	AUUUAUGAGAUGU AUCUUUUUGCU	5044

AD-12232 12.1	A-22828 03.1	2345	usasugAfuGfUfAfuuuu ugcuaL96	A-228280 4.1	2794	VPusAfsagAfaagauaA fuCfucuasasa	UUUAUGAGAUGUA UCUUUUGCUC	5045
AD-12232 13.1	A-22828 05.1	2346	asusgagaUfgUfAfuuuuug cucaL96	A-228280 6.1	2795	VPusGfsagAfaagauaC faUfucuasasa	UUUAUGAGAUGUAUC UUUUGCUCU	5046
AD-12232 14.1	A-22828 07.1	2347	usgsagauGfuAfuCfuuuugc ucuaL96	A-228280 8.1	2796	VPusAfsagCfaaaagauA fcAfuucasasa	UAUGAGAUGUAUCU UUUUGCUCUC	5047
AD-12232 15.1	A-22828 09.1	2348	gsasgaugUfaUfCfuuuugcu cucaL96	A-228281 0.1	2797	VPusGfsagaGfcaaaagaU faCfaucucsa	AUGAGAUGUAUCUU UUGCUCUCU	5048
AD-12232 16.1	A-22828 11.1	2349	asgsauguAfuCfuUfufugcuc ucuaL96	A-228281 2.1	2798	VPusAfsagAfgcaaaagA fuAfaucucsa	UGAGAUGUAUCUUU UGCUCUCUC	5049
AD-12232 17.1	A-22828 13.1	2350	gsasuguaUfcUfUfufugcucu cucaL96	A-228281 4.1	2799	VPusGfsagaGfagcaaaaG faUfacaucusc	GAGAUGUAUCUUUU GCUCUCUCU	5050
AD-12232 18.1	A-22828 15.1	2351	asusguauCfuUfUfufgucuc ucuaL96	A-228281 6.1	2800	VPusAfsagAfgagcaaaA fgAfuacauscu	AGAUGUAUCUUUUUG CUCUCUCUU	5051
AD-12232 19.1	A-22828 17.1	2352	gscsucUfcUfUfGfGfcucucu uauaL96	A-228281 8.1	2801	VPusAfsuaaGfagagcaaG faGfagagcsasa	UUGCUCUCUCUUGC UCUCUUAUU	5052
AD-12232 20.1	A-22828 19.1	2353	csuscucuCfuUfGfCfucucuu auuaL96	A-228282 0.1	2802	VPusAfsuaaAfgagagcaA fgAfgagagsasa	UGCUCUCUCUUGCUCU CUCUUAUUU	5053
AD-12232 21.1	A-22828 21.1	2354	uscsucUfuGfCfufcucuaa uuuaL96	A-228282 2.1	2803	VPusAfsaaAfgagagcaA faGfagagagsc	GCUCUCUCUUGCUC UCUUAUUUG	5054
AD-12232 22.1	A-22828 23.1	2355	csuscucuUfgCfufcucuaau uugaL96	A-228282 4.1	2804	VPusCfsaaaUfaagagagC faAfgagagsag	CUCUCUCUUGCUCU CUUAUUUGU	5055
AD-12232 23.1	A-22828 25.1	2356	uscsucuuGfcUfCfufcuaauu uguaL96	A-228282 6.1	2805	VPusAfscaaAfuagagagG fcAfgagagsasa	UCUCUCUUGCUCUC UUAUUUGUA	5056

AD-12232 24.1	A-22828 27.1	2357	csuscuugCfuCfUfCfuauuu gualL96	A-228282 8.1	2806	VpusUfsacaAfaaaagA fgCfaagagsasg	CUCUCUUGCUCUCU UAUUUGUAC	5057
AD-12232 25.1	A-22828 29.1	2358	uscsuugeUfcUfCfufuauug uacaL96	A-228283 0.1	2807	VpusGfsuacAfaaaagA faGfcaagsasg	UCUCUUGCUCUCU AUUUGUACC	5058
AD-12232 26.1	A-22828 31.1	2359	csusugcuCfuCfUfufauuugu accaL96	A-228283 2.1	2808	VpusGfsguaCfaaaagA fgAfgcaagsasg	CUCUUGCUCUCUA UUUGUACCG	5059
AD-12232 27.1	A-22828 33.1	2360	usugcucUfcUfUfufuugua ccgaL96	A-228283 4.1	2809	VpusCfsgguAfaaaagA faGfagcaagsa	UCUUGCUCUCUUA UUGUACCGG	5060
AD-12232 28.1	A-22828 35.1	2361	usgscucuCfuUfAfufuugua cggaL96	A-228283 6.1	2810	VpusCfscggUfacaauaA fgAfgagcasasg	CUUGCUCUCUUAU UGUACCGGU	5061
AD-12232 29.1	A-22828 37.1	2362	csuscucuUfaUfUfufuacgg guuaL96	A-228283 8.1	2811	VpusAfsaccGfguaaaaU faAfgagagsesa	UGCUCUCUUAUUU UACCGGUUU	5062
AD-12232 30.1	A-22828 39.1	2363	uscsucuAfuUfUfGfuaecgg uuuaL96	A-228284 0.1	2812	VpusAfsaacCfsguaaaaA fuAfgagagsc	GCUCUCUUAUUUG ACCGGUUUU	5063
AD-12232 31.1	A-22828 41.1	2364	csuscuuaUfuUfGfufacgggu uuuaL96	A-228284 2.1	2813	VpusAfsaaaCfsgguacaA faUfaagagsasg	CUCUCUUAUUUGA CCGGUUUUU	5064
AD-12232 32.1	A-22828 43.1	2365	uscsuuaUfuGfUfAfccgggu uuuaL96	A-228284 4.1	2814	VpusAfsaaaAfccgguaaA faAfaaagsasg	UCUCUUAUUUGUAC CGGUUUUUU	5065
AD-12232 33.1	A-22828 45.1	2366	csusuauUfgUfAfCfCGguu uugaL96	A-228284 6.1	2815	VpusCfsaaaAfaccgguac faAfaaagsasg	CUCUUAUUUGUACC GGUUUUUUU	5066
AD-12232 34.1	A-22828 47.1	2367	ususauuuGfuAfCfCfCGguu uuguaL96	A-228284 8.1	2816	VpusAfscaaAfaaccgguA fcAfaaagsasg	UCUUAUUUGUACCG GUUUUUUGA	5067
AD-12232 35.1	A-22828 49.1	2368	usasuuugUfaCfCfCfCGguuu gualL96	A-228285 0.1	2817	VpusUfsacaAfaaacggU faCfaaagsasg	CUUAUUUGUACCG UUUUUGUAU	5068

AD-12232 36.1	A-22828 51.1	2369	asusuuguAfcCfGfGfuuuuu guauaL96	A-228285 2.1	2818	VPusAfsuacAfaaaacgG fuAfaaaasasa	UUAUUUGUACCGGU UUUUGUAUA	5069
AD-12232 37.1	A-22828 53.1	2370	ususuguaCfcGfGfufuuug uauaaL96	A-228285 4.1	2819	VPusUfsauaCfaaaacgG fgUfacaasasa	UAUUUGUACCGGUU UUUGUAUAU	5070
AD-12232 38.1	A-22828 55.1	2371	ususguacCfcGfUfufuuugua uauaL96	A-228285 6.1	2820	VPusAfsuauAfaaaacC fgGfuacaasasa	AUUUGUACCGGUUU UUGUAUAUA	5071
AD-12232 39.1	A-22828 57.1	2372	usgsuaccGfcUfUfufuugua auaaL96	A-228285 8.1	2821	VPusUfsauaUfacaacaaC fcGfguacasa	UUUGUACCGGUUUU UGUAUAUA	5072
AD-12232 40.1	A-22828 59.1	2373	gsusaccgGfuUfUfufuugua uaaaL96	A-228286 0.1	2822	VPusUfsuauAfuacaaaA fcCfkguacsasa	UUGUACCGGUUUUU GUAUAUAAA	5073
AD-12232 41.1	A-22828 61.1	2374	usascggUfuUfUfufuugua aaaaL96	A-228286 2.1	2823	VPusUfsuuaUfauacaaaA faCfcgguacsasa	UGUACCGGUUUUUG UAUAUAAAA	5074
AD-12232 42.1	A-22828 63.1	2375	ascscggUfuUfUfGfuuaaua aaaaL96	A-228286 4.1	2824	VPusUfsuuuAfuauacaa AfaAfcggusasc	GUACCGGUUUUUUGU AUUAUAAAAU	5075
AD-12232 43.1	A-22828 65.1	2376	asuscauGfuUfUfCfaucuc cucaL96	A-228286 6.1	2825	VPusGfsagaGfaugga AfcAfugaasusu	AAAUUCAUGUUUCC AAUCUCUCU	5076
AD-12232 44.1	A-22828 67.1	2377	ususcaugUfuUfCfCfaucuc ucuaL96	A-228286 8.1	2826	VPusAfsagAfgauugga AfaCfaugaasusu	AAUUCAUGUUUCCA AUCUCUCUC	5077
AD-12232 45.1	A-22828 69.1	2378	uscsaugUfuCfCfAfaucuc cucaL96	A-228287 0.1	2827	VPusGfsagaGfagaugg AfaAfaugasasa	AUUAUGUUUCCAA UCUCUCUCU	5078
AD-12232 46.1	A-22828 71.1	2379	csasuguuUfcCfAfaucuc ucuaL96	A-228287 2.1	2828	VPusAfsagAfgagaug GfaAfaugasasa	UUAUGUUUCCAAU CUCUCUCUC	5079
AD-12232 47.1	A-22828 73.1	2380	asusguuuCfcAfaUfcucuc cucaL96	A-228287 4.1	2829	VPusGfsagaGfagagau GfgAfaacausga	UCAUGUUUCCAAUC UCUCUCUCUC	5080

AD-12232 48.1	A-22828 75.1	2381	usgsuucCfaAfUfCfucucuccaL96	A-228287 6.1	2830	VpUsGfsgagAfgagagauUfgGfaaacasug	CAUGUUUCCAAUCUCUCUCCCC	5081
AD-12232 49.1	A-22828 77.1	2382	ususuccaAfuCfUfCfucucuccaL96	A-228287 8.1	2831	VpUsAfsgggAfgagagagAfuUfggaaasca	UGUUUCCAAUCUCUCUCUCUCCCCUG	5082
AD-12232 50.1	A-22828 79.1	2383	uscsaauCfuCfUfCfucucuccugaL96	A-228288 0.1	2832	VpUsUfscagGfgagagagAfgAfuuggasasa	UUUCCAAUCUCUCUCUCUCUCCCCUGAU	5083
AD-12232 51.1	A-22828 81.1	2384	csrgsugaCfaGfUfCfacuagcuuaL96	A-228288 2.1	2833	VpUsUfsaagCfuagugacUfgUfcaccgsasu	AUCGGUGACAGUCACUAGCUUAU	5084
AD-12232 52.1	A-22828 83.1	2385	gsgsugacAfgUfCfAfcuagcuuaL96	A-228288 4.1	2834	VpUsAfsuaaGfcuagugaCfuGfucaccgsa	UCGGUGACAGUCACUAGCUUAUC	5085
AD-12232 53.1	A-22828 85.1	2386	asgsucacUfaGfCfUfuaucuuuaL96	A-228288 6.1	2835	VpUsUfsucaAfgauaagCfaGfugacusgu	ACAGUCACUAGCUUAUCUUGAAC	5086
AD-12232 54.1	A-22828 87.1	2387	gsusacuAfgCfUfuaucuuuaL96	A-228288 8.1	2836	VpUsGfsuucAfgauaagCfuAfgugacsug	CAGUCACUAGCUUAUCUUGAAC	5087
AD-12232 55.1	A-22828 89.1	2388	uscsacuaGfcUfUfAfcuugaacaL96	A-228289 0.1	2837	VpUsUfsguuCfaagauaaGfeUfagugacsu	AGUCACUAGCUUAUCUUGAACAG	5088
AD-12232 56.1	A-22828 91.1	2389	ascsuagUfuAfuCfuaagaagaL96	A-228289 2.1	2838	VpUsUfscugUfuaagauAfaGfcuagusa	UCACUAGCUUAUCUCUUGAACAGAU	5089
AD-12232 57.1	A-22828 93.1	2390	csusagcuUfaUfCfUfugaagaauL96	A-228289 4.1	2839	VpUsAfsucuGfuaaagaUfaAfgcuagsug	CACUAGCUUAUCUCUUGAACAGAU	5090
AD-12232 58.1	A-22828 95.1	2391	usasgcuuAfuCfUfUfgaagaauaL96	A-228289 6.1	2840	VpUsUfsaucUfguuaagAfuAfgcuagsu	ACUAGCUUAUCUCUUGAACAGAU	5091
AD-12232 59.1	A-22828 97.1	2392	asgsuuaUfcUfUfGfaagacuuaL96	A-228289 8.1	2841	VpUsAfsuauCfuguuaaGfaUfaagcusag	CUAGCUUAUCUCUUGAACAGAU	5092

AD-12232 60.1	A-22828 99.1	2393	gscsuuauCfuUfGfAfacagau auuaL96	A-228290 0.1	2842	VpusAfsauuUfcuguuca AfgAfuagcsusa	UAGCUUAUCUUGAA CAGAUUUU	5093
AD-12232 61.1	A-22829 01.1	2394	csasgcacAfcAfuUfucuuug aaaal96	A-228290 2.1	2843	VpusUfsuucAfaaggaau GfuGfugcugsgsg	CCCAGCACACAUUC CUUUGAAAU	5094
AD-12232 62.1	A-22829 03.1	2395	asgcacaCfaUfUfCfcuuuga auuaL96	A-228290 4.1	2844	VpusAfsuuuCfaaggaau fgUfugcugsgsg	CCAGCACACAUUCC UUUGAAUA	5095
AD-12232 63.1	A-22829 05.1	2396	gscsacacAfuUfCfCfuugaa auaal96	A-228290 6.1	2845	VpusUfsauuUfcaaggaA fuGfugcugsgsg	CAGCACACAUUCCU UUGAAUA	5096
AD-12232 64.1	A-22829 07.1	2397	csascacaUfuCfCfufuugaau uaaal96	A-228290 8.1	2846	VpusUfsuauUfcaagga AfaUfugugsgscsu	AGCACACAUUCCUU UGAAUAUAAAG	5097
AD-12232 65.1	A-22829 09.1	2398	csascauuCfcUfUfUfgaaaua aggaL96	A-228291 0.1	2847	VpusCfscuuAfuuaaaaG fgAfaugugsgsg	CACACAUUCCUUUG AAAUAAAGGU	5098
AD-12232 66.1	A-22829 11.1	2399	uscsuuuGfaAfaUfaagguu ucaal96	A-228291 2.1	2848	VpusUfsgaaAfccuuaau UfcAfaaggasasu	AUUCUUUUGAAUA AGGUUUCAA	5099
AD-12232 67.1	A-22829 13.1	2400	csusuugaAfaUfAfafgguuc auuaL96	A-228291 4.1	2849	VpusAfsuugAfaaccuua UfuUfcaagsgsa	UCCUUUGAAAAAAG GUUUCAAUA	5100
AD-12232 68.1	A-22829 15.1	2401	ususugaaAfuAfaGfguuuca auaal96	A-228291 6.1	2850	VpusUfsauuGfaaaccuuA fuUfcaaaagsgsg	CCUUUGAAAUAAAG UUUCAAUUAU	5101
AD-12232 69.1	A-22829 17.1	2402	asgsguuuCfaAfuAfuacauc uacal96	A-228291 8.1	2851	VpusGfsuagAfuuaauu UfgAfaaccusasa	UAAAGGUUUCAAUAU ACAUCUACA	5102
AD-12232 70.1	A-22829 19.1	2403	gsgsuuucAfaUfAfuacaucu acaaL96	A-228292 0.1	2852	VpusUfsguaGfauguaa UfuGfaaacscsu	AAGGUUUCAAUAUA CAUCUACAU	5103
AD-12232 71.1	A-22829 21.1	2404	gsusuucaAfuAfuAfaucua caual96	A-228292 2.1	2853	VpusAfsuguAfgaugua AfuUfgaaacscsu	AGGUUUCAAUAUA AUCUACAUA	5104

AD-12232 72.1	A-22829 23.1	2405	ususuaaUfaUfAfCfaucauac auaaL96	A-228292 4.1	2854	VPusUfsaugUfagaugua UfaUfugaasasc	GGUUUCAAUUAACA UCUACAUAAC	5105
AD-12232 73.1	A-22829 25.1	2406	ususcaauAfuAfCfAfucuaaca uacaL96	A-228292 6.1	2855	VPusGfsuauGfuagaugu AfuAfuagaasasc	GUUUCAAUAUAUAU CUACAUAACU	5106
AD-12232 74.1	A-22829 27.1	2407	usasuungGfcAfAfCfuuguauu uugaL96	A-228292 8.1	2856	VPusCfsaaUfacaaguG fcCfaaauasusa	UAUAUUUGGCAACU UGUAUUUUGU	5107
AD-12232 75.1	A-22829 29.1	2408	ususuggcAfaCfUfUfguauuu gugaL96	A-228293 0.1	2857	VPusCfsacaAfaacaagU fuGfcaaaasusa	UAUUUGGCAACUUG UAUUUGUGU	5108
AD-12232 76.1	A-22829 31.1	2409	usgsgcaaCfuUfGfUfauuugu gugaL96	A-228293 2.1	2858	VPusCfsacaCfaaauacaA fgUfugccasasa	UUUGGCAACUUGUA UUUGUGUGU	5109
AD-12232 77.1	A-22829 33.1	2410	gsgscaacUfuGfUfAfuugug uguaL96	A-228293 4.1	2859	VPusAfsacAfcaauaacA faGfuugccsasa	UUGGCAACUUGUAU UUGUGUGUA	5110
AD-12232 78.1	A-22829 35.1	2411	gscsaacuUfgUfAfUfuugugu guuaL96	A-228293 6.1	2860	VPusUfsacaCfacaauaC faAfguugccsasa	UGGCAACUUGUAU UGUGUGUAU	5111
AD-12232 79.1	A-22829 37.1	2412	csasacuGfuAfUfUfugugug uuaaL96	A-228293 8.1	2861	VPusAfsuacAfcaaaaA fcAfuugsgsc	GGCAACUUGUAUUU GUGUGUAUA	5112
AD-12232 80.1	A-22829 39.1	2413	asascuugUfaUfUfUfgugugu auaaL96	A-228294 0.1	2862	VPusUfsauaCfacaauaU faCfaaguusgsc	GCAACUUGUAUUUG UGUGUAUAU	5113
AD-12232 81.1	A-22829 41.1	2414	ascsuuguAfuUfUfGfugugu auuaL96	A-228294 2.1	2863	VPusAfsuauAfcacacaaaA fuAfaagusg	CAACUUGUAUUUGU GUGUAUAUA	5114
AD-12232 82.1	A-22829 43.1	2415	ususcugaUfaAfAfAfuagaca uugaL96	A-228294 4.1	2864	VPusCfsauGfucuauuu UfaUfagaasusc	GAUCUGAUAAAUA AGACAUAUGC	5115
AD-12232 83.1	A-22829 45.1	2416	usgsauaaAfaUfAfGfacaug cuuaL96	A-228294 6.1	2865	VPusUfsagcAfaugucua UfuUfuaucasgsa	UCUGAUAAAUAUA CAUUGCUAU	5116

AD-12232 84.1	A-22829 47.1	2417	gsasuaaaAfuAfGfAfaucg uuaaL96	A-228294 8.1	2866	VpusAfsuagCfaugucu AfuUfuuaucsaag	CUGAUAAAAUAGAC AUUGCUAUU	5117
AD-12232 85.1	A-22829 49.1	2418	usasaaauAfgAfCfAfuugcua uuaaL96	A-228295 0.1	2867	VpusGfsaaufAfgcaaugC fuAfuuuuasusc	GAUAAAAUAGACAU UGCUAUUCU	5118
AD-12232 86.1	A-22829 51.1	2419	usasgacaUfuGfCfUfaucucg uuuaaL96	A-228295 2.1	2868	VpusAfsaacAfgaaugcA faUfugcuasusu	AAUAGACAUUGCUA UUCUGUUUU	5119
AD-12232 87.1	A-22829 53.1	2420	asgsacauUfgCfUfAfuucugu uuuaaL96	A-228295 4.1	2869	VpusAfsaaaCfagaauagC faAfuugcusasu	AUAGACAUUGCUAU UCUGUUUUU	5120
AD-12232 88.1	A-22829 55.1	2421	uscsuacaUfaCfUfAfaucuc ucuaaL96	A-228295 6.1	2870	VpusAfsagAfgaaucg UfaUfuguagasa	AUUCUACAUACUAA AUCUCUCUC	5121
AD-12232 89.1	A-22829 57.1	2422	csusacauAfcUfAfAfaucucu cucaL96	A-228295 8.1	2871	VpusGfsagaGfagaauua GfuAfuuguagsasa	UUCUACAUACUAAA UCUCUCUCC	5122
AD-12232 90.1	A-22829 59.1	2423	usascauaCfuAfAfAfuucuc uccaaL96	A-228296 0.1	2872	VpusGfsagAfgagaauu AfgUfaguagsa	UCUACAUACUAAAU CUCUCUCU	5123
AD-12232 91.1	A-22829 61.1	2424	ascsaucUfaAfAfUfucucu ccuaaL96	A-228296 2.1	2873	VpusAfsaggAfgagaau UfaGfuauagsag	CUACAUACUAAAU UCUCUCU	5124
AD-12232 92.1	A-22829 63.1	2425	csasuacuAfaAfUfCfuucuc cuuaaL96	A-228296 4.1	2874	VpusAfsaggAfgagaau UfuAfguaugsusa	UACAUACUAAAU CUCUCU	5125
AD-12232 93.1	A-22829 65.1	2426	asusacuaAfaUfCfUfucucc uuuaaL96	A-228296 6.1	2875	VpusAfsaagGfagagagaU fuUfaguaugsu	ACAUAUACUAAAU UCUCU	5126
AD-12232 94.1	A-22829 67.1	2427	usascuaaAfuCfUfucuccu uuuaaL96	A-228296 8.1	2876	VpusAfsaaaGfagagagaA fuUfaguauugs	CAUAUACUAAAU CUCU	5127
AD-12232 95.1	A-22829 69.1	2428	csasuuaUfuUfaAfUfugguc uacaL96	A-228297 0.1	2877	VpusGfsuagCfaccuaaA faUfaaugsasu	AUCAUUUAUUUAU GGUGCUACU	5128

AD-12232 96.1	A-22829 71.1	2429	asusuauUfuAfUfUfgugc uacuaL96	A-228297 2.1	2878	VPusAfsguaGfcaccauA faAfaaausgsa	UCAUUUAUUUAUUG GUGCUACUG	5129
AD-12232 97.1	A-22829 73.1	2430	ususuauUfaUfUfGfgucua cugaL96	A-228297 4.1	2879	VPusCfsaguAfgcaccuaU faAfaaaasusg	CAUUUAUUUAUUGG UGCUACUGU	5130
AD-12232 98.1	A-22829 75.1	2431	ususuauUfaUfUfGfgucua uguaL96	A-228297 6.1	2880	VPusAfsagUfagcaccA fuAfaaaasasu	AUUUAUUUAUUGG UGCUACUGUU	5131
AD-12232 99.1	A-22829 77.1	2432	ususuauUfaUfUfGfgucua guuaL96	A-228297 8.1	2881	VPusAfsagaGfuagcaccA faUfaaauasasa	UUUAUUUAUUGGU GCUACUGUUU	5132
AD-12233 00.1	A-22829 79.1	2433	asusuauUfgGfUfGfucacug uuuaL96	A-228298 0.1	2882	VPusAfsaacAfguagcacC faAfaaaasasa	UUUAUUUAUUGGUGC UACUGUUUA	5133
AD-12233 01.1	A-22829 81.1	2434	ususuauUfgGfUfGfucacug uuaL96	A-228298 2.1	2883	VPusAfsuaaAfcaguagcA fcCfaaauasasu	AUUUAUUGGUGCUA CUGUUUAUC	5134
AD-12233 02.1	A-22829 83.1	2435	asusugguGfcUfAfCfuguua uccaL96	A-228298 4.1	2884	VPusGfsgauAfaacaguaG fcAfcaaausasa	UUUAUUGGUGCUACU GUUUUAUCCG	5135
AD-12233 03.1	A-22829 85.1	2436	gsasaaagAfuAfUfUfaacac acgaL96	A-228298 6.1	2885	VPusCfsgugAfguuuaau AfuCfuuuucscsc	GGGAAAAGAUUU AACAUACACGU	5136
AD-12233 04.1	A-22829 87.1	2437	asascaucAfcGfUfCfuunguc ucuaL96	A-228298 8.1	2886	VPusAfsagAfcagaagacG fuGfauguusasa	UUACAUCACGUCU UUGUCUCUA	5137
AD-12233 05.1	A-22829 89.1	2438	ascsaucaCfGfUfCfuunguc cuuaL96	A-228299 0.1	2887	VPusUfsagaGfacaagaC fgUfgaugusasa	UAACAUCACGUCUU UGUCUCUAG	5138
AD-12233 06.1	A-22829 91.1	2439	gsusuuuGfuCfUfCfuaguc aguaL96	A-228299 2.1	2888	VPusAfsagCfaguagacA fcAfaagacgsu	ACGUCUUUGUCUCU AGUGCAGUU	5139
AD-12233 07.1	A-22829 93.1	2440	uscsuuugUfcUfCfUfaguc guuaL96	A-228299 4.1	2889	VPusAfsacuGfcacuagaG faCfaaaagacsg	CGUCUUUGUCUCUA GUGCAGUUU	5140

AD-12233 08.1	A-22829 95.1	2441	csusuuguCfuCfUfAfgucag uuuaL96	A-228299 6.1	2890	VPusAfsaacUfgacuagA fgAfaaaagsasc	GUCUUUGUCUCUAG UGCAGUUUU	5141
AD-12233 09.1	A-22829 97.1	2442	gsasgaauUfuCfCfGfuguac auuaL96	A-228299 8.1	2891	VPusUfsaugUfacuacgg AfaUfaucucsgsa	UCGAGAUUUUCCGU AGUACAUAU	5142
AD-12233 10.1	A-22829 99.1	2443	agsauauUfcCfGfUfaguaca uauaL96	A-228300 0.1	2892	VPusAfsuauGfuacuacg GfaAfaucucsg	CGAGAUUUUCCGUA GUACAUAUU	5143
AD-12233 11.1	A-22830 01.1	2444	gsasuauCfcGfUfAfguacau auuaL96	A-228300 2.1	2893	VPusAfsauUfguacuacG fgAfaucucsc	GAGAUUUUCCGUAG UACAUAUUU	5144
AD-12233 12.1	A-22830 03.1	2445	csgsacaaAfgAfaAfaucaga uauaL96	A-228300 4.1	2894	VPusAfsuauCfuguauuu CfuUfugucgsu	AACGACAAAGAAAU ACAGAUUAU	5145
AD-12233 13.1	A-22830 05.1	2446	gsascaaGfaAfaUfagacau auuaL96	A-228300 6.1	2895	VPusUfsauUfuguauuu UfcUfugucgsu	ACGACAAAGAAUA CAGAUUAU	5146
AD-12233 14.1	A-22830 07.1	2447	ascsaagAfaAfaUfagacau uauaL96	A-228300 8.1	2896	VPusAfsuauAfuuguauu UfuCfuungucsg	CGACAAAGAAUAC AGAUUAUC	5147
AD-12233 15.1	A-22830 09.1	2448	csasaagaAfaUfAfaCfagauu aucaL96	A-228301 0.1	2897	VPusGfsauUfaucugua UfuUfcuungusc	GACAAAGAAUACA GAUAUAUCU	5148

Table 8B. Exemplary Human VEGF-A siRNA Unmodified Single Strands and Duplex Sequences

Duplex Name	Sense Oligo Name	SEQ ID NO: (Sense)	Sense Sequence	mRNA Target Range	Antisense Oligo Name	SEQ ID NO: (Anti-sense)	Antisense Sequence	mRNA Target Range
AD-122286 6.1	A-228211 1.1	2898	CGGUGCUGGAAUUU GAUUAU	123-143	A-2282112. 1	3347	UAAUAUCAAUUCCA GCACCGAG	121-143
AD-122286 7.1	A-228211 3.1	2899	GGUGCUGGAAUUUG AUAUUA	124-144	A-2282114. 1	3348	UGAAUAUCAAUUCC AGCACCGA	122-144
AD-122286 8.1	A-228211 5.1	2900	UGCUGGAAUUUGAU AUUCAU	126-146	A-2282116. 1	3349	UAUGAAUAUCAAUU CCAGCAC	124-146
AD-122286 9.1	A-228211 7.1	2901	GCUGGAAUUUGAU UUAUUA	127-147	A-2282118. 1	3350	UAAUGAAUAUCAAU UCCAGCAC	125-147
AD-122287 0.1	A-228211 9.1	2902	UGGAAUUUGAUUU CAUUGAA	129-149	A-2282120. 1	3351	UCAAUGAAUAUCAA AUUCCAGC	127-149
AD-122287 1.1	A-228212 1.1	2903	GGAAUUUGAUUUUC AUUGAU	130-150	A-2282122. 1	3352	UAUCAAUGAAUAUCA AAUCCAG	128-150
AD-122287 2.1	A-228212 3.1	2904	GAAUUUGAUUUUCA UUGAUCA	131-151	A-2282124. 1	3353	UGAUCAAUGAAUAUC AAAUUCCA	129-151
AD-122287 3.1	A-228212 5.1	2905	AAUUUGAUUUUCAU UGAUCCA	132-152	A-2282126. 1	3354	UGGAUCAAAUGAAUAU CAAAUUC	130-152
AD-122287 4.1	A-228212 7.1	2906	AUUUGAUUUUCAUU GAUCCGA	133-153	A-2282128. 1	3355	UCGGAUCAAAUGAAUA UCAAAUUC	131-153
AD-122287 5.1	A-228212 9.1	2907	UUUGAUUUUCAUUG AUCCGGA	134-154	A-2282130. 1	3356	UCCGGAUCAAAUGAAU AUCAAAUU	132-154

AD-122287 6.1	A-228213 1.1	2908	UUUAUUUUUGCUUG CCAUAUA	217-237	A-2282132. 1	3357	UGAAUGGCAAGCAA AAUAAAUU	215-237
AD-122287 7.1	A-228213 3.1	2909	UUUUUUUUUGCUUGCC AUUCCA	218-238	A-2282134. 1	3358	UGGAAUGGCAAGCAA AAAUAAAU	216-238
AD-122287 8.1	A-228213 5.1	2910	CAAAUCACUGUGGAU UUUGGA	283-303	A-2282136. 1	3359	UCCAAAAUCCACAGU GAUUUGG	281-303
AD-122287 9.1	A-228213 7.1	2911	AAAUACACUGUGGAU UUUGGA	284-304	A-2282138. 1	3360	UUCCAAAAUCCACAG UGAUUUGG	282-304
AD-122288 0.1	A-228213 9.1	2912	AAUCACUGUGGAUU UUGGAA	285-305	A-2282140. 1	3361	UUUCCAAAAUCCACA GUGAUUUG	283-305
AD-122288 1.1	A-228214 1.1	2913	AUCACUGUGGAUUU UGGAAA	286-306	A-2282142. 1	3362	UUUCCAAAAUCCAC AGUGAUUU	284-306
AD-122288 2.1	A-228214 3.1	2914	UCACUGUGGAUUUU GGAAACA	287-307	A-2282144. 1	3363	UGUUUCCAAAAUCCA CAGUGAUU	285-307
AD-122288 3.1	A-228214 5.1	2915	CACUGUGGAUUUUG GAAACCA	288-308	A-2282146. 1	3364	UGGUUUCCAAAAUCC ACAGUGAU	286-308
AD-122288 4.1	A-228214 7.1	2916	ACUGUGGAUUUUUGG AAACCAA	289-309	A-2282148. 1	3365	UUGGUUUCCAAAAUC CACAGUGA	287-309
AD-122288 5.1	A-228214 9.1	2917	CUGUGGAUUUUUGGA AACCAGA	290-310	A-2282150. 1	3366	UCUGGUUUCCAAAAU CCACAGUG	288-310
AD-122288 6.1	A-228215 1.1	2918	UGUGGAUUUUUGGAA ACCAGCA	291-311	A-2282152. 1	3367	UGCUGGUUUCCAAAA UCCACAGU	289-311
AD-122288 7.1	A-228215 3.1	2919	GUGGAUUUUUGGAAA CCAGCAA	292-312	A-2282154. 1	3368	UUGCUGGUUUCCAAA AUCCACAG	290-312

AD-122288 8.1	A-228215 5.1	2920	GAUUUGGAAACCA GCAGAAA	295-315	A-2282156. 1	3369	UUUCUGCUGGUUUCC AAAAUCCA	293-315
AD-122288 9.1	A-228215 7.1	2921	AUUUGGAAACCAGC AGAAA	296-316	A-2282158. 1	3370	UUUCUGCUGGUUUCC CAAAAUCC	294-316
AD-122289 0.1	A-228215 9.1	2922	UUUGGAAACCAGCA GAAAGA	297-317	A-2282160. 1	3371	UCUUUCUGCUGGUUU CCAAAAC	295-317
AD-122289 1.1	A-228216 1.1	2923	UUUGGAAACCAGCAG AAAGAA	298-318	A-2282162. 1	3372	UUCUUUCUGCUGGUUU UCCAAAUA	296-318
AD-122289 2.1	A-228216 3.1	2924	GGAAACCAGCAGAGAA GAGGAA	301-321	A-2282164. 1	3373	UUCUCUUUCUGCUG GUUUCCAA	299-321
AD-122289 3.1	A-228216 5.1	2925	AAACCAGCAGAAAAGA GGAAA	303-323	A-2282166. 1	3374	UUUCCUCUUUCUGC UGGUUUCC	301-323
AD-122289 4.1	A-228216 7.1	2926	AACCAGCAGAAAGAG GAAAGA	304-324	A-2282168. 1	3375	UCUUUCCUCUUUCUG CUGGUUUCC	302-324
AD-122289 5.1	A-228216 9.1	2927	ACCAGCAGAAAGAGG AAAGAA	305-325	A-2282170. 1	3376	UUCUUUCCUCUUUCU GCUGGUUU	303-325
AD-122289 6.1	A-228217 1.1	2928	CCAGCAGAAAGAGGA AAGAGA	306-326	A-2282172. 1	3377	UCUCUUUCCUCUUUC UGCUGGUU	304-326
AD-122289 7.1	A-228217 3.1	2929	CAGCAGAAAGAGGA AAGAGGA	307-327	A-2282174. 1	3378	UCCUCUUUCCUCUUUC UGCUGGU	305-327
AD-122289 8.1	A-228217 5.1	2930	AGCAGAAAGAGGAA AGAGGUA	308-328	A-2282176. 1	3379	UACCUCUUUCCUCUU UCUGCUGG	306-328
AD-122289 9.1	A-228217 7.1	2931	GCAGAAAGAGGAA GAGGUA	309-329	A-2282178. 1	3380	UUACCUCUUUCCUCU UUCUGCUG	307-329

AD-122290 0.1	A-228217 9.1	2932	CAGAAAAGAGGAAAG AGGUAGA	310-330	A-2282180. 1	3381	UCUACCUCUUUCCUCU UUCUGCU	308-330
AD-122290 1.1	A-228218 1.1	2933	AAAGAGGAAAAGAGG UAGCAA	313-333	A-2282182. 1	3382	UUUGCUACCUCUUUC CUCUUUCU	311-333
AD-122290 2.1	A-228218 3.1	2934	AAGAGGAAAAGAGGU AGCAAAGA	314-334	A-2282184. 1	3383	UCUUGCUACCUCUUU CCUCUUUC	312-334
AD-122290 3.1	A-228218 5.1	2935	AGAGGAAAAGAGGUA GCAAGAA	315-335	A-2282186. 1	3384	UUCUUGCUACCUCUU UCCUCUUU	313-335
AD-122290 4.1	A-228218 7.1	2936	GAGGAAAAGAGGUAG CAAGAGA	316-336	A-2282188. 1	3385	UCUCUUUGCUACCUCU UCCUCUCU	314-336
AD-122290 5.1	A-228218 9.1	2937	GGAAAAGAGGUAGCA AGAGCUA	318-338	A-2282190. 1	3386	UAGCUCUUUGCUACC CUUUCUC	316-338
AD-122290 6.1	A-228219 1.1	2938	AGUAGCAAGAGCUC CAGAGA	324-344	A-2282192. 1	3387	UCUCUGGAGCUCUUG CUACCUCU	322-344
AD-122290 7.1	A-228219 3.1	2939	UCCAGAGAGAAGUCG AGGAAA	337-357	A-2282194. 1	3388	UUUCCUCGACUUCUC UCUGGAGC	335-357
AD-122290 8.1	A-228219 5.1	2940	CCAGAGAGAAGUCGA GGAAGA	338-358	A-2282196. 1	3389	UCUCCUCGACUUCUC UCUGGAG	336-358
AD-122290 9.1	A-228219 7.1	2941	CAGAGAGAAGUCGA GGAAGAA	339-359	A-2282198. 1	3390	UUCUCCUCGACUUC UCUCUGGA	337-359
AD-122291 0.1	A-228219 9.1	2942	AGAGAAAGUCGAGGA AGAGAGA	342-362	A-2282200. 1	3391	UCUCUCUUCCUCGACU UCUCUCU	340-362
AD-122291 1.1	A-228220 1.1	2943	GAGAAAGUCGAGGAA GAGAGAA	343-363	A-2282202. 1	3392	UUCUCUCUUCCUCGAC UUCUCUC	341-363

AD-122291 2.1	A-228220 3.1	2944	GAAGUCGAGGAAGA GAGAGAA	345-365	A-2282204. 1	3393	UUCUCUCUCUCCUCG ACUUCUC	343-365
AD-122291 3.1	A-228220 5.1	2945	AGUGAGUGACCUUGCU UUUGGA	417-437	A-2282206. 1	3394	UCCAAAAAGCAGGUCA CUCACUUU	415-437
AD-122291 4.1	A-228220 7.1	2946	GGGUCGCGACUGAAA CUUUUA	643-663	A-2282208. 1	3395	UAAAGUUUUCAGUGC GACGCCGC	641-663
AD-122291 5.1	A-228220 9.1	2947	GUCGCACUGAAACUU UUCGUA	646-666	A-2282210. 1	3396	UACGAAAAGUUUUCAG UGCGACGC	644-666
AD-122291 6.1	A-228221 1.1	2948	UCGCACUGAAACUUU UCGUCA	647-667	A-2282212. 1	3397	UGACGAAAAGUUUUCA GUGCGACG	645-667
AD-122291 7.1	A-228221 3.1	2949	CACUGAAACUUUUCG UCCAAA	650-670	A-2282214. 1	3398	UUUGGACGAAAAGUU UCAGUGCG	648-670
AD-122291 8.1	A-228221 5.1	2950	ACUGAAACUUUUCGU CCAACA	651-671	A-2282216. 1	3399	UGUUGGACGAAAAGU UUCAGUGC	649-671
AD-122292 0.1	A-228221 9.1	2951	UGAAACUUUUCGUCC AACUUA	653-673	A-2282220. 1	3400	UAAGUUGGACGAAA GUUUCAGU	651-673
AD-122292 1.1	A-228222 1.1	2952	AACUUUUCGUCCAAC UUCUGA	656-676	A-2282222. 1	3401	UCAGAAAGUUGGACGA AAAGUUUC	654-676
AD-122292 2.1	A-228222 3.1	2953	CUGGGCUGUUCUCGC UUCGGA	673-693	A-2282224. 1	3402	UCCGAAGCGAGAACA GCCCAGAA	671-693
AD-122292 3.1	A-228222 5.1	2954	UGGGCUGUUCUCGCU UCGGAA	674-694	A-2282226. 1	3403	UCCGAAAGCGAGAAC AGCCCAGA	672-694
AD-122292 4.1	A-228222 7.1	2955	GGGCUGUUCUCGCUU CGGAGA	675-695	A-2282228. 1	3404	UCUCCGAAGCGAGAA CAGCCCAG	673-695

AD-122292 5.1	A-228222 9.1	2956	GCUGUUCUCGCUUCG GAGGAA	677-697	A-2282230. 1	3405	UCCUCCGAAGCGAG AACAGCCC	675-697
AD-122292 6.1	A-228223 1.1	2957	GCCGCGAGAAAGUGCU AGCUCA	733-753	A-2282232. 1	3406	UGAGCUAGCACUUCU CGCGGCUC	731-753
AD-122292 7.1	A-228223 3.1	2958	CCGCGAGAAAGUGCUA GCUCGA	734-754	A-2282234. 1	3407	UCGAGCUAGCACUUC UCGCGGCU	732-754
AD-122292 8.1	A-228223 5.1	2959	GCCUCCGAAAACCAUG AACUUA	1027-1047	A-2282236. 1	3408	UAGUUCAUUGGUUUC GGAGGCC	1025-1047
AD-122292 9.1	A-228223 7.1	2960	AAGGAGGAGGGCAG AAUCAUA	1130-1150	A-2282238. 1	3409	UAUGAUUCUGCCCUC CUCCUUCU	1128-1150
AD-122293 0.1	A-228223 9.1	2961	GGCAGAAUCAUCACG AAGUGA	1139-1159	A-2282240. 1	3410	UCACUUCGUGAUGAU UCUGGCCU	1137-1159
AD-122293 1.1	A-228224 1.1	2962	AAUCAUCACGAAGUG GUGAAA	1144-1164	A-2282242. 1	3411	UUUACCCACUUCGUG AUGAUUCU	1142-1164
AD-122293 2.1	A-228224 3.1	2963	AUCAUCACGAAGUGG UGAAGA	1145-1165	A-2282244. 1	3412	UCUUCACCCACUUCGU GAUGAUUC	1143-1165
AD-122293 3.1	A-228224 5.1	2964	UCAUCACGAAGUGGU GAAGUA	1146-1166	A-2282246. 1	3413	UACUUCACCCACUUCG UGAUGAUU	1144-1166
AD-122293 4.1	A-228224 7.1	2965	CAUCACGAAGUGGUG AAGUUA	1147-1167	A-2282248. 1	3414	UAACUUCACCCACUUC GUGAUGAU	1145-1167
AD-122293 5.1	A-228224 9.1	2966	UCACGAAAGUGGUGA AGUUCAA	1149-1169	A-2282250. 1	3415	UUGAACUUCACCCACU UCGUGAUG	1147-1169
AD-122293 6.1	A-228225 1.1	2967	AAGUGGUGAAGUUC AUGGAUA	1154-1174	A-2282252. 1	3416	UAUCCAUGAACUUCA CCACUUCG	1152-1174

AD-122293 7.1	A-228225 3.1	2968	AGUGGUGAAGUUCA UGGAUA	1155-1175	A-2282254. 1	3417	UCAUCCAUGAACUUC ACCACUUC	1153-1175
AD-122293 8.1	A-228225 5.1	2969	GUGGUGAAGUUCAU GGAUGUA	1156-1176	A-2282256. 1	3418	UACAUCCAUGAACUU CACCACUU	1154-1176
AD-122293 9.1	A-228225 7.1	2970	GGUGAAGUUCAUGG AUGUCUA	1158-1178	A-2282258. 1	3419	UAGACAUCCAUGAAC UUCACCAC	1156-1178
AD-122294 0.1	A-228225 9.1	2971	GUGAAGUUCAUGGA UGUCUAA	1159-1179	A-2282260. 1	3420	UUAGACAUCCAUGAA CUUCACCA	1157-1179
AD-122294 1.1	A-228226 1.1	2972	UGAAGUUCAUGGAU GUCUAUA	1160-1180	A-2282262. 1	3421	UAUAGACAUCCAUGA ACUUCACC	1158-1180
AD-122294 2.1	A-228226 3.1	2973	AAGUUCAUGGAUGU CUAUCAA	1162-1182	A-2282264. 1	3422	UUGAUAGACAUCCA GAACUUA	1160-1182
AD-122294 3.1	A-228226 5.1	2974	AGUUCAUGGAUGUC UAUCAGA	1163-1183	A-2282266. 1	3423	UCUGAUAGACAUCCA UGAACUUC	1161-1183
AD-122294 4.1	A-228226 7.1	2975	UUCAUGGAUGUCUA UCAGCGA	1165-1185	A-2282268. 1	3424	UCGCUGAUAGACAUC CAUGAACU	1163-1185
AD-122294 5.1	A-228226 9.1	2976	GUGGACAUCUCCAG GAGUAA	1213-1233	A-2282270. 1	3425	UUACUCCUGGAAGAU GUCCACCA	1211-1233
AD-122294 6.1	A-228227 1.1	2977	UCGAGUACAUCUUA AGCCAA	1244-1264	A-2282272. 1	3426	UUGGCUUGAAGAUGU ACUCGAUC	1242-1264
AD-122294 7.1	A-228227 3.1	2978	CGAGUACAUCUUA GCCAUA	1245-1265	A-2282274. 1	3427	UAUGGCUUGAAGAUG UACUCGAU	1243-1265
AD-122294 8.1	A-228227 5.1	2979	GAGUACAUCUUAAG CCAUA	1246-1266	A-2282276. 1	3428	UGAUGGCUUGAAGAU GUACUCGA	1244-1266

AD-122294 9.1	A-228227 7.1	2980	GUACAUCUUAAGCC AUCCUA	1248-1268	A-2282278. 1	3429	UAGGAUGGCUUGAAG AUGUACUC	1246-1268
AD-122295 0.1	A-228227 9.1	2981	CCAACAUCACCAUGC AGAUUA	1337-1357	A-2282280. 1	3430	UAAUCUGCAUGGUGA UGUUGGAC	1335-1357
AD-122295 1.1	A-228228 1.1	2982	CAACAUCACCAUGCA GAUUA	1338-1358	A-2282282. 1	3431	UUAUCUGCAUGGUG AUGUUGGA	1336-1358
AD-122295 2.1	A-228228 3.1	2983	ACAUCACCAUGCAGA UUAUGA	1340-1360	A-2282284. 1	3432	UCAUAAUCUGCAUGG UGAUGUUG	1338-1360
AD-122295 3.1	A-228228 5.1	2984	CAUCACCAUGCAGAU UAUGCA	1341-1361	A-2282286. 1	3433	UGCAUAAUCUGCAUG GUGAUGUU	1339-1361
AD-122295 4.1	A-228228 7.1	2985	ACCAUGCAGAUUAUG CGGAUA	1345-1365	A-2282288. 1	3434	UAUCCGCAUAAUCUG CAUGGUGA	1343-1365
AD-122295 5.1	A-228228 9.1	2986	AUGCAGAUUAUGCG GAUCAA	1348-1368	A-2282290. 1	3435	UUUGAUCCGCAUAAU CUGCAUGG	1346-1368
AD-122295 6.1	A-228229 1.1	2987	UGCAGAUUAUGCGG AUCAAA	1349-1369	A-2282292. 1	3436	UUUGAUCCGCAUAA UCUGCAUG	1347-1369
AD-122295 7.1	A-228229 3.1	2988	GCAGAUUAUGCGGA UCAACA	1350-1370	A-2282294. 1	3437	UGUUUGAUCCGCAUA AUCUGCAU	1348-1370
AD-122295 8.1	A-228229 5.1	2989	GAUUAUGCGGAUCA AACCUC	1353-1373	A-2282296. 1	3438	UGAGGUUUGAUCCGC AUAUCUG	1351-1373
AD-122295 9.1	A-228229 7.1	2990	AUUAUGCGGAUCAA ACCUC	1354-1374	A-2282298. 1	3439	UUGAGGUUUGAUCCG CAUAAUCU	1352-1374
AD-122296 0.1	A-228229 9.1	2991	CGGAUCAAAACCUCAC CAAGGA	1360-1380	A-2282300. 1	3440	UCCUUGGUGAGGUUU GAUCCGCA	1358-1380

AD-122296 1.1	A-228230 1.1	2992	GGAGAGAUGAGCUU CCUACAA	1390-1410	A-2282302. 1	3441	UUGUAGGAAGCUCAU CUCUCCUA	1388-1410
AD-122296 2.1	A-228230 3.1	2993	GAGAUGAGCUUCCUA CAGCAA	1393-1413	A-2282304. 1	3442	UUGCUGUAGGAAGCU CAUCUCUC	1391-1413
AD-122296 3.1	A-228230 5.1	2994	GAUGAGCUUCCUACA GCACAA	1395-1415	A-2282306. 1	3443	UUGUGCUGUAGGAAG CUCAUCUC	1393-1415
AD-122296 4.1	A-228230 7.1	2995	AUGAGCUUCCUACAG CACAAA	1396-1416	A-2282308. 1	3444	UUUGUGCUGUAGGAA GCUCAUCU	1394-1416
AD-122296 5.1	A-228230 9.1	2996	GAGCUUCCUACAGCA CAACAA	1398-1418	A-2282310. 1	3445	UUGUUGUGCUGUAGG AAGCUCAU	1396-1418
AD-122296 6.1	A-228231 1.1	2997	AGCUUCCUACAGCAC AACAAA	1399-1419	A-2282312. 1	3446	UUUGUUGUGCUGUAG GAAAGCUA	1397-1419
AD-122296 7.1	A-228231 3.1	2998	GCUUCCUACAGCACAA ACAAAA	1400-1420	A-2282314. 1	3447	UUUUGUUGUGCUGUA GGAAGCUC	1398-1420
AD-122296 8.1	A-228231 5.1	2999	CUUCCUACAGCACAA CAAAUA	1401-1421	A-2282316. 1	3448	UAUUUGUUGUGCUGU AGGAAGCU	1399-1421
AD-122296 9.1	A-228231 7.1	3000	UCCUACAGCACAAACA AAUGUA	1403-1423	A-2282318. 1	3449	UACAUUUUGUUGUGCU GUAGGAAG	1401-1423
AD-122297 0.1	A-228231 9.1	3001	CUACAGCACAAACAAA UGUGAA	1405-1425	A-2282320. 1	3450	UUCACAUUUUGUUGUG CUGUAGGA	1403-1425
AD-122297 1.1	A-228232 1.1	3002	UACAGCACAAACAAAU GUGAAA	1406-1426	A-2282322. 1	3451	UUUCACAUUUUGUUGU GCUGUAGG	1404-1426
AD-122297 2.1	A-228232 3.1	3003	AGCACAAACAAAUUGUG AAUGCA	1409-1429	A-2282324. 1	3452	UGCAUUCACAUUUUGU UGUGCUGU	1407-1429

AD-122297 3.1	A-228232 5.1	3004	GCACAAACAAUUGUGA AUGCAA	1410-1430	A-2282326. 1	3453	UUGCAUUCACAUUUG UUGUGCUG	1408-1430
AD-122297 4.1	A-228232 7.1	3005	CUCACCAGGAAAGAC UGAUAA	1786-1806	A-2282328. 1	3454	UUAUCAGUCUUUCCU GGUGAGAG	1784-1806
AD-122297 5.1	A-228232 9.1	3006	UCACCAGGAAAGACU GAUACA	1787-1807	A-2282330. 1	3455	UGUAUCAGUCUUUCC UGGUGAGA	1785-1807
AD-122297 6.1	A-228233 1.1	3007	CACCAGGAAAGACUG AUACAA	1788-1808	A-2282332. 1	3456	UUGUAUCAGUCUUUC CUGGUGAG	1786-1808
AD-122297 7.1	A-228233 3.1	3008	ACCAGGAAAGACUGA UACAGA	1789-1809	A-2282334. 1	3457	UCUGUAUCAGUCUUU CCUGGUGA	1787-1809
AD-122297 8.1	A-228233 5.1	3009	CCAGGAAAGACUGAU ACAGAA	1790-1810	A-2282336. 1	3458	UUCUGUAUCAGUCUU UCCUGGUG	1788-1810
AD-122297 9.1	A-228233 7.1	3010	CAGGAAAGACUGAU ACAGAAA	1791-1811	A-2282338. 1	3459	UUUCUGUAUCAGUCU UUCUGGU	1789-1811
AD-122298 0.1	A-228233 9.1	3011	AGGAAAAGACUGAUA CAGAAACA	1792-1812	A-2282340. 1	3460	UGUUCUGUAUCAGUC UUUCCUGG	1790-1812
AD-122298 1.1	A-228234 1.1	3012	GGAAAGACUGAUAC AGAACGA	1793-1813	A-2282342. 1	3461	UCGUUCUGUAUCAGU CUUUCCUG	1791-1813
AD-122298 2.1	A-228234 3.1	3013	GAAAGACUGAUACA GAACGAA	1794-1814	A-2282344. 1	3462	UUCGUUCUGUAUCAG UCUUUCCU	1792-1814
AD-122298 3.1	A-228234 5.1	3014	AAAGACUGAUACAG AACGAUA	1795-1815	A-2282346. 1	3463	UAUCGUUCUGUAUCA GUCUUUCC	1793-1815
AD-122298 4.1	A-228234 7.1	3015	AAGACUGAUACAGA ACGAUCA	1796-1816	A-2282348. 1	3464	UGAUCGUUCUGUAUC AGUCUUUC	1794-1816

AD-122298 5.1	A-228234 9.1	3016	AGACUGAUACAGAAC GAUCGA	1797-1817	A-2282350. 1	3465	UCGAUCGUUCUGUAU CAGUCUUU	1795-1817
AD-122298 6.1	A-228235 1.1	3017	GACUGAUACAGAACG AUCGAA	1798-1818	A-2282352. 1	3466	UUCGAUCGUUCUGUA UCAGUCUU	1796-1818
AD-122298 7.1	A-228235 3.1	3018	ACUGAUACAGAACGA UCGAUA	1799-1819	A-2282354. 1	3467	UAUCGAUCGUUCUGU AUCAGUCU	1797-1819
AD-122298 8.1	A-228235 5.1	3019	CUGAUACAGAACGAU CGAUAA	1800-1820	A-2282356. 1	3468	UUAUCGAUCGUUCUG UAUCAGUC	1798-1820
AD-122298 9.1	A-228235 7.1	3020	UGAUACAGAACGAUC GAUACA	1801-1821	A-2282358. 1	3469	UGUAUCGAUCGUUCU GUAUCAGU	1799-1821
AD-122299 0.1	A-228235 9.1	3021	GAUACAGAACGAUCG AUACAA	1802-1822	A-2282360. 1	3470	UUGUAUCGAUCGUUC UGUAUCAG	1800-1822
AD-122299 1.1	A-228236 1.1	3022	AUACAGAACGAUCGA UACAGA	1803-1823	A-2282362. 1	3471	UCUGUAUCGAUCGUU CUGUAUCA	1801-1823
AD-122299 2.1	A-228236 3.1	3023	UACAGAACGAUCGAU ACAGAA	1804-1824	A-2282364. 1	3472	UUCUGUAUCGAUCGU UCUGUAUC	1802-1824
AD-122299 3.1	A-228236 5.1	3024	ACAGAACGAUCGAUA CAGAAA	1805-1825	A-2282366. 1	3473	UUUCUGUAUCGAUCG UUCUGUAU	1803-1825
AD-122299 4.1	A-228236 7.1	3025	CAGAACGAUCGAUAC AGAAAA	1806-1826	A-2282368. 1	3474	UUUUCUGUAUCGAUC GUUCUGUA	1804-1826
AD-122299 5.1	A-228236 9.1	3026	AGAACGAUCGAUACA GAAACA	1807-1827	A-2282370. 1	3475	UGUUUCUGUAUCGAU CGUUCUGU	1805-1827
AD-122299 6.1	A-228237 1.1	3027	GAACGAUCGAUACAG AAACCA	1808-1828	A-2282372. 1	3476	UGGUUUCUGUAUCGA UCGUUCUG	1806-1828

AD-122299 7.1	A-228237 3.1	3028	AACGAUCGAUACAGA AACCAA	1809-1829	A-2282374. 1	3477	UUGGUUUCUGUAUCG AUCGUUCU	1807-1829
AD-122299 8.1	A-228237 5.1	3029	ACGAUCGAUACAGAA ACCACA	1810-1830	A-2282376. 1	3478	UGUGGUUUCUGUAUC GAUCGUUC	1808-1830
AD-122299 9.1	A-228237 7.1	3030	CGAUCGAUACAGAAA CCACGA	1811-1831	A-2282378. 1	3479	UCGUGGUUUCUGUAU CGAUCGUU	1809-1831
AD-122300 0.1	A-228237 9.1	3031	CACCAUCACCAUCGA CAGAAA	1843-1863	A-2282380. 1	3480	UUUCUGUCGAUGGUG AUGGUGUG	1841-1863
AD-122300 1.1	A-228238 1.1	3032	CAUCACCAUCGACAG AACAGA	1846-1866	A-2282382. 1	3481	UCUGUUCUGUCGAUG GUGAUGGU	1844-1866
AD-122300 2.1	A-228238 3.1	3033	UCACCAUCGACAGAA CAGUCA	1848-1868	A-2282384. 1	3482	UGACUGUUCUGUCGA UGGUGAUG	1846-1868
AD-122300 3.1	A-228238 5.1	3034	CACCAUCGACAGAAC AGUCCA	1849-1869	A-2282386. 1	3483	UGGACUGUUCUGUCG AUGGUGAU	1847-1869
AD-122300 4.1	A-228238 7.1	3035	ACCAUCGACAGAACA GUCCUA	1850-1870	A-2282388. 1	3484	UAGGACUGUUCUGUC GAUGGUGA	1848-1870
AD-122300 5.1	A-228238 9.1	3036	CCAUCGACAGAACAG UCCUUA	1851-1871	A-2282390. 1	3485	UAAGGACUGUUCUGU CGAUGGUG	1849-1871
AD-122300 6.1	A-228239 1.1	3037	CAUCGACAGAACAGU CCUUA	1852-1872	A-2282392. 1	3486	UUAAGGACUGUUCUG UCGAUGGU	1850-1872
AD-122300 7.1	A-228239 3.1	3038	AUCGACAGAACAGUC CUUAAA	1853-1873	A-2282394. 1	3487	UUUAAGGACUGUUCU GUCGAUGG	1851-1873
AD-122300 8.1	A-228239 5.1	3039	UCGACAGAACAGUCC UUAAUA	1854-1874	A-2282396. 1	3488	UAUUAAGGACUGUUC UGUCCGAUG	1852-1874

AD-122300 9.1	A-228239 7.1	3040	CGACAGAACAGUCCU UAAUCA	1855-1875	A-2282398. 1	3489	UGAUUAAAGGACUGU CUGUCGAU	1853-1875
AD-122301 0.1	A-228239 9.1	3041	GACAGAACAGUCCUU AAUCCA	1856-1876	A-2282400. 1	3490	UGGAUUAAAGGACUGU UCUGUCGA	1854-1876
AD-122301 1.1	A-228240 1.1	3042	ACAGAACAGUCCUUA AUCCAA	1857-1877	A-2282402. 1	3491	UUGGAUUAAAGGACUG UUCUGUCG	1855-1877
AD-122301 2.1	A-228240 3.1	3043	AGAACAGUCCUUAU CCAGAA	1859-1879	A-2282404. 1	3492	UUCUGGAUUAAAGGAC UGUUCUGU	1857-1879
AD-122301 3.1	A-228240 5.1	3044	GAACAGUCCUUAUCC CAGAAA	1860-1880	A-2282406. 1	3493	UUUCUGGAUUAAAGGA CUGUUCUG	1858-1880
AD-122301 4.1	A-228240 7.1	3045	AACAGUCCUUAUCC AGAAAA	1861-1881	A-2282408. 1	3494	UUUCUGGAUUAAAGG ACUGUUCU	1859-1881
AD-122301 5.1	A-228240 9.1	3046	ACAGUCCUUAUCCA GAAACA	1862-1882	A-2282410. 1	3495	UGUUUCUGGAUUAAAG GACUGUUC	1860-1882
AD-122301 6.1	A-228241 1.1	3047	CAGUCCUUAUCCAG AAACCA	1863-1883	A-2282412. 1	3496	UGGUUUUCUGGAUUAA GGACUGUU	1861-1883
AD-122301 7.1	A-228241 3.1	3048	AGUCCUUAUCCAGAA AACCUA	1864-1884	A-2282414. 1	3497	UAGGUUUUCUGGAUUAA AGGACUGU	1862-1884
AD-122301 8.1	A-228241 5.1	3049	GUCCUUAUCCAGAA ACCUGA	1865-1885	A-2282416. 1	3498	UCAGGUUUUCUGGAUU AAGGACUG	1863-1885
AD-122301 9.1	A-228241 7.1	3050	UCCUUAUCCAGAAA CCUGAA	1866-1886	A-2282418. 1	3499	UUCAGGUUUUCUGGAU UAAAGGACU	1864-1886
AD-122302 0.1	A-228241 9.1	3051	CCUUAUCCAGAAAC CUGAAA	1867-1887	A-2282420. 1	3500	UUUCAGGUUUUCUGGA UUAAGGAC	1865-1887

AD-122302 1.1	A-228242 1.1	3052	CUUAAUCCAGAAACC UGAAAA	1868-1888	A-2282422. 1	3501	UUUCAGGUUUCUGG AUUAAGGA	1866-1888
AD-122302 2.1	A-228242 3.1	3053	UUAUCCAGAAACCU GAAUA	1869-1889	A-2282424. 1	3502	UAUUUCAGGUUUCUG GAUUAAGG	1867-1889
AD-122302 3.1	A-228242 5.1	3054	CAGAAACCUGAAAUG AAGGA	1875-1895	A-2282426. 1	3503	UCCUUCAUUUCAGG UUUCUGGA	1873-1895
AD-122302 4.1	A-228242 7.1	3055	AGAAACCUGAAAUG AAGGAA	1876-1896	A-2282428. 1	3504	UUUCCUUCAUUUCAG GUUUCUGG	1874-1896
AD-122302 5.1	A-228242 9.1	3056	GAAACCUGAAAUGA AGGAAGA	1877-1897	A-2282430. 1	3505	UCUUCUUCAUUUCU GGUUCUG	1875-1897
AD-122302 6.1	A-228243 1.1	3057	AAACCUGAAAUGAA GGAAGAA	1878-1898	A-2282432. 1	3506	UUCUUCUUCAUUUC AGGUUUCU	1876-1898
AD-122302 7.1	A-228243 3.1	3058	AACCUGAAAUGAAG GAAAGAA	1879-1899	A-2282434. 1	3507	UCUUCUUCUUCAUUU CAGGUUUC	1877-1899
AD-122302 8.1	A-228243 5.1	3059	CCUGAAAUGAAGGA AGAGGAA	1881-1901	A-2282436. 1	3508	UCCUCUUCUUCU UUCAGGUU	1879-1901
AD-122302 9.1	A-228243 7.1	3060	AUGAAGGAAGAGGA GACUCUA	1887-1907	A-2282438. 1	3509	UAGAGUCUCCUUC CUUCAUUU	1885-1907
AD-122303 0.1	A-228243 9.1	3061	UCCUCUUGGAAUUG GAUUA	1977-1997	A-2282440. 1	3510	UGAAUCCAAUUC GAGGGACC	1975-1997
AD-122303 1.1	A-228244 1.1	3062	CCUCUUGGAAUUGGA UUCGCA	1979-1999	A-2282442. 1	3511	UGCGAAUCCAAUUC AAGAGGGA	1977-1999
AD-122303 2.1	A-228244 3.1	3063	CUCUUGGAAUUGGA UUCGCCA	1980-2000	A-2282444. 1	3512	UGGCGAAUCCAAUUC CAAGAGGG	1978-2000

AD-122303 3.1	A-228244 5.1	3064	UGGAAUUGGAUUC GCCAUUA	1983- 2003	A-2282446. 1	3513	UAAUGGCGAAUCCAA UUCCAAGA	1981- 2003
AD-122303 4.1	A-228244 7.1	3065	UGGAAUUGGAUUCG CCAUUA	1984- 2004	A-2282448. 1	3514	UAAUGGCGAAUCCA AUUCCAAG	1982- 2004
AD-122303 5.1	A-228244 9.1	3066	GGAAUUGGAUUCGCC AUUUUA	1985- 2005	A-2282450. 1	3515	UAAAUUGGCGAAUCC AAUUCCAA	1983- 2005
AD-122303 6.1	A-228245 1.1	3067	GAAUUGGAUUCGCCA UUUUAA	1986- 2006	A-2282452. 1	3516	UUAUUUUGGCGAAUC CAAUCCA	1984- 2006
AD-122303 7.1	A-228245 3.1	3068	AAUUGGAUUCGCCAU UUUAUA	1987- 2007	A-2282454. 1	3517	UAUAAAUGGCGAAU CCAUUUCC	1985- 2007
AD-122303 8.1	A-228245 5.1	3069	AUUUGGAUUCGCCAUU UUUAUA	1988- 2008	A-2282456. 1	3518	UAAUAAAUGGCGGAA UCCAAUUC	1986- 2008
AD-122303 9.1	A-228245 7.1	3070	UUGGAUUCGCCAUUU UAUUUA	1989- 2009	A-2282458. 1	3519	UAAUAAAUGGCGGA AUCCAUAU	1987- 2009
AD-122304 0.1	A-228245 9.1	3071	UGGAUUCGCCAUUUU AUUUUA	1990- 2010	A-2282460. 1	3520	UAAAUAAAUGGCGG AAUCCAAU	1988- 2010
AD-122304 1.1	A-228246 1.1	3072	GGAUUCGCCAUUUUA UUUUUA	1991- 2011	A-2282462. 1	3521	UAAAUAAAUGGCGC GAUCCA	1989- 2011
AD-122304 2.1	A-228246 3.1	3073	GAUUCGCCAUUUUAU UUUUUA	1992- 2012	A-2282464. 1	3522	UGAAAAAUAAAUGG CGAAUCCA	1990- 2012
AD-122304 3.1	A-228246 5.1	3074	UCGCCAUUUUAUUUU UCUUGA	1995- 2015	A-2282466. 1	3523	UCAAGAAAAUAAA UGGCGAAU	1993- 2015
AD-122304 4.1	A-228246 7.1	3075	CGCCAUUUUAUUUUU CUUGCA	1996- 2016	A-2282468. 1	3524	UGCAAGAAAAUAAA AUGGCGAA	1994- 2016

AD-122304 5.1	A-228246 9.1	3076	GCCAUUUUAUUUUUC UUGCUA	1997- 2017	A-2282470. 1	3525	UAGCAAGAAAAUAA AAUGGCGA	1995- 2017
AD-122304 6.1	A-228247 1.1	3077	CCAUUUAUUUUUCU UGCUGA	1998- 2018	A-2282472. 1	3526	UCAGCAAGAAAAUA AAUUGGCG	1996- 2018
AD-122304 7.1	A-228247 3.1	3078	CAUUUAUUUUUCU UGCUGCA	1999- 2019	A-2282474. 1	3527	UGCAGCAAGAAAAU AAA AUGGCG	1997- 2019
AD-122304 8.1	A-228247 5.1	3079	AUUUAUUUUUCUU GCUGCUA	2000- 2020	A-2282476. 1	3528	UAGCAGCAAGAAAA UAAA AUGG	1998- 2020
AD-122304 9.1	A-228247 7.1	3080	UUUAUUUUUCUUG CUGCUAA	2001- 2021	A-2282478. 1	3529	UUAGCAGCAAGAAA AUAAA AUG	1999- 2021
AD-122305 0.1	A-228247 9.1	3081	UUUCUUGCUGCUAA UCACCA	2008- 2028	A-2282480. 1	3530	UGGUGAUUUAGCAGC AAGAAAA	2006- 2028
AD-122305 1.1	A-228248 1.1	3082	UCACCGAGCCCGGAA GAUUAA	2023- 2043	A-2282482. 1	3531	UUAUCUUCGGGCU CGGUGAUU	2021- 2043
AD-122305 2.1	A-228248 3.1	3083	GCCCGGAAGAUUAGA GAGUUA	2030- 2050	A-2282484. 1	3532	UAAUCUCUAAUCUU CCGGGCGC	2028- 2050
AD-122305 3.1	A-228248 5.1	3084	CCCGGAAGAUUAGAG AGUUUA	2031- 2051	A-2282486. 1	3533	UAAACUCUCUAAUCU UCCGGGCU	2029- 2051
AD-122305 4.1	A-228248 7.1	3085	CGGAAGAUUAGAGA GUUUUA	2033- 2053	A-2282488. 1	3534	UUAAAACUCUCUAAU CUUCCGGG	2031- 2053
AD-122305 5.1	A-228248 9.1	3086	GGAAGAUUAGAGAG UUUUUA	2034- 2054	A-2282490. 1	3535	UAUAAAACUCUCUAA UCUCCGG	2032- 2054
AD-122305 6.1	A-228249 1.1	3087	GAAGAUUAGAGAGU UUUAUA	2035- 2055	A-2282492. 1	3536	UAAUAAAAACUCUCU AUCUCCG	2033- 2055

AD-122305 7.1	A-228249 3.1	3088	AAGAUUAGAGAGUU UUAUUUA	2036-2056	A-2282494. 1	3537	UAAAUAAAACUCUCU AAUCUUC	2034-2056
AD-122305 8.1	A-228249 5.1	3089	AGAUUAGAGAGUUU UAUUUA	2037-2057	A-2282496. 1	3538	UGAAAUAACUCUC UAAUCUUC	2035-2057
AD-122305 9.1	A-228249 7.1	3090	AUUAGAGAGUUUUA UUUCUGA	2039-2059	A-2282498. 1	3539	UCAGAAAUAACUC UCUAAUCU	2037-2059
AD-122306 0.1	A-228249 9.1	3091	UUAGAGAGUUUAU UUCUGGA	2040-2060	A-2282500. 1	3540	UCCAGAAUAAAACU CUCUAAUC	2038-2060
AD-122306 1.1	A-228250 1.1	3092	UAGAGAGUUUAUU UCUGGGA	2041-2061	A-2282502. 1	3541	UCCAGAAUAAAAC UCUCUAAU	2039-2061
AD-122306 2.1	A-228250 3.1	3093	AGAGAGUUUAUUU CUGGGAA	2042-2062	A-2282504. 1	3542	UUCCAGAAAUAAA CUCUCUAA	2040-2062
AD-122306 3.1	A-228250 5.1	3094	GAGAGUUUAUUUC UGGGAUA	2043-2063	A-2282506. 1	3543	UAUCCAGAAAUAAA ACUCUCUA	2041-2063
AD-122306 4.1	A-228250 7.1	3095	AGAGUUUAUUUCU GGGAUUA	2044-2064	A-2282508. 1	3544	UAAUCCAGAAAUAA AACUCUCU	2042-2064
AD-122306 5.1	A-228250 9.1	3096	GAGUUUAUUUCUG GGAUUCA	2045-2065	A-2282510. 1	3545	UGAAUCCAGAAUA AAACUCUC	2043-2065
AD-122306 6.1	A-228251 1.1	3097	AGUUUAUUUCUGG GAUUGCA	2046-2066	A-2282512. 1	3546	UGGAAUCCAGAAAU AAACUCUC	2044-2066
AD-122306 7.1	A-228251 3.1	3098	GUUUUAUUUCUGG AUUCCUA	2047-2067	A-2282514. 1	3547	UAGGAAUCCAGAAA UAAACUC	2045-2067
AD-122306 8.1	A-228251 5.1	3099	UUUUAUUUCUGGA UUCUGA	2048-2068	A-2282516. 1	3548	UCAGGAAUCCAGAA AUAAAACU	2046-2068

AD-122306 9.1	A-228251 7.1	3100	UUUAAUUUCUGGGAU UCCUGUA	2049-2069	A-2282518. 1	3549	UACAGGAAUCCCAGA AAUAAAAC	2047-2069
AD-122307 0.1	A-228251 9.1	3101	UUUAAUUUCUGGGAU CCUGUAA	2050-2070	A-2282520. 1	3550	UUACAGGAAUCCCAG AAAUAAA	2048-2070
AD-122307 1.1	A-228252 1.1	3102	UAUUUCUGGGAUUCC UGUAGA	2051-2071	A-2282522. 1	3551	UCUACAGGAAUCCCA GAAAUAAA	2049-2071
AD-122307 2.1	A-228252 3.1	3103	AUUUCUGGGAUUCCU GUAGAA	2052-2072	A-2282524. 1	3552	UUCUACAGGAAUCCC AGAAAUAA	2050-2072
AD-122307 3.1	A-228252 5.1	3104	UUUCUGGGAUUCCUG UAGACA	2053-2073	A-2282526. 1	3553	UGUCUACAGGAAUCC CAGAAUA	2051-2073
AD-122307 4.1	A-228252 7.1	3105	UCUGGGAUUCCUGUA GACACA	2055-2075	A-2282528. 1	3554	UGUGUCUACAGGAAU CCCAGAAA	2053-2075
AD-122307 5.1	A-228252 9.1	3106	CUGGGAUUCCUGUAG ACACAA	2056-2076	A-2282530. 1	3555	UUGUGUCUACAGGAA UCCCAGAA	2054-2076
AD-122307 6.1	A-228253 1.1	3107	UGGGAUUCCUGUAG ACACACA	2057-2077	A-2282532. 1	3556	UGUGUGUCUACAGGA AUCCCAGA	2055-2077
AD-122307 7.1	A-228253 3.1	3108	GGGAUUCCUGUAGAC ACACCA	2058-2078	A-2282534. 1	3557	UGGUGUGUCUACAGG AAUCCCAG	2056-2078
AD-122307 8.1	A-228253 5.1	3109	ACACACCCACCCACA UACAUA	2071-2091	A-2282536. 1	3558	UAUGUAUGUGGGUGG GUGUGUCU	2069-2091
AD-122307 9.1	A-228253 7.1	3110	ACCCACCCACAUAACA UACAUA	2075-2095	A-2282538. 1	3559	UAUGUAUGUAUGUGG GUGGGUGU	2073-2095
AD-122308 0.1	A-228253 9.1	3111	CCCACCCACAUAACA ACAUA	2076-2096	A-2282540. 1	3560	UAAUGUAUGUAUGUG GGUGGGUG	2074-2096

AD-122308 1.1	A-228254 1.1	3112	CCACCCACAUAACAUA CAUUA	2077-2097	A-2282542. 1	3561	UAAUGUAUGUAUG GGGUGGG	2075-2097
AD-122308 2.1	A-228254 3.1	3113	CACCCACAUAACAUA AUUUA	2078-2098	A-2282544. 1	3562	UAAAUUGUAUGUAUG UGGUGGG	2076-2098
AD-122308 3.1	A-228254 5.1	3114	CCACAUAACAUAACAUA UAUAUA	2081-2101	A-2282546. 1	3563	UAUAUAAAUGUAUG AUGUGGG	2079-2101
AD-122308 4.1	A-228254 7.1	3115	CACAUAACAUAACAUA AUUUA	2082-2102	A-2282548. 1	3564	UUAUAUAAAUGUAUG UAUGUGGG	2080-2102
AD-122308 5.1	A-228254 9.1	3116	UUAUUUAACAGUG CUAAUGA	2171-2191	A-2282550. 1	3565	UCAUUAGCACUGUUA AUUUAAA	2169-2191
AD-122308 6.1	A-228255 1.1	3117	UAAUUUAACAGUGC UAAUGUA	2172-2192	A-2282552. 1	3566	UACAUUAGCACUGUU AAUUUAA	2170-2192
AD-122308 7.1	A-228255 3.1	3118	AAUUUAACAGUGCU AAUGUUA	2173-2193	A-2282554. 1	3567	UACAUAUAGCACUGU UAAUUUAA	2171-2193
AD-122308 8.1	A-228255 5.1	3119	AAUUUAACAGUGCUA AUGUUA	2174-2194	A-2282556. 1	3568	UUAACAUAUAGCACUG UUAAUUUA	2172-2194
AD-122308 9.1	A-228255 7.1	3120	AUUUAACAGUGCUAA UGUUUAU	2175-2195	A-2282558. 1	3569	UAUAACAUAUAGCACU GUUAAUUU	2173-2195
AD-122309 0.1	A-228255 9.1	3121	UUAACAGUGCUAAU GUUAAUA	2176-2196	A-2282560. 1	3570	UAAUAAACAUAUAGCAC UGUUAAUU	2174-2196
AD-122309 1.1	A-228256 1.1	3122	UACAGUGCUAAUG UUAUUGA	2177-2197	A-2282562. 1	3571	UCAUAACAUAUAGCA CUGUUAAU	2175-2197
AD-122309 2.1	A-228256 3.1	3123	AACAGUGCUAAUGU UAUUGGA	2178-2198	A-2282564. 1	3572	UCCAUAACAUAUAGC ACUGUUAA	2176-2198

AD-122309 3.1	A-228256 5.1	3124	ACAGUGCUAAUGUU AUUGGUA	2179-2199	A-2282566. 1	3573	UACCAAUAACAUUA CACUGUA	2177-2199
AD-122309 4.1	A-228256 7.1	3125	CAGUGCUAAUGUUA UUGGUA	2180-2200	A-2282568. 1	3574	UCACCAAUAACAUUA GCACUGUU	2178-2200
AD-122309 5.1	A-228256 9.1	3126	GUGCUAAUGUUAUU GGUGUA	2182-2202	A-2282570. 1	3575	UGACACCAAUAACAU UAGCACUG	2180-2202
AD-122309 6.1	A-228257 1.1	3127	UGC UAAUGUUAUUG GUGUCUA	2183-2203	A-2282572. 1	3576	UAGACACCAAUAA UAGCACU	2181-2203
AD-122309 7.1	A-228257 3.1	3128	GCUAAUGUUAUUGG UGUCUUA	2184-2204	A-2282574. 1	3577	UAGACACCAAUAA AUUAGCAC	2182-2204
AD-122309 8.1	A-228257 5.1	3129	CUAAUGUUAUUGGU GUCUUA	2185-2205	A-2282576. 1	3578	UGAAGACACCAAUAA CAUUAGCA	2183-2205
AD-122309 9.1	A-228257 7.1	3130	UAAUGUUAUUGGUG UCUUCAA	2186-2206	A-2282578. 1	3579	UGAAGACACCAAUAA ACAUUAGC	2184-2206
AD-122310 0.1	A-228257 9.1	3131	AAUGUUAUUGGUGU CUUCACA	2187-2207	A-2282580. 1	3580	UGUGAAGACACCAAU AACAUUAG	2185-2207
AD-122310 1.1	A-228258 1.1	3132	AUGUUAUUGGUGUC UUCACUA	2188-2208	A-2282582. 1	3581	UAGUGAAGACACCAA UAACAUA	2186-2208
AD-122310 2.1	A-228258 3.1	3133	UGUUAUUGGUGUCU UCACUGA	2189-2209	A-2282584. 1	3582	UCAGUGAAGACACCA AUAACAUA	2187-2209
AD-122310 3.1	A-228258 5.1	3134	GUUAUUGGUGUCUU CACUGGA	2190-2210	A-2282586. 1	3583	UCCAGUGAAGACACC AAUAACAUA	2188-2210
AD-122310 4.1	A-228258 7.1	3135	UUAUUGGUGUCUUC ACUGGAA	2191-2211	A-2282588. 1	3584	UCCAGUGAAGACAC CAAUAACA	2189-2211

AD-122310 5.1	A-228258 9.1	3136	UGGUGUCUUCACUGG AUGUAA	2195- 2215	A-2282590. 1	3585	UACAUCACAGUGAAG ACACCAAU	2193- 2215
AD-122310 6.1	A-228259 1.1	3137	UGUCUUACACUGGAUG UAUUUA	2198- 2218	A-2282592. 1	3586	UAAAUACAUCACAGUG AAGACACC	2196- 2218
AD-122310 7.1	A-228259 3.1	3138	CACUGGAUGUAUUU GACUGCA	2204- 2224	A-2282594. 1	3587	UGCAGUCAAAAUACA CCAGUGAA	2202- 2224
AD-122310 8.1	A-228259 5.1	3139	ACUGGAUGUAUUUG ACUGCUA	2205- 2225	A-2282596. 1	3588	UAGCAGUCAAAUACA UCCAGUGA	2203- 2225
AD-122310 9.1	A-228259 7.1	3140	UGGAUGUAUUUGAC UGCUGUA	2207- 2227	A-2282598. 1	3589	UACAGCAGUCAAAUA CAUCCAGU	2205- 2227
AD-122311 0.1	A-228259 9.1	3141	UAUUUGACUGCUGU GGACUUA	2213- 2233	A-2282600. 1	3590	UAAGUCCACACGCAGU CAAAUACA	2211- 2233
AD-122311 1.1	A-228260 1.1	3142	UUUGACUGCUGUGG ACUUGAA	2215- 2235	A-2282602. 1	3591	UUCAAGUCCACACGCA GUCAAAUA	2213- 2235
AD-122311 2.1	A-228260 3.1	3143	GCUGUGGACUUGAG UUUGGAA	2222- 2242	A-2282604. 1	3592	UUCCCAACUCAAGUCC ACAGCAG	2220- 2242
AD-122311 3.1	A-228260 5.1	3144	UCCACUCAGAUCCU GACAGA	2251- 2271	A-2282606. 1	3593	UCUGUCAGGAUCUGA GUGGGAAC	2249- 2271
AD-122311 4.1	A-228260 7.1	3145	CCCACUCAGAUCCUG ACAGGA	2252- 2272	A-2282608. 1	3594	UCCUGUCAGGAUCUG AGUGGGAA	2250- 2272
AD-122311 5.1	A-228260 9.1	3146	GGAGGAGAUAGAGAG ACUCUGA	2277- 2297	A-2282610. 1	3595	UCAGAGUCUCUCAUC UCCUCCUC	2275- 2297
AD-122311 6.1	A-228261 1.1	3147	GAGGAGAUAGAGAGA CUCUGGA	2278- 2298	A-2282612. 1	3596	UCCAGAGUCUCUCAU CUCCUCCU	2276- 2298

AD-122311 7.1	A-228261 3.1	3148	GGAGAUAGAGACU CUGCAA	2280-2300	A-2282614. 1	3597	UUGCCAGAGUCUCUC AUCUCCUC	2278-2300
AD-122311 8.1	A-228261 5.1	3149	GAGACUCUGGCAUGA UCUUUA	2288-2308	A-2282616. 1	3598	UAAAGAUAUGCCAG AGUCUCUC	2286-2308
AD-122311 9.1	A-228261 7.1	3150	AGACUCUGGCAUGAU CUUUUA	2289-2309	A-2282618. 1	3599	UAAAGAUAUGCCA GAGUCUCU	2287-2309
AD-122312 0.1	A-228261 9.1	3151	UUUUGGGAACACCGA CAAACA	2392-2412	A-2282620. 1	3600	UGUUUGUCGGUGUUC CCAAAACU	2390-2412
AD-122312 1.1	A-228262 1.1	3152	GAGCUUCAGGACAUU GCUGUA	2511-2531	A-2282622. 1	3601	UACAGCAAUGUCCUG AAGCUCCC	2509-2531
AD-122312 2.1	A-228262 3.1	3153	GCUUCAGGACAUUGC UGUGCA	2513-2533	A-2282624. 1	3602	UGCACAGCAAUGUCC UGAAGCUC	2511-2533
AD-122312 3.1	A-228262 5.1	3154	CUUCAGGACAUUGC GUGCUA	2514-2534	A-2282626. 1	3603	UAGCACAGCAAUGUC CUGAAGCU	2512-2534
AD-122312 4.1	A-228262 7.1	3155	UUCAGGACAUUGCUG UGCUIA	2515-2535	A-2282628. 1	3604	UAAAGCACAGCAAUGU CCUGAAGC	2513-2535
AD-122312 5.1	A-228262 9.1	3156	UCAGGACAUUGCUGU GCUUUA	2516-2536	A-2282630. 1	3605	UAAAGCACAGCAAUG UCCUGAAG	2514-2536
AD-122312 6.1	A-228263 1.1	3157	CAGGACAUUGCUGUG CUUUGA	2517-2537	A-2282632. 1	3606	UCAAAGCACAGCAAU GUCCUGAA	2515-2537
AD-122312 7.1	A-228263 3.1	3158	CGCUUACUCUCACCU GCUUCA	2615-2635	A-2282634. 1	3607	UGAAGCAGGUGAGAG UAAAGCGAA	2613-2635
AD-122312 8.1	A-228263 5.1	3159	GCUUACUCUCACCU CUUCUA	2616-2636	A-2282636. 1	3608	UAGAAGCAGGUGAGA GUAAGCGA	2614-2636

AD-122312 9.1	A-228263 7.1	3160	UUACUCUCACCUUGCU UCUGAA	2618-2638	A-2282638. 1	3609	UUCAGAAAGCAGGUGA GAGUAAAGC	2616-2638
AD-122313 0.1	A-228263 9.1	3161	CUCUCACCUUGCUUUCU GAGUUA	2621-2641	A-2282640. 1	3610	UAAUCUCAGAAAGCAGG UGAGAGUA	2619-2641
AD-122313 1.1	A-228264 1.1	3162	UCUCACCUUGCUUUCUG AGUUGA	2622-2642	A-2282642. 1	3611	UCAAUCUCAGAAAGCAG GUGAGAGU	2620-2642
AD-122313 2.1	A-228264 3.1	3163	CUCACCUUGCUUUCUGA GUUGCA	2623-2643	A-2282644. 1	3612	UGCAACUCAGAAAGCA GGUGAGAG	2621-2643
AD-122313 3.1	A-228264 5.1	3164	UCACCUUGCUUUCUGAG UUGCCA	2624-2644	A-2282646. 1	3613	UGGCAACUCAGAAAGC AGGUGAGA	2622-2644
AD-122313 4.1	A-228264 7.1	3165	CACCUUGCUUUCUGAGU UGCCCA	2625-2645	A-2282648. 1	3614	UGGGCAACUCAGAAAG CAGGUGAG	2623-2645
AD-122313 5.1	A-228264 9.1	3166	ACCUGCUUUCUGAGUU GCCCAA	2626-2646	A-2282650. 1	3615	UUGGGCAACUCAGAA GCAGGUGA	2624-2646
AD-122313 6.1	A-228265 1.1	3167	CCUGCUUUCUGAGUUG CCCAGA	2627-2647	A-2282652. 1	3616	UCUGGGCAACUCAGAG AGCAGGUG	2625-2647
AD-122313 7.1	A-228265 3.1	3168	CGGCGAAGAGAGAAGA GACACAA	2667-2687	A-2282654. 1	3617	UUGUGUCUCUUCUCU UCGCCGGG	2665-2687
AD-122313 8.1	A-228265 5.1	3169	GGCGAAGAGAGAAGAG ACACAU	2668-2688	A-2282656. 1	3618	UAUGUGUCUCUUCUC UUCGCCGG	2666-2688
AD-122313 9.1	A-228265 7.1	3170	GCGAAGAGAGAAGAGA CACAUUA	2669-2689	A-2282658. 1	3619	UAAUGUGUCUCUUCU CUUCGCCG	2667-2689
AD-122314 0.1	A-228265 9.1	3171	CGAAGAGAAGAGAC ACAUUA	2670-2690	A-2282660. 1	3620	UCAAUGUGUCUCUUC UCUUCGCC	2668-2690

AD-122314 1.1	A-228266 1.1	3172	GAAAGAGAGAGACA CAUUGUA	2671-2691	A-2282662. 1	3621	UACAAUGUGUCUCUU CUCUUCGC	2669-2691
AD-122314 2.1	A-228266 3.1	3173	AAGAGAGAGACAC AUUGUUA	2672-2692	A-2282664. 1	3622	UAACAAUGUGUCUCU UCUCUUCG	2670-2692
AD-122314 3.1	A-228266 5.1	3174	AGAGAGAGAGACACA UUGUUGA	2673-2693	A-2282666. 1	3623	UACAAUGUGUCUCUC UUCUCUUC	2671-2693
AD-122314 4.1	A-228266 7.1	3175	GAGAGAGACACAU UGUUGGA	2674-2694	A-2282668. 1	3624	UCCAACAUGUGUCU CUUCUCUU	2672-2694
AD-122314 5.1	A-228266 9.1	3176	AGAAGAGACACAUU GUUGGAA	2675-2695	A-2282670. 1	3625	UCCAACAUGUGUC UCUUCUCU	2673-2695
AD-122314 6.1	A-228267 1.1	3177	GAGAGACACAUUG UUGGAAA	2676-2696	A-2282672. 1	3626	UUUCCAACAUGUGU CUCUUCUC	2674-2696
AD-122314 7.1	A-228267 3.1	3178	AAGAGACACAUUGU UGGAAGA	2677-2697	A-2282674. 1	3627	UCUCCAACAUGUG UCUCUUCU	2675-2697
AD-122314 8.1	A-228267 5.1	3179	AGAGACACAUUGUU GGAAGAA	2678-2698	A-2282676. 1	3628	UUCUCCAACAUGU GUCUCUUC	2676-2698
AD-122314 9.1	A-228267 7.1	3180	GAGACACAUUGUUG GAAAGAA	2679-2699	A-2282678. 1	3629	UUUCUCCAACAUG UGUCUCUU	2677-2699
AD-122315 0.1	A-228267 9.1	3181	AGACACAUUGUUGG AAGAAGA	2680-2700	A-2282680. 1	3630	UCUUCUCCAACA GUGUCUCU	2678-2700
AD-122315 1.1	A-228268 1.1	3182	GACACAUUGUUGGA AGAAGCA	2681-2701	A-2282682. 1	3631	UGCUUCUCCAACA UGUGUCUC	2679-2701
AD-122315 2.1	A-228268 3.1	3183	ACACAUUGUUGGAA GAAGCAA	2682-2702	A-2282684. 1	3632	UUGCUUCUCCAACA AUGUGUCU	2680-2702

AD-122315 3.1	A-228268 5.1	3184	CACAUUGUUGGAAG AAGCAGA	2683-2703	A-2282686. 1	3633	UCUGCUUCUCCAAC AAUGUGUC	2681-2703
AD-122315 4.1	A-228268 7.1	3185	UAUGUCCUCACACCA UGAAA	2781-2801	A-2282688. 1	3634	UUUCAAUGGUGUGAG GACAUAGG	2779-2801
AD-122315 5.1	A-228268 9.1	3186	UCCUCACACCAUUGA AACCAA	2785-2805	A-2282690. 1	3635	UUGUUUCAAUGGUG UGAGGACA	2783-2805
AD-122315 6.1	A-228269 1.1	3187	CCUCACACCAUUGAA ACCACA	2786-2806	A-2282692. 1	3636	UGUGGUUUCAAUGGU GUGAGGAC	2784-2806
AD-122315 7.1	A-228269 3.1	3188	CUCACACCAUUGAAA CCACUA	2787-2807	A-2282694. 1	3637	UAGUGGUUUCAAUGG UGUGAGGA	2785-2807
AD-122315 8.1	A-228269 5.1	3189	UCACACCAUUGAAAC CACUAA	2788-2808	A-2282696. 1	3638	UUAGUGGUUUCAAUG GUGUGAGG	2786-2808
AD-122315 9.1	A-228269 7.1	3190	CACACCAUUGAAACC ACUAGA	2789-2809	A-2282698. 1	3639	UCUAGUGGUUUCAAU GGUGUGAG	2787-2809
AD-122316 0.1	A-228269 9.1	3191	CCAUUGAAACCACUA GUUCUA	2793-2813	A-2282700. 1	3640	UAGAACUAGUGGUUU CAAUGGUG	2791-2813
AD-122316 1.1	A-228270 1.1	3192	CAUUGAAACCACUAG UUCUGA	2794-2814	A-2282702. 1	3641	UCAGAACUAGUGGUU UCAUGGU	2792-2814
AD-122316 2.1	A-228270 3.1	3193	AUUGAAACCACUAGU UCUGUA	2795-2815	A-2282704. 1	3642	UACAGAACUAGUGGU UUCAAUGG	2793-2815
AD-122316 3.1	A-228270 5.1	3194	UUGAAACCACUAGUU CUGUCA	2796-2816	A-2282706. 1	3643	UGACAGAACUAGUGG UUUCAAUG	2794-2816
AD-122316 4.1	A-228270 7.1	3195	UGAAACCACUAGUUC UGUCCA	2797-2817	A-2282708. 1	3644	UGGACAGAACUAGUG GUUCAAU	2795-2817

AD-122316 5.1	A-228270 9.1	3196	GACCUGGUUGUGUG UGUGUGA	2825-2845	A-2282710. 1	3645	UCACACACACACAACC AGGUCUC	2823-2845
AD-122316 6.1	A-228271 1.1	3197	ACCUGGUUGUGUGU GUGUGAA	2826-2846	A-2282712. 1	3646	UUCACACACACACAAC CAGGUCU	2824-2846
AD-122316 7.1	A-228271 3.1	3198	CCUGGUUGUGUGUG UGUGAGA	2827-2847	A-2282714. 1	3647	UCUCACACACACACAA CCAGGUC	2825-2847
AD-122316 8.1	A-228271 5.1	3199	CUGGUUGUGUGUGU GUGAGUA	2828-2848	A-2282716. 1	3648	UACUCACACACACACA ACCAGGU	2826-2848
AD-122316 9.1	A-228271 7.1	3200	UGGUUGUGUGUGUG UGAGUGA	2829-2849	A-2282718. 1	3649	UCACUCACACACACAC AACCAGG	2827-2849
AD-122317 0.1	A-228271 9.1	3201	GGUUGUGUGUGUGU GAGUGGA	2830-2850	A-2282720. 1	3650	UCCACUCACACACACA CAACCAG	2828-2850
AD-122317 1.1	A-228272 1.1	3202	GUGUGUGUGUGAGU GGUUGAA	2834-2854	A-2282722. 1	3651	UUCAACCACUCACACA CACACAA	2832-2854
AD-122317 2.1	A-228272 3.1	3203	UGUGUGUGUGAGUG GUUGACA	2835-2855	A-2282724. 1	3652	UGUCAACCACUCACAC ACACACA	2833-2855
AD-122317 3.1	A-228272 5.1	3204	UGUGUGUGAGUGGU UGACCUA	2837-2857	A-2282726. 1	3653	UAGGUAACCACUCA CACACACA	2835-2857
AD-122317 4.1	A-228272 7.1	3205	UGUGUGAGUGGUUG ACCUUCA	2839-2859	A-2282728. 1	3654	UGAAGGUCAACCACU CACACACA	2837-2859
AD-122317 5.1	A-228272 9.1	3206	GUGUGAGUGGUUGA CCUUCCA	2840-2860	A-2282730. 1	3655	UGGAAGGUCAACCAC UCACACAC	2838-2860
AD-122317 6.1	A-228273 1.1	3207	UGUGAGUGGUUGAC CUUCCUA	2841-2861	A-2282732. 1	3656	UAGGAAGGUCAACCA CUCACACA	2839-2861

AD-122317 7.1	A-228273 3.1	3208	UGAGUGGUUGACCU UCCUCCA	2843-2863	A-2282734. 1	3657	UGGAGGAAGGUCAAC CACUCACA	2841-2863
AD-122317 8.1	A-228273 5.1	3209	GUGGUUGACCUUCCU CCAUCA	2846-2866	A-2282736. 1	3658	UGAUGGAGGAAGGUC AACCACUC	2844-2866
AD-122317 9.1	A-228273 7.1	3210	UUGUGGAGGCAGAG AAAAGAA	2926-2946	A-2282738. 1	3659	UUCUUUUUCUCUGCCU CCACAAUG	2924-2946
AD-122318 0.1	A-228273 9.1	3211	UGUGGAGGCAGAGA AAAGAGA	2927-2947	A-2282740. 1	3660	UCUCUUUUUCUCUGCC UCCACAAU	2925-2947
AD-122318 1.1	A-228274 1.1	3212	GUGGAGGCAGAGAA AAGAGAA	2928-2948	A-2282742. 1	3661	UUCUCUUUUUCUCUGC CUCCACAA	2926-2948
AD-122318 2.1	A-228274 3.1	3213	UGGAGGCAGAGAAA AGAGAAA	2929-2949	A-2282744. 1	3662	UUUCUCUUUUUCUCUG CCUCCACA	2927-2949
AD-122318 3.1	A-228274 5.1	3214	GGAGGCAGAGAAA GAGAAA	2930-2950	A-2282746. 1	3663	UUUCUCUUUUUCUCU GCCUCCAC	2928-2950
AD-122318 4.1	A-228274 7.1	3215	GAGGCAGAGAAAAG AGAAAAG	2931-2951	A-2282748. 1	3664	UCUUUCUCUUUUUCUC UGCCUCCA	2929-2951
AD-122318 5.1	A-228274 9.1	3216	AGGCAGAGAAAAGA GAAAGUA	2932-2952	A-2282750. 1	3665	UACUUUCUCUUUUUCU CUGCCUCC	2930-2952
AD-122318 6.1	A-228275 1.1	3217	GGCAGAGAAAAGAG AAAGUGA	2933-2953	A-2282752. 1	3666	UCACUUUCUCUUUUUC UCUGCCUC	2931-2953
AD-122318 7.1	A-228275 3.1	3218	GCAGAGAAAAGAGA AAGUGUA	2934-2954	A-2282754. 1	3667	UACACUUUCUCUUUU CUCUGCCU	2932-2954
AD-122318 8.1	A-228275 5.1	3219	CAGAGAAAAGAGAA AGUGUUA	2935-2955	A-2282756. 1	3668	UAAACACUUUCUCUU UCUCUGCC	2933-2955

AD-122318 9.1	A-228275 7.1	3220	AGAGAAAAGAGAAA GUGUUUA	2936-2956	A-2282758. 1	3669	UAAACACUUUCUCUU UUCUCUGC	2934-2956
AD-122319 0.1	A-228275 9.1	3221	GAGAAAAGAGAAAAG UGUUUUA	2937-2957	A-2282760. 1	3670	UAAACACUUUCUCUU UUUCUCUG	2935-2957
AD-122319 1.1	A-228276 1.1	3222	AGAAAAGAGAAAAGU GUUUUUA	2938-2958	A-2282762. 1	3671	UAAAACACUUUCUC UUUUCUCU	2936-2958
AD-122319 2.1	A-228276 3.1	3223	GAAGAAGAGAAAAGUG UUUUUAU	2939-2959	A-2282764. 1	3672	UAUAAAACACUUUCU CUUUUCUC	2937-2959
AD-122319 3.1	A-228276 5.1	3224	AAAAGAGAAAAGUGU UUUAUUA	2940-2960	A-2282766. 1	3673	UAUAAAACACUUUC UCUUUUUCU	2938-2960
AD-122319 4.1	A-228276 7.1	3225	AAAGAGAAAAGUGUU UUUAUUA	2941-2961	A-2282768. 1	3674	UAUAUAAAACACUUU CUCUUUUC	2939-2961
AD-122319 5.1	A-228276 9.1	3226	AAGAGAAAAGUGUUU UAUAUUA	2942-2962	A-2282770. 1	3675	UAUAUAAAACACUU UCUCUUUU	2940-2962
AD-122319 6.1	A-228277 1.1	3227	AGAGAAAAGUGUUUU AUUAUUA	2943-2963	A-2282772. 1	3676	UGUAUAUAAAACACU UUCUCUUU	2941-2963
AD-122319 7.1	A-228277 3.1	3228	GAGAAAAGUGUUUUUA UAUACGA	2944-2964	A-2282774. 1	3677	UCGUUAUAUAAAACAC UUUCUCUU	2942-2964
AD-122319 8.1	A-228277 5.1	3229	AGAAAAGUGUUUUUAU AUACGGA	2945-2965	A-2282776. 1	3678	UCCGUUAUAUAAAACA CUUUCUCU	2943-2965
AD-122319 9.1	A-228277 7.1	3230	AAAGUGUUUUUAUUAU ACGGUUA	2947-2967	A-2282778. 1	3679	UUACCGUAUAUAAA CACUUUCU	2945-2967
AD-122320 0.1	A-228277 9.1	3231	AAGUGUUUUUAUUA CGGUACA	2948-2968	A-2282780. 1	3680	UGUACCGUAUAUAAA ACACUUUC	2946-2968

AD-122320 1.1	A-228278 1.1	3232	AGUGUUUUAUAC GGUACUA	2949-2969	A-2282782. 1	3681	UAGUACCGUAUAA AACACUUU	2947-2969
AD-122320 2.1	A-228278 3.1	3233	GUGUUUUAUACG GUACUUA	2950-2970	A-2282784. 1	3682	UAAAGUACCGUAUA AAACACUU	2948-2970
AD-122320 3.1	A-228278 5.1	3234	UGUUUUUAUACGG UACUUAA	2951-2971	A-2282786. 1	3683	UUAAGUACCGUAUAU AAACACU	2949-2971
AD-122320 4.1	A-228278 7.1	3235	GUUUUAUACGGU ACUUUA	2952-2972	A-2282788. 1	3684	UAUAAGUACCGUAUA UAAACAC	2950-2972
AD-122320 5.1	A-228278 9.1	3236	UUUAUAUACGGUA CUUAUA	2953-2973	A-2282790. 1	3685	UAAUAAGUACCGUAU AUAAAACA	2951-2973
AD-122320 6.1	A-228279 1.1	3237	UUUAUAUACGGUAC UUUUUA	2954-2974	A-2282792. 1	3686	UAAUAAGUACCGUA UAUAAAAC	2952-2974
AD-122320 7.1	A-228279 3.1	3238	UUUAUAUACGGUACU UAUUUA	2955-2975	A-2282794. 1	3687	UAAUAAGUACCGU AUUAUAAA	2953-2975
AD-122320 8.1	A-228279 5.1	3239	UAUAUACGGUACUU AUUUAAA	2956-2976	A-2282796. 1	3688	UUUAAAUAAGUACCG UAUAUAAA	2954-2976
AD-122320 9.1	A-228279 7.1	3240	GUACUUUUUAAUA UCCCUUA	2964-2984	A-2282798. 1	3689	UAAAGGGAUUAUAAU AAGUACCG	2962-2984
AD-122321 0.1	A-228279 9.1	3241	UACUUUUUAAUAU CCCUUA	2965-2985	A-2282800. 1	3690	UAAAGGGAUUAUAAA UAAGUACC	2963-2985
AD-122321 1.1	A-228280 1.1	3242	UUAUGAGAUUAUC UUUUGCA	3068-3088	A-2282802. 1	3691	UGCAAAAAGAUACAUC UCAUAAA	3066-3088
AD-122321 2.1	A-228280 3.1	3243	UAUGAGAUUAUCU UUUUGCUA	3069-3089	A-2282804. 1	3692	UAGCAAAAAGAUACA CUCAUAAA	3067-3089

AD-122321 3.1	A-228280 5.1	3244	AUGAGUUAUCUU UUGCUC	3070-3090	A-2282806. 1	3693	UGAGCAAAAGAUACA UCUCAUA	3068-3090
AD-122321 4.1	A-228280 7.1	3245	UGAGAUUAUCUU UGCUCUA	3071-3091	A-2282808. 1	3694	UAGAGCAAAAGAUAC AUCUCAUA	3069-3091
AD-122321 5.1	A-228280 9.1	3246	GAGAUUAUCUUU GCUCUC	3072-3092	A-2282810. 1	3695	UGAGAGCAAAAGAU CAUCUCAU	3070-3092
AD-122321 6.1	A-228281 1.1	3247	AGAUGUAUCUUU CUCUCUA	3073-3093	A-2282812. 1	3696	UAGAGAGCAAAAGAU ACAUCUCA	3071-3093
AD-122321 7.1	A-228281 3.1	3248	GAUGUAUCUUU UCUCUC	3074-3094	A-2282814. 1	3697	UGAGAGAGCAAAAGA UACAUCUC	3072-3094
AD-122321 8.1	A-228281 5.1	3249	AUGUAUCUUU UCUCUA	3075-3095	A-2282816. 1	3698	UAGAGAGAGCAAAAG AUACAUCU	3073-3095
AD-122321 9.1	A-228281 7.1	3250	GCUCUCUUGCUCU CUUAUA	3086-3106	A-2282818. 1	3699	UAUAAGAGAGCAAGA GAGAGCAA	3084-3106
AD-122322 0.1	A-228281 9.1	3251	CUCUCUCUUGCUCU UUAUUA	3087-3107	A-2282820. 1	3700	UAUAAGAGAGCAAG AGAGAGCA	3085-3107
AD-122322 1.1	A-228282 1.1	3252	UCUCUCUUGCUCUCU UAUUUA	3088-3108	A-2282822. 1	3701	UAUAUAAGAGAGCAA GAGAGAGC	3086-3108
AD-122322 2.1	A-228282 3.1	3253	CUCUCUUGCUCUCU AUUUGA	3089-3109	A-2282824. 1	3702	UCAAAUAAGAGAGCA AGAGAGAG	3087-3109
AD-122322 3.1	A-228282 5.1	3254	UCUCUUGCUCUCUUA UUUGUA	3090-3110	A-2282826. 1	3703	UACAAUAAGAGAGC AAGAGAGA	3088-3110
AD-122322 4.1	A-228282 7.1	3255	CUCUUGCUCUCUUAU UUGUAA	3091-3111	A-2282828. 1	3704	UUACAAUAAGAGAG CAAGAGAG	3089-3111

AD-122322 5.1	A-228282 9.1	3256	UCUUGCUCUCUUAUU UGUACA	3092-3112	A-2282830. 1	3705	UGUACAAAUAAAGAGA GCAAGAGA	3090-3112
AD-122322 6.1	A-228283 1.1	3257	CUUUGCUCUCUUAUUU GUACCA	3093-3113	A-2282832. 1	3706	UGGUACAAAUAAAGAG AGCAAGAG	3091-3113
AD-122322 7.1	A-228283 3.1	3258	UUGCUCUCUUAUUUG UACCGA	3094-3114	A-2282834. 1	3707	UCGGUACAAAUAAAGA GAGCAAGA	3092-3114
AD-122322 8.1	A-228283 5.1	3259	UGCUCUCUUAUUUGU ACCGGA	3095-3115	A-2282836. 1	3708	UCCGGUACAAAUAAAG AGAGCAAG	3093-3115
AD-122322 9.1	A-228283 7.1	3260	CUCUCUUAUUUGUAC CGGUUA	3097-3117	A-2282838. 1	3709	UAAACCGGUACAAUA AGAGAGCA	3095-3117
AD-122323 0.1	A-228283 9.1	3261	UCUCUUAUUUGUACC GGUUUA	3098-3118	A-2282840. 1	3710	UAAACCGGUACAAAU AAGAGAGC	3096-3118
AD-122323 1.1	A-228284 1.1	3262	CUCUUAUUUGUACCG GUUUUA	3099-3119	A-2282842. 1	3711	UAAACCGGUACAA UAAAGAGAG	3097-3119
AD-122323 2.1	A-228284 3.1	3263	UCUUAUUUGUACCGG UUUUUA	3100-3120	A-2282844. 1	3712	UAAAAACCGGUACAA AUAAAGAGA	3098-3120
AD-122323 3.1	A-228284 5.1	3264	CUUUAUUUGUACCGGU UUUUUA	3101-3121	A-2282846. 1	3713	UCAAAAAACCGGUACA AAUAAAGAG	3099-3121
AD-122323 4.1	A-228284 7.1	3265	UUAUUUGUACCGGU UUUUUA	3102-3122	A-2282848. 1	3714	UACAAAAACCGGUAC AAAUAAAGA	3100-3122
AD-122323 5.1	A-228284 9.1	3266	UAUUUGUACCGGUU UUUGUA	3103-3123	A-2282850. 1	3715	UUACAAAAACCGGUUA CAAAUAAAG	3101-3123
AD-122323 6.1	A-228285 1.1	3267	AUUUGUACCGGUUU UUGUAUA	3104-3124	A-2282852. 1	3716	UAUACAAAAACCGGU ACAAAUAA	3102-3124

AD-122323 7.1	A-228285 3.1	3268	UUUGUACCGGUUUU UGUAUA	3105-3125	A-2282854. 1	3717	UUUAUACAAAACCGG UACAAUA	3103-3125
AD-122323 8.1	A-228285 5.1	3269	UUGUACCGGUUUU GUAUAUA	3106-3126	A-2282856. 1	3718	UAUAUACAAAACCG GUACAAU	3104-3126
AD-122323 9.1	A-228285 7.1	3270	UGUACCGGUUUUUG UAUAUA	3107-3127	A-2282858. 1	3719	UUUAUACAAAACCG GGUACAA	3105-3127
AD-122324 0.1	A-228285 9.1	3271	GUACCGGUUUUUGU AUAUA	3108-3128	A-2282860. 1	3720	UUUAUACAAAACCG CGGUACAA	3106-3128
AD-122324 1.1	A-228286 1.1	3272	UACCGGUUUUUGUA UAUAAA	3109-3129	A-2282862. 1	3721	UUUAUACAAAACCG CGGUACA	3107-3129
AD-122324 2.1	A-228286 3.1	3273	ACCGGUUUUUGUAU AUAAAA	3110-3130	A-2282864. 1	3722	UUUUUAUACAAAACCG GUAC	3108-3130
AD-122324 3.1	A-228286 5.1	3274	AUUAUGUUUCCAAU CUCUCA	3129-3149	A-2282866. 1	3723	UGAGAGAUUGGAAAC AUGAAUU	3127-3149
AD-122324 4.1	A-228286 7.1	3275	UUAUGUUUCCAAUC UCUCUA	3130-3150	A-2282868. 1	3724	UAGAGAGAUUGGAAA CAUGAAU	3128-3150
AD-122324 5.1	A-228286 9.1	3276	UCAUGUUUCCAAUCU CUCUCA	3131-3151	A-2282870. 1	3725	UGAGAGAGAUUGGAA ACAUGAAU	3129-3151
AD-122324 6.1	A-228287 1.1	3277	CAUGUUUCCAAUCUC UCUCUA	3132-3152	A-2282872. 1	3726	UAGAGAGAGAUUGGA AACAUGAA	3130-3152
AD-122324 7.1	A-228287 3.1	3278	AUGUUUCCAAUCUCU CUCUCA	3133-3153	A-2282874. 1	3727	UGAGAGAGAGAUUGG AAACAUGA	3131-3153
AD-122324 8.1	A-228287 5.1	3279	UGUUUCCAAUCUCUC UCUCCA	3134-3154	A-2282876. 1	3728	UGGAGAGAGAGAUUG GAAACAUG	3132-3154

AD-122324 9.1	A-228287 7.1	3280	UUUCCAAUCUCUCUC UCCCUA	3136-3156	A-2282878. 1	3729	UAGGGAGAGAGAU UGGAAACA	3134-3156
AD-122325 0.1	A-228287 9.1	3281	UCCAAUCUCUCUC CCUGAA	3138-3158	A-2282880. 1	3730	UUCAGGGAGAGAG AUUGGAAA	3136-3158
AD-122325 1.1	A-228288 1.1	3282	CGGUGACAGUCACUA GCUUAA	3159-3179	A-2282882. 1	3731	UUAAGCUAGUGACUG UCACCCGAU	3157-3179
AD-122325 2.1	A-228288 3.1	3283	GGUGACAGUCACUAG CUUAUA	3160-3180	A-2282884. 1	3732	UAUAAGCUAGUGACU GUCACCGA	3158-3180
AD-122325 3.1	A-228288 5.1	3284	AGUCACUAGCUUAUC UUGAAA	3166-3186	A-2282886. 1	3733	UUUCAAGAUAAAGCUA GUGACUGU	3164-3186
AD-122325 4.1	A-228288 7.1	3285	GUCACUAGCUUAUCU UGAACA	3167-3187	A-2282888. 1	3734	UGUUCAAGAUAAAGCU AGUGACUG	3165-3187
AD-122325 5.1	A-228288 9.1	3286	UCACUAGCUUAUCUU GAACAA	3168-3188	A-2282890. 1	3735	UUGUUCAAGAUAAAGC UAGUGACU	3166-3188
AD-122325 6.1	A-228289 1.1	3287	ACUAGCUUAUCUUGA ACAGAA	3170-3190	A-2282892. 1	3736	UUCUGUUCAAGAUAA GCUAGUGA	3168-3190
AD-122325 7.1	A-228289 3.1	3288	CUAGCUUAUCUUGAA CAGAUAA	3171-3191	A-2282894. 1	3737	UAUCUGUUCAAGAUAA AGCUAGUG	3169-3191
AD-122325 8.1	A-228289 5.1	3289	UAGCUUAUCUUGAAC AGAUAA	3172-3192	A-2282896. 1	3738	UUAUCUGUUCAAGAU AAGCUAGU	3170-3192
AD-122325 9.1	A-228289 7.1	3290	AGCUUAUCUUGAACAA GAUAUA	3173-3193	A-2282898. 1	3739	UAUAUCUGUUCAAGAA UAAAGCUAG	3171-3193
AD-122326 0.1	A-228289 9.1	3291	GCUUAUCUUGAACAG AUAUA	3174-3194	A-2282900. 1	3740	UAAUAUCUGUUCAAG AUAAGCUA	3172-3194

AD-122326 1.1	A-228290 1.1	3292	CAGCACACAUUCCUU UGAAAA	3241-3261	A-2282902. 1	3741	UUUCAAAGGAAUGU GUGCUGG	3239-3261
AD-122326 2.1	A-228290 3.1	3293	AGCACACAUUCCUUU GAAUA	3242-3262	A-2282904. 1	3742	UAUUUCAAAGGAAUG UGUGCUGG	3240-3262
AD-122326 3.1	A-228290 5.1	3294	GCACACAUUCCUUUG AAAUAA	3243-3263	A-2282906. 1	3743	UAUUUCAAAGGAAU GUGUGCGU	3241-3263
AD-122326 4.1	A-228290 7.1	3295	CACACAUUCCUUUGA AAUAAA	3244-3264	A-2282908. 1	3744	UUUAAUUCAAAGGAA UGUGUGCU	3242-3264
AD-122326 5.1	A-228290 9.1	3296	CACAUUCCUUUGAAA UAAAGGA	3246-3266	A-2282910. 1	3745	UCCUUAAUUCAAAGG AAUGUGUG	3244-3266
AD-122326 6.1	A-228291 1.1	3297	UCCUUUGAAAUAAG GUUUCAA	3251-3271	A-2282912. 1	3746	UUGAAAACCUUAAUUC AAAAGGAAU	3249-3271
AD-122326 7.1	A-228291 3.1	3298	CUUUGAAAUAAGGU UUCAAUA	3253-3273	A-2282914. 1	3747	UAUUGAAACCUUAAU UCAAGGA	3251-3273
AD-122326 8.1	A-228291 5.1	3299	UUUGAAAUAAGGUU UCAAUAA	3254-3274	A-2282916. 1	3748	UUAUUGAAAACCUUAAU UUCAAAAGG	3252-3274
AD-122326 9.1	A-228291 7.1	3300	AGGUUUCAAUAUAC AUCUACA	3263-3283	A-2282918. 1	3749	UGUAGAUGUAUAAUUG AAACCUUA	3261-3283
AD-122327 0.1	A-228291 9.1	3301	GGUUUCAUAUACA UCUACAA	3264-3284	A-2282920. 1	3750	UUGAGAUGUAUAAU GAAACCUU	3262-3284
AD-122327 1.1	A-228292 1.1	3302	GUUUCAAUAUACAUC UACAUA	3265-3285	A-2282922. 1	3751	UAUGAGAUGUAUAAU UGAAACCU	3263-3285
AD-122327 2.1	A-228292 3.1	3303	UUUCAAUUAUACAUCU ACAUA	3266-3286	A-2282924. 1	3752	UUAUGAGAUGUAUA UUGAAACC	3264-3286

AD-122327 3.1	A-228292 5.1	3304	UCAAUAUACAUCUA CAUACA	3267-3287	A-2282926. 1	3753	UGUAUGUAGAUAU AUUGAAAC	3265-3287
AD-122327 4.1	A-228292 7.1	3305	UAUUUGGCAACUUG UAUUUGA	3295-3315	A-2282928. 1	3754	UCAAUAUACAAGUUGC CAAAUAUA	3293-3315
AD-122327 5.1	A-228292 9.1	3306	UUUGGCAACUUGUA UUUGUGA	3297-3317	A-2282930. 1	3755	UCACAAAUAACAAGUU GCCAAAUA	3295-3317
AD-122327 6.1	A-228293 1.1	3307	UGGCAACUUGUAUU UGUGUGA	3299-3319	A-2282932. 1	3756	UCACACAAAUAACAAG UUGCCAAA	3297-3319
AD-122327 7.1	A-228293 3.1	3308	GGCAACUUGUAUUU GUGUGUA	3300-3320	A-2282934. 1	3757	UACACACAAAUAACAA GUUGCCAA	3298-3320
AD-122327 8.1	A-228293 5.1	3309	GCAACUUGUAUUUG UGUGUAA	3301-3321	A-2282936. 1	3758	UUACACACAAAUAACA AGUUGCCA	3299-3321
AD-122327 9.1	A-228293 7.1	3310	CAACUUGUAUUUGU GUGUAUA	3302-3322	A-2282938. 1	3759	UAUACACACAAAUAAC AAGUUGCC	3300-3322
AD-122328 0.1	A-228293 9.1	3311	AACUUGUAUUUGUG UGUAUAA	3303-3323	A-2282940. 1	3760	UUAUACACACAAAUA CAAGUUGC	3301-3323
AD-122328 1.1	A-228294 1.1	3312	ACUUGUAUUUGUGU GUAUAUA	3304-3324	A-2282942. 1	3761	UAUUAUACACACAAA ACAAGUUG	3302-3324
AD-122328 2.1	A-228294 3.1	3313	UUCUGAUAUUUAG ACAUUGA	3354-3374	A-2282944. 1	3762	UCAUGUCUAUUUUA UCAGAAUC	3352-3374
AD-122328 3.1	A-228294 5.1	3314	UGAUAUUUAGACA UUGCUAA	3357-3377	A-2282946. 1	3763	UUAGCAAUGUCUAUU UUUAUCAGA	3355-3377
AD-122328 4.1	A-228294 7.1	3315	GAUAAUAUAGACAU UGCUAUA	3358-3378	A-2282948. 1	3764	UAUAGCAAUGUCUAU UUUAUCAG	3356-3378

AD-122328 5.1	A-228294 9.1	3316	UAAAAUAGACAUUG CUAUUA	3360-3380	A-2282950. 1	3765	UGAAUAGCAAUGUCU AUUUUAUC	3358-3380
AD-122328 6.1	A-228295 1.1	3317	UAGACAUUGCUAUUC UGUUUA	3365-3385	A-2282952. 1	3766	UAAACAGAAUAGCAA UGUCUAUU	3363-3385
AD-122328 7.1	A-228295 3.1	3318	AGACAUUGCUAUUCU GUUUUA	3366-3386	A-2282954. 1	3767	UAAACAGAAUAGCA AUGUCUAU	3364-3386
AD-122328 8.1	A-228295 5.1	3319	UCUACAUACUAAAUC UCUCUA	3422-3442	A-2282956. 1	3768	UAGAGAGAUUUAGUA UGUAGAAU	3420-3442
AD-122328 9.1	A-228295 7.1	3320	CUACAUACUAAAUCU CUCUCA	3423-3443	A-2282958. 1	3769	UGAGAGAGAUUUAGU AUGUAGAA	3421-3443
AD-122329 0.1	A-228295 9.1	3321	UACAUACUAAAUCUC UCUCCA	3424-3444	A-2282960. 1	3770	UGGAGAGAGAUUUAG UAUGUAGA	3422-3444
AD-122329 1.1	A-228296 1.1	3322	ACAUACUAAAUCUCU CUCCUA	3425-3445	A-2282962. 1	3771	UAGGAGAGAGAUUUUA GUAUGUAG	3423-3445
AD-122329 2.1	A-228296 3.1	3323	CAUACUAAAUCUCUC UCCUUA	3426-3446	A-2282964. 1	3772	UAAAGGAGAGAGAUUU AGUAUGUA	3424-3446
AD-122329 3.1	A-228296 5.1	3324	AUACUAAAUCUCUCU CCUUUA	3427-3447	A-2282966. 1	3773	UAAAGGAGAGAGAUUU UAGUAUGU	3425-3447
AD-122329 4.1	A-228296 7.1	3325	UACUAAAUCUCUCUC CUUUUA	3428-3448	A-2282968. 1	3774	UAAAAGGAGAGAGAU UUAGUAUG	3426-3448
AD-122329 5.1	A-228296 9.1	3326	CAUUUAUUUAUUGG UGCUACA	3468-3488	A-2282970. 1	3775	UGUAGCACCAAUAAA UAAAUAGU	3466-3488
AD-122329 6.1	A-228297 1.1	3327	AUUUAUUUAUUGGU GCUACUA	3469-3489	A-2282972. 1	3776	UAGUAGCACCAAUAAA AUAAAUGA	3467-3489

AD-122329 7.1	A-228297 3.1	3328	UUUAUUUAUUGGUG CUACUGA	3470-3490	A-2282974. 1	3777	UCAGUAGCACCAAUA AAUAAAUG	3468-3490
AD-122329 8.1	A-228297 5.1	3329	UUUAUUUAUUGGUGC UACUGUA	3471-3491	A-2282976. 1	3778	UACAGUAGCACCAAU AAAUAAA	3469-3491
AD-122329 9.1	A-228297 7.1	3330	UAUUUAUUGGUGCU ACUGUUA	3472-3492	A-2282978. 1	3779	UAAACAGUAGCACCAA UAAAUA	3470-3492
AD-122330 0.1	A-228297 9.1	3331	AUUUAUUGGUGCUA CUGUUUA	3473-3493	A-2282980. 1	3780	UAAACAGUAGCACCA AUAAAUA	3471-3493
AD-122330 1.1	A-228298 1.1	3332	UUUAUUGGUGCUACU GUUUUA	3475-3495	A-2282982. 1	3781	UAUAAAACAGUAGCAC CAAUAAA	3473-3495
AD-122330 2.1	A-228298 3.1	3333	AUUUGGUGCUACUGU UUAUCCA	3477-3497	A-2282984. 1	3782	UGGAUAAAACAGUAGC ACCAAUA	3475-3497
AD-122330 3.1	A-228298 5.1	3334	GAAAGAUUAUAAAC AUCACGA	3511-3531	A-2282986. 1	3783	UCGUGAUGUUAAUAU CUUUUCCC	3509-3531
AD-122330 4.1	A-228298 7.1	3335	AACAUCACGUCUUUG UCUCUA	3522-3542	A-2282988. 1	3784	UAGAGACAAAAGACGU GAUGUUA	3520-3542
AD-122330 5.1	A-228298 9.1	3336	ACAUCACGUCUUUGU CUCUAA	3523-3543	A-2282990. 1	3785	UUAGAGACAAAAGACG UGAUGUUA	3521-3543
AD-122330 6.1	A-228299 1.1	3337	GUCUUUGUCUCUAGU GCAGUA	3530-3550	A-2282992. 1	3786	UACUGCACUAGAGAC AAAAGACGU	3528-3550
AD-122330 7.1	A-228299 3.1	3338	UCUUUGUCUCUAGUG CAGUUA	3531-3551	A-2282994. 1	3787	UAAACUGCACUAGAGA CAAAGACG	3529-3551
AD-122330 8.1	A-228299 5.1	3339	CUUUGUCUCUAGUGC AGUUUA	3532-3552	A-2282996. 1	3788	UAAACUGCACUAGAG ACAAAGAC	3530-3552

AD-122330 9.1	A-228299 7.1	3340	GAGAUUCCGUAG UACAUAA	3555-3575	A-2282998. 1	3789	UUAUGUACUACGGAA UAUCUCGA	3553-3575
AD-122331 0.1	A-228299 9.1	3341	AGAUUCCGUAGU ACAUAA	3556-3576	A-2283000. 1	3790	UUAUGUACUACGG AUAUCUG	3554-3576
AD-122331 1.1	A-228300 1.1	3342	GAUUAUCCGUAGUAC AUAAUA	3557-3577	A-2283002. 1	3791	UAAUAUGUACUACGG AAUAUCUC	3555-3577
AD-122331 2.1	A-228300 3.1	3343	CGACAAAAGAAUACA GAUAA	3590-3610	A-2283004. 1	3792	UAUAUCUGUAUUUCU UUGUCGUU	3588-3610
AD-122331 3.1	A-228300 5.1	3344	GACAAAAGAAUACA GAUAA	3591-3611	A-2283006. 1	3793	UUAUAUCUGUAUUUC UUUGUCGU	3589-3611
AD-122331 4.1	A-228300 7.1	3345	ACAAAAGAAUACAG AUAAUA	3592-3612	A-2283008. 1	3794	UAUAUAUCUGUAUUU CUUUGUCG	3590-3612
AD-122331 5.1	A-228300 9.1	3346	CAAAGAAUACAGA UAUAUCA	3593-3613	A-2283010. 1	3795	UGAUAAUUCUGUAUU UCUUUGUC	3591-3613

Table 10A. Exemplary Human VEGF-A siRNA Modified Single Strands and Duplex Sequences

Duplex Name	Sense Oligo Name	SEQ ID NO: (Sense)	Sense Sequence	Anti-sense Oligo Name	SEQ ID NO: (Anti-sense)	Antisense Sequence	mRNA Target Sequence	SEQ ID NO: (mRNA target)
AD-13535 14.1	A-252132 2.1	3796	asasaag(Ahd)gadAadGuguuuuauasasa	A-2521323 .1	3886	VPusdTsaudAadAaacdTudTcdTcuuuuscsu	AGAAAAAGAGAAA GUGUUUUUAUUAU	5149
AD-13534 84.1	A-252126 4.1	3797	asasaag(Ahd)gaAfAfGfuguuuuauasasa	A-2521265 .1	3887	VPusdTsaudAadAaacdTudTcdTcuuuuscsu	AGAAAAAGAGAAA GUGUUUUUAUUAU	5150
AD-13534 54.1	A-252121 2.1	3798	asasaag(Ahd)GfaAfAfGfuguuuuauasasa	A-2282766 .1	3888	VPusUfsauaAfaacacuUfcUfcuuuuscsu	AGAAAAAGAGAAA GUGUUUUUAUUAU	5151
AD-13534 68.1	A-252123 2.1	3799	asasaga(Chd)ugAfUfAfcaagaacgasusa	A-2521233 .1	3889	VPusdAsuedGudTcugudAuCfagucuuuscsu	GGAAAGACUGAU ACAGAACGAUC	5152
AD-13534 98.1	A-252129 2.1	3800	asasaga(Chd)ugdAudAcagaacgasusa	A-1800369 .1	3890	VPusdAsuedGudTcugudAudCadGucuuuscsu	GGAAAGACUGAU ACAGAACGAUC	5153
AD-13534 38.1	A-170081 9.1	3801	asasaga(Chd)UfgAfUfAfcaagaacgasusa	A-2282346 .1	3891	VPusdAfsucgUfucuguaCfaGfucuuuscsu	GGAAAGACUGAU ACAGAACGAUC	5154
AD-13535 15.1	A-252132 4.1	3802	asasagagaadAgdTguuu(Uhd)auasusa	A-2521325 .1	3892	VPusdAsuadTadAaacadCudTudCucuuuscsu	GAAAAAGAGAAA UGUUUUUAUUA	5155
AD-13534 85.1	A-252126 6.1	3803	asasagagaaAfGfUfguuu(Uhd)auasusa	A-2521267 .1	3893	VPusdAsuadTadAaacadCuUfucuuuscsu	GAAAAAGAGAAA UGUUUUUAUUA	5156
AD-13534 55.1	A-252121 3.1	3804	asasagagAfaAfGfUfguuu(Uhd)auasusa	A-2282768 .1	3894	VPusdAfsuauAfaaacacuUfuCfucuuuscsu	GAAAAAGAGAAA UGUUUUUAUUA	5157

AD-13535 13.1	A-252132 0.1	3805	asascag(Uhd)gcdTadAugu uauugsgsa	A-2521321 .1	3895	VPusdCscadAudAaca udTadGcdAcugnuusgsg	UUAACAGUGCUA AUGUUUUAUUGGU	5158
AD-13534 83.1	A-252126 2.1	3806	asascag(Uhd)gcUfAfAfug uuauugsgsa	A-2521263 .1	3896	VPusdCscadAudAaca udTaGfcacugnuusgsg	UUAACAGUGCUA AUGUUUUAUUGGU	5159
AD-13534 53.1	A-170083 2.1	3807	asascag(Uhd)GfcUfAfAf guuauugsgsa	A-2521211 .1	3897	VPusdCfscadUfaaca uuaGfcacugnuusgsg	UUAACAGUGCUA AUGUUUUAUUGGU	5160
AD-13535 02.1	A-252129 8.1	3808	asascga(Uhd)cgdAudAcag aaaccsasa	A-2521299 .1	3898	VPusdTsggdTu(U2p)c ugudAudCgdAucguus csu	AGAACGAUCGAU ACAGAAAACCCAC	5161
AD-13534 72.1	A-252124 0.1	3809	asascga(Uhd)cgAfUfAfca gaaaccsasa	A-2521241 .1	3899	VPusdTsggdTu(U2p)c ugudAuCfgaucguuscs u	AGAACGAUCGAU ACAGAAAACCCAC	5162
AD-13534 42.1	A-252119 5.1	3810	asascga(Uhd)CfGaUfAfca agaaccsasa	A-2521196 .1	3900	VPusUfsggdTu(U2p)c uguaUCfgAfueguuscsu	AGAACGAUCGAU ACAGAAAACCCAC	5163
AD-13534 99.1	A-248362 3.1	3811	asascga(Uhd)gadTadCaga acgauscsa	A-2521293 .1	3901	VPusdGsaudCg(U2p) ucugdTadTcdAgucuu usc	GAAAGACUGAUA CAGAACGAUCG	5164
AD-13534 69.1	A-252123 4.1	3812	asascga(Uhd)gaUfAfCfag aacgauscsa	A-2521235 .1	3902	VPusdGsaudCg(U2p) ucugdTaUfcagucuu c	GAAAGACUGAUA CAGAACGAUCG	5165
AD-13534 39.1	A-170082 0.1	3813	asascga(Uhd)GfaUfAfCfa gaacgauscsa	A-2521191 .1	3903	VPusdGfsaudCg(U2p)u cuguaUfcAfueguuscsu	GAAAGACUGAUA CAGAACGAUCG	5166
AD-13535 16.1	A-252132 6.1	3814	asascga(Ahd)aadGudGuu uuauausasa	A-2521327 .1	3904	VPusdTaudAudAaaa cdAcdTudTcucuu susu	AAAAGAGAAAAGU GUUUUUAUUAUAC	5167
AD-13534 86.1	A-252126 8.1	3815	asascga(Ahd)aaGfUfGfu uuauausasa	A-2521269 .1	3905	VPusdTaudAudAaaa cdAcUfuucuu susu	AAAAGAGAAAAGU GUUUUUAUUAUAC	5168
AD-13534 56.1	A-252121 4.1	3816	asascga(Ahd)AfaGfUfGfu uuuauausasa	A-2282770 .1	3906	VPusUfsauaUfaaacac UfuUfcuu susu	AAAAGAGAAAAGU GUUUUUAUUAUAC	5169

AD-1353509.1	A-2521312.1	3817	asasuungaudTcdGccau(Uhd)uuasusa	A-2521313.1	3907	VPusdAsuadAadAuggcdGadAudCcaauuscsc	GGAAUUGGAUUCGCCAUUUUAUU	5170
AD-1353479.1	A-2521254.1	3818	asasuunggauUfCfGfccaau(Uhd)uuasusa	A-2521255.1	3908	VPusdAsuadAadAuggcdGaAfuccaauuscsc	GGAAUUGGAUUCGCCAUUUUAUU	5171
AD-1353449.1	A-2521206.1	3819	asasuunggAfuUfCfGfccaau(Uhd)uuasusa	A-2282454.1	3909	VPusdAfsuadAfauggcdGaAfuccaauuscsc	GGAAUUGGAUUCGCCAUUUUAUU	5172
AD-1353503.1	A-2521300.1	3820	ascsaga(Ahd)cadGudCcuuauuccsasa	A-2521301.1	3910	VPusdTsggdAudTaaggdAcdTgdTucuguscsg	CGACAGAACAGUCCUUAAUCCAG	5173
AD-1353473.1	A-2521242.1	3821	ascsaga(Ahd)caGfUfCfcuuauuccsasa	A-2521243.1	3911	VPusdTsggdAudTaaggdAcUfguucuguscsg	CGACAGAACAGUCCUUAAUCCAG	5174
AD-1353443.1	A-2521197.1	3822	ascsaga(Ahd)CfaGfUfCfcuuauuccsasa	A-2282402.1	3912	VPusUfsggaUfuaaggaUfUfUfucuguscsg	CGACAGAACAGUCCUUAAUCCAG	5175
AD-1353506.1	A-2521306.1	3823	ascsagu(Chd)audTadAuccagaauacsasa	A-2521307.1	3913	VPusdGsuudTc(U2p)ggaudTadAgdGacugususc	GAAACAGUCCUUAUCCAGAAACC	5176
AD-1353476.1	A-2521248.1	3824	ascsagu(Chd)cuUfAfAfucagaauacsasa	A-2521249.1	3914	VPusdGsuudTc(U2p)ggaudTaAfaggacugususc	GAAACAGUCCUUAUCCAGAAACC	5177
AD-1353446.1	A-2521201.1	3825	ascsagu(Chd)CfuUfAfAfuccagaauacsasa	A-2521202.1	3915	VPusdGfsuudTc(U2p)ggaunaAfaggacugususc	GAAACAGUCCUUAUCCAGAAACC	5178
AD-1353497.1	A-2521290.1	3826	ascsaggaaadAgdAcuga(Uhd)acagsa	A-2521291.1	3916	VPusdCsugdTadTcagudCudTudCcuguguscsg	UCACACAGGAAAGACUGAUACAGA	5179
AD-1353467.1	A-2521230.1	3827	ascsaggaaAfGfAfeuga(Uhd)acagsa	A-2521231.1	3917	VPusdCsugdTadTcagudCuUfuccuguguscsg	UCACACAGGAAAGACUGAUACAGA	5180
AD-1353437.1	A-2521189.1	3828	ascsaggAfaAfGfAfcuga(Uhd)acagsa	A-2521190.1	3918	VPusdCsugdAfcagucUfuCfcuguguscsg	UCACACAGGAAAGACUGAUACAGA	5181

AD-13534 94.1	A-252128 4.1	3829	ascsaugcadGadTuaug(Chd)ggasusa	A-2521285 .1	3919	VPusdAsucdCg(C2p)a uadTcdTgdCauggusc sc	UACCAUGCAGAU UAUGCGGAUC	5182
AD-13534 64.1	A-252122 4.1	3830	ascsaugcaGfAfUfuaug(C hd)ggasusa	A-2521225 .1	3920	VPusdAsucdCg(C2p)a uadTcUfgcauggusc	UACCAUGCAGAU UAUGCGGAUC	5183
AD-13534 34.1	A-252118 3.1	3831	ascsaugCfaGfAfUfuaug(Chd)ggasusa	A-2521184 .1	3921	VPusdAfsucdCg(C2p)a uaucUfgCfauggusc	UACCAUGCAGAU UAUGCGGAUC	5184
AD-13535 05.1	A-252130 4.1	3832	asgsaac(Ahd)gudCedTuaa uccagsasa	A-2521305 .1	3922	VPusdTscudGg(A2p)u uadGgdAcdTguucusc su	ACAGAACAGUCCU UAAUCCAGAA	5185
AD-13534 75.1	A-252124 6.1	3833	asgsaac(Ahd)guCfCfUfua auccagsasa	A-2521247 .1	3923	VPusdTscudGg(A2p)u uadGgAfcuguucusc u	ACAGAACAGUCCU UAAUCCAGAA	5186
AD-13534 45.1	A-252119 9.1	3834	asgsaac(Ahd)GfuCfCfUfu aauccagsasa	A-2521200 .1	3924	VPusUfscudGg(A2p)u uaaggAfcUfguucusc su	ACAGAACAGUCCU UAAUCCAGAA	5187
AD-13535 18.1	A-252133 0.1	3835	asgsaug(Uhd)audCudTuug cucucscusa	A-2521331 .1	3925	VPusdAsgadGa(G2p)c aaadAgdAudAcaucusc sg	UGAGAUGUAUCU UUUGCUCUCUC	5188
AD-13534 90.1	A-252127 6.1	3836	asgsaug(Uhd)auCfUfUfuu geucucscusa	A-2521277 .1	3926	VPusdAsgadGa(G2p)c aaadAgAfuacucuscsg	UGAGAUGUAUCU UUUGCUCUCUC	5189
AD-13534 60.1	A-252121 7.1	3837	asgsaug(Uhd)AfuCfUfUfu ugeucucscusa	A-2521218 .1	3927	VPusAfsadGa(G2p)c aaaagAfuAfeaucuscsg	UGAGAUGUAUCU UUUGCUCUCUC	5190
AD-13535 12.1	A-252131 8.1	3838	asgsauu(Ahd)gadGadGuu uuauuucsa	A-2521319 .1	3928	VPusdGsaadAudAaaa cdTcdTcdTaauusc	GAAGAUUAGAGA GUUUUAUUUCU	5191
AD-13534 82.1	A-252126 0.1	3839	asgsauu(Ahd)gaGfAfGfu uuauuucsa	A-2521261 .1	3929	VPusdGsaadAudAaaa cdTcUfcuaauusc	GAAGAUUAGAGA GUUUUAUUUCU	5192
AD-13534 52.1	A-252121 0.1	3840	asgsauu(Ahd)GfaGfAfGfu uuuauuucsa	A-2282496 .1	3930	VPusGfsaaaUfaaacuc UfcUfaucusc	GAAGAUUAGAGA GUUUUAUUUCU	5193

AD-1353501.1	A-2521296.1	3841	asusacagaadCgdAucga(Uhd)acasgsa	A-2521297.1	3931	VPusdCsugdTa(U2p)cgaudCgdTudCuguausc _{sg}	UGAUACAGAACG AUCGAUACAGA	5194
AD-1353471.1	A-2521238.1	3842	asusacagaaCfGfAfuca(Uhd)acasgsa	A-2521239.1	3932	VPusdCsugdTa(U2p)cgaudCgUfucuguausc _g	UGAUACAGAACG AUCGAUACAGA	5195
AD-1353441.1	A-2521193.1	3843	asusacagAfaCfGfAfuca(Uhd)acasgsa	A-2521194.1	3933	VPusdCsugdTa(U2p)cgaucgUfuCfuguausc _g	UGAUACAGAACG AUCGAUACAGA	5196
AD-1353495.1	A-2521286.1	3844	asusgcagaudTadTgcgg(Ahd)ucasasa	A-2521287.1	3934	VPusdTsugdAu(C2p)cgcadTadAudCugcausc _{sg}	CCAUGCAGAUUAU GCGGAUCAAA	5197
AD-1353465.1	A-2521226.1	3845	asusgcagauUfaUfugcg(Ahd)ucasasa	A-2521227.1	3935	VPusdTsugdAu(C2p)cgcadTaAfucugcausc _{sg}	CCAUGCAGAUUAU GCGGAUCAAA	5198
AD-1353435.1	A-2521185.1	3846	asusgcagAfuUfaUfugcg(Ahd)ucasasa	A-2521186.1	3936	VPusUfsugdAu(C2p)cgcuaaAfuCfugcausc _{sg}	CCAUGCAGAUUAU GCGGAUCAAA	5199
AD-1353510.1	A-2521314.1	3847	asusugg(Ahd)uudCgdCcauuuuuusasa	A-2521315.1	3937	VPusdAsaudAadAauggdCgdAadTccaausc	GAAUUGGAUUCG CCAUUUUUAUUU	5200
AD-1353480.1	A-2521256.1	3848	asusugg(Ahd)uuCfGfCfcauuuuuusasa	A-2521257.1	3938	VPusdAsaudAadAauggdCgAfaucuausc	GAAUUGGAUUCG CCAUUUUUAUUU	5201
AD-1353450.1	A-2521207.1	3849	asusugg(Ahd)UfuCfGfCfcauuuuuusasa	A-2282456.1	3939	VPusAfsauaAfaaugcgAfaUfccaausc	GAAUUGGAUUCG CCAUUUUUAUUU	5202
AD-1353492.1	A-2521280.1	3850	csasaca(Uhd)cadCcdAugcagaauusasa	A-2521281.1	3940	VPusdTsadTc(U2p)gcaudGgdTgdAugu _{gsc}	UCCAACAUCACCA UGCAGAUUAU	5203
AD-1353462.1	A-2521220.1	3851	csasaca(Uhd)caCfCfAfucaagaauusasa	A-2521221.1	3941	VPusdTsadTc(U2p)gcaudGgUfgaug _c	UCCAACAUCACCA UGCAGAUUAU	5204
AD-1353432.1	A-2521180.1	3852	csasaca(Uhd)CfaCfCfAfu _{gc} gcagaauusasa	A-2521181.1	3942	VPusUfsadTc(U2p)gcauggUfgAfug _{gsc}	UCCAACAUCACCA UGCAGAUUAU	5205

AD-13535 04.1	A-252130 2.1	3853	csasgaa(Chd)agdTcdCuua auccasgsa	A-2521303 .1	3943	VPusdCsugdGa(U2p) uaagdGadCudGuucug susc	GACAGAACAGUCC UUAUCCAGA	5206
AD-13534 74.1	A-252124 4.1	3854	csasgaa(Chd)agUfCfCfu auccasgsa	A-2521245 .1	3944	VPusdCsugdGa(U2p) uaagdGaCfuguucgusu sc	GACAGAACAGUCC UUAUCCAGA	5207
AD-13534 44.1	A-170082 6.1	3855	csasgaa(Chd)AfgUfCfCfu uaauccasgsa	A-2521198 .1	3945	VPusdCsugdGa(U2p)u aaggaCfuGfuucgususc	GACAGAACAGUCC UUAUCCAGA	5208
AD-13534 93.1	A-252128 2.1	3856	csasuca(Chd)cadTgdCaga uuauccgsa	A-2521283 .1	3946	VPusdGscadTadAucu gdCadTgdGugaugsusu	AACAUCACCAUGC AGAUUAUGCG	5209
AD-13534 63.1	A-252122 2.1	3857	csasuca(Chd)caUfGfCfaga uuauccgsa	A-2521223 .1	3947	VPusdGscadTadAucu gdCaUfGgugaugsusu	AACAUCACCAUGC AGAUUAUGCG	5210
AD-13534 33.1	A-252118 2.1	3858	csasuca(Chd)CfaUfGfCfa gaauuagcsa	A-2282286 .1	3948	VPusdGfscadAfaucugc aUfgGfugaugsusu	AACAUCACCAUGC AGAUUAUGCG	5211
AD-13535 08.1	A-252131 0.1	3859	cscsucu(Uhd)ggdAadTugg auuagcsa	A-2521311 .1	3949	VPusdGscgdAadTcca adTudCcdAagagsgsc	UCCUCUUGGAAU UGGAUUCGCC	5212
AD-13534 78.1	A-252125 2.1	3860	cscsucu(Uhd)ggAfAfUfug gaauccgsa	A-2521253 .1	3950	VPusdGscgdAadTcca adTuCfcaagagsgsc	UCCUCUUGGAAU UGGAUUCGCC	5213
AD-13534 48.1	A-252120 4.1	3861	cscsucu(Uhd)GfgAfAfUfu ggaucgcsa	A-2521205 .1	3951	VPusdGfscgaAfuccaau uCfcAfagagsgsc	UCCUCUUGGAAU UGGAUUCGCC	5214
AD-13534 96.1	A-252128 8.1	3862	csusacagcadAcaaaa(Uh d)gugsasa	A-2521289 .1	3952	VPusdTscadCadTuug udTgdTgdCuguaugsug	UCCUACAGCACAA CAAUUGUGAA	5215
AD-13534 66.1	A-252122 8.1	3863	csusacagcaCfAfAfcaaaa(U hd)gugsasa	A-2521229 .1	3953	VPusdTscadCadTuug udTgUfgcuguaugsug	UCCUACAGCACAA CAAUUGUGAA	5216
AD-13534 36.1	A-252118 7.1	3864	csusacagCfAfAfcaaaa(U hd)gugsasa	A-2521188 .1	3954	VPusUfscadAfuuuuu gUfgCfugaugsug	UCCUACAGCACAA CAAUUGUGAA	5217

AD-1353500.1	A-2521294.1	3865	csusgau(Ahd)cadGadAcgaucgausasa	A-2521295.1	3955	VPusdTsaudCg(A2p)ucgudTcdTgdTaucagsusc	GACUGAUACAGAACGAUCGAUAC	5218
AD-1353470.1	A-2521236.1	3866	csusgau(Ahd)caGfAfAfagaucgausasa	A-2521237.1	3956	VPusdTsaudCg(A2p)ucgudTcUfguaucaugsusc	GACUGAUACAGAACGAUCGAUAC	5219
AD-1353440.1	A-1700824.1	3867	csusgau(Ahd)CfaGfAfAfcgaucgausasa	A-2521192.1	3957	VPusUfsaudCg(A2p)ucguucUfgUfaucagsusc	GACUGAUACAGAACGAUCGAUAC	5220
AD-1334067.3	A-2483626.1	3868	gsasaag(Uhd)gudTudTauauacggsusa	A-1800443.1	3958	VPusdAsccdGudAuauadAadAcdAcuucugsusc	GAGAAAAGUGUUUUAUAUACGGUA	5221
AD-1353488.1	A-2521272.1	3869	gsasaag(Uhd)guUfUfUfaauacggsusa	A-2521273.1	3959	VPusdAsccdGudAuauadAaAfcuucugsusc	GAGAAAAGUGUUUUAUAUACGGUA	5222
AD-1353458.1	A-1700894.1	3870	gsasaag(Uhd)GfuUfUfUfaauacggsusa	A-2521215.1	3960	VPusAfscgUfauauaaAfcAfcuucugsusc	GAGAAAAGUGUUUUAUAUACGGUA	5223
AD-1334065.3	A-2483624.1	3871	gsasga(Ahd)gudGudTuuaauacgsa	A-1800396.1	3961	VPusdCsgdAudAuuaadAcdAcdTuucugsusu	AAGAGAAAGUGUUUAUAUACGG	5224
AD-1353487.1	A-2521270.1	3872	gsasga(Ahd)guGfUfUfuuaucgsa	A-2521271.1	3962	VPusdCsgdAudAuuaadAcAfcuucugsusu	AAGAGAAAGUGUUUAUAUACGG	5225
AD-1353457.1	A-1700845.1	3873	gsasga(Ahd)GfuGfUfUfuuaucgsa	A-2282774.1	3963	VPusCfsguaUfauaaacAfcUfuucugsusu	AAGAGAAAGUGUUUAUAUACGG	5226
AD-1353511.1	A-2521316.1	3874	gsasuucgccAudTuua(Uhd)uuuscsa	A-2521317.1	3964	VPusdGsaadAadAuuaadAudGgdCgaucscsg	UGGAUUUCGCCAUUUUAUUUUUCU	5227
AD-1353481.1	A-2521258.1	3875	gsasuucgccAfUfUfuua(Uhd)uuuscsa	A-2521259.1	3965	VPusdGsaadAadAuuaadAuGfgcgaucscsg	UGGAUUUCGCCAUUUUAUUUUUCU	5228
AD-1353451.1	A-2521208.1	3876	gsasuucGfcAfUfUfuua(Uhd)uuuscsa	A-2521209.1	3966	VPusGfsaaaAfauaaaauGfgCfgaucscsg	UGGAUUUCGCCAUUUUAUUUUUCU	5229

AD-13535 07.1	A-252130 8.1	3877	gsusccu(Uhd)aadTcdCaga aaaccusgsa	A-2521309 .1	3967	VPusdCsagdGudTucu gdGadTudAaggacsusg	CAGUCCUUAAUCC AGAAACCUGA	5230
AD-13534 77.1	A-252125 0.1	3878	gsusccu(Uhd)aaUfCfCfag aaaccusgsa	A-2521251 .1	3968	VPusdCsagdGudTucu gdGaUfuaaggacsusg	CAGUCCUUAAUCC AGAAACCUGA	5231
AD-13534 47.1	A-252120 3.1	3879	gsusccu(Uhd)AfaUfCfCfa gaaaccusgsa	A-2282416 .1	3969	VPusdCsagdGudTucu aUfuAfaaggacsusg	CAGUCCUUAAUCC AGAAACCUGA	5232
AD-13535 17.1	A-252132 8.1	3880	gsusguu(Uhd)uadTadTaeg guacususa	A-2521329 .1	3970	VPusdAsagdTadCcgu adTadTadAaacacsusu	AAGUGUUUUUAUA UACGGUACUUA	5233
AD-13534 89.1	A-252127 4.1	3881	gsusguu(Uhd)uaUfAfUfac gguacususa	A-2521275 .1	3971	VPusdAsagdTadCcgu adTaUfaaaacsusu	AAGUGUUUUUAUA UACGGUACUUA	5234
AD-13534 59.1	A-252121 6.1	3882	gsusguu(Uhd)UfaUfAfUfa cgguacususa	A-2282784 .1	3972	VPusdAfsaguAfcgguau aUfaAfaacsusu	AAGUGUUUUUAUA UACGGUACUUA	5235
AD-13535 19.1	A-252133 2.1	3883	usasgac(Ahd)uudGcdTauu cuguususa	A-2521333 .1	3973	VPusdAsaadCadGaau adGcdAadTgucuasusu	AAUAGACAUUGC UAUUCUGUUUU	5236
AD-13534 91.1	A-252127 8.1	3884	usasgac(Ahd)uuGfCfUfau ucuguususa	A-2521279 .1	3974	VPusdAsaadCadGaau adGcAfaugucuasusu	AAUAGACAUUGC UAUUCUGUUUU	5237
AD-13534 61.1	A-252121 9.1	3885	usasgac(Ahd)UfuGfCfUfa uucuguususa	A-2282952 .1	3975	VPusdAfsaacAfgaauag cAfaUfgucuasusu	AAUAGACAUUGC UAUUCUGUUUU	5238

Table 10B. Exemplary Human VEGF-A siRNA Unmodified Single Strands and Duplex Sequences

Duplex Name	Sense Oligo Name	SEQ ID NO: (Sense)	Sense Sequence	mRNA Target Range	Antisense Oligo Name	SEQ ID NO: (Anti-sense)	Antisense Sequence	mRNA Target Range
AD-135351 4.1	A-252132 2.1	3976	AAAAGAGAAAGUGU UUUAUAA	2940-2960	A-2521323. 1	4066	UTAUAAAACACTUTCT CUUUUCU	2938-2960
AD-135348 4.1	A-252126 4.1	3977	AAAAGAGAAAGUGU UUUAUAA	2940-2960	A-2521265. 1	4067	UTAUAAAACACTUUUCU CUUUUCU	2938-2960
AD-135345 4.1	A-252121 2.1	3978	AAAAGAGAAAGUGU UUUAUAA	2940-2960	A-2282766. 1	4068	UUAUAAAACACUUUC UCUUUUUCU	2938-2960
AD-135346 8.1	A-252123 2.1	3979	AAAGACUGAUACAG AACGAUA	1795-1815	A-2521233. 1	4069	UAUCGUTCUGUAUCA GUCUUUCC	1793-1815
AD-135349 8.1	A-252129 2.1	3980	AAAGACUGAUACAG AACGAUA	1795-1815	A-1800369. 1	4070	UAUCGUTCUGUAUCA GUCUUUCC	1793-1815
AD-135343 8.1	A-170081 9.1	3981	AAAGACUGAUACAG AACGAUA	1795-1815	A-2282346. 1	4071	UAUCGUUCUGUAUCA GUCUUUCC	1793-1815
AD-135351 5.1	A-252132 4.1	3982	AAAAGAGAAAGTGUGU UUUAUAA	2941-2961	A-2521325. 1	4072	UAUATAAAAACACUTUC UCUUUUUC	2939-2961
AD-135348 5.1	A-252126 6.1	3983	AAAAGAGAAAGUGUGU UUUAUAA	2941-2961	A-2521267. 1	4073	UAUATAAAAACACUUU CUCUUUUC	2939-2961
AD-135345 5.1	A-252121 3.1	3984	AAAAGAGAAAGUGUGU UUUAUAA	2941-2961	A-2282768. 1	4074	UAUATAAAAACACUUU CUCUUUUC	2939-2961
AD-135351 3.1	A-252132 0.1	3985	AACAGUGCTAAUGUU AUUGGA	2178-2198	A-2521321. 1	4075	UCCAAUAAACAUTAGC ACUGUUUGG	2176-2198

AD-135348 3.1	A-252126 2.1	3986	AACAGUGCUAAUGU UAUUGGA	2178-2198	A-2521263. 1	4076	UCCAUAACAUTAGC ACUGUUGG	2176-2198
AD-135345 3.1	A-170083 2.1	3987	AACAGUGCUAAUGU UAUUGGA	2178-2198	A-2521211. 1	4077	UCCAUAACAUAUAGC ACUGUUGG	2176-2198
AD-135350 2.1	A-252129 8.1	3988	AACGAUCGAUACAGA AACCAA	1809-1829	A-2521299. 1	4078	UTGGTUUCUGUAUCG AUCGUUCU	1807-1829
AD-135347 2.1	A-252124 0.1	3989	AACGAUCGAUACAGA AACCAA	1809-1829	A-2521241. 1	4079	UTGGTUUCUGUAUCG AUCGUUCU	1807-1829
AD-135344 2.1	A-252119 5.1	3990	AACGAUCGAUACAGA AACCAA	1809-1829	A-2521196. 1	4080	UUGGTUUCUGUAUCG AUCGUUCU	1807-1829
AD-135349 9.1	A-248362 3.1	3991	AAGACUGATACAGAA CGAUC	1796-1816	A-2521293. 1	4081	UGAUCGUUCUGTATCA GUCUUUC	1794-1816
AD-135346 9.1	A-252123 4.1	3992	AAGACUGAUACAGA ACGAUCA	1796-1816	A-2521235. 1	4082	UGAUCGUUCUGTAUC AGUCUUUC	1794-1816
AD-135343 9.1	A-170082 0.1	3993	AAGACUGAUACAGA ACGAUCA	1796-1816	A-2521191. 1	4083	UGAUCGUUCUGUAUC AGUCUUUC	1794-1816
AD-135351 6.1	A-252132 6.1	3994	AAGAGAAAGUGUUU UAUAUAA	2942-2962	A-2521327. 1	4084	UTAUUAUAAACACTUT CUCUUUU	2940-2962
AD-135348 6.1	A-252126 8.1	3995	AAGAGAAAGUGUUU UAUAUAA	2942-2962	A-2521269. 1	4085	UTAUUAUAAACACUU UCUCUUUU	2940-2962
AD-135345 6.1	A-252121 4.1	3996	AAGAGAAAGUGUUU UAUAUAA	2942-2962	A-2282770. 1	4086	UUUAUAUAAACACUU UCUCUUUU	2940-2962
AD-135350 9.1	A-252131 2.1	3997	AAUUGGAUTCGCCAU UUUAUA	1987-2007	A-2521313. 1	4087	UAUAAAAUGGCGAAU CCAAUUC	1985-2007

AD-135347 9.1	A-252125 4.1	3998	AAUUGGAUUCGCCAU UUUAUA	1987-2007	A-2521255. 1	4088	UAUAAA AUGCGAAU CCAAUUC	1985-2007
AD-135344 9.1	A-252120 6.1	3999	AAUUGGAUUCGCCAU UUUAUA	1987-2007	A-2282454. 1	4089	UAUAAA AUGCGAAU CCAAUUC	1985-2007
AD-135350 3.1	A-252130 0.1	4000	ACAGAACAGUCCUUA AUCCAA	1857-1877	A-2521301. 1	4090	UTGGAUTAAAGGACTGT UCUGUCG	1855-1877
AD-135347 3.1	A-252124 2.1	4001	ACAGAACAGUCCUUA AUCCAA	1857-1877	A-2521243. 1	4091	UTGGAUTAAAGGACUG UUCUGUCG	1855-1877
AD-135344 3.1	A-252119 7.1	4002	ACAGAACAGUCCUUA AUCCAA	1857-1877	A-2282402. 1	4092	UUGGAUUAAGGACUG UUCUGUCG	1855-1877
AD-135350 6.1	A-252130 6.1	4003	ACAGUCCUTAAUCCA GAAACA	1862-1882	A-2521307. 1	4093	UGUUTCUGGAUTAAAG GACUGUUC	1860-1882
AD-135347 6.1	A-252124 8.1	4004	ACAGUCCUUA AUCCA GAAACA	1862-1882	A-2521249. 1	4094	UGUUTCUGGAUTAAAG GACUGUUC	1860-1882
AD-135344 6.1	A-252120 1.1	4005	ACAGUCCUUA AUCCA GAAACA	1862-1882	A-2521202. 1	4095	UGUUTCUGGAUUAAG GACUGUUC	1860-1882
AD-135349 7.1	A-252129 0.1	4006	ACCAGGAAAGACUGA UACAGA	1789-1809	A-2521291. 1	4096	UCUGTATCAGUCUTUC CUGGUC	1787-1809
AD-135346 7.1	A-252123 0.1	4007	ACCAGGAAAGACUGA UACAGA	1789-1809	A-2521231. 1	4097	UCUGTATCAGUCUUUC CUGGUC	1787-1809
AD-135343 7.1	A-252118 9.1	4008	ACCAGGAAAGACUGA UACAGA	1789-1809	A-2521190. 1	4098	UCUGUAUCAGUCUUU CCUGGUC	1787-1809
AD-135349 4.1	A-252128 4.1	4009	ACCAUGCAGATUAUG CGGAUA	1345-1365	A-2521285. 1	4099	UAUCCGCAUAATCTGC AUGGUC	1343-1365

AD-135346 4.1	A-252122 4.1	4010	ACCAUGCAGAUUAUG CGGAUA	1345-1365	A-2521225. 1	4100	UAUCCGCAUAAATCUGC AUGGUGC	1343-1365
AD-135343 4.1	A-252118 3.1	4011	ACCAUGCAGAUUAUG CGGAUA	1345-1365	A-2521184. 1	4101	UAUCCGCAUAAUCUG CAUGGUGC	1343-1365
AD-135350 5.1	A-252130 4.1	4012	AGAACAGUCCCTUAAU CCAGAA	1859-1879	A-2521305. 1	4102	UTCUGGAUUAAAGGAC TGUUCUGU	1857-1879
AD-135347 5.1	A-252124 6.1	4013	AGAACAGUCCCUAAU CCAGAA	1859-1879	A-2521247. 1	4103	UTCUGGAUUAAAGGAC UGUUCUGU	1857-1879
AD-135344 5.1	A-252119 9.1	4014	AGAACAGUCCCUAAU CCAGAA	1859-1879	A-2521200. 1	4104	UUCUGGAUUAAAGGAC UGUUCUGU	1857-1879
AD-135351 8.1	A-252133 0.1	4015	AGAUGUAUCUTUUGC UCUCUA	3073-3093	A-2521331. 1	4105	UAGAGAGCAAAAAGAU ACAUCUCG	3071-3093
AD-135349 0.1	A-252127 6.1	4016	AGAUGUAUCUUUUG CUCUCUA	3073-3093	A-2521277. 1	4106	UAGAGAGCAAAAAGAU ACAUCUCG	3071-3093
AD-135346 0.1	A-252121 7.1	4017	AGAUGUAUCUUUUG CUCUCUA	3073-3093	A-2521218. 1	4107	UAGAGAGCAAAAAGAU ACAUCUCG	3071-3093
AD-135351 2.1	A-252131 8.1	4018	AGAUUAGAGAGUUU UAUUUCA	2037-2057	A-2521319. 1	4108	UGAAAUAAAACCTCTCT AAUCUUC	2035-2057
AD-135348 2.1	A-252126 0.1	4019	AGAUUAGAGAGUUU UAUUUCA	2037-2057	A-2521261. 1	4109	UGAAAUAAAACCTCUC UAAUCUUC	2035-2057
AD-135345 2.1	A-252121 0.1	4020	AGAUUAGAGAGUUU UAUUUCA	2037-2057	A-2282496. 1	4110	UGAAAUAAAACUCUC UAAUCUUC	2035-2057
AD-135350 1.1	A-252129 6.1	4021	AUACAGAACGAUCGA UACAGA	1803-1823	A-2521297. 1	4111	UCUGTAUCGAUCGTUC UGUAUCG	1801-1823

AD-135347 1.1	A-252123 8.1	4022	AUACAGAACGAUCGA UACAGA	1803-1823	A-2521239. 1	4112	UCUGTAUCGAUCGUU CUGUAUCG	1801-1823
AD-135344 1.1	A-252119 3.1	4023	AUACAGAACGAUCGA UACAGA	1803-1823	A-2521194. 1	4113	UCUGTAUCGAUCGUU CUGUAUCG	1801-1823
AD-135349 5.1	A-252128 6.1	4024	AUGCAGAUTATGCGG AUCAAA	1348-1368	A-2521287. 1	4114	UTUGAUCCGCATAAUC UGCAUGG	1346-1368
AD-135346 5.1	A-252122 6.1	4025	AUGCAGAUUAUGCG GAUCAA	1348-1368	A-2521227. 1	4115	UTUGAUCCGCATAAUC UGCAUGG	1346-1368
AD-135343 5.1	A-252118 5.1	4026	AUGCAGAUUAUGCG GAUCAA	1348-1368	A-2521186. 1	4116	UUUGAUCCGCATAAUC CUGCAUGG	1346-1368
AD-135351 0.1	A-252131 4.1	4027	AUUGGAUUCGCCAUU UUAUUA	1988-2008	A-2521315. 1	4117	UAAUAAAAUUGGCGAA TCCAAUUC	1986-2008
AD-135348 0.1	A-252125 6.1	4028	AUUGGAUUCGCCAUU UUAUUA	1988-2008	A-2521257. 1	4118	UAAUAAAAUUGGCGAA UCCAAUUC	1986-2008
AD-135345 0.1	A-252120 7.1	4029	AUUGGAUUCGCCAUU UUAUUA	1988-2008	A-2282456. 1	4119	UAAUAAAAUUGGCGAA UCCAAUUC	1986-2008
AD-135349 2.1	A-252128 0.1	4030	CAACAUCACCCAUGCA GAUUAA	1338-1358	A-2521281. 1	4120	UTAAATCUGCAUGGTGA UGUUGGC	1336-1358
AD-135346 2.1	A-252122 0.1	4031	CAACAUCACCCAUGCA GAUUAA	1338-1358	A-2521221. 1	4121	UTAAATCUGCAUGGTGA AUGUUGGC	1336-1358
AD-135343 2.1	A-252118 0.1	4032	CAACAUCACCCAUGCA GAUUAA	1338-1358	A-2521181. 1	4122	UUAATCUGCAUGGTGA AUGUUGGC	1336-1358
AD-135350 4.1	A-252130 2.1	4033	CAGAACAGTCCUUA UCCAGA	1858-1878	A-2521303. 1	4123	UCUGGAUUAAGGACU GUUCUGUC	1856-1878

AD-135347 4.1	A-252124 4.1	4034	CAGAACAGUCCUUA UCCAGA	1858-1878	A-2521245. 1	4124	UCUGGAUUAAGGACU GUUCUGUC	1856-1878
AD-135344 4.1	A-170082 6.1	4035	CAGAACAGUCCUUA UCCAGA	1858-1878	A-2521198. 1	4125	UCUGGAUUAAGGACU GUUCUGUC	1856-1878
AD-135349 3.1	A-252128 2.1	4036	CAUCACCATGCAGAU UAUGCA	1341-1361	A-2521283. 1	4126	UGCATAAUCUGCATGG UGAUGUU	1339-1361
AD-135346 3.1	A-252122 2.1	4037	CAUCACCAUGCAGAU UAUGCA	1341-1361	A-2521223. 1	4127	UGCATAAUCUGCAUG GUGAUGUU	1339-1361
AD-135343 3.1	A-252118 2.1	4038	CAUCACCAUGCAGAU UAUGCA	1341-1361	A-2282286. 1	4128	UGCAUAAUCUGCAUG GUGAUGUU	1339-1361
AD-135350 8.1	A-252131 0.1	4039	CCUCUUGGAATUGGA UUCGCA	1979-1999	A-2521311. 1	4129	UGCGAATCCAAATUCCA AGAGGGC	1977-1999
AD-135347 8.1	A-252125 2.1	4040	CCUCUUGGAUUGGA UUCGCA	1979-1999	A-2521253. 1	4130	UGCGAATCCAAATUCCA AGAGGGC	1977-1999
AD-135344 8.1	A-252120 4.1	4041	CCUCUUGGAUUGGA UUCGCA	1979-1999	A-2521205. 1	4131	UGCGAAUCCAAUUC AAGAGGGC	1977-1999
AD-135349 6.1	A-252128 8.1	4042	CUACAGCACAAACAA UGUGAA	1405-1425	A-2521289. 1	4132	UTCACATUUGUTGTGC UGUAGGG	1403-1425
AD-135346 6.1	A-252122 8.1	4043	CUACAGCACAAACAA UGUGAA	1405-1425	A-2521229. 1	4133	UTCACATUUGUTGTGC UGUAGGG	1403-1425
AD-135343 6.1	A-252118 7.1	4044	CUACAGCACAAACAA UGUGAA	1405-1425	A-2521188. 1	4134	UUCACAUUUGUUGUG CUGUAGGG	1403-1425
AD-135350 0.1	A-252129 4.1	4045	CUGAUACAGAACGUA CGAUAA	1800-1820	A-2521295. 1	4135	UTAUCGAUCGUTCTGT AUCAGUC	1798-1820

AD-135347 0.1	A-252123 6.1	4046	CUGAUAACAGAACGAU CGAUAA	1800-1820	A-2521237. 1	4136	UTAUCGAUCGUTCUGU AUCAGUC	1798-1820
AD-135344 0.1	A-170082 4.1	4047	CUGAUAACAGAACGAU CGAUAA	1800-1820	A-2521192. 1	4137	UUAUCGAUCGUUCUG UAUCAGUC	1798-1820
AD-133406 7.3	A-248362 6.1	4048	GAAAGUGUTUTAUUAU ACGGUA	2946-2966	A-1800443. 1	4138	UACCGUAUAUAAAAC ACUUUCUC	2944-2966
AD-135348 8.1	A-252127 2.1	4049	GAAAGUGUUUUUAUA UACGGUA	2946-2966	A-2521273. 1	4139	UACCGUAUAUAAAAC ACUUUCUC	2944-2966
AD-135345 8.1	A-170089 4.1	4050	GAAAGUGUUUUUAUA UACGGUA	2946-2966	A-2521215. 1	4140	UACCGUAUAUAAAAC ACUUUCUC	2944-2966
AD-133406 5.3	A-248362 4.1	4051	GAGAAAAGUGUTUUA UAUACGA	2944-2964	A-1800396. 1	4141	UCGUUAUAUAAAACAC TUUCUCUU	2942-2964
AD-135348 7.1	A-252127 0.1	4052	GAGAAAAGUGUUUUA UAUACGA	2944-2964	A-2521271. 1	4142	UCGUUAUAUAAAACAC UUUCUCUU	2942-2964
AD-135345 7.1	A-170084 5.1	4053	GAGAAAAGUGUUUUA UAUACGA	2944-2964	A-2282774. 1	4143	UCGUUAUAUAAAACAC UUUCUCUU	2942-2964
AD-135351 1.1	A-252131 6.1	4054	GAUUCGCCAUTUUUAU UUUUCA	1992-2012	A-2521317. 1	4144	UGAAAAAUAAAUGG CGAAUCCG	1990-2012
AD-135348 1.1	A-252125 8.1	4055	GAUUCGCCAUUUUAU UUUUCA	1992-2012	A-2521259. 1	4145	UGAAAAAUAAAUGG CGAAUCCG	1990-2012
AD-135345 1.1	A-252120 8.1	4056	GAUUCGCCAUUUUAU UUUUCA	1992-2012	A-2521209. 1	4146	UGAAAAAUAAAUGG CGAAUCCG	1990-2012
AD-135350 7.1	A-252130 8.1	4057	GUCCUUAATCCAGAA ACCUGA	1865-1885	A-2521309. 1	4147	UCAGGUTUCUGGATU AAGGACUG	1863-1885

AD-135347 7.1	A-252125 0.1	4058	GUCCUUAUCCAGAA ACCUGA	1865-1885	A-2521251. 1	4148	UCAGGUTUCUGGAUU AAGGACUG	1863-1885
AD-135344 7.1	A-252120 3.1	4059	GUCCUUAUCCAGAA ACCUGA	1865-1885	A-2282416. 1	4149	UCAGGUUUCUGGAUU AAGGACUG	1863-1885
AD-135351 7.1	A-252132 8.1	4060	GUGUUUATATACGG UACUUA	2950-2970	A-2521329. 1	4150	UAAGTACCGUATATAA AACACUU	2948-2970
AD-135348 9.1	A-252127 4.1	4061	GUGUUUUAUUAUCG GUACUUA	2950-2970	A-2521275. 1	4151	UAAGTACCGUATAUA AAACACUU	2948-2970
AD-135345 9.1	A-252121 6.1	4062	GUGUUUUAUUAUCG GUACUUA	2950-2970	A-2282784. 1	4152	UAAGUACCGUAUAUA AAACACUU	2948-2970
AD-135351 9.1	A-252133 2.1	4063	UAGACAUUGCTAUUC UGUUUA	3365-3385	A-2521333. 1	4153	UAAACAGAAUAGCAA TGUCUAUU	3363-3385
AD-135349 1.1	A-252127 8.1	4064	UAGACAUUGCUAUUC UGUUUA	3365-3385	A-2521279. 1	4154	UAAACAGAAUAGCAA UGUCUAUU	3363-3385
AD-135346 1.1	A-252121 9.1	4065	UAGACAUUGCUAUUC UGUUUA	3365-3385	A-2282952. 1	4155	UAAACAGAAUAGCAA UGUCUAUU	3363-3385

Table 18A. Exemplary Human VEGF-A siRNA Modified Single Strands and Duplex Sequences

Duplex Name	Sense Oligo Name	SEQ ID NO: (Sense)	Sense Sequence	Anti-sense Oligo Name	SEQ ID NO: (Anti-sense)	Antisense Sequence	mRNA Target Sequence	SEQ ID NO: (mRNA target)
AD-1020574	A-11107 70.1	4164	csgsaca(Ghd)AfaCfAfGfuccuuaucsa	A-1701268. 1	4176	VPusGfsauua(Agn)ggacugUfuCfugucgsasu	AUCGACAGAAACAGUCCUUAUAUCC	4188
AD-901094	A-17008 26.1	4165	csasgaa(Chd)AfgUfCfCfuuauuccasgsa	A-1068918. 1	4177	VPusCfsuggaAfuUfAfaggaCfuGfuucugsusc	GACAGAACAGUCUUUAUCCAGA	4189
AD-1020575	A-17008 26.1	4166	csasgaa(Chd)AfgUfCfCfuuauuccasgsa	A-1701270. 1	4178	VPusCfsugga(Tgn)uaaggaCfuGfuucugsusc	GACAGAACAGUCUUUAUCCAGA	4190
AD-901100	A-17008 32.1	4167	asascag(Uhd)GfcUfAfAfuguuauucgsa	A-1069342. 1	4179	VPusCfscaaUfaAfCfaaauaGfcAfcuguusasa	UUAACAGUGCUAUGUUUAUUGGU	4191
AD-901101	A-17008 33.1	4168	asgsugc(Uhd)AfaUfGfUfuuuuguggsusa	A-1069348. 1	4180	VPusAfsaacCfaAfUfaaauUfuAfcacugsu	ACAGUGCUAAAGUUUAUUGGUGUC	4192
AD-901113	A-17008 45.1	4169	gsasgaa(Ahd)GfuGfUfUfuuauauacgsa	A-1070290. 1	4181	VPusCfsguaUfaUfAfaaacAfcUfuucucsusu	AAGAGAAAGUGUUUAUAUACGG	4193
AD-901123	A-17008 55.1	4170	asasaau(Ahd)GfaCfAfUfugcuauucsa	A-1070790. 1	4182	VPusAfsгааUfaGfCfaauggUfcUfauuuusasu	AUAAAAUAGACAUUGCUAUUCUG	4194
AD-901124	A-17008 56.1	4171	asasaau(Ahd)AfcAfUfUfgcuauucgsa	A-1070792. 1	4183	VPusCfsagaAfuAfGfcaauGfuCfuauuusasa	UAAAAUAGACAUUGCUAUUCUGU	4195
AD-901158	A-17008 94.1	4172	gsasaag(Uhd)GfuUfUfUfaauacgsa	A-1070294. 1	4184	VPusAfscegUfaUfAfaaauaAfcAfcuuucusc	GAGAAAGUGUUUAUAUAACGGUA	4196

AD-901159	A-17008 95.1	4173	gsusuuu(Ahd)UfaUfAfCf gguaauuasusa	A-1070306. 1	4185	VPusAfsuaaGfuAfCfegu aUfaUfaaaacsasc	GUGUUUUUAUAUA CGGUACUUUAUU	4197
AD-1020573	A-18905 20.1	4174	asgsugc(Uhd)aadTgdTua uuggugsusa	A-1800384. 1	4186	VPusdAscadCcdAauaad CadTudAgcausgsu	ACAGUGCUAAUG UUAUUGGUGUC	4198
AD-1023143	A-18956 07.1	4175	asasaau(Ahd)gadCadTug cuauucsusa	A-1800407. 1	4187	VPusdAsgadAudAgcaad TgdTcdTauuuusasu	AUAAAAUAGACA UUGCUAUUUCUG	4199

Table 18B. Exemplary Human VEGF-A siRNA Unmodified Single Strands and Duplex Sequences

Duplex Name	Sense Oligo Name	SEQ ID NO: (Sense)	Sense Sequence	mRNA Target Range	Antisense Oligo Name	SEQ ID NO: (Anti-sense)	Antisense Sequence	mRNA Target Range
AD-1020574	A-11107 70.1	4200	CGACAGAACAGUCCU UAAUCA	1855-1875	A-1701268. 1	4212	UGAUUAAAGGACUGUU CUGUCGAU	1853-1875
AD-901094	A-17008 26.1	4201	CAGAACAGUCCUUA UCCAGA	1858-1878	A-1068918. 1	4213	UCUGGAUUAAAGGACU GUUCUGUC	1856-1878
AD-1020575	A-17008 26.1	4202	CAGAACAGUCCUUA UCCAGA	1858-1878	A-1701270. 1	4214	UCUGGATUAAAGGACU GUUCUGUC	1856-1878
AD-901100	A-17008 32.1	4203	AACAGUGCUAAUGU UAUUGGA	2178-2198	A-1069342. 1	4215	UCCAAUAACAUUAGC ACUGUUAA	2176-2198
AD-901101	A-17008 33.1	4204	AGUGCUAAUGUUUAU UGGUGUA	2181-2201	A-1069348. 1	4216	UACACCAAUAAACA AGCACUGU	2179-2201
AD-901113	A-17008 45.1	4205	GAGAAAAGUGUUUUA UAUACGA	2944-2964	A-1070290. 1	4217	UCGUAAUAAAAACAC UUUCUCUU	2942-2964
AD-901123	A-17008 55.1	4206	AAAUAAGACAUUGC UAUUCUA	3361-3381	A-1070790. 1	4218	UAGAAUAGCAAUGUC UAUUUUUAU	3359-3381

AD-901124	A-17008 56.1	4207	AAAUAGACAUUGCU AUUCUGA	3362-3382	A-1070792. 1	4219	UCAGAAUAGCAAUGU CUAUUUUA	3360-3382
AD-901158	A-17008 94.1	4208	GAAAGUGUUUUAUA UACGGUA	2946-2966	A-1070294. 1	4220	UACCGUAUUAUAAAC ACUUUCUC	2944-2966
AD-901159	A-17008 95.1	4209	GUUUUAUAUACGGU ACUUAUA	2952-2972	A-1070306. 1	4221	UAUAAAGUACCGUAUA UAAAACAC	2950-2972
AD-1020573	A-18905 20.1	4210	AGUGCUAATGTUAUU GGUGUA	2181-2201	A-1800384. 1	4222	UACACCAAUAAACATU AGCACUGU	2179-2201
AD-1023143	A-18956 07.1	4211	AAAUAGACATUGCU AUUCUA	3361-3381	A-1800407. 1	4223	UAGAAUAGCAATGTCT AUUUUAU	3359-3381

Example 2. *In vitro* screening of VEGF-A siRNA**Experimental Methods****Cell culture and transfections:***Cos 7 Cell Transfections*

Cos-7 (ATCC) were transfected by adding 5 μ l of 1 ng/ μ l psiCHECK2 vector (Blue Heron Biotechnology) containing either Cynomolgus monkey (XM_005552887) or mouse (NM_001025250), 4.9 μ l of Opti-MEM, 0.1 μ l of Lipofectamine 2000 (Invitrogen, Carlsbad CA. cat #11668-019), and 5 μ l of siRNA duplexes per well into a 384-well plate. Following a 15-minute incubation at room temperature, thirty-five μ l of Dulbecco's Modified Eagle Medium (ThermoFisher) containing $\sim 5 \times 10^3$ cells were then added to the siRNA-transfection mixture. Cells were incubated for 48 hours followed by Firefly (transfection control) and Renilla (fused to target sequence) luciferase measurements. Experiments were performed at 10 nM, 1 nM, and 0.1 nM.

ARPE-19 Cell, hTERT REP-1, and Primary Human Hepatocyte Cell Transfections

ARPE-19 cells, hTERT RPE-1, or primary human hepatocyte cells (ATCC) were transfected by adding 4.9 μ l of Opti-MEM plus 0.1 μ l of RNAiMAX per well (Invitrogen, Carlsbad CA. cat # 13778-150) to 5 μ l of siRNA duplexes per well, with 4 replicates of each siRNA duplex, into a 384-well plate, and incubated at room temperature for 15 minutes. Forty μ l of DMEM:F12 Medium (ThermoFisher) containing $\sim 5 \times 10^3$ cells were then added to the siRNA-transfection mixture. Cells were incubated for 24 hours prior to RNA purification. Experiments were performed at 50 nM, 10 nM, 1 nM, and 0.1 nM.

Free uptake transfection:

Cryopreserved primary human hepatocytes were thawed at 37°C in a water bath immediately prior to usage and re-suspended at 0.26×10^6 cells/mL in InVitroGRO CP (plating) medium (Celsis In Vitro Technologies, catalog number Z99029). During transfections, cells were plated onto a BD BioCoat 96 well collagen plate (BD, 356407) at 25,000 cells per well and incubated at 37°C in an atmosphere of 5% CO₂. Free Uptake experiments were performed by adding 10 μ L of siRNA duplexes in PBS per well into a 96 well plate. Ninety μ L of complete growth media containing appropriate cell number for the cell was then added to the siRNA. Cells were incubated for 24 hours prior to RNA purification. Single dose experiments were performed at 500nM, 100nM, 10nM, and 1nM final duplex.

Total RNA isolation using DYNABEADS mRNA Isolation Kit:

RNA was isolated using an automated protocol on a BioTek-EL406 platform using DYNABEADS (Invitrogen, cat#61012). Briefly, 70 μ l of Lysis/Binding Buffer and 10 μ l of lysis buffer containing 3 μ l of magnetic beads were added to the plate with cells. Plates were incubated on an electromagnetic shaker for 10 minutes at room temperature and then magnetic beads were captured and the supernatant was removed. Bead-bound RNA was then washed 2 times with 150 μ l Wash Buffer A and once with Wash Buffer B. Beads were then washed with 150 μ l Elution Buffer, re-captured and supernatant removed.

cDNA synthesis using ABI High capacity cDNA reverse transcription kit (Applied Biosystems, Foster City, CA, Cat #4368813):

Ten μ l of a master mix containing 1 μ l 10X Buffer, 0.4 μ l 25X dNTPs, 1 μ l 10x Random primers, 0.5 μ l Reverse Transcriptase, 0.5 μ l RNase inhibitor and 6.6 μ l of H₂O per reaction was added to RNA isolated above. Plates were sealed, mixed, and incubated on an electromagnetic shaker for 10 minutes at room temperature, followed by 2 h 37°C.

Real time PCR:

Two μ l of cDNA and 5 μ l Lightcycler 480 probe master mix (Roche Cat # 04887301001) were added to either 0.5 μ l of Human GAPDH TaqMan Probe (4326317E) and 0.5 μ l VEGFA Human probe (Hs00900055_m1, Thermo) per well in a 384 well plates (Roche cat # 04887301001). Real time PCR was done in a LightCycler480 Real Time PCR system (Roche). Each duplex was tested at least two times and data were normalized to cells transfected with a non-targeting control siRNA. To calculate relative fold change, real time data were analyzed using the $\Delta\Delta$ Ct method and normalized to assays performed with cells transfected with a non-targeting control siRNA.

Results

The results of the multi-dose screen in human retinal pigment epithelial cells (ARPE-19) and human hTERT-immortalized retinal pigment epithelial cells (hTERT RPE-1) with three sets of exemplary human VEGF-A siRNAs are shown in Table 6A (correspond to siRNAs in Table 2A and Table 2B), Table 6B (correspond to siRNAs in Table 3A and Table 3B), and 6C (correspond to siRNAs in Table 4A and Table 4B). The multi-dose experiments were performed at 50 nM, 10 nM, 1 nM, and 0.1 nM final duplex concentrations and the data are expressed as percent message remaining relative to non-targeting control. Of the exemplary siRNA duplexes evaluated, 28 achieved a knockdown of VEGF-A of $\geq 90\%$, 108 achieved a knockdown of

VEGF-A of $\geq 60\%$, and 229 achieved a knockdown of VEGF-A of $\geq 30\%$ in in ARPE-19 cells when administered at the 10 nM concentration.

Table 6A. VEGF-A endogenous *in vitro* multi-dose screen with one set of exemplary human VEGF-A siRNAs

	ARPE-19								hTERT RPE-1							
Sample_Name	50 nM	StdDev	10 nM	StdDev	1 nM	StdDev	0.1 nM	StdDev	50 nM	StdDev	10 nM	StdDev	1 nM	StdDev	0.1 nM	StdDev
AD-901349.1	29.9	4.1	24.7	3.0	34.0	3.0	54.3	5.7	26.5	7.9	26.0	1.7	64.1	11.3	94.0	17.7
AD-901376.1	28.3	4.6	25.4	7.6	35.7	8.8	50.3	14.1	15.1	2.7	20.9	4.1	37.6	8.3	46.9	4.6
AD-901356.1	30.6	2.9	27.9	2.8	36.5	2.5	60.3	7.6	21.0	3.5	25.3	9.7	39.3	8.9	91.6	12.5
AD-901355.1	42.0	2.2	28.7	3.7	39.6	0.2	65.7	11.5	26.9	2.3	27.4	9.6	44.8	4.0	92.6	22.9
AD-901407.1	27.8	11.7	30.9	4.0	55.4	6.2	106.1	19.2	39.0	7.9	41.1	12.4	69.5	10.9	87.5	21.1
AD-901367.1	39.0	4.8	31.5	3.7	38.6	7.1	50.4	2.2	31.0	6.3	39.3	5.5	38.1	5.2	77.0	13.4
AD-901352.1	42.7	1.8	34.6	6.1	48.5	6.6	57.4	4.9	27.1	7.7	28.9	4.5	51.6	10.4	76.8	15.3
AD-901348.1	44.5	7.3	35.0	7.2	40.6	4.7	62.4	9.1	35.4	6.8	23.0	4.2	50.0	18.5	97.9	21.6
AD-901354.1	45.0	3.6	35.9	7.1	40.9	2.1	61.2	4.0	34.1	8.9	27.0	6.2	34.7	8.7	81.9	18.7
AD-901353.1	50.8	5.9	37.6	8.6	29.8	4.7	52.4	2.4	36.1	6.5	21.5	4.3	40.4	8.7	98.2	11.7
AD-901375.1	44.5	7.1	40.2	2.0	43.0	6.6	60.0	12.2	30.5	1.8	30.4	3.3	46.9	24.4	61.3	4.9
AD-901345.1	53.1	6.0	42.9	9.0	74.3	13.7	73.0	16.3	74.8	12.7	62.2	18.1	61.7	9.5	85.2	14.5
AD-901357.1	39.8	11.7	42.9	1.1	54.2	3.3	78.1	14.9	37.2	7.4	42.3	15.4	43.2	2.9	97.9	19.8
AD-901334.1	55.7	4.7	43.4	7.2	77.4	9.8	76.7	6.0	74.9	18.4	47.9	12.8	73.3	17.2	85.9	8.5
AD-901313.1	32.9	3.6	44.2	9.8	77.8	17.5	64.1	7.0	39.7	12.8	47.9	5.8	101.3	4.5	69.6	18.2
AD-901344.1	71.9	5.4	46.9	6.7	78.6	16.2	59.4	9.0	75.8	6.0	72.9	21.0	62.0	13.2	78.4	7.8
AD-901366.1	56.1	9.1	47.2	7.4	61.9	5.7	69.1	6.6	42.5	11.3	49.6	12.8	58.3	14.2	97.4	18.8
AD-901337.1	70.7	7.9	47.7	9.4	101.6	21.1	82.6	9.4	91.8	17.2	64.0	25.7	80.8	21.3	86.4	7.4
AD-901335.1	58.7	9.2	48.0	7.7	109.6	32.9	84.5	9.8	75.6	4.6	62.1	15.5	72.2	19.6	92.4	18.7
AD-901398.1	51.6	2.2	48.0	8.3	63.3	5.6	91.1	11.3	39.6	8.2	55.7	9.8	71.8	10.1	56.2	8.4
AD-901314.1	43.1	10.7	48.7	10.8	94.3	25.4	99.6	15.1	49.9	6.0	50.9	10.9	67.9	15.4	100.9	31.8
AD-901386.1	51.7	6.0	49.5	2.7	82.7	59.5	75.9	21.6	62.6	20.0	42.9	8.8	55.4	20.7	45.8	8.9
AD-901336.1	67.6	5.1	51.4	12.8	88.0	14.9	74.3	9.5	88.1	10.2	51.7	16.0	77.8	19.7	85.0	16.0
AD-901310.1	40.9	8.2	53.0	5.6	88.6	18.3	82.0	5.8	46.8	7.6	52.4	10.7	71.9	11.7	76.1	7.3
AD-901321.1	41.4	7.4	53.1	13.3	87.7	15.2	67.0	16.0	36.4	8.2	40.2	4.3	87.2	13.0	89.2	8.0
AD-901382.1	57.5	4.2	53.7	3.0	62.8	4.5	90.1	19.4	41.0	12.4	37.9	9.3	68.2	10.5	63.9	9.5

AD-901384.1	49.7	6.8	53.8	12.8	54.0	12.3	87.8	38.9	43.5	5.7	52.6	5.1	60.1	9.4	56.1	12.1
AD-901339.1	80.3	16.6	54.0	7.4	76.7	11.8	74.7	3.5	96.3	18.7	68.3	12.5	68.9	13.3	89.7	11.8
AD-901363.1	68.5	11.9	55.2	9.3	54.3	4.3	71.2	8.6	52.2	5.7	54.8	12.0	45.5	1.5	86.0	15.8
AD-901325.1	71.6	2.4	55.6	7.1	111.4	11.4	95.5	4.4	77.5	15.7	69.8	10.8	88.4	10.0	96.8	6.0
AD-901350.1	60.4	9.5	56.5	8.4	66.9	6.6	73.3	3.1	50.7	6.7	45.6	3.9	85.0	8.9	92.4	12.9
AD-901365.1	68.6	5.1	56.5	6.6	64.8	7.6	79.6	12.3	48.9	18.5	52.3	13.3	56.8	16.7	96.1	8.8
AD-901306.1	55.1	12.5	57.7	5.8	96.6	17.2	97.3	24.5	66.5	10.5	74.7	16.8	75.6	9.7	108.6	25.5
AD-901361.1	50.8	6.9	58.5	18.8	45.6	3.1	68.6	10.3	44.9	4.3	36.2	9.9	57.7	6.5	95.4	14.9
AD-901320.1	52.3	11.4	60.0	5.7	94.3	23.4	69.8	3.8	48.1	19.3	48.3	3.8	68.9	13.2	84.4	18.8
AD-901405.1	64.5	3.4	60.5	9.8	80.4	7.5	83.6	15.4	63.1	9.2	72.3	21.9	74.6	9.3	55.6	6.4
AD-901338.1	52.7	5.1	61.7	4.1	82.0	12.2	86.9	13.2	73.4	8.4	60.8	20.1	58.8	9.8	103.1	16.6
AD-901383.1	62.0	8.9	62.2	7.7	78.2	11.8	92.7	14.8	57.0	9.8	62.6	11.9	75.1	16.6	75.2	7.0
AD-901333.1	82.0	7.2	62.5	12.2	94.1	17.3	85.2	6.9	92.2	5.4	66.8	12.1	79.2	15.9	70.5	37.8
AD-901330.1	75.7	8.7	63.0	9.7	96.4	6.3	104.5	23.5	90.8	8.4	63.2	16.4	82.5	16.6	109.3	30.1
AD-901360.1	61.4	8.8	64.0	10.3	59.9	6.5	90.6	32.4	77.5	3.7	63.7	6.4	64.1	14.7	95.1	14.9
AD-901358.1	67.4	11.4	65.3	5.4	71.0	3.6	82.3	6.7	58.5	5.3	49.5	6.5	62.8	4.6	94.4	11.9
AD-901406.1	67.6	7.4	65.6	7.7	77.2	6.7	93.5	2.0	63.3	13.4	65.2	5.7	69.4	9.5	86.9	30.3
AD-901326.1	78.8	14.8	65.8	16.8	120.8	26.0	88.1	8.0	85.9	5.7	69.6	11.8	88.6	15.2	98.3	14.6
AD-901377.1	47.2	7.3	65.8	11.4	57.5	12.7	68.0	22.8	42.8	6.2	47.4	6.3	54.8	10.2	63.4	15.1
AD-901351.1	69.4	9.6	66.9	10.1	82.5	6.8	85.7	5.3	73.9	8.0	56.8	13.1	81.2	30.7	97.6	36.5
AD-901415.1	77.8	13.7	68.1	18.4	78.6	14.7	119.6	45.3	85.6	6.4	57.2	10.5	83.8	7.7	78.5	19.4
AD-901342.1	87.4	20.2	70.1	10.3	113.4	21.8	79.3	12.1	90.5	27.6	56.2	11.2	80.2	21.4	91.5	14.4
AD-901420.1	61.1	7.0	71.0	5.7	75.3	4.0	107.9	37.3	52.4	2.8	43.5	7.9	67.8	13.7	80.8	8.9
AD-901312.1	62.1	10.7	71.2	8.0	102.4	22.9	76.5	2.4	75.1	7.7	60.1	15.4	100.2	30.7	73.8	17.5
AD-901340.1	88.8	12.8	71.6	10.3	100.4	19.9	93.3	12.4	94.1	31.9	69.3	11.0	87.6	24.7	100.6	10.9
AD-901392.1	49.7	9.0	71.6	13.2	69.0	4.0	81.0	47.1	41.3	2.9	61.4	10.0	77.7	12.1	74.3	5.4
AD-901327.1	72.4	15.6	71.8	8.7	114.4	13.3	80.6	2.7	89.8	13.6	75.7	12.3	82.7	23.2	92.0	8.8
AD-901328.1	77.7	13.0	72.6	6.3	104.1	10.6	76.9	7.7	87.2	16.3	70.5	4.1	89.5	8.4	86.4	10.7
AD-901370.1	65.9	6.5	72.9	7.8	79.9	6.7	70.6	4.4	67.8	9.5	81.6	5.6	70.3	16.6	52.8	35.3
AD-901399.1	63.2	10.4	72.9	7.8	79.3	5.9	98.0	11.8	52.6	4.9	78.5	18.2	62.3	12.7	68.9	7.0

AD-901359.1	83.7	13.3	73.4	12.1	66.6	8.8	69.4	7.1	80.2	20.5	63.3	20.6	70.5	6.9	90.7	19.1
AD-901373.1	81.5	10.9	73.4	4.6	73.5	2.4	69.8	8.7	52.1	11.0	61.9	17.9	60.7	10.9	56.7	12.5
AD-901332.1	79.6	17.9	73.7	4.9	123.3	17.1	93.6	6.1	95.2	13.6	56.4	15.2	96.5	7.9	89.0	14.4
AD-901311.1	53.7	10.4	74.5	9.5	98.0	27.9	72.0	4.0	67.5	16.0	69.0	9.2	64.6	10.3	73.9	3.3
AD-901423.1	61.8	10.6	74.5	9.5	72.3	8.7	104.0	24.4	48.8	3.6	56.4	10.5	68.3	12.8	73.5	8.2
AD-901374.1	92.4	18.4	74.5	9.6	86.9	12.5	71.0	14.7	90.5	13.9	52.7	13.4	81.5	12.0	61.3	12.7
AD-901319.1	73.3	19.5	75.1	6.3	126.0	19.4	77.4	7.6	88.5	16.0	81.3	7.2	64.0	20.9	93.5	33.9
AD-901341.1	88.8	12.2	75.5	8.1	107.3	10.6	79.2	5.8	77.2	20.8	86.1	24.0	96.8	15.9	93.0	10.6
AD-901422.1	51.3	3.2	75.8	5.2	55.6	5.8	95.6	25.5	40.2	4.1	39.9	9.4	61.8	15.0	76.2	19.9
AD-901385.1	67.7	13.9	75.8	16.1	86.8	10.9	93.1	21.7	72.9	11.6	72.2	14.5	76.4	13.2	65.1	10.3
AD-901391.1	72.0	11.9	76.2	8.8	82.3	12.0	76.8	22.5	71.6	14.7	63.4	16.7	81.2	6.6	85.9	13.3
AD-901329.1	72.5	10.6	76.3	11.1	107.1	12.2	79.8	9.2	98.2	17.4	75.5	10.9	100.5	15.9	93.9	6.9
AD-901331.1	101.1	11.5	77.9	13.7	120.0	24.9	84.0	10.0	126.3	25.1	76.3	19.3	82.2	6.1	79.0	22.0
AD-901368.1	73.7	9.1	79.5	11.1	82.4	5.5	90.1	31.1	98.3	21.8	97.4	7.8	64.4	19.9	85.4	4.9
AD-901364.1	82.5	10.9	79.5	16.7	75.7	8.9	81.4	2.6	65.8	7.1	65.3	18.7	48.4	7.4	90.9	5.5
AD-901389.1	69.1	10.2	80.3	6.1	80.4	9.2	87.2	22.8	50.7	2.4	55.9	6.4	82.8	21.5	59.0	16.1
AD-901421.1	54.9	7.1	80.9	6.9	63.4	9.2	96.5	25.7	50.4	9.2	37.8	3.8	70.9	15.3	61.1	11.7
AD-901380.1	85.6	16.8	81.0	6.5	60.9	9.0	83.7	9.2	74.9	12.3	77.7	6.6	54.5	11.3	75.8	19.3
AD-901343.1	102.8	17.6	81.8	13.7	127.7	32.4	99.8	11.8	133.1	18.9	81.7	20.5	93.1	6.4	81.8	13.4
AD-901317.1	89.8	12.2	81.8	4.8	131.2	51.1	90.6	5.2	120.7	22.3	86.4	4.5	69.7	11.0	76.7	7.1
AD-901424.1	62.9	4.8	82.2	14.8	64.9	10.2	86.0	8.1	68.7	13.3	63.1	22.6	76.5	15.9	71.8	24.4
AD-901431.1	84.8	11.4	82.9	20.5	75.7	10.5	96.4	29.5	79.4	15.9	88.8	25.2	85.1	8.9	80.8	21.7
AD-901378.1	71.4	5.4	82.9	5.5	77.3	8.5	80.6	9.3	56.8	14.3	40.8	13.4	82.0	24.4	78.9	14.1
AD-901434.1	70.3	11.3	83.8	8.4	59.4	1.3	92.1	11.3	62.6	8.3	72.7	17.5	69.9	12.0	82.0	11.3
AD-901412.1	83.4	15.9	84.5	32.2	94.4	4.4	81.6	19.4	82.3	3.9	50.8	5.2	85.6	21.9	74.5	8.0
AD-901426.1	96.7	7.7	85.1	13.5	68.2	7.2	104.4	9.3	92.5	15.3	61.5	4.0	56.0	7.0	80.4	15.0
AD-901322.1	74.9	14.5	85.5	12.4	118.1	15.9	117.4	22.0	107.2	20.0	92.5	15.9	98.9	16.0	107.3	8.5
AD-901381.1	92.6	10.5	85.7	4.9	93.9	10.2	90.8	17.0	72.5	15.0	74.0	16.8	85.0	21.6	71.5	16.1
AD-901324.1	93.0	10.1	87.3	14.3	142.1	25.2	92.9	5.5	133.9	8.1	94.9	11.1	94.3	9.2	91.4	4.7
AD-901347.1	84.2	11.6	87.7	9.5	101.8	19.4	83.9	4.4	96.1	10.3	84.6	25.5	105.8	6.4	96.3	13.4

AD-901379.1	81.1	5.9	87.8	6.2	72.1	6.9	80.4	6.7	79.3	7.6	59.9	15.5	82.5	18.4	59.1	18.7
AD-901428.1	71.8	4.4	88.2	18.3	74.5	8.0	93.0	16.6	89.7	13.0	52.5	12.6	65.9	17.7	76.7	13.3
AD-901371.1	75.5	7.5	88.2	15.6	77.3	5.7	82.5	5.9	71.7	8.5	56.8	12.0	68.6	10.7	71.2	20.0
AD-901408.1	74.4	14.1	88.8	30.8	91.5	5.1	85.5	11.2	75.4	14.5	57.2	15.1	97.4	21.5	76.5	13.3
AD-901417.1	94.8	14.8	89.2	14.0	101.7	5.9	117.2	33.3	85.4	23.1	76.9	12.4	92.6	6.8	76.2	21.6
AD-901400.1	82.9	10.1	89.7	8.6	97.9	11.3	97.7	22.9	97.5	12.8	101.9	12.3	98.8	13.0	65.3	17.5
AD-901323.1	74.6	14.8	90.4	12.0	130.1	25.7	86.8	3.3	101.8	5.7	93.7	18.2	80.4	12.4	96.3	20.5
AD-901316.1	91.0	18.0	90.8	8.3	139.5	42.5	96.3	3.1	99.6	17.7	93.6	8.8	80.1	28.4	96.5	18.2
AD-901315.1	86.7	14.1	90.8	6.4	130.0	40.3	92.6	4.0	125.3	13.0	107.4	11.9	72.7	22.2	97.5	7.6
AD-901395.1	77.9	11.7	90.9	5.9	80.0	4.0	86.9	20.7	65.9	13.2	63.8	10.5	87.3	8.0	74.9	19.2
AD-901318.1	78.6	6.2	92.1	11.8	131.0	50.7	90.2	11.5	112.5	21.6	91.5	12.2	73.0	12.4	83.6	15.4
AD-901390.1	75.3	12.2	93.3	5.9	95.8	9.4	96.1	23.2	47.0	6.9	66.4	7.4	71.5	4.7	64.3	14.3
AD-901387.1	91.5	9.4	94.9	6.0	100.0	18.9	93.5	10.9	131.7	17.8	89.3	10.7	89.1	17.7	69.4	13.4
AD-901307.1	66.0	13.3	95.4	11.1	105.1	21.0	90.1	4.9	119.0	15.4	100.5	12.7	74.3	28.2	105.8	10.9
AD-901410.1	91.1	15.6	96.5	28.2	104.3	15.4	91.4	7.4	93.9	9.4	55.3	10.6	98.9	32.4	79.6	13.4
AD-901433.1	86.9	4.6	96.9	18.9	74.6	2.3	98.2	8.3	81.1	19.2	58.0	15.9	81.0	12.6	73.6	12.0
AD-901308.1	67.0	5.1	97.7	18.4	136.0	31.1	89.2	5.3	116.8	18.1	109.3	4.6	99.4	12.4	80.8	8.5
AD-901414.1	88.8	12.1	98.1	31.3	94.5	2.6	94.0	16.9	88.5	4.8	64.8	17.5	70.2	8.3	82.3	11.3
AD-901309.1	67.5	6.9	98.7	12.4	124.9	29.1	91.8	3.9	111.9	21.4	84.7	12.8	97.9	16.1	88.3	18.1
AD-901362.1	75.1	11.6	99.1	22.7	91.0	7.1	91.6	12.6	93.3	9.1	99.8	38.1	69.3	19.5	92.9	13.0
AD-901397.1	86.1	9.0	99.3	8.7	94.9	5.6	88.4	19.5	99.2	14.2	119.6	15.6	83.0	11.1	67.2	17.1
AD-901419.1	74.3	12.2	100.1	11.9	80.7	8.0	116.8	34.6	74.5	14.5	49.9	4.4	89.7	14.6	72.7	12.1
AD-901413.1	92.5	12.3	101.4	37.9	97.6	3.4	96.1	18.3	77.1	5.9	59.3	11.9	75.0	18.1	67.4	2.0
AD-901401.1	95.3	6.8	101.8	10.4	116.3	16.9	98.8	24.7	138.0	19.8	97.0	15.7	102.4	24.1	81.1	10.2
AD-901411.1	83.9	8.7	102.6	36.0	93.3	8.6	105.0	4.3	79.2	14.1	55.2	8.4	80.4	7.4	75.1	28.5
AD-901372.1	85.7	9.4	103.1	18.7	89.3	4.3	89.9	12.5	100.5	7.7	97.0	20.4	73.8	9.6	47.5	4.4
AD-901425.1	86.6	13.9	104.1	15.8	100.2	12.0	110.9	21.8	88.0	11.6	66.1	22.7	87.1	20.1	74.9	17.6
AD-901409.1	110.5	16.6	106.3	26.4	112.3	10.1	98.9	9.1	102.0	12.9	53.7	18.0	90.5	8.8	87.0	24.0
AD-901418.1	91.4	17.7	106.6	12.5	104.2	5.8	115.4	41.5	84.9	16.8	58.5	14.0	94.1	2.4	79.4	3.5
AD-901393.1	95.9	14.4	107.2	19.2	104.5	7.5	79.9	14.8	95.8	15.0	101.9	28.1	94.8	18.2	65.6	22.0

AD-901388.1	83.2	14.1	108.9	4.0	102.2	9.0	96.5	10.3	69.7	4.2	93.0	12.0	90.5	5.4	63.6	22.4
AD-901404.1	99.7	7.5	110.2	6.7	119.3	24.1	94.8	6.8	130.3	22.2	108.2	6.2	83.6	13.6	84.4	9.4
AD-901346.1	78.3	11.7	110.7	28.7	97.5	15.9	70.1	4.8	89.4	8.0	75.4	20.2	76.7	24.4	105.1	10.9
AD-901403.1	92.7	11.1	111.4	9.2	101.5	5.3	96.1	9.3	94.2	13.5	111.6	19.8	79.3	7.0	62.3	6.4
AD-901396.1	95.6	12.6	112.1	20.6	101.1	10.1	97.7	11.4	88.7	6.9	116.5	36.0	89.3	3.2	79.8	22.4
AD-901432.1	86.4	16.0	113.4	16.6	68.0	6.3	97.4	15.6	98.3	13.9	67.9	6.9	81.5	17.3	77.7	17.1
AD-901435.1	93.4	6.6	115.4	12.9	82.5	12.0	97.1	10.8	100.4	9.0	68.1	31.6	82.2	25.7	78.0	11.7
AD-901416.1	103.4	18.0	116.6	18.3	110.7	16.3	98.3	27.8	102.4	25.4	77.5	16.6	100.2	4.4	82.1	22.3
AD-901394.1	106.8	12.4	118.1	11.0	111.8	9.5	92.1	16.4	137.8	38.9	117.2	37.8	100.6	17.2	71.2	11.1
AD-901429.1	94.4	7.7	118.8	28.5	93.2	6.7	101.2	12.0	92.5	7.3	64.3	18.4	85.1	6.6	75.3	16.0
AD-901402.1	99.4	13.8	118.9	25.5	107.3	6.3	100.5	9.5	99.8	15.7	108.9	8.5	94.6	9.5	75.2	18.7
AD-901430.1	95.7	16.4	119.8	30.7	82.8	5.5	98.2	12.4	95.2	10.9	90.0	30.2	72.8	6.4	74.4	9.7
AD-901369.1	79.4	12.7	135.3	57.4	89.5	2.4	75.0	10.6	112.5	21.8	82.9	15.8	88.4	2.8	66.5	21.4

Table 6B. VEGF-A endogenous *in vitro* multi-dose screen with one set of exemplary human VEGF-A siRNAs

Sample Name	ARPE-19							hTERT RPE-1								
	50 nM	StDev	10 nM	StDev	1 nM	StDev	0.1 nM	StDev	50 nM	StDev	10 nM	StDev	1 nM	StDev	0.1 nM	StDev
AD-953340.1	18.6	2.1	2.7	0.7	28.5	3.4	106.5	28.3	40.1	3.9	25.2	10.0	38.7	7.5	52.2	15.2
AD-953336.1	25.7	1.4	3.7	0.9	26.5	0.5	159.2	61.6	45.5	5.2	26.3	8.1	41.0	8.9	68.2	8.3
AD-953363.1	17.3	2.9	3.9	0.9	33.5	6.0	57.0	7.1	37.2	6.8	24.6	5.6	38.1	5.9	39.4	8.0
AD-953338.1	23.1	2.7	4.8	1.8	41.2	8.4	92.1	21.1	54.6	7.9	35.3	7.5	51.1	1.4	76.1	10.8
AD-953367.1	25.6	1.6	5.1	0.6	39.3	6.9	55.8	5.1	62.2	8.0	33.2	10.3	61.2	8.6	49.4	7.6
AD-953337.1	29.5	4.0	5.6	3.4	28.2	2.0	129.8	30.5	45.4	8.6	23.8	4.5	44.8	3.6	60.6	8.0
AD-953342.1	18.9	2.3	5.6	3.6	31.6	4.9	149.8	56.1	35.2	4.0	28.4	6.6	39.0	2.7	73.7	11.9
AD-953350.1	30.0	3.6	5.8	4.1	46.6	8.3	78.3	22.9	70.5	10.7	42.6	14.8	49.3	14.2	85.8	3.8
AD-953352.1	28.5	2.8	6.1	0.5	41.5	5.7	113.4	13.2	52.8	5.8	40.1	9.3	53.0	7.6	72.9	7.3
AD-953368.1	33.3	1.6	6.2	1.0	35.2	2.3	48.2	3.6	58.8	5.7	39.5	11.2	50.1	7.2	50.5	2.2
AD-953344.1	17.8	1.6	6.5	1.9	38.5	5.7	66.5	11.3	29.5	4.0	28.9	7.1	49.6	7.0	75.8	12.9

AD-953339.1	26.5	4.9	6.7	5.5	34.4	6.2	120.0	30.4	41.7	3.6	26.2	3.7	36.0	9.0	59.1	7.0
AD-953387.1	20.6	1.0	6.9	0.3	40.9	5.4	64.9	6.1	21.0	2.8	31.3	5.4	69.7	15.0	57.4	7.3
AD-953375.1	37.1	2.8	7.4	1.1	48.8	6.5	73.4	3.9	90.7	19.7	62.5	8.1	72.2	11.9	64.3	16.3
AD-953355.1	42.7	5.3	7.5	0.7	62.2	2.4	137.9	24.5	43.9	5.5	40.6	8.0	52.6	10.0	67.1	5.5
AD-953341.1	20.2	2.9	7.7	4.5	22.3	3.3	106.6	21.7	55.5	5.5	34.7	7.7	32.2	8.3	68.4	5.8
AD-953370.1	36.8	3.0	7.8	1.9	55.5	7.5	72.3	6.0	38.0	7.8	26.9	4.7	63.9	12.6	51.9	6.9
AD-953362.1	57.6	4.3	8.2	1.1	54.3	8.3	76.8	3.6	108.9	11.3	48.1	10.1	63.0	11.0	52.1	10.4
AD-953322.1	59.6	3.6	8.2	1.3	61.4	4.5	105.4	14.2	103.5	9.6	55.4	15.9	66.5	7.4	78.4	11.5
AD-953332.1	59.2	3.3	8.3	1.3	58.3	3.8	106.7	20.6	95.1	15.8	55.0	9.1	74.5	1.5	66.2	8.9
AD-953371.1	41.1	3.2	8.5	2.6	49.1	7.2	64.1	10.0	75.1	16.0	51.2	18.1	60.0	8.7	53.0	11.6
AD-953331.1	68.0	1.2	8.8	1.7	60.3	5.5	92.6	24.7	151.3	18.2	88.8	33.3	85.2	21.0	87.4	5.6
AD-953323.1	66.8	5.0	9.1	1.7	64.2	2.1	109.8	19.9	93.6	2.2	53.0	7.3	74.7	4.9	77.0	11.6
AD-953351.1	21.2	2.3	9.2	9.5	39.8	6.9	74.4	8.0	49.7	3.2	26.0	2.5	41.2	11.0	63.6	8.2
AD-953386.1	31.8	1.6	9.3	1.0	65.3	6.3	87.4	5.1	38.7	0.4	50.4	11.0	82.9	17.7	67.9	13.0
AD-953394.1	35.4	2.0	9.5	5.1	50.8	5.3	72.7	3.3	66.5	16.5	49.7	10.5	77.2	14.7	57.8	21.7
AD-953359.1	36.4	3.8	9.7	2.9	46.9	6.3	72.9	7.4	74.8	9.6	46.2	6.0	63.9	10.8	50.7	7.9
AD-953329.1	68.0	10.2	9.7	1.7	59.7	1.6	100.3	22.8	94.3	7.1	56.9	16.4	76.7	10.0	79.8	9.0
AD-953361.1	45.2	2.9	10.4	8.6	53.6	4.8	68.4	5.4	78.6	10.9	50.2	11.3	68.6	9.3	47.8	9.6
AD-953319.1	100.2	2.8	10.6	1.4	71.5	10.3	161.5	76.4	189.6	19.4	69.0	22.5	84.3	4.7	93.2	18.2
AD-953360.1	96.2	10.8	10.7	1.5	49.6	5.2	76.7	6.2	140.9	16.5	69.1	20.5	82.4	9.0	54.9	2.8
AD-953324.1	63.0	2.8	11.2	4.8	53.8	4.5	96.6	27.2	131.1	18.6	67.5	16.9	86.3	18.2	75.5	18.1
AD-953378.1	57.9	8.3	11.5	2.3	72.2	7.6	92.4	6.2	47.1	10.1	55.3	8.2	85.7	17.9	60.5	14.4
AD-953369.1	43.6	4.7	11.8	6.0	64.4	10.3	79.8	5.1	68.6	9.7	56.3	9.1	70.2	5.4	58.7	14.7
AD-953347.1	77.6	5.1	11.9	3.7	63.3	7.7	66.5	16.2	112.3	25.0	62.1	13.1	62.8	13.8	76.4	6.3
AD-953365.1	28.7	4.1	12.3	3.5	35.7	4.9	61.7	7.9	36.6	7.3	23.6	5.0	56.5	3.9	50.9	4.6
AD-953374.1	10.7	0.3	12.3	18.3	35.8	27.4	33.8	7.4	30.0	3.5	33.2	4.8	39.2	4.0	46.2	7.9
AD-953384.1	57.1	2.9	12.9	4.8	76.3	9.0	82.4	5.1	86.2	5.2	67.4	3.8	105.9	23.9	66.1	13.2
AD-953376.1	57.8	2.7	12.9	2.0	81.7	9.3	94.3	1.0	69.2	14.7	73.1	23.1	96.7	8.4	70.3	10.8
AD-953354.1	49.1	5.5	13.5	5.6	67.9	5.6	141.1	30.9	40.5	6.7	42.2	10.8	57.0	6.1	78.8	9.6
AD-953385.1	65.0	3.9	13.5	2.0	79.8	8.9	97.1	13.1	115.8	16.5	107.5	18.6	124.6	8.8	71.9	7.1

AD-953346.1	38.0	3.2	14.1	11.9	56.3	4.7	68.3	13.8	58.6	8.1	42.7	7.4	53.9	11.6	75.2	5.3
AD-953366.1	28.1	3.0	14.3	18.9	47.6	4.2	72.4	7.9	47.0	5.3	32.5	6.0	40.4	8.8	61.7	14.1
AD-953382.1	67.1	5.3	14.6	3.6	80.8	7.7	99.5	6.7	143.5	30.8	67.6	18.2	91.3	11.9	67.0	12.6
AD-953320.1	65.2	3.4	14.7	6.0	69.8	9.1	139.3	11.6	121.6	7.8	55.2	11.1	97.9	7.0	92.3	10.4
AD-953379.1	64.5	8.5	17.0	5.4	76.3	3.5	85.5	6.7	60.1	12.9	68.0	26.1	85.4	3.5	49.6	12.0
AD-953321.1	66.2	5.0	17.1	13.7	58.7	5.7	125.7	34.8	111.0	19.6	59.2	14.5	72.7	12.4	80.3	11.7
AD-953377.1	55.4	3.9	17.2	8.0	75.0	6.1	83.8	4.1	54.9	8.5	57.6	9.1	82.9	6.1	70.7	12.3
AD-953392.1	88.8	1.4	17.5	2.0	90.9	10.8	96.0	3.6	125.6	16.1	102.0	20.4	117.0	26.2	88.2	14.3
AD-953373.1	35.7	3.9	17.7	12.7	41.4	3.3	61.2	9.4	56.7	9.0	50.8	5.4	66.6	5.1	70.4	14.3
AD-953364.1	22.5	1.9	18.1	6.4	35.7	2.4	53.4	3.8	21.2	2.6	20.1	5.9	30.5	4.3	45.0	7.9
AD-953330.1	56.3	6.5	18.2	8.1	54.0	2.8	97.5	23.3	109.0	14.5	69.9	11.8	68.7	8.6	74.6	9.6
AD-953353.1	30.9	2.4	19.3	14.9	51.1	3.9	145.6	33.7	59.1	11.7	45.4	10.7	57.3	8.9	80.5	6.8
AD-953343.1	28.4	1.6	19.4	24.7	31.5	2.1	50.2	12.1	51.1	7.7	41.1	4.8	50.6	3.0	76.9	6.2
AD-953390.1	82.4	4.8	19.8	2.3	92.7	10.4	103.4	7.6	132.1	19.0	96.0	20.4	114.6	24.4	80.3	14.4
AD-953345.1	26.9	4.4	20.4	16.6	51.9	6.3	91.9	13.0	35.7	10.4	33.1	6.6	37.6	9.9	65.9	6.8
AD-953358.1	30.5	1.7	20.6	17.0	40.7	6.0	66.2	3.7	67.1	7.3	46.2	13.7	62.8	16.0	52.4	10.8
AD-953383.1	58.5	4.0	21.4	9.2	65.7	5.7	83.3	3.1	70.5	9.4	65.2	10.6	82.7	14.0	80.7	8.9
AD-953372.1	34.3	4.8	24.0	7.7	45.9	5.8	65.7	4.7	52.6	5.2	42.1	13.1	65.9	9.1	54.7	6.6
AD-953328.1	54.5	3.9	24.1	19.0	60.6	5.7	112.1	3.8	137.7	50.8	66.1	5.8	82.7	13.1	79.1	7.2
AD-953393.1	42.8	3.6	25.9	33.0	63.6	6.1	87.9	3.4	49.7	9.2	56.8	6.9	81.0	6.8	74.0	14.3
AD-953307.1	39.3	2.0	26.1	2.3	50.3	3.0	144.4	30.6	49.9	4.0	34.1	7.3	65.1	4.0	56.8	9.9
AD-953308.1	36.9	6.6	26.3	1.3	50.9	3.7	136.2	32.8	30.3	7.1	24.2	4.4	53.4	4.8	42.3	8.9
AD-953327.1	63.7	9.2	27.4	29.5	52.5	1.5	108.8	24.5	85.5	42.1	48.8	10.7	72.2	10.9	82.3	7.2
AD-953335.1	77.1	5.8	28.3	19.0	53.0	4.4	115.1	32.1	144.1	17.3	72.8	17.2	84.8	11.6	95.4	8.0
AD-953414.1	21.5	1.7	28.3	1.6	41.8	4.6	61.5	8.3	40.1	2.5	31.3	7.9	49.3	12.3	66.0	17.8
AD-953412.1	16.3	0.7	28.4	3.6	33.1	5.3	65.1	4.0	37.5	11.0	35.3	3.6	35.8	9.0	70.7	14.2
AD-953411.1	15.4	2.0	29.5	3.7	42.7	5.0	65.5	6.0	30.9	9.0	26.2	4.3	48.9	7.9	57.2	13.3
AD-953410.1	16.4	1.2	29.6	2.0	44.7	3.6	68.0	2.7	26.2	3.8	26.4	7.0	49.8	9.2	55.9	17.7
AD-953408.1	21.0	1.4	29.7	2.3	38.4	4.8	72.1	6.4	33.1	4.7	35.5	2.9	60.9	14.6	80.9	23.6
AD-953326.1	53.8	7.2	30.2	17.6	50.4	3.4	115.3	25.4	115.2	12.1	59.7	19.5	77.5	18.1	83.0	11.6

AD-9533300.1	49.4	5.2	30.6	1.7	52.2	5.5	176.7	31.5	51.7	16.4	44.1	6.6	65.9	17.3	39.7	7.3
AD-9533389.1	90.9	7.3	31.6	16.2	93.6	8.0	99.4	7.4	144.1	18.2	126.7	8.2	114.4	15.0	93.8	22.2
AD-953415.1	23.3	1.8	32.0	1.8	41.3	3.0	62.8	8.8	65.9	6.6	52.5	5.9	53.3	18.2	70.5	19.8
AD-9533309.1	42.1	1.6	32.3	3.0	69.9	2.0	148.4	9.6	40.6	7.2	42.0	7.1	91.4	19.0	48.5	11.7
AD-9533391.1	78.3	7.4	32.9	32.3	86.1	7.2	95.6	4.9	108.7	4.5	93.3	10.9	119.0	24.5	87.2	15.4
AD-9533395.1	53.9	5.2	33.3	21.8	70.2	7.5	87.9	3.9	42.9	5.1	49.4	8.8	83.2	6.3	62.2	11.3
AD-9533303.1	48.8	2.8	34.0	9.2	44.4	3.8	133.6	33.0	69.9	7.6	42.4	3.8	62.7	7.0	54.4	12.6
AD-953405.1	37.6	9.8	34.2	5.3	42.1	8.8	60.5	3.6	58.3	17.4	37.6	7.0	59.1	16.6	78.3	6.9
AD-9533305.1	52.0	6.9	34.8	1.6	56.5	5.1	108.4	23.2	73.0	10.3	41.9	6.0	68.4	9.8	69.3	6.9
AD-9533380.1	63.5	8.0	35.1	28.6	72.8	5.2	84.6	3.4	54.0	2.4	49.6	9.1	82.2	16.6	54.1	9.0
AD-9533349.1	62.9	2.8	35.3	4.1	61.4	6.2	71.3	23.0	106.7	20.9	64.7	14.2	67.5	26.3	92.3	7.5
AD-9533381.1	66.3	2.9	35.5	22.1	83.5	7.5	99.8	6.3	80.8	10.0	67.8	8.9	99.2	18.4	76.9	21.1
AD-9533318.1	73.1	4.0	37.6	32.2	63.4	2.6	198.1	91.7	132.1	16.9	66.1	30.7	81.7	17.2	88.7	3.1
AD-9533348.1	46.6	2.7	38.4	9.6	52.5	5.4	136.3	31.4	46.5	14.1	38.9	9.4	48.8	9.2	74.5	10.8
AD-953409.1	24.1	1.4	39.4	2.8	46.7	7.0	76.5	7.7	32.7	3.5	28.5	4.8	59.1	9.8	65.9	21.4
AD-9533306.1	69.9	8.3	39.7	4.7	62.4	5.2	134.9	32.7	127.5	9.5	69.9	20.8	84.4	4.7	44.9	5.0
AD-9533316.1	59.6	4.5	40.3	3.9	54.4	3.5	94.5	8.4	129.3	20.3	58.5	9.4	72.2	12.8	58.6	15.8
AD-9533325.1	69.2	6.7	41.8	24.8	68.9	7.7	153.7	53.1	112.9	25.0	66.6	11.7	76.9	13.0	70.1	9.9
AD-9533299.1	64.9	6.3	42.3	2.6	70.3	5.0	164.5	59.7	67.8	20.4	65.1	16.9	83.0	9.2	50.0	7.5
AD-953416.1	29.1	3.7	42.4	3.1	41.8	3.8	53.8	4.6	79.4	10.1	51.0	9.1	57.1	5.1	63.4	7.3
AD-9533315.1	62.1	5.3	42.6	1.1	55.8	2.8	95.3	27.0	134.9	23.0	84.8	6.7	73.0	6.5	58.6	17.0
AD-9533314.1	55.4	5.5	42.6	2.8	55.8	3.3	115.4	15.1	106.7	3.2	62.9	8.0	81.7	8.5	53.3	21.1
AD-9533298.1	65.3	4.3	44.0	2.2	67.5	6.6	165.9	13.3	60.5	6.8	46.5	9.6	89.0	8.6	57.6	7.6
AD-953406.1	27.2	1.4	44.5	5.0	58.8	5.8	84.3	2.0	50.0	4.6	37.8	4.4	74.7	8.6	75.2	29.3
AD-9533399.1	32.1	2.3	45.5	1.4	44.3	3.6	64.6	2.8	84.3	9.4	43.2	8.2	80.6	5.7	79.7	20.7
AD-9533333.1	54.7	4.9	45.7	17.9	63.1	3.7	139.5	14.5	104.8	10.4	50.6	15.6	65.9	13.4	66.1	14.1
AD-9533313.1	57.3	3.7	45.9	2.5	64.6	2.4	107.6	22.5	81.2	19.1	61.7	8.4	89.7	4.0	83.2	4.5
AD-9533302.1	49.5	2.8	47.0	5.0	61.7	3.9	108.3	31.0	41.6	11.9	48.7	7.2	57.5	8.9	68.8	4.8
AD-9533317.1	76.9	5.3	50.0	3.1	72.6	9.3	145.3	34.8	77.9	18.1	60.9	12.4	71.3	9.7	50.4	14.7
AD-9533357.1	61.0	5.5	50.3	33.1	70.6	8.6	94.4	5.1	70.4	16.9	59.5	19.7	99.6	27.9	52.4	8.5

AD-953301.1	62.2	7.8	50.5	5.6	82.8	5.7	193.0	33.0	47.3	16.7	38.2	3.8	63.5	8.8	53.8	10.8
AD-953304.1	60.9	6.6	51.4	2.2	75.4	1.9	133.7	36.1	133.7	5.8	89.6	12.1	95.5	8.0	65.9	8.4
AD-953297.1	77.5	3.2	52.2	4.2	74.9	4.8	142.3	32.5	118.2	19.7	85.8	5.2	99.1	11.6	59.7	8.0
AD-953388.1	80.1	5.6	53.7	40.5	91.0	9.7	95.9	10.1	139.5	8.4	89.7	6.8	107.9	17.8	98.0	21.3
AD-953407.1	37.2	4.3	53.9	9.4	47.8	6.2	72.1	4.3	61.2	7.6	43.4	16.4	66.1	17.3	74.5	6.9
AD-953397.1	56.1	5.0	57.1	3.8	58.1	9.9	77.8	5.1	96.4	13.5	52.9	9.6	94.9	13.8	76.0	9.4
AD-953398.1	47.8	2.1	57.4	6.6	51.1	5.3	71.6	2.3	62.1	7.0	51.9	7.5	99.5	13.7	93.8	13.7
AD-953396.1	52.3	7.4	59.5	5.6	63.4	6.2	86.9	5.8	85.3	10.0	52.7	5.7	98.7	8.2	101.8	11.6
AD-953356.1	80.6	1.8	63.1	11.3	82.1	13.5	119.0	27.2	93.5	11.4	65.8	9.2	76.8	20.8	61.8	12.3
AD-953422.1	47.6	4.2	63.3	7.6	189.1	56.5	87.2	3.9	56.5	5.7	58.9	8.6	36.4	2.3	74.3	18.0
AD-953413.1	56.5	4.9	64.0	8.2	68.9	4.5	95.5	9.7	78.1	8.7	72.4	12.0	81.1	9.4	90.4	15.6
AD-953294.1	97.1	15.2	64.2	4.2	77.3	15.5	96.7	15.6	96.8	35.0	71.6	5.9	76.3	3.3	69.9	12.0
AD-953421.1	53.2	6.7	65.0	2.9	197.8	29.8	101.0	7.9	102.0	13.5	65.6	7.9	49.4	12.2	94.1	8.4
AD-953310.1	117.3	11.7	66.7	16.2	93.9	3.2	148.4	45.0	149.3	31.4	91.4	14.3	97.9	3.5	72.3	17.0
AD-953296.1	103.9	2.9	67.6	5.3	85.2	8.1	137.2	17.9	187.5	42.8	110.2	4.6	116.2	10.5	56.8	9.4
AD-953402.1	55.1	2.2	67.6	4.0	63.8	6.1	84.1	7.6	83.2	19.9	75.6	8.7	89.0	23.0	77.5	11.6
AD-953312.1	86.0	14.3	71.1	4.1	74.3	3.3	145.1	57.4	171.9	22.0	84.6	5.5	100.5	13.7	94.5	9.6
AD-953295.1	94.5	4.7	71.6	3.7	83.7	11.4	136.9	20.4	122.9	21.2	90.4	14.2	85.2	26.5	64.3	18.0
AD-953420.1	58.3	2.3	72.8	7.3	177.1	37.4	91.6	3.5	74.6	3.6	60.0	6.7	52.2	7.9	96.5	11.0
AD-953423.1	47.1	3.4	73.0	14.3	215.7	13.2	93.0	6.7	90.7	6.7	64.9	9.2	43.6	7.2	89.1	15.2
AD-953403.1	62.9	12.6	73.9	5.6	58.5	5.9	77.8	6.5	102.6	12.5	62.1	6.0	96.2	14.6	75.4	7.3
AD-953400.1	52.1	2.7	74.8	10.9	58.9	4.4	78.3	6.7	83.2	11.5	48.5	14.9	86.8	26.5	84.6	8.4
AD-953404.1	73.3	4.0	76.2	8.8	72.0	3.4	92.1	3.5	133.1	19.8	70.7	8.1	103.8	14.5	97.1	12.4
AD-953334.1	59.9	3.8	76.5	27.3	57.6	1.4	115.3	6.2	178.1	16.6	89.4	25.1	78.2	17.1	98.1	8.5
AD-953418.1	57.2	3.7	79.6	12.5	81.6	6.1	92.3	4.1	100.0	20.4	57.2	11.1	70.4	11.1	79.1	4.1
AD-953401.1	61.5	3.7	81.6	4.1	78.6	9.2	96.9	10.8	93.0	8.4	67.9	27.9	105.6	5.0	84.0	6.1
AD-953417.1	57.8	1.8	82.5	1.5	84.7	11.1	89.1	6.1	86.4	8.4	65.7	14.4	69.9	7.2	82.8	8.5
AD-953311.1	113.2	5.8	91.3	6.1	93.9	8.2	108.7	25.4	156.0	13.3	86.4	10.1	92.6	5.7	77.0	15.2
AD-953419.1	74.7	3.6	94.8	6.4	93.2	5.5	92.2	5.3	85.9	13.4	57.3	8.4	84.5	16.8	76.8	7.9

Table 6C. VEGF-A endogenous *in vitro* multi-dose screen with one set of exemplary human VEGF-A siRNAs

ARPE-19		hTERT RPE-1														
Sample Name	50 nM	StDev	10 nM	StDev	1 nM	StDev	0.1 nM	StDev	50 nM	StDev	10 nM	StDev	1 nM	StDev	0.1 nM	StDev
AD-953504.1	17.3	0.6	19.8	5.4	48.7	32.4	56.5	9.3	19.9	3.2	22.2	2.8	61.7	21.8	65.7	15.9
AD-953481.1	33.7	2.2	28.1	2.4	60.4	3.8	72.8	1.5	42.5	9.2	25.3	3.5	68.8	28.1	78.2	28.1
AD-953472.1	31.3	1.6	30.1	1.2	54.1	4.4	80.0	6.6	45.9	7.1	30.6	2.9	64.9	14.9	91.0	18.4
AD-953517.1	29.5	3.2	30.3	1.4	45.6	5.1	74.4	4.9	37.6	4.9	36.3	7.9	69.4	18.5	74.5	10.3
AD-953471.1	33.4	0.9	30.5	2.2	47.1	5.1	87.8	15.3	39.7	11.2	28.0	5.0	68.2	12.1	77.6	14.1
AD-953493.1	46.0	10.0	33.3	4.0	64.9	9.0	81.1	4.1	24.9	5.5	22.5	2.5	50.8	23.2	54.0	12.0
AD-953498.1	46.8	3.8	34.5	1.5	55.9	5.9	76.7	8.9	43.1	2.2	31.2	4.9	64.8	16.8	78.0	19.6
AD-953467.1	42.3	6.8	34.6	3.5	59.8	14.0	78.3	11.6	42.8	3.2	31.1	8.9	56.9	9.0	94.4	12.2
AD-953545.1	31.2	0.8	35.4	8.1	48.5	6.1	73.7	7.0	55.3	8.9	42.0	8.6	85.9	16.6	79.4	7.1
AD-953466.1	53.7	2.9	36.9	3.0	61.5	20.5	74.1	8.9	62.8	5.4	39.6	3.4	65.3	7.7	103.3	34.2
AD-953494.1	49.2	2.9	38.4	1.6	66.3	7.1	85.6	4.5	32.7	3.4	26.5	8.0	46.1	7.1	45.7	6.8
AD-953470.1	66.5	2.0	40.5	3.4	63.8	13.5	74.9	5.0	56.4	9.5	34.8	7.3	64.6	9.9	105.6	20.0
AD-953473.1	59.2	2.9	42.3	5.7	61.7	4.1	80.9	4.5	72.8	11.9	44.2	3.0	77.6	25.2	110.0	27.1
AD-953474.1	61.5	7.9	42.4	1.6	72.9	7.5	86.4	5.6	63.8	4.5	48.8	2.4	85.5	29.3	107.1	18.8
AD-953480.1	41.7	3.9	43.3	1.9	72.9	5.0	91.6	11.4	47.1	9.2	47.2	16.2	77.8	38.4	93.8	27.0
AD-953503.1	56.4	2.3	43.9	4.9	59.9	7.6	88.7	10.2	44.2	13.0	57.5	9.7	90.0	9.8	83.2	11.7
AD-953478.1	55.1	8.7	44.3	4.1	64.1	4.5	83.3	8.7	38.9	3.2	52.3	22.9	70.3	23.4	78.1	9.5
AD-953540.1	29.4	2.2	44.6	10.3	60.9	5.7	94.9	10.3	23.4	6.6	22.7	7.9	59.7	12.0	81.5	3.3
AD-953500.1	46.3	10.0	45.8	4.0	70.6	10.0	91.2	4.6	30.4	4.6	31.2	1.2	79.7	16.0	80.1	10.5
AD-953476.1	45.9	6.5	46.7	2.3	78.7	3.7	91.8	4.7	40.4	4.4	44.7	10.0	84.2	14.5	118.2	21.3
AD-953492.1	61.2	1.9	47.1	3.8	71.8	6.2	85.2	8.4	58.2	7.0	44.7	4.1	79.6	20.6	73.1	13.5
AD-953495.1	60.7	3.5	47.4	3.9	64.3	15.3	84.0	5.7	54.3	7.7	39.5	8.5	69.7	9.1	68.8	26.1
AD-953497.1	55.5	1.6	47.9	5.1	65.9	9.6	89.9	8.5	61.5	11.8	45.8	11.0	81.4	21.9	86.5	11.4
AD-953535.1	52.1	10.8	48.3	10.8	56.0	5.5	76.1	4.9	52.6	8.9	42.6	8.1	94.1	22.4	100.5	4.2
AD-953505.1	60.3	6.1	48.4	2.0	64.4	2.4	94.7	10.5	54.9	8.8	59.1	7.3	104.2	19.2	88.3	14.3
AD-953524.1	57.5	1.2	48.9	2.1	50.9	20.8	93.7	6.7	44.2	4.8	51.2	8.8	68.3	25.3	64.5	14.1

AD-953475.1	55.7	2.1	49.6	3.8	69.2	7.9	83.9	5.0	54.2	11.0	41.8	8.6	87.2	24.9	105.6	23.8
AD-953491.1	68.9	9.7	49.9	4.6	69.4	2.7	92.7	10.9	54.5	8.4	54.9	20.8	72.8	15.0	73.5	16.3
AD-953436.1	96.6	1.6	50.6	2.1	63.1	13.9	80.4	4.8	72.6	8.9	72.9	2.2	108.8	9.8	67.6	24.6
AD-953502.1	62.8	9.4	50.8	3.8	74.9	6.4	87.0	13.4	52.2	4.0	42.0	8.7	75.8	17.7	49.4	4.5
AD-953461.1	61.7	5.8	51.1	5.0	74.3	17.8	74.6	2.7	66.9	10.6	62.6	8.7	78.9	3.2	94.0	19.6
AD-953544.1	42.2	3.8	51.3	8.4	61.5	6.6	89.4	2.2	47.4	9.0	45.8	10.0	83.1	19.6	92.4	16.0
AD-953462.1	64.6	3.0	51.5	5.9	84.5	16.8	80.3	6.5	53.0	14.9	48.2	11.8	84.0	18.2	114.8	20.3
AD-953496.1	52.0	5.9	51.6	5.0	79.2	5.6	89.8	6.5	55.1	5.5	58.3	4.8	97.3	22.7	83.9	25.2
AD-953516.1	59.7	7.4	51.9	2.3	71.2	11.2	93.4	13.2	49.8	14.2	43.5	13.2	86.5	9.4	78.4	11.1
AD-953483.1	61.6	4.6	52.0	2.3	69.5	17.6	92.7	9.0	52.2	7.3	47.3	13.2	99.1	21.9	94.1	22.9
AD-953499.1	64.5	8.2	52.7	3.2	71.1	11.7	105.8	6.7	70.7	10.1	46.6	5.0	90.6	15.3	85.6	14.6
AD-953541.1	48.8	10.7	53.1	12.9	55.9	6.0	90.1	9.3	32.7	6.8	31.2	3.2	68.9	24.2	79.9	10.0
AD-953538.1	38.4	5.2	54.1	10.1	68.1	9.3	99.0	6.5	32.1	8.8	29.3	3.2	89.4	17.2	88.1	7.9
AD-953430.1	85.4	7.5	54.7	2.9	90.8	20.1	82.8	2.9	57.6	4.4	55.1	11.1	80.2	14.7	65.6	13.5
AD-953485.1	66.8	2.1	54.9	3.8	84.8	6.5	90.0	2.2	39.0	8.2	42.3	5.6	66.0	8.7	95.6	22.6
AD-953468.1	65.7	3.5	55.1	2.6	86.4	11.6	97.3	11.9	50.2	8.8	41.0	3.6	88.9	21.6	108.5	25.1
AD-953444.1	63.2	2.2	55.3	3.8	81.6	15.3	87.3	9.0	55.0	5.1	76.5	12.6	108.8	22.7	70.4	18.1
AD-953460.1	65.6	10.0	55.6	3.2	85.2	10.4	83.1	6.6	56.8	15.0	46.3	6.9	87.1	6.8	121.0	12.9
AD-953539.1	67.0	8.5	56.1	11.5	62.2	2.9	97.3	4.3	47.1	5.3	30.5	6.1	65.5	15.9	89.6	10.6
AD-953484.1	60.1	16.2	56.6	5.9	86.0	4.8	94.4	6.4	41.3	9.9	46.9	10.8	81.1	26.2	97.8	20.4
AD-953457.1	69.0	26.0	57.8	5.5	79.7	22.5	78.0	8.4	96.5	61.4	42.8	3.1	85.0	11.8	84.4	28.0
AD-953459.1	67.3	9.8	57.9	4.0	82.0	15.1	85.5	2.9	66.1	9.8	52.4	5.4	90.4	4.6	111.4	7.6
AD-953437.1	74.6	5.0	58.6	4.4	87.7	20.7	84.6	6.4	53.5	5.2	70.2	20.0	89.8	7.7	77.7	21.8
AD-953458.1	70.7	8.8	59.3	2.4	81.8	21.2	79.2	5.7	75.8	13.1	47.7	2.1	97.0	12.3	107.7	31.1
AD-953453.1	69.9	3.5	59.5	4.3	74.0	17.2	84.4	11.6	61.1	9.9	59.0	5.7	89.6	5.5	88.0	27.3
AD-953428.1	67.5	3.0	60.6	2.3	92.1	20.1	86.2	0.7	36.2	5.6	59.5	10.0	108.5	13.2	70.4	11.3
AD-953501.1	77.3	7.8	60.9	5.8	91.7	5.6	100.8	7.2	67.9	9.6	61.3	14.9	80.5	24.9	73.2	5.7
AD-953482.1	76.7	1.5	61.5	3.4	94.6	8.4	100.1	5.4	71.8	9.0	53.7	8.6	115.9	9.7	101.9	20.8
AD-953446.1	94.0	4.3	61.6	5.8	76.4	15.8	75.6	5.7	64.1	4.6	74.9	8.7	96.8	19.8	64.5	10.4
AD-953488.1	65.7	3.3	61.8	3.9	81.2	15.8	95.9	9.8	81.3	5.3	60.2	18.5	123.3	46.3	76.4	23.7

AD-953434.1	58.9	3.9	61.9	3.1	91.4	17.9	94.1	10.6	49.7	5.3	92.6	15.2	123.1	12.0	71.5	10.1
AD-953546.1	49.9	1.9	63.3	14.5	59.7	4.4	80.8	2.1	48.2	2.7	41.6	12.9	72.9	5.4	72.9	8.7
AD-953529.1	59.0	3.6	64.8	9.9	63.9	2.4	78.3	1.9	61.5	5.7	48.5	7.4	117.3	20.3	91.1	15.1
AD-953433.1	95.2	10.7	64.8	6.3	78.5	16.2	82.5	2.6	69.0	5.2	109.4	7.2	107.4	13.2	98.9	35.0
AD-953456.1	68.1	8.4	64.9	4.7	95.7	22.5	94.1	2.7	86.8	14.7	56.3	7.0	89.1	10.7	89.1	12.9
AD-953435.1	69.8	3.4	65.1	4.1	88.1	18.6	92.9	4.8	57.5	9.2	75.3	5.7	104.3	2.4	71.9	13.2
AD-953438.1	70.2	4.8	66.4	5.8	105.5	19.6	88.2	3.9	46.0	7.7	61.7	19.7	90.1	14.9	71.7	16.9
AD-953452.1	80.0	5.5	66.9	6.7	96.6	21.5	89.5	10.8	53.2	3.6	46.9	7.7	94.3	14.7	104.6	25.8
AD-953489.1	86.9	6.5	69.3	5.5	89.1	10.0	97.0	8.7	82.0	16.1	80.6	15.6	125.9	15.7	77.4	19.4
AD-953445.1	104.1	7.0	71.5	3.4	88.6	21.2	85.2	10.1	68.1	3.0	91.0	8.8	103.1	9.2	80.5	32.1
AD-953432.1	62.6	4.1	71.6	4.0	106.7	23.0	109.1	13.6	38.2	5.3	69.3	6.0	104.2	19.0	88.8	34.4
AD-953509.1	96.2	8.8	71.8	2.2	68.5	36.5	93.1	7.2	71.0	33.3	70.4	7.3	77.7	11.3	65.4	12.1
AD-953490.1	89.4	6.4	72.2	2.5	85.2	6.8	95.5	8.7	109.5	9.8	68.7	8.2	106.9	14.9	74.4	6.7
AD-953448.1	67.8	3.6	72.7	5.1	101.5	20.3	94.8	9.3	76.1	25.3	61.8	6.4	110.6	35.5	79.5	29.6
AD-953450.1	78.6	2.3	72.8	5.4	96.9	14.3	91.0	7.6	72.1	7.7	53.3	4.3	120.8	11.3	117.2	41.1
AD-953443.1	96.4	8.9	73.3	2.2	96.4	22.9	90.7	4.5	60.8	3.2	100.7	16.4	95.8	18.2	83.7	14.5
AD-953525.1	81.5	6.2	73.4	4.5	79.8	16.8	90.4	2.8	53.0	4.5	69.3	8.5	86.0	16.0	90.0	8.6
AD-953523.1	74.3	4.9	73.4	8.8	88.1	6.8	100.9	5.1	58.3	15.3	91.1	6.6	116.2	14.1	78.2	3.5
AD-953507.1	78.1	8.2	73.7	5.3	86.3	6.8	98.8	5.4	51.1	14.2	64.7	6.5	104.2	32.5	75.3	23.7
AD-953451.1	87.6	7.6	74.0	8.2	92.4	16.6	90.3	3.1	95.8	23.0	56.1	5.2	112.4	8.5	110.3	6.9
AD-953429.1	91.2	8.9	74.2	4.9	99.8	24.4	93.0	7.0	57.0	9.1	66.7	10.2	99.6	11.7	79.4	16.7
AD-953469.1	84.5	11.2	74.6	5.1	109.2	18.8	95.6	5.9	75.1	4.5	62.7	8.0	88.1	7.8	117.5	17.4
AD-953463.1	88.7	17.1	74.8	4.8	101.9	20.8	99.2	5.1	70.1	8.6	75.6	20.8	80.2	25.5	88.4	11.1
AD-953454.1	106.1	7.0	74.9	6.7	95.6	26.8	86.4	9.1	76.3	20.1	67.7	21.9	95.9	14.3	84.0	35.8
AD-953455.1	99.0	14.1	75.0	5.4	101.7	25.0	98.1	5.5	81.5	17.4	72.9	19.3	76.3	14.6	69.1	15.5
AD-953511.1	83.7	3.8	75.3	6.2	86.7	5.4	100.7	8.8	76.0	31.8	71.6	10.7	131.4	22.1	94.7	13.1
AD-953447.1	95.2	8.5	75.6	4.2	101.4	18.3	89.6	4.2	67.5	9.6	73.0	10.4	75.9	14.6	76.1	16.4
AD-953424.1	78.8	3.7	75.8	8.2	96.4	26.2	99.3	5.8	56.2	9.0	98.3	31.6	112.0	18.9	68.1	16.5
AD-953506.1	82.9	3.4	76.4	3.9	94.6	10.2	98.2	7.0	54.4	7.9	80.4	12.3	104.5	27.0	85.1	2.6
AD-953537.1	71.6	3.2	76.4	16.4	81.7	10.1	93.7	6.6	61.5	11.6	52.7	14.9	104.7	9.9	102.3	8.2

AD-953477.1	104.2	11.7	76.5	4.8	93.7	6.9	90.6	5.6	77.5	20.8	62.6	12.8	75.1	22.1	105.4	29.2
AD-953479.1	90.5	8.9	77.0	10.7	99.9	16.6	109.0	9.6	99.6	9.7	74.8	9.6	116.9	25.5	104.0	21.8
AD-953439.1	102.3	7.6	77.2	4.5	100.8	26.6	97.8	5.7	68.0	8.2	80.5	24.1	72.4	18.5	66.2	17.0
AD-953431.1	86.4	7.7	77.5	7.5	116.2	20.7	93.5	15.3	52.4	2.4	45.7	9.6	71.9	3.0	62.8	10.1
AD-953442.1	89.4	4.5	78.2	5.5	99.8	20.9	90.2	7.4	69.0	13.2	95.2	19.1	119.3	10.1	77.5	19.9
AD-953449.1	81.5	5.9	78.3	5.3	95.1	23.3	90.1	7.6	82.6	15.4	72.5	14.2	113.9	14.0	93.2	12.8
AD-953510.1	94.1	6.6	78.6	6.2	85.2	8.5	88.6	4.2	62.7	11.1	74.3	3.6	73.1	12.6	30.5	6.0
AD-953514.1	98.5	10.4	78.8	9.3	95.6	4.4	89.4	4.6	80.1	19.3	89.0	3.5	118.7	18.7	94.8	19.4
AD-953508.1	96.9	7.3	78.9	7.1	96.5	24.7	98.7	8.7	68.5	15.8	76.9	13.9	94.3	15.5	75.2	11.5
AD-953531.1	70.3	2.0	80.7	17.0	82.8	4.0	90.6	4.3	80.9	15.6	62.5	12.3	98.0	12.4	73.4	7.0
AD-953427.1	105.8	12.1	81.1	4.6	91.0	25.6	90.0	3.7	65.3	3.7	100.2	12.6	109.0	17.8	66.6	15.2
AD-953512.1	94.6	2.1	83.9	4.5	91.3	10.6	96.7	7.7	84.8	13.3	84.0	11.0	129.5	10.3	88.3	15.8
AD-953533.1	102.2	9.2	85.2	21.1	82.6	15.3	108.6	13.4	85.5	12.3	66.0	13.3	89.2	14.1	73.0	12.3
AD-953464.1	76.9	3.8	86.1	6.5	104.6	21.8	99.9	10.3	110.5	10.6	74.5	5.0	87.7	18.7	111.9	6.1
AD-953542.1	51.8	2.5	86.3	24.8	66.0	11.3	98.1	17.1	54.8	9.9	69.8	2.3	95.8	13.9	104.4	4.4
AD-953426.1	102.2	10.9	87.8	5.7	103.4	24.0	97.1	2.0	67.3	5.4	120.7	18.0	117.5	16.3	74.5	27.0
AD-953515.1	92.6	5.7	88.4	6.2	84.6	21.4	98.2	9.4	95.5	21.8	84.9	10.3	124.9	28.4	86.9	4.2
AD-953487.1	99.3	9.8	88.7	12.4	90.1	13.7	95.1	3.2	106.9	17.5	88.1	5.6	118.9	35.4	57.1	14.7
AD-953521.1	104.2	20.4	89.0	1.5	109.1	13.9	96.2	9.4	76.6	12.8	89.5	10.4	131.6	23.9	81.8	10.5
AD-953425.1	81.5	13.2	90.2	4.0	99.5	24.2	94.8	6.2	63.6	4.3	114.5	27.3	142.3	60.9	75.3	25.7
AD-953536.1	75.4	13.1	90.2	23.7	86.6	4.9	98.4	8.1	75.0	8.5	58.1	20.2	120.5	32.6	96.6	11.8
AD-953465.1	97.2	10.0	91.4	6.6	114.1	30.7	91.7	5.7	92.3	7.4	78.6	6.8	99.2	29.1	131.0	23.9
AD-953552.1	82.6	7.9	92.5	22.4	88.2	4.8	102.3	6.4	86.4	15.8	85.2	16.6	55.7	16.7	89.0	12.2
AD-953528.1	87.5	15.0	93.5	11.1	83.9	8.8	85.7	4.5	111.2	40.7	69.5	16.7	142.9	10.9	103.3	8.0
AD-953519.1	107.5	2.3	93.5	4.8	96.1	5.2	91.0	3.3	92.7	9.0	113.7	6.9	146.7	24.6	121.8	38.4
AD-953486.1	105.6	3.7	94.2	5.6	103.9	8.6	96.7	6.1	75.6	1.5	106.1	34.1	83.7	17.1	78.1	21.7
AD-953522.1	97.7	9.0	94.3	4.2	100.0	16.6	99.0	8.4	98.8	21.3	87.2	16.4	106.8	15.9	84.1	7.4
AD-953530.1	76.4	4.7	94.3	19.0	90.2	8.9	93.8	9.9	72.4	16.7	67.0	12.1	93.5	11.7	93.3	11.8
AD-953513.1	104.1	3.5	95.5	7.9	92.8	9.4	103.5	10.8	90.2	28.8	76.6	6.8	144.6	24.5	101.7	12.6
AD-953441.1	97.5	8.0	95.5	5.0	114.8	18.2	106.5	8.7	63.8	4.1	105.6	4.8	125.4	24.0	80.4	27.5

AD-953440.1	87.8	6.4	95.5	12.2	112.8	26.2	97.9	1.2	83.3	7.9	106.5	13.4	118.0	10.0	75.4	27.2
AD-953518.1	91.0	4.9	96.1	3.4	99.6	2.8	93.9	12.4	96.6	24.0	91.4	16.4	126.5	19.7	108.8	16.1
AD-953520.1	92.8	7.3	96.1	3.8	99.9	18.5	99.9	7.3	91.8	18.0	89.3	13.6	140.3	21.3	96.0	17.7
AD-953532.1	92.3	7.2	99.5	16.4	96.9	11.9	93.0	4.9	87.9	12.7	67.9	9.0	89.9	24.8	70.6	13.2
AD-953548.1	85.7	8.0	100.5	20.0	89.8	7.6	99.4	7.1	58.8	8.9	67.7	24.6	80.1	6.0	78.0	9.0
AD-953527.1	91.5	2.8	101.9	15.1	92.3	14.5	102.6	4.5	113.8	41.2	69.2	18.2	132.4	36.0	108.0	10.6
AD-953551.1	91.4	4.5	103.0	24.3	94.8	1.1	101.1	5.4	130.4	41.4	78.2	20.9	65.8	13.8	102.2	11.8
AD-953553.1	93.9	1.2	103.2	25.6	93.3	6.6	100.2	4.2	88.5	10.1	93.5	20.0	65.1	15.8	93.0	13.6
AD-953547.1	89.1	3.6	104.0	18.7	94.3	7.6	97.6	3.0	65.0	6.4	60.7	16.1	85.8	9.7	86.6	8.6
AD-953526.1	88.7	5.7	110.0	23.2	95.7	3.2	100.8	12.4	117.9	52.9	75.4	16.8	115.9	12.6	102.1	10.6
AD-953549.1	94.4	8.8	113.8	25.9	70.6	23.4	106.6	12.7	54.1	8.2	55.2	18.7	85.6	31.6	81.4	15.2
AD-953534.1	102.5	8.5	117.9	27.3	95.0	14.1	79.9	5.5	137.0	23.5	81.4	20.8	141.1	19.1	103.4	12.1
AD-953543.1	99.3	3.5	118.0	17.9	89.7	4.0	96.9	4.6	111.5	41.1	99.7	30.4	123.8	17.6	104.4	15.0
AD-953550.1	96.0	5.8	121.6	19.6	98.9	12.3	99.0	9.0	119.6	20.5	101.5	20.0	52.7	10.9	93.6	13.1

The results of the multi-dose screen in African green monkey kidney cells (Cos-7) transfected with Cynomolgus monkey VEGF-A with a set of exemplary rat VEGF-A siRNAs are shown in Table 7A (correspond to siRNAs in Table 5A and Table 5B). The results of the multi-dose screen in Cos-7 cells transfected with mouse VEGF-A with a set of exemplary rat VEGF-A siRNAs are shown in Table 7B (correspond to siRNAs in Table 5A and Table 5B). The multi-dose experiments were performed at 10 nM, 1 nM, and 0.1 nM final duplex concentrations and the data are expressed as percent message remaining relative to non-targeting control.

Table 7A. Cynomolgus monkey VEGF-A *in vitro* multi-dose screen with one set of exemplary rat VEGF-A siRNAs

Duplex Name	Average	StDev	Dose	Dose Unit
AD-579911.1	21.79	0.50	10	nM
AD-579912.1	20.38	3.81	10	nM
AD-579913.1	16.71	8.39	10	nM
AD-579914.1	45.98	4.11	10	nM
AD-579915.1	35.03	7.59	10	nM
AD-579916.1	12.14	1.83	10	nM
AD-579917.1	25.40	3.24	10	nM
AD-579918.1	26.56	2.53	10	nM
AD-579919.1	10.58	2.15	10	nM
AD-579921.1	12.64	2.73	10	nM
AD-579922.1	13.78	0.77	10	nM
AD-579923.1	17.37	1.62	10	nM
AD-579924.1	49.49	4.24	10	nM
AD-579925.1	10.62	1.31	10	nM
AD-579926.1	13.23	2.83	10	nM
AD-579927.1	25.34	3.60	10	nM
AD-579929.1	26.33	1.74	10	nM
AD-579930.1	81.28	12.54	10	nM
AD-579931.1	41.52	7.38	10	nM
AD-579932.1	12.14	3.92	10	nM
AD-579933.1	30.75	3.29	10	nM
AD-579934.1	186.16	29.32	10	nM
AD-579935.1	67.60	6.57	10	nM
AD-579936.1	81.10	20.59	10	nM
AD-579937.1	25.95	3.27	10	nM
AD-579938.1	60.65	8.90	10	nM

AD-579939.1	72.01	14.89	10	nM
AD-579940.1	96.52	8.39	10	nM
AD-579941.1	106.40	13.04	10	nM
AD-579942.1	61.87	12.12	10	nM
AD-579943.1	12.46	4.75	10	nM
AD-579944.1	28.49	4.13	10	nM
AD-579945.1	70.53	8.74	10	nM
AD-579946.1	24.47	6.19	10	nM
AD-579947.1	68.58	4.38	10	nM
AD-579948.1	77.63	5.92	10	nM
AD-579949.1	96.51	8.80	10	nM
AD-579950.1	230.10	21.51	10	nM
AD-579951.1	66.36	16.79	10	nM
AD-579953.1	18.42	5.42	10	nM
AD-579954.1	21.24	4.31	10	nM
AD-579955.1	69.32	6.99	10	nM
AD-579956.1	99.49	25.18	10	nM
AD-579957.1	49.05	14.80	10	nM
AD-579958.1	88.74	8.73	10	nM
AD-579959.1	100.41	9.53	10	nM
AD-579960.1	39.31	3.68	10	nM
AD-579961.1	96.81	13.20	10	nM
AD-579962.1	53.43	6.50	10	nM
AD-579963.1	21.24	3.25	10	nM
AD-579964.1	17.83	7.13	10	nM
AD-579965.1	92.27	14.22	10	nM
AD-579966.1	88.97	9.79	10	nM
AD-579967.1	47.49	7.04	10	nM
AD-579968.1	76.96	8.70	10	nM
AD-579969.1	90.81	8.30	10	nM
AD-579970.1	104.42	26.45	10	nM
AD-579971.1	14.37	6.47	10	nM
AD-579972.1	57.43	2.61	10	nM
AD-579973.1	103.95	3.97	10	nM
AD-579974.1	81.04	3.86	10	nM
AD-579975.1	33.28	7.01	10	nM
AD-579976.1	79.49	2.88	10	nM
AD-579977.1	80.67	6.29	10	nM
AD-579978.1	66.72	3.59	10	nM
AD-579979.1	92.24	3.77	10	nM
AD-579980.1	25.30	3.08	10	nM

AD-579981.1	48.69	11.03	10	nM
AD-579982.1	49.50	15.70	10	nM
AD-579983.1	10.78	4.14	10	nM
AD-579984.1	16.79	1.90	10	nM
AD-579985.1	11.35	0.96	10	nM
AD-579986.1	33.51	4.42	10	nM
AD-579987.1	26.04	3.89	10	nM
AD-579988.1	30.67	3.01	10	nM
AD-579989.1	33.51	6.72	10	nM
AD-579990.1	72.51	4.50	10	nM
AD-579992.1	61.70	6.74	10	nM
AD-579993.1	92.69	10.40	10	nM
AD-579995.1	30.40	4.51	10	nM
AD-579996.1	94.02	11.86	10	nM
AD-579997.1	34.79	5.90	10	nM
AD-579998.1	31.10	6.52	10	nM
AD-579999.1	137.05	8.03	10	nM
AD-580000.1	162.84	26.73	10	nM
AD-580001.1	125.00	7.31	10	nM
AD-580002.1	186.90	14.34	10	nM
AD-579911.1	34.63	4.90	1	nM
AD-579912.1	31.99	3.89	1	nM
AD-579913.1	36.38	2.19	1	nM
AD-579914.1	47.66	5.91	1	nM
AD-579915.1	33.92	0.98	1	nM
AD-579916.1	25.64	5.85	1	nM
AD-579917.1	38.41	8.43	1	nM
AD-579918.1	37.12	9.78	1	nM
AD-579919.1	13.33	2.62	1	nM
AD-579921.1	24.01	3.06	1	nM
AD-579922.1	21.65	1.29	1	nM
AD-579923.1	32.00	1.21	1	nM
AD-579924.1	74.46	5.43	1	nM
AD-579925.1	27.19	4.59	1	nM
AD-579926.1	23.17	2.37	1	nM
AD-579927.1	44.62	10.37	1	nM
AD-579929.1	32.40	3.90	1	nM
AD-579930.1	82.85	10.31	1	nM
AD-579931.1	53.35	11.21	1	nM
AD-579932.1	25.97	4.61	1	nM
AD-579933.1	64.26	11.63	1	nM

AD-579934.1	110.08	21.79	1	nM
AD-579935.1	75.45	3.94	1	nM
AD-579936.1	88.42	7.56	1	nM
AD-579937.1	25.63	2.94	1	nM
AD-579938.1	67.82	2.00	1	nM
AD-579939.1	69.81	7.16	1	nM
AD-579940.1	99.17	5.18	1	nM
AD-579941.1	108.34	7.84	1	nM
AD-579942.1	70.36	12.47	1	nM
AD-579943.1	26.50	3.47	1	nM
AD-579944.1	35.87	5.32	1	nM
AD-579945.1	82.17	15.84	1	nM
AD-579946.1	28.27	2.22	1	nM
AD-579947.1	77.96	16.94	1	nM
AD-579948.1	79.99	3.99	1	nM
AD-579949.1	108.10	12.09	1	nM
AD-579950.1	134.00	16.20	1	nM
AD-579951.1	66.05	9.65	1	nM
AD-579953.1	27.50	5.68	1	nM
AD-579954.1	20.74	3.51	1	nM
AD-579955.1	74.44	17.09	1	nM
AD-579956.1	113.45	9.64	1	nM
AD-579957.1	73.78	1.80	1	nM
AD-579958.1	94.21	11.02	1	nM
AD-579959.1	95.73	17.31	1	nM
AD-579960.1	37.92	6.36	1	nM
AD-579961.1	95.86	5.08	1	nM
AD-579962.1	79.16	6.58	1	nM
AD-579963.1	22.85	4.33	1	nM
AD-579964.1	23.33	2.88	1	nM
AD-579965.1	96.34	24.13	1	nM
AD-579966.1	85.86	12.83	1	nM
AD-579967.1	59.03	6.42	1	nM
AD-579968.1	72.33	7.43	1	nM
AD-579969.1	86.79	3.22	1	nM
AD-579970.1	100.80	8.64	1	nM
AD-579971.1	12.62	2.38	1	nM
AD-579972.1	52.06	7.34	1	nM
AD-579973.1	96.38	18.09	1	nM
AD-579974.1	90.54	6.77	1	nM
AD-579975.1	54.49	4.18	1	nM

AD-579976.1	83.49	18.12	1	nM
AD-579977.1	86.21	10.51	1	nM
AD-579978.1	73.79	28.62	1	nM
AD-579979.1	102.91	17.40	1	nM
AD-579980.1	22.61	1.11	1	nM
AD-579981.1	62.79	8.71	1	nM
AD-579982.1	57.63	7.73	1	nM
AD-579983.1	17.63	2.73	1	nM
AD-579984.1	25.44	1.54	1	nM
AD-579985.1	20.01	6.16	1	nM
AD-579986.1	45.92	2.90	1	nM
AD-579987.1	35.60	5.94	1	nM
AD-579988.1	41.30	3.29	1	nM
AD-579989.1	35.25	1.19	1	nM
AD-579990.1	75.79	12.51	1	nM
AD-579992.1	70.19	10.59	1	nM
AD-579993.1	81.86	8.27	1	nM
AD-579995.1	32.90	4.47	1	nM
AD-579996.1	91.93	9.06	1	nM
AD-579997.1	54.91	2.41	1	nM
AD-579998.1	35.62	5.31	1	nM
AD-579999.1	105.80	11.56	1	nM
AD-580000.1	151.28	8.84	1	nM
AD-580001.1	117.48	17.60	1	nM
AD-580002.1	148.64	32.44	1	nM
AD-579911.1	60.59	5.99	0.1	nM
AD-579912.1	58.68	4.12	0.1	nM
AD-579913.1	64.23	5.02	0.1	nM
AD-579914.1	74.48	8.13	0.1	nM
AD-579915.1	56.70	3.72	0.1	nM
AD-579916.1	41.93	5.43	0.1	nM
AD-579917.1	78.90	9.40	0.1	nM
AD-579918.1	66.57	10.31	0.1	nM
AD-579919.1	29.08	2.79	0.1	nM
AD-579921.1	59.28	4.60	0.1	nM
AD-579922.1	56.67	8.89	0.1	nM
AD-579923.1	75.33	12.81	0.1	nM
AD-579924.1	100.79	20.47	0.1	nM
AD-579925.1	72.05	13.30	0.1	nM
AD-579926.1	63.98	8.75	0.1	nM
AD-579927.1	78.12	11.58	0.1	nM

AD-579929.1	67.27	19.11	0.1	nM
AD-579930.1	96.27	17.88	0.1	nM
AD-579931.1	75.81	15.09	0.1	nM
AD-579932.1	61.06	2.54	0.1	nM
AD-579933.1	85.95	8.05	0.1	nM
AD-579934.1	100.61	4.77	0.1	nM
AD-579935.1	88.00	10.57	0.1	nM
AD-579936.1	88.13	9.64	0.1	nM
AD-579937.1	55.87	4.99	0.1	nM
AD-579938.1	90.35	12.54	0.1	nM
AD-579939.1	100.22	5.50	0.1	nM
AD-579940.1	117.60	9.00	0.1	nM
AD-579941.1	100.53	13.72	0.1	nM
AD-579942.1	100.72	12.00	0.1	nM
AD-579943.1	41.23	3.38	0.1	nM
AD-579944.1	73.67	9.65	0.1	nM
AD-579945.1	101.57	13.70	0.1	nM
AD-579946.1	42.00	1.99	0.1	nM
AD-579947.1	88.52	29.57	0.1	nM
AD-579948.1	94.78	13.34	0.1	nM
AD-579949.1	106.50	4.63	0.1	nM
AD-579950.1	112.38	10.41	0.1	nM
AD-579951.1	81.88	7.61	0.1	nM
AD-579953.1	65.43	5.35	0.1	nM
AD-579954.1	29.05	3.98	0.1	nM
AD-579955.1	101.64	8.13	0.1	nM
AD-579956.1	109.12	12.60	0.1	nM
AD-579957.1	95.19	6.14	0.1	nM
AD-579958.1	99.02	14.55	0.1	nM
AD-579959.1	96.08	7.16	0.1	nM
AD-579960.1	65.43	20.16	0.1	nM
AD-579961.1	89.02	11.37	0.1	nM
AD-579962.1	107.63	11.06	0.1	nM
AD-579963.1	54.55	6.58	0.1	nM
AD-579964.1	37.19	5.60	0.1	nM
AD-579965.1	93.32	9.87	0.1	nM
AD-579966.1	93.21	13.54	0.1	nM
AD-579967.1	78.97	5.07	0.1	nM
AD-579968.1	83.13	8.48	0.1	nM
AD-579969.1	97.62	21.40	0.1	nM
AD-579970.1	102.49	8.36	0.1	nM

AD-579971.1	22.84	3.85	0.1	nM
AD-579972.1	83.71	13.31	0.1	nM
AD-579973.1	97.02	12.16	0.1	nM
AD-579974.1	87.05	8.86	0.1	nM
AD-579975.1	85.49	9.25	0.1	nM
AD-579976.1	89.61	16.73	0.1	nM
AD-579977.1	93.52	7.83	0.1	nM
AD-579978.1	87.68	5.19	0.1	nM
AD-579979.1	93.22	6.02	0.1	nM
AD-579980.1	39.04	7.41	0.1	nM
AD-579981.1	75.66	11.68	0.1	nM
AD-579982.1	90.44	10.96	0.1	nM
AD-579983.1	50.03	2.51	0.1	nM
AD-579984.1	58.06	3.26	0.1	nM
AD-579985.1	33.30	3.60	0.1	nM
AD-579986.1	74.91	4.29	0.1	nM
AD-579987.1	71.15	8.39	0.1	nM
AD-579988.1	81.86	6.80	0.1	nM
AD-579989.1	59.63	7.75	0.1	nM
AD-579990.1	95.13	9.94	0.1	nM
AD-579992.1	94.26	5.07	0.1	nM
AD-579993.1	99.78	15.90	0.1	nM
AD-579995.1	73.91	9.98	0.1	nM
AD-579996.1	101.07	13.27	0.1	nM
AD-579997.1	89.33	7.03	0.1	nM
AD-579998.1	60.03	5.93	0.1	nM
AD-579999.1	109.04	17.76	0.1	nM
AD-580000.1	108.28	13.14	0.1	nM
AD-580001.1	88.49	11.96	0.1	nM
AD-580002.1	122.07	18.09	0.1	nM

Table 7B. Mouse VEGF-A *in vitro* multi-dose screen with one set of exemplary rat VEGF-A siRNAs

Duplex Name	Average	StDev	Dose	Dose Unit
AD-579911.1	21.27	3.91	10	nM
AD-579912.1	16.53	5.79	10	nM
AD-579913.1	16.73	4.22	10	nM
AD-579914.1	16.51	1.15	10	nM
AD-579915.1	18.33	6.95	10	nM
AD-579916.1	25.18	1.82	10	nM

AD-579917.1	12.22	1.48	10	nM
AD-579918.1	11.07	2.65	10	nM
AD-579919.1	12.63	1.67	10	nM
AD-579921.1	11.45	2.37	10	nM
AD-579922.1	14.90	3.21	10	nM
AD-579923.1	13.67	3.59	10	nM
AD-579924.1	26.37	2.49	10	nM
AD-579925.1	10.16	1.07	10	nM
AD-579926.1	14.22	0.82	10	nM
AD-579927.1	32.32	5.45	10	nM
AD-579929.1	22.15	6.29	10	nM
AD-579930.1	74.90	13.83	10	nM
AD-579931.1	53.69	19.88	10	nM
AD-579932.1	24.54	2.62	10	nM
AD-579933.1	20.31	4.52	10	nM
AD-579934.1	36.61	3.37	10	nM
AD-579935.1	24.55	4.10	10	nM
AD-579936.1	22.50	4.65	10	nM
AD-579937.1	32.75	3.55	10	nM
AD-579938.1	13.39	2.36	10	nM
AD-579939.1	4.62	0.19	10	nM
AD-579940.1	3.68	1.38	10	nM
AD-579941.1	8.87	1.96	10	nM
AD-579942.1	3.71	1.54	10	nM
AD-579943.1	11.89	1.92	10	nM
AD-579944.1	12.26	1.40	10	nM
AD-579945.1	16.73	1.86	10	nM
AD-579946.1	18.67	5.27	10	nM
AD-579947.1	6.39	1.71	10	nM
AD-579948.1	27.00	3.21	10	nM
AD-579949.1	35.57	2.31	10	nM
AD-579950.1	53.80	4.29	10	nM
AD-579951.1	17.89	3.43	10	nM
AD-579953.1	24.48	3.96	10	nM
AD-579954.1	21.78	1.63	10	nM
AD-579955.1	30.54	3.58	10	nM
AD-579956.1	27.17	1.58	10	nM
AD-579957.1	16.61	1.30	10	nM
AD-579958.1	53.03	4.43	10	nM
AD-579959.1	40.73	3.55	10	nM
AD-579960.1	41.68	1.59	10	nM

AD-579961.1	29.58	7.59	10	nM
AD-579962.1	19.90	1.25	10	nM
AD-579963.1	14.55	3.30	10	nM
AD-579964.1	23.53	4.62	10	nM
AD-579965.1	5.85	1.35	10	nM
AD-579966.1	3.37	0.46	10	nM
AD-579967.1	8.12	3.03	10	nM
AD-579968.1	15.39	2.69	10	nM
AD-579969.1	41.77	5.27	10	nM
AD-579970.1	35.40	4.42	10	nM
AD-579971.1	9.46	1.20	10	nM
AD-579972.1	13.66	4.21	10	nM
AD-579973.1	15.20	4.13	10	nM
AD-579974.1	3.60	1.49	10	nM
AD-579975.1	3.08	0.33	10	nM
AD-579976.1	7.90	0.37	10	nM
AD-579977.1	22.23	1.40	10	nM
AD-579978.1	15.03	2.22	10	nM
AD-579979.1	29.83	5.08	10	nM
AD-579980.1	25.34	2.41	10	nM
AD-579981.1	20.80	1.40	10	nM
AD-579982.1	20.12	8.04	10	nM
AD-579983.1	22.13	4.26	10	nM
AD-579984.1	11.34	1.30	10	nM
AD-579985.1	10.84	0.91	10	nM
AD-579986.1	22.36	1.53	10	nM
AD-579987.1	26.77	5.29	10	nM
AD-579988.1	25.91	6.97	10	nM
AD-579989.1	17.89	1.51	10	nM
AD-579990.1	29.33	3.43	10	nM
AD-579992.1	19.38	7.67	10	nM
AD-579993.1	23.19	0.70	10	nM
AD-579995.1	4.97	1.31	10	nM
AD-579996.1	63.08	6.91	10	nM
AD-579997.1	26.46	4.46	10	nM
AD-579998.1	17.58	4.81	10	nM
AD-579999.1	33.79	5.04	10	nM
AD-580000.1	28.19	4.07	10	nM
AD-580001.1	23.17	4.55	10	nM
AD-580002.1	51.58	4.73	10	nM
AD-579911.1	29.66	4.64	1	nM

AD-579912.1	26.43	3.94	1	nM
AD-579913.1	40.12	5.03	1	nM
AD-579914.1	24.93	2.78	1	nM
AD-579915.1	34.06	4.64	1	nM
AD-579916.1	45.46	4.47	1	nM
AD-579917.1	19.16	2.98	1	nM
AD-579918.1	16.77	1.65	1	nM
AD-579919.1	17.09	1.57	1	nM
AD-579921.1	21.90	0.76	1	nM
AD-579922.1	24.16	3.67	1	nM
AD-579923.1	28.64	5.98	1	nM
AD-579924.1	54.14	8.12	1	nM
AD-579925.1	27.88	2.54	1	nM
AD-579926.1	29.26	2.01	1	nM
AD-579927.1	44.60	5.25	1	nM
AD-579929.1	31.53	4.15	1	nM
AD-579930.1	93.72	13.68	1	nM
AD-579931.1	54.78	5.31	1	nM
AD-579932.1	46.12	4.65	1	nM
AD-579933.1	27.01	5.56	1	nM
AD-579934.1	40.35	6.96	1	nM
AD-579935.1	31.13	5.41	1	nM
AD-579936.1	29.73	3.71	1	nM
AD-579937.1	44.09	4.36	1	nM
AD-579938.1	21.66	3.66	1	nM
AD-579939.1	4.58	0.75	1	nM
AD-579940.1	3.56	0.91	1	nM
AD-579941.1	7.55	2.31	1	nM
AD-579942.1	5.56	2.57	1	nM
AD-579943.1	19.30	3.06	1	nM
AD-579944.1	18.70	1.80	1	nM
AD-579945.1	26.86	1.35	1	nM
AD-579946.1	21.86	3.32	1	nM
AD-579947.1	9.84	0.95	1	nM
AD-579948.1	26.84	1.26	1	nM
AD-579949.1	57.75	9.08	1	nM
AD-579950.1	54.60	4.99	1	nM
AD-579951.1	23.18	1.60	1	nM
AD-579953.1	35.85	4.89	1	nM
AD-579954.1	33.37	3.57	1	nM
AD-579955.1	43.72	4.02	1	nM

AD-579956.1	40.52	0.43	1	nM
AD-579957.1	22.05	1.37	1	nM
AD-579958.1	63.71	6.37	1	nM
AD-579959.1	54.17	7.09	1	nM
AD-579960.1	45.58	4.07	1	nM
AD-579961.1	40.91	2.43	1	nM
AD-579962.1	28.65	3.39	1	nM
AD-579963.1	22.65	6.61	1	nM
AD-579964.1	28.01	5.38	1	nM
AD-579965.1	3.88	1.04	1	nM
AD-579966.1	4.08	1.00	1	nM
AD-579967.1	14.72	0.97	1	nM
AD-579968.1	19.71	4.24	1	nM
AD-579969.1	54.35	7.63	1	nM
AD-579970.1	52.04	1.90	1	nM
AD-579971.1	13.28	3.80	1	nM
AD-579972.1	22.49	5.22	1	nM
AD-579973.1	23.49	2.63	1	nM
AD-579974.1	6.50	0.84	1	nM
AD-579975.1	3.65	1.14	1	nM
AD-579976.1	10.00	2.25	1	nM
AD-579977.1	30.06	5.34	1	nM
AD-579978.1	21.05	2.77	1	nM
AD-579979.1	54.05	6.94	1	nM
AD-579980.1	26.38	3.38	1	nM
AD-579981.1	22.68	2.02	1	nM
AD-579982.1	39.84	3.32	1	nM
AD-579983.1	34.64	6.02	1	nM
AD-579984.1	16.95	2.53	1	nM
AD-579985.1	31.39	1.48	1	nM
AD-579986.1	27.74	3.81	1	nM
AD-579987.1	51.76	4.91	1	nM
AD-579988.1	29.45	2.77	1	nM
AD-579989.1	21.33	2.08	1	nM
AD-579990.1	47.89	1.76	1	nM
AD-579992.1	30.71	4.73	1	nM
AD-579993.1	35.91	7.25	1	nM
AD-579995.1	6.70	0.49	1	nM
AD-579996.1	74.23	4.02	1	nM
AD-579997.1	51.99	10.00	1	nM
AD-579998.1	20.92	4.64	1	nM

AD-579999.1	40.31	1.99	1	nM
AD-580000.1	38.17	1.63	1	nM
AD-580001.1	28.86	5.37	1	nM
AD-580002.1	51.52	7.91	1	nM
AD-579911.1	59.37	8.87	0.1	nM
AD-579912.1	59.39	5.09	0.1	nM
AD-579913.1	64.08	23.73	0.1	nM
AD-579914.1	49.48	3.64	0.1	nM
AD-579915.1	56.56	6.31	0.1	nM
AD-579916.1	96.79	16.03	0.1	nM
AD-579917.1	45.36	7.75	0.1	nM
AD-579918.1	57.38	4.03	0.1	nM
AD-579919.1	55.62	5.60	0.1	nM
AD-579921.1	53.70	9.76	0.1	nM
AD-579922.1	62.44	4.87	0.1	nM
AD-579923.1	63.54	9.06	0.1	nM
AD-579924.1	92.45	9.57	0.1	nM
AD-579925.1	61.94	18.45	0.1	nM
AD-579926.1	70.86	8.69	0.1	nM
AD-579927.1	78.15	23.69	0.1	nM
AD-579929.1	71.46	14.26	0.1	nM
AD-579930.1	90.78	6.27	0.1	nM
AD-579931.1	68.75	9.57	0.1	nM
AD-579932.1	77.69	9.74	0.1	nM
AD-579933.1	51.36	9.29	0.1	nM
AD-579934.1	77.13	7.91	0.1	nM
AD-579935.1	49.67	7.46	0.1	nM
AD-579936.1	44.13	6.15	0.1	nM
AD-579937.1	77.96	4.22	0.1	nM
AD-579938.1	29.19	7.09	0.1	nM
AD-579939.1	10.14	1.04	0.1	nM
AD-579940.1	6.98	3.06	0.1	nM
AD-579941.1	7.68	1.31	0.1	nM
AD-579942.1	8.97	1.33	0.1	nM
AD-579943.1	37.14	5.93	0.1	nM
AD-579944.1	39.47	3.54	0.1	nM
AD-579945.1	54.76	10.45	0.1	nM
AD-579946.1	54.38	7.47	0.1	nM
AD-579947.1	22.79	5.03	0.1	nM
AD-579948.1	38.00	6.15	0.1	nM
AD-579949.1	80.25	7.57	0.1	nM

AD-579950.1	73.79	5.42	0.1	nM
AD-579951.1	47.34	5.57	0.1	nM
AD-579953.1	75.21	13.06	0.1	nM
AD-579954.1	49.75	4.87	0.1	nM
AD-579955.1	84.04	10.95	0.1	nM
AD-579956.1	73.48	18.05	0.1	nM
AD-579957.1	37.29	3.15	0.1	nM
AD-579958.1	96.73	8.67	0.1	nM
AD-579959.1	86.90	10.17	0.1	nM
AD-579960.1	71.64	12.07	0.1	nM
AD-579961.1	86.22	11.71	0.1	nM
AD-579962.1	59.52	4.17	0.1	nM
AD-579963.1	53.65	1.36	0.1	nM
AD-579964.1	60.89	5.53	0.1	nM
AD-579965.1	10.37	1.33	0.1	nM
AD-579966.1	9.37	1.18	0.1	nM
AD-579967.1	33.20	1.60	0.1	nM
AD-579968.1	36.38	8.49	0.1	nM
AD-579969.1	83.90	5.81	0.1	nM
AD-579970.1	104.17	11.38	0.1	nM
AD-579971.1	29.04	4.62	0.1	nM
AD-579972.1	47.77	5.87	0.1	nM
AD-579973.1	67.38	5.17	0.1	nM
AD-579974.1	21.80	3.23	0.1	nM
AD-579975.1	10.78	2.10	0.1	nM
AD-579976.1	20.60	3.17	0.1	nM
AD-579977.1	86.60	5.20	0.1	nM
AD-579978.1	53.36	3.32	0.1	nM
AD-579979.1	92.09	11.37	0.1	nM
AD-579980.1	52.60	2.36	0.1	nM
AD-579981.1	46.23	7.60	0.1	nM
AD-579982.1	94.15	11.36	0.1	nM
AD-579983.1	76.94	11.93	0.1	nM
AD-579984.1	34.98	2.84	0.1	nM
AD-579985.1	69.50	9.11	0.1	nM
AD-579986.1	62.04	6.78	0.1	nM
AD-579987.1	89.22	9.48	0.1	nM
AD-579988.1	72.80	14.40	0.1	nM
AD-579989.1	52.85	3.85	0.1	nM
AD-579990.1	94.01	8.85	0.1	nM
AD-579992.1	67.82	6.38	0.1	nM

AD-579993.1	81.30	15.42	0.1	nM
AD-579995.1	19.72	5.72	0.1	nM
AD-579996.1	97.03	10.38	0.1	nM
AD-579997.1	87.06	12.93	0.1	nM
AD-579998.1	52.54	4.98	0.1	nM
AD-579999.1	71.80	3.62	0.1	nM
AD-580000.1	75.04	9.15	0.1	nM
AD-580001.1	59.52	8.32	0.1	nM
AD-580002.1	90.07	10.26	0.1	nM

The results of the multi-dose screen in primary human hepatocytes transfected with one set of exemplary human VEGF-A siRNAs is shown in Table 9A (correspond to siRNAs in Table 8A and 8B) The multi-dose experiments were performed at 50 nM, 10 nM, 1 nM, and 0.1 nM final duplex concentrations and the data are expressed as percent message remaining relative to non-targeting control.

Of the exemplary siRNA duplexes evaluated in Table 9A, 1 achieved a knockdown of VEGF-A of $\geq 80\%$, 119 achieved a knockdown of VEGF-A of $\geq 60\%$, and 363 achieved a knockdown of VEGF-A of $\geq 30\%$ when administered at the 50 nM concentration.

Of the exemplary siRNA duplexes evaluated in Table 9A, 2 achieved a knockdown of VEGF-A of $\geq 80\%$, 103 achieved a knockdown of VEGF-A of $\geq 60\%$, and 364 achieved a knockdown of VEGF-A of $\geq 30\%$ when administered at the 10 nM concentration.

Of the exemplary siRNA duplexes evaluated in Table 9A, 13 achieved a knockdown of VEGF-A of $\geq 70\%$, 52 achieved a knockdown of VEGF-A of $\geq 60\%$, and 312 achieved a knockdown of VEGF-A of $\geq 30\%$ when administered at the 1 nM concentration.

Of the exemplary siRNA duplexes evaluated in Table 9A, 8 achieved a knockdown of VEGF-A of $\geq 50\%$, 75 achieved a knockdown of VEGF-A of $\geq 40\%$, and 170 achieved a knockdown of VEGF-A of $\geq 30\%$ when administered at the 0.1 nM concentration.

Table 9A. VEGF-A endogenous *in vitro* multi-dose screen following cellular transfection with one set of exemplary human VEGF-A siRNAs

DuplexID	50nM	StDev	10nM	StDev	1nM	StDev	0.1nM	StDev
AD-1222866.1	70	22	58	9	69	9	60	6
AD-1222867.1	64	14	38	6	55	3	54	2
AD-1222868.1	60	7	42	6	56	8	55	3
AD-1222869.1	61	3	51	1	56	3	56	0
AD-1222870.1	43	7	39	6	47	7	52	4
AD-1222871.1	41	3	38	7	42	2	56	3

AD-1222872.1	54	4	46	9	50	1	56	2
AD-1222873.1	44	1	44	4	46	2	58	1
AD-1222874.1	78	22	66	18	69	4	70	2
AD-1222875.1	56	7	51	5	64	3	59	4
AD-1222876.1	56	9	64	6	71	8	67	4
AD-1222877.1	60	19	50	5	59	7	67	3
AD-1222878.1	64	7	60	2	63	3	72	4
AD-1222879.1	64	3	57	9	52	4	64	9
AD-1222880.1	54	4	53	9	49	4	57	4
AD-1222881.1	58	10	51	2	46	1	63	9
AD-1222882.1	93	12	74	14	93	12	91	12
AD-1222883.1	72	12	59	10	64	7	78	9
AD-1222884.1	63	5	58	8	61	0	79	10
AD-1222885.1	70	12	66	9	69	11	81	4
AD-1222886.1	77	7	76	7	69	3	80	6
AD-1222887.1	62	5	58	11	57	4	70	9
AD-1222888.1	69	6	68	8	64	7	65	4
AD-1222889.1	95	16	81	13	98	11	128	54
AD-1222890.1	88	4	85	11	81	10	97	15
AD-1222891.1	91	15	70	7	77	7	84	16
AD-1222892.1	77	3	75	16	82	22	84	5
AD-1222893.1	84	4	77	14	74	4	85	3
AD-1222894.1	66	6	53	0	61	8	77	10
AD-1222895.1	66	8	68	11	69	6	71	8
AD-1222896.1	99	18	82	25	88	13	124	18
AD-1222897.1	94	10	95	6	76	7	88	14
AD-1222898.1	107	13	93	3	85	10	91	15
AD-1222899.1	98	15	108	5	78	3	90	9
AD-1222900.1	83	14	83	2	82	1	91	8
AD-1222901.1	85	11	81	10	90	15	82	11
AD-1222902.1	71	11	70	6	78	7	87	11
AD-1222903.1	85	5	66	10	80	11	81	6
AD-1222904.1	99	13	87	18	87	9	109	20
AD-1222905.1	109	10	97	14	91	10	103	20
AD-1222906.1	117	6	94	14	85	8	78	3
AD-1222907.1	91	15	85	11	73	20	81	13
AD-1222908.1	82	5	77	11	81	19	90	11
AD-1222909.1	83	8	85	16	62	13	89	8
AD-1222910.1	71	7	78	9	70	2	86	9

AD-1222911.1	129	1	93	17	102	3	116	24
AD-1222912.1	117	11	115	10	98	10	114	7
AD-1222913.1	103	9	89	6	91	5	110	19
AD-1222914.1	72	3	63	3	80	16	91	11
AD-1222915.1	59	11	60	6	80	7	100	8
AD-1222916.1	49	6	42	5	43	12	94	10
AD-1222917.1	61	2	49	6	62	7	85	4
AD-1222918.1	70	12	69	4	77	4	94	4
AD-1222920.1	87	15	71	6	59	5	90	10
AD-1222921.1	104	8	105	6	89	10	103	13
AD-1222922.1	68	7	78	3	88	18	78	14
AD-1222923.1	58	4	64	8	64	5	90	2
AD-1222924.1	82	10	84	13	83	17	100	2
AD-1222925.1	71	7	83	11	84	13	91	0
AD-1222926.1	90	9	87	9	80	2	101	2
AD-1222927.1	95	14	84	3	76	4	103	21
AD-1222928.1	62	4	54	5	54	4	84	3
AD-1222929.1	79	9	61	6	69	2	87	23
AD-1222930.1	59	1	62	1	68	2	95	8
AD-1222931.1	55	4	58	2	64	3	89	16
AD-1222932.1	75	18	87	8	93	11	88	7
AD-1222933.1	40	12	47	5	45	3	87	17
AD-1222934.1	56	8	42	5	48	10	68	8
AD-1222935.1	41	0	41	2	46	4	66	8
AD-1222936.1	39	3	50	2	54	1	73	8
AD-1222937.1	50	13	52	10	63	7	89	9
AD-1222938.1	46	5	67	8	72	4	96	7
AD-1222939.1	37	2	41	7	57	13	82	4
AD-1222940.1	36	6	45	8	47	8	74	17
AD-1222941.1	89	12	76	9	85	6	85	17
AD-1222942.1	44	7	39	3	43	6	67	4
AD-1222943.1	81	17	77	6	85	5	100	5
AD-1222944.1	53	11	50	4	59	14	85	9
AD-1222945.1	74	12	73	0	84	23	92	4
AD-1222946.1	37	3	44	4	76	7	89	7
AD-1222947.1	31	4	31	3	52	3	54	4
AD-1222948.1	58	12	60	6	88	14	111	52
AD-1222949.1	52	12	52	11	63	17	109	13
AD-1222950.1	52	18	51	1	72	7	113	21

AD-1222951.1	37	12	34	5	42	1	95	19
AD-1222952.1	78	4	89	6	103	1	137	44
AD-1222953.1	27	6	30	2	57	6	119	47
AD-1222954.1	33	4	40	4	68	12	102	35
AD-1222955.1	38	9	39	3	53	5	116	54
AD-1222956.1	34	6	42	7	58	20	69	5
AD-1222957.1	23	3	30	2	55	20	62	9
AD-1222958.1	21	3	35	15	35	8	59	4
AD-1222959.1	21	2	30	8	39	7	65	1
AD-1222960.1	25	2	32	6	39	1	68	11
AD-1222961.1	32	5	25	1	41	7	54	2
AD-1222962.1	33	3	34	6	34	8	55	5
AD-1222963.1	26	3	24	0	34	13	61	3
AD-1222964.1	37	1	47	7	78	10	87	14
AD-1222965.1	49	0	58	19	81	11	88	3
AD-1222966.1	48	7	51	4	59	6	82	3
AD-1222967.1	36	2	34	2	49	6	67	8
AD-1222968.1	39	3	47	5	53	10	73	7
AD-1222969.1	30	1	28	3	41	11	55	5
AD-1222970.1	18	1	19	2	25	10	41	2
AD-1222971.1	40	5	35	2	44	4	58	4
AD-1222972.1	41	4	47	8	87	7	87	11
AD-1222973.1	28	2	31	10	52	7	71	8
AD-1222974.1	38	4	29	2	57	8	67	11
AD-1222975.1	35	3	28	2	48	15	72	6
AD-1222976.1	24	1	23	5	33	2	49	2
AD-1222977.1	22	1	20	2	28	5	47	4
AD-1222978.1	27	6	24	6	31	7	50	3
AD-1222979.1	52	11	52	0	71	13	103	26
AD-1222980.1	46	5	41	5	65	9	91	2
AD-1222981.1	49	4	41	3	59	11	76	2
AD-1222982.1	35	5	29	1	44	7	64	4
AD-1222983.1	32	4	28	2	35	10	54	1
AD-1222984.1	29	2	25	1	32	1	53	3
AD-1222985.1	37	3	34	7	43	6	57	3
AD-1222986.1	34	2	34	1	65	13	94	23
AD-1222987.1	38	5	35	7	48	10	73	9
AD-1222988.1	31	0	27	1	38	2	59	7
AD-1222989.1	35	2	29	5	42	2	59	4

AD-1222990.1	30	4	34	10	37	7	59	6
AD-1222991.1	26	1	21	2	37	9	59	9
AD-1222992.1	39	5	38	0	49	14	65	1
AD-1222993.1	39	1	36	3	43	5	80	17
AD-1222994.1	46	3	48	6	54	1	82	3
AD-1222995.1	47	5	36	5	67	16	76	7
AD-1222996.1	58	7	50	4	60	4	79	2
AD-1222997.1	40	8	37	5	50	4	53	9
AD-1222998.1	43	8	39	4	51	3	51	7
AD-1222999.1	40	1	43	12	45	2	60	5
AD-1223000.1	55	12	45	4	53	2	69	4
AD-1223001.1	56	7	62	9	77	15	103	15
AD-1223002.1	69	1	65	1	78	6	86	9
AD-1223003.1	52	10	46	10	60	9	72	5
AD-1223004.1	34	2	32	3	41	9	58	4
AD-1223005.1	47	1	51	12	51	12	67	7
AD-1223006.1	35	2	32	2	39	1	61	7
AD-1223007.1	55	7	42	3	54	10	61	6
AD-1223008.1	32	4	29	1	37	1	68	10
AD-1223009.1	40	3	47	7	54	6	97	15
AD-1223010.1	52	2	46	3	58	8	85	6
AD-1223011.1	44	2	39	5	39	7	58	7
AD-1223012.1	32	3	37	4	39	5	61	7
AD-1223013.1	78	9	65	10	60	4	79	4
AD-1223014.1	64	10	50	4	46	7	76	4
AD-1223015.1	38	5	29	3	43	8	64	4
AD-1223016.1	47	11	31	3	35	6	81	17
AD-1223017.1	55	4	52	2	53	8	89	23
AD-1223018.1	39	0	45	12	47	1	75	16
AD-1223019.1	39	5	36	4	46	14	67	2
AD-1223020.1	48	9	47	15	44	9	68	2
AD-1223021.1	50	7	42	5	41	1	68	13
AD-1223022.1	34	4	31	2	37	5	61	13
AD-1223023.1	66	7	56	2	59	9	80	13
AD-1223024.1	55	10	52	6	78	9	115	31
AD-1223025.1	49	4	47	4	60	1	109	9
AD-1223026.1	55	6	55	6	59	14	86	10
AD-1223027.1	66	3	63	10	70	19	90	1
AD-1223028.1	54	6	48	6	53	3	82	15

AD-1223029.1	52	3	50	8	62	1	81	7
AD-1223030.1	53	7	49	7	48	2	74	12
AD-1223031.1	44	8	38	3	60	5	88	14
AD-1223032.1	51	2	53	2	57	4	88	8
AD-1223033.1	46	2	49	15	63	10	77	18
AD-1223034.1	53	18	36	4	57	19	81	11
AD-1223035.1	50	2	49	15	50	9	65	4
AD-1223036.1	40	3	34	6	43	5	77	31
AD-1223037.1	42	3	33	5	37	6	55	8
AD-1223038.1	30	4	32	1	29	1	62	2
AD-1223039.1	67	3	48	8	68	12	74	14
AD-1223040.1	61	1	54	13	56	9	73	10
AD-1223041.1	57	7	44	4	65	17	91	7
AD-1223042.1	62	32	46	6	55	13	71	4
AD-1223043.1	41	5	40	3	46	8	79	6
AD-1223044.1	53	17	39	2	43	6	73	9
AD-1223045.1	54	0	40	2	44	3	67	9
AD-1223046.1	49	13	43	3	32	3	103	1
AD-1223047.1	55	4	41	4	26	7	97	8
AD-1223048.1	43	2	39	3	25	8	99	14
AD-1223049.1	31	2	35	1	36	10	107	9
AD-1223050.1	32	4	37	3	63	5	106	21
AD-1223051.1	55	4	48	3	74	30	114	16
AD-1223052.1	50	12	39	3	62	4	107	14
AD-1223053.1	37	2	44	6	41	13	90	12
AD-1223054.1	51	23	48	1	28	5	98	11
AD-1223055.1	63	41	44	1	22	2	79	8
AD-1223056.1	49	1	45	1	25	5	83	11
AD-1223057.1	41	13	42	6	39	15	79	11
AD-1223058.1	26	3	33	2	53	25	77	10
AD-1223059.1	32	2	37	0	50	11	71	10
AD-1223060.1	41	13	38	3	50	2	78	2
AD-1223061.1	40	16	43	2	52	5	80	20
AD-1223062.1	52	15	57	4	29	7	99	2
AD-1223063.1	40	8	52	7	31	1	91	10
AD-1223064.1	61	13	60	12	60	14	94	5
AD-1223065.1	51	11	42	5	69	19	72	11
AD-1223066.1	30	7	34	2	57	16	73	16
AD-1223067.1	33	0	49	3	83	21	85	14

AD-1223068.1	44	14	49	7	50	3	71	6
AD-1223069.1	48	3	69	1	49	3	111	5
AD-1223070.1	40	16	66	5	44	18	89	7
AD-1223071.1	38	6	48	12	45	13	89	11
AD-1223072.1	55	8	58	4	82	10	78	9
AD-1223073.1	39	5	47	7	96	9	69	5
AD-1223074.1	38	3	43	2	60	10	68	6
AD-1223075.1	35	2	46	2	55	14	66	8
AD-1223076.1	42	9	67	2	30	2	108	21
AD-1223077.1	43	4	75	5	58	20	99	7
AD-1223078.1	63	9	74	10	79	22	91	6
AD-1223079.1	76	13	52	2	75	10	92	23
AD-1223080.1	39	3	45	4	70	8	69	11
AD-1223081.1	53	14	57	4	76	4	74	14
AD-1223082.1	34	3	43	3	46	7	60	4
AD-1223083.1	41	11	50	0	47	12	53	4
AD-1223084.1	53	11	58	7	44	9	64	4
AD-1223085.1	46	0	60	1	58	7	91	12
AD-1223086.1	57	11	51	1	73	6	67	9
AD-1223087.1	68	3	71	1	87	5	84	17
AD-1223088.1	64	17	61	12	86	1	88	9
AD-1223089.1	35	5	37	4	50	8	71	7
AD-1223090.1	48	11	51	4	56	7	65	2
AD-1223091.1	45	13	54	5	60	15	63	4
AD-1223092.1	48	18	63	5	83	13	86	7
AD-1223093.1	52	5	48	1	79	18	73	1
AD-1223094.1	40	14	52	10	81	13	76	10
AD-1223095.1	41	11	42	1	66	14	65	7
AD-1223096.1	33	5	51	2	81	23	71	4
AD-1223097.1	31	3	48	6	52	2	77	10
AD-1223098.1	31	8	39	3	41	6	57	1
AD-1223099.1	42	15	58	5	56	8	60	1
AD-1223100.1	35	9	55	7	54	5	62	5
AD-1223101.1	52	3	57	8	111	6	62	8
AD-1223102.1	43	13	62	1	75	13	62	6
AD-1223103.1	54	13	50	8	79	7	72	6
AD-1223104.1	36	17	50	12	50	4	53	5
AD-1223105.1	29	4	46	3	50	12	56	2
AD-1223106.1	43	14	50	9	63	22	54	5

AD-1223107.1	31	3	56	2	63	33	68	3
AD-1223108.1	41	13	53	4	55	11	68	5
AD-1223109.1	58	11	69	12	71	2	73	3
AD-1223110.1	65	10	80	11	87	6	83	7
AD-1223111.1	54	14	58	10	58	15	68	4
AD-1223112.1	52	4	82	2	75	14	78	4
AD-1223113.1	55	11	73	6	81	21	84	1
AD-1223114.1	60	8	66	1	83	16	82	1
AD-1223115.1	81	10	73	6	77	1	84	10
AD-1223116.1	79	3	87	8	79	13	82	6
AD-1223117.1	58	6	92	2	74	18	74	5
AD-1223118.1	38	1	82	2	57	2	71	8
AD-1223119.1	51	9	67	5	79	47	78	8
AD-1223120.1	43	1	72	2	53	10	73	3
AD-1223121.1	46	5	68	5	69	5	67	6
AD-1223122.1	61	26	63	8	75	11	78	7
AD-1223123.1	43	12	59	3	59	8	69	4
AD-1223124.1	66	17	76	3	75	14	67	3
AD-1223125.1	54	15	77	3	68	3	64	4
AD-1223126.1	56	10	70	2	53	2	75	16
AD-1223127.1	47	13	70	4	41	7	62	6
AD-1223128.1	52	3	87	1	50	5	75	1
AD-1223129.1	39	1	65	9	55	11	70	5
AD-1223130.1	43	8	66	4	62	8	71	8
AD-1223131.1	48	14	63	5	55	2	70	3
AD-1223132.1	51	8	74	6	75	13	72	2
AD-1223133.1	37	2	61	0	60	4	70	6
AD-1223134.1	41	3	69	2	55	1	71	9
AD-1223135.1	59	20	85	10	54	8	73	4
AD-1223136.1	79	12	134	13	62	9	118	26
AD-1223137.1	65	7	99	30	69	10	127	19
AD-1223138.1	77	19	100	23	68	6	112	28
AD-1223139.1	53	1	127	15	60	15	106	20
AD-1223140.1	59	22	67	7	46	8	98	23
AD-1223141.1	50	6	69	4	52	19	73	22
AD-1223142.1	49	3	63	5	42	11	72	6
AD-1223143.1	45	10	56	11	52	13	68	14
AD-1223144.1	50	8	54	11	60	2	115	5
AD-1223145.1	49	4	74	13	62	19	90	2

AD-1223146.1	81	3	97	35	111	9	107	21
AD-1223147.1	65	15	71	18	62	9	106	13
AD-1223148.1	63	8	74	12	63	11	100	31
AD-1223149.1	49	6	59	13	51	10	100	26
AD-1223150.1	49	2	67	14	47	16	89	21
AD-1223151.1	51	1	62	11	42	5	98	6
AD-1223152.1	67	9	90	20	63	11	123	11
AD-1223153.1	77	3	88	18	109	9	126	12
AD-1223154.1	53	9	46	2	70	8	87	3
AD-1223155.1	55	15	40	4	53	15	129	41
AD-1223156.1	54	9	48	3	48	12	91	13
AD-1223157.1	49	8	53	14	52	11	92	13
AD-1223158.1	45	3	49	9	40	9	84	9
AD-1223159.1	42	7	77	29	59	13	109	7
AD-1223160.1	55	8	55	4	98	7	122	18
AD-1223161.1	49	10	57	9	66	18	118	16
AD-1223162.1	73	5	59	6	52	2	91	13
AD-1223163.1	57	16	59	7	61	13	94	20
AD-1223164.1	58	18	70	8	54	3	120	9
AD-1223165.1	49	13	65	2	50	6	98	6
AD-1223166.1	70	13	72	14	92	9	125	21
AD-1223167.1	78	8	71	9	101	34	119	26
AD-1223168.1	75	17	77	10	98	18	115	15
AD-1223169.1	87	3	57	2	76	27	133	23
AD-1223170.1	87	11	73	12	93	19	85	8
AD-1223171.1	67	20	72	31	70	4	96	12
AD-1223172.1	41	10	44	4	54	9	93	5
AD-1223173.1	62	14	81	21	58	24	116	16
AD-1223174.1	60	14	65	2	96	2	101	9
AD-1223175.1	80	29	61	6	91	19	98	15
AD-1223176.1	77	4	85	6	123	19	109	22
AD-1223177.1	72	14	51	6	70	17	92	1
AD-1223178.1	80	3	77	8	72	16	96	11
AD-1223179.1	82	14	111	9	66	9	81	15
AD-1223180.1	47	9	45	2	54	15	81	12
AD-1223181.1	82	8	76	11	74	17	131	27
AD-1223182.1	58	11	56	13	72	15	80	7
AD-1223183.1	79	20	55	4	94	11	90	9
AD-1223184.1	39	3	38	1	51	4	72	5

AD-1223185.1	63	4	52	10	48	5	76	8
AD-1223186.1	56	17	54	11	48	11	70	4
AD-1223187.1	37	2	39	3	45	14	74	9
AD-1223188.1	32	6	42	7	34	2	68	3
AD-1223189.1	43	14	41	5	56	1	65	12
AD-1223190.1	38	7	41	3	53	14	53	1
AD-1223191.1	55	13	41	7	50	2	56	12
AD-1223192.1	33	3	38	5	43	6	57	6
AD-1223193.1	34	2	30	2	33	9	44	9
AD-1223194.1	45	11	33	6	25	5	48	3
AD-1223195.1	50	19	31	4	39	13	51	4
AD-1223196.1	42	2	29	6	29	11	62	4
AD-1223197.1	42	2	29	0	26	1	59	12
AD-1223198.1	54	10	41	10	61	2	79	8
AD-1223199.1	39	4	36	6	52	16	70	4
AD-1223200.1	35	11	31	2	32	12	57	3
AD-1223201.1	46	18	36	7	32	1	55	7
AD-1223202.1	38	8	31	3	39	3	66	6
AD-1223203.1	39	6	39	6	34	9	66	1
AD-1223204.1	45	4	40	7	45	5	78	2
AD-1223205.1	60	14	54	15	58	4	72	10
AD-1223206.1	43	11	31	5	40	3	57	5
AD-1223207.1	73	2	65	10	57	10	77	12
AD-1223208.1	73	22	68	8	57	10	73	8
AD-1223209.1	48	9	44	10	45	5	73	15
AD-1223210.1	46	9	34	2	43	16	84	9
AD-1223211.1	26	4	40	12	39	7	63	3
AD-1223212.1	46	10	33	3	49	11	68	1
AD-1223213.1	58	6	36	4	46	3	57	2
AD-1223214.1	34	1	35	1	43	6	62	8
AD-1223215.1	41	9	33	6	39	8	61	9
AD-1223216.1	43	8	31	2	47	13	59	4
AD-1223217.1	41	6	39	2	38	7	66	7
AD-1223218.1	31	6	36	4	43	10	65	7
AD-1223219.1	35	7	47	7	48	4	68	1
AD-1223220.1	36	9	39	3	40	11	62	3
AD-1223221.1	43	13	31	0	39	13	58	6
AD-1223222.1	65	27	50	7	57	10	68	9
AD-1223223.1	45	2	39	5	47	2	66	11

AD-1223224.1	32	4	33	5	40	6	60	2
AD-1223225.1	35	8	37	3	31	5	70	9
AD-1223226.1	93	9	62	10	55	5	74	16
AD-1223227.1	100	15	77	12	69	6	69	5
AD-1223228.1	83	5	44	7	44	5	55	3
AD-1223229.1	101	29	59	9	56	7	62	11
AD-1223230.1	85	16	45	6	48	2	52	8
AD-1223231.1	97	18	56	2	57	3	68	12
AD-1223232.1	110	15	79	9	60	2	54	1
AD-1223233.1	95	9	62	4	60	9	58	3
AD-1223234.1	105	8	68	14	72	1	78	13
AD-1223235.1	81	5	64	14	69	12	67	3
AD-1223236.1	83	12	53	6	63	5	90	15
AD-1223237.1	146	33	95	26	82	15	92	16
AD-1223238.1	72	5	68	17	60	5	69	7
AD-1223239.1	75	17	49	3	51	5	67	5
AD-1223240.1	63	2	59	10	53	2	55	9
AD-1223241.1	78	18	55	10	49	5	53	7
AD-1223242.1	77	10	57	6	64	8	70	6
AD-1223243.1	108	1	60	10	70	2	66	11
AD-1223244.1	50	9	62	9	56	9	75	15
AD-1223245.1	59	0	63	12	72	1	79	5
AD-1223246.1	52	4	51	9	44	4	71	9
AD-1223247.1	68	9	58	4	49	3	61	9
AD-1223248.1	80	9	58	8	50	5	54	7
AD-1223249.1	81	16	69	4	96	25	63	13
AD-1223250.1	77	16	72	11	123	20	65	14
AD-1223251.1	58	15	65	7	88	7	60	9
AD-1223252.1	69	12	60	8	80	12	80	21
AD-1223253.1	68	31	48	5	67	13	53	1
AD-1223254.1	49	7	56	12	84	0	54	7
AD-1223255.1	46	5	50	8	59	6	46	8
AD-1223256.1	63	21	53	5	75	16	73	2
AD-1223257.1	74	34	70	3	88	14	71	11
AD-1223258.1	68	19	73	14	91	17	104	7
AD-1223259.1	92	37	106	2	114	20	101	3
AD-1223260.1	59	12	79	8	79	16	99	13
AD-1223261.1	47	13	66	15	86	8	77	15
AD-1223262.1	39	6	45	4	68	12	58	4

AD-1223263.1	39	3	44	2	64	1	44	9
AD-1223264.1	42	10	43	3	79	20	59	8
AD-1223265.1	58	11	56	10	101	7	88	8
AD-1223266.1	49	5	48	7	68	5	72	6
AD-1223267.1	79	30	70	14	95	11	102	19
AD-1223268.1	54	7	64	7	83	9	96	6
AD-1223269.1	45	13	49	8	78	16	80	9
AD-1223270.1	53	14	70	16	76	4	70	6
AD-1223271.1	55	17	61	5	88	14	83	13
AD-1223272.1	57	28	60	6	75	9	77	6
AD-1223273.1	33	3	56	7	77	17	94	6
AD-1223274.1	49	5	67	14	81	9	110	17
AD-1223275.1	53	4	63	11	67	6	115	15
AD-1223276.1	53	3	80	15	89	6	98	9
AD-1223277.1	41	7	67	14	75	6	82	19
AD-1223278.1	47	2	60	7	69	6	58	7
AD-1223279.1	57	9	64	8	93	12	102	24
AD-1223280.1	59	8	72	2	86	11	100	9
AD-1223281.1	52	5	66	8	86	17	95	13
AD-1223282.1	35	4	56	9	67	4	103	18
AD-1223283.1	36	5	43	3	46	2	97	3
AD-1223284.1	32	1	51	9	60	15	65	7
AD-1223285.1	37	4	64	19	57	7	76	6
AD-1223286.1	37	7	38	6	51	7	56	8
AD-1223287.1	36	8	40	5	60	8	73	23
AD-1223288.1	46	6	64	10	87	5	77	6
AD-1223289.1	41	7	61	7	78	1	119	2
AD-1223290.1	46	6	56	5	76	12	98	9
AD-1223291.1	41	4	68	9	81	9	94	15
AD-1223292.1	39	10	84	36	71	4	73	9
AD-1223293.1	47	7	53	1	65	11	59	7
AD-1223294.1	38	1	53	4	59	1	61	20
AD-1223295.1	58	3	67	7	81	8	106	8
AD-1223296.1	72	1	87	10	87	14	113	19
AD-1223297.1	54	9	73	11	78	9	99	2
AD-1223298.1	55	17	65	10	75	9	94	11
AD-1223299.1	58	9	78	8	85	12	73	12
AD-1223300.1	54	6	67	7	79	20	70	9
AD-1223301.1	44	6	61	4	66	4	58	8

AD-1223302.1	44	6	67	10	77	3	75	9
AD-1223303.1	37	2	70	9	79	8	74	14
AD-1223304.1	49	3	71	8	75	9	111	13
AD-1223305.1	42	4	53	6	71	11	79	9
AD-1223306.1	39	1	60	12	64	4	71	9
AD-1223307.1	37	2	62	5	70	17	76	4
AD-1223308.1	33	1	51	12	57	15	58	6
AD-1223309.1	45	10	62	14	61	3	63	14
AD-1223310.1	41	6	54	14	62	2	62	20
AD-1223311.1	54	5	66	11	72	16	66	12
AD-1223312.1	38	7	39	2	54	8	67	19
AD-1223313.1	29	2	40	2	57	6	51	3
AD-1223314.1	33	9	43	1	47	7	58	8
AD-1223315.1	28	1	40	4	48	11	61	15

The results of the multi-dose screen in primary human hepatocytes allowed to freely uptake one set of exemplary human VEGF-A siRNAs is shown in Table 9B (correspond to siRNAs in Table 8A and 8B) The multi-dose experiments were performed at 500 nM, 100 nM, 10 nM, and 1 nM final duplex concentrations and the data are expressed as percent message remaining relative to non-targeting control.

Of the exemplary siRNA duplexes evaluated in Table 9B, 2 achieved a knockdown of VEGF-A of $\geq 80\%$, 53 achieved a knockdown of VEGF-A of $\geq 60\%$, and 239 achieved a knockdown of VEGF-A of $\geq 30\%$ when administered at the 500 nM concentration.

Of the exemplary siRNA duplexes evaluated in Table 9B, 4 achieved a knockdown of VEGF-A of $\geq 70\%$, 33 achieved a knockdown of VEGF-A of $\geq 60\%$, and 235 achieved a knockdown of VEGF-A of $\geq 30\%$ when administered at the 100 nM concentration.

Of the exemplary siRNA duplexes evaluated in Table 9B, 3 achieved a knockdown of VEGF-A of $\geq 60\%$, 52 achieved a knockdown of VEGF-A of $\geq 40\%$, and 113 achieved a knockdown of VEGF-A of $\geq 30\%$ when administered at the 10 nM concentration.

Of the exemplary siRNA duplexes evaluated in Table 9B, 13 achieved a knockdown of VEGF-A of $\geq 50\%$, 88 achieved a knockdown of VEGF-A of $\geq 30\%$, and 146 achieved a knockdown of VEGF-A of $\geq 20\%$ when administered at the 1 nM concentration.

Table 9B. VEGF-A endogenous *in vitro* multi-dose screen following free uptake of one set of exemplary human VEGF-A siRNAs

DuplexID	500nM	StDev	100nM	StDev	10nM	StDev	1nM	StDev
AD-1222866.1	114	23	103	40	117	14	117	9
AD-1222867.1	114	11	176	58	104	9	134	24
AD-1222868.1	140	19	168	85	123	18	134	6
AD-1222869.1	110	12	149	62	149	23	131	25
AD-1222870.1	107	20	191	9	138	24	124	15
AD-1222871.1	102	11	140	48	130	13	138	18
AD-1222872.1	95	20	112	27	112	15	120	9
AD-1222873.1	73	17	94	10	107	1	110	6
AD-1222874.1	148	27	109	6	137	5	113	9
AD-1222875.1	132	7	93	4	161	25	139	11
AD-1222876.1	142	12	141	1	131	11	145	8
AD-1222877.1	119	2	111	3	176	15	132	4
AD-1222878.1	160	43	128	10	139	8	128	16
AD-1222879.1	150	21	119	13	139	22	116	16
AD-1222880.1	107	22	113	9	145	21	120	7
AD-1222881.1	90	28	91	4	106	2	113	7
AD-1222882.1	151	4	118	7	136	4	114	4
AD-1222883.1	143	13	120	11	147	12	129	8
AD-1222884.1	137	22	135	23	174	18	120	12
AD-1222885.1	162	16	130	13	169	15	120	4
AD-1222886.1	128	26	114	1	155	16	107	14
AD-1222887.1	143	32	128	24	124	10	116	13
AD-1222888.1	77	7	113	2	123	1	116	10
AD-1222889.1	142	11	92	18	143	31	113	13
AD-1222890.1	160	11	129	12	166	27	133	2
AD-1222891.1	138	12	126	6	173	27	136	17
AD-1222892.1	136	7	127	9	153	27	106	7
AD-1222893.1	111	11	118	6	141	10	130	16
AD-1222894.1	111	12	118	10	119	24	123	2
AD-1222895.1	96	8	103	0	121	27	122	18
AD-1222896.1	142	23	97	18	134	6	113	3
AD-1222897.1	155	13	126	6	157	21	129	12
AD-1222898.1	152	53	124	18	141	19	111	10
AD-1222899.1	138	21	110	9	147	28	120	1
AD-1222900.1	123	15	115	20	166	13	108	8
AD-1222901.1	106	6	116	6	161	17	105	15
AD-1222902.1	86	7	106	12	126	28	91	3
AD-1222903.1	84	5	95	2	138	6	112	23
AD-1222904.1	115	19	92	3	127	2	103	7
AD-1222905.1	137	10	129	11	132	22	107	3
AD-1222906.1	122	23	142	8	131	19	119	15
AD-1222907.1	126	35	120	11	143	22	103	3
AD-1222908.1	113	12	108	7	155	32	91	10
AD-1222909.1	104	2	106	13	134	23	106	2
AD-1222910.1	79	1	102	4	104	14	82	9

AD-1222911.1	114	8	106	22	98	11	102	6
AD-1222912.1	107	4	120	14	119	4	114	13
AD-1222913.1	126	31	115	5	109	13	103	11
AD-1222914.1	109	17	118	20	116	5	108	18
AD-1222915.1	88	3	95	11	120	21	88	14
AD-1222916.1	91	12	98	13	114	27	99	18
AD-1222917.1	70	1	93	6	88	16	86	2
AD-1222918.1	93	6	104	6	85	3	101	5
AD-1222920.1	88	12	90	10	95	6	100	8
AD-1222921.1	109	19	108	5	111	27	105	18
AD-1222922.1	91	20	87	5	124	12	104	10
AD-1222923.1	70	19	91	6	109	11	82	2
AD-1222924.1	85	14	103	13	107	14	83	17
AD-1222925.1	82	22	97	14	88	12	78	4
AD-1222926.1	103	9	86	14	92	18	93	13
AD-1222927.1	73	8	59	11	78	16	80	2
AD-1222928.1	80	1	71	11	85	9	94	7
AD-1222929.1	80	8	85	3	80	5	94	17
AD-1222930.1	76	6	85	6	97	11	74	3
AD-1222931.1	79	18	89	9	90	15	74	10
AD-1222932.1	85	1	81	16	76	3	57	7
AD-1222933.1	62	2	64	4	77	5	67	10
AD-1222934.1	43	3	45	9	63	6	62	1
AD-1222935.1	43	3	53	12	73	2	78	2
AD-1222936.1	66	11	56	11	65	10	75	6
AD-1222937.1	72	13	75	5	90	16	72	5
AD-1222938.1	65	6	71	14	78	11	81	8
AD-1222939.1	55	6	70	4	77	10	85	7
AD-1222940.1	61	16	44	1	71	6	74	2
AD-1222941.1	44	7	42	10	51	5	43	4
AD-1222942.1	31	0	37	3	64	8	59	6
AD-1222943.1	58	7	54	11	65	2	58	11
AD-1222944.1	46	6	49	6	69	7	63	12
AD-1222945.1	57	6	62	14	69	11	55	11
AD-1222946.1	50	5	60	16	55	2	57	3
AD-1222947.1	37	4	43	9	59	5	62	9
AD-1222948.1	60	1	63	16	61	13	57	1
AD-1222949.1	40	7	41	12	61	7	46	1
AD-1222950.1	36	4	36	7	55	1	44	4
AD-1222951.1	34	5	32	6	52	4	41	5
AD-1222952.1	61	6	48	14	65	7	44	8
AD-1222953.1	34	6	30	5	51	6	43	1
AD-1222954.1	15	2	25	5	47	4	36	1
AD-1222955.1	19	3	26	5	52	8	40	1
AD-1222956.1	64	8	72	5	110	6	123	6
AD-1222957.1	132	19	98	5	109	14	122	3
AD-1222958.1	72	10	96	7	120	26	133	3
AD-1222959.1	76	13	88	2	119	29	125	4
AD-1222960.1	71	3	123	14	136	39	141	8

AD-1222961.1	112	10	119	10	128	41	115	1
AD-1222962.1	88	4	97	16	120	31	142	12
AD-1222963.1	81	13	83	7	129	23	123	2
AD-1222964.1	90	6	89	2	130	39	134	10
AD-1222965.1	141	16	118	6	118	10	145	19
AD-1222966.1	105	8	119	9	113	11	145	20
AD-1222967.1	127	12	126	3	116	6	143	6
AD-1222968.1	128	7	144	9	120	19	138	11
AD-1222969.1	114	12	121	17	110	6	126	7
AD-1222970.1	58	6	92	7	104	10	120	5
AD-1222971.1	81	6	109	9	106	7	127	8
AD-1222972.1	95	21	76	5	100	11	119	12
AD-1222973.1	97	12	87	2	101	34	143	1
AD-1222974.1	119	8	122	8	105	11	116	5
AD-1222975.1	115	11	113	8	102	9	130	10
AD-1222976.1	97	22	100	13	91	8	106	11
AD-1222977.1	90	13	86	12	98	5	109	4
AD-1222978.1	66	7	77	2	104	12	136	1
AD-1222979.1	92	5	93	4	98	1	125	4
AD-1222980.1	98	1	117	12	103	3	133	9
AD-1222981.1	147	17	147	19	110	10	119	10
AD-1222982.1	95	10	99	16	92	10	114	6
AD-1222983.1	77	9	86	14	86	3	108	10
AD-1222984.1	73	15	93	5	78	3	108	10
AD-1222985.1	89	12	103	20	101	22	119	10
AD-1222986.1	65	1	75	1	97	8	120	10
AD-1222987.1	105	10	92	6	106	9	122	6
AD-1222988.1	74	0	79	1	90	11	128	7
AD-1222989.1	116	1	99	7	112	29	114	11
AD-1222990.1	87	1	95	8	97	15	116	7
AD-1222991.1	81	11	95	14	100	10	109	6
AD-1222992.1	78	10	100	5	89	7	109	6
AD-1222993.1	78	3	111	9	105	10	124	7
AD-1222994.1	78	12	76	0	99	13	116	16
AD-1222995.1	103	18	93	0	97	6	120	3
AD-1222996.1	108	4	122	17	104	5	114	11
AD-1222997.1	108	12	96	3	94	8	113	15
AD-1222998.1	101	11	77	3	87	7	106	2
AD-1222999.1	94	8	99	8	116	8	105	5
AD-1223000.1	80	14	97	25	80	10	97	8
AD-1223001.1	79	10	84	8	108	17	111	5
AD-1223002.1	95	15	93	12	109	11	120	16
AD-1223003.1	97	9	105	9	105	10	115	8
AD-1223004.1	64	9	80	9	93	16	101	10
AD-1223005.1	85	11	104	1	89	16	93	11
AD-1223006.1	70	1	83	9	82	5	96	1
AD-1223007.1	76	2	86	15	88	20	100	8
AD-1223008.1	37	3	66	9	88	2	110	2
AD-1223009.1	57	9	73	10	83	9	102	4

AD-1223010.1	73	7	82	6	108	19	109	9
AD-1223011.1	71	2	86	16	89	15	107	7
AD-1223012.1	71	10	92	14	96	11	99	6
AD-1223013.1	99	9	114	19	79	23	100	5
AD-1223014.1	77	4	95	10	87	4	101	5
AD-1223015.1	69	13	86	8	82	14	97	12
AD-1223016.1	52	1	76	7	95	18	101	11
AD-1223017.1	45	6	55	1	67	7	84	8
AD-1223018.1	39	9	60	2	80	9	90	4
AD-1223019.1	62	6	59	11	87	6	86	4
AD-1223020.1	60	13	65	2	68	28	82	13
AD-1223021.1	76	6	73	19	70	10	85	8
AD-1223022.1	60	10	64	3	70	3	77	5
AD-1223023.1	56	4	62	3	90	24	73	7
AD-1223024.1	52	3	60	3	63	5	71	21
AD-1223025.1	53	10	64	3	76	3	86	10
AD-1223026.1	63	5	53	7	62	15	85	10
AD-1223027.1	72	14	79	14	80	10	83	4
AD-1223028.1	64	7	68	7	74	3	81	11
AD-1223029.1	78	4	75	17	68	11	82	6
AD-1223030.1	41	8	49	6	68	4	69	7
AD-1223031.1	26	1	34	1	37	6	48	4
AD-1223032.1	35	1	49	5	56	8	73	1
AD-1223033.1	34	6	43	3	59	13	71	3
AD-1223034.1	49	5	50	1	68	2	82	6
AD-1223035.1	36	3	42	8	55	1	74	8
AD-1223036.1	32	5	39	11	49	2	75	5
AD-1223037.1	28	8	29	4	47	11	68	6
AD-1223038.1	23	4	38	6	49	5	69	5
AD-1223039.1	26	9	40	1	41	4	61	11
AD-1223040.1	29	5	37	6	37	4	54	3
AD-1223041.1	31	1	35	2	41	1	53	6
AD-1223042.1	29	4	32	5	42	12	64	10
AD-1223043.1	27	3	40	7	47	6	58	4
AD-1223044.1	29	2	40	3	39	1	55	1
AD-1223045.1	31	2	44	3	42	8	62	5
AD-1223046.1	39	2	42	3	69	4	92	15
AD-1223047.1	35	8	38	5	69	5	80	7
AD-1223048.1	30	2	40	4	71	4	92	21
AD-1223049.1	38	1	45	11	65	2	86	16
AD-1223050.1	36	5	51	6	67	3	82	17
AD-1223051.1	47	7	56	7	68	3	66	10
AD-1223052.1	39	12	47	2	68	1	66	7
AD-1223053.1	42	4	58	15	63	1	56	6
AD-1223054.1	43	9	53	5	87	2	88	1
AD-1223055.1	38	10	52	10	84	6	93	2
AD-1223056.1	49	17	51	9	80	6	125	26
AD-1223057.1	50	3	45	11	81	3	95	12
AD-1223058.1	29	6	38	8	77	4	92	27

AD-1223059.1	28	2	37	6	77	7	67	15
AD-1223060.1	33	1	51	10	68	3	58	1
AD-1223061.1	31	1	44	4	67	3	68	13
AD-1223062.1	57	10	59	4	103	8	80	13
AD-1223063.1	66	5	57	5	102	6	98	24
AD-1223064.1	65	16	75	11	109	14	91	1
AD-1223065.1	50	2	67	22	103	2	91	19
AD-1223066.1	30	5	37	4	84	6	76	1
AD-1223067.1	40	3	54	12	81	9	71	11
AD-1223068.1	36	1	37	5	70	6	61	6
AD-1223069.1	67	27	73	11	99	17	103	21
AD-1223070.1	65	19	58	3	105	3	116	24
AD-1223071.1	40	5	58	14	96	8	90	2
AD-1223072.1	65	14	85	24	115	15	74	15
AD-1223073.1	39	1	59	9	110	14	79	17
AD-1223074.1	42	6	54	5	87	4	63	5
AD-1223075.1	47	10	38	2	78	3	54	2
AD-1223076.1	78	20	70	16	68	14	99	22
AD-1223077.1	70	14	76	11	103	19	90	5
AD-1223078.1	105	6	113	26	106	9	122	9
AD-1223079.1	64	11	76	4	107	7	98	16
AD-1223080.1	79	10	67	19	87	4	89	19
AD-1223081.1	67	21	80	17	99	5	82	16
AD-1223082.1	37	4	45	16	85	13	68	15
AD-1223083.1	44	16	50	7	78	6	64	12
AD-1223084.1	59	12	57	1	96	17	95	3
AD-1223085.1	86	28	79	8	100	3	101	15
AD-1223086.1	67	8	58	6	93	9	123	3
AD-1223087.1	82	21	101	5	95	13	97	8
AD-1223088.1	76	25	92	2	127	20	100	21
AD-1223089.1	78	17	68	17	93	2	83	17
AD-1223090.1	38	3	55	13	84	10	63	16
AD-1223091.1	78	15	60	9	97	23	113	3
AD-1223092.1	66	3	69	16	112	13	79	18
AD-1223093.1	65	1	60	5	119	23	95	15
AD-1223094.1	57	10	61	11	92	7	87	11
AD-1223095.1	67	2	60	9	88	11	97	4
AD-1223096.1	52	20	57	5	100	23	66	13
AD-1223097.1	40	2	64	8	80	7	57	4
AD-1223098.1	41	13	47	6	72	2	50	6
AD-1223099.1	60	18	66	5	76	17	103	20
AD-1223100.1	46	15	54	10	77	6	81	4
AD-1223101.1	76	8	67	16	110	15	91	17
AD-1223102.1	45	6	69	13	96	15	90	6
AD-1223103.1	70	17	71	2	107	18	65	1
AD-1223104.1	57	22	52	8	73	9	55	4
AD-1223105.1	48	15	69	16	84	25	64	16
AD-1223106.1	61	8	59	13	95	6	53	4
AD-1223107.1	71	2	60	20	77	9	89	11

AD-1223108.1	78	3	62	5	85	13	78	5
AD-1223109.1	74	18	63	18	85	0	84	19
AD-1223110.1	64	4	78	9	104	29	73	10
AD-1223111.1	90	8	74	19	83	21	72	15
AD-1223112.1	71	10	87	14	78	14	66	8
AD-1223113.1	62	12	80	1	83	20	60	5
AD-1223114.1	71	18	62	9	68	1	62	10
AD-1223115.1	111	5	80	15	82	7	82	3
AD-1223116.1	80	22	80	10	73	7	92	2
AD-1223117.1	84	23	98	2	92	23	73	17
AD-1223118.1	71	25	67	17	82	26	63	5
AD-1223119.1	66	15	91	33	82	31	87	21
AD-1223120.1	61	6	64	13	88	7	59	4
AD-1223121.1	66	9	49	11	66	5	59	6
AD-1223122.1	90	11	68	20	62	10	74	15
AD-1223123.1	61	22	52	20	53	0	63	4
AD-1223124.1	89	12	72	16	65	5	83	11
AD-1223125.1	77	22	72	18	65	7	73	8
AD-1223126.1	96	18	80	20	77	32	74	13
AD-1223127.1	54	11	60	9	53	9	64	12
AD-1223128.1	58	16	45	1	67	1	65	8
AD-1223129.1	45	7	39	6	56	5	60	1
AD-1223130.1	37	2	50	3	51	5	74	7
AD-1223131.1	57	17	45	13	66	5	70	2
AD-1223132.1	72	16	53	5	71	18	92	7
AD-1223133.1	42	3	57	7	54	2	61	9
AD-1223134.1	49	11	46	1	59	1	84	22
AD-1223135.1	46	3	50	11	57	5	69	1
AD-1223136.1	101	19	100	15	88	26	159	78
AD-1223137.1	88	14	92	13	98	19	91	23
AD-1223138.1	75	9	67	4	71	17	86	26
AD-1223139.1	89	19	63	6	97	31	82	10
AD-1223140.1	90	28	71	8	59	10	76	12
AD-1223141.1	83	3	64	9	62	6	75	14
AD-1223142.1	102	5	61	1	74	19	73	2
AD-1223143.1	96	31	54	1	57	15	88	15
AD-1223144.1	91	16	82	10	112	9	129	35
AD-1223145.1	86	15	74	10	86	5	125	21
AD-1223146.1	81	10	85	3	94	1	143	21
AD-1223147.1	99	15	80	17	86	10	109	24
AD-1223148.1	93	22	82	12	91	17	115	18
AD-1223149.1	88	6	74	4	88	15	110	11
AD-1223150.1	79	6	66	1	71	5	103	17
AD-1223151.1	98	20	64	9	61	17	108	20
AD-1223152.1	121	28	92	14	78	5	102	17
AD-1223153.1	80	15	93	9	105	7	122	23
AD-1223154.1	73	14	85	5	87	13	109	10
AD-1223155.1	87	2	68	3	92	12	108	17
AD-1223156.1	74	19	72	2	73	8	102	12

AD-1223157.1	83	21	76	5	78	12	101	20
AD-1223158.1	78	22	64	12	75	2	97	24
AD-1223159.1	102	36	75	9	115	22	104	16
AD-1223160.1	116	20	122	15	105	13	154	18
AD-1223161.1	80	14	96	7	114	14	99	6
AD-1223162.1	60	5	76	7	97	18	111	24
AD-1223163.1	85	18	79	10	83	15	118	22
AD-1223164.1	75	1	95	21	78	8	113	7
AD-1223165.1	73	7	68	8	66	2	111	28
AD-1223166.1	106	19	92	4	98	37	100	11
AD-1223167.1	111	12	116	21	121	5	124	11
AD-1223168.1	102	20	93	2	124	25	145	4
AD-1223169.1	93	23	89	18	132	17	133	5
AD-1223170.1	85	14	79	25	111	11	119	26
AD-1223171.1	82	19	77	9	89	12	121	30
AD-1223172.1	90	3	76	5	92	7	89	6
AD-1223173.1	74	14	79	15	85	18	119	36
AD-1223174.1	135	52	80	8	90	3	95	15
AD-1223175.1	86	20	96	8	87	4	116	5
AD-1223176.1	88	17	104	12	99	15	123	3
AD-1223177.1	81	14	78	6	90	8	109	23
AD-1223178.1	106	7	80	14	88	2	118	15
AD-1223179.1	83	14	71	10	93	8	95	18
AD-1223180.1	61	19	67	9	79	9	127	4
AD-1223181.1	105	31	80	5	99	12	106	12
AD-1223182.1	69	2	81	12	88	5	105	20
AD-1223183.1	108	38	85	6	106	9	123	17
AD-1223184.1	45	6	61	4	75	8	82	12
AD-1223185.1	59	4	76	15	75	3	107	20
AD-1223186.1	66	12	62	10	88	11	89	7
AD-1223187.1	63	10	58	10	72	7	99	20
AD-1223188.1	51	12	47	8	71	9	90	19
AD-1223189.1	73	15	56	3	75	11	85	2
AD-1223190.1	57	13	61	5	80	13	89	18
AD-1223191.1	55	14	68	9	71	1	100	8
AD-1223192.1	39	3	61	9	73	4	92	16
AD-1223193.1	41	9	51	2	72	9	69	4
AD-1223194.1	34	2	44	5	61	9	79	18
AD-1223195.1	52	17	38	5	65	11	89	12
AD-1223196.1	36	4	39	4	89	22	85	20
AD-1223197.1	66	13	40	6	62	16	70	10
AD-1223198.1	56	8	66	5	78	23	95	14
AD-1223199.1	56	17	61	6	75	5	113	30
AD-1223200.1	51	14	51	9	68	14	102	17
AD-1223201.1	60	15	53	3	59	6	81	3
AD-1223202.1	36	10	46	3	57	9	95	1
AD-1223203.1	43	13	34	1	66	13	82	19
AD-1223204.1	63	16	49	3	60	5	57	3
AD-1223205.1	51	14	57	5	75	3	75	12

AD-1223206.1	30	4	49	10	69	14	67	6
AD-1223207.1	67	11	67	6	67	7	77	11
AD-1223208.1	64	11	61	8	68	4	84	24
AD-1223209.1	56	12	62	7	73	11	86	16
AD-1223210.1	58	33	40	2	69	8	93	2
AD-1223211.1	39	0	48	4	52	15	57	5
AD-1223212.1	65	5	57	2	53	2	95	20
AD-1223213.1	55	11	57	3	69	5	78	10
AD-1223214.1	28	2	46	1	53	8	70	5
AD-1223215.1	37	2	52	1	61	12	80	11
AD-1223216.1	42	14	47	3	67	31	72	6
AD-1223217.1	43	7	52	3	66	5	86	2
AD-1223218.1	64	26	45	6	59	13	86	11
AD-1223219.1	70	10	55	7	56	8	58	3
AD-1223220.1	54	15	64	3	42	4	57	2
AD-1223221.1	51	15	55	6	45	8	62	8
AD-1223222.1	70	5	66	5	58	6	86	20
AD-1223223.1	37	5	54	4	59	14	61	15
AD-1223224.1	55	4	40	1	51	4	61	3
AD-1223225.1	49	17	41	6	61	11	68	1
AD-1223226.1	57	3	46	12	71	4	83	19
AD-1223227.1	73	7	55	1	80	7	92	14
AD-1223228.1	51	5	41	3	72	4	89	6
AD-1223229.1	63	7	54	11	86	5	99	13
AD-1223230.1	52	7	46	8	81	8	81	12
AD-1223231.1	61	4	52	1	78	9	88	11
AD-1223232.1	76	6	64	7	75	8	80	13
AD-1223233.1	70	8	53	6	77	5	66	12
AD-1223234.1	68	11	56	14	81	5	94	14
AD-1223235.1	58	4	41	2	94	2	96	7
AD-1223236.1	72	4	62	19	101	10	99	6
AD-1223237.1	78	10	63	3	109	5	103	20
AD-1223238.1	67	16	65	22	102	14	100	15
AD-1223239.1	58	2	57	3	90	8	89	21
AD-1223240.1	57	1	53	8	87	7	79	12
AD-1223241.1	62	9	50	10	73	11	70	18
AD-1223242.1	54	9	55	11	70	8	87	4
AD-1223243.1	62	11	48	4	77	6	114	6
AD-1223244.1	57	5	54	9	94	9	105	18
AD-1223245.1	75	8	78	2	111	28	116	9
AD-1223246.1	51	4	49	3	85	8	92	6
AD-1223247.1	61	7	53	11	87	10	81	6
AD-1223248.1	60	2	54	11	75	1	72	11
AD-1223249.1	65	7	71	5	85	12	111	8
AD-1223250.1	85	15	89	3	118	14	131	1
AD-1223251.1	74	6	88	5	108	8	102	2
AD-1223252.1	55	3	78	19	107	19	95	11
AD-1223253.1	48	7	69	6	94	9	90	13
AD-1223254.1	58	11	59	21	96	15	83	5

AD-1223255.1	48	5	58	11	79	5	68	2
AD-1223256.1	51	9	53	7	75	4	99	11
AD-1223257.1	44	2	43	6	98	10	120	15
AD-1223258.1	68	8	67	6	107	12	111	6
AD-1223259.1	96	7	103	8	111	15	106	1
AD-1223260.1	82	2	80	7	114	15	112	11
AD-1223261.1	62	1	64	3	99	20	95	1
AD-1223262.1	48	10	48	9	86	8	90	6
AD-1223263.1	51	5	49	6	71	3	71	5
AD-1223264.1	51	2	56	13	75	7	79	3
AD-1223265.1	48	3	47	1	82	1	94	12
AD-1223266.1	42	6	49	5	84	1	105	9
AD-1223267.1	76	2	101	20	105	7	108	11
AD-1223268.1	63	12	83	28	96	13	86	17
AD-1223269.1	43	4	51	17	93	0	84	10
AD-1223270.1	63	3	56	7	96	6	95	1
AD-1223271.1	58	1	63	18	71	2	93	11
AD-1223272.1	55	7	56	11	82	1	106	7
AD-1223273.1	66	10	63	18	106	9	120	15
AD-1223274.1	67	6	64	13	97	13	98	12
AD-1223275.1	67	8	88	17	103	9	79	8
AD-1223276.1	75	10	64	13	94	13	84	3
AD-1223277.1	73	5	62	6	88	15	82	1
AD-1223278.1	60	3	61	7	83	10	81	5
AD-1223279.1	65	3	64	12	88	12	93	13
AD-1223280.1	67	2	67	9	89	4	119	9
AD-1223281.1	68	8	62	16	95	10	96	2
AD-1223282.1	57	7	73	2	87	8	95	3
AD-1223283.1	50	3	75	3	75	2	80	1
AD-1223284.1	51	7	61	26	84	9	80	2
AD-1223285.1	70	13	70	10	89	15	87	8
AD-1223286.1	43	1	48	8	73	18	77	8
AD-1223287.1	50	4	46	16	65	4	76	0
AD-1223288.1	56	9	55	20	75	10	78	3
AD-1223289.1	72	19	57	10	87	3	91	10
AD-1223290.1	67	2	73	5	88	13	89	6
AD-1223291.1	74	11	69	15	81	1	70	8
AD-1223292.1	61	2	58	5	81	2	78	1
AD-1223293.1	63	9	60	6	82	4	74	6
AD-1223294.1	54	2	56	10	53	2	68	1
AD-1223295.1	80	14	90	3	75	10	76	13
AD-1223296.1	92	20	109	8	87	10	95	11
AD-1223297.1	75	9	89	2	80	5	96	4
AD-1223298.1	75	6	79	10	86	11	94	2
AD-1223299.1	77	8	79	6	89	6	82	1
AD-1223300.1	78	15	72	5	76	5	71	8
AD-1223301.1	64	4	67	9	57	2	60	8
AD-1223302.1	66	5	79	17	66	4	71	9
AD-1223303.1	78	9	86	14	68	1	74	9

AD-1223304.1	64	2	76	10	72	7	72	5
AD-1223305.1	59	4	72	11	66	3	78	13
AD-1223306.1	58	1	51	33	77	23	81	13
AD-1223307.1	61	9	78	15	63	4	70	5
AD-1223308.1	52	7	52	10	63	5	58	6
AD-1223309.1	60	1	39	4	59	4	60	5
AD-1223310.1	52	5	40	7	60	2	55	4
AD-1223311.1	62	7	59	13	62	2	54	5
AD-1223312.1	49	8	44	8	50	5	56	8
AD-1223313.1	43	5	44	9	51	3	50	0
AD-1223314.1	45	8	39	4	53	5	49	6
AD-1223315.1	53	4	46	7	56	5	50	6

The results of the multi-dose screen in primary human hepatocytes transfected with an additional set of exemplary human VEGF-A siRNAs is shown in Table 11 (correspond to modified siRNAs in Table 10A). The multi-dose experiments were performed at 50 nM, 10 nM, 1 nM, and 0.1 nM final duplex concentrations and the data are expressed as percent message remaining relative to non-targeting control.

Of the exemplary siRNA duplexes evaluated in Table 11, 6 achieved a knockdown of VEGF-A of $\geq 70\%$, 34 achieved a knockdown of VEGF-A of $\geq 60\%$, 49 achieved a knockdown of VEGF-A of $\geq 50\%$, 62 achieved a knockdown of VEGF-A of $\geq 30\%$, and 75 achieved a knockdown of VEGF-A of $\geq 20\%$ when administered at the 50 nM concentration.

Of the exemplary siRNA duplexes evaluated in Table 11, 2 achieved a knockdown of VEGF-A of $\geq 70\%$, 18 achieved a knockdown of VEGF-A of $\geq 60\%$, 35 achieved a knockdown of VEGF-A of $\geq 50\%$, 66 achieved a knockdown of VEGF-A of $\geq 30\%$, and 77 achieved a knockdown of VEGF-A of $\geq 20\%$ when administered at the 10 nM concentration.

Of the exemplary siRNA duplexes evaluated in Table 11, 13 achieved a knockdown of VEGF-A of $\geq 50\%$, 33 achieved a knockdown of VEGF-A of $\geq 40\%$, 49 achieved a knockdown of VEGF-A of $\geq 30\%$, 62 achieved a knockdown of VEGF-A of $\geq 20\%$, and 74 achieved a knockdown of VEGF-A of $\geq 10\%$ when administered at the 1 nM concentration.

Of the exemplary siRNA duplexes evaluated in Table 11, 2 achieved a knockdown of VEGF-A of $\geq 40\%$, 7 achieved a knockdown of VEGF-A of $\geq 30\%$, 25 achieved a knockdown of VEGF-A of $\geq 20\%$, 46 achieved a knockdown of VEGF-A of $\geq 10\%$, and 55 achieved a knockdown of VEGF-A of $\geq 5\%$ when administered at the 0.1 nM concentration.

Table 11. VEGF-A endogenous *in vitro* multi-dose screen following cellular transfection with additional set of exemplary human VEGF-A siRNAs

Duplex	50 nM dose		10 nM dose		1 nM dose		0.1 nM dose	
	Avg	SD	Avg	SD	Avg	SD	Avg	SD
AD-1353514.1	73.2	14.7	47.83	6.33	89.52	8.82	108.56	17.50
AD-1353484.1	60.9	2.1	30.99	3.11	46.98	8.32	74.34	10.43
AD-1353454.1	32.1	2.1	31.33	5.04	48.05	7.92	52.74	3.79
AD-1353468.1	36.5	10.1	37.70	11.20	54.44	8.95	76.93	5.45
AD-1353498.1	71.4	8.9	70.68	17.79	91.31	15.16	119.43	2.90
AD-1353438.1	30.4	5.0	36.17	11.97	49.92	9.56	68.61	10.47
AD-1353515.1	85.4	4.7	59.45	15.56	86.89	15.76	119.70	10.55
AD-1353485.1	61.2	3.6	67.37	28.56	73.00	19.46	101.36	12.30
AD-1353455.1	37.7	5.8	39.73	4.39	57.46	11.43	75.26	9.60
AD-1353513.1	72.4	19.2	70.36	7.66	65.81	2.00	99.31	4.26
AD-1353483.1	45.4	7.9	59.48	13.52	63.00	1.14	88.59	7.06
AD-1353453.1	49.4	3.1	52.47	11.81	73.02	14.48	87.42	1.86
AD-1353502.1	111.8	3.9	122.89	9.45	108.63	2.65	101.24	12.32
AD-1353472.1	77.7	1.1	77.95	21.21	82.89	10.59	110.13	1.33
AD-1353442.1	43.1	5.9	58.75	26.58	53.92	6.62	86.50	13.94
AD-1353499.1	52.6	8.5	50.86	1.41	60.86	4.25	68.29	32.87
AD-1353469.1	34.2	4.9	26.91	8.25	52.31	12.97	68.94	3.00
AD-1353439.1	40.5	7.0	33.92	5.01	47.72	5.18	59.98	0.64
AD-1353516.1	73.4	2.3	91.54	6.70	96.22	13.84	109.69	16.01
AD-1353486.1	55.2	10.8	69.54	22.45	66.89	15.26	85.60	12.44
AD-1353456.1	36.7	2.3	40.99	2.33	47.06	0.75	77.80	12.27
AD-1353509.1	78.2	15.5	65.05	19.24	79.91	15.99	92.15	6.76
AD-1353479.1	34.1	1.7	59.07	11.65	61.37	12.56	81.86	11.12
AD-1353449.1	37.2	3.1	43.76	2.00	64.46	14.54	94.21	15.51
AD-1353503.1	107.2	12.2	124.19	25.48	129.99	12.55	103.32	5.51
AD-1353473.1	69.5	12.8	81.70	4.74	73.09	4.34	96.57	7.16
AD-1353443.1	56.0	5.3	47.76	1.37	60.14	2.14	78.45	2.90
AD-1353506.1	125.4	15.1	72.10	10.55	98.53	31.92	139.95	25.71
AD-1353476.1	31.1	0.9	52.33	18.02	53.46	8.06	81.81	20.46
AD-1353446.1	33.5	3.9	49.43	19.14	48.57	12.81	89.09	18.37
AD-1353497.1	73.7	15.2	76.17	18.94	110.55	19.54	108.38	14.24
AD-1353467.1	24.1	1.6	68.83	36.91	60.52	9.05	88.11	6.79
AD-1353437.1	26.6	1.3	36.54	18.99	58.73	11.11	78.39	13.30
AD-1353494.1	78.9	18.5	64.78	5.56	80.76	28.61	105.16	8.40
AD-1353464.1	39.2	11.1	43.51	10.28	46.64	1.22	86.15	13.43
AD-1353434.1	25.8	2.3	35.87	7.53	46.49	2.58	88.48	12.93

AD-1353505.1	79.3	14.0	90.37	26.82	88.87	9.99	118.05	27.89
AD-1353475.1	45.8	4.4	81.74	24.42	61.65	9.73	113.65	24.35
AD-1353445.1	33.1	4.6	34.12	2.32	58.71	12.42	76.70	5.84
AD-1353518.1	106.7	9.5	66.77	10.60	101.34	19.91	116.14	13.23
AD-1353490.1	57.6	2.9	65.55	2.51	59.72	1.89	82.32	10.94
AD-1353460.1	43.3	2.2	57.20	17.51	57.83	6.41	81.60	3.42
AD-1353512.1	49.3	2.8	56.05	16.30	73.12	5.01	80.00	12.61
AD-1353482.1	31.8	7.0	41.02	4.08	49.87	13.58	75.30	11.76
AD-1353452.1	22.0	0.8	27.69	6.99	49.18	8.36	64.25	8.77
AD-1353501.1	93.4	14.4	73.05	23.54	91.52	22.64	118.07	3.73
AD-1353471.1	35.3	16.6	55.66	10.36	62.03	8.43	74.30	10.30
AD-1353441.1	42.8	12.1	37.07	2.05	55.05	11.83	87.87	11.35
AD-1353495.1	64.9	6.6	57.36	3.08	76.11	7.59	91.83	2.54
AD-1353465.1	46.1	9.0	52.06	2.82	71.33	9.34	96.77	3.94
AD-1353435.1	26.6	0.6	34.92	2.32	52.83	10.26	75.24	2.38
AD-1353510.1	119.8	18.1	101.24	29.18	93.46	10.24	113.16	12.92
AD-1353480.1	31.4	6.3	39.32	0.42	41.34	14.17	67.02	5.59
AD-1353450.1	34.6	7.4	66.32	23.95	50.20	0.35	73.85	1.29
AD-1353492.1	77.7	10.8	71.56	11.36	77.86	8.02	121.84	4.81
AD-1353462.1	77.9	8.7	61.05	3.21	84.55	11.04	95.78	4.27
AD-1353432.1	53.3	2.4	54.18	15.15	77.02	10.61	91.59	3.58
AD-1353504.1	112.3	16.9	103.54	22.58	96.95	21.25	104.68	1.67
AD-1353474.1	37.3	0.8	45.61	7.93	64.86	13.55	90.57	9.24
AD-1353444.1	34.6	2.7	46.49	12.28	64.50	3.69	90.43	15.39
AD-1353493.1	115.2	3.5	109.69	24.35	115.11	15.22	148.20	6.03
AD-1353463.1	37.4	10.6	39.98	1.58	67.51	13.18	101.55	10.32
AD-1353433.1	41.6	2.6	49.27	11.07	57.69	7.11	85.23	1.77
AD-1353508.1	99.1	18.5	108.35	7.54	119.28	22.06	127.04	26.81
AD-1353478.1	61.3	7.9	80.29	6.74	84.40	5.07	106.24	18.11
AD-1353448.1	46.8	10.5	45.28	0.83	70.79	13.97	93.49	2.61
AD-1353496.1	71.4	11.4	72.67	26.10	75.08	10.38	78.24	0.83
AD-1353466.1	27.1	2.2	41.23	4.27	46.93	8.96	74.57	10.13
AD-1353436.1	34.3	12.7	44.21	16.99	76.15	17.23	100.46	13.86
AD-1353500.1	93.3	10.4	71.79	21.42	90.97	13.97	121.98	8.36
AD-1353470.1	56.5	18.5	68.60	21.85	66.08	16.35	98.20	16.07
AD-1353440.1	42.7	13.9	32.74	2.42	47.72	4.01	87.22	13.60
AD-1334067.3	62.0	5.0	66.03	15.65	104.31	6.24	118.77	15.26
AD-1353488.1	45.4	9.5	54.95	18.87	66.30	5.64	93.92	6.82
AD-1353458.1	49.9	2.7	42.68	4.29	52.79	7.82	86.26	5.91
AD-1334065.3	71.1	12.6	78.09	22.23	84.66	18.18	114.25	13.96
AD-1353487.1	34.9	4.5	66.90	18.73	56.96	8.69	78.72	9.61

AD-1353457.1	38.2	9.3	58.10	28.97	54.23	13.92	72.52	6.80
AD-1353511.1	83.9	11.7	62.66	20.11	82.39	4.29	108.94	17.57
AD-1353481.1	37.4	5.3	33.15	14.70	53.45	6.54	89.49	20.18
AD-1353451.1	36.5	3.0	50.19	3.34	70.69	2.05	89.11	5.24
AD-1353507.1	88.8	24.1	103.80	3.43	118.16	22.78	109.81	8.53
AD-1353477.1	58.1	13.7	71.67	24.75	89.22	12.01	97.98	5.38
AD-1353447.1	35.9	5.8	35.44	0.37	69.83	7.21	93.70	5.60
AD-1353517.1	81.4	27.8	65.25	15.18	87.98	15.64	87.33	5.55
AD-1353489.1	39.1	8.5	48.80	14.60	53.72	2.50	78.25	4.63
AD-1353459.1	36.3	3.0	42.48	5.66	55.07	0.79	88.61	15.57
AD-1353519.1	99.4	27.7	81.48	9.81	93.30	21.44	129.30	24.38
AD-1353491.1	49.6	22.3	68.94	16.28	84.63	0.34	82.41	4.90
AD-1353461.1	36.0	7.6	42.22	11.83	52.71	11.40	75.56	6.49

Example 3. *In vivo* screening of VEGF-A siRNA

This Example investigates the effects of the exemplary VEGF-A targeting siRNAs for *in vivo* efficacy for human VEGF-A knockdown in AAV mice. The first exemplary set of VEGF-A targeting siRNAs investigated includes AD-64228, AD-953374, AD-953504, AD-953336, AD-953337, AD-901376, AD-953364, AD-953340, AD-953351, AD-953342, AD-953308, AD-953344, AD-953339, and AD-953363 (summarized in Table 12 and **FIGs. 1A-1B**). The second set of exemplary VEGF-A targeting siRNAs investigated included AD-901349, AD-953481, AD-901356, AD-901355, AD-953365, AD-953410, AD-953411, AD-953338, AD-953350, AD-953375, AD-953341, AD-953370, AD-953386, AD-64958 (summarized in Table 13 and **FIGs. 3A-3B**). The final set of exemplary VEGF-A targeting siRNAs investigated included AD-1397050, AD-1397051, AD-1397052, AD-1397053, AD-1397054, AD-1397055, AD-1397056, AD-1397058, AD-1397059, AD-1397060, AD-1397061, AD-1397062, AD-1397064, AD-1397065, AD-1397066, AD-1397067, AD-1397068, AD-1397069, and AD-64958 (summarized in Table 14 and **FIGs. 5A-5C**).

Table 12. VEGF-A *in vivo* single-dose screen with one set of exemplary VEGF-A siRNA duplexes. In this table the column “Duplex Name” provides the numerical part of the duplex name. The duplex name can comprise a suffix (number following the decimal point in a duplex name) that merely refers to a batch production number. The suffix can be omitted from the duplex name without changing the chemical structure. For example, duplex AD-953504.1 in Table 4A refers to the same duplex as AD-953504 in Table 12.

Duplex Name	Strand	Target	Modified Sequence (5'-3')	SEQ ID NO
AD-64228	sense	None	asascaguGfuUfCfUfugcucuauaaL96	4162
	anti-sense	mTTR	usUfsauaGfaGfCfaagaAfcAfcuguususu	4163
AD-953504	sense	VEGF-A	asasaau(Ahd)gadCadTugcuauucuaL96	1037
	anti-sense	VEGF-A	VPusdAsgadAudAgcaadTgdTcdTauuuusasu	1167
AD-953308	sense	VEGF-A	csascca(Uhd)GfcAfGfAfuaugcggaal96	579
	anti-sense	VEGF-A	VPusUfscgcCfaUfAfaucuGfcAfuggugsasu	709
AD-953336	sense	VEGF-A	asasaga(Chd)UfgAfUfAfcagaacgauaL96	518
	anti-sense	VEGF-A	VPusAfsucgUfuCfUfguauCfaGfucuuuscsc	648
AD-953337	sense	VEGF-A	asasgac(Uhd)GfaUfAfCfagaacgaucaL96	522
	anti-sense	VEGF-A	VPusGfsaucGfuUfCfuguaUfcAfgucuuusc	652
AD-953339	sense	VEGF-A	gsascug(Ahd)UfaCfAfGfaacgaucgaal96	528
	anti-sense	VEGF-A	VPusUfscgaUfcGfUfucugUfaUfcagucsusu	658
AD-953340	sense	VEGF-A	ascsuga(Uhd)AfcAfGfAfacgaucgauaL96	517
	anti-sense	VEGF-A	VPusAfsucgAfuCfGfuucuGfuAfcaguscusu	647
AD-953342	sense	VEGF-A	asusaca(Ghd)AfaCfGfAfucgauacagaL96	523
	anti-sense	VEGF-A	VPusCfsuguAfuCfGfaucgUfuCfuguauscsa	653
AD-953344	sense	VEGF-A	csasgaa(Chd)AfgUfCfCfuuaauccagaL96	527
	anti-sense	VEGF-A	VPusCfsuggAfuUfAfaggaCfuGfuucugsusc	657
AD-953351	sense	VEGF-A	asgsugc(Uhd)AfaUfGfUfuauugguguaL96	540
	anti-sense	VEGF-A	VPusAfsacCfaAfUfaacaUfuAfgcacusgsu	670
AD-953363	sense	VEGF-A	gsasgaa(Ahd)GfuGfUfUfuauauacgaL96	519
	anti-sense	VEGF-A	VPusCfsguaUfaUfAfaaacAfcUfuucucsusu	649
AD-953364	sense	VEGF-A	ascsggu(Ahd)CfuUfAfUfuuaauauccaL96	567
	anti-sense	VEGF-A	VPusGfsgauAfuUfAfaauaAfgUfaccgusasu	697
AD-901376	sense	VEGF-A	ascsggu(Ahd)CfuUfAfUfuuaauauccaL96	4157

	anti-sense	VEGF-A	VPusGfsgaua(Tgn)uaaaauAfgUfaccgusasu	131
AD-953374	sense	VEGF-A	asasaau(Ahd)GfaCfAfUfugcuaauucuaL96	553
	anti-sense	VEGF-A	VPusAfsgaaUfaGfCfaaugUfcUfauuuusasu	683

Table 13. VEGF-A *in vivo* single-dose screen with one set of exemplary VEGF-A siRNA duplexes. In this table the column “Duplex Name” provides the numerical part of the duplex name. The duplex name can comprise a suffix (number following the decimal point in a duplex name) that merely refers to a batch production number. The suffix can be omitted from the duplex name without changing the chemical structure. For example, duplex AD-953481.1 in Table 4A refers to the same duplex as AD-953481 in Table 13.

Duplex Name	Strand	Target	Modified Sequence (5'-3')	SEQ ID NO
AD-64958	sense	None	asascaguGfuUfCfUfugcucuaauaaL96	5003
	anti-sense	None	usUfsauaGfagcaagaAfcAfcugususu	5004
AD-953481	sense	VEGF-A	asgsugc(Uhd)aadTgdTuauugguguaL96	1038
	anti-sense	VEGF-A	VPusdAscadCcdAauaadCadTudAgcacusgsu	1168
AD-901349	sense	VEGF-A	asasgac(Uhd)GfaUfAfCfagaacgaucuaL96	4156
	anti-sense	VEGF-A	VPusGfsaucg(Tgn)ucuguaUfcAfgucuuususc	130
AD-953338	sense	VEGF-A	asgsacu(Ghd)AfuAfCfAfgaacgaucgaL96	520
	anti-sense	VEGF-A	VPusCfsgauCfGfUfUfcuguAfuCfagucususu	650
AD-953341	sense	VEGF-A	csusgau(Ahd)CfaGfAfAfcgaucgauaaL96	532
	anti-sense	VEGF-A	VPusUfsaucGfaUfCfGuucUfgUfaucagsusc	662
AD-901355	sense	VEGF-A	csgsaca(Ghd)AfaCfAfGfuccuuaaucaL96	4
	anti-sense	VEGF-A	VPusGfsauua(Agn)ggacugUfuCfugucgsasu	133
AD-901356	sense	VEGF-A	csasgaa(Chd)AfgUfCfCfuuaauccagaL96	3
	anti-sense	VEGF-A	VPusCfsugga(Tgn)uaaggaCfuGfuucugsusc	132
AD-953350	sense	VEGF-A	asascag(Uhd)GfcUfAfAfuguuauuggaL96	524
	anti-sense	VEGF-A	VPusCfscaaUfaAfCfaauaGfcAfcugusasa	654
AD-953365	sense	VEGF-A	csgsgua(Chd)UfuAfUfUfaauaucccaL96	552
	anti-sense	VEGF-A	VPusGfsggaUfaUfUfaaaUfaGfuaccgsusa	682
AD-953370	sense	VEGF-A	gscsucu(Chd)UfuAfUfUfuguaccgguaL96	533
	anti-sense	VEGF-A	VPusAfscggGfuAfCfaaaUfaGfagagcsasa	663
AD-953375	sense	VEGF-A	asasaau(Ghd)AfcAfUfUfugcuaauucugaL96	530

	anti-sense	VEGF-A	VPusCfsagaAfuAfGfcaauGfuCfuauuususa	660
AD-953386	sense	VEGF-A	csgsaag(Uhd)GfgUfGfAfagucauggaL96	541
	anti-sense	VEGF-A	VPusCfscauGfaAfCfuucaCfcAfcuucgsusg	671
AD-953410	sense	VEGF-A	gsasaag(Uhd)GfuUfUfUfauauacgguaL96	585
	anti-sense	VEGF-A	VPusAfsccgUfaUfAfuaaaAfcAfcuuucsusc	715
AD-953411	sense	VEGF-A	gsusuuu(Ahd)UfaUfAfCfpgguacuuuaL96	584
	anti-sense	VEGF-A	VPusAfsuaaGfuAfCfcguaUfaUfaaaacsasc	714

Table 14. VEGF-A *in vivo* single-dose screen with one set of exemplary VEGF-A siRNA duplexes. In this table, the columns “Duplex Name” and “Strand Name” provide the numerical part of the duplex or strand name. The duplex or strand name can comprise a suffix (number following the decimal point in a duplex name) that merely refers to a batch production number. The suffix can be omitted from the duplex name without changing the chemical structure. For example, the antisense strand name A-2521293.1 in Table 10A refers to the same antisense strand as A-2521293 in Table 14.

Duplex Name	Strand Name	Strand	Target	SEQ ID NO (modified)	Modified Sequence (5'-3')	Unmodified Sequence (5'-3')	SEQ ID NO (unmodified)
AD-64958	A-128009	sense	None	5003	asascaguGfuUfCfUfugcucuaualL96	AACAGUGUUCUUGCUCUAUA A	5021
	A-126312	anti-sense	None	5004	usUfsauaGfagcaagaAfcAfcuguususu	UUAUAGAGCAAGAACACUGU UUU	5022
AD-1397068	A-1700995	sense	VEGF-A	1044	asasgac(Uhd)gadTadCagaacgaucaL96	AAGACUGATACAGAACGAUCA	1304
	A-2521293	anti-sense	VEGF-A	3901	VPusdGsaudCg(U2p)ucugdTadTcdAgucususuc	UGAUCGUUCU GTATCAGUCU UUC	4081
AD-1397052	A-1701263	sense	VEGF-A	10	csusgau(Ahd)CfaGfAfAfcgaucgauaalL96	CUGAUACAGAACGAUCGAUA A	268
	A-2521192	anti-sense	VEGF-A	3957	VPusUfsaudCg(A2p)ucguucUfgUfaucagsusc	UUAUCGAUCGUUCUGUAUCA GUC	4137
AD-1397050	A-2600337	sense	VEGF-A	5005	asusgcagAfuUfAfUfgcgg(Ahd)ucaaaL96	AUGCAGAUUAUGCGGAUCAA A	5023
	A-2521186	anti-sense	VEGF-A	3936	VPusUfsugdAu(C2p)cgcauaAfuCfugcausgsg	UUUGAUCCGC AUAAUCUGCA UGG	4116

AD-1397051	A-2600338	sense	VEGF-A	5006	ascscaggAfaAfGfAfcuga(Uhd)acagaL96	ACCAGGAAAGACUGAUACAG A	5024
	A-2521190	anti-sense	VEGF-A	3918	VPusCfsuguAfucagucUfuCfcuggusgsc	UCUGUAUCAGUCUUUCCUGGUGC	4098
AD-1397053	A-2600339	sense	VEGF-A	5007	asgsaac(Ahd)GfuCfCfUfuaauccagaaL96	AGAACAGUCCUUAUCCAG A	5025
	A-2521200	anti-sense	VEGF-A	3924	VPusUfscudGg(A2p)uuaaggAfcUfguucusgsu	UUCUGGAUUAAGGACUGUUCUGU	4104
AD-1397054	A-2600340	sense	VEGF-A	5008	asgsauu(Ahd)GfaGfAfGfuuuuuuuuL96	AGAUUAGAGAGUUUUAUUUC A	5026
	A-2282496	anti-sense	VEGF-A	2640	VPusGfsaaaUfaaacucUfcUfaaucususc	UGAAAUAAAA CUCUCUAAUCUUC	4110
AD-1397055	A-2600341	sense	VEGF-A	5009	asasaag(Ahd)GfaAfAfGfuguuuuuuL96	AAAAGAGAAA GUGUUUUAUA A	5027
	A-2282766	anti-sense	VEGF-A	2775	VPusUfsauaAfaacacuuUfcUfcuuuuscscu	UUAUAAAAACA CUUUCUCUUUCU	3673
AD-1397056	A-2600342	sense	VEGF-A	5010	asasagagAfaAfGfUfguuu(Uhd)auauaL96	AAAGAGAAAGUGUUUUUAUA A	5028
	A-2282768	anti-sense	VEGF-A	2776	VPusAfsuauAfaaacacuUfuCfucuuuscsc	UAUAUAAAACACUUUCUCUUUUC	3674
AD-1397058	A-2600344	sense	VEGF-A	5011	csusacagcaCfAfAfcaaa(Uhd)gugaal96	CUACAGCACAA CAAAUGUGAA	5029
	A-2521229	anti-sense	VEGF-A	3953	VPusdTscadCadTuugudTgUfgcuguagsgsg	UTCACATUUGUTGUGCUGUAGGG	4133
AD-1397059	A-2600345	sense	VEGF-A	5012	asasaga(Chd)ugAfUfAfcagaacgauaL96	AAAGACUGAUACAGAACGAU A	5030
	A-2521233	anti-sense	VEGF-A	3889	VPusdAsucdGudTcugudAuCfagucuuuscsc	UAUCGUTCUGUAUCAGUCUUUCC	4069
AD-1397060	A-2600346	sense	VEGF-A	5013	asasgac(Uhd)gaUfAfCfagaacgaucaL96	AAGACUGAUA CAGAACGAUC A	5031

	A-2521235	anti-sense	VEGF-A	3902	VPusdGsaudCg(U2p)ucugdTaUfcagucuuusc	UGAUCGUUCU GTAUCAGUCU UUC	5039
AD-1397061	A-2600347	sense	VEGF-A	5014	asusacagaaCfGfAfucga(Uhd)acagaL96	AUACAGAACG AUCGAUACAG A	5032
	A-2521239	anti-sense	VEGF-A	3932	VPusdCsugdTa(U2p)cgaudCgUfucuguauscsg	UCUGTAUCGA UCGUUCUGUA UCG	4112
AD-1397062	A-2600348	sense	VEGF-A	5015	csasgaa(Chd)agUfCfCfuuaauccagaL96	CAGAACAGUCC UUAUCCAGA	5033
	A-2521245	anti-sense	VEGF-A	3944	VPusdCsugdGa(U2p)uaagdGaCfuguucugsusc	UCUGGAUUAA GGACUGUUCU GUC	4124
AD-1397064	A-2600350	sense	VEGF-A	5016	asusugg(Ahd)uuCfGfCfcauuuuauuaL96	AUUGGAUUCG CCAUUUUAAU A	5034
	A-2521257	anti-sense	VEGF-A	3938	VPusdAsaudAadAauggdCgAfauccaususc	UAAUAAAAUG GCGAAUCCAA UUC	4118
AD-1397065	A-2600351	sense	VEGF-A	5017	gsasuucgccAfUfUfuuau(Uhd)uuucaL96	GAUUCGCCAU UUUAUUUUUC A	5035
	A-2521259	anti-sense	VEGF-A	3965	VPusdGsaaAadAuaaadAuGfgcgaaucscsg	UGAAAAUAA AAUGGCGAAU CCG	4145
AD-1397066	A-2600352	sense	VEGF-A	5018	gsasgaa(Ahd)guGfUfUfuuauauacgaL96	GAGAAAGUGU UUUAUAUACG A	5036
	A-2521271	anti-sense	VEGF-A	3962	VPusdCsgudAudAuaaadAcAfcuuucucsusu	UCGUAAUAA AACACUUUCU CUU	4142
AD-1397067	A-2600353	sense	VEGF-A	5019	gsusguu(Uhd)uaUfAfUfacgguacuuaL96	GUGUUUUAA UACGGUACUU A	5037
	A-2521275	anti-sense	VEGF-A	3971	VPusdAsagdTadCcguaadTaUfaaaacacsusu	UAAGTACCGU ATAUAAAACAC UU	4151
AD-1397069	A-2600354	sense	VEGF-A	5020	asgsauu(Ahd)gadGadGuuuuauuucaL96	AGAUUAGAGA GUUUUAUUUC A	5038
	A-2521319	anti-sense	VEGF-A	3928	VPusdGsaaAadAaaacdTcdTcdTaaucususc	UGAAAUAAAA CTCTCTAAUCU UC	4108

Experimental Methods

An AAV vector harboring *Homo sapiens* VEGF-A was injected in 6-8 week old C57BL/6 female mice (2×10^{11} viral particles/mouse), and at 14 days post-AAV administration, a selected siRNA or a control agent were subcutaneously injected at 3 mg/kg in mice (n=3 per group). Mice were sacrificed and their livers were assessed for VEGF-A mRNA levels at 14 days post-injection of the siRNAs or control.

Results

Table 15 and **FIG. 2** demonstrate the results of the *in vivo* screen with the siRNA duplexes corresponding to the siRNA sequences in Table 12. Of the siRNA duplexes evaluated *in vivo* in Table 15, 2 achieved a knockdown of VEGF-A of $\geq 60\%$, 4 achieved a knockdown of VEGF-A of $\geq 50\%$, 9 achieved a knockdown of VEGF-A of $\geq 40\%$, 11 achieved a knockdown of VEGF-A of $\geq 30\%$, and 13 achieved a knockdown of VEGF-A of $\geq 15\%$.

Table 15. Efficacy of exemplary VEGF-A siRNAs in mice. In this table the column “Duplex Name” provides the numerical part of the duplex name with a suffix (number following the decimal point in a duplex name) that merely refers to a batch production number. The suffix can be omitted from the duplex name without changing the chemical structure. For example, duplex AD-953504 in Table 12 refers to the same duplex as AD-953504.2 in Table 15.

Duplex (Administered at 3 mg/kg)	Day 14 post-treatment	
	% VEGF-A Message Remaining	St Dev
PBS	101.85	21.59
Naïve	106.47	14.34
AD-64228.39	62.99	16.53
AD-901376.2	72.86	10.62
AD-953308.2	81.89	34.49
AD-953336.2	51.31	16.11
AD-953337.2	44.93	5.57
AD-953339.2	58.33	25.29
AD-953340.2	33.05	18.66
AD-953342.2	35.97	8.19
AD-953344.2	56.71	14.45
AD-953351.2	43.75	29.11
AD-953363.2	52.28	10.56
AD-953364.2	69.25	10.87
AD-953374.2	59.51	18.65
AD-953504.2	63.66	10.61

Table 16 and **FIG. 4** demonstrate the results of the *in vivo* screen with the siRNA duplexes corresponding to the siRNA sequences in Table 13. Of the siRNA duplexes evaluated *in vivo* in Table 16, 3 achieved a knockdown of VEGF-A of $\geq 70\%$, 6 achieved a knockdown of VEGF-A of $\geq 60\%$, 9 achieved a knockdown of VEGF-A of $\geq 50\%$, 12 achieved a knockdown of VEGF-A of $\geq 40\%$, and 13 achieved a knockdown of VEGF-A of $\geq 30\%$.

Table 16. Efficacy of exemplary VEGF-A siRNAs in mice. In this table the column “Duplex Name” provides the numerical part of the duplex name with a suffix (number following the decimal point in a duplex name) that merely refers to a batch production number. The suffix can be omitted from the duplex name without changing the chemical structure. For example, duplex AD-901349 in Table 13 refers to the same duplex as AD-901349.1 in Table 16.

Duplex (Administered at 3 mg/kg)	Day 14 post-treatment	
	% VEGF-A Message Remaining	St Dev
PBS	102.2	24.0
Naïve	56.8	8.9
AD-901349.1	26.4	14.1
AD-953481.1	22.6	26.2
AD-901356.1	34.5	6.4
AD-901355.1	43.0	4.4
AD-953365.1	60.5	3.3
AD-953410.1	38.8	16.4
AD-953411.1	56.2	10.5
AD-953338.1	58.1	5.6
AD-953350.1	42.0	2.5
AD-953375.1	45.6	6.1
AD-953341.1	30.1	12.4
AD-953370.1	28.3	8.5
AD-953386.1	52.9	13.3
AD-64958 (ELF8 TTR control)	57.1	6.1

Table 17 and **FIG. 6** demonstrate the results of the *in vivo* screen with the siRNA duplexes corresponding to the siRNA sequences in Table 14. Of the siRNA duplexes evaluated *in vivo* in Table 17, 5 achieved a knockdown of VEGF-A of $\geq 40\%$, 10 achieved a knockdown of VEGF-A of $\geq 30\%$, 15 achieved a knockdown of VEGF-A of $\geq 20\%$, and 17 achieved a knockdown of VEGF-A of $\geq 10\%$.

Table 17. Efficacy of exemplary VEGF-A siRNAs in mice. In this table the column “Duplex Name” provides the numerical part of the duplex name with a suffix (number following the decimal point in a duplex name) that merely refers to a batch production number. The suffix can be omitted from the duplex name without changing the chemical structure. For example, duplex AD-1397050 in Table 14 refers to the same duplex as AD-1397050.2 in Table 17.

Duplex (Administered at 3 mg/kg)	Day 14 post-treatment	
	% VEGF-A Message Remaining	St Dev
PBS	89.7	45.3
Naïve	100.0	17.4
AD-1397050.2	50.1	15.3
AD-1397051.2	76.7	28.9
AD-1397052.2	63.6	19.6
AD-1397053.2	50.9	15.6
AD-1397054.2	53.0	12.1
AD-1397055.2	84.4	32.4
AD-1397056.2	59.2	23.8
AD-1397058.2	77.5	20.7
AD-1397059.2	77.1	13.4
AD-1397060.2	68.9	6.8
AD-1397061.2	58.2	12.9
AD-1397062.2	68.7	12.0
AD-1397064.2	62.9	6.7
AD-1397065.2	85.2	29.9
AD-1397066.2	77.7	8.7
AD-1397067.2	93.5	37.3
AD-1397068.2	62.0	15.7
AD-1397069.2	76.9	26.1
AD-64958.100	66.0	2.6

WE CLAIM:

1. A double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of vascular endothelial growth factor A (VEGF-A), wherein the dsRNA agent comprises a sense strand and an antisense strand forming a double stranded region, wherein the antisense strand comprises a nucleotide sequence comprising at least 15 contiguous nucleotides, with 0, 1, 2, or 3 mismatches, from one of the antisense sequences listed in any one of Tables 2A, 2B, 3A, 3B, 4A, 4B, 5A, 5B, 8A, 8B, 10A, 10B, 12, 13, 14, 18A, and 18B, and wherein the sense strand comprises a nucleotide sequence comprising at least 15 contiguous nucleotides, with 0, 1, 2, or 3 mismatches, from a sense sequence listed in any one of Tables 2A, 2B, 3A, 3B, 4A, 4B, 5A, 5B, 8A, 8B, 10A, 10B, 12, 13, 14, 18A, and 18B that corresponds to the antisense sequence.
2. The dsRNA agent of claim 1, wherein the portion of the sense strand is a portion within nucleotides 1855-1875, 1858-1878, 2178-2198, 2181-2201, 2944-2964, 2946-2966, 2952-2972, 3361-3381, or 3362-3382 of SEQ ID NO: 1.
3. The dsRNA agent of claim 1 or 2, wherein the portion of the sense strand is a portion within a sense strand from a duplex chosen from AD-1020574 (CGACAGAACAGUCCUUAUAUCA (SEQ ID NO: 4200)), AD-901094 (CAGAACAGUCCUUAUAUCCAGA (SEQ ID NO: 4201)), AD-1020575 (CAGAACAGUCCUUAUAUCCAGA (SEQ ID NO: 4202)), AD-901100 (AACAGUGCUAAUGUUAUUGGA (SEQ ID NO: 4203)), AD-901101 (AGUGCUAAUGUUAUUGGUGUA (SEQ ID NO: 4204)), AD-901113 (GAGAAAGUGUUUUAUAUACGA (SEQ ID NO: 4205)), AD-901123 (AAAAUAGACAUUGCUAUUCUA (SEQ ID NO: 4206)), AD-901124 (AAAUAGACAUUGCUAUUCUGA (SEQ ID NO: 4207)), AD-901158 (GAAAGUGUUUUAUAUACGGUA (SEQ ID NO: 4208)), AD-901159 (GUUUUAUAUACGGUACUUAUA (SEQ ID NO: 4209)), AD-1020573 (AGUGCUAATGTUAUUGGUGUA (SEQ ID NO: 4210)), or AD-1023143 (AAAAUAGACATUGCUAUUCUA (SEQ ID NO: 4211)).

4. The dsRNA agent of any one of claims 1-3, wherein the portion of the sense strand is a sense strand chosen from the sense strands of AD-1020574 (CGACAGAACAGUCCUUAUAUCA (SEQ ID NO: 4200)), AD-901094 (CAGAACAGUCCUUAUCCAGA (SEQ ID NO: 4201)), AD-1020575 (CAGAACAGUCCUUAUCCAGA (SEQ ID NO: 4202)), AD-901100 (AACAGUGCUAAUGUUAUUGGA (SEQ ID NO: 4203)), AD-901101 (AGUGCUAAUGUUAUUGGUGUA (SEQ ID NO: 4204)), AD-901113 (GAGAAAGUGUUUUAUAUACGA (SEQ ID NO: 4205)), AD-901123 (AAAAUAGACAUUGCUAUUCUA (SEQ ID NO: 4206)), AD-901124 (AAAUAGACAUUGCUAUUCUGA (SEQ ID NO: 4207)), AD-901158 (GAAAGUGUUUUAUAUACGGUA (SEQ ID NO: 4208)), AD-901159 (GUUUUAUAUACGGUACUUAUA (SEQ ID NO: 4209)), AD-1020573 (AGUGCUAATGTUAUUGGUGUA (SEQ ID NO: 4210)), or AD-1023143 (AAAAUAGACATUGCUAUUCUA (SEQ ID NO: 4211)).

5. The dsRNA of any one of claims 1-4, wherein the portion of the antisense strand is a portion within an antisense strand from a duplex chosen from AD-1020574 (UGAUUAAGGACUGUUCUGUCGAU (SEQ ID NO: 4212)), AD-901094 (UCUGGAUUAAGGACUGUUCUGUC (SEQ ID NO: 4213)), AD-1020575 (UCUGGATUAAGGACUGUUCUGUC (SEQ ID NO: 4214)), AD-901100 (UCCAAUAACAUUAGCACUGUUAU (SEQ ID NO: 4215)), AD-901101 (UACACCAUAACAUUAGCACUGU (SEQ ID NO: 4216)), AD-901113 (UCGUUAUUAACACUUCUCUU (SEQ ID NO: 4217)), AD-901123 (UAGAAUAGCAAUGUCUAUUUUAU (SEQ ID NO: 4218)), AD-901124 (UCAGAAUAGCAAUGUCUAUUUUA (SEQ ID NO: 4219)), AD-901158 (UACCGUAUAUAAACACUUCUC (SEQ ID NO: 4220)), AD-901159 (UAUAAGUACCGUAUAUAAACAC (SEQ ID NO: 4221)), AD-1020573 (UACACCAUAACATUAGCACUGU (SEQ ID NO: 4222)), or AD-1023143 (UAGAAUAGCAATGTCTAUUUUAU (SEQ ID NO: 4223)).

6. The dsRNA of any one of claims 1-5, wherein the portion of the antisense strand is an antisense strand chosen the antisense strands of AD-1020574

(UGAUUAAGGACUGUUCUGUCGAU (SEQ ID NO: 4212)), AD-901094
 (UCUGGAUUAAGGACUGUUCUGUC (SEQ ID NO: 4213)), AD-1020575
 (UCUGGATUAAGGACUGUUCUGUC (SEQ ID NO: 4214)), AD-901100
 (UCCAAUAACAUUAGCACUGUUA (SEQ ID NO: 4215)), AD-901101
 (UACACCAUAACAUUAGCACUGU (SEQ ID NO: 4216)), AD-901113
 (UCGUUAUAAAAACACUUUCUCU (SEQ ID NO: 4217)), AD-901123
 (UAGAAUAGCAAUGUCUAUUUUAU (SEQ ID NO: 4218)), AD-901124
 (UCAGAAUAGCAAUGUCUAUUUUA (SEQ ID NO: 4219)), AD-901158
 (UACCGUAUAUAAAAACACUUUCUC (SEQ ID NO: 4220)), AD-901159
 (UAUAAGUACCGUAUAUAAAAACAC (SEQ ID NO: 4221)), AD-1020573
 (UACACCAUAACATUAGCACUGU (SEQ ID NO: 4222)), or AD-1023143
 (UAGAAUAGCAATGTCTAUUUUAU (SEQ ID NO: 4223)).

7. The dsRNA of any one of claims 1-6, wherein the sense strand and the antisense strand comprise nucleotide sequences of the paired sense strand and antisense strand of a duplex selected from AD-1020574 (SEQ ID NO: 4200 and 4212), AD-901094 (SEQ ID NO: 4201 and 4213), AD-1020575 (SEQ ID NO: 4202 and 4214), AD-901100 (SEQ ID NO: 4203 and 4215), AD-901101 (SEQ ID NO: 4204 and 4216), AD-901113 (SEQ ID NO: 4205 and 4217), AD-901123 (SEQ ID NO: 4206 and 4218), AD-901124 (SEQ ID NO: 4207 and 4219), AD-901158 (SEQ ID NO: 4208 and 4220), AD-901159 (SEQ ID NO: 4209 and 4221), AD-1020573 (SEQ ID NO: 4210 and 4222), or AD-1023143 (SEQ ID NO: 4211 and 4223).

8. The dsRNA agent of any one of claims 1-7, wherein the antisense strand comprises a nucleotide sequence of an antisense sequence listed in Table 18A, and the sense strand comprises a nucleotide sequence of a sense sequence listed in Table 18A that corresponds to the antisense sequence.

9. The dsRNA agent of any one of claims 1-8, wherein the dsRNA agent is AD-1020574, AD-901094, AD-1020575, AD-901100, AD-901101, AD-901113, AD-901123, AD-901124, AD-901158, AD-901159, AD-1020573, or AD-1023143.

10. The dsRNA agent of any one of claims 1-9, wherein at least one of the sense strand and the antisense strand is conjugated to one or more lipophilic moieties.
11. The dsRNA agent of claim 10, wherein the lipophilic moiety is conjugated via a linker or carrier.
12. The dsRNA agent of claim 10 or 11, wherein one or more lipophilic moieties are conjugated to one or more internal positions on at least one strand.
13. The dsRNA agent of claim 12, wherein the one or more lipophilic moieties are conjugated to one or more internal positions on at least one strand via a linker or carrier.
14. The dsRNA agent of any one of claims 10-13, wherein the lipophilic moiety is an aliphatic, alicyclic, or polyalicyclic compound.
15. The dsRNA agent of claim 14, wherein the lipophilic moiety contains a saturated or unsaturated C16 hydrocarbon chain.
16. The dsRNA agent of any one of claims 10-15, wherein the lipophilic moiety is conjugated via a carrier that replaces one or more nucleotide(s) in the internal position(s) or the double stranded region.
17. The dsRNA agent of any one of claims 10-15, wherein the lipophilic moiety is conjugated to the sense strand or the antisense strand via a linker containing an ether, thioether, urea, carbonate, amine, amide, maleimide-thioether, disulfide, phosphodiester, sulfonamide linkage, a product of a click reaction, or carbamate.
18. The dsRNA agent of any one of claims 10-16, wherein the lipophilic moiety is conjugated to a nucleobase, sugar moiety, or internucleosidic linkage.

19. The dsRNA agent of any of the preceding claims, wherein the dsRNA agent comprises at least one modified nucleotide.
20. The dsRNA agent of claim 19, wherein no more than five of the sense strand nucleotides and not more than five of the nucleotides of the antisense strand are unmodified nucleotides.
21. The dsRNA agent of claim 19, wherein all of the nucleotides of the sense strand and all of the nucleotides of the antisense strand comprise a modification.
22. The dsRNA agent of any one of claims 19-21, wherein at least one of the modified nucleotides is selected from the group consisting of a deoxy-nucleotide, a 3'-terminal deoxy-thymine (dT) nucleotide, a 2'-O-methyl modified nucleotide, a 2'-fluoro modified nucleotide, a 2'-deoxy-modified nucleotide, a locked nucleotide, an unlocked nucleotide, a conformationally restricted nucleotide, a constrained ethyl nucleotide, an abasic nucleotide, a 2'-amino-modified nucleotide, a 2'-O-allyl-modified nucleotide, 2'-C-alkyl-modified nucleotide, a 2'-methoxyethyl modified nucleotide, a 2'-O-alkyl-modified nucleotide, a morpholino nucleotide, a phosphoramidate, a non-natural base comprising nucleotide, a tetrahydropyran modified nucleotide, a 1,5-anhydrohexitol modified nucleotide, a cyclohexenyl modified nucleotide, a nucleotide comprising a phosphorothioate group, a nucleotide comprising a methylphosphonate group, a nucleotide comprising a 5'-phosphate, a nucleotide comprising a 5'-phosphate mimic, a glycol modified nucleotide, and a 2-O-(N-methylacetamide) modified nucleotide; and combinations thereof.
23. The dsRNA agent of any of the preceding claims, wherein at least one strand comprises a 3' overhang of at least 2 nucleotides.
24. The dsRNA agent of any of the preceding claims, wherein the double stranded region is 15-30 nucleotide pairs in length.
25. The dsRNA agent of claim 24, wherein the double stranded region is 17-23 nucleotide pairs in length.

26. The dsRNA agent of any of the preceding claims, wherein each strand has 19-30 nucleotides.
27. The dsRNA agent of any of the preceding claims, wherein the agent comprises at least one phosphorothioate or methylphosphonate internucleotide linkage.
28. The dsRNA agent of any one of claims 10-27, further comprising a targeting ligand, *e.g.*, a ligand that targets an ocular tissue.
29. The dsRNA agent of claim 28, wherein the ocular tissue is a retinal pigment epithelium (RPE) or choroid tissue, *e.g.*, a choroid vessel.
30. The dsRNA agent of any one of the preceding claims, further comprising a phosphate or phosphate mimic at the 5'-end of the antisense strand.
31. The dsRNA agent of claim 30, wherein the phosphate mimic is a 5'-vinyl phosphonate (VP).
32. The dsRNA agent of any one of the preceding claims, comprising:
- (i) the sense strand comprises the sequence and all the modifications of SEQ ID NO: 4164, and the antisense strand comprises the sequence and all the modifications of SEQ ID NO: 4176;
 - (ii) the sense strand comprises the sequence and all the modifications of SEQ ID NO: 1465, and the antisense strand comprises the sequence and all the modifications of SEQ ID NO: 4177;
 - (iii) the sense strand comprises the sequence and all the modifications of SEQ ID NO: 1466, and the antisense strand comprises the sequence and all the modifications of SEQ ID NO: 4178;
 - (iv) the sense strand comprises the sequence and all the modifications of SEQ ID NO: 1467, and the antisense strand comprises the sequence and all the modifications of SEQ ID NO: 4179;

(v) the sense strand comprises the sequence and all the modifications of SEQ ID NO: 1468, and the antisense strand comprises the sequence and all the modifications of SEQ ID NO: 4180;

(vi) the sense strand comprises the sequence and all the modifications of SEQ ID NO: 1469, and the antisense strand comprises the sequence and all the modifications of SEQ ID NO: 4181;

(vii) the sense strand comprises the sequence and all the modifications of SEQ ID NO: 1470, and the antisense strand comprises the sequence and all the modifications of SEQ ID NO: 4182;

(viii) the sense strand comprises the sequence and all the modifications of SEQ ID NO: 1471, and the antisense strand comprises the sequence and all the modifications of SEQ ID NO: 4183;

(ix) the sense strand comprises the sequence and all the modifications of SEQ ID NO: 1472, and the antisense strand comprises the sequence and all the modifications of SEQ ID NO: 4184;

(x) the sense strand comprises the sequence and all the modifications of SEQ ID NO: 1473, and the antisense strand comprises the sequence and all the modifications of SEQ ID NO: 4185;

(xi) the sense strand comprises the sequence and all the modifications of SEQ ID NO: 1474, and the antisense strand comprises the sequence and all the modifications of SEQ ID NO: 4186; or

(xii) the sense strand comprises the sequence and all the modifications of SEQ ID NO: 1475, and the antisense strand comprises the sequence and all the modifications of SEQ ID NO: 4187.

33. A cell containing the dsRNA agent of any one of claims 1-32.

34. A pharmaceutical composition for inhibiting expression of a VEGF-A, comprising the dsRNA agent of any one of claims 1-32.

35. A method of inhibiting expression of VEGF-A in a cell, the method comprising:

(a) contacting the cell with the dsRNA agent of any one of claims 1-32, or a pharmaceutical composition of claim 34; and

(b) maintaining the cell produced in step (a) for a time sufficient to reduce levels of VEGF-A mRNA, VEGF-A protein, or both of VEGF-A mRNA and protein, thereby inhibiting expression of VEGF-A in the cell.

36. The method of claim 35, wherein the cell is within a subject.

37. The method of claim 36, wherein the subject is a human.

38. The method of claim 37, wherein the subject has been diagnosed with a VEGF-A-associated disorder, *e.g.*, wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR), diabetic macular edema (DME), retinal vein occlusion (RVO), macular edema following retinal vein occlusion (MEfRVO), retinopathy of prematurity (ROP), or myopic choroidal neovascularization (mCNV).

39. A method of treating a subject diagnosed with a VEGF-A-associated disorder comprising administering to the subject a therapeutically effective amount of the dsRNA agent of any one of claims 1-23 or a pharmaceutical composition of claim 25, thereby treating the disorder.

40. The method of claim 39, wherein the VEGF-A-associated disorder is an angiogenic ocular disorder.

41. The method of claim 40, wherein the angiogenic ocular disorder is selected from the group consisting of AMD, DR, DME, RVO, MEfRVO, ROP, and mCNV.

42. The method of any one of claims 39-41, wherein treating comprises amelioration of at least one sign or symptom of the disorder.

43. The method of any one of claims 39-42, wherein the treating comprises (a) inhibiting angiogenesis; (b) inhibiting or reducing the expression or activity of VEGF-A; (c) inhibiting

choroidal neovascularization; (d) inhibiting growth of new blood vessels in the choriocapillaris; (e) reducing retinal thickness; (f) increasing visual acuity; or (g) reducing intraocular inflammation.

44. The method of any one of claims 36-43, wherein the dsRNA agent is administered to the subject intraocularly, intravenously, or topically.

45. The method of claim 44, wherein the intraocular administration comprises intravitreal administration (e.g., intravitreal injection), transscleral administration (e.g., transscleral injection), subconjunctival administration (e.g., subconjunctival injection), retrobulbar administration (e.g., retrobulbar injection), intracameral administration (e.g., intracameral injection), or subretinal administration (e.g., subretinal injection).

46. The method of any one of claims 36-45, further comprising administering to the subject an additional agent or therapy suitable for treatment or prevention of an VEGF-A-associated disorder (e.g., one or more of a photodynamic therapy, photocoagulation therapy, a steroid, a non-steroidal anti-inflammatory agent, an anti-VEGF agent, or a vitrectomy).

1/10




FIG. 1A

2/10




FIG. 1B

3/10




FIG. 2

4/10




FIG. 3A

5/10




FIG. 3B

6/10




FIG. 4

7/10




FIG. 5A

8/10




FIG. 5B

9/10




FIG. 5C

10/10




FIG. 6

SEQUENCE LISTING

<110> ALNYLAM PHARMACEUTICALS, INC.

<120> COMPOSITIONS AND METHODS FOR SILENCING VEGF-A EXPRESSION

<130> A2038-7236W0

<140>

<141>

<150> 63/140,714

<151> 2021-01-22

<150> 63/055,627

<151> 2020-07-23

<150> 62/972,519

<151> 2020-02-10

<160> 5238

<170> PatentIn version 3.5

<210> 1

<211> 3677

<212> DNA

<213> Homo sapiens

<400> 1

tcgcggaggc ttggggcagc cgggtagctc ggaggctcgtg gcgctggggg ctagcaccag	60
cgctctgtcg ggaggcgcag cggttaggtg gaccggtcag cggactcacc ggccagggcg	120
ctcggtgctg gaatttgata ttcattgatc cgggttttat ccctcttctt ttttcttaaa	180
catttttttt taaaactgta ttgtttctcg ttttaattta tttttgcttg ccattcccca	240
cttgaatcgg gccgacggct tggggagatt gctctacttc cccaaatcac tgtggatttt	300
ggaaaccagc agaaagagga aagaggtagc aagagctcca gagagaagtc gaggaagaga	360
gagacgggggt cagagagagc gcgcgggctg gcgagcagcg aaagcgacag gggcaaagtg	420
agtgacctgc ttttgggggt gaccgccgga gcgcggcgtg agccctcccc cttgggatcc	480
cgcagctgac cagtcgcgct gacggacaga cagacagaca ccgccccag cccagctac	540
cacctctcc ccggccggcg gcggacagtg gacgcggcgg cgagccgcgg gcaggggccc	600
gagcccgcgc ccggaggcgg ggtggagggg gtcggggctc gcggcgctgc actgaaactt	660
ttcgtccaac ttctgggctg ttctcgcttc ggaggagccg tgggtccgcgc gggggaagcc	720

gagccgagcg gagccgagcg aagtgtctagc tcggggccggg aggagccgca gccggaggag	780
ggggaggagg aagaagagaa ggaagaggag agggggccgc agtggcgact cggcgctcgg	840
aagccggggct catggacggg tgaggcggcg gtgtgcgcag acagtgtctcc agccgcgcgc	900
gctccccagg ccctggcccc ggccctcgggc cggggaggaa gagtagctcg ccgaggcgcc	960
gaggagagcg ggccgcccc cagcccagagc cggagaggga gcgcgagccg cgccggcccc	1020
ggtcgggcct ccgaaaccat gaactttctg ctgtcttggg tgcattggag ccttgccttg	1080
ctgtcttacc tccaccatgc caagtgggtc caggctgcac ccatggcaga aggaggaggg	1140
cagaatcatc acgaagtggg gaagttcatg gatgtctatc agcgcagcta ctgccatcca	1200
atcgagaccc tgggtggacat cttccaggag taccctgatg agatcgagta catcttcaag	1260
ccatcctgtg tgcccctgat gcgatgcggg ggctgtctgca atgacgaggg cctggagtgt	1320
gtgcccactg aggagtccaa catcaccatg cagattatgc ggatcaaacc tcaccaaggc	1380
cagcacatag gagagatgag cttcctacag cacaacaaat gtgaatgcag accaaagaaa	1440
gatagagcaa gacaagaaaa aaaatcagtt cgaggaaagg gaaaggggca aaaacgaaag	1500
cgcaagaaat cccggtataa gtcctggagc gtgtacgttg gtgcccgtg ctgtctaattg	1560
ccctggagcc tccctggccc ccatccctgt gggccttgct cagagcggag aaagcatttg	1620
tttgtacaag atccgcagac gtgtaaatgt tcctgcaaaa acacagactc gcgttgcaag	1680
gcgaggcagc ttgagttaaa cgaacgtact tgcagatgtg acaagccgag gcggtgagcc	1740
gggcaggagg aaggagcctc cctcagggtt tcgggaacca gatctctcac caggaaagac	1800
tgatacagaa cgatcgatac agaaaccacg ctgccgccac cacaccatca ccatcgacag	1860
aacagtcctt aatccagaaa cctgaaatga aggaagagga gactctgcgc agagcacttt	1920
gggtccggag ggcgagactc cggcggaagc attcccgggc gggtgaccca gcacggtccc	1980
tcttggaatt ggattcgcca ttttattttt cttgctgcta aatcaccgag cccggaagat	2040
tagagagttt tatttctggg attcctgtag acacaccac ccacatacat acatttatat	2100
atatatatat tatatatata taaaaataaa tatctctatt ttatatatat aaaatatata	2160
tattcttttt ttaaattaac agtgctaatt ttattgggtg cttcactgga tgtatttgac	2220
tgctgtggac ttgagttggg aggggaatgt tcccactcag atcctgacag ggaagaggag	2280
gagatgagag actctggcat gatctttttt ttgtcccact tgggtggggcc agggtcctct	2340

cccctgcca ggaatgtgca aggccagggc atgggggcaa atatgacca gttttgggaa	2400
caccgacaaa cccagccctg gcgctgagcc tctctacccc aggtcagacg gacagaaaga	2460
cagatcacag gtacagggat gaggacaccg gctctgacca ggagtttggg gagcttcagg	2520
acattgctgt gctttgggga ttccctccac atgctgcacg cgcctctcgc cccaggggc	2580
actgcctgga agattcagga gcctgggcgg ccttcgctta ctctcacctg cttctgagtt	2640
gcccaggaga cactggcag atgtcccggc gaagagaaga gacacattgt tggaagaagc	2700
agcccatgac agctcccctt cctgggactc gccctcatcc tcttcctgct ccccttcctg	2760
gggtgcagcc taaaaggacc tatgtcctca caccattgaa accactagtt ctgtcccccc	2820
aggagacctg gttgtgtgtg tgtgagtggg tgaccttcct ccatcccctg gtccttcctt	2880
tcccttcccg aggcacagag agacagggca ggatccacgt gccatttgtg gaggcagaga	2940
aaagagaaag tgttttatat acggtactta tttaatatcc ctttttaatt agaaattaa	3000
acagttaatt taattaaaga gtagggtttt ttttcagtat tcttggttaa tatttaattt	3060
caactattta tgagatgtat cttttgctct ctcttgctct cttatttgta ccggtttttg	3120
tatataaaat tcatgtttcc aatctctctc tccctgatcg gtgacagtca ctagcttatc	3180
ttgaacagat atttaatttt gctaacactc agctctgccc tccccgatcc cctggctccc	3240
cagcacacat tcctttgaaa taaggtttca atatacatct acatactata tatatatattg	3300
gcaacttgta tttgtgtgta tatatatata tatatgttta tgtatatatg tgattctgat	3360
aaaatagaca ttgctattct gttttttata tgtaaaaaca aaacaagaaa aaatagagaa	3420
ttctacatac taaatctctc tcctttttta attttaatat ttgttatcat ttatttattg	3480
gtgctactgt ttatccgtaa taattgtggg gaaaagatat taacatcacg tctttgtctc	3540
tagtgcagtt tttcgagata ttccgtagta catatttatt tttaaacaac gacaaagaaa	3600
tacagatata tcttaaaaaa aaaaaagcat tttgtattaa agaatttaat tctgatctca	3660
aaaaaaaaaa aaaaaaa	3677

<210> 2

<211> 3677

<212> DNA

<213> Homo sapiens

<400> 2

tttttttttt ttttttttga gatcagaatt aaattcttta atacaaaatg cttttttttt	60
---	----

tttaagatat atctgtat	ctttgtcg	gtttaaaa	aatatgtac	tacggaatat	120
ctcgaaaaac tgcactagag	acaaagacgt	gatgttaata	tcttttcccc	acaattatta	180
cggataaaca gtagcaccaa	taaataaatg	ataacaaata	ttaaaattaa	aaaaggagag	240
agatttagta tgtagaattc	tctat	cttg	ttttacatat	aaaaacaga	300
atagcaatgt ctat	agaatcacat	atatacataa	acatatatat	atatatatac	360
acacaaatac aagttgccaa	atatatatat	agtatgtaga	tgtatat	aaccttattt	420
caaaggaatg tgtgctgggg	agccagggga	tcggggaggg	cagagctgag	tgtagcaaa	480
attaaatatc tgttcaagat	aagctagtga	ctgtcaccga	tcaggagag	agagattgga	540
aacatgaatt ttatatacaa	aaaccggtac	aaataagaga	gcaagagaga	gcaaaagata	600
catctcataa atagttgaaa	ttaaatatta	accaagaata	ctgaaaaaaa	accctactct	660
ttaattaaat taactgtttt	aatttcta	taaaaaggga	tattaaataa	gtaccgtata	720
taaaacactt tctcttttct	ctgcctccac	aatgggcacg	tggatcctgc	cctgtctctc	780
tgtgcctcgg gaagggaagg	gaaggaccag	gggatggagg	aaggtcaacc	actcacacac	840
acacaaccag gtctcctggg	gggacagaac	tagtggtttc	aatggtgtga	ggacataggt	900
ccttttaggc tgcacccag	gaaggggagc	aggaagagga	tgagggcgag	tcccaggaag	960
gggagctgtc atgggctgct	tcttccaaca	atgtgtctct	tctcttcgcc	gggacatctg	1020
ccagtgggtct cctgggcaac	tcagaagcag	gtgagagtaa	gcgaaggccg	cccagggtcc	1080
tgaatcttcc aggcagtgcc	cctgggggag	agatgcgcgt	gcagcatgtg	gagggaatcc	1140
ccaaagcaca gcaatgtcct	gaagctcccc	aaactcctgg	tcagagccgg	gtcctcatc	1200
cctgtacctg tgatctgtct	ttctgtccgt	ctgacctggg	gtagagaggc	tcagcgccag	1260
ggctggggtt gtcggtgttc	ccaaaactgg	gtcatatttg	cccccatgcc	ctggccttgc	1320
acattcctgg gcaggggaga	ggaccctggc	cccaccaagt	gggacaaaaa	aaagatcatg	1380
ccagagtctc tcatctcctc	ctcttccctg	tcaggatctg	agtgggaaca	ttcccctccc	1440
aactcaagtc cacagcagtc	aaatacatcc	agtgaagaca	ccaataacat	tagcactgtt	1500
aatttaaaaa aagaatatat	atattttata	tatatataa	agagatattt	atttttatat	1560
atatataata tatatatata	taaatgtatg	tatgtgggtg	ggtgtgtcta	caggaatccc	1620
agaaataaaa ctctcta	ttccgggctc	ggtgatttag	cagcaagaaa	aataaaatgg	1680

cgaatccaat tccaagaggg accgtgctgg gtcacccgcc cgggaatgct tccgccggag	1740
tctcgcctc cggacccaaa gtgctctgcg cagagtctcc tcttccttca tttcaggttt	1800
ctggattaag gactgttctg tcgatgggtga tgggtgtggtg gcggcagcgt ggtttctgta	1860
tcgatcgttc tgtatcagtc tttcctggtg agagatctgg ttcccgaac cctgaggggag	1920
gctccttcct cctgcccggc tcaccgcctc ggcttgtcac atctgcaagt acgttcgttt	1980
aactcaagct gcctcgcctt gcaacgcgag tctgtgtttt tgcaggaaca ttacacgtc	2040
tgcggatctt gtacaaaca atgctttctc cgctctgagc aaggcccaca gggatggggg	2100
ccaggagggc tccaggcat tagacagcag cgggcaccaa cgtacacgct ccaggactta	2160
taccgggatt tcttgcgctt tcgtttttgc ccctttccct ttcctcgaac tgattttttt	2220
tcttgtcttg ctctatcttt ctttggcttg cattcacatt tgttgtgctg taggaagctc	2280
atctctccta tgtgctggcc ttggtgaggt ttgatccgca taatctgcat ggtgatgttg	2340
gactcctcag tgggcacaca ctccaggccc tcgtcattgc agcagcccc gcacgcac	2400
aggggcacac aggatggctt gaagatgtac tcgatctcat cagggtactc ctggaagatg	2460
tccaccaggg tctcgattgg atggcagtag ctgcgctgat agacatccat gaacttcacc	2520
acttcgtgat gattctgccc tcctccttct gccatgggtg cagcctggga ccacttgga	2580
tgggtggagg agagcagcaa ggcaaggctc caatgcaccc aagacagcag aaagttcatg	2640
gtttcggagg cccgaccggg gccggcgcggt ctcgcgtcc ctctccggct cgggctgtgg	2700
ggcggccccgc tctcctcggc gcctcggcga gctactcttc ctccccggcc cgaggccccg	2760
gccagggcct ggggagcgcg cgcggctgga gactgtctg cgcacaccgc cgcctcacc	2820
gtccatgagc ccggcttccg agcgccgagt cgccactgcg gccccctctc ctcttccttc	2880
tcttcttcct cctccccctc ctccggctgc ggctcctccc ggcccagact agcacttctc	2940
gcggctccgc tcggctcggc ttcccccgcg cggaccacgg ctctccgaa gcgagaacag	3000
cccagaagtt ggacgaaaag tttcagtgcg acgccgcgag ccccgacccc ctccacccc	3060
cctccgggcg cgggctccgg cccctgcccg cggctcgccg ccggtccac tgtccgccgc	3120
cggccgggga ggaggtggta gctggggctg ggggcggtgt ctgtctgtct gtccgtcagc	3180
gcgactggtc agctgcggga tcccaagggg gagggctcac gccgcgctcc ggcggtcacc	3240
cccaaaagca ggtcactcac tttgcccctg tcgctttcgc tgctcgcacg cccgcgcgct	3300

ctctctgacc ccgtctctct cttcctcgac ttctctctgg agctcttgct acctctttcc	3360
tctttctgct ggtttccaaa atccacagtg atttggggaa gtagagcaat ctccccaagc	3420
cgtcggcccg attcaagtgg ggaatggcaa gcaaaaataa attaaaacga gaaacaatac	3480
agttttaaaa aaaaatgttt aagaaaaaag aagagggata aaacccggat caatgaatat	3540
caaattccag caccgagcgc cctggccggt gaggccgctg accgggtccac ctaaccgctg	3600
cgcctcccga cagagcgtg gtgctagccc ccagcgccac gacctccgag ctacccggct	3660
gcccgaagcc tccgca	3677

<210> 3
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 3	
cagaacaguc cuuaauccag a	21

<210> 4
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 4	
cgacagaaca guccuuauc a	21

<210> 5
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 5
gcuuuuguuu guacaagau a 21

<210> 6
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 6
uauugguguc uucacuggau a 21

<210> 7
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 7
acugauacag aacgaucgau a 21

<210> 8
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 8
aaagacugau acagaacgau a 21

<210> 9
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<400> 9
auacagaacg aucgauacag a 21

<210> 10
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 10
cugauacaga acgaucgaua a 21

<210> 11
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 11
gagaaagugu uuuauauacg a 21

<210> 12
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 12
acgaacguac uugcagaugu a 21

<210> 13
<211> 21
<212> RNA
<213> Artificial Sequence

<220>

<221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 13
 cuuggaauug gauucgccau a 21

<210> 14
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 14
 ggcagcuuga guuaaacgaa a 21

<210> 15
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 15
 gggcagauc aucacgaagu a 21

<210> 16
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 16
 uuaaacgaac guacuugcag a 21

<210> 17
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<p><220></p> <p><221> source</p> <p><223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"</p>	
<p><400> 17</p> <p>guuauuggug ucuucacugg a</p>	21
<p><210> 18</p> <p><211> 21</p> <p><212> RNA</p> <p><213> Artificial Sequence</p>	
<p><220></p> <p><221> source</p> <p><223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"</p>	
<p><400> 18</p> <p>agcuugaguu aaacgaacgu a</p>	21
<p><210> 19</p> <p><211> 21</p> <p><212> RNA</p> <p><213> Artificial Sequence</p>	
<p><220></p> <p><221> source</p> <p><223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"</p>	
<p><400> 19</p> <p>gcagcuugag uuaaacgaac a</p>	21
<p><210> 20</p> <p><211> 21</p> <p><212> RNA</p> <p><213> Artificial Sequence</p>	
<p><220></p> <p><221> source</p> <p><223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"</p>	
<p><400> 20</p> <p>cgaaguggug aagucaugg a</p>	21
<p><210> 21</p> <p><211> 21</p>	

<212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 21
 cagaaucauc acgaaguggu a 21

 <210> 22
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 22
 aaaauagaca uugcuauucu a 21

 <210> 23
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 23
 cagcuugagu uaaacgaacg a 21

 <210> 24
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 24
 cgcacugaaa cuuuucgucc a 21

<210> 25
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 25
 agauuauugcg gaucaaaccu a 21

<210> 26
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 26
 gcucucuau uuguaccggu a 21

<210> 27
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 27
 ugacagucac uagcuuau a 21

<210> 28
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 28
 cuugaguuaa acgaacguac a 21

<210> 29
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 29
agugcuaaug uuauuggugu a 21

<210> 30
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 30
auccgcagac guguaaangu a 21

<210> 31
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 31
agacugauac agaacgaucg a 21

<210> 32
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 32
uguuauuggu gucuucacug a 21

<210> 33
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 33
gugcuggaau uugauauuca a 21

<210> 34
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 34
uugcugcuaa aucaccgagc a 21

<210> 35
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 35
caccaugcag auuaugcgga a 21

<210> 36
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<400> 36
gaaagcauuu guuuguacaa a 21

<210> 37
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 37
gcuugaguua aacgaacgua a 21

<210> 38
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 38
ucggugacag ucacuagcuu a 21

<210> 39
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 39
aggcagcuug aguuaaacga a 21

<210> 40
<211> 21
<212> RNA
<213> Artificial Sequence

<220>

<221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 40
 cugcaaaaac acagacucgc a 21

<210> 41
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 41
 cuugcugcua aaucaccgag a 21

<210> 42
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 42
 uucuugcugc uaaaucaccg a 21

<210> 43
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 43
 aaagcauuug uuuguacaag a 21

<210> 44
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 44
 uccgcagacg uguaaauguu a 21

 <210> 45
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 45
 cggacuauu uuaauauccc a 21

 <210> 46
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 46
 gacugauaca gaacgaucga a 21

 <210> 47
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 47
 aaaacacaga cucgcguugc a 21

 <210> 48
 <211> 21

<212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 48
 gaguuaaacg aacguacuug a 21

 <210> 49
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 49
 ucacuggaug uauuugacug a 21

 <210> 50
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 50
 ccuccgaaac caugaacuuu a 21

 <210> 51
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 51
 uugaguuaaaa cgaacguacu a 21

<210> 52
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 52
 ugcucacuguu uauccguaau a 21

<210> 53
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 53
 ccgcagacgu guaaauguuc a 21

<210> 54
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 54
 cgcagacgug uaaauguucc a 21

<210> 55
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 55
 agagaagaga cacauuguug a 21

<210> 56
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 56
acagcacaac aaaugugaau a 21

<210> 57
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 57
ucuugcugcu aaauaccga a 21

<210> 58
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 58
acaccauuga aaccacuagu a 21

<210> 59
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 59
gaggcagcuu gaguuaaacg a 21

<210> 60
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 60
gcacugaaac uuuucgucca a 21

<210> 61
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 61
guuuuauaua cggacuau a 21

<210> 62
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 62
caccauugaa accacuaguu a 21

<210> 63
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<400> 63
aucaccaugc agauuaugcg a 21

<210> 64
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 64
ugaguuaaac gaacguacuu a 21

<210> 65
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 65
gaaaguguuu uauauacggu a 21

<210> 66
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 66
acagucacua gcuuaucuug a 21

<210> 67
<211> 21
<212> RNA
<213> Artificial Sequence

<220>

<221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 67
 gugcuacugu uuauccguaa a 21

<210> 68
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 68
 ccugcaaaaa cacagacucg a 21

<210> 69
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 69
 caaaaacaca gacucgcguu a 21

<210> 70
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 70
 ugcuguggac uugaguuggg a 21

<210> 71
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 71 gugcuaaugu uauugguguc a	21
<210> 72 <211> 21 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 72 uggugcuacu guuuauccgu a	21
<210> 73 <211> 21 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 73 agaaaguguu uuauauacgg a	21
<210> 74 <211> 21 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 74 aacuauuuau gagauguauc a	21
<210> 75 <211> 21	

<212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 75
 aguuaaacga acguacuugc a 21

 <210> 76
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 76
 caucucaag ccauccugug a 21

 <210> 77
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 77
 uuuuuuuuca guauucuugg a 21

 <210> 78
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 78
 uuauccguaa uaauuguggg a 21

<210> 79
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 79
 gguacuuauu uaauaucccu a 21

<210> 80
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 80
 cacgucuuug ucucuagugc a 21

<210> 81
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 81
 ugcaaaaaca cagacucgcg a 21

<210> 82
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 82
 acuauuuauug agauguau cu a 21

<210> 83
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 83
aggggcaaaa acgaaagcgc a 21

<210> 84
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 84
uugcucucuu auuuguaccg a 21

<210> 85
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 85
auuuguuugu acaagauccg a 21

<210> 86
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 86
uugcagaugu gacaagccga a 21

<210> 87
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 87
caacuauuuu ugagauguau a 21

<210> 88
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 88
aauucuacau acuaaaucuc a 21

<210> 89
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 89
auguccucac accauugaaa a 21

<210> 90
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<400> 90
uuguuuguac aagaucgca a 21

<210> 91
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 91
uaauccagaa accugaaaug a 21

<210> 92
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 92
gaaaaaaaau caguucgagg a 21

<210> 93
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 93
gggcaaaaac gaaagcgcaa a 21

<210> 94
<211> 21
<212> RNA
<213> Artificial Sequence

<220>

<221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 94
 ugaaguucau ggaugucau a 21

<210> 95
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 95
 cacgaagugg ugaaguucau a 21

<210> 96
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 96
 acgucuuugu cucuagugca a 21

<210> 97
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 97
 aacaucacca ugcagauuau a 21

<210> 98
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 98
 ggugcuacug uuuaucgua a 21

 <210> 99
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 99
 aaauagacau ugcuaauucug a 21

 <210> 100
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 100
 uuccccaaau cacuguggau a 21

 <210> 101
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 101
 gauccgcaga cguguaaaug a 21

 <210> 102
 <211> 21

<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 102
uuaacaucac gucuuugucu a 21

<210> 103
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 103
aaagugagug accugcuuuu a 21

<210> 104
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 104
aaaaacacag acucgcuug a 21

<210> 105
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 105
cgucgcacug aaacuuuucg a 21

<210> 106
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 106
 aacagugcua auguuauugg a 21

<210> 107
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 107
 uucguccaac uucugggcug a 21

<210> 108
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 108
 auuggugucu ucacuggaug a 21

<210> 109
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 109
 gcaaaaacac agacucgcgu a 21

<210> 110
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 110
aaaaaucagu ucgaggaaag a 21

<210> 111
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 111
cagacgugua aauguuccug a 21

<210> 112
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 112
uguccucaca ccauugaaac a 21

<210> 113
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 113
uuuuuuucag uauucuuggu a 21

<210> 114
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 114
agauccgcag acguguaaa u a 21

<210> 115
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 115
cccucuugga auuggauucg a 21

<210> 116
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 116
gauauuaaca ucacgucuuu a 21

<210> 117
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<400> 117
uuggugcuac uguuuauccg a 21

<210> 118
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 118
aaggggcaaa aacgaaagcg a 21

<210> 119
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 119
cuugcagaug ugacaagccg a 21

<210> 120
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 120
aaaucaguuc gaggaaaggg a 21

<210> 121
<211> 21
<212> RNA
<213> Artificial Sequence

<220>

<221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 121
 acuuuucguc caacuucugg a 21

<210> 122
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 122
 auuaacauca cgucuuuguc a 21

<210> 123
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 123
 cgucuuuguc ucuagugcag a 21

<210> 124
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 124
 aacacagacu cgcgugcaa a 21

<210> 125
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 125
 auauuaacau cacgucuuug a 21

 <210> 126
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 126
 guuuauccgu aaauuugug a 21

 <210> 127
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 127
 aaaucaguu cgaggaaagg a 21

 <210> 128
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 128
 uuuaucgua auauuugugg a 21

 <210> 129
 <211> 21

<212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 129
 aggacauugc ugugcuuugg a 21

<210> 130
 <211> 23
 <212> DNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

 <400> 130
 ugaucgtucu guaucagucu uuc 23

<210> 131
 <211> 23
 <212> DNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

 <400> 131
 uggauatuaa auaaguaccg uau 23

<210> 132
 <211> 23
 <212> DNA
 <213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 132
ucuggatuaa ggacuguucu guc 23

<210> 133
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 133
ugauuaagga cuguucuguc gau 23

<210> 134
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 134
ugaucutgua caaacaaaug cuu 23

<210> 135
<211> 23
<212> RNA
<213> Artificial Sequence

<220>

<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 135
uauccaguga agacaccaau aac

23

<210> 136
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 136
uauccgatcgu ucuguaucag ucu

23

<210> 137
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 137
uauccgutcgu uauccagucuu ucc

23

<210> 138
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 138

ucuguatcga ucguucugua uca

23

<210> 139

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 139

uuaucgaucg uucuguaucg guc

23

<210> 140

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 140

ucguauauaa aacacuuucu cuu

23

<210> 141

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 141
uacauctgca aguacguucg uuu 23

<210> 142
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 142
uauggcgaau ccaauuccaa gag 23

<210> 143
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 143
uuucgutuaa cucaagcugc cuc 23

<210> 144
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 144
uacuucguga ugauucugcc cuc 23

<210> 145
<211> 23
<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 145

ucugcaagua cguucguuuu acu

23

<210> 146

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 146

uccagugaag acaccaauaa cau

23

<210> 147

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 147

uacguucguu uaacucaagc ugc

23

<210> 148

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 148
uguucgtuua acucaagcug ccu 23

<210> 149
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 149
uccaugaacu ucaccacuuc gug 23

<210> 150
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 150
uaccactucg ugaugauucu gcc 23

<210> 151
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 151
uagaauagca augucuauuu uau 23

<210> 152
<211> 23
<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 152

ucguucguuu aacucaagcu gcc

23

<210> 153

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 153

uggacgaaaa guuucagugc gac

23

<210> 154

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 154

uagguutgau ccgcauaauc ugc

23

<210> 155

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

 <400> 155
 uaccgtaca aaauagagag caa 23

<210> 156
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 156
 uagauagcu agugacuguc acc 23

<210> 157
 <211> 23
 <212> DNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

 <400> 157
 uguacgtucg uuuaacucuaa gcu 23

<210> 158
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 158
 uacaccaua acuuagcac ugu 23

<210> 159
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 159
uacauutaca cgucugcgga ucu 23

<210> 160
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 160
ucgaucguuc uguaucaguc uuu 23

<210> 161
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 161
ucagugaaga caccauaaac auu 23

<210> 162
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 162
 uugaauauca aaauccagca ccg 23

 <210> 163
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 163
 ugcucgguga uuagcagca aga 23

 <210> 164
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 164
 uuccgcauaa ucugcauggu gau 23

 <210> 165
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 165
 uuuguacaaa caaagcuuu cuc 23

 <210> 166
 <211> 23
 <212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 166

uuacgutcg uuaacucaag cug

23

<210> 167

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 167

uaagcuagug acugucaccg auc

23

<210> 168

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 168

uucguutaac ucaagcugcc ucg

23

<210> 169

<211> 23

<212> DNA

<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 169
ugcgagtcug uguuuuugca gga 23

<210> 170
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 170
ucucggtgau uuagcagcaa gaa 23

<210> 171
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 171
ucggugauuu agcagcaaga aaa 23

<210> 172
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 172

ucuuguacaa acaaaugcuu ucu

23

<210> 173

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 173

uaacautuac acgucugcgg auc

23

<210> 174

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 174

ugggauauua aaauaguacc gua

23

<210> 175

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 175

uucgaucguu cuguauca cuu

23

<210> 176
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 176
ugcaacgcga gucuguguuu uug 23

<210> 177
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 177
ucaaguacgu ucguuuaacu caa 23

<210> 178
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 178
ucagucaaaau acauccagug aag 23

<210> 179
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 179

uaaagutcau gguuucggag gcc

23

<210> 180

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 180

uaguacguuc guuuuacuca agc

23

<210> 181

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 181

uauuacggau aaacaguagc acc

23

<210> 182

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 182

ugaacatuua cacgucugcg gau

23

<210> 183
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 183
 uggaacauuu acacgucugc gga 23

<210> 184
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 184
 ucaacaaugu gucucuucuc uuc 23

<210> 185
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 185
 uauucacauu uguugugcug uag 23

<210> 186
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 186
 uucggugauu uagcagcaag aaa 23

<210> 187
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 187
uacuagtggg uucaauggug uga 23

<210> 188
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 188
ucguuuuacu caagcugccu cgc 23

<210> 189
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 189
uuggacgaaa aguuucagug cga 23

<210> 190
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

<400> 190
 uauaagtacc guauauaaaa cac 23

<210> 191
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 191
 uaacuagugg uuucuauggu gug 23

<210> 192
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 192
 ucgcauaauc ugcaugguga ugu 23

<210> 193
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 193
 uaaguacguu cguuuaacuc aag 23

<210> 194
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 194
uaccguauau aaaacacuuu cuc 23

<210> 195
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 195
ucaagataag cuagugacug uca 23

<210> 196
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 196
uuuacggaua aacaguagca cca 23

<210> 197
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 197
 ucgagucugu guuuuugcag gaa 23

 <210> 198
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 198
 uaacgcgagu cuguguuuuu gca 23

 <210> 199
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 199
 uccaacuca aguccacagc agu 23

 <210> 200
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 200
 ugacaccau aacauuagca cug 23

 <210> 201
 <211> 23
 <212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 201

uacggataaa caguagcacc aa

23

<210> 202

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 202

uccguataua aaacacuuuc ucu

23

<210> 203

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 203

ugauacaucu cauaauagu uga

23

<210> 204

<211> 23

<212> DNA

<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

<400> 204
 ugcaagtacg uucguuuuac uca 23

<210> 205
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 205
 ucacaggau gcuugaagau gua 23

<210> 206
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 206
 uccaagaaua cugaaaaaaaa acc 23

<210> 207
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 207
 ucccacaauu auuacggaua aac 23

<210> 208
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 208
uagggatauu aaauaaguac cgu 23

<210> 209
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 209
ugcacuagag acaaagacgu gau 23

<210> 210
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 210
ucgcgagucu guguuuuugc agg 23

<210> 211
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 211
uagauacauc ucauaaaauag uug 23

<210> 212
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 212
ugcgcutucg uuuuugcccc uuu 23

<210> 213
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 213
ucgguacaaa uaagagagca aga 23

<210> 214
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 214
ucggaucuug uacaaacaaa ugc 23

<210> 215
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 215
uucggctugu cacaucugca agu 23

<210> 216
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 216
uauacatcuc auaaaauaguu gaa 23

<210> 217
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 217
ugagautuag uauguagaau ucu 23

<210> 218
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 218
uuuucaaugg ugugaggaca uag 23

<210> 219
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 219
uugcggaucu uguacaaaca aaU 23

<210> 220
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 220
ucauuucagg uuucuggauu aag 23

<210> 221
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 221

uccucgaacu gauuuuuuuu cuu

23

<210> 222

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 222

uuugcgcuuu cguuuuugcc ccu

23

<210> 223

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 223

uauagacau caugaacuuc acc

23

<210> 224

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 224

uaugaacuuc accacuucgu gau

23

<210> 225

<211> 23

<212> DNA

<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

<400> 225
 uugcactaga gacaaagacg uga 23

<210> 226
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 226
 uauaaucugc auggugaugu ugg 23

<210> 227
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 227
 uuacggauaa acaguagcac caa 23

<210> 228
 <211> 23
 <212> DNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<220>
 <221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 228

ucagaatagc aaugucuauu uua

23

<210> 229

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 229

uauccacagu gauuugggga agu

23

<210> 230

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 230

ucauuuacac gucugcggau cuu

23

<210> 231

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 231

uagacaaaga cgugauguua aua

23

<210> 232

<211> 23

<212> RNA

<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 232
 uaaaagcagg ucacucacuu ugc 23

 <210> 233
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 233
 ucaacgcgag ucuguguuuu ugc 23

 <210> 234
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 234
 ucgaaaaguu ucagugcgac gcc 23

 <210> 235
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 235
 uccaauaaca uuagcacugu uaa 23

 <210> 236
 <211> 23
 <212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 236

ucagcccaga aguuggacga aaa

23

<210> 237

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 237

ucauccagug aagacaccaa uaa

23

<210> 238

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 238

uacgcgaguc uguguuuuug cag

23

<210> 239

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 239

ucuuuccucg aacugauuuu uuu

23

<210> 240

<211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 240
 ucaggaacau uuacacgucu gcg 23

<210> 241
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 241
 uguuucaaug gugugaggac aua 23

<210> 242
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 242
 uaccaagaau acugaaaaaa aac 23

<210> 243
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 243
 uauuuacacg ucugcggauc uug 23

<210> 244
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 244
ucgaauccaa uuccaagagg gac 23

<210> 245
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 245
uaaagacgug auguuaauau cuu 23

<210> 246
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 246
ucggauaaac aguagcacca aua 23

<210> 247
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 247
ucgcuutcg uuuugcccu uuc 23

<210> 248
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 248
ucggcutguc acaucugcaa gua 23

<210> 249
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 249
ucccuutccu cgaacugauu uu 23

<210> 250
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<400> 250
uccagaaguu ggacgaaaag uuu 23

<210> 251
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 251
ugacaaagac gugauguuua uau 23

<210> 252
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 252
ucugcacuag agacaaagac gug 23

<210> 253
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 253
uuugcaacgc gagucugugu uuu 23

<210> 254
<211> 23
<212> RNA
<213> Artificial Sequence

<220>

<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 254
ucaaagacgu gauguuaaua ucu 23

<210> 255
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 255
ucacaatuau uacggauaaa cag 23

<210> 256
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 256
uccuuuccuc gaacugauuu uuu 23

<210> 257
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 257
uccacaauua uuacggauaa aca 23

<210> 258
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 258
uccaaagcac agcaaugucc uga 23

<210> 259
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 259
aagacugaua cagaacgauc a 21

<210> 260
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 260
acgguacuua uuuaauaucc a 21

<210> 261
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 261

cagaacaguc cuuaauccag a 21

<210> 262
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 262
cgacagaaca guccuuauc a 21

<210> 263
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 263
gcuuuuguuu guacaagau a 21

<210> 264
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 264
uauugguguc uucacuggau a 21

<210> 265
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 265
acugauacag aacgaucgau a 21

<210> 266
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 266
aaagacugau acagaacgau a 21

<210> 267
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 267
auacagaacg aucgauacag a 21

<210> 268
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 268
cugauacaga acgaucgau a 21

<210> 269
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 269

gagaaagugu uuuaauauacg a

21

<210> 270

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 270

acgaacguac uugcagaugu a

21

<210> 271

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 271

cuuggaauug gauucgccau a

21

<210> 272

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 272

ggcagcuuga guuaaacgaa a

21

<210> 273

<211> 21

<212> RNA

<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 273
 gggcagaau aucacgaagu a 21

<210> 274
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 274
 uuaaacgaac guacuugcag a 21

<210> 275
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 275
 guuauuggug ucuucacugg a 21

<210> 276
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 276
 agcuugaguu aaacgaacgu a 21

<210> 277
 <211> 21
 <212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 277

gcagcuugag uaaaacgaac a

21

<210> 278

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 278

cgaaguggug aagucaugg a

21

<210> 279

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 279

cagaaucauc acgaaguggu a

21

<210> 280

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 280

aaaauagaca uugcuauucu a

21

<210> 281

<211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 281
 cagcuugagu uaaacgaacg a 21

 <210> 282
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 282
 cgcacugaaa cuuuucgucc a 21

 <210> 283
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 283
 agauuaugcg gaucaaaccu a 21

 <210> 284
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 284
 gcucucuuau uuguaccggu a 21

<210> 285
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 285
ugacagucac uagcuuau cu a 21

<210> 286
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 286
cuugaguuaa acgaacguac a 21

<210> 287
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 287
agugcuaaug uuauuggugu a 21

<210> 288
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 288

auccgcagac guguaaaugu a 21

<210> 289
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 289
agacugauac agaacgaucg a 21

<210> 290
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 290
uguuauuggu gucuucacug a 21

<210> 291
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 291
gugcuggaau uugauauuca a 21

<210> 292
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 292
uugcugcuaa aucaccgagc a 21

<210> 293
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 293
caccaugcag auuaugcgga a 21

<210> 294
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 294
gaaagcauuu guuuguacaa a 21

<210> 295
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 295
gcuugaguua aacgaacgua a 21

<210> 296
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 296

ucggugacag ucacuagcuu a

21

<210> 297

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 297

aggcagcuug aguuaaacga a

21

<210> 298

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 298

cugcaaaaac acagacucgc a

21

<210> 299

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 299

cuugcugcua aaucaccgag a

21

<210> 300

<211> 21

<212> RNA

<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 300
 uucuugcugc uaaaucaccg a 21

<210> 301
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 301
 aaagcauuug uuuguacaag a 21

<210> 302
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 302
 uccgcagacg uguaaauguu a 21

<210> 303
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 303
 cgguacuuau uuaauauccc a 21

<210> 304
 <211> 21
 <212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 304

gacugauaca gaacgaucga a

21

<210> 305

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 305

aaaacacaga cucgcuugc a

21

<210> 306

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 306

gaguuaaacg aacguacuug a

21

<210> 307

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 307

ucacuggaug uauuugacug a

21

<210> 308

<211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 308
 ccuccgaaac caugaacuuu a 21

<210> 309
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 309
 uugaguuaaa cgaacguacu a 21

<210> 310
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 310
 ugcuauguu uaucgguuu a 21

<210> 311
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 311
 ccgcagacgu guaaauguuc a 21

<210> 312
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 312
cgagagcug uaaauuuu a 21

<210> 313
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 313
agagaagaga cacauuuu a 21

<210> 314
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 314
acagcacaac aaauuuuu a 21

<210> 315
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 315

ucuugcugcu aaaucaccga a 21

<210> 316
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 316
 acaccauuga aaccacuagu a 21

<210> 317
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 317
 gaggcagcuu gaguuaaacg a 21

<210> 318
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 318
 gcacugaaac uuuucgucca a 21

<210> 319
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 319
guuuuauaua cgguacuuau a 21

<210> 320
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 320
caccauugaa accacuaguu a 21

<210> 321
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 321
aucaccaugc agauuaugcg a 21

<210> 322
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 322
ugaguuaaac gaacguacuu a 21

<210> 323
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 323

gaaaguguuu uauauacggu a

21

<210> 324

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 324

acagucacua gcuuaucuug a

21

<210> 325

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 325

gugcuacugu uuauccguaa a

21

<210> 326

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 326

ccugcaaaaa cacagacucg a

21

<210> 327

<211> 21

<212> RNA

<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 327
 caaaaacaca gacucgcguu a 21

<210> 328
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 328
 ugcuguggac uugaguuggg a 21

<210> 329
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 329
 gugcuaaugu uauugguguc a 21

<210> 330
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 330
 uggugcuacu guuuauccgu a 21

<210> 331
 <211> 21
 <212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 331

agaaaguguu uuauauacgg a

21

<210> 332

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 332

aacuaauuuau gagauguauc a

21

<210> 333

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 333

aguuaaacga acguacuugc a

21

<210> 334

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 334

caucuucaag ccauccugug a

21

<210> 335

<211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 335
 uuuuuuuuca guauucuugg a 21

<210> 336
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 336
 uuauccguaa uaauuguggg a 21

<210> 337
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 337
 gguacuuauu uaauaucccu a 21

<210> 338
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 338
 cacgucuuug ucucuagugc a 21

<210> 339
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 339
ugcaaaaaca cagacucgcg a 21

<210> 340
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 340
acuauuuauag agauguauca a 21

<210> 341
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 341
aggggcaaaa acgaaagcgc a 21

<210> 342
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 342

uugcucucuu auuuguaccg a 21

<210> 343
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 343
 auuuguuuugu acaagaucg a 21

<210> 344
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 344
 uugcagaugu gacaagccga a 21

<210> 345
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 345
 caacuauua ugagauguau a 21

<210> 346
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 346
aauucuacau acuaaaucuc a 21

<210> 347
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 347
auguccucac accauugaaa a 21

<210> 348
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 348
uuguuuuguac aagaucgca a 21

<210> 349
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 349
uaauccagaa accugaaaug a 21

<210> 350
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 350

gaaaaaaaau caguucgagg a

21

<210> 351

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 351

gggcaaaaac gaaagcgcaa a

21

<210> 352

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 352

ugaagucau ggaugucuau a

21

<210> 353

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 353

cacgaagugg ugaagucau a

21

<210> 354

<211> 21

<212> RNA

<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 354
 acgucuuugu cucuagugca a 21

<210> 355
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 355
 aacaucacca ugcagauuau a 21

<210> 356
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 356
 ggugcuacug uuuaucggu a 21

<210> 357
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 357
 aaauagacau ugcuaauucug a 21

<210> 358
 <211> 21
 <212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 358

uuccccaaau cacuguggau a

21

<210> 359

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 359

gauccgcaga cguguaaaug a

21

<210> 360

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 360

uuaacaucac gucuuugucu a

21

<210> 361

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 361

aaagugagug accugcuuuu a

21

<210> 362

<211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 362
 aaaaacacag acucgcuug a 21

<210> 363
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 363
 cgucgcacug aaacuuuucg a 21

<210> 364
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 364
 aacagucua auguuauugg a 21

<210> 365
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 365
 uucguccaac uucugggcug a 21

<210> 366
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 366
auuggugucu ucacuggaug a 21

<210> 367
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 367
gcaaaaacac agacucgcgu a 21

<210> 368
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 368
aaaaaucagu ucgaggaaag a 21

<210> 369
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 369

cagacgugua aauguuccug a 21

<210> 370
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 370
uguccucaca ccauugaaac a 21

<210> 371
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 371
uuuuuuucag uauucuuggu a 21

<210> 372
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 372
agauccgcag acguguaaaau a 21

<210> 373
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 373
cccucuugga auuggauucg a 21

<210> 374
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 374
gauauuaaca ucacgucuuu a 21

<210> 375
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 375
uuggugcuac uguuuauccg a 21

<210> 376
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 376
aaggggcaaa aacgaaagcg a 21

<210> 377
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 377

cuugcagaug ugacaagccg a

21

<210> 378

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 378

aaaucaguuc gaggaaggg a

21

<210> 379

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 379

acuuuucguc caacuucgg a

21

<210> 380

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 380

auuaacauca cgucuuguc a

21

<210> 381

<211> 21

<212> RNA

<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 381
 cgucuuuguc ucuagugcag a 21

<210> 382
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 382
 aacacagacu cgcgugcaa a 21

<210> 383
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 383
 auauuaacau cacgucuuug a 21

<210> 384
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 384
 guuuauccgu aaauuugug a 21

<210> 385
 <211> 21
 <212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 385

aaaaucaguu cgaggaaagg a

21

<210> 386

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 386

uuuauccgua auaauugugg a

21

<210> 387

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 387

aggacauugc ugugcuuugg a

21

<210> 388

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 388
ugaucgtucu guaucagucu uuc 23

<210> 389
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 389
uggauatuaa auaaguaccg uau 23

<210> 390
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 390
ucuggatuaa ggacuguucu guc 23

<210> 391
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 391
ugauuaagga cuguucuguc gau 23

<210> 392
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 392
ugaucutgua caaacaaaug cuu 23

<210> 393
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 393
uauccaguga agacaccaau aac 23

<210> 394
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 394
uaucgatcgu ucuguaucag ucu 23

<210> 395
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 395
uauugutcg uauagucuu ucc 23

<210> 396
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 396
ucuguatcga ucguucugua uca 23

<210> 397
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 397
uuaucaugc uucuguauc guc 23

<210> 398
<211> 23

<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 398
ucguauauaa aacacuuucu cuu 23

<210> 399
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 399
uacauctgca aguacguucg uuu 23

<210> 400
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 400
uauggcgaau ccaauuccaa gag 23

<210> 401
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

 <400> 401
 uuucgutuaa cucaagcugc cuc 23

 <210> 402
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 402
 uacuucguga ugauucugcc cuc 23

 <210> 403
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 403
 ucugcaagua cguucguuaa acu 23

 <210> 404
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 404
 uccagugaag acaccaauaa cau 23

 <210> 405
 <211> 23

<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 405
uacguucguu uaacucaagc ugc 23

<210> 406
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 406
uguucgtuua acucaagcug ccu 23

<210> 407
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 407
uccaugaacu ucaccacuuc gug 23

<210> 408
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 408
uaccactucg ugaugauucu gcc 23

<210> 409
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 409
uagaauagca augucuauuu uau 23

<210> 410
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 410
ucguucguuu aacucaagcu gcc 23

<210> 411
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 411
uggacgaaaa guuucagugc gac 23

<210> 412
<211> 23

<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 412
uagguutgau ccgcauaauc ugc 23

<210> 413
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 413
uaccggtaca aaauagagag caa 23

<210> 414
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 414
uagauaagcu agugacuguc acc 23

<210> 415
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 415
uguacgtucg uuuaacucac gcu 23

<210> 416
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 416
uacaccaua acauuagcac ugu 23

<210> 417
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 417
uacauutaca cgucugcgga ucu 23

<210> 418
<211> 23
<212> RNA
<213> Artificial Sequence

<220>

<221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 418
 ucgaucguuc uguaucaguc uuu 23

<210> 419
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 419
 ucagugaaga caccauaaac auu 23

<210> 420
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 420
 uugaauauca aauccagca ccg 23

<210> 421
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 421
 ugcucgguga uuagcagca aga 23

<210> 422
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 422
uuccgcauaa ucugcauggu gau

23

<210> 423
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 423
uuuguacaaa caaaugcuuu cuc

23

<210> 424
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 424
uuacgutcg uuaacucaag cug

23

<210> 425
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 425

uaagcuagug acugucaccg auc

23

<210> 426
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 426
uucguutaac ucaagcugcc ucg

23

<210> 427
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 427
ugcgagtcug uguuuuugca gga

23

<210> 428
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic

oligonucleotide"

<400> 428
ucucggtgau uuagcagcaa gaa 23

<210> 429
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 429
ucggugauuu agcagcaaga aaa 23

<210> 430
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 430
ucuuguacaa acaaaugcuu ucu 23

<210> 431
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 431
uaacautuac acgucugcgg auc 23

<210> 432

<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 432
ugggauauua aauaaguacc gua 23

<210> 433
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 433
uucgaucguu cuguauagu cuu 23

<210> 434
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 434
ugcaacgcga gucuguguuu uug 23

<210> 435
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 435
ucaaguacgu ucguuuuacu caa 23

<210> 436
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 436
ucagucaaaau acauccagug aag 23

<210> 437
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 437
uaaagutcau gguuucggag gcc 23

<210> 438
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 438
uaguacguuc guuuuacuca agc 23

<210> 439
<211> 23
<212> RNA
<213> Artificial Sequence

<220>

<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 439
uauuacggau aaacaguagc acc 23

<210> 440
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 440
ugaacatuua cacgucugcg gau 23

<210> 441
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 441
uggaacauuu acacgucugc gga 23

<210> 442
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 442
ucaacaangu gucucuucuc uuc 23

<210> 443
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 443
uauucacauu uguugugcug uag 23

<210> 444
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 444
uucggugauu uagcagcaag aaa 23

<210> 445
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 445
uacuagtggg uucaugggug uga 23

<210> 446
<211> 23
<212> RNA
<213> Artificial Sequence

<220>

<221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 446
 ucguuaacu caagcugccu cgc 23

<210> 447
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 447
 uuggacgaaa aguuucagug cga 23

<210> 448
 <211> 23
 <212> DNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

 <400> 448
 uauaagtacc guauauaaaa cac 23

<210> 449
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 449
 uaacuagugg uuucaauggu gug 23

<210> 450
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 450
ucgcuaaauc ugcaugguga ugu 23

<210> 451
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 451
uaaguacguu cguuuaacuc aag 23

<210> 452
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 452
uaccguauau aaaacacuuu cuc 23

<210> 453
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

<400> 453
 ucaagataag cuagugacug uca 23

<210> 454
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 454
 uuuacggaua aacaguagca cca 23

<210> 455
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 455
 ucgagucugu guuuuugcag gaa 23

<210> 456
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 456
 uaacgcgagu cuguguuuuu gca 23

<210> 457
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 457
ucccaacuca aguccacagc agu

23

<210> 458
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 458
ugacaccaau aacauuagca cug

23

<210> 459
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 459
uacggataaa caguagcacc aa

23

<210> 460
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 460
uccguataua aaacacuuuc ucu 23

<210> 461
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 461
ugauacaucu cauaaaugu uga 23

<210> 462
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 462
ugcaagtacg uucguuaac uca 23

<210> 463
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 463
ucacaggaug gcuugaagau gua 23

<210> 464
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 464
uccaagaaua cugaaaaaaaa acc 23

<210> 465
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 465
ucccacaauu auuacggaua aac 23

<210> 466
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 466
uagggatauu aaauaaguac cgu 23

<210> 467
<211> 23
<212> RNA
<213> Artificial Sequence

<220>

<221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 467
 ugcacuagag acaaagacgu gau 23

<210> 468
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 468
 ucgcgagucu guguuuuugc agg 23

<210> 469
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 469
 uagauacauc ucauaaaauag uug 23

<210> 470
 <211> 23
 <212> DNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

<400> 470
 ugcgcutucg uuuuugcccc uuu 23

<210> 471
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 471
ucgguacaaa uaagagagca aga

23

<210> 472
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 472
ucggaucuug uacaaacaaa ugc

23

<210> 473
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 473
uucggctugu ccaucugca agu

23

<210> 474
<211> 23
<212> DNA
<213> Artificial Sequence

<220>

<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 474
uauacatcuc auaaauaguu gaa 23

<210> 475
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 475
ugagautuag uauguagaau ucu 23

<210> 476
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 476
uuuucaaugg ugugaggaca uag 23

<210> 477
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<400> 477

uugcggaucu uguacaaaca aau

23

<210> 478

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 478

ucauuucagg uuucuggauu aag

23

<210> 479

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 479

uccucgaacu gauuuuuuuu cuu

23

<210> 480

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 480

uuugcgcuuu cguuuuugcc ccu

23

<210> 481

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 481
uauagacauc caugaacuuc acc 23

<210> 482
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 482
uauagaacuuc accacuucgu gau 23

<210> 483
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 483
uugcactaga gacaaagacg uga 23

<210> 484
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 484
uauaaucugc auggugaugu ugg 23

<210> 485
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 485
uuacggauaa acaguagcac caa

23

<210> 486
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 486
ucagaatagc aaugucuauu uua

23

<210> 487
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 487
uauccacagu gauuugggga agu

23

<210> 488
<211> 23
<212> RNA
<213> Artificial Sequence

<220>

<221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 488
 ucauuuacac gucugcggau cuu 23

<210> 489
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 489
 uagacaaaga cgugauguua aua 23

<210> 490
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 490
 uaaaagcagg ucacucacuu ugc 23

<210> 491
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 491
 ucaacgcgag ucuguguuuu ugc 23

<210> 492
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 492 ucgaaaaguu ucagugcgac gcc	23
<210> 493 <211> 23 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 493 uccaauaaca uuagcacugu uaa	23
<210> 494 <211> 23 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 494 ucagcccaga aguuggacga aaa	23
<210> 495 <211> 23 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 495 ucauccagug aagacaccaa uaa	23
<210> 496 <211> 23	

<212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 496
 uacgcgaguc uguguuuuug cag 23

<210> 497
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 497
 ucuuuccucg aacugauuuu uuu 23

<210> 498
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 498
 ucaggaacau uuacacgucu gcg 23

<210> 499
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 499
 uguuucaaug gugugaggac aua 23

<210> 500
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 500
uaccaagaau acugaaaaaa aac 23

<210> 501
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 501
uauuuacacg ucugcggauc uug 23

<210> 502
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 502
ucgaauccaa uucaagagg gac 23

<210> 503
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 503
uaaagacgug auguuaauau cuu 23

<210> 504
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 504
ucggauaaac aguagcacca aua

23

<210> 505
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 505
ucgcuutcg uuuugccccc uuc

23

<210> 506
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 506
ucggcutguc acaucugcaa gua

23

<210> 507
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 507
ucccuutccu cgaacugauu uuu 23

<210> 508
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 508
uccagaaguu ggacgaaaag uuu 23

<210> 509
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 509
ugacaaagac gugauguuua uau 23

<210> 510
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 510

ucugcacuag agacaaagac gug

23

<210> 511

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 511

uuugcaacgc gagucugugu uuu

23

<210> 512

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 512

ucaaagacgu gauguuaaua ucu

23

<210> 513

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 513

ucacaatuau uacggauaaa cag

23

<210> 514
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 514
 uccuuuccuc gaacugauuu uuu 23

<210> 515
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 515
 uccacaauua uuacggauaa aca 23

<210> 516
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 516
 uccaaagcac agcaaugucc uga 23

<210> 517
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 517
 acugauacag aacgaucgau a 21

<210> 518
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 518
aaagacugau acagaacgau a 21

<210> 519
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 519
gagaaagugu uuuaauauacg a 21

<210> 520
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 520
agacugauac agaacgaucg a 21

<210> 521
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 521
caacuauuuu ugagauau a 21

<210> 522
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 522
aagacugaua cagaacgauc a 21

<210> 523
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 523
auacagaacg aucgauacag a 21

<210> 524
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 524
aacagugcua auguuauugg a 21

<210> 525
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<400> 525
gugcuaaugu uauugguguc a 21

<210> 526
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 526
aacuauuuau gagauguauc a 21

<210> 527
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 527
cagaacaguc cuuaauccag a 21

<210> 528
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 528
gacugauaca gaacgaucga a 21

<210> 529
<211> 21
<212> RNA
<213> Artificial Sequence

<220>

<221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 529
 acagcacaac aaaugugaau a 21

<210> 530
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 530
 aaauagacau ugcuaauucug a 21

<210> 531
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 531
 uauugguguc uucacuggau a 21

<210> 532
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 532
 cugauacaga acgaucgau a 21

<210> 533
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 533
 gcucucuau uuguaccggu a 21

 <210> 534
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 534
 caccauugaa accacuaguu a 21

 <210> 535
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 535
 ggcagcuuga guuaaacgaa a 21

 <210> 536
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 536
 uuaaacgaac guacuugcag a 21

 <210> 537
 <211> 21

<212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 537
 ucggugacag ucacuagcuu a 21

<210> 538
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 538
 aguuaaacga acguacuugc a 21

<210> 539
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 539
 gcagcuugag uuaaacgaac a 21

<210> 540
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 540
 agugcuaaug uuauuggugu a 21

<210> 541
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 541
 cgaaguggug aagucaugg a 21

<210> 542
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 542
 aaagcauug uuuguacaag a 21

<210> 543
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 543
 auguccucac accauugaaa a 21

<210> 544
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 544
 ugaguuaaac gaacguacuu a 21

<210> 545
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 545
acaccauga aaccacuaga 21

<210> 546
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 546
caaaaacaca gacucgcguu a 21

<210> 547
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 547
uguccucaca ccaugaaac a 21

<210> 548
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 548
cagcuugagu uaaacgaacg a 21

<210> 549
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 549
ggugcuacug uuuaucggu a 21

<210> 550
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 550
uugcucucuu auuuguaccg a 21

<210> 551
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 551
ucuugcugcu aaauaccga a 21

<210> 552
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<400> 552
cgguacuuau uuaauauccc a 21

<210> 553
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 553
aaaauagaca uugcuauucu a 21

<210> 554
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 554
acuuuucguc caacuucugg a 21

<210> 555
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 555
uuggugcuac uguuuauccg a 21

<210> 556
<211> 21
<212> RNA
<213> Artificial Sequence

<220>

<221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 556
 guuauuggug ucuucacugg a 21

<210> 557
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 557
 uucguccaac uucugggcug a 21

<210> 558
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 558
 uucuugcugc uaaaucccg a 21

<210> 559
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 559
 gguacuuaau uaauaucccu a 21

<210> 560
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 560
auauuaacau cacgucuuug a 21

<210> 561
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 561
gaggcagcuu gaguuaaacg a 21

<210> 562
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 562
gugcuacugu uuauccguaa a 21

<210> 563
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 563
aggcagcuug aguuaaacga a 21

<210> 564
<211> 21

<212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 564
 uggugcuacu guuuauccgu a 21

 <210> 565
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 565
 aaggggcaaa aacgaaagcg a 21

 <210> 566
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 566
 acagucacua gcuuaucuug a 21

 <210> 567
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 567
 acgguacuua uuuuauaucc a 21

<210> 568
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 568
 gaguuaaacg aacguacuug a 21

<210> 569
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 569
 uguuauuggu gucuucacug a 21

<210> 570
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 570
 cgacagaaca guccuuaauc a 21

<210> 571
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 571
 aaaaucaguu cgaggaaagg a 21

<210> 572
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 572
cuuggaauug gauucgccau a 21

<210> 573
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 573
agagaagaga cacauuguug a 21

<210> 574
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 574
acgucuuugu cucuagugca a 21

<210> 575
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 575
ugacagucac uagcuuau cu a 21

<210> 576
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 576
uugaguuaaa cgaacguacu a 21

<210> 577
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 577
gaaagcauuu guuuguacaa a 21

<210> 578
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 578
aucaccaugc agauuaugcg a 21

<210> 579
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<400> 579
caccaugcag auuaugcgga a 21

<210> 580
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 580
cuugaguuaa acgaacguac a 21

<210> 581
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 581
uugcagaugu gacaagccga a 21

<210> 582
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 582
acuauuuuauag agauguaucu a 21

<210> 583
<211> 21
<212> RNA
<213> Artificial Sequence

<220>

<221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 583
 uuuuuuuuca guauucuugg a 21

<210> 584
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 584
 guuuuauaua cgguacuuau a 21

<210> 585
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 585
 gaaaguguuu uauauacggu a 21

<210> 586
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 586
 ucacuggaug uauuugacug a 21

<210> 587
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 587
 gcuugaguua aacgaacgua a 21

 <210> 588
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 588
 ccuccgaaac caugaacuuu a 21

 <210> 589
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 589
 aaaaaucagu ucgaggaaag a 21

 <210> 590
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 590
 gagaauucua cauacuaaaau a 21

 <210> 591
 <211> 21

<212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 591
 agauuaugcg gaucaaaccu a 21

 <210> 592
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 592
 aaaucaguuc gaggaaggg a 21

 <210> 593
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 593
 gcuuuuuuu guacaagau a 21

 <210> 594
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 594
 cacgaagugg ugaagucau a 21

<210> 595
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 595
 uaauccagaa accugaaaug a 21

<210> 596
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 596
 caucucaag ccauccugug a 21

<210> 597
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 597
 ugcuauguu uaucgguuu a 21

<210> 598
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 598
 uugcugcuua aucaccgagc a 21

<210> 599
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 599
gauauuaaca ucacgucuuu a 21

<210> 600
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 600
cugcaaaaac acagacucgc a 21

<210> 601
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 601
cuugcugcua aaucaccgag a 21

<210> 602
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 602
agaaaguguu uuauauacgg a 21

<210> 603
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 603
aacaucacca ugcagauuau a 21

<210> 604
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 604
cgcagacgug uaaauguucc a 21

<210> 605
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 605
agcuugaguu aaacgaacgu a 21

<210> 606
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<400> 606
gcacugaaac uuuucgucca a 21

<210> 607
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 607
aauucuacau acuaaaucuc a 21

<210> 608
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 608
ccgcagacgu guaaauguuc a 21

<210> 609
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 609
uccgcagacg uguaaauguu a 21

<210> 610
<211> 21
<212> RNA
<213> Artificial Sequence

<220>

<221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 610
 cgcacugaaa cuuuucgucc a 21

<210> 611
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 611
 cccucuugga auuggauucg a 21

<210> 612
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 612
 cagacgugua aauguuccug a 21

<210> 613
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 613
 acgaacguac uugcagaugu a 21

<210> 614
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 614
 auccgcagac guguaaaugu a 21

 <210> 615
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 615
 cagaaucauc acgaaguggu a 21

 <210> 616
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 616
 ccugcaaaaa cacagacucg a 21

 <210> 617
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 617
 aggacauugc ugugcuuugg a 21

 <210> 618
 <211> 21

<212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 618
 gggcagaauc aucacgaagu a 21

<210> 619
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 619
 ugaaguucan ggaugucuan a 21

<210> 620
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 620
 cgucgcacug aaacuuuucg a 21

<210> 621
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 621
 gaaaaaaaau caguucgagg a 21

<210> 622
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 622
auuggugucu ucacuggaug a 21

<210> 623
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 623
agauccgcag acguguaaaau a 21

<210> 624
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 624
gauccgcaga cguguaaaug a 21

<210> 625
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 625
uuguuuguac aagauccgca a 21

<210> 626
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 626
ugcuguggac uugaguuggg a 21

<210> 627
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 627
cacgucuuug ucucuagugc a 21

<210> 628
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 628
uuuuuuucag uauucuuggu a 21

<210> 629
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 629
gugcuggaau uugauauuca a 21

<210> 630
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 630
uuaacaucac gucuuugucu a 21

<210> 631
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 631
aggggcaaaa acgaaagcgc a 21

<210> 632
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 632
aaagugagug accugcuuuu a 21

<210> 633
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<400> 633
aaaaacacag acucgcuug a 21

<210> 634
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 634
auuuguuugu acaagaucg a 21

<210> 635
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 635
uuccccaaau cacuguggau a 21

<210> 636
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 636
auuaacauca cgucuuguc a 21

<210> 637
<211> 21
<212> RNA
<213> Artificial Sequence

<220>

<221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 637
 cgucuuuguc ucuagugcag a 21

<210> 638
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 638
 aaaacacaga cucgcguugc a 21

<210> 639
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 639
 ugcaaaaaca cagacucgcg a 21

<210> 640
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 640
 aacacagacu cgcgugcaa a 21

<210> 641
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>		
<221>	source	
<223>	/note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400>	641	
	cuugcagaug ugacaagccg a	21
<210>	642	
<211>	21	
<212>	RNA	
<213>	Artificial Sequence	
<220>		
<221>	source	
<223>	/note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400>	642	
	uuuauccgua auaauugugg a	21
<210>	643	
<211>	21	
<212>	RNA	
<213>	Artificial Sequence	
<220>		
<221>	source	
<223>	/note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400>	643	
	gcaaaaacac agacucgcgu a	21
<210>	644	
<211>	21	
<212>	RNA	
<213>	Artificial Sequence	
<220>		
<221>	source	
<223>	/note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400>	644	
	guuuauccgu aaauaugug a	21
<210>	645	
<211>	21	

<212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 645
 gggcaaaaac gaaagcgcaa a 21

<210> 646
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 646
 uuauccguaa uaauuguggg a 21

<210> 647
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 647
 uaucgaucgu ucuguaucag ucu 23

<210> 648
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 648
 uaucguucug uaucagucuu ucc 23

<210> 649
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 649
ucguauauaa aacacuuucu cuu 23

<210> 650
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 650
ucgaucguuc uguaucaguc uuu 23

<210> 651
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 651
uauacaucuc auaaauaguu gaa 23

<210> 652
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 652
ugaucguucu guaucagucu uuc 23

<210> 653
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 653
ucuguauauga ucguucugua uca 23

<210> 654
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 654
uccaauaaca uuagcacugu uaa 23

<210> 655
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 655
ugacaccaau aacauuagca cug 23

<210> 656
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 656
ugauacau cuauaaugu uga 23

<210> 657
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 657
ucuggauuaa ggacuguucu guc 23

<210> 658
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 658
uucgaucguu cuguaucagu cuu 23

<210> 659
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 659
uauucacauu uguugugcug uag 23

<210> 660
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<400> 660
ucagaauagc aaugucuauu uua 23

<210> 661
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 661
uauccaguga agacaccaau aac 23

<210> 662
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 662
uuaucaugc uucugauca guc 23

<210> 663
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 663
uaccgguaca aaauagagag caa 23

<210> 664
<211> 23
<212> RNA
<213> Artificial Sequence

<220>

<221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 664
 uaacuagugg uuucaauggu gug 23

<210> 665
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 665
 uuucguuuuaa cucaagcugc cuc 23

<210> 666
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 666
 ucugcaagua cguucguuua acu 23

<210> 667
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 667
 uaagcuagug acugucaccg auc 23

<210> 668
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 668
ugcaaguacg uucguuuuac uca 23

<210> 669
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 669
uguucguuuu acucaagcug ccu 23

<210> 670
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 670
uacaccaaua acauuagcac ugu 23

<210> 671
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 671
uccaugaacu ucaccacuuc gug 23

<210> 672
<211> 23

<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 672
ucuuguacaa acaaaugcuu ucu 23

<210> 673
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 673
uuuucaaugg ugugaggaca uag 23

<210> 674
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 674
uaaguacguu cguuuaacuc aag 23

<210> 675
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 675
uacuaguggu uucaauggug uga 23

<210> 676
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 676
uaacgcgagu cuguguuuuu gca 23

<210> 677
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 677
uguuucaaug gugugaggac aua 23

<210> 678
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 678
ucguucguuu aacucaagcu gcc 23

<210> 679
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 679
uuacggauaa acaguagcac caa 23

<210> 680
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 680
ucgguacaaa uaagagagca aga

23

<210> 681
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 681
uucggugauu uagcagcaag aaa

23

<210> 682
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 682
ugggauuuua aauaaguacc gua

23

<210> 683
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 683
uagaauagca augucuauuu uau 23

<210> 684
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 684
uccagaaguu ggacgaaaag uuu 23

<210> 685
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 685
ucggauaaac aguagcacca aua 23

<210> 686
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 686
uccagugaag acaccaauaa cau 23

<210> 687
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<400> 687
ucagcccaga aguuggacga aaa 23

<210> 688
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 688
ucggugauuu agcagcaaga aaa 23

<210> 689
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 689
uagggauuu aaauaaguac cgu 23

<210> 690
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 690
ucaaagacgu gauguuaaua ucu 23

<210> 691
<211> 23
<212> RNA
<213> Artificial Sequence

<220>

<221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 691
 ucguuaacu caagcugccu cgc 23

<210> 692
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 692
 uuuacggaua aacaguagca cca 23

<210> 693
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 693
 uucguuaac ucaagcugcc ucg 23

<210> 694
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 694
 uacggauaaa caguagcacc aaU 23

<210> 695
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 695
ucgcuuucgu uuuugcccu uuc 23

<210> 696
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 696
ucaagauaag cuagugacug uca 23

<210> 697
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 697
uggauauuaa auaaguaccg uau 23

<210> 698
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 698
ucaaguacgu ucguuuaacu caa 23

<210> 699
<211> 23

<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 699
ucagugaaga caccauaaac auu 23

<210> 700
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 700
ugauuaagga cuguucuguc gau 23

<210> 701
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 701
uccuuuccuc gaacugauuu uuu 23

<210> 702
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 702
uauggcgaau ccaauuccaa gag 23

<210> 703
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 703
ucaacaaugu gucucuucuc uuc 23

<210> 704
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 704
uugcacuaga gacaaagacg uga 23

<210> 705
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 705
uagauaagcu agugacuguc acc 23

<210> 706
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 706
uaguacguuc guuuuacuca agc 23

<210> 707
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 707
uuuguacaaa caaaugcuu cuc

23

<210> 708
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 708
ucgcuaaau ucgaugguga ugu

23

<210> 709
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 709
uuccgcauaa ucugcauggu gau

23

<210> 710
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 710
uguacguucg uuuaacucac gcu 23

<210> 711
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 711
uucggcuugu cacaucugca agu 23

<210> 712
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 712
uagauacauc ucauaaaauag uug 23

<210> 713
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 713
uccaagaaua cugaaaaaaaa acc 23

<210> 714
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<400> 714
uauaaguacc guauauaaaa cac 23

<210> 715
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 715
uaccguauau aaaacacuuu cuc 23

<210> 716
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 716
ucagucaaaau acauccagug aag 23

<210> 717
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 717
uuacguucgu uuaacucaag cug 23

<210> 718
<211> 23
<212> RNA
<213> Artificial Sequence

<220>

<221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 718
 uaaaguucau gguuucggag gcc 23

<210> 719
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 719
 ucuuuccucg aacugauuuu uuu 23

<210> 720
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 720
 uauuuaguau guagaauucu cua 23

<210> 721
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 721
 uagguuugau ccgcauaauc ugc 23

<210> 722
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 722
ucccuuuccu cgaacugauu uuu 23

<210> 723
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 723
ugaucuugua caaacaaaug cuu 23

<210> 724
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 724
uauaacuuc accacuucgu gau 23

<210> 725
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 725
ucauuucagg uuucuggauu aag 23

<210> 726
<211> 23

<212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 726
 ucacaggaug gcuugaagau gua 23

 <210> 727
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 727
 uauuacggau aaacaguagc acc 23

 <210> 728
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 728
 ugcucgguga uuuagcagca aga 23

 <210> 729
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 729
 uaaagacgug auguuaauau cuu 23

<210> 730
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 730
ugcgagucug uguuuuugca gga 23

<210> 731
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 731
ucucggugau uuagcagcaa gaa 23

<210> 732
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 732
uccguauaua aaacacuuuc ucu 23

<210> 733
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 733
uauaaucugc auggugaugu ugg 23

<210> 734
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 734
uggaacauuu acacgucugc gga 23

<210> 735
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 735
uacguucguu uaacucaagc ugc 23

<210> 736
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 736
uuggacgaaa aguuucagug cga 23

<210> 737
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 737
ugagauuuag uauguagaau ucu 23

<210> 738
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 738
ugaacauuuu cacgucugcg gau 23

<210> 739
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 739
uaacauuuac acgucugcgg auc 23

<210> 740
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 740
uggacgaaaa guuucagugc gac 23

<210> 741
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<400> 741
ucgaauccaa uucaagagg gac 23

<210> 742
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 742
ucaggaacau uuacacgucu gcg 23

<210> 743
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 743
uacaucugca aguacguucg uuu 23

<210> 744
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 744
uacauuuaca cgucugcgga ucu 23

<210> 745
<211> 23
<212> RNA
<213> Artificial Sequence

<220>

<221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 745
 uaccacuucg ugaugauucu gcc 23

<210> 746
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 746
 ucgagucugu guuuuugcag gaa 23

<210> 747
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 747
 uccaaagcac agcaaugucc uga 23

<210> 748
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 748
 uacuucguga ugauucugcc cuc 23

<210> 749
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 749
 uauagacauc caugaacuuc acc 23

 <210> 750
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 750
 ucgaaaaguu ucagugcgac gcc 23

 <210> 751
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 751
 uccucgaacu gauuuuuuuu cuu 23

 <210> 752
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 752
 ucauccagug aagacaccaa uaa 23

 <210> 753
 <211> 23

<212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 753
 uauuuacacg ucugcggauc uug 23

<210> 754
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 754
 ucauuuacac gucugcggau cuu 23

<210> 755
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 755
 uugcggaucu uguacaaaca aa 23

<210> 756
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 756
 uccaacuca aguccacagc agu 23

<210> 757
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 757
ugcacuagag acaaagacgu gau 23

<210> 758
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 758
uaccaagaau acugaaaaaa aac 23

<210> 759
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 759
uugaauauca aauccagca ccg 23

<210> 760
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 760
uagacaaaga cgugauguua aua 23

<210> 761
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 761
ugcgcuuucg uuuuugcccc uuu 23

<210> 762
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 762
uaaaagcagg ucacucacuu ugc 23

<210> 763
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 763
ucaacgcgag ucuguguuuu ugc 23

<210> 764
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 764
ucggaucuug uacaaacaaa ugc 23

<210> 765
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 765
uauccacagu gauuugggga agu 23

<210> 766
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 766
ugacaaagac gugauguuaa uau 23

<210> 767
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 767
ucugcacuag agacaaagac gug 23

<210> 768
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<400> 768
ugcaacgcga gucuguguuu uug 23

<210> 769
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 769
ucgcgagucu guguuuuugc agg 23

<210> 770
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 770
uuugcaacgc gagucugugu uuu 23

<210> 771
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 771
ucggcuuguc acaucugcaa gua 23

<210> 772
<211> 23
<212> RNA
<213> Artificial Sequence

<220>

<221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 772
 uccacaauua uuacggauaa aca 23

<210> 773
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 773
 uacgcgaguc uguguuuuug cag 23

<210> 774
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 774
 ucacaauuau uacggauaaa cag 23

<210> 775
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 775
 uuugcgcuuu cguuuuugcc ccu 23

<210> 776
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 776
 ucccacaauu auuacggaua aac 23

 <210> 777
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 777
 acugauacag aacgaucgau a 21

 <210> 778
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 778
 aaagacugau acagaacgau a 21

 <210> 779
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 779
 gagaaagugu uuuauauacg a 21

 <210> 780
 <211> 21

<212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 780
 agacugauac agaacgaucg a 21

<210> 781
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 781
 caacuauuuu ugagauguau a 21

<210> 782
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 782
 aagacugaua cagaacgauc a 21

<210> 783
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 783
 auacagaacg aucgauacag a 21

<210> 784
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 784
 aacagugcua auguuauugg a 21

<210> 785
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 785
 gugcuaaugu uauugguguc a 21

<210> 786
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 786
 aacuaauuuau gagauguauc a 21

<210> 787
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 787
 cagaacaguc cuuaauccag a 21

<210> 788
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 788
gacugauaca gaacgaucga a 21

<210> 789
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 789
acagcacaac aaaugugaau a 21

<210> 790
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 790
aaauagacau ugcuaauucug a 21

<210> 791
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 791
uauugguguc uucacuggau a 21

<210> 792
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 792
cugauacaga acgaucgau a 21

<210> 793
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 793
gcucucuau uuguaccggu a 21

<210> 794
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 794
caccauugaa accacuaguu a 21

<210> 795
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<400> 795
ggcagcuuga guuaaacgaa a 21

<210> 796
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 796
uuaaacgaac guacuugcag a 21

<210> 797
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 797
ucggugacag ucacuagcuu a 21

<210> 798
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 798
aguuaaacga acguacuugc a 21

<210> 799
<211> 21
<212> RNA
<213> Artificial Sequence

<220>

<221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 799
 gcagcuugag uaaaacgaac a 21

<210> 800
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 800
 agugcuaaug uuauuggugu a 21

<210> 801
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 801
 cgaaguggug aagucaugg a 21

<210> 802
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 802
 aaagcauuug uuuguacaag a 21

<210> 803
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 803
 auguccucac accauugaaa a 21

 <210> 804
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 804
 ugaguuaaac gaacguacuu a 21

 <210> 805
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 805
 acaccauuga aaccacuagu a 21

 <210> 806
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 806
 caaaaacaca gacucgcguu a 21

 <210> 807
 <211> 21

<212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 807
 uguccucaca ccaugaaac a 21

<210> 808
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 808
 cagcuugagu uaaacgaacg a 21

<210> 809
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 809
 ggugcuacug uuuaucggu a 21

<210> 810
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 810
 uugcucucuu auuuguaccg a 21

<210> 811
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 811
 ucuugcugcu aaauaccga a 21

<210> 812
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 812
 cgguacuau uuaauauccc a 21

<210> 813
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 813
 aaaauagaca uugcuauucu a 21

<210> 814
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 814
 acuuuucguc caacuucugg a 21

<210> 815
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 815
uuggugcuac uguuuauccg a 21

<210> 816
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 816
guuauuggug ucuucacugg a 21

<210> 817
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 817
uucguccaac uucugggcug a 21

<210> 818
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 818
uucuugcugc uaaaucaccg a 21

<210> 819
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 819
gguacuuauu uaauaucccu a 21

<210> 820
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 820
auauuaacau cacgucuuug a 21

<210> 821
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 821
gaggcagcuu gaguuaaacg a 21

<210> 822
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<400> 822
gugcuacugu uuauccguaa a 21

<210> 823
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 823
aggcagcuug aguuaaacga a 21

<210> 824
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 824
uggugcuacu guuuauccgu a 21

<210> 825
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 825
aaggggcaaa aacgaaagcg a 21

<210> 826
<211> 21
<212> RNA
<213> Artificial Sequence

<220>

<221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 826
 acagucacua gcuuaucuug a 21

<210> 827
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 827
 acgguacuua uuuaauaucc a 21

<210> 828
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 828
 gaguuaaacg aacguacuug a 21

<210> 829
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 829
 uguuauuggu gucuucacug a 21

<210> 830
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 830
cgacagaaca guccuuaauc a 21

<210> 831
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 831
aaaaucaguu cgaggaaagg a 21

<210> 832
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 832
cuuggaaauug gauucgccau a 21

<210> 833
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 833
agagaagaga cacauuguug a 21

<210> 834
<211> 21

<212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 834
 acgucuuugu cucuagugca a 21

<210> 835
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 835
 ugacagucac uagcuuau cu a 21

<210> 836
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 836
 uugaguuaaa cgaacguacu a 21

<210> 837
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 837
 gaaagcauuu guuuguacaa a 21

<210> 838
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 838
 aucaccaugc agauuaugcg a 21

<210> 839
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 839
 caccaugcag auuaugcgga a 21

<210> 840
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 840
 cuugaguuaa acgaacguac a 21

<210> 841
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 841
 uugcagaugu gacaagccga a 21

<210> 842
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 842
acuauuuuag agaugaucu a 21

<210> 843
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 843
uuuuuuuuc guauucuugg a 21

<210> 844
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 844
guuuuauaua cgguacuuau a 21

<210> 845
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 845
gaaaguguuu uauauacggu a 21

<210> 846
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 846
ucacuggaug uauuugacug a 21

<210> 847
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 847
gcuugaguua aacgaacgua a 21

<210> 848
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 848
ccuccgaaac caugaacuuu a 21

<210> 849
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<400> 849
aaaaaucagu ucgaggaaag a 21

<210> 850
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 850
gagaauucua cauacuaaa a 21

<210> 851
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 851
agauuaugcg gaucaaaccu a 21

<210> 852
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 852
aaaucaguuc gaggaaaggg a 21

<210> 853
<211> 21
<212> RNA
<213> Artificial Sequence

<220>

<221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 853
 gcuuuuguuu guacaagau a 21

 <210> 854
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 854
 cacgaagugg ugaagucau a 21

 <210> 855
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 855
 uauccagaa accugaaaug a 21

 <210> 856
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 856
 caucucaag ccauccugug a 21

 <210> 857
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 857
 ugcuaacuguu uauccguaau a 21

 <210> 858
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 858
 uugcugcuaa aucaccgagc a 21

 <210> 859
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 859
 gauauuaaca ucacgucuuu a 21

 <210> 860
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 860
 cugcaaaaac acagacucgc a 21

 <210> 861
 <211> 21

<212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 861
 cuugcugcua aaucaccgag a 21

 <210> 862
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 862
 agaaaguguu uuauauacgg a 21

 <210> 863
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 863
 aacaucacca ugcagauuau a 21

 <210> 864
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 864
 cgcagacgug uaaauguucc a 21

<210> 865
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 865
 agcuugaguu aaacgaacgu a 21

<210> 866
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 866
 gcacugaaac uuuucgucca a 21

<210> 867
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 867
 aauucuacau acuaaaucuc a 21

<210> 868
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 868
 ccgcagacgu guaaauguuc a 21

<210> 869
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 869
uccgcagacg uguaaauguu a 21

<210> 870
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 870
cgcacugaaa cuuuucgucc a 21

<210> 871
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 871
cccucuugga auuggauucg a 21

<210> 872
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 872
cagacgugua aauguuccug a 21

<210> 873
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 873
acgaacguac uugcagaugu a 21

<210> 874
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 874
auccgcagac guguaaaugu a 21

<210> 875
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 875
cagaaucauc acgaaguggu a 21

<210> 876
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<400> 876
ccugcaaaaa cacagacucg a 21

<210> 877
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 877
aggacauugc ugugcuuugg a 21

<210> 878
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 878
gggcagaauc aucacgaagu a 21

<210> 879
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 879
ugaaguucau ggaugucuau a 21

<210> 880
<211> 21
<212> RNA
<213> Artificial Sequence

<220>

<221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 880
 cgucgcacug aaacuuuucg a 21

<210> 881
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 881
 gaaaaaaaau caguucgagg a 21

<210> 882
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 882
 auuggugucu ucacuggaug a 21

<210> 883
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 883
 agauccgcag acguguaaaau a 21

<210> 884
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 884
 gauccgcaga cguguaaaug a 21

 <210> 885
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 885
 uuguuuuguac aagauccgca a 21

 <210> 886
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 886
 ugcuguggac uugaguuggg a 21

 <210> 887
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 887
 cacgucuuug ucucuagugc a 21

 <210> 888
 <211> 21

<212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 888
 uuuuuuucag uauucuuggu a 21

<210> 889
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 889
 gugcuggaau uugauauuca a 21

<210> 890
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 890
 uuaacaucac gucuuugucu a 21

<210> 891
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 891
 aggggcaaaa acgaaagcgc a 21

<210> 892
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 892
aaagugagug accugcuuuu a 21

<210> 893
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 893
aaaaacacag acucgcuug a 21

<210> 894
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 894
auuuguuugu acaagaucg a 21

<210> 895
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 895
uuccccaaau cacuguggau a 21

<210> 896
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 896
auuaacauca cgucuuuguc a 21

<210> 897
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 897
cgucuuuguc ucuagugcag a 21

<210> 898
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 898
aaaacacaga cucgcguugc a 21

<210> 899
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 899
ugcaaaaaca cagacucgcg a 21

<210> 900
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 900
aacacagacu cgcguugcaa a 21

<210> 901
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 901
cuugcagaug ugacaagccg a 21

<210> 902
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 902
uuuauccgua auaauugugg a 21

<210> 903
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<400> 903
gcaaaaacac agacucgcgu a 21

<210> 904
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 904
guuuauccgu aaauugug a 21

<210> 905
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 905
gggcaaaaac gaaagcgcaa a 21

<210> 906
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 906
uuauccguaa uuauuguggg a 21

<210> 907
<211> 23
<212> RNA
<213> Artificial Sequence

<220>

<221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 907
 uaucgaucgu ucuguaucag ucu 23

<210> 908
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 908
 uaucguucug uaucagucuu ucc 23

<210> 909
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 909
 ucguauauaa aacacuuucu cuu 23

<210> 910
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 910
 ucgaucguuc uguaucaguc uuu 23

<210> 911
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 911
 uauacaucuc auaaaauaguu gaa 23

 <210> 912
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 912
 ugaucguucu guaucagucu uuc 23

 <210> 913
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 913
 ucuguauca ucguucugua uca 23

 <210> 914
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 914
 uccaauaaca uuagcacugu uaa 23

 <210> 915
 <211> 23

<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 915
ugacaccaau aacauuagca cug 23

<210> 916
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 916
ugauacaucu cauaaaugu uga 23

<210> 917
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 917
ucuggauuaa ggacuguucu guc 23

<210> 918
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 918
uucgaucguu cuguaucagu cuu 23

<210> 919
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 919
 uauucacauu uguugugcug uag 23

<210> 920
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 920
 ucagaauagc aaugucuaau uua 23

<210> 921
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 921
 uauccaguga agacaccaau aac 23

<210> 922
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 922
 uuauCGaucg uucuguaucg guc 23

<210> 923
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 923
uaccgguaca aaauagagag caa 23

<210> 924
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 924
uaacuagugg uuucuauggu gug 23

<210> 925
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 925
uuucguuuuaa cucaagcugc cuc 23

<210> 926
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 926
ucugcaagua cguucguuaa acu 23

<210> 927
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 927
uaagcuagug acugucaccg auc 23

<210> 928
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 928
ugcaaguacg uucguuaaac uca 23

<210> 929
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 929
uguucguuaa acucaagcug ccu 23

<210> 930
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<400> 930
uacaccaaua acauuagcac ugu 23

<210> 931
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 931
uccaugaacu ucaccacuuc gug 23

<210> 932
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 932
ucuuguacaa acaaaugcuu ucu 23

<210> 933
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 933
uuuucaaugg ugugaggaca uag 23

<210> 934
<211> 23
<212> RNA
<213> Artificial Sequence

<220>

<221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 934
 uaaguacguu cguuuaacuc aag 23

<210> 935
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 935
 uacuaguggu uucaauggug uga 23

<210> 936
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 936
 uaacgcgagu cuguguuuuu gca 23

<210> 937
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 937
 uguuucaaug gugugaggac aua 23

<210> 938
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 938
 ucguucguuu aacucaagcu gcc 23

 <210> 939
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 939
 uuacggauaa acaguagcac caa 23

 <210> 940
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 940
 ucgguacaaa uaagagagca aga 23

 <210> 941
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 941
 uucggugauu uagcagcaag aaa 23

 <210> 942
 <211> 23

<212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 942
 uggaauua aauaaguacc gua 23

 <210> 943
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 943
 uagaauagca augucuauuu uau 23

 <210> 944
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 944
 uccagaagu ggacgaaaag uuu 23

 <210> 945
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 945
 ucggauaaac aguagcacca aua 23

<210> 946
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 946
uccagugaag acaccaauaa cau 23

<210> 947
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 947
ucagcccaga aguuggacga aaa 23

<210> 948
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 948
ucggugauuu agcagcaaga aaa 23

<210> 949
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 949
uagggauuu aaauaaguac cgu 23

<210> 950
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 950
ucaaagacgu gauguuaaua ucu 23

<210> 951
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 951
ucguuuuacu caagcugccu cgc 23

<210> 952
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 952
uuuacggaua aacaguagca cca 23

<210> 953
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 953
uucguuuuac ucaagcugcc ucg 23

<210> 954
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 954
uacggauaaa caguagcacc aaau 23

<210> 955
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 955
ucgcuuuucgu uuuugccccc uuc 23

<210> 956
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 956
ucaagauaag cuagugacug uca 23

<210> 957
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<400> 957
uggauauuaa auaaguaccg uau 23

<210> 958
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 958
ucaaguacgu ucguuaacu caa 23

<210> 959
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 959
ucagugaaga caccauaaac auu 23

<210> 960
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 960
ugauuaagga cuguucuguc gau 23

<210> 961
<211> 23
<212> RNA
<213> Artificial Sequence

<220>

<221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 961
 uccuuuccuc gaacugauuu uuu 23

<210> 962
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 962
 uauggcgaau ccaauuccaa gag 23

<210> 963
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 963
 ucaacaaugu gucucuucuc uuc 23

<210> 964
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 964
 uugcacuaga gacaaagacg uga 23

<210> 965
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 965
 uagauaagcu agugacuguc acc 23

 <210> 966
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 966
 uaguacguuc guuuuacuca agc 23

 <210> 967
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 967
 uuuguacaaa caaaugcuuu cuc 23

 <210> 968
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 968
 ucgcauaauc ugcaugguga ugu 23

 <210> 969
 <211> 23

<212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 969
 uuccgcauaa ucugcauggu gau 23

<210> 970
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 970
 uguacguucg uuuaacucaa gcu 23

<210> 971
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 971
 uucggcuugu cacaucugca agu 23

<210> 972
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 972
 uagauacauc ucauaaaauag uug 23

<210> 973
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 973
 uccaagaaua cugaaaaaaaa acc 23

<210> 974
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 974
 uauaaguacc guauauaaaa cac 23

<210> 975
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 975
 uaccguauau aaaacacuuu cuc 23

<210> 976
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 976
 ucagucaaa acauccagug aag 23

<210> 977
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 977
uuacguucgu uuaacucaag cug 23

<210> 978
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 978
uaaagucau gguuucggag gcc 23

<210> 979
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 979
ucuuuccucg aacugauuuu uuu 23

<210> 980
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 980
uauuuaguau guagaauucu cua 23

<210> 981
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 981
uagguuuugau ccgcauaauc ugc 23

<210> 982
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 982
ucccuuuuccu cgaacugauu uuu 23

<210> 983
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 983
ugaucuugua caaacaaug cuu 23

<210> 984
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<400> 984
uaugaacuuc accacuucgu gau 23

<210> 985
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 985
ucauuucagg uuucuggauu aag 23

<210> 986
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 986
ucacaggaug gcuugaagau gua 23

<210> 987
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 987
uauuacggau aaacaguagc acc 23

<210> 988
<211> 23
<212> RNA
<213> Artificial Sequence

<220>

<221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 988
 ugcucgguga uuuagcagca aga 23

<210> 989
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 989
 uaaagacgug auguuaauau cuu 23

<210> 990
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 990
 ugcgagucug uguuuuugca gga 23

<210> 991
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 991
 ucucggugau uuagcagcaa gaa 23

<210> 992
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 992
 uccguauaua aaacacuuuc ucu 23

 <210> 993
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 993
 uauaaucugc auggugaugu ugg 23

 <210> 994
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 994
 uggaacauuu acacgucugc gga 23

 <210> 995
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 995
 uacguucguu uaacucaagc ugc 23

 <210> 996
 <211> 23

<212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 996
 uuggacgaaa aguuucagug cga 23

<210> 997
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 997
 ugagauuuag uauguagaau ucu 23

<210> 998
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 998
 ugaacauuuu cacgucugcg gau 23

<210> 999
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 999
 uaacauuuac acgucugcgg auc 23

<210> 1000
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1000
 uggacgaaaa guuucagugc gac 23

<210> 1001
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1001
 ucgaauccaa uucaagagg gac 23

<210> 1002
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1002
 ucaggaacau uuacacgucu gcg 23

<210> 1003
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1003
 uacaucugca aguacguucg uuu 23

<210> 1004
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1004
uacauuuaca cgucugcgga ucu

23

<210> 1005
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1005
uaccacuucg ugaugauucu gcc

23

<210> 1006
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1006
ucgagucugu guuuuugcag gaa

23

<210> 1007
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1007
uccaaagcac agcaaugucc uga 23

<210> 1008
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1008
uacuucguga ugauucugcc cuc 23

<210> 1009
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1009
uauagacauc caugaacuuc acc 23

<210> 1010
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1010
ucgaaaaguu ucagugcgac gcc 23

<210> 1011
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<400> 1011
uccucgaacu gauuuuuuuu cuu 23

<210> 1012
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1012
ucauccagug aagacaccaa uaa 23

<210> 1013
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1013
uaauuacacg ucugcggauc uug 23

<210> 1014
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1014
ucauuuacac gucugcggau cuu 23

<210> 1015
<211> 23
<212> RNA
<213> Artificial Sequence

<220>

<221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 1015
 uugcggaucu uguacaaaca aaau
 23

<210> 1016
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 1016
 uccaacuca aguccacagc agu
 23

<210> 1017
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 1017
 ugcacuagag acaaagacgu gau
 23

<210> 1018
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 1018
 uaccaagaau acugaaaaaa aac
 23

<210> 1019
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1019
uugaauauca aaauccagca ccg 23

<210> 1020
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1020
uagacaaaga cgugauguua aua 23

<210> 1021
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1021
ugcgcuuucg uuuuugcccc uuu 23

<210> 1022
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1022
uaaaagcagg ucacucacuu ugc 23

<210> 1023
<211> 23

<212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1023
 ucaacgcgag ucuguguuuu ugc

23

<210> 1024
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1024
 ucggaucuug uacaaacaaa ugc

23

<210> 1025
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1025
 uauccacagu gauuugggga agu

23

<210> 1026
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1026
 ugacaaagac gugauguuua uau

23

<210> 1027
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1027
 ucugcacuag agacaaagac gug 23

<210> 1028
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1028
 ugcaacgcga gucuguguuu uug 23

<210> 1029
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1029
 ucgcgagucu guguuuuugc agg 23

<210> 1030
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1030
 uuugcaacgc gagucugugu uuu 23

<210> 1031
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1031
ucggcuuguc acaucugcaa gua

23

<210> 1032
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1032
uccacaauua uuacggauaa aca

23

<210> 1033
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1033
uacgcgaguc uguguuuuug cag

23

<210> 1034
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1034
ucacaauuau uacggauaaa cag 23

<210> 1035
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1035
uuugcgcuuu cguuuuugcc ccu 23

<210> 1036
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1036
ucccacaauu auuacggaua aac 23

<210> 1037
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1037
aaaauagaca tugcuauucu a 21

<210> 1038
<211> 21
<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1038

agugcuaatg tuauuggugu a

21

<210> 1039

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1039

auacagaacg aucgauacag a

21

<210> 1040

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1040

acagcacaac aaaugugaau a

21

<210> 1041

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1041
cugauacaga acgaucgaua a 21

<210> 1042
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1042
gagaaagugu tuuauauacg a 21

<210> 1043
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1043
aacuauuuau gagauguauc a 21

<210> 1044
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1044
aagacugata cagaacgauc a 21

<210> 1045
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1045
gagaauucta cauacuaau a 21

<210> 1046
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1046
aaagacugau acagaacgau a 21

<210> 1047
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1047
acgguacuta tuuaauaucc a 21

<210> 1048
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1048
acugauacag aacgaucgau a 21

<210> 1049
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1049
cgacagaaca guccuuaauc a 21

<210> 1050
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1050
cagaacagtc cuuaauccag a 21

<210> 1051
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1051

aacagugcta auguauugg a

21

<210> 1052

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1052

acagucacta gcuaucug a

21

<210> 1053

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1053

cuugcugcta aaucaccgag a

21

<210> 1054

<211> 21

<212> DNA

<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1054
gaaagugutu tauauacggu a 21

<210> 1055
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1055
gcucucuau tuguaccggu a 21

<210> 1056
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1056
uucuugcugc taaucaccg a 21

<210> 1057

<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1057
caccauugaa accacuaguu a 21

<210> 1058
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1058
cgguacuuau tuaauauccc a 21

<210> 1059
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1059
caacuauuta tgagauguau a 21

<210> 1060
<211> 21
<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1060

uaauccagaa accugaaaug a

21

<210> 1061

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1061

aaauagacau tgcuaauucug a

21

<210> 1062

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1062

aaagcautg tuuguacaag a

21

<210> 1063

<211> 21

<212> DNA

<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1063
cuuggaautg gauucgccau a 21

<210> 1064
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1064
acaccauuga aaccacuagu a 21

<210> 1065
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1065
aacaucacca tgcagauuau a 21

<210> 1066
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1066

ugacagucac tagcuuau cu a

21

<210> 1067

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1067

aguuaaacga acguacuugc a

21

<210> 1068

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1068

acuauuuatg agauguau cu a

21

<210> 1069

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1069
uuaaacgaac guacuugcag a 21

<210> 1070
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1070
gguacuuatu taauaucccu a 21

<210> 1071
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1071
cgaaguggtg aagucaugg a 21

<210> 1072
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1072

uguuauuggu gucuucacug a

21

<210> 1073
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1073
uugcucuctu auuuguaccg a

21

<210> 1074
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1074
guuuuauata cgguacuuau a

21

<210> 1075
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic

oligonucleotide"

<400> 1075
ucacuggatg tauuugacug a 21

<210> 1076
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1076
ccuccgaaac caugaacuuu a 21

<210> 1077
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1077
uauuggugtc tucacuggau a 21

<210> 1078
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1078
agacugauac agaacgaucg a 21

<210> 1079

<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1079
uccgcagacg tguaaauguu a 21

<210> 1080
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1080
gaguuaaacg aacguacuug a 21

<210> 1081
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1081
agaaagugtu tuauauacgg a 21

<210> 1082
<211> 21
<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1082

guuauuggtg tcuucacugg a

21

<210> 1083

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1083

cuugaguuaa acgaacguac a

21

<210> 1084

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1084

ugaguuaaac gaacguacuu a

21

<210> 1085

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1085
aucaccaugc agauuaugcg a 21

<210> 1086
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1086
uugaguuaaaa cgaacguacu a 21

<210> 1087
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1087
gcagcuugag tuaaacgaac a 21

<210> 1088
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1088
cgcacugaaa cuuuucgucc a 21

<210> 1089
<211> 21
<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1089

ucggugacag tcacuagcuu a

21

<210> 1090

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1090

gugcuaaugu tauugguguc a

21

<210> 1091

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1091

cgcagacgtg taaauguucc a

21

<210> 1092
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1092
agagaagaga cacauuguug a 21

<210> 1093
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1093
ugaaguucan ggaugucuan a 21

<210> 1094
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1094
aaauucacau acuaaaucuc a 21

<210> 1095
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic oligonucleotide"

<400> 1095

cagacgugta aauguuccug a

21

<210> 1096

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic oligonucleotide"

<400> 1096

cacgaagugg tgaagucau a

21

<210> 1097

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic oligonucleotide"

<400> 1097

gcuugaguta aacgaacgua a

21

<210> 1098

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"

<400> 1098
caucuucaag ccauccugug a 21

<210> 1099
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1099
caccaugcag auuaugcgga a 21

<210> 1100
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1100
ggcagcuuga guuaaacgaa a 21

<210> 1101
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1101
auguccucac accauugaaa a 21

<210> 1102
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1102

ccgcagacgu guaaauguuc a

21

<210> 1103

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1103

cagaauatc acgaaguggu a

21

<210> 1104

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1104

gugcuacugu tuauccguaa a

21

<210> 1105

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1105
uguccucaca ccauugaaac a 21

<210> 1106
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1106
cugcaaaaac acagacucgc a 21

<210> 1107
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1107
gaggcagctu gaguuaaacg a 21

<210> 1108
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1108
auccgcagac guguaaaugu a 21

<210> 1109
<211> 21

<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1109
gcuuuugutu guacaagau a 21

<210> 1110
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1110
gaaagcautu guuuguacaa a 21

<210> 1111
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1111
uggugcuacu guuuauccgu a 21

<210> 1112
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1112
aggcagcutg aguuaaacga a 21

<210> 1113
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1113
gcacugaaac tuuucgucca a 21

<210> 1114
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1114
gacugauaca gaacgaucga a 21

<210> 1115
<211> 21
<212> DNA
<213> Artificial Sequence

<220>

<221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

 <400> 1115
 acgaacguac tugcagaugu a 21

<210> 1116
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

<400> 1116
 cagcuugagu taaacgaacg a 21

<210> 1117
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

<400> 1117
 agcuugagtu aaacgaacgu a 21

<210> 1118
 <211> 21
 <212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1118

gauauuaaca tcacgucuuu a

21

<210> 1119

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1119

ccugcaaaaa cacagacucg a

21

<210> 1120

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1120

gugcuggaau tugauauuca a

21

<210> 1121

<211> 21

<212> DNA

<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1121
uuggugcuac tguuuauccg a 21

<210> 1122
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1122
auuggugucu tcacuggaug a 21

<210> 1123
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1123
ucuugcugcu aaauccaccga a 21

<210> 1124
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1124

uugcugcuaa aucaccgagc a

21

<210> 1125

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1125

agauuaugcg gaucaaaccu a

21

<210> 1126

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1126

gggcagaatc aucacgaagu a

21

<210> 1127

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1127

auuuguuuugu acaagaucg a

21

<210> 1128
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1128
caaaaacaca gacucgcguu a 21

<210> 1129
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1129
ugcuacugtu tauccguaau a 21

<210> 1130
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1130
acuuuucgtc caacuucugg a 21

<210> 1131
<211> 21

<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1131
ggugcuactg tuuauccgua a 21

<210> 1132
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1132
gcaaaaacac agacucgcgu a 21

<210> 1133
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1133
cgucgcactg aaacuuuucg a 21

<210> 1134
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1134
auauuaacau cacgucuug a

21

<210> 1135
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1135
aaaacacaga cucgcuugc a

21

<210> 1136
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1136
cuugcagatg tgacaagccg a

21

<210> 1137
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1137

uuuuuuuuuca guauucuugg a

21

<210> 1138
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1138
aaagugagtg accugcuuuu a

21

<210> 1139
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1139
uucguccaac tucugggcug a

21

<210> 1140
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic

oligonucleotide"

<400> 1140
aggacauugc tgugcuuugg a 21

<210> 1141
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1141
aaaucagutc gaggaaggg a 21

<210> 1142
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1142
uuccccaaau cacuguggau a 21

<210> 1143
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1143
cccucuugga auuggauucg a 21

<210> 1144

<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1144
uugcagaugu gacaagccga a 21

<210> 1145
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1145
cacgucuutg tcucuagugc a 21

<210> 1146
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1146
gauccgcaga cguguaaaug a 21

<210> 1147
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1147

aaaaaucagu tcgaggaaag a

21

<210> 1148

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1148

ugcuguggac tugaguuggg a

21

<210> 1149

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1149

aaggggcaaa aacgaaagcg a

21

<210> 1150

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1150
ugcaaaaaca cagacucgcg a 21

<210> 1151
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1151
acgucuuugu cucuagugca a 21

<210> 1152
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1152
gggcaaaaac gaaagcgcaa a 21

<210> 1153
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1153
aggggcaaaa acgaaagcgc a 21

<210> 1154
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<400> 1154
gaaaaaaaau caguucgagg a 21

<210> 1155
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1155
aaaauagtu cgaggaaagg a 21

<210> 1156
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1156
aaaaacacag acucgcuug a 21

<210> 1157
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1157
uuuauccgta auaauugugg a 21

<210> 1158
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1158
agauccgcag acguguaau a 21

<210> 1159
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1159
uuaacaucaac gucuuugucu a 21

<210> 1160
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1160
cgucuugtc tcuagugcag a 21

<210> 1161
<211> 21
<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1161

guuuauccgu aaauaugug a

21

<210> 1162

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1162

uuguuuguac aagaucgca a

21

<210> 1163

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1163

uuauccguaa taauuguggg a

21

<210> 1164

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1164
aacacagacu cgcgugcaa a 21

<210> 1165
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1165
uuuuuuucag tauucuuggu a 21

<210> 1166
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1166
auuaacauca cgucuuuguc a 21

<210> 1167
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1167
uagaauagca atgtctauuu uau 23

<210> 1168
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1168
uacaccaua acatuagcac ugu 23

<210> 1169
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1169
ucugtattcga ucgtucugua uca 23

<210> 1170
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1170
uauucacauu ugutgtgcug uag 23

<210> 1171
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1171
utaucgaucg utctgtauca guc 23

<210> 1172
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1172
ucguauauaa aacactuucu cuu 23

<210> 1173
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1173

ugauacaucu cauaaaugu uga

23

<210> 1174
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1174
ugaucgtucu gtatcagucu uuc

23

<210> 1175
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1175
uauutaguau gtagaaucucu cua

23

<210> 1176
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic

oligonucleotide"

<400> 1176
uau~~cg~~ut~~c~~g uau~~c~~agucuu ucc 23

<210> 1177
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1177
uggatatu~~aa~~ ataag~~t~~accg uau 23

<210> 1178
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1178
uau~~c~~gat~~c~~gu ucugu~~a~~u~~c~~ag ucu 23

<210> 1179
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1179
ugautaagga ctgtucuguc gau 23

<210> 1180
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1180
ucuggatuaa ggacuguucu guc 23

<210> 1181
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1181
uccaauaaca utagcacugu uaa 23

<210> 1182
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1182

ucaagataag ctagugacug uca

23

<210> 1183

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1183

ucucggtgau utagcagcaa gaa

23

<210> 1184

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1184

uaccguauau aaaacacuuu cuc

23

<210> 1185

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1185
uaccggtaca aaauagagag caa 23

<210> 1186
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1186
ucggtgauuu agcagcaaga aaa 23

<210> 1187
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1187
uaactagugg utucaauggu gug 23

<210> 1188
<211> 23
<212> RNA
<213> Artificial Sequence

<220>

<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1188
ugggauuuu aaauaguacc gua

23

<210> 1189
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1189
uauacatcuc ataaataguu gaa

23

<210> 1190
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1190
ucautucagg utucuggauu aag

23

<210> 1191
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1191

ucagaatagc aaugucuauu uua

23

<210> 1192

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1192

ucuuguacaa acaaatgcuu ucu

23

<210> 1193

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1193

uauggcgaau ccaautccaa gag

23

<210> 1194

<211> 23

<212> DNA

<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

 <400> 1194
 uacuagtggg utcaatggug uga 23

<210> 1195
 <211> 23
 <212> DNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

<400> 1195
 uauaaucugc atggugaugu ugg 23

<210> 1196
 <211> 23
 <212> DNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

<400> 1196
 uagataagcu agugacuguc acc 23

<210> 1197
 <211> 23

<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1197
ugcaagtacg utcgutuaac uca 23

<210> 1198
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1198
uagatacauc ucataaaauag uug 23

<210> 1199
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1199
ucugcaagua cgutcguuua acu 23

<210> 1200
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1200
uagggatauu aaataaguac cgu 23

<210> 1201
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1201
uccatgaacu ucaccacuuc gug 23

<210> 1202
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1202
ucagtgaaga caccaauaac auu 23

<210> 1203
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1203
ucggtacaaa uaagagagca aga 23

<210> 1204
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1204
uauaagtacc gtatataaaa cac 23

<210> 1205
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1205

ucagtcaaau acatccagug aag

23

<210> 1206

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1206

uaaagutcau ggutucggag gcc

23

<210> 1207

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1207

uauccaguga agacaccaau aac

23

<210> 1208

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1208
ucgatcguuc uguaucaguc uuu 23

<210> 1209
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1209
uaacautuac acgtctgcgg auc 23

<210> 1210
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1210
ucaaguacgu ucgtutaacu caa 23

<210> 1211
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1211
uccgtataua aaacacuuuc ucu 23

<210> 1212
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1212
uccagugaag acaccaauaa cau 23

<210> 1213
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1213
uguacgtucg utuaacucuaa gcu 23

<210> 1214
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic

oligonucleotide"

<400> 1214
uaagtacguu cgutuaacuc aag 23

<210> 1215
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1215
ucgcauaauc ugcaugguga ugu 23

<210> 1216
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1216
uaguacguuc gtutaacuca agc 23

<210> 1217
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1217
uguucgtuua acucaagcug ccu 23

<210> 1218
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1218
uggacgaaaa gtutcagugc gac 23

<210> 1219
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1219
uaagcuagug acugucaccg auc 23

<210> 1220
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1220
ugacaccaau aacautagca cug 23

<210> 1221
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1221
uggaacauuu acacgtcugc gga 23

<210> 1222
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1222
ucaacaaugu gtctctucuc uuc 23

<210> 1223
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1223
uauagacauc caugaacuuc acc 23

<210> 1224
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1224
ugagautuag uauguagaau ucu 23

<210> 1225
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1225
ucaggaacau utacacgucu gcg 23

<210> 1226
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1226

uaugaacuuc accactucgu gau

23

<210> 1227
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1227
utacgutcgu utaactcaag cug

23

<210> 1228
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1228
ucacaggaug gcutgaagau gua

23

<210> 1229
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic

oligonucleotide"

<400> 1229
utccgcaguaa ucugcauggu gau 23

<210> 1230
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1230
utucgutuaa ctcaagcugc cuc 23

<210> 1231
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1231
utuucgaugg ugugaggaca uag 23

<210> 1232
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1232
ugaacatuua cacgucugcg gau 23

<210> 1233
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1233
uaccactucg ugatgauucu gcc 23

<210> 1234
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1234
utuacggaua aacagtagca cca 23

<210> 1235
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1235

uguutcaaug gtgtgaggac aua

23

<210> 1236

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1236

ugcgagtcug ugututugca gga

23

<210> 1237

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1237

ucgutuaacu caagctgccu cgc

23

<210> 1238

<211> 23

<212> DNA

<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1238
uacatutaca cgucugcgga ucu 23

<210> 1239
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1239
ugaucutgua caaacaaaug cuu 23

<210> 1240
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1240
utugtacaaa caaaugcuuu cuc 23

<210> 1241

<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1241
uacggataaaa cagtagcacc aaau
23

<210> 1242
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1242
utcgutataac ucaagcugcc ucg
23

<210> 1243
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1243
utggacgaaa agutucagug cga
23

<210> 1244
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1244
utcgauCGuu ctgtatcagu cuu 23

<210> 1245
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1245
uacatctgca aguacguucg uuu 23

<210> 1246
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1246
ucgutcguuu aactcaagcu gcc 23

<210> 1247
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1247
uacgtucguu uaacucaagc ugc 23

<210> 1248
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1248
uaaagacgug atgtuaauau cuu 23

<210> 1249
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1249
ucgagucugu gtututgcag gaa 23

<210> 1250
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1250
utgaauauca aautccagca ccg 23

<210> 1251
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1251
ucggauaaac aguagcacca aua 23

<210> 1252
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1252
ucauccagug aagacaccaa uaa 23

<210> 1253
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1253
utcggugauu uagcagcaag aaa 23

<210> 1254
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1254
ugcucgguga utuagcagca aga 23

<210> 1255
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1255
uaggtutgau ccgcataauc ugc 23

<210> 1256
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1256
uacutcguga ugatucugcc cuc 23

<210> 1257
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1257
ucggaucuug uacaaacaaa ugc 23

<210> 1258
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1258
uaacgcgagu ctgtgtuuuu gca 23

<210> 1259
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1259
uauuacggau aaacaguagc acc

23

<210> 1260
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1260
uccagaaguu ggacgaaaag uuu

23

<210> 1261
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1261
utacggauaa acaguagcac caa

23

<210> 1262
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1262
uacgcgaguc ugugutuuug cag 23

<210> 1263
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1263
ucgaaaaguu ucagugcgac gcc 23

<210> 1264
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1264
ucaaagacgu gaugutaaua ucu 23

<210> 1265
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1265

ugcaacgcga gtctgtguuu uug

23

<210> 1266

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1266

ucggcutguc acatctgcaa gua

23

<210> 1267

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1267

uccaagaaua ctgaaaaaaa acc

23

<210> 1268

<211> 23

<212> RNA

<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1268
uaaaagcagg ucacucacuu ugc

23

<210> 1269
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1269
ucagcccaga agutggacga aaa

23

<210> 1270
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1270
uccaaagcac agcaatgucc uga

23

<210> 1271
<211> 23
<212> DNA
<213> Artificial Sequence

<220>

<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1271
uccctutccu cgaactgauu uuu 23

<210> 1272
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1272
uauccacagu gautugggga agu 23

<210> 1273
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1273
ucgaauccaa utccaagagg gac 23

<210> 1274
<211> 23
<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1274

utcggctugu cacaucugca agu

23

<210> 1275

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1275

ugcacuagag acaaagacgu gau

23

<210> 1276

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1276

ucautuacac gtctgcggau cuu

23

<210> 1277

<211> 23

<212> DNA

<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1277
ucuutccucg aactgauuuu uuu 23

<210> 1278
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1278
ucccaacuca aguccacagc agu 23

<210> 1279
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1279
ucgctutcg ututgccccu uuc 23

<210> 1280
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1280

ucgcgagucu gtgtutuugc agg

23

<210> 1281

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1281

utgcactaga gacaaagacg uga

23

<210> 1282

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1282

utugcgcuuu cgututugcc ccu

23

<210> 1283

<211> 23

<212> DNA

<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1283
ugcgcutucg ututugcccc uuu 23

<210> 1284
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1284
uccucgaacu gaututuuuu cuu 23

<210> 1285
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1285
uccutuccuc gaacugauuu uuu 23

<210> 1286

<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1286
ucaacgcgag ucuguguuuu ugc 23

<210> 1287
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1287
uccacaauua utacggauaa aca 23

<210> 1288
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1288
uauutacacg ucugcggauc uug 23

<210> 1289
<211> 23
<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1289

uagacaaaga cgugatguua aua

23

<210> 1290

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1290

ucugcacuag agacaaagac gug

23

<210> 1291

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1291

ucacaatuau uacggauaaa cag

23

<210> 1292

<211> 23

<212> DNA

<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

 <400> 1292
 utgcggaucu uguacaaaca aaau

23

<210> 1293
 <211> 23
 <212> DNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

<400> 1293
 ucccacaauu atuacggaua aac

23

<210> 1294
 <211> 23
 <212> DNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

<400> 1294
 utugcaacgc gagtctgugu uuu

23

<210> 1295
 <211> 23

<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1295
uaccaagaau acugaaaaaa aac 23

<210> 1296
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1296
ugacaaagac gtgauguuaa uau 23

<210> 1297
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1297
aaaauagaca tugcuauucu a 21

<210> 1298
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

 <400> 1298
 agugcuaatg tuauuggugu a 21

 <210> 1299
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1299
 auacagaacg aucgauacag a 21

 <210> 1300
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1300
 acagcacaac aaaugugaau a 21

 <210> 1301
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1301

cugauacaga acgaucgaua a 21

<210> 1302
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1302
gagaaagugu tuuauauacg a 21

<210> 1303
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1303
aacuauuuau gagauguauc a 21

<210> 1304
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1304
aagacugata cagaacgauc a 21

<210> 1305
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1305
gagaauucta cauacuaaaau a 21

<210> 1306
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1306
aaagacugau acagaacgau a 21

<210> 1307
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1307
acgguacuta tuuaauaucc a 21

<210> 1308

<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1308
acugauacag aacgaucgau a 21

<210> 1309
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1309
cgacagaaca guccuuaauc a 21

<210> 1310
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1310
cagaacagtc cuuaauccag a 21

<210> 1311
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1311

aacagugcta auguauugg a

21

<210> 1312

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1312

acagucacta gcuuauaug a

21

<210> 1313

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1313

cuugcugcta aaucaccgag a

21

<210> 1314

<211> 21

<212> DNA

<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1314
gaaagugutu tauauacggu a 21

<210> 1315
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1315
gcucucuau tuguaccggu a 21

<210> 1316
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1316
uucuugcugc taaucaccg a 21

<210> 1317
<211> 21

<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1317
caccauugaa accacuaguu a 21

<210> 1318
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1318
cgguacuuau tuaauauccc a 21

<210> 1319
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1319
caacuauuta tgagauguau a 21

<210> 1320
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1320
uaauccagaa accugaaaug a

21

<210> 1321
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1321
aaauagacau tgcuaauucug a

21

<210> 1322
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1322
aaagcautg tuuguacaag a

21

<210> 1323
<211> 21
<212> DNA
<213> Artificial Sequence

<220>

<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1323
cuuggaautg gauucgccau a 21

<210> 1324
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1324
acaccauuga aaccacuagu a 21

<210> 1325
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1325
aacaucacca tgcagauuau a 21

<210> 1326
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1326

ugacagucac tagcuuau cu a

21

<210> 1327

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1327

aguuaaacga acguacuugc a

21

<210> 1328

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1328

acuauuuatg agauguau cu a

21

<210> 1329

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1329
uuaaacgaac guacuugcag a 21

<210> 1330
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1330
gguacuuatu taauaucccu a 21

<210> 1331
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1331
cgaaguggtg aagucaugg a 21

<210> 1332
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1332
uguuauuggu gucuucacug a 21

<210> 1333
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1333
uugcucuctu auuuguaccg a 21

<210> 1334
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1334
guuuuuauata cgguacuuau a 21

<210> 1335
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1335
ucacuggatg tauuugacug a 21

<210> 1336
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1336
ccuccgaaac caugaacuuu a 21

<210> 1337
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1337
uauuggugtc tucacuggau a 21

<210> 1338
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1338
agacugauac agaacgaucg a 21

<210> 1339
<211> 21

<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1339
uccgcagacg tguaaauguu a 21

<210> 1340
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1340
gaguuaaacg aacguacuug a 21

<210> 1341
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1341
agaaagugtu tuauauacgg a 21

<210> 1342
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

 <400> 1342
 guuauuggtg tcuucacugg a 21

 <210> 1343
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1343
 cuugaguuaa acgaacguac a 21

 <210> 1344
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1344
 ugaguuaaac gaacguacuu a 21

 <210> 1345
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1345

aucaccaugc agauuaugcg a 21

<210> 1346
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1346
uugaguuaaa cgaacguacu a 21

<210> 1347
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1347
gcagcuugag tuaaacgaac a 21

<210> 1348
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1348
cgcacugaaa cuuuucgucc a 21

<210> 1349
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1349
ucggugacag tcacuagcuu a 21

<210> 1350
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1350
gugcuaaugu tauugguguc a 21

<210> 1351
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1351
cgacagacgtg taaauguucc a 21

<210> 1352

<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1352
agagaagaga cacauuguug a 21

<210> 1353
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1353
ugaaguucan ggaugucuan a 21

<210> 1354
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1354
aaucucacn acuaaauuc a 21

<210> 1355
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic

oligonucleotide"

<400> 1355
cagacgugta aauguuccug a 21

<210> 1356
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1356
cacgaagugg tgaagucau a 21

<210> 1357
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1357
gcuugaguta aacgaacgua a 21

<210> 1358
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1358
caucuucaag ccauccugug a 21

<210> 1359
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1359
caccaugcag auuaugcgga a 21

<210> 1360
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1360
ggcagcuuga guuaaacgaa a 21

<210> 1361
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1361
auguccucac accauugaaa a 21

<210> 1362
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<400> 1362
ccgcagacgu guaaauguuc a 21

<210> 1363
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1363
cagaauatc acgaaguggu a 21

<210> 1364
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1364
gugcuacugu tuauccguaa a 21

<210> 1365
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1365
uguccucaca ccuugaaac a 21

<210> 1366
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1366
cugcaaaaac acagacucgc a 21

<210> 1367
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1367
gaggcagctu gaguuaaacg a 21

<210> 1368
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1368
auccgcagac guguaaangu a 21

<210> 1369
<211> 21
<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1369

gcuuuugutu guacaagau a

21

<210> 1370

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1370

gaaagcautu guuuguacaa a

21

<210> 1371

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1371

uggugcuacu guuuauccgu a

21

<210> 1372

<211> 21

<212> DNA

<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1372
aggcagcutg aguuaaacga a 21

<210> 1373
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1373
gcacugaaac tuuucgucca a 21

<210> 1374
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1374
gacugauaca gaacgaucga a 21

<210> 1375
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1375

acgaacguac tugcagaugu a

21

<210> 1376

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1376

cagcuugagu taaacgaacg a

21

<210> 1377

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1377

agcuugagtu aaacgaacgu a

21

<210> 1378

<211> 21

<212> DNA

<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1378
gauauuaaca tcacgucuuu a 21

<210> 1379
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1379
ccugcaaaaa cacagacucg a 21

<210> 1380
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1380
gugcuggaau tugauauuca a 21

<210> 1381
<211> 21
<212> DNA
<213> Artificial Sequence

<220>

<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1381
uuggugcuac tguuuauccg a 21

<210> 1382
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1382
auuggugucu tcacuggaug a 21

<210> 1383
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1383
ucuugcugcu aaauccaccga a 21

<210> 1384
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<400> 1384
uugcugcuaa aucaccgagc a 21

<210> 1385
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1385
agauuaugcg gaucaaaccu a 21

<210> 1386
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1386
gggcagaatc aucacgaagu a 21

<210> 1387
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1387
auuuguuuugu acaagaucg a 21

<210> 1388

<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1388
caaaaacaca gacucgCGUu a 21

<210> 1389
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1389
ugcuacugtu taucCGuaau a 21

<210> 1390
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1390
acuuuucgtc caacuucugg a 21

<210> 1391
<211> 21
<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1391

ggugcuactg tuuauccgua a

21

<210> 1392

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1392

gcaaaaacac agacucgcgu a

21

<210> 1393

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1393

cgucgcactg aaacuuuucg a

21

<210> 1394

<211> 21

<212> RNA

<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1394
auauuaacau cacgucuug a

21

<210> 1395
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1395
aaaacacaga cucgcuugc a

21

<210> 1396
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1396
cuugcagatg tgacaagccg a

21

<210> 1397
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1397
uuuuuuuuuca guauucuugg a

21

<210> 1398
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1398
aaagugagtg accugcuuuu a 21

<210> 1399
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1399
uucguccaac tucugggcug a 21

<210> 1400
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1400
aggacauugc tgugcuuugg a 21

<210> 1401
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1401
aaaucagutc gaggaaaggg a 21

<210> 1402
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1402
uuccccaaau cacuguggau a 21

<210> 1403
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1403
cccucuugga auuggauucg a 21

<210> 1404
<211> 21

<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1404
uugcagaugu gacaagccga a 21

<210> 1405
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1405
cacgucuutg tcucuagugc a 21

<210> 1406
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1406
gauccgcaga cguguaaaug a 21

<210> 1407
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1407
aaaaaucagu tcgaggaaag a 21

<210> 1408
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1408
ugcuguggac tugaguuggg a 21

<210> 1409
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1409
aaggggcaaa aacgaaagcg a 21

<210> 1410
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1410

ugcaaaaaca cagacucgcg a 21

<210> 1411
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1411
acgucuuugu cucuagugca a 21

<210> 1412
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1412
gggcaaaaac gaaagcgcaa a 21

<210> 1413
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1413
aggggcaaaa acgaaagcgc a 21

<210> 1414
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1414
gaaaaaaaau caguucgagg a 21

<210> 1415
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1415
aaaauagtu cgaggaaagg a 21

<210> 1416
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1416
aaaaacacag acucgcuug a 21

<210> 1417
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1417

uuuauccgta auaauugugg a 21

<210> 1418
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1418
agauccgcag acguguaaa a 21

<210> 1419
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1419
uuaacaucaac gucuuugucu a 21

<210> 1420
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1420
cgucuugtc tcuagugcag a 21

<210> 1421
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1421
guuuauccgu aaauaugug a

21

<210> 1422
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1422
uuguuuguac aagaucgca a

21

<210> 1423
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1423
uuauccguaa taauuguggg a

21

<210> 1424
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1424

aacacagacu cgcguugcaa a 21

<210> 1425
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1425
uuuuuuucag tauucuuggu a 21

<210> 1426
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1426
auuaacauca cgucuuuguc a 21

<210> 1427
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1427
uagaauagca atgtctauuu uau 23

<210> 1428
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1428
uacaccaua acatuagcac ugu 23

<210> 1429
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1429
ucugtattcga ucgtucugua uca 23

<210> 1430
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1430
uauucacauu ugutgtgcug uag 23

<210> 1431
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1431
utaucgaucg utctgtauca guc 23

<210> 1432
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1432
ucguauauaa aacactuucu cuu 23

<210> 1433
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1433
ugauacaucu cauaaaugu uga 23

<210> 1434
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1434
ugaucgtucu gtatcagucu uuc 23

<210> 1435
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1435
uauutaguau gtagaaucua cua 23

<210> 1436
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1436
uaucgutcug uaucagucuu ucc 23

<210> 1437
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1437
uggatatuua ataagtaccg uau 23

<210> 1438
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1438
uaucgatcgu ucuguaucag ucu 23

<210> 1439
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1439
ugautaagga ctgtucuguc gau 23

<210> 1440
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1440
ucuggatuaa ggacuguucu guc 23

<210> 1441
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1441
uccaauaaca utagcacugu uaa 23

<210> 1442
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1442

ucaagataag ctagugacug uca

23

<210> 1443

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1443

ucucggtgau utagcagcaa gaa

23

<210> 1444

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1444

uaccguauau aaaacacuuu cuc

23

<210> 1445

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1445
uaccggtaca aaauagagag caa 23

<210> 1446
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1446
ucggtgauuu agcagcaaga aaa 23

<210> 1447
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1447
uaactagugg utucaauggu gug 23

<210> 1448
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1448
ugggauauua aauaaguacc gua

23

<210> 1449
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1449
uauacatcuc ataaataguu gaa

23

<210> 1450
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1450
ucautucagg utucuggauu aag

23

<210> 1451
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1451
ucagaatagc aaugucuauu uua 23

<210> 1452
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1452
ucuuguacaa acaaatgcuu ucu 23

<210> 1453
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1453
uauggcgaau ccaautccaa gag 23

<210> 1454
<211> 23
<212> DNA
<213> Artificial Sequence

<220>

<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1454
uacuagtggg utcaatggug uga 23

<210> 1455
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1455
uauaaucugc atggugaugu ugg 23

<210> 1456
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1456
uagataagcu agugacuguc acc 23

<210> 1457
<211> 23
<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1457

ugcaagtacg utcgutuaac uca

23

<210> 1458

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1458

uagatacauc ucataaaauag uug

23

<210> 1459

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1459

ucugcaagua cgutcguuua acu

23

<210> 1460
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1460
uagggatauu aaataaguac cgu 23

<210> 1461
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1461
uccatgaacu ucaccacuuc gug 23

<210> 1462
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1462

ucagtgaaga caccaauaac auu

23

<210> 1463
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1463
ucggtacaaa uaagagagca aga

23

<210> 1464
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1464
uauaagtacc gtatataaaa cac

23

<210> 1465
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic

oligonucleotide"

<400> 1465
ucagtcaaau acatccagug aag 23

<210> 1466
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1466
uaaagutcau ggutucggag gcc 23

<210> 1467
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1467
uauccaguga agacaccaau aac 23

<210> 1468
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1468
ucgatcguuc uguaucaguc uuu 23

<210> 1469
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1469
uaacautuac acgtctgcgg auc 23

<210> 1470
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1470
ucaaguacgu ucgtutaacu caa 23

<210> 1471
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1471

uccgtataua aaacacuuuc ucu

23

<210> 1472

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1472

uccagugaag acaccaauaa cau

23

<210> 1473

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1473

uguacgtucg utuaacucuaa gcu

23

<210> 1474

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1474
uaagtacguu cgutuaacuc aag 23

<210> 1475
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1475
ucgcauaauc ugcaugguga ugu 23

<210> 1476
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1476
uaguacguuc gtutaacuca agc 23

<210> 1477
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1477

uguucgtuua acucaagcug ccu

23

<210> 1478
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1478
uggacgaaaa gtutcagugc gac

23

<210> 1479
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1479
uaagcuagug acugucaccg auc

23

<210> 1480
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1480
ugacaccaau aacautagca cug

23

<210> 1481
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1481
uggaacauuu acacgtcugc gga 23

<210> 1482
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1482
ucaacaaugu gtctctucuc uuc 23

<210> 1483
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1483
uauagacau caugaacuuc acc 23

<210> 1484

<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1484
ugagautuag uauguagaau ucu 23

<210> 1485
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1485
ucaggaacau utacacgucu gcg 23

<210> 1486
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1486
uaugaacuuc accactucgu gau 23

<210> 1487
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1487
utacgutcg u taactcaag cug 23

<210> 1488
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1488
ucacaggaug gcutgaagau gua 23

<210> 1489
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1489
utccgcauaa ucugcauggu gau 23

<210> 1490
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1490
utucgutuaa ctcaagcugc cuc 23

<210> 1491
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1491
utuucaugg ugugaggaca uag 23

<210> 1492
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1492
ugaacatuua cacgucugcg gau 23

<210> 1493
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1493
uaccactucg ugatgauucu gcc 23

<210> 1494
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1494
utuacggaua aacagtagca cca 23

<210> 1495
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1495

uguutcaaug gtgtgaggac aua

23

<210> 1496

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1496

ugcgagtcug ugututugca gga

23

<210> 1497

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1497

ucgutuaacu caagctgccu cgc

23

<210> 1498

<211> 23

<212> DNA

<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

 <400> 1498
 uacatutaca cgucugcgga ucu 23

<210> 1499
 <211> 23
 <212> DNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

<400> 1499
 ugaucutgua caaacaaaug cuu 23

<210> 1500
 <211> 23
 <212> DNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

<400> 1500
 utugtacaaa caaaugcuuu cuc 23

<210> 1501
 <211> 23

<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1501
uacggataaa cagtagcacc aau 23

<210> 1502
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1502
utcgutataac ucaagcugcc ucg 23

<210> 1503
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1503
utggacgaaa agutucagug cga 23

<210> 1504
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1504
utcgauCGUU ctgtatcagu cuu 23

<210> 1505
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1505
uacatctgca aguacguucg uuu 23

<210> 1506
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1506
ucgutcguuu aactcaagcu gcc 23

<210> 1507
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1507
uacgtucguu uaacucaagc ugc 23

<210> 1508
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1508
uaaagacgug atgtuaauau cuu 23

<210> 1509
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic oligonucleotide"

<400> 1509
ucgagucugu gtututgcag gaa 23

<210> 1510
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic oligonucleotide"

<400> 1510
utgaauauca aautccagca ccg 23

<210> 1511
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"

<400> 1511
ucggauaaac aguagcacca aua 23

<210> 1512
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"

<400> 1512
ucauccagug aagacaccaa uaa 23

<210> 1513
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1513
utcggugauu uagcagcaag aaa 23

<210> 1514
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1514
ugcucgguga utuagcagca aga 23

<210> 1515
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1515

uaggtutgau ccgcataauc ugc

23

<210> 1516
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1516
uacutcguga ugatucugcc cuc

23

<210> 1517
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1517
ucggaucuug uacaaacaaa ugc

23

<210> 1518
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1518
uaacgcgagu ctgtgtuuuu gca

23

<210> 1519
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1519
uauuacggau aaacaguagc acc 23

<210> 1520
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1520
uccagaaguu ggacgaaaag uuu 23

<210> 1521
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1521
utacggauaa acaguagcac caa 23

<210> 1522
<211> 23
<212> DNA
<213> Artificial Sequence

<220>

<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1522
uacgcgaguc ugugutuuug cag 23

<210> 1523
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1523
ucgaaaaguu ucagugcgac gcc 23

<210> 1524
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1524
ucaaagacgu gaugutaaua ucu 23

<210> 1525
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1525

ugcaacgcga gtctgtguuu uug

23

<210> 1526

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1526

ucggcutguc acatctgcaa gua

23

<210> 1527

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1527

uccaagaaua ctgaaaaaaaa acc

23

<210> 1528

<211> 23

<212> RNA

<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1528
uaaaagcagg ucacucacuu ugc

23

<210> 1529
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1529
ucagcccaga agutggacga aaa

23

<210> 1530
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1530
uccaaagcac agcaatgucc uga

23

<210> 1531
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1531

uccctutccu cgaactgauu uuu

23

<210> 1532

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1532

uauccacagu gautugggga agu

23

<210> 1533

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1533

ucgaauccaa utccaagagg gac

23

<210> 1534

<211> 23

<212> DNA

<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1534
utcggtugu cacaugca agu 23

<210> 1535
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1535
ugcacuagag acaaagacgu gau 23

<210> 1536
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1536
ucautuacac gtctgcggau cuu 23

<210> 1537
<211> 23
<212> DNA
<213> Artificial Sequence

<220>

<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1537
ucuutccucg aactgauuuu uuu 23

<210> 1538
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1538
ucccaacuca aguccacagc agu 23

<210> 1539
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1539
ucgctutcg ututgccccu uuc 23

<210> 1540
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1540

ucgcgagucu gtgtutuugc agg

23

<210> 1541

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1541

utgcactaga gacaaagacg uga

23

<210> 1542

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1542

utugcgcuuu cgututugcc ccu

23

<210> 1543

<211> 23

<212> DNA

<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1543
ugcgcutucg ututugcccc uuu 23

<210> 1544
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1544
uccucgaacu gaututuuuu cuu 23

<210> 1545
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1545
uccutuccuc gaacugauuu uuu 23

<210> 1546
<211> 23

<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1546
ucaacgcgag ucuguguuuu ugc 23

<210> 1547
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1547
uccacaauua utacggauaa aca 23

<210> 1548
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1548
uauutacacg ucugcggauc uug 23

<210> 1549
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1549
uagacaaaga cgugatguua aua 23

<210> 1550
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1550
ucugcacuag agacaaagac gug 23

<210> 1551
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1551
ucacaatuau uacggauaaa cag 23

<210> 1552
<211> 23
<212> DNA
<213> Artificial Sequence

<220>

<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1552
utgcggaucu uguacaaaca aaau 23

<210> 1553
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1553
ucccacaauu atuacggaua aac 23

<210> 1554
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1554
utugcaacgc gagtctgugu uuu 23

<210> 1555
<211> 23
<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1555

uaccaagaau acugaaaaaa aac

23

<210> 1556

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 1556

ugacaaagac gtgauguuaa uau

23

<210> 1557

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1557

cggaaacuuu ucguccaacu a

21

<210> 1558

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1558
ggaaacuuuu cguccaacu a 21

<210> 1559
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1559
cgacagaaca guccuaauc a 21

<210> 1560
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1560
cugcuaaugu uauugguguc a 21

<210> 1561
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1561
uccgagauau uccguaguac a 21

<210> 1562
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<400> 1562
cgagauauuc cguaguacau a 21

<210> 1563
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1563
gcacggaaac uuuucgucca a 21

<210> 1564
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1564
cacggaaacu uuucguccaa a 21

<210> 1565
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1565
gagauauucc guaguacaua a 21

<210> 1566
<211> 21
<212> RNA
<213> Artificial Sequence

<220>

<221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 1566
 uuguuugucc aagaucgca a 21

<210> 1567
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 1567
 acggaaacuu uucguccaac a 21

<210> 1568
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 1568
 aucaugcgga ucaaaccuca a 21

<210> 1569
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 1569
 augcggauca aaccucacca a 21

<210> 1570
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1570
gaucaugcgg aucaaaccuc a 21

<210> 1571
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1571
uuuguuuuguc caagaucgcg a 21

<210> 1572
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1572
gaucggugac agucacuagc a 21

<210> 1573
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1573
aagaucgcga gacguguaaa a 21

<210> 1574
<211> 21

<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1574
uguccaagau ccgcagacgu a 21

<210> 1575
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1575
aucacgucuu ugucucuaga a 21

<210> 1576
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1576
ugaaaccaug aacuuucugc a 21

<210> 1577
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1577
uugucucuag agcaguuuuc a 21

<210> 1578
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1578
 cacuuccaga aacacgacaa a 21

<210> 1579
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1579
 ugaaaucugu guuuccaauc a 21

<210> 1580
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1580
 gaaaucugug uuuccaaucu a 21

<210> 1581
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1581
 uuugucucua gagcaguuuu a 21

<210> 1582
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1582
ugucucuaga gcaguuuucc a 21

<210> 1583
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1583
aacuguauug uuuuacgcuu a 21

<210> 1584
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1584
acuguauugu uuuacgcuuu a 21

<210> 1585
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1585
cuguauuguu uuacgcuuaa a 21

<210> 1586
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1586
uguauuguuu uacgcuuaa a 21

<210> 1587
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1587
auugaaacca cuaauucugu a 21

<210> 1588
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1588
acuuauuuuaa uagcccuuuu a 21

<210> 1589
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<400> 1589
ucucuagagc aguuuuccga a 21

<210> 1590
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1590
ccgagauauu ccguaguaca a 21

<210> 1591
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1591
ucugggauuu gauauucaaa a 21

<210> 1592
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1592
uucacuggau auguuugacu a 21

<210> 1593
<211> 21
<212> RNA
<213> Artificial Sequence

<220>

<221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 1593
 ggcucacuuc cagaaacacg a 21

<210> 1594
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 1594
 cuuccagaaa cacgacaaac a 21

<210> 1595
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 1595
 gaccauugaa accacuaauu a 21

<210> 1596
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 1596
 agucacuagc uuguccugag a 21

<210> 1597
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1597
accacacauu ccuuugaaau a 21

<210> 1598
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1598
accggaaaga ccgauuaacc a 21

<210> 1599
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1599
agaccgauua accaugucac a 21

<210> 1600
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1600
cuucacugga uauguuugac a 21

<210> 1601
<211> 21

<212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1601
 uuggcucacu uccagaaaca a 21

<210> 1602
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1602
 cucacuucca gaaacacgac a 21

<210> 1603
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1603
 gugacaguca cuagcuuguc a 21

<210> 1604
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1604
 gucucuagag caguuuuccg a 21

<210> 1605
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1605
cucuagagca guuuuccgag a 21

<210> 1606
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1606
guuuuccgag auauuccgua a 21

<210> 1607
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1607
uuccgagaua uuccguagua a 21

<210> 1608
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1608
uuaaacugua uuguuuuacg a 21

<210> 1609
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1609
aaacugauuu guuuuacgcu a 21

<210> 1610
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1610
gauucgccau uuucuauau a 21

<210> 1611
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1611
ucacuggaua uguuugacug a 21

<210> 1612
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1612
guuggcucac uuccagaaac a 21

<210> 1613
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1613
acuuccagaa acacgacaaa a 21

<210> 1614
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1614
uacuuauuuu auagcccuu a 21

<210> 1615
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1615
agagcaguuu uccgagauau a 21

<210> 1616
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<400> 1616
ugggauuuga uauucaaaacc a 21

<210> 1617
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1617
gggauuugau auucaaaaccu a 21

<210> 1618
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1618
gauuugauau ucaaaccucu a 21

<210> 1619
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1619
uaaacuguau uguuuuacgc a 21

<210> 1620
<211> 21
<212> RNA
<213> Artificial Sequence

<220>

<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1620
ucaccggaaa gaccgauuaa a 21

<210> 1621
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1621
caccggaaag accgauuaac a 21

<210> 1622
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1622
ccggaaagac cgauuaacca a 21

<210> 1623
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1623
gaacuggauu cgccauuuuc a 21

<210> 1624
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1624
 cacuggauau guuugacugc a 21

 <210> 1625
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1625
 ggaccuugug ugaucagacc a 21

 <210> 1626
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1626
 ucagaccuu gaaaccacua a 21

 <210> 1627
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1627
 caugaaacc acuaauucug a 21

 <210> 1628
 <211> 21

<212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1628
 cuagagcagu uuuccgagau a 21

 <210> 1629
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1629
 uagagcaguu uuccgagaua a 21

 <210> 1630
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1630
 aguuuuccga gauauuccgu a 21

 <210> 1631
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1631
 gcggaucaaa ccucaccaaa a 21

<210> 1632
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1632
 agcauuuguu uguccaagau a 21

<210> 1633
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1633
 ucucaccgga aagaccgauu a 21

<210> 1634
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1634
 ucuagagcag uuuuccgaga a 21

<210> 1635
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1635
 auugcacgga aacuuuucgu a 21

<210> 1636
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1636
gcucugggau uugauauuca a 21

<210> 1637
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1637
ugagccuugu ucagagcgga a 21

<210> 1638
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1638
agccuuguuc agagcggaga a 21

<210> 1639
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1639
cauuuguuug uccaagaucc a 21

<210> 1640
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1640
ggaaagaccg auuaaccaug a 21

<210> 1641
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1641
gaaagaccga uuaaccaugu a 21

<210> 1642
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1642
aagaccgauu aaccauguca a 21

<210> 1643
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<400> 1643
gaccgauuaa ccaugucacc a 21

<210> 1644
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1644
uaguuggacg aaaaguuucc gug 23

<210> 1645
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1645
uaaguuggac gaaaaguuuc cgu 23

<210> 1646
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1646
ugauuaagga cuguucuguc gac 23

<210> 1647
<211> 23
<212> RNA
<213> Artificial Sequence

<220>

<221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 1647
 ugacaccaau aacauuagca gag 23

<210> 1648
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 1648
 uguacuacgg aaauaucucgg aaa 23

<210> 1649
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 1649
 uauguacuac ggaauaucuc gga 23

<210> 1650
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 1650
 uuggacgaaa aguuuccgug caa 23

<210> 1651
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 1651 uuuggacgaa aaguuuccgu gca	23
<210> 1652 <211> 23 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 1652 uuauuguacua cggaauaucu cgg	23
<210> 1653 <211> 23 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 1653 uugcggaucu uggacaaaca aa	23
<210> 1654 <211> 23 <212> RNA <213> Artificial Sequence	
<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 1654 uguuggacga aaaguuuccg ugc	23
<210> 1655 <211> 23	

<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1655
uugagguuug auccgcauga ucu 23

<210> 1656
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1656
uuggugaggu uugaucgcga uga 23

<210> 1657
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1657
ugagguuuga uccgcaugau cug 23

<210> 1658
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1658
ugcggaucuu ggacaaacaa aug 23

<210> 1659
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1659
 ugcuagugac ugucaccgau cug 23

<210> 1660
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1660
 uuuuacacgu cugcggaucu ugg 23

<210> 1661
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1661
 uacgucugcg gaucuuggac aaa 23

<210> 1662
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1662
 uucuagagac aaagacguga ugu 23

<210> 1663
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1663
ugcagaaagu ucaugguuuc aga 23

<210> 1664
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1664
ugaaaacugc ucuagagaca aag 23

<210> 1665
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1665
uuugucgugu uucuggaagu gag 23

<210> 1666
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1666
ugauuggaaa cacagauuuc aua 23

<210> 1667
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1667
uagauuggaa acacagauuu cau 23

<210> 1668
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1668
uaaaacugcu cuagagaca aga 23

<210> 1669
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1669
uggaaaacug cucuagagac aaa 23

<210> 1670
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<400> 1670
uaagcguaaa acaauacagu uua 23

<210> 1671
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1671
uaaagcguaa aacaauacag uuu 23

<210> 1672
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1672
uuaaagcgua aaacaauaca guu 23

<210> 1673
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1673
uuuaaagcgu aaaacaauac agu 23

<210> 1674
<211> 23
<212> RNA
<213> Artificial Sequence

<220>

<221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 1674
 uacagaauua gugguuucaa ugg 23

<210> 1675
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 1675
 uaaaagggcu auuaaaauaag uac 23

<210> 1676
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 1676
 uucggaaaac ugcucuagag aca 23

<210> 1677
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 1677
 uuguacuacg gaauaucucg gaa 23

<210> 1678
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1678
uuuugaauau caaaucccag agc 23

<210> 1679
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1679
uagucaaaca uauccaguga aga 23

<210> 1680
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1680
ucguguuucu ggaagugagc caa 23

<210> 1681
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1681
uguuugucgu guuucuggaa gug 23

<210> 1682
<211> 23

<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1682
uaauuagugg uuucaauggu cug 23

<210> 1683
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1683
ucucaggaca agcuagugac ugu 23

<210> 1684
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1684
uauuucaaag gaaugugugg ugg 23

<210> 1685
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1685
ugguuaaucg gucuuuccgg uga 23

<210> 1686
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1686
 ugugacaugg uuaaucgguc uuu 23

<210> 1687
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1687
 ugucaaacau auccagugaa gac 23

<210> 1688
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1688
 uuguuucugg aagugagcca acg 23

<210> 1689
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1689
 ugucguguuu cuggaaguga gcc 23

<210> 1690
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1690
ugacaagcua gugacuguca ccg 23

<210> 1691
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1691
ucggaaaacu gcucuagaga caa 23

<210> 1692
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1692
ucucggaaaa cugcucuaga gac 23

<210> 1693
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1693
uuacggaaua ucucggaaaa cug 23

<210> 1694
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1694
uuacuacgga auaucucgga aaa 23

<210> 1695
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1695
ucguaaaaca auacaguuua aga 23

<210> 1696
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1696
uagcguaaaa caauacaguu uaa 23

<210> 1697
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<400> 1697
uauauaagaa aauggcgaau cca 23

<210> 1698
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1698
ucagucaaac auauccagug aag 23

<210> 1699
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1699
uguuucugga agugagccaa cgu 23

<210> 1700
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1700
uuuugucgug uuucuggaag uga 23

<210> 1701
<211> 23
<212> RNA
<213> Artificial Sequence

<220>

<221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 1701
 uaaagggcua uaaaauaagu acc 23

<210> 1702
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 1702
 uauaucucgg aaaacugcuc uag 23

<210> 1703
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 1703
 ugguuugaau aucaaauccc aga 23

<210> 1704
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 1704
 uagguuugaa uaucaaaucc cag 23

<210> 1705
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1705
uagagguuug aaaucaaaau ccc 23

<210> 1706
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1706
ugcguaaaac aaauacaguuu aag 23

<210> 1707
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1707
uuuaaucggu cuuuccggug aga 23

<210> 1708
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1708
uguuaaucgg ucuuuccggu gag 23

<210> 1709
<211> 23

<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1709
uugguuaauc ggucuuuccg gug 23

<210> 1710
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1710
ugaaaauggc gaauccaguu cca 23

<210> 1711
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1711
ugcagucaaa cauauccagu gaa 23

<210> 1712
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1712
uggucugauc acacaagguc cuc 23

<210> 1713
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1713
 uuagugguuu caauggucug auc 23

<210> 1714
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1714
 ucagaauuag ugguuucuu ggu 23

<210> 1715
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1715
 uaucucggaa aacugcucua gag 23

<210> 1716
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1716
 uuauaucucgga aaacugcucu aga 23

<210> 1717
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1717
uacggaaauau cucggaaaac ugc 23

<210> 1718
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1718
uuuuggugag guuugaucgc cau 23

<210> 1719
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1719
uauuuggac aaacaaugc uuu 23

<210> 1720
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1720
uaaucggucu uuccggugag agg 23

<210> 1721
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1721
uucucggaaa acugcucuag aga 23

<210> 1722
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1722
uacgaaaagu uuccgugcaa ucc 23

<210> 1723
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1723
uugaauauca aaucccagag cac 23

<210> 1724
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<400> 1724
uuccgcucug aacaaggcuc aca 23

<210> 1725
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1725
uucuccgcuc ugaacaaggc uca 23

<210> 1726
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1726
uggaucuugg acaaacaaau gcu 23

<210> 1727
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1727
ucaugguuaa ucggucuuuc cgg 23

<210> 1728
<211> 23
<212> RNA
<213> Artificial Sequence

<220>

<221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 1728
 uacaugguua aucggucuuu ccg 23

<210> 1729
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 1729
 uugacauggu uaaucggucu uuc 23

<210> 1730
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 1730
 uggugacaug guuaaucggu cuu 23

<210> 1731
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 1731
 cggaacuuiu ucguccaacu a 21

<210> 1732
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1732
 ggaaacuuuu cguccaacuu a 21

 <210> 1733
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1733
 cgacagaaca guccuuaauc a 21

 <210> 1734
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1734
 cugcuaaugu uauugguguc a 21

 <210> 1735
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1735
 uccgagauau uccguaguac a 21

 <210> 1736
 <211> 21

<212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1736
 cgagauauuc cguaguacau a 21

<210> 1737
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1737
 gcacggaaac uuuucgucca a 21

<210> 1738
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1738
 cacggaaacu uuucguccaa a 21

<210> 1739
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1739
 gagauauucc guaguacaua a 21

<210> 1740
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1740
 uuguuugucc aagaucgcga a 21

<210> 1741
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1741
 acggaaacuu uucguccaac a 21

<210> 1742
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1742
 aucaugcggg ucaaaccuca a 21

<210> 1743
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1743
 augcggauca aaccucacca a 21

<210> 1744
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1744
gaucaugcgg aucaaaccuc a 21

<210> 1745
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1745
uuuguuuguc caagaucgcg a 21

<210> 1746
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1746
gaucggugac agucacuagc a 21

<210> 1747
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1747
aagaucgcga gacguguaaa a 21

<210> 1748
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1748
uguccaagau ccgcagacgu a 21

<210> 1749
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1749
aucacgucuu ugucucuaga a 21

<210> 1750
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1750
ugaaaccaug aacuuucugc a 21

<210> 1751
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<400> 1751
uugucucuag agcaguuuuc a 21

<210> 1752
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1752
cacuuccaga aacacgacaa a 21

<210> 1753
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1753
ugaaaucugu guuuccaauc a 21

<210> 1754
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1754
gaaaucugug uuuccaaucu a 21

<210> 1755
<211> 21
<212> RNA
<213> Artificial Sequence

<220>

<221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 1755
 uuugucucua gagcaguuuu a 21

<210> 1756
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 1756
 ugucucuaga gcaguuuucc a 21

<210> 1757
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 1757
 aacuguauug uuuuacgcuu a 21

<210> 1758
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 1758
 acuguauugu uuuacgcuu a 21

<210> 1759
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1759
 cuguauuguu uuacgcuuaa a 21

 <210> 1760
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1760
 uguauuguuu uacgcuuaa a 21

 <210> 1761
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1761
 auugaaacca cuaauucugu a 21

 <210> 1762
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1762
 acuuauuuuaa uagcccuuuu a 21

 <210> 1763
 <211> 21

<212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1763
 ucucuagagc aguuuuccga a 21

<210> 1764
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1764
 ccgagauauu ccguaguaca a 21

<210> 1765
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1765
 ucugggauuu gauauucaaa a 21

<210> 1766
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1766
 uucacuggau auguuugacu a 21

<210> 1767
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1767
 ggcucacuuc cagaaacacg a 21

<210> 1768
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1768
 cuuccagaaa cacgacaaac a 21

<210> 1769
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1769
 gaccauugaa accacuaauu a 21

<210> 1770
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1770
 agucacuagc uuguccugag a 21

<210> 1771
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1771
accacacauu ccuuugaaau a 21

<210> 1772
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1772
accggaaaga ccgauuaacc a 21

<210> 1773
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1773
agaccgauua accaugucac a 21

<210> 1774
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1774
cuucacugga uauguuugac a 21

<210> 1775
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1775
uuggcucacu uccagaaaca a 21

<210> 1776
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1776
cucacuucca gaaacacgac a 21

<210> 1777
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1777
gugacaguca cuagcuuguc a 21

<210> 1778
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<400> 1778
gucucuagag caguuuuccg a 21

<210> 1779
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1779
cucuagagca guuuuccgag a 21

<210> 1780
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1780
guuuuccgag auauuccgua a 21

<210> 1781
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1781
uuccgagaua uuccguagua a 21

<210> 1782
<211> 21
<212> RNA
<213> Artificial Sequence

<220>

<221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 1782
 uuaaacugua uuguuuuacg a 21

<210> 1783
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 1783
 aaacuguaau guuuuacgcu a 21

<210> 1784
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 1784
 gauucgccau uuucuauau a 21

<210> 1785
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 1785
 ucacuggaua uguuugacug a 21

<210> 1786
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 1786
 guuggcucac uuccagaaac a 21

<210> 1787
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 1787
 acuuccagaa acacgacaaa a 21

<210> 1788
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 1788
 uacuuauuuu auagcccuu a 21

<210> 1789
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 1789
 agagcaguuu uccgagauau a 21

<210> 1790
 <211> 21

<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1790
ugggauuuga uauucaaacc a 21

<210> 1791
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1791
gggauuugau auucaaaccu a 21

<210> 1792
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1792
gauuugauau ucaaaccucu a 21

<210> 1793
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1793
uaaacuguau uguuuuacgc a 21

<210> 1794
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1794
ucaccggaaa gaccgauuaa a 21

<210> 1795
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1795
caccggaaag accgauuaac a 21

<210> 1796
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1796
ccggaaagac cgauuaacca a 21

<210> 1797
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1797
gaacuggauu cgccauuuuc a 21

<210> 1798
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1798
cacuggauau guuugacugc a 21

<210> 1799
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1799
ggaccuugug ugaucagacc a 21

<210> 1800
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1800
ucagaccuu gaaaccacua a 21

<210> 1801
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1801
cauugaaacc acuaauucug a 21

<210> 1802
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1802
cuagagcagu uuuccgagau a 21

<210> 1803
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1803
uagagcaguu uuuccgagua a 21

<210> 1804
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1804
aguuuuccga gauauuccgu a 21

<210> 1805
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<400> 1805
gcggaucaaa ccucaccaaa a 21

<210> 1806
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1806
agcauuuguu uguccaagau a 21

<210> 1807
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1807
ucucaccgga aagaccgauu a 21

<210> 1808
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1808
ucuagagcag uuuuccgaga a 21

<210> 1809
<211> 21
<212> RNA
<213> Artificial Sequence

<220>

<221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 1809
 auugcacgga aacuuuucgu a 21

<210> 1810
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 1810
 gcucugggau uugauauuca a 21

<210> 1811
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 1811
 ugagccuugu ucagagcgga a 21

<210> 1812
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 1812
 agccuuguuc agagcggaga a 21

<210> 1813
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1813
cauuuguuuug uccaagaucc a 21

<210> 1814
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1814
ggaaagaccg auuaaccaug a 21

<210> 1815
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1815
gaaagaccga uuaaccaugu a 21

<210> 1816
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1816
aagaccgauu aaccauguca a 21

<210> 1817
<211> 21

<212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1817
 gaccgauuaa ccaugucacc a 21

<210> 1818
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1818
 uaguuggacg aaaaguuucc gug 23

<210> 1819
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1819
 uaaguuggac gaaaaguuuc cgu 23

<210> 1820
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1820
 ugauuaagga cuguucuguc gac 23

<210> 1821
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1821
ugacaccaau aacauuagca gag 23

<210> 1822
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1822
uguacuacgg aaauaucugg aaa 23

<210> 1823
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1823
uauquacuac ggaauaucuc gga 23

<210> 1824
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1824
uuggacgaaa aguuuccgug caa 23

<210> 1825
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1825
uuuggacgaa aaguuccgu gca 23

<210> 1826
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1826
uuauguacua cggaauaucu cgg 23

<210> 1827
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1827
uugcggaucu uggacaaaca aaU 23

<210> 1828
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1828
uguuggacga aaaguuuccg ugc 23

<210> 1829
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1829
uugagguuug auccgcauga ucu 23

<210> 1830
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1830
uuggugaggu uugauccgca uga 23

<210> 1831
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1831
ugagguuuga uccgcaugau cug 23

<210> 1832
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<400> 1832
ugcggaucuu ggacaaacaa aug 23

<210> 1833
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1833
ugcuagugac ugucaccgau cug 23

<210> 1834
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1834
uuuuacacgu cugcggaucu ugg 23

<210> 1835
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1835
uacgucugcg gaucuuggac aaa 23

<210> 1836
<211> 23
<212> RNA
<213> Artificial Sequence

<220>

<221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 1836
 uucuagagac aaagacguga ugu 23

<210> 1837
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 1837
 ugcagaaagu ucaugguuuc aga 23

<210> 1838
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 1838
 ugaaaacugc ucuagagaca aag 23

<210> 1839
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 1839
 uuugucgugu uucuggaagu gag 23

<210> 1840
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1840
ugauuggaaa cacagauuuc aua 23

<210> 1841
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1841
uagauuggaa acacagauuu cau 23

<210> 1842
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1842
uaaaacugcu cuagagaaa aga 23

<210> 1843
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1843
uggaaaacug cucuagagac aaa 23

<210> 1844
<211> 23

<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1844
uaagcguaaa acaauacagu uua 23

<210> 1845
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1845
uaaagcguaa aacaauacag uuu 23

<210> 1846
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1846
uuaaagcgua aaacaauaca guu 23

<210> 1847
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1847
uuuaaagcgu aaaacaauac agu 23

<210> 1848
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1848
 uacagaauua gugguucaa ugg 23

<210> 1849
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1849
 uaaaaggguu auuaaauaag uac 23

<210> 1850
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1850
 uucggaaaac ugcucuagag aca 23

<210> 1851
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1851
 uuguacuacg gaauaucucg gaa 23

<210> 1852
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1852
uuuugaauau caaaucccag agc

23

<210> 1853
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1853
uagucaaaca uauccaguga aga

23

<210> 1854
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1854
ucguguuucu ggaagugagc caa

23

<210> 1855
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1855
uguuugucgu guuucuggaa gug 23

<210> 1856
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1856
uaauuagugg uuucaauggu cug 23

<210> 1857
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1857
ucucaggaca agcuagugac ugu 23

<210> 1858
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1858
uaauucaaag gaaugugugg ugg 23

<210> 1859
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<400> 1859
ugguuaaucg gucuuuccgg uga 23

<210> 1860
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1860
ugugacaugg uuaaucgguc uuu 23

<210> 1861
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1861
ugucaaacau auccagugaa gac 23

<210> 1862
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1862
uuguuucugg aagugagcca acg 23

<210> 1863
<211> 23
<212> RNA
<213> Artificial Sequence

<220>

<221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 1863
 ugucguguuu cuggaaguga gcc 23

<210> 1864
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 1864
 ugacaagcua gugacuguca ccg 23

<210> 1865
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 1865
 ucggaaaacu gcucuagaga caa 23

<210> 1866
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 1866
 ucucggaaaa cugcucuaga gac 23

<210> 1867
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1867
uuacggaaua ucucgaaaaa cug 23

<210> 1868
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1868
uuacuacgga auaucucgga aaa 23

<210> 1869
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1869
ucguaaaaca auacaguuaa aga 23

<210> 1870
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1870
uagcguaaaa caauacaguu uaa 23

<210> 1871
<211> 23

<212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1871
 uauauaagaa aauggcgaau cca 23

<210> 1872
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1872
 ucagucaaac auaucagug aag 23

<210> 1873
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1873
 uguuucugga agugagccaa cgu 23

<210> 1874
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1874
 uuuugucgug uuucuggaag uga 23

<210> 1875
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1875
 uaaagggcua uuaaauaagu acc 23

<210> 1876
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1876
 uauaucucgg aaaacugcuc uag 23

<210> 1877
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1877
 ugguuugaau aucaaauccc aga 23

<210> 1878
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1878
 uagguuugaa uaucaaaucc cag 23

<210> 1879
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1879
uagagguuug aaaucaaaau ccc

23

<210> 1880
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1880
ugcguaaaac aaucaguuu aag

23

<210> 1881
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1881
uuuaaucggu cuuuccggug aga

23

<210> 1882
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1882
uguuaaucgg ucuuuccggu gag 23

<210> 1883
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1883
uugguuaauc ggucuuuccg gug 23

<210> 1884
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1884
ugaaaauggc gaauccaguu cca 23

<210> 1885
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1885
ugcagucaaa cauauccagu gaa 23

<210> 1886
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<400> 1886
uggucugauc acacaagguc cuc 23

<210> 1887
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1887
uuagugguuu caauggucug auc 23

<210> 1888
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1888
ucagaauuag ugguuucuuu ggu 23

<210> 1889
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1889
uauucuggaa aacugcucua gag 23

<210> 1890
<211> 23
<212> RNA
<213> Artificial Sequence

<220>

<221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 1890
 uuaucucgga aaacugcucu aga 23

<210> 1891
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 1891
 uacggaauau cucggaaaac ugc 23

<210> 1892
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 1892
 uuuuggugag guuugaucgc cau 23

<210> 1893
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 1893
 uaucuuggac aaacaaaugc uuu 23

<210> 1894
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1894
uaaucggucu uuccggugag agg 23

<210> 1895
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1895
uucucggaaa acugcucuag aga 23

<210> 1896
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1896
uacgaaaagu uuccgugcaa ucc 23

<210> 1897
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1897
uugaauauca aaucccagag cac 23

<210> 1898
<211> 23

<212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1898
 uuccgcucug aacaaggcuc aca 23

 <210> 1899
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1899
 uucuccgcuc ugaacaaggc uca 23

 <210> 1900
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1900
 uggaucuugg acaaacaaau gcu 23

 <210> 1901
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 1901
 ucaugguuaa ucggucuuuc cgg 23

<210> 1902
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1902
uacaugguua aucggucuuu ccg 23

<210> 1903
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1903
uugacauggu uaaucggucu uuc 23

<210> 1904
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 1904
uggugacaug guuaaucggu cuu 23

<210> 1905
<211> 431
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"

<400> 1905
Ser Asp Thr Gly Arg Pro Phe Val Glu Met Tyr Ser Glu Ile Pro Glu

1		5		10		15													
Ile	Ile	His	Met	Thr	Glu	Gly	Arg	Glu	Leu	Val	Ile	Pro	Cys	Arg	Val				
			20					25					30						
Thr	Ser	Pro	Asn	Ile	Thr	Val	Thr	Leu	Lys	Lys	Phe	Pro	Leu	Asp	Thr				
		35					40					45							
Leu	Ile	Pro	Asp	Gly	Lys	Arg	Ile	Ile	Trp	Asp	Ser	Arg	Lys	Gly	Phe				
	50					55					60								
Ile	Ile	Ser	Asn	Ala	Thr	Tyr	Lys	Glu	Ile	Gly	Leu	Leu	Thr	Cys	Glu				
65					70					75					80				
Ala	Thr	Val	Asn	Gly	His	Leu	Tyr	Lys	Thr	Asn	Tyr	Leu	Thr	His	Arg				
				85					90					95					
Gln	Thr	Asn	Thr	Ile	Ile	Asp	Val	Val	Leu	Ser	Pro	Ser	His	Gly	Ile				
			100					105					110						
Glu	Leu	Ser	Val	Gly	Glu	Lys	Leu	Val	Leu	Asn	Cys	Thr	Ala	Arg	Thr				
		115					120					125							
Glu	Leu	Asn	Val	Gly	Ile	Asp	Phe	Asn	Trp	Glu	Tyr	Pro	Ser	Ser	Lys				
	130					135					140								
His	Gln	His	Lys	Lys	Leu	Val	Asn	Arg	Asp	Leu	Lys	Thr	Gln	Ser	Gly				
145					150					155					160				
Ser	Glu	Met	Lys	Lys	Phe	Leu	Ser	Thr	Leu	Thr	Ile	Asp	Gly	Val	Thr				
			165						170					175					
Arg	Ser	Asp	Gln	Gly	Leu	Tyr	Thr	Cys	Ala	Ala	Ser	Ser	Gly	Leu	Met				
			180					185					190						
Thr	Lys	Lys	Asn	Ser	Thr	Phe	Val	Arg	Val	His	Glu	Lys	Asp	Lys	Thr				
		195					200					205							
His	Thr	Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu	Leu	Gly	Gly	Pro	Ser				
	210					215					220								

Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg
225 230 235 240

Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro
245 250 255

Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala
260 265 270

Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val
275 280 285

Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr
290 295 300

Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr
305 310 315 320

Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu
325 330 335

Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys
340 345 350

Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser
355 360 365

Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp
370 375 380

Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser
385 390 395 400

Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala
405 410 415

Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
420 425 430

<210> 1906

<211> 252
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic polypeptide"

<400> 1906
Met Glu Ile Val Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val
1 5 10 15

Gly Asp Arg Val Ile Ile Thr Cys Gln Ala Ser Glu Ile Ile His Ser
20 25 30

Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu
35 40 45

Ile Tyr Leu Ala Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe Ser
50 55 60

Gly Ser Gly Ser Gly Ala Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln
65 70 75 80

Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Asn Val Tyr Leu Ala Ser
85 90 95

Thr Asn Gly Ala Asn Phe Gly Gln Gly Thr Lys Leu Thr Val Leu Gly
100 105 110

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
115 120 125

Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val
130 135 140

Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Ser
145 150 155 160

Leu Thr Asp Tyr Tyr Tyr Met Thr Trp Val Arg Gln Ala Pro Gly Lys
165 170 175

Gly Leu Glu Trp Val Gly Phe Ile Asp Pro Asp Asp Asp Pro Tyr Tyr
180 185 190

Ala Thr Trp Ala Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys
195 200 205

Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala
210 215 220

Val Tyr Tyr Cys Ala Gly Gly Asp His Asn Ser Gly Trp Gly Leu Asp
225 230 235 240

Ile Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
245 250

<210> 1907
<211> 120
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"

<400> 1907
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Ser Leu Thr Asp Tyr
20 25 30

Tyr Tyr Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp
35 40 45

Val Gly Phe Ile Asp Pro Asp Asp Asp Pro Tyr Tyr Ala Thr Trp Ala
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Gly Gly Asp His Asn Ser Gly Trp Gly Leu Asp Ile Trp Gly Gln
100 105 110

Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 1908
<211> 112
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"

<400> 1908
Met Glu Ile Val Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val
1 5 10 15

Gly Asp Arg Val Ile Ile Thr Cys Gln Ala Ser Glu Ile Ile His Ser
20 25 30

Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu
35 40 45

Ile Tyr Leu Ala Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe Ser
50 55 60

Gly Ser Gly Ser Gly Ala Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln
65 70 75 80

Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Asn Val Tyr Leu Ala Ser
85 90 95

Thr Asn Gly Ala Asn Phe Gly Gln Gly Thr Lys Leu Thr Val Leu Gly
100 105 110

<210> 1909
<211> 20
<212> PRT
<213> Artificial Sequence

<220>

<221> source
<223> /note="Description of Artificial Sequence: Synthetic peptide"

<400> 1909
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
1 5 10 15

Gly Gly Gly Ser
20

<210> 1910
<211> 231
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic polypeptide"

<400> 1910
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr
20 25 30

Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe
50 55 60

Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr
65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Lys Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val
100 105 110

Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125

Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140

Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160

Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175

Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190

Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205

Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys
210 215 220

Ser Cys Asp Lys Thr His Leu
225 230

<210> 1911
<211> 214
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"

<400> 1911
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30

Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile
35 40 45

Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly

50

55

60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp
85 90 95

Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110

Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125

Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140

Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160

Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175

Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190

Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205

Phe Asn Arg Gly Glu Cys
210

<210> 1912

<211> 123

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic polypeptide"

<400> 1912

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr
20 25 30

Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe
50 55 60

Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr
65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Lys Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val
100 105 110

Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 1913
<211> 107
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"

<400> 1913
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30

Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile
35 40 45

Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp
85 90 95

Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105

<210> 1914
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1914
cugguugugu gugugugagu ggu 23

<210> 1915
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1915
uugugugugu gugagugguu gac 23

<210> 1916
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1916
ugugugugug ugagugguug acc 23

<210> 1917
<211> 23
<212> RNA
<213> Homo sapiens

<400> 1917
ugugugugug agugguugac cuu 23

<210> 1918

<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 1918	
ugugugugag ugguugaccu ucc	23
<210> 1919	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 1919	
gugugugagu gguugaccuu ccu	23
<210> 1920	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 1920	
ugugugagug guugaccuuc cuc	23
<210> 1921	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 1921	
ugugaguggu ugaccuuccu cca	23
<210> 1922	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 1922	
gagugguuga ccuuccucca ucc	23
<210> 1923	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 1923	
cauuguggag gcagagaaaa gag	23
<210> 1924	

<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 1924	
auuggaggagg cagagaaaag aga	23
<210> 1925	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 1925	
uuguggaggc agagaaaaga gaa	23
<210> 1926	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 1926	
uguggaggca gagaaaagag aaa	23
<210> 1927	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 1927	
guggaggcag agaaaagaga aag	23
<210> 1928	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 1928	
uggaggcaga gaaaagagaa agu	23
<210> 1929	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 1929	
ggaggcagag aaaagagaaa gug	23
<210> 1930	

<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 1930	
gaggcagaga aaagagaaag ugu	23
<210> 1931	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 1931	
aggcagagaa aagagaaagu guu	23
<210> 1932	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 1932	
ggcagagaaa agagaaagug uuu	23
<210> 1933	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 1933	
gcagagaaaa gagaaagugu uuu	23
<210> 1934	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 1934	
cagagaaaag agaaaguguu uua	23
<210> 1935	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 1935	
agagaaaaga gaaaguguuu uau	23
<210> 1936	

<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 1936	
gagaaaagag aaaguguuuu aua	23
<210> 1937	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 1937	
agaaaagaga aaguguuuuu uau	23
<210> 1938	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 1938	
gaaaagagaa aguguuuuau aua	23
<210> 1939	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 1939	
aaaagagaaa guguuuuaua uac	23
<210> 1940	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 1940	
aaagagaaag uguuuuuauau acg	23
<210> 1941	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 1941	
aagagaaagu guuuuuauaua cgg	23
<210> 1942	

<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 1942	
agagaaagug uuuuauauac ggu	23
<210> 1943	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 1943	
agaaaguguu uuauauacgg uac	23
<210> 1944	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 1944	
gaaaguguuu uauauacggu acu	23
<210> 1945	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 1945	
aaaguguuuu auauacggua cuu	23
<210> 1946	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 1946	
aaguguuuuu uauacgguac uua	23
<210> 1947	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 1947	
aguguuuuau auacgguacu uau	23
<210> 1948	

<211> 23
 <212> RNA
 <213> Homo sapiens

 <400> 1948
 guguuuuaua uacgguacuu auu 23

<210> 1949
 <211> 23
 <212> RNA
 <213> Homo sapiens

 <400> 1949
 uguuuuuauau acgguacuua uuu 23

<210> 1950
 <211> 23
 <212> RNA
 <213> Homo sapiens

 <400> 1950
 guuuuuauaua cgguacuua uua 23

<210> 1951
 <211> 30
 <212> PRT
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic polypeptide"

<220>
 <221> SITE
 <222> (1)..(30)
 <223> /note="This sequence may encompass 1-6 'Gly Gly Gly Gly Ser' repeating units"

<220>
 <221> source
 <223> /note="See specification as filed for detailed description of substitutions and preferred embodiments"

<400> 1951
 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
 1 5 10 15

Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser

20

25

30

<210> 1952

<400> 1952
000

<210> 1953

<400> 1953
000

<210> 1954

<400> 1954
000

<210> 1955

<400> 1955
000

<210> 1956

<400> 1956
000

<210> 1957

<400> 1957
000

<210> 1958

<400> 1958
000

<210> 1959

<400> 1959
000

<210> 1960

<400> 1960

000

<210> 1961

<400> 1961
000

<210> 1962

<400> 1962
000

<210> 1963

<400> 1963
000

<210> 1964

<400> 1964
000

<210> 1965

<400> 1965
000

<210> 1966

<400> 1966
000

<210> 1967

<400> 1967
000

<210> 1968

<400> 1968
000

<210> 1969

<400> 1969

000

<210> 1970

<400> 1970
000

<210> 1971

<400> 1971
000

<210> 1972

<400> 1972
000

<210> 1973

<400> 1973
000

<210> 1974

<400> 1974
000

<210> 1975

<400> 1975
000

<210> 1976

<400> 1976
000

<210> 1977

<400> 1977
000

<210> 1978

<400> 1978

000

<210> 1979

<400> 1979
000

<210> 1980

<400> 1980
000

<210> 1981

<400> 1981
000

<210> 1982

<400> 1982
000

<210> 1983

<400> 1983
000

<210> 1984

<400> 1984
000

<210> 1985

<400> 1985
000

<210> 1986

<400> 1986
000

<210> 1987

<400> 1987

000

<210> 1988

<400> 1988
000

<210> 1989

<400> 1989
000

<210> 1990

<400> 1990
000

<210> 1991

<400> 1991
000

<210> 1992

<400> 1992
000

<210> 1993

<400> 1993
000

<210> 1994

<400> 1994
000

<210> 1995

<400> 1995
000

<210> 1996

<400> 1996

000

<210> 1997

<400> 1997
000

<210> 1998

<400> 1998
000

<210> 1999

<400> 1999
000

<210> 2000
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2000
cggugcugga auuugauauu a

21

<210> 2001
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2001
ggugcuggaa uuugauauuc a

21

<210> 2002
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2002
ugcuggaauu ugauauucau a 21

<210> 2003
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2003
gcuggaauuu gauauucauu a 21

<210> 2004
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2004
uggaauuuga uauucauuga a 21

<210> 2005
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2005
ggaauuugau auucauugau a 21

<210> 2006
<211> 21
<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2006

gaauuugaua uucauugauc a

21

<210> 2007

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2007

aaauuugauau ucauugaucc a

21

<210> 2008

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2008

auuugauauu cauugaucg a

21

<210> 2009

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2009

uuugauauuc auugaucgg a

21

<210> 2010

<211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2010
 uuuauuuuug cuugccauuc a 21

<210> 2011
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2011
 uuauuuuugc uugccauucc a 21

<210> 2012
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2012
 caaaucaucug uggauuuugg a 21

<210> 2013
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2013
 aaaucaucugu ggauuuugga a 21

<210> 2014
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2014
aaucacugug gauuuuggaa a 21

<210> 2015
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2015
aucacugugg auuuuggaaa a 21

<210> 2016
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2016
ucacugugga uuuuggaaac a 21

<210> 2017
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2017

cacuguggau uuuggaaacc a 21

<210> 2018
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2018
acuguggauu uuggaaacca a 21

<210> 2019
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2019
cuguggauuu uggaaccag a 21

<210> 2020
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2020
uguggauuuu ggaaaccagc a 21

<210> 2021
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2021
guggauuuug gaaaccagca a 21

<210> 2022
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2022
gauuuuggaa accagcagaa a 21

<210> 2023
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2023
auuuuuggaaa ccagcagaaa a 21

<210> 2024
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2024
uuuuggaaac cagcagaaag a 21

<210> 2025
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2025

uuuggaaacc agcagaaaga a

21

<210> 2026

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2026

ggaaaccagc agaaagagga a

21

<210> 2027

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2027

aaaccagcag aaagaggaaa a

21

<210> 2028

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2028

aaccagcaga aagaggaaag a

21

<210> 2029

<211> 21

<212> RNA

<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2029
accagcagaa agaggaaaga a 21

<210> 2030
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2030
ccagcagaaa gaggaaagag a 21

<210> 2031
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2031
cagcagaaag aggaaagagg a 21

<210> 2032
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2032
agcagaaaga ggaaagaggu a 21

<210> 2033
<211> 21
<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2033

gcagaaagag gaaagaggua a

21

<210> 2034

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2034

cagaaagagg aaagagguag a

21

<210> 2035

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2035

aaagaggaaa gagguagcaa a

21

<210> 2036

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2036

aagaggaaag agguagcaag a

21

<210> 2037

<211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2037
 agaggaaaga gguagcaaga a 21

<210> 2038
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2038
 gaggaaagag guagcaagag a 21

<210> 2039
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2039
 ggaaagaggu agcaagagcu a 21

<210> 2040
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2040
 agguagcaag agcuccagag a 21

<210> 2041
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2041
uccagagaga agucgaggaa a 21

<210> 2042
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2042
ccagagagaa gucgaggaag a 21

<210> 2043
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2043
cagagagaag ucgaggaaga a 21

<210> 2044
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2044

agagaagucg aggaagagag a 21

<210> 2045
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2045
gagaagucga ggaagagaga a 21

<210> 2046
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2046
gaagucgagg aagagagaga a 21

<210> 2047
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2047
agugagugac cugcuuuugg a 21

<210> 2048
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2048
ggcgucgcac ugaaacuuuu a 21

<210> 2049
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2049
gucgcacuga aacuuuucgu a 21

<210> 2050
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2050
ucgcacugaa acuuuucguc a 21

<210> 2051
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2051
cacugaaacu uuucguccaa a 21

<210> 2052
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2052

acugaaacuu uucguccaac a

21

<210> 2053

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2053

ugaaacuuuu cguccaacuu a

21

<210> 2054

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2054

aacuuuucgu ccaacuucug a

21

<210> 2055

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2055

cugggcuguu cucgcuucgg a

21

<210> 2056

<211> 21

<212> RNA

<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2056
 ugggcuguuc ucgcucgga a 21

<210> 2057
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2057
 gggcuguucu cgcuucggag a 21

<210> 2058
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2058
 gcuguucucg cuucggagga a 21

<210> 2059
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2059
 gccgcgagaa gugcuagcuc a 21

<210> 2060
 <211> 21
 <212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2060

ccgcgagaag ugcua gcucg a

21

<210> 2061

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2061

gccuccgaaa ccaugaacuu a

21

<210> 2062

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2062

aaggaggagg gcagaaucau a

21

<210> 2063

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2063

ggcagaauca ucacgaagug a

21

<210> 2064

<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2064
aaucaucacg aaguggugaa a 21

<210> 2065
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2065
aucaucacga aguggugaag a 21

<210> 2066
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2066
ucaucacgaa guggugaagu a 21

<210> 2067
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2067
caucacgaag uggugaaguu a 21

<210> 2068
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2068
ucacgaagug gugaaguca a 21

<210> 2069
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2069
aaguggugaa guucauggau a 21

<210> 2070
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2070
aguggugaag uucauggaug a 21

<210> 2071
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2071

guggugaagu ucauggaugu a 21

<210> 2072
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2072
ggugaaguuc auggaugucu a 21

<210> 2073
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2073
gugaaguuca uggaugucua a 21

<210> 2074
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2074
ugaaguucau ggaugucuau a 21

<210> 2075
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2075
aaguucaugg augucuauca a 21

<210> 2076
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2076
aguucaugga ugucuaucag a 21

<210> 2077
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2077
uucauggaug ucuaucagcg a 21

<210> 2078
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2078
guggacauca uccaggagua a 21

<210> 2079
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2079

ucgaguacau cuucaagcca a

21

<210> 2080

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2080

cgaguacauc uucaagccau a

21

<210> 2081

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2081

gaguacaucu ucaagccauc a

21

<210> 2082

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2082

guacaucuuc aagccauccu a

21

<210> 2083

<211> 21

<212> RNA

<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2083
 ccaacauac caugcagauu a 21

<210> 2084
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2084
 caacauacc augcagauua a 21

<210> 2085
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2085
 acauaccau gcagauuaug a 21

<210> 2086
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2086
 caucacaug cagauuaugc a 21

<210> 2087
 <211> 21
 <212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2087

accaugcaga uuaugcggau a

21

<210> 2088

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2088

augcagauua ugcggaucaa a

21

<210> 2089

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2089

ugcagauuau gcggaucaaa a

21

<210> 2090

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2090

gcagauuaug cggaucaaac a

21

<210> 2091

<211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2091
 gauuauugcgg aucaaaccuc a 21

<210> 2092
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2092
 auuauugcgg ucaaaccuca a 21

<210> 2093
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2093
 cggaucaaac cucaccaagg a 21

<210> 2094
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2094
 ggagagauga gcuuccuaca a 21

<210> 2095
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2095
gagaugagcu uccuacagca a 21

<210> 2096
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2096
gaugagcuuc cuacagcaca a 21

<210> 2097
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2097
augagcuucc uacagcaca a 21

<210> 2098
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2098

gagcuuccua cagcacaaca a 21

<210> 2099
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 2099
 agcuuccuac agcacaacaa a 21

<210> 2100
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 2100
 gcuuccuaca gcacaacaaa a 21

<210> 2101
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 2101
 cuuccuacag cacaacaaau a 21

<210> 2102
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 2102
uccuacagca caacaaaugu a 21

<210> 2103
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2103
cuacagcaca acaaauguga a 21

<210> 2104
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2104
uacagcacia caaaugugaa a 21

<210> 2105
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2105
agcacaacia augugaaugc a 21

<210> 2106
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2106

gcacaacaaa ugugaaugca a

21

<210> 2107

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2107

cucaccagga aagacugaua a

21

<210> 2108

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2108

ucaccaggaa agacugauac a

21

<210> 2109

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2109

caccaggaaa gacugauaca a

21

<210> 2110

<211> 21

<212> RNA

<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2110
accaggaaag acugauacag a 21

<210> 2111
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2111
ccaggaaaga cugauacaga a 21

<210> 2112
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2112
caggaaagac ugauacagaa a 21

<210> 2113
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2113
aggaaagacu gauacagaac a 21

<210> 2114
<211> 21
<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2114

ggaaagacug auacagaacg a

21

<210> 2115

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2115

gaaagacuga uacagaacga a

21

<210> 2116

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2116

aaagacugau acagaacgau a

21

<210> 2117

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2117

aagacugaua cagaacgauc a

21

<210> 2118

<211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2118
 agacugauac agaacgaucg a 21

<210> 2119
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2119
 gacugauaca gaacgaucga a 21

<210> 2120
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2120
 acugauacag aacgaucgau a 21

<210> 2121
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2121
 cugauacaga acgaucgaua a 21

<210> 2122
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2122
ugauacagaa cgaucgauac a 21

<210> 2123
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2123
gauacagaac gaucgauaca a 21

<210> 2124
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2124
auacagaacg aucgauacag a 21

<210> 2125
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2125

uacagaacga ucgauacaga a	21
<210> 2126 <211> 21 <212> RNA <213> Artificial Sequence <220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 2126 acagaacgau cgauacagaa a	21
<210> 2127 <211> 21 <212> RNA <213> Artificial Sequence <220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 2127 cagaacgauc gauacagaaa a	21
<210> 2128 <211> 21 <212> RNA <213> Artificial Sequence <220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 2128 agaacgaucg auacagaaac a	21
<210> 2129 <211> 21 <212> RNA <213> Artificial Sequence <220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	

<400> 2129
gaacgaucga uacagaaacc a 21

<210> 2130
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2130
aacgaucgau acagaaacca a 21

<210> 2131
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2131
acgaucgaua cagaaaccac a 21

<210> 2132
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2132
cgaucgauac agaaaccacg a 21

<210> 2133
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2133

caccaucacc aucgacagaa a

21

<210> 2134

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2134

caucaccauc gacagaacag a

21

<210> 2135

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2135

ucaccaucga cagaacaguc a

21

<210> 2136

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2136

caccaucgac agaacagucc a

21

<210> 2137

<211> 21

<212> RNA

<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2137
accaucgaca gaacaguccu a 21

<210> 2138
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2138
ccaucgacag aacaguccuu a 21

<210> 2139
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2139
caucgacaga acaguccuua a 21

<210> 2140
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2140
aucgacagaa caguccuuaa a 21

<210> 2141
<211> 21
<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2141

ucgacagaac aguccuuaau a

21

<210> 2142

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2142

cgacagaaca guccuuaauc a

21

<210> 2143

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2143

gacagaacag uccuuaaucc a

21

<210> 2144

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2144

acagaacagu ccuuaaucca a

21

<210> 2145

<211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2145
 agaacagucc uaaauccaga a 21

<210> 2146
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2146
 gaacaguccu uaauccagaa a 21

<210> 2147
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2147
 aacaguccuu aauccagaaa a 21

<210> 2148
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2148
 acaguccuua auccagaaac a 21

<210> 2149
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2149
caguccuuaa uccagaaacc a 21

<210> 2150
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2150
aguccuuaau ccagaaaccu a 21

<210> 2151
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2151
guccuuaauc cagaaaccug a 21

<210> 2152
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2152

uccuuaaucc agaaaccuga a 21

<210> 2153
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 2153
 ccuuaaucca gaaaccugaa a 21

<210> 2154
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 2154
 cuuaauccag aaaccugaaa a 21

<210> 2155
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 2155
 uuaauccaga aaccugaaau a 21

<210> 2156
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 2156
cagaaaccug aaaugaagga a 21

<210> 2157
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2157
agaaaccuga aaugaaggaa a 21

<210> 2158
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2158
gaaaccugaa augaaggaag a 21

<210> 2159
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2159
aaaccugaaa ugaaggaaga a 21

<210> 2160
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2160

aaccugaaau gaaggaagag a

21

<210> 2161

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2161

ccugaaauga aggaagagga a

21

<210> 2162

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2162

augaaggaag aggagacucu a

21

<210> 2163

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2163

ucccucuugg aauggauuc a

21

<210> 2164

<211> 21

<212> RNA

<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2164
 ccucuuggaa uuggauucgc a 21

 <210> 2165
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2165
 cucuuggaau uggauucgcc a 21

 <210> 2166
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2166
 uuggaauugg auucgccauu a 21

 <210> 2167
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2167
 uggauugga uucgccauuu a 21

 <210> 2168
 <211> 21
 <212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2168

ggaauuggau ucgccauuuu a

21

<210> 2169

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2169

gaauuggauu cgccauuuua a

21

<210> 2170

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2170

aauggauuc gccauuuuau a

21

<210> 2171

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2171

auuggauucg ccuuuuuuu a

21

<210> 2172

<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2172
uuggauucgc cauuuuauuu a 21

<210> 2173
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2173
uggauucgcc auuuuauuuu a 21

<210> 2174
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2174
ggauucgcca uuuuauuuuu a 21

<210> 2175
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2175
gauucgccau uuuuuuuuuc a 21

<210> 2176
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2176
ucgccauuuu auuuuucuug a 21

<210> 2177
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2177
cgccauuuua uuuuucuugc a 21

<210> 2178
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2178
gccauuuuau uuuuucuugcu a 21

<210> 2179
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2179

ccaauuuuuuu uuucuugcug a 21

<210> 2180
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2180
cauuuuuuuu uuucuugcugc a 21

<210> 2181
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2181
auuuuuuuuu ucuugcugcu a 21

<210> 2182
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2182
uuuuuuuuuu cuugcugcua a 21

<210> 2183
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2183
uuucuugcug cuaaaucacc a 21

<210> 2184
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2184
ucaccgagcc cggaagauua a 21

<210> 2185
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2185
gcccggaaga uuagagaguu a 21

<210> 2186
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2186
cccggaagau uagagaguuu a 21

<210> 2187
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2187

cggaagauua gagaguuua a

21

<210> 2188

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2188

ggaagauuag agaguuuau a

21

<210> 2189

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2189

gaagauuaga gaguuuuau a

21

<210> 2190

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2190

aagauuagag aguuuuauu a

21

<210> 2191

<211> 21

<212> RNA

<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 2191
 agauuagaga guuuuauuuc a 21

<210> 2192
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 2192
 auuagagagu uuuuuuucug a 21

<210> 2193
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 2193
 uuagagaguu uuauuucugg a 21

<210> 2194
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 2194
 uagagaguuu uauuucuggg a 21

<210> 2195
 <211> 21
 <212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2195

agagaguuuuu auuucuggga a

21

<210> 2196

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2196

gagaguuuuu uuucugggau a

21

<210> 2197

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2197

agaguuuuuau uucugggauu a

21

<210> 2198

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2198

gaguuuuuau ucugggauuc a

21

<210> 2199

<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2199
aguuuuuuuu cugggauucc a 21

<210> 2200
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2200
guuuuuuuuc ugggauuccu a 21

<210> 2201
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2201
uuuuuuuuuc gggauuccug a 21

<210> 2202
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2202
uuuauuuucug ggauuccugu a 21

<210> 2203
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2203
uuauuucugg gauuccugua a 21

<210> 2204
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2204
uauuucuggg auuccuguag a 21

<210> 2205
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2205
auuucuggga uuccuguaga a 21

<210> 2206
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2206

uuucugggau uccuguagac a 21

<210> 2207
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 2207
 ucugggauuc cuguagacac a 21

<210> 2208
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 2208
 cugggauucc uguagacaca a 21

<210> 2209
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 2209
 ugggauuccu guagacacac a 21

<210> 2210
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 2210
gggauuccug uagacacacc a 21

<210> 2211
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2211
acacacccac ccacauacau a 21

<210> 2212
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2212
accacccac auacauacau a 21

<210> 2213
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2213
cccaccaca uacauacau a 21

<210> 2214
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2214

ccacccacau acauacauuu a

21

<210> 2215

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2215

cacccacaua cauacauuuu a

21

<210> 2216

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2216

ccacauacau acauuuauau a

21

<210> 2217

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2217

cacauacaua cauuuauaua a

21

<210> 2218

<211> 21

<212> RNA

<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2218
 uaaaauaac agugcuaaug a 21

<210> 2219
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2219
 uaaauaaca gugcuaaugu a 21

<210> 2220
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2220
 aaauaacag ugcuaauguu a 21

<210> 2221
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2221
 aaauaacagu gcuaauguua a 21

<210> 2222
 <211> 21
 <212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2222

auuaacagug cuaauguuau a

21

<210> 2223

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2223

uuaacagugc uaauguuauu a

21

<210> 2224

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2224

uaacagugcu aauguuauug a

21

<210> 2225

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2225

aacagugcua auguuauugg a

21

<210> 2226

<211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2226
 acagugcuaa uguuauuggu a 21

<210> 2227
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2227
 cagugcuaau guuauuggug a 21

<210> 2228
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2228
 gugcuaaugu uauugguguc a 21

<210> 2229
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2229
 ugcuaauguu auuggugucu a 21

<210> 2230
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2230
gcuaauguua uggugucuu a 21

<210> 2231
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2231
cuaauguuau uggugucuuc a 21

<210> 2232
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2232
uaauguuauu ggugucuuca a 21

<210> 2233
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2233

aauguuauug gugucuucac a 21

<210> 2234
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2234
auguuauugg ugucuucacu a 21

<210> 2235
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2235
uguuauuggu gucuucacug a 21

<210> 2236
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2236
guuauuggug ucuucacugg a 21

<210> 2237
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2237
uuauuggugu cuucacugga a 21

<210> 2238
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2238
uggugucuuc acuggaugua a 21

<210> 2239
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2239
ugucuucacu ggaugauuu a 21

<210> 2240
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2240
cacuggaugu auuugacugc a 21

<210> 2241
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2241

acuggaugua uuugacugcu a

21

<210> 2242

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2242

uggauguauu ugacugcugu a

21

<210> 2243

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2243

uauuugacug cuguggacuu a

21

<210> 2244

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2244

uuugacugcu guggacuuga a

21

<210> 2245

<211> 21

<212> RNA

<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2245
 gcuguggacu ugaguuggga a 21

 <210> 2246
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2246
 uccacucag auccugacag a 21

 <210> 2247
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2247
 cccacucaga uccugacagg a 21

 <210> 2248
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2248
 ggaggagaug agagacucug a 21

 <210> 2249
 <211> 21
 <212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2249

gaggagauga gagacucugg a

21

<210> 2250

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2250

ggagaugaga gacucuggca a

21

<210> 2251

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2251

gagacucugg caugaucuuu a

21

<210> 2252

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2252

agacucuggc augaucuuuu a

21

<210> 2253

<211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2253
 uuuugggaac accgacaaac a 21

<210> 2254
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2254
 gagcuucagg acauugcugu a 21

<210> 2255
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2255
 gcuucaggac auugcugugc a 21

<210> 2256
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2256
 cuucaggaca uugcugugcu a 21

<210> 2257
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2257
uucaggacau ugcugugcuu a 21

<210> 2258
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2258
ucaggacauu gcugugcuuu a 21

<210> 2259
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2259
caggacauug cugugcuuug a 21

<210> 2260
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2260

cgcuuacucu caccugcuuc a 21

<210> 2261
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2261
gcuuacucuc accugcuuc a 21

<210> 2262
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2262
uuacucucac cugcuucuga a 21

<210> 2263
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2263
cucucaccug cuucugaguu a 21

<210> 2264
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2264
ucucaccugc uucugaguug a 21

<210> 2265
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2265
cucaccugcu ucugaguugc a 21

<210> 2266
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2266
ucaccugcuu cugaguugcc a 21

<210> 2267
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2267
caccugcuuc ugaguugccc a 21

<210> 2268
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2268

accugcuucu gaguugccca a

21

<210> 2269

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2269

ccugcuucug aguugcccag a

21

<210> 2270

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2270

cggcgaagag aagagacaca a

21

<210> 2271

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2271

ggcgaagaga agagacacau a

21

<210> 2272

<211> 21

<212> RNA

<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2272
 gcgaagagaa gagacacauu a 21

<210> 2273
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2273
 cgaagagaag agacacauug a 21

<210> 2274
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2274
 gaagagaaga gacacauugu a 21

<210> 2275
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2275
 aagagaagag acacauuguu a 21

<210> 2276
 <211> 21
 <212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2276

agagaagaga cacauuguug a

21

<210> 2277

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2277

gagaagagac acauuguugg a

21

<210> 2278

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2278

agaagagaca cauuguugga a

21

<210> 2279

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2279

gaagagacac auuguuggaa a

21

<210> 2280

<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2280
aagagacaca uuguuggaag a 21

<210> 2281
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2281
agagacacau uguuggaaga a 21

<210> 2282
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2282
gagacacauu guuggaagaa a 21

<210> 2283
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2283
agacacauug uuggaagaag a 21

<210> 2284
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2284
gacacauugu uggaagaagc a 21

<210> 2285
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2285
acacauuguu ggaagaagca a 21

<210> 2286
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2286
cacauuguug gaagaagcag a 21

<210> 2287
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2287

uau <u>g</u> uccu <u>c</u> a cac <u>c</u> au <u>g</u> aa a	21
<210> 2288	
<211> 21	
<212> RNA	
<213> Artificial Sequence	
<220>	
<221> source	
<223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 2288	
uccu <u>c</u> acacc au <u>g</u> aaac <u>c</u> a a	21
<210> 2289	
<211> 21	
<212> RNA	
<213> Artificial Sequence	
<220>	
<221> source	
<223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 2289	
ccu <u>c</u> acac <u>c</u> a uu <u>g</u> aaaccac a	21
<210> 2290	
<211> 21	
<212> RNA	
<213> Artificial Sequence	
<220>	
<221> source	
<223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 2290	
cucacac <u>c</u> au ugaaaccac <u>u a</u>	21
<210> 2291	
<211> 21	
<212> RNA	
<213> Artificial Sequence	
<220>	
<221> source	
<223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	

<400> 2291
ucacaccauu gaaaccacua a 21

<210> 2292
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2292
cacaccauug aaaccacuag a 21

<210> 2293
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2293
ccauugaaac cacuaguucu a 21

<210> 2294
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2294
cauugaaacc acuaguucug a 21

<210> 2295
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2295
auugaaacca cuaguucugu a 21

<210> 2296
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2296
uugaaaccac uaguucuguc a 21

<210> 2297
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2297
ugaaaccacu aguucugucc a 21

<210> 2298
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2298
gaccugguug ugugugugug a 21

<210> 2299
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2299
accugguugu guguguguga a 21

<210> 2300
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2300
ccugguugug ugugugugag a 21

<210> 2301
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2301
cugguugugu gugugugagu a 21

<210> 2302
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2302
ugguugugug ugugugagug a 21

<210> 2303
<211> 21
<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2303

gguugugugu gugugagugg a

21

<210> 2304

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2304

gugugugugu gagugguuga a

21

<210> 2305

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2305

ugugugugug agugguugac a

21

<210> 2306

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2306

ugugugugag uggugaccu a

21

<210> 2307

<211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2307
 ugugugagug guugaccuuc a 21

<210> 2308
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2308
 gugugagugg uugaccuucc a 21

<210> 2309
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2309
 ugugaguggu ugaccuuccu a 21

<210> 2310
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2310
 ugagugguug accuuccucc a 21

<210> 2311
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2311
gugguugacc uuccuccauc a 21

<210> 2312
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2312
uuguggaggc agagaaaaga a 21

<210> 2313
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2313
uguggaggca gagaaaagag a 21

<210> 2314
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2314

guggaggcag agaaaagaga a 21

<210> 2315
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2315
uggaggcaga gaaaagagaa a 21

<210> 2316
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2316
ggaggcagag aaaagagaaa a 21

<210> 2317
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2317
gaggcagaga aaagagaaag a 21

<210> 2318
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2318
aggcagagaa aagagaaagu a 21

<210> 2319
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2319
ggcagagaaa agagaaagug a 21

<210> 2320
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2320
gcagagaaaa gagaaagugu a 21

<210> 2321
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2321
cagagaaaag agaaaguguu a 21

<210> 2322
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2322

agagaaaaga gaaaguguuu a

21

<210> 2323

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2323

gagaaaagag aaaguguuuu a

21

<210> 2324

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2324

agaaaagaga aaguguuuuu a

21

<210> 2325

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2325

gaaaagagaa aguguuuuau a

21

<210> 2326

<211> 21

<212> RNA

<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2326
aaaagagaaa guguuuuaua a 21

<210> 2327
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2327
aaagagaaag uguuuuauau a 21

<210> 2328
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2328
aagagaaagu guuuuauaua a 21

<210> 2329
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2329
agagaaagug uuuuauauac a 21

<210> 2330
<211> 21
<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2330

gagaaagugu uuauauacg a

21

<210> 2331

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2331

agaaaguguu uuauauacgg a

21

<210> 2332

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2332

aaaguguuuu auauacggua a

21

<210> 2333

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2333

aaguguuuuu uauacggua a

21

<210> 2334

<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2334
aguguuuuau auacgguacu a 21

<210> 2335
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2335
guguuuuaua uacgguacuu a 21

<210> 2336
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2336
uguuuuuauau acgguacuua a 21

<210> 2337
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2337
guuuuuauaua cgguacuua a 21

<210> 2338
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2338
uuuuauauac gguacuuauu a 21

<210> 2339
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2339
uuuauauacg guacuuauuu a 21

<210> 2340
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2340
uuauauacgg uacuuuuua a 21

<210> 2341
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2341

uauauacggu acuuauuuuaa a 21

<210> 2342
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2342
guacuuuuuu aaaucccuu a 21

<210> 2343
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2343
uacuuuuuuu aaaucccuu a 21

<210> 2344
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2344
uuagagaug uaucuuuugc a 21

<210> 2345
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2345
uaugagaugu aucuuuugcu a 21

<210> 2346
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2346
augagaugua ucuuuugcuc a 21

<210> 2347
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2347
ugagauguau cuuuugcucu a 21

<210> 2348
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2348
gagauguauc uuuugcucuc a 21

<210> 2349
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2349

agaugauacu uuugcucucu a

21

<210> 2350

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2350

gaugauacuu uugcucucuc a

21

<210> 2351

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2351

auguaucuuu ugcucucucu a

21

<210> 2352

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2352

gcucucucuu gcucucuau a

21

<210> 2353

<211> 21

<212> RNA

<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2353
 cucucucuug cucucuauu a 21

<210> 2354
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2354
 ucucucuugc ucucuauuu a 21

<210> 2355
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2355
 cucucuugcu cucuuauuug a 21

<210> 2356
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2356
 ucucuugcuc ucuuauuugu a 21

<210> 2357
 <211> 21
 <212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2357

cucuugcucu cuuauuugua a

21

<210> 2358

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2358

ucuugcucuc uuauuuguac a

21

<210> 2359

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2359

cuugcucucu uauuuguacc a

21

<210> 2360

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2360

uugcucucuu auuuguaccg a

21

<210> 2361

<211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2361
 ugcucucuua uuuguaccgg a 21

<210> 2362
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2362
 cucucuuaau uguaccgguu a 21

<210> 2363
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2363
 ucucuuaauuu guaccgguuu a 21

<210> 2364
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2364
 cucuuauuuug uaccgguuuu a 21

<210> 2365
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2365
ucuuuuugu accgguuuu a 21

<210> 2366
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2366
cuuauuugua ccgguuuuug a 21

<210> 2367
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2367
uuauuuguac cgguuuuugu a 21

<210> 2368
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2368

uauuuuguacc gguuuuugua a 21

<210> 2369
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 2369
 auuuguaccg guuuuugua a 21

<210> 2370
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 2370
 uuuguaccgg uuuuuguaua a 21

<210> 2371
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 2371
 uuguaccggu uuuuguauau a 21

<210> 2372
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 2372
uguaccgguu uuuguauaua a 21

<210> 2373
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2373
guaccgguuu uuguauauaa a 21

<210> 2374
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2374
uaccgguuuu uguauauaaa a 21

<210> 2375
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2375
accgguuuuu guauauaaaa a 21

<210> 2376
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2376

auucauguuu ccaaucucuc a

21

<210> 2377

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2377

uucauguuuc caaucucucu a

21

<210> 2378

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2378

ucauguuucc aaucucucuc a

21

<210> 2379

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2379

cauguuucca aucucucucu a

21

<210> 2380

<211> 21

<212> RNA

<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2380
auguuuccaa ucucucucuc a 21

<210> 2381
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2381
uguuuccaau cucucucucc a 21

<210> 2382
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2382
uuuccaau cu cucucuccu a 21

<210> 2383
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2383
uccaau cu cu cucuccuga a 21

<210> 2384
<211> 21
<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2384

cggugacagu cacuagcuua a

21

<210> 2385

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2385

ggugacaguc acuagcuuau a

21

<210> 2386

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2386

agucacuagc uuaucuugaa a

21

<210> 2387

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2387

gucacuagcu uaucuugaac a

21

<210> 2388

<211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2388
 ucacuagcuu aucuugaaca a 21

<210> 2389
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2389
 acuagcuuau cuugaacaga a 21

<210> 2390
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2390
 cuagcuuau uugaacagau a 21

<210> 2391
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2391
 uagcuuau ugaacagau a 21

<210> 2392
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2392
agcuuauuu gaacagauau a 21

<210> 2393
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2393
gcuuauuuu aacagauuu a 21

<210> 2394
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2394
cagcacau uccuuugaaa a 21

<210> 2395
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2395

agcacacauu ccuuugaaau a 21

<210> 2396
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2396
gcacacauuc cuuugaaau a 21

<210> 2397
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2397
cacacauucc uuugaaaua a 21

<210> 2398
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2398
cacauuccuu ugaaauaagg a 21

<210> 2399
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2399
uccuuugaaa uaagguuuc a 21

<210> 2400
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2400
cuuugaaaua agguuuc a 21

<210> 2401
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2401
uuugaaaua gguuuc a 21

<210> 2402
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2402
agguuuc a auacauc a 21

<210> 2403
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2403

gguuucaaua uacaucuaca a

21

<210> 2404

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2404

guuucaauau acaucuacau a

21

<210> 2405

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2405

uuucaauaua caucuacaua a

21

<210> 2406

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2406

uucaauauac aucuacauac a

21

<210> 2407

<211> 21

<212> RNA

<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2407
 uauuuggcaa cuuguauuug a 21

<210> 2408
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2408
 uuuggcaacu uguauuugug a 21

<210> 2409
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2409
 uggcaacuug uauuugugug a 21

<210> 2410
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2410
 ggcaacuugu auuugugugu a 21

<210> 2411
 <211> 21
 <212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2411

gcaacuugua uuugugugua a

21

<210> 2412

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2412

caacuuguau uuuguguguau a

21

<210> 2413

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2413

aacuuguauu uguguguaua a

21

<210> 2414

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2414

acuuguauuu guguguauau a

21

<210> 2415

<211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2415
 uucugauaaa auagacauug a 21

<210> 2416
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2416
 ugauaaaaua gacauugcua a 21

<210> 2417
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2417
 gauaaaauag acauugcuau a 21

<210> 2418
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2418
 uaaaauagac auugcuauuc a 21

<210> 2419
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2419
uagacauugc uauucuguuu a 21

<210> 2420
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2420
agacauugcu auucuguuuu a 21

<210> 2421
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2421
ucuacauacu aaaucucucu a 21

<210> 2422
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2422

cuacauacua aaucucucuc a 21

<210> 2423
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 2423
 uacauacuaa aucucucucc a 21

<210> 2424
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 2424
 acauacuaaa ucucucuccu a 21

<210> 2425
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 2425
 cauacuaaau cucucuccuu a 21

<210> 2426
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 2426
auacuaaauc ucucuccuuu a 21

<210> 2427
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2427
uacuaaaucu cucuccuuu a 21

<210> 2428
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2428
cauuuauuuu uuggugcuac a 21

<210> 2429
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2429
auuuuuuuau uggugcuacu a 21

<210> 2430
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2430

uuuauuuauu ggugcuacug a

21

<210> 2431

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2431

uuauuuauug gugcuacugu a

21

<210> 2432

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2432

uauuuauugg ugcucuguu a

21

<210> 2433

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2433

auuuauuggu gcuacuguu a

21

<210> 2434

<211> 21

<212> RNA

<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2434
 uuauuggugc uacuguuuau a 21

<210> 2435
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2435
 auuggugcua cuguuuaucc a 21

<210> 2436
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2436
 gaaaagauau uaacaucacg a 21

<210> 2437
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2437
 aacaucacgu cuuugucucu a 21

<210> 2438
 <211> 21
 <212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2438

acaucacguc uuugucucua a

21

<210> 2439

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2439

gucuuugucu cuagugcagu a

21

<210> 2440

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2440

ucuuugucuc uagugcaguu a

21

<210> 2441

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2441

cuuugucucu agugcaguuu a

21

<210> 2442

<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2442
gagauauucc guaguacaua a 21

<210> 2443
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2443
agauauuccg uaguacauau a 21

<210> 2444
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2444
gauauuccgu aguacauauu a 21

<210> 2445
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2445
cgacaaagaa auacagauau a 21

<210> 2446
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2446
gacaaagaaa uacagauaua a 21

<210> 2447
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2447
acaaagaaau acagauauau a 21

<210> 2448
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2448
caaagaaaua cagauauauc a 21

<210> 2449
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2449

uaauaucaaa uuccagcacc gag

23

<210> 2450
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2450
ugaauaucaa auuccagcac cga

23

<210> 2451
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2451
uaugaauauc aaauuccagc acc

23

<210> 2452
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2452
uaugaauau caauuccag cac

23

<210> 2453
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2453
uucaaugau aucaauucc agc 23

<210> 2454
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2454
uaucaaugaa uaucaauuc cag 23

<210> 2455
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2455
ugaucauga auaucaauu cca 23

<210> 2456
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2456
uggaucaug aaaucaau ucc 23

<210> 2457
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2457

ucggaucaau gaauaucaaa uuc

23

<210> 2458

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2458

uccggaucaa ugaauaucaa auu

23

<210> 2459

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2459

ugaauggcaa gcaaaaauaa auu

23

<210> 2460

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2460

uggaauggca agcaaaaaua aa

23

<210> 2461

<211> 23

<212> RNA

<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2461
 ucaaaaaucc acagugauuu ggg 23

<210> 2462
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2462
 uuccaaaauc cacagugauu ugg 23

<210> 2463
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2463
 uuuccaaaau ccacagugau uug 23

<210> 2464
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2464
 uuuuccaaaaa uccacaguga uuu 23

<210> 2465
 <211> 23
 <212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2465

uguuuccaaa auccacagug auu

23

<210> 2466

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2466

ugguuuccaa aauccacagu gau

23

<210> 2467

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2467

uugguuucca aaauccacag uga

23

<210> 2468

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2468

ucugguuucc aaaauccaca gug

23

<210> 2469

<211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2469
 ugcugguuuc caaaauccac agu 23

<210> 2470
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2470
 uugcugguuu ccaaaaucca cag 23

<210> 2471
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2471
 uuucugcugg uuuccaaaau cca 23

<210> 2472
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2472
 uuuucugcug guuuccaaaa ucc 23

<210> 2473
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2473
ucuuucugcu gguuuccaaa auc

23

<210> 2474
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2474
uucuuucugc ugguuuccaa aa

23

<210> 2475
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2475
uuccucuuuc ugcugguuuc caa

23

<210> 2476
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2476

uuuuuccucuu ucugcugguu ucc

23

<210> 2477
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2477
ucuuuuccucu uucugcuggu uuc

23

<210> 2478
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2478
uucuuuuccuc uuucugcugg uuu

23

<210> 2479
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2479
ucucuuuccu cuuucugcug guu

23

<210> 2480
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2480
uccucuuucc ucuuucugcu ggu 23

<210> 2481
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2481
uaccucuuuc cucuuucugc ugg 23

<210> 2482
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2482
uuaccucuuu ccucuuucug cug 23

<210> 2483
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2483
ucuaccucuu uccucuuucu gcu 23

<210> 2484
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2484

uuugcuaccu cuuuccucuu ucu

23

<210> 2485

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2485

ucuugcuacc ucuuuccucu uuc

23

<210> 2486

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2486

uucuugcuac cucuuuccuc uuu

23

<210> 2487

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2487

ucucuugcua ccucuuccu cuu

23

<210> 2488

<211> 23

<212> RNA

<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2488
 uagcucuugc uaccucuuc cuc 23

 <210> 2489
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2489
 ucucuggagc ucuugcuacc ucu 23

 <210> 2490
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2490
 uuuccucgac uucucucugg agc 23

 <210> 2491
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2491
 ucuuccucga cuucucucug gag 23

 <210> 2492
 <211> 23
 <212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2492

uucuuccug acuucucu gga

23

<210> 2493

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2493

ucucucuucc ucgacuuc ucu

23

<210> 2494

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2494

uucucucuuc cugacuuc cuc

23

<210> 2495

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2495

uucucucu uccugacuu cuc

23

<210> 2496

<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2496
uccaaaagca ggucacucac uuu 23

<210> 2497
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2497
uaaaaguuuc agugcgacgc cgc 23

<210> 2498
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2498
uacgaaaagu uucagugcga cgc 23

<210> 2499
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2499
ugacgaaaag uuucagugcg acg 23

<210> 2500
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2500
uuuggacgaa aaguucagu gcg 23

<210> 2501
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2501
uguuggacga aaaguucag ugc 23

<210> 2502
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2502
uaaguuggac gaaaaguuc agu 23

<210> 2503
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2503

ucagaaguug gacgaaaagu uuc 23

<210> 2504
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 2504
 uccgaagcga gaacagccca gaa 23

<210> 2505
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 2505
 uuccgaagcg agaacagccc aga 23

<210> 2506
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 2506
 ucuccgaagc gagaacagcc cag 23

<210> 2507
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 2507
uuccuccgaa gcgagaacag ccc 23

<210> 2508
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2508
ugagcuagca cuucucgcgg cuc 23

<210> 2509
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2509
ucgagcuagc acuucucgcg gcu 23

<210> 2510
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2510
uaaguucaug guuucggagg ccc 23

<210> 2511
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2511
uaugauucug cccuccuccu ucu 23

<210> 2512
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2512
ucacuucgug augauucugc ccu 23

<210> 2513
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2513
uuucaccacu ucgugaugau ucu 23

<210> 2514
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2514
ucuucaccac uucgugauga uuc 23

<210> 2515
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2515
 uacuucacca cuucgugaug auu 23

 <210> 2516
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2516
 uaacuucacc acuucgugau gau 23

 <210> 2517
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2517
 uugaacuuca ccacuucgug aug 23

 <210> 2518
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2518
 uauccaugaa cuucaccacu ucg 23

 <210> 2519
 <211> 23
 <212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2519

ucauccauga acuucaccac uuc

23

<210> 2520

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2520

uacauccaug aacuucacca cuu

23

<210> 2521

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2521

uagacaucca ugaacuucac cac

23

<210> 2522

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2522

uuagacaucc augaacuca cca

23

<210> 2523

<211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2523
 uauagacauc caugaacuuc acc 23

<210> 2524
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2524
 uugauagaca uccaugaacu uca 23

<210> 2525
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2525
 ucugauagac auccaugaac uuc 23

<210> 2526
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2526
 ucgcugauag acauccauga acu 23

<210> 2527
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2527
uuacuccugg aagaugucca cca

23

<210> 2528
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2528
uuggcuugaa gauguacucg auc

23

<210> 2529
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2529
uauggcuuga agaaguacuc gau

23

<210> 2530
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2530

ugauggcuug aagauguacu cga 23

<210> 2531
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2531
uaggauggcu ugaagauga cuc 23

<210> 2532
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2532
uaaucugcau ggugauguug gac 23

<210> 2533
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2533
uaaaucugca uggugauguu gga 23

<210> 2534
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2534
ucauaaucug cauggugaug uug 23

<210> 2535
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2535
ugcauaaucu gcauggugau guu 23

<210> 2536
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2536
uauccgcaua aucugcaugg uga 23

<210> 2537
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2537
uuugaucgc auaaucugca ugg 23

<210> 2538
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2538
uuuugauccg cauaaucugc aug 23

<210> 2539
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2539
uguuugaucc gcauaaucug cau 23

<210> 2540
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2540
ugagguuuga uccgcauaau cug 23

<210> 2541
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2541
uugagguuug auccgcauaa ucu 23

<210> 2542
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2542
 uccuugguga gguuugaucc gca 23

 <210> 2543
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2543
 uuguaggaag cucaucucuc cua 23

 <210> 2544
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2544
 uugcuguagg aagcucaucu cuc 23

 <210> 2545
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2545
 uugugcugua ggaagcucau cuc 23

 <210> 2546
 <211> 23
 <212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2546

uuugugcugu aggaagcuca ucu

23

<210> 2547

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2547

uuguugucu guaggaagcu cau

23

<210> 2548

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2548

uuuguugugc uguaggaagc uca

23

<210> 2549

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2549

uuuuguugug cuguaggaag cuc

23

<210> 2550

<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2550
uauuuguugu gcuguaggaa gcu 23

<210> 2551
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2551
uacauuuguu gugcuguagg aag 23

<210> 2552
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2552
uucacauuug uugugcugua gga 23

<210> 2553
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2553
uuucacauuu guugugcugu agg 23

<210> 2554
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2554
ugcauacaca uuuguugugc ugu 23

<210> 2555
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2555
uugcauacac auuuguugug cug 23

<210> 2556
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2556
uuaucaagucu uuccugguga gag 23

<210> 2557
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2557

uguaucaguc uuuccuggug aga <210> 2558 <211> 23 <212> RNA <213> Artificial Sequence <220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide" <400> 2558 uuuguacagu cuuuccuggu gag	23 23
<210> 2559 <211> 23 <212> RNA <213> Artificial Sequence <220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide" <400> 2559 ucuguacag ucuuuccugg uga	23 23
<210> 2560 <211> 23 <212> RNA <213> Artificial Sequence <220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide" <400> 2560 uucuguauca gucuuuccug gug	23 23
<210> 2561 <211> 23 <212> RNA <213> Artificial Sequence <220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	

<400> 2561
uuucuguauc agucuuuccu ggu 23

<210> 2562
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2562
uguucuguau cagucuuucc ugg 23

<210> 2563
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2563
ucguucugua ucagucuuuc cug 23

<210> 2564
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2564
uucguucugu aucagucuuu ccu 23

<210> 2565
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2565

uaucguucg uaucagucuu ucc

23

<210> 2566

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2566

ugaucguucu gaucagucu uuc

23

<210> 2567

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2567

ucgaucguuc ugaucaguc uuu

23

<210> 2568

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2568

uucgaucguu cugaucagu cuu

23

<210> 2569

<211> 23

<212> RNA

<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2569
uau~~c~~gaucgu ucuguaucag ucu 23

<210> 2570
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2570
uuau~~c~~gaucg uucuguauc~~a~~ guc 23

<210> 2571
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2571
uguau~~c~~gauc guucuguauc agu 23

<210> 2572
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2572
uuguau~~c~~gau cguucuguau cag 23

<210> 2573
<211> 23
<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2573

ucuguau~~cga~~ ucguucugua uca

23

<210> 2574

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2574

uucuguau~~cga~~ aucguucugu auc

23

<210> 2575

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2575

uuucuguau~~c~~ gaucguucug uau

23

<210> 2576

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2576

uuuucuguau~~c~~ cgaucguucu gua

23

<210> 2577

<211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2577
 uguuucugua ucgaucguuc ugu 23

<210> 2578
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2578
 ugguuucugu aucgaucguu cug 23

<210> 2579
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2579
 uugguuucug uaucgaucgu ucu 23

<210> 2580
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2580
 ugugguuucu guaucgaucg uuc 23

<210> 2581
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2581
ucgugguuuc uguaucgauc guu 23

<210> 2582
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2582
uuucugucga uggugauggu gug 23

<210> 2583
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2583
ucuguucugu cgauggugau ggu 23

<210> 2584
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2584

ugacuguucu gucgauaggug aug 23

<210> 2585
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2585
uggacuguuc ugucgauggu gau 23

<210> 2586
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2586
uaggacuguu cugucgaugg uga 23

<210> 2587
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2587
uaaggacugu ucugucgaug gug 23

<210> 2588
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2588
uuaaggacug uucugucgau ggu 23

<210> 2589
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2589
uuuaaggacu guucugucga ugg 23

<210> 2590
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2590
uauuaaggac uguucugucg aug 23

<210> 2591
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2591
ugauuaagga cuguucuguc gau 23

<210> 2592
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2592

uggauuaagg acuguucugu cga

23

<210> 2593

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2593

uuggauuaag gacuguucug ucg

23

<210> 2594

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2594

uucuggauua aggacuguuc ugu

23

<210> 2595

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2595

uuucuggauu aaggacuguu cug

23

<210> 2596

<211> 23

<212> RNA

<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 2596
 uuuucuggau uaaggacugu ucu 23

<210> 2597
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 2597
 uguuucugga uuaaggacug uuc 23

<210> 2598
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 2598
 ugguuucugg auuaaggacu guu 23

<210> 2599
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 2599
 uagguuucug gauuaaggac ugu 23

<210> 2600
 <211> 23
 <212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2600

ucagguuucu ggauuaagga cug

23

<210> 2601

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2601

uucagguuuc uggauuaagg acu

23

<210> 2602

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2602

uuucagguuu cuggauuaag gac

23

<210> 2603

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2603

uuuucagguu ucuggauuaa gga

23

<210> 2604

<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2604
uauuucaggu uucuggauua agg 23

<210> 2605
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2605
uuccuucuu ucagguuucu gga 23

<210> 2606
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2606
uuuccuucuu uucagguuuc ugg 23

<210> 2607
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2607
ucuuccuucuu uuucagguuu cug 23

<210> 2608
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2608
uucuuccuuc auuucaggu ucu 23

<210> 2609
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2609
ucucuuccuu cauucaggu uuc 23

<210> 2610
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2610
uuccucuucc uucauuucag guu 23

<210> 2611
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2611

uagagucucc ucuuccuuca uuu 23

<210> 2612
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2612
ugaauccaau uccaagaggg acc 23

<210> 2613
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2613
ugcgaaucca auuccaagag gga 23

<210> 2614
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2614
uggcgaaucc aauccaaga ggg 23

<210> 2615
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2615
uaauggcgaa uccaauucca aga 23

<210> 2616
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2616
uaaauggcga auccaauucc aag 23

<210> 2617
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2617
uaaaauggcg aauccaaauuc caa 23

<210> 2618
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2618
uuaaaauggc gaauccaaau cca 23

<210> 2619
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2619

uauaaaaugg cgaauccaau ucc

23

<210> 2620

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2620

uaauaaaaug gcgaauccaa uuc

23

<210> 2621

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2621

uaauaaaaau ggcgaaucca auu

23

<210> 2622

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2622

uaaaauaaaa uggcgaucc aa

23

<210> 2623

<211> 23

<212> RNA

<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2623
 uaaaaauaaa auggcgauc caa 23

 <210> 2624
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2624
 ugaaaaauaa aauggcgaau cca 23

 <210> 2625
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2625
 ucaagaaaaa uaaaauaggcg aaau 23

 <210> 2626
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2626
 ugcaagaaaa auaaaauaggc gaa 23

 <210> 2627
 <211> 23
 <212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2627

uagcaagaaa aauaaaaugg cga

23

<210> 2628

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2628

ucagcaagaa aaauaaaug gcg

23

<210> 2629

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2629

ugcagcaaga aaaauaaaau ggc

23

<210> 2630

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2630

uagcagcaag aaaaauaaaa ugg

23

<210> 2631

<211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2631
 uuagcagcaa gaaaauaaa aug 23

<210> 2632
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2632
 uggugauuua gcagcaagaa aaa 23

<210> 2633
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2633
 uuaaucuucc gggcucggug auu 23

<210> 2634
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2634
 uaacucucua aucuuccggg cuc 23

<210> 2635
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2635
uaaacucucu aaucuuccgg gcu

23

<210> 2636
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2636
uuaaaacucu cuaaucuucc ggg

23

<210> 2637
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2637
uauaaaacuc ucuaaucuuc cgg

23

<210> 2638
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2638

uaauaaaacu cucuaaucuu ccg 23

<210> 2639
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 2639
 uaaauaaaac ucucuaaucu ucc 23

<210> 2640
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 2640
 ugaaauaaaa cucucuaauc uuc 23

<210> 2641
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 2641
 ucagaaauaa aacucucuaa ucu 23

<210> 2642
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 2642
uccagaaaua aaacucucua auc 23

<210> 2643
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2643
ucccagaaau aaaacucucu aau 23

<210> 2644
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2644
uucccagaaa uaaaacucuc uaa 23

<210> 2645
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2645
uaucccagaa auaaaacucu cua 23

<210> 2646
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2646

uauuuccaga aaauaaacuc ucu

23

<210> 2647

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2647

ugaauccag aaauaaacu cuc

23

<210> 2648

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2648

uggauccca gaaauaaac ucu

23

<210> 2649

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2649

uaggauccc agaaauaaaa cuc

23

<210> 2650

<211> 23

<212> RNA

<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2650
ucaggaaucc cagaaauaaa acu 23

<210> 2651
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2651
uacaggauc ccagaaauaa aac 23

<210> 2652
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2652
uuacaggaau cccagaaaua aaa 23

<210> 2653
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2653
ucuacaggaa ucccagaaau aaa 23

<210> 2654
<211> 23
<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2654

uucuacagga auccagaaa uaa

23

<210> 2655

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2655

ugucuacagg aauccagaa aua

23

<210> 2656

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2656

ugugucuaca ggaauccag aaa

23

<210> 2657

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2657

uugugucuac aggaauccca gaa

23

<210> 2658

<211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2658
 ugugugucua caggaaucac aga 23

<210> 2659
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2659
 uggugugucu acaggaaucac cag 23

<210> 2660
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2660
 uauguaugug ggugggugug ucu 23

<210> 2661
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2661
 uauguaugua uguggguggg ugu 23

<210> 2662
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2662
uauuguaugu augugggugg gug 23

<210> 2663
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2663
uaauugaug uaugugggug ggu 23

<210> 2664
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2664
uuauauguau guaugugggu ggg 23

<210> 2665
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2665

uauauaaaug uauguaugug ggu

23

<210> 2666
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2666
uuauauaaaau guauguaugu ggg

23

<210> 2667
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2667
ucauuagcac uguuaauuuu aaa

23

<210> 2668
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2668
uacauuagca cuguuaauuu aaa

23

<210> 2669
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2669
uaacauuagc acuguaauu uaa 23

<210> 2670
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2670
uuaacauuag cacuguaau uua 23

<210> 2671
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2671
uauaacauua gcacuguuaa uuu 23

<210> 2672
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2672
uaauaacauu agcacuguua auu 23

<210> 2673
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2673
ucaauaacau uagcacuguu aaau
23

<210> 2674
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2674
uccaauaaca uuagcacugu uaa
23

<210> 2675
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2675
uaccaauaac auuagcacug uua
23

<210> 2676
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2676
ucaccauaa cauuagcacu guu
23

<210> 2677
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 2677
 ugacaccaau aacauuagca cug 23

<210> 2678
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 2678
 uagacaccaa uaacauuagc acu 23

<210> 2679
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 2679
 uaagacacca auaacauuag cac 23

<210> 2680
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 2680
 ugaagacacc aaauacauua gca 23

<210> 2681
 <211> 23
 <212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2681

uugaagacac caauaacaau agc

23

<210> 2682

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2682

ugugaagaca ccauaacau uag

23

<210> 2683

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2683

uagugaagac accaauaaca uua

23

<210> 2684

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2684

ucagugaaga caccauaac auu

23

<210> 2685

<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2685
uccagugaag acaccaaua cau 23

<210> 2686
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2686
uuccagugaa gacaccaua aca 23

<210> 2687
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2687
uuacauccag ugaagacacc aa 23

<210> 2688
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2688
uaaaaucauc cagugaagac acc 23

<210> 2689
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2689
ugcagucaaa uacauccagu gaa 23

<210> 2690
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2690
uagcagucaa auacauccag uga 23

<210> 2691
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2691
uacagcaguc aaauacauc agu 23

<210> 2692
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2692

uaaguccaca gcagucaaaau aca 23

<210> 2693
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2693
uucaagucca cagcagucaa aua 23

<210> 2694
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2694
uucccaacuc aaguccacag cag 23

<210> 2695
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2695
ucugucagga ucugaguggg aac 23

<210> 2696
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2696
uccugucagg aucugagugg gaa 23

<210> 2697
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2697
ucagagucuc ucauccucuc cuc 23

<210> 2698
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2698
uccagagucu cucauccu ccu 23

<210> 2699
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2699
uugccagagu cucucaucuc cuc 23

<210> 2700
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2700

uaaagaucau gccagagucu cuc

23

<210> 2701

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2701

uaaaagauca ugccagaguc ucu

23

<210> 2702

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2702

uguuugucgg uguucccaaa acu

23

<210> 2703

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2703

uacagcaaug uccugaagcu ccc

23

<210> 2704

<211> 23

<212> RNA

<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2704
ugcacagcaa uguccugaag cuc 23

<210> 2705
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2705
uagcacagca auguccugaa gcu 23

<210> 2706
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2706
uaagcacagc aauguccuga agc 23

<210> 2707
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2707
uaaagcacag caauguccug aag 23

<210> 2708
<211> 23
<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2708

ucaaagcaca gcaauguccu gaa

23

<210> 2709

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2709

ugaagcaggu gagaguaagc gaa

23

<210> 2710

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2710

uagaagcagg ugagaguaag cga

23

<210> 2711

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2711

uucagaagca ggugagagua agc

23

<210> 2712

<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2712
uaacucagaa gcaggugaga gua 23

<210> 2713
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2713
ucaacucaga agcaggugag agu 23

<210> 2714
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2714
ugcaacucag aagcagguga gag 23

<210> 2715
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2715
uggcaacuca gaagcaggug aga 23

<210> 2716
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2716
ugggcaacuc agaagcaggu gag 23

<210> 2717
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2717
uugggcaacu cagaagcagg uga 23

<210> 2718
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2718
ucugggcaac ucagaagcag gug 23

<210> 2719
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2719

uugugucucu ucucuucgcc ggg

23

<210> 2720
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2720
uauugugucuc uucucuucgc cgg

23

<210> 2721
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2721
uaaugugucu cuucucuucg ccg

23

<210> 2722
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2722
ucaauguguc ucuucucuuc gcc

23

<210> 2723
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2723
uacaaugugu cucuucucuu cgc 23

<210> 2724
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2724
uaacaaugug ucucuucucu ucg 23

<210> 2725
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2725
ucaacaaugu gucucuucuc uuc 23

<210> 2726
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2726
uccaacaaug ugucucuucu cuu 23

<210> 2727
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2727

uuccaacaau gugucucuuc ucu

23

<210> 2728

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2728

uuuccaaca ugugucucu cuc

23

<210> 2729

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2729

ucuuccaaca augugucucu ucu

23

<210> 2730

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2730

uucuuccaac aaugugucuc uuc

23

<210> 2731

<211> 23

<212> RNA

<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2731
 uuucuuccaa caaugugucu cuu 23

 <210> 2732
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2732
 ucuucuucca acaauguguc ucu 23

 <210> 2733
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2733
 ugcucuucc aacaugugu cuc 23

 <210> 2734
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2734
 uugcuucuc caacaugug ucu 23

 <210> 2735
 <211> 23
 <212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2735

ucugcuucuu ccaacaugu guc

23

<210> 2736

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2736

uuucaauggu gugaggacau agg

23

<210> 2737

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2737

uugguuucaa uggugugagg aca

23

<210> 2738

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2738

uguguuuca auggugugag gac

23

<210> 2739

<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2739
uagugguuuc aaugguguga gga 23

<210> 2740
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2740
uuagugguuu caauggugug agg 23

<210> 2741
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2741
ucuagugguu ucaauggugu gag 23

<210> 2742
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2742
uagaacuagu gguucaaug gug 23

<210> 2743
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2743
ucagaacuag ugguucaaau ggu 23

<210> 2744
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2744
uacagaacua gugguucaa ugg 23

<210> 2745
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2745
ugacagaacu agugguucaa aug 23

<210> 2746
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2746

uggacagaac uagugguuuc aaau 23

<210> 2747
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 2747
 ucacacacac acaaccaggu cuc 23

<210> 2748
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 2748
 uucacacaca cacaaccagg ucu 23

<210> 2749
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 2749
 ucucacacac acacaaccag guc 23

<210> 2750
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 2750
uacucacaca cacacaacca ggu 23

<210> 2751
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2751
ucacucacac acacacaacc agg 23

<210> 2752
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2752
uccacucaca cacacacaac cag 23

<210> 2753
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2753
uucaaccacu cacacacaca caa 23

<210> 2754
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2754

ugucaaccac ucacacacac aca

23

<210> 2755

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2755

uaggucaacc acucacacac aca

23

<210> 2756

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2756

ugaaggucaa ccacucacac aca

23

<210> 2757

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2757

uggaagguca accacucaca cac

23

<210> 2758

<211> 23

<212> RNA

<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2758
 uaggaagguc aaccacucac aca 23

 <210> 2759
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2759
 uggaggaagg ucaaccacuc aca 23

 <210> 2760
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2760
 ugauggagga aggucaacca cuc 23

 <210> 2761
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2761
 uucuuuucuc ugccuccaca aug 23

 <210> 2762
 <211> 23
 <212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2762

ucucuuuuucu cugccuccac aa

23

<210> 2763

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2763

uucucuuuuuc ucugccucca ca

23

<210> 2764

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2764

uuucucuuuuu cucugccucc aca

23

<210> 2765

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2765

uuuucucuuu ucucugccuc cac

23

<210> 2766

<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2766
ucuuucucu uucucugccu cca 23

<210> 2767
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2767
uacuuucucu uuucucugcc ucc 23

<210> 2768
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2768
ucacuuucuc uuucucugc cuc 23

<210> 2769
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2769
uacacuuucu cuuucucug ccu 23

<210> 2770
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2770
uaacacuuuc uuuuuucucu gcc 23

<210> 2771
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2771
uaaacacuuu cuuuuuucuc ugc 23

<210> 2772
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2772
uaaaacacuu ucucuuuuucu cug 23

<210> 2773
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2773

uuaaaaacacu uucucuuuuc ucu 23

<210> 2774
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 2774
 uuaaaaacac uuucucuuuu cuc 23

<210> 2775
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 2775
 uuauaaaaca cuuucucuuu ucu 23

<210> 2776
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 2776
 uuauauaaaac acuuucucuu uuc 23

<210> 2777
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 2777
uuauauaaaa cacuuucucu uuu 23

<210> 2778
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2778
uguauauaaa acacuuucuc uuu 23

<210> 2779
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2779
ucguauauaa aacacuuucu cuu 23

<210> 2780
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2780
uccguauaua aaacacuuuc ucu 23

<210> 2781
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2781

uuaccguaua uaaaacacuu ucu

23

<210> 2782

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2782

uguaccguau auaaaacacu uuc

23

<210> 2783

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2783

uaguaccgua uauaaaacac uuu

23

<210> 2784

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2784

uaaguaccgu auauaaaaca cuu

23

<210> 2785

<211> 23

<212> RNA

<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 2785
 uuaaguaccg uauauaaaac acu 23

<210> 2786
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 2786
 uauaaguacc guauauaaaa cac 23

<210> 2787
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 2787
 uaauaaguac cguauauaaa aca 23

<210> 2788
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 2788
 uaaauaagua ccguauauaa aac 23

<210> 2789
 <211> 23
 <212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2789

uuaaaauaagu accguauaua aaa

23

<210> 2790

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2790

uuuaaaauaag uaccguauau aaa

23

<210> 2791

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2791

uaagggauau uaaaauaagua ccg

23

<210> 2792

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2792

uaaagggaua uuaaaauaagu acc

23

<210> 2793

<211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2793
 ugcaaaagau acaucucuaa aaau
 23

<210> 2794
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2794
 uagcaaaaga uacaucucuu aaa
 23

<210> 2795
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2795
 ugagcaaaag auacaucua uaa
 23

<210> 2796
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2796
 uagagcaaaa gauacaucuc aua
 23

<210> 2797
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2797
ugagagcaaa agauacau cu 23

<210> 2798
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2798
uagagagcaa aagauacau uca 23

<210> 2799
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2799
ugagagagca aaagauacau cuc 23

<210> 2800
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2800

uagagagagc aaaagauaca ucu 23

<210> 2801
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 2801
 uauaagagag caagagagag caa 23

<210> 2802
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 2802
 uaauaagaga gcaagagaga gca 23

<210> 2803
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 2803
 uaaauaagag agcaagagag agc 23

<210> 2804
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 2804
ucaaauaaga gagcaagaga gag 23

<210> 2805
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2805
uacaaauaag agagcaagag aga 23

<210> 2806
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2806
uuacaaauaa gagagcaaga gag 23

<210> 2807
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2807
uguacaaaua agagagcaag aga 23

<210> 2808
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2808

ugguacaaau aagagagcaa gag

23

<210> 2809

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2809

ucgguacaaa uaagagagca aga

23

<210> 2810

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2810

uccgguacaa auaagagagc aag

23

<210> 2811

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2811

uaaccgguac aaauaagaga gca

23

<210> 2812

<211> 23

<212> RNA

<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 2812
 uaaaccggua caaauaagag agc 23

<210> 2813
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 2813
 uaaaaccggu acaauaaga gag 23

<210> 2814
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 2814
 uaaaaaccgg uacaaauaag aga 23

<210> 2815
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 2815
 ucaaaaaccg guacaaauaa gag 23

<210> 2816
 <211> 23
 <212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2816

uacaaaaacc gguacaaaua aga

23

<210> 2817

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2817

uuacaaaaac cgguacaaau aag

23

<210> 2818

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2818

uauacaaaaa ccgguacaaa uaa

23

<210> 2819

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2819

uuauacaaaa accgguacaa aua

23

<210> 2820

<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2820
uauauacaaa aaccgguaca aau 23

<210> 2821
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2821
uuauauacaa aaaccgguac aaa 23

<210> 2822
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2822
uuuauauaca aaaaccgguac caa 23

<210> 2823
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2823
uuuuauauac aaaaaccggu aca 23

<210> 2824
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2824
uuuuuauaua caaaaaccgg uac

23

<210> 2825
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2825
ugagagauug gaaacaugaa uuu

23

<210> 2826
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2826
uagagagauu ggaaacauga auu

23

<210> 2827
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2827

ugagagagau uggaaacaug aaU 23

<210> 2828
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2828
uagagagaga uggaaacau gaa 23

<210> 2829
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2829
ugagagagag auuggaaaca uga 23

<210> 2830
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2830
uggagagaga gauuggaaac aug 23

<210> 2831
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2831
uagggagaga gagauuggaa aca 23

<210> 2832
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2832
uucagggaga gagagauugg aaa 23

<210> 2833
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2833
uuaagcuagu gacugucacc gau 23

<210> 2834
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2834
uauaagcuag ugacugucac cga 23

<210> 2835
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2835

uuucaagaua agcuagugac ugu

23

<210> 2836

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2836

uguucaagau aagcuaguga cug

23

<210> 2837

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2837

uuguucaaga uaagcuagug acu

23

<210> 2838

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2838

uucuguucaa gauaagcuag uga

23

<210> 2839

<211> 23

<212> RNA

<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2839
 uaucuguuca agauaagcua gug 23

 <210> 2840
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2840
 uuaucuguuc aagauaagcu agu 23

 <210> 2841
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2841
 uauaucuguu caagauaagc uag 23

 <210> 2842
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2842
 uaauaucugu ucaagauaag cua 23

 <210> 2843
 <211> 23
 <212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2843

uuuucaaagg aaugugugcu ggg

23

<210> 2844

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2844

uauuucaaag gaaugugugc ugg

23

<210> 2845

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2845

uuauuucaaa ggaaugugug cug

23

<210> 2846

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2846

uuuauuucaa aggaugugu gcu

23

<210> 2847

<211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2847
 uccuuauuuc aaaggaaugu gug 23

<210> 2848
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2848
 uugaaaccuu auuucaaagg aa 23

<210> 2849
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2849
 uauugaaacc uuauuucaaa gga 23

<210> 2850
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2850
 uuauugaaac cuuauuucaa agg 23

<210> 2851
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2851
uguagaugua uauugaaacc uua 23

<210> 2852
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2852
uuguagaugu auauugaaac cuu 23

<210> 2853
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2853
uanguaug uauauugaaa ccu 23

<210> 2854
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2854

uuauuguagau guauauugaa acc 23

<210> 2855
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 2855
 uguauuguaga uguauauuga aac 23

<210> 2856
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 2856
 ucaaaauacaa guugccaaau aua 23

<210> 2857
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 2857
 ucacaaauac aaguugccaa aua 23

<210> 2858
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 2858
ucacacaaau acaaguugcc aaa 23

<210> 2859
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2859
uacacacaaa uacaaguugc caa 23

<210> 2860
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2860
uuacacacaa auacaaguug cca 23

<210> 2861
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2861
uauacacaca aaauacaaguu gcc 23

<210> 2862
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2862

uuauacacac aaauacaagu ugc

23

<210> 2863

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2863

uauauacaca caauacaag uug

23

<210> 2864

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2864

ucaaugucua uuuuaucauga auc

23

<210> 2865

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2865

uuagcaugu cuuuuuuaucau aga

23

<210> 2866

<211> 23

<212> RNA

<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2866
 uauagcaaug ucuauuuuau cag 23

 <210> 2867
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2867
 ugaauagcaa ugucuauuuu auc 23

 <210> 2868
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2868
 uaaacagaau agcaaugucu auu 23

 <210> 2869
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2869
 uaaaacagaa uagcaauguc uau 23

 <210> 2870
 <211> 23
 <212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2870

uagagagauu uaguauguag aa

23

<210> 2871

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2871

ugagagagau uuaguaugua ga

23

<210> 2872

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2872

uggagagaga uuuaguaugu aga

23

<210> 2873

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2873

uaggagagag auuuaguaug uag

23

<210> 2874

<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2874
uaaggagaga gauuuaguau gua 23

<210> 2875
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2875
uaaaggagag agauuuagua ugu 23

<210> 2876
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2876
uaaaaggaga gagauuuagu aug 23

<210> 2877
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2877
uguagcacca auaaaauaaau gau 23

<210> 2878
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2878
uaguagcacc aaauaaauaaa uga 23

<210> 2879
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2879
ucaguagcac caauaaauaa aug 23

<210> 2880
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2880
uacaguagca ccaauaaaua aaau 23

<210> 2881
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2881

uaacaguagc accaauaaa aaa

23

<210> 2882
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2882
uaaacaguag caccauaaa uaa

23

<210> 2883
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2883
uauaaacagu agcaccaua aa

23

<210> 2884
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2884
uggauaaaca guagaccaa uaa

23

<210> 2885
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2885
ucgugauguu aaauaucuuuu ccc 23

<210> 2886
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2886
uagagacaaa gacgugaugu uaa 23

<210> 2887
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2887
uuagagacaa agacgugaug uua 23

<210> 2888
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2888
uacugcacua gagacaaaga cgu 23

<210> 2889
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2889

uaacugcacu agagacaaag acg

23

<210> 2890

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2890

uaaacugcac uagagacaaa gac

23

<210> 2891

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2891

uuauuguacua cggaauaucu cga

23

<210> 2892

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2892

uuauuguacu acggaauauc ucg

23

<210> 2893

<211> 23

<212> RNA

<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2893
 uaauauguac uacggaauau cuc 23

 <210> 2894
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2894
 uauaucugua uuucuuuguc guu 23

 <210> 2895
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2895
 uuauaucugu auuucuuugu cgu 23

 <210> 2896
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2896
 uauauaucug uauuucuuug ucg 23

 <210> 2897
 <211> 23
 <212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2897

ugauauaucu guauuucuuu guc

23

<210> 2898

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2898

cggugcugga auuugauauu a

21

<210> 2899

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2899

ggugcuggaa uuugauauuc a

21

<210> 2900

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2900

ugcuggaauu ugauauucau a

21

<210> 2901

<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2901
gcuggaauuu gauauucauu a 21

<210> 2902
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2902
uggaauuuga uauucauuga a 21

<210> 2903
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2903
ggaauuugau auucauugau a 21

<210> 2904
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2904
gaauuugaua uucauugauc a 21

<210> 2905
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2905
aaauugauau ucauugaucc a 21

<210> 2906
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2906
auuugauauu cauugaucg a 21

<210> 2907
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2907
uuugauauuc auugaucgg a 21

<210> 2908
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2908

uuuauuuuuug cuugccauuc a 21

<210> 2909
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2909
uuauuuuuugc uugccauucc a 21

<210> 2910
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2910
caaaucaugc uggauuuugg a 21

<210> 2911
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2911
aaaucaugu ggauuuugga a 21

<210> 2912
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2912
aaucacugug gauuuuggaa a 21

<210> 2913
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2913
aucacugugg auuuuggaaa a 21

<210> 2914
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2914
ucacugugga uuuuuggaaac a 21

<210> 2915
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2915
cacuguggau uuuggaaacc a 21

<210> 2916
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2916

acuguggauu uuggaaacca a

21

<210> 2917

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2917

cuguggauuu uggaaaccag a

21

<210> 2918

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2918

uguggauuuu ggaaaccagc a

21

<210> 2919

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2919

guggauuuug gaaaccagca a

21

<210> 2920

<211> 21

<212> RNA

<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2920
gauuuuggaa accagcagaa a 21

<210> 2921
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2921
auuuuggaaa ccagcagaaa a 21

<210> 2922
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2922
uuuuggaaac cagcagaaag a 21

<210> 2923
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2923
uuuggaaacc agcagaaaga a 21

<210> 2924
<211> 21
<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2924

ggaaaccagc agaaagagga a

21

<210> 2925

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2925

aaaccagcag aaagaggaaa a

21

<210> 2926

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2926

aaccagcaga aagaggaaag a

21

<210> 2927

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2927

accagcagaa agaggaaaga a

21

<210> 2928

<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2928
ccagcagaaa gaggaaagag a 21

<210> 2929
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2929
cagcagaaag aggaaagagg a 21

<210> 2930
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2930
agcagaaaga ggaaagaggu a 21

<210> 2931
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2931
gcagaaagag gaaagaggua a 21

<210> 2932
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2932
cagaaagagg aaagagguag a 21

<210> 2933
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2933
aaagaggaaa gagguagcaa a 21

<210> 2934
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2934
aagaggaaag agguagcaag a 21

<210> 2935
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2935

agaggaaaga gguagcaaga a 21

<210> 2936
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2936
gaggaaagag guagcaagag a 21

<210> 2937
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2937
ggaaagaggu agcaagagcu a 21

<210> 2938
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2938
agguagcaag agcuccagag a 21

<210> 2939
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2939
uccagagaga agucgaggaa a 21

<210> 2940
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2940
ccagagagaa gucgaggaag a 21

<210> 2941
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2941
cagagagaag ucgaggaaga a 21

<210> 2942
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2942
agagaagucg aggaagagag a 21

<210> 2943
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2943

gagaagucga ggaagagaga a

21

<210> 2944

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2944

gaagucgagg aagagagaga a

21

<210> 2945

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2945

agugagugac cugcuuuugg a

21

<210> 2946

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2946

ggcgucgcac ugaaacuuuu a

21

<210> 2947

<211> 21

<212> RNA

<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2947
 gucgcacuga aacuuuucgu a 21

<210> 2948
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2948
 ucgcacugaa acuuuucguc a 21

<210> 2949
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2949
 cacugaaacu uuucguccaa a 21

<210> 2950
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2950
 acugaaacuu uucguccaac a 21

<210> 2951
 <211> 21
 <212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2951

ugaaacuuuu cguccaacuu a

21

<210> 2952

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2952

aacuuuucgu ccaacuucug a

21

<210> 2953

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2953

cugggcuguu cucgcuucgg a

21

<210> 2954

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2954

ugggcuguuc ucgcuucgga a

21

<210> 2955

<211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2955
 gggcuguucu cgcuucggag a 21

<210> 2956
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2956
 gcuguucucg cuucggagga a 21

<210> 2957
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2957
 gccgcgagaa gugcuagcuc a 21

<210> 2958
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2958
 ccgcgagaag ugcuaagcucg a 21

<210> 2959
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2959
gccuccgaaa ccaugaacuu a 21

<210> 2960
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2960
aaggaggagg gcagaaucau a 21

<210> 2961
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2961
ggcagaauca ucacgaagug a 21

<210> 2962
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2962

aaucaucacg aaguggugaa a 21

<210> 2963
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2963
aucaucacga aguggugaag a 21

<210> 2964
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2964
ucaucacgaa guggugaagu a 21

<210> 2965
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2965
caucacgaag uggugaaguu a 21

<210> 2966
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2966
ucacgaagug gugaaguca a 21

<210> 2967
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2967
aaguggugaa guucauggau a 21

<210> 2968
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2968
aguggugaag uucauggaug a 21

<210> 2969
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2969
guggugaagu ucauggaugu a 21

<210> 2970
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2970

ggugaaguuc auggaugucu a

21

<210> 2971

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2971

gugaaguuca uggaugucua a

21

<210> 2972

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2972

ugaaguucan ggaugucuan a

21

<210> 2973

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2973

aagucaugg augucuaucan a

21

<210> 2974

<211> 21

<212> RNA

<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2974
 aguucaugga ugucuaucag a 21

<210> 2975
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2975
 uucauggaug ucuaucagcg a 21

<210> 2976
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2976
 guggacau cuccaggagua a 21

<210> 2977
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 2977
 ucgaguacau cuucaagcca a 21

<210> 2978
 <211> 21
 <212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2978

cgaguacauc uucaagccau a

21

<210> 2979

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2979

gaguacaucu ucaagccauc a

21

<210> 2980

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2980

guacaucuuc aagccauccu a

21

<210> 2981

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2981

ccaacaucac caugcagauu a

21

<210> 2982

<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2982
caacaucacc augcagauua a 21

<210> 2983
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2983
acaucaccau gcagauuaug a 21

<210> 2984
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2984
caucaccaug cagauuaugc a 21

<210> 2985
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2985
accaugcaga uuaugcggau a 21

<210> 2986
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2986
augcagauua ugcggauc aa 21

<210> 2987
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2987
ugcagauuau gcggaucaaa a 21

<210> 2988
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2988
gcagauuaug cggauc aaac a 21

<210> 2989
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2989

gauuauugcgg aucaaaccuc a 21

<210> 2990
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2990
auuauugcggg ucaaaccuca a 21

<210> 2991
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2991
cggaucacac cucaccaagg a 21

<210> 2992
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2992
ggagagauga gcuuccuaca a 21

<210> 2993
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2993
gagaugagcu uccuacagca a 21

<210> 2994
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2994
gaugagcuuc cuacagcaca a 21

<210> 2995
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2995
augagcuucc uacagcacao a 21

<210> 2996
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2996
gagcuuccua cagcacaaca a 21

<210> 2997
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2997

agcuuccuac agcacaacaa a

21

<210> 2998

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2998

gcuuccuaca gcacaacaaa a

21

<210> 2999

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 2999

cuuccuacag cacaacaaau a

21

<210> 3000

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3000

uccuacagca caacaaaugu a

21

<210> 3001

<211> 21

<212> RNA

<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3001
cuacagcaca acaaauguga a 21

<210> 3002
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3002
uacagcaca caaaugugaa a 21

<210> 3003
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3003
agcacaacaa augugaaugc a 21

<210> 3004
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3004
gcacaacaaa ugugaaugca a 21

<210> 3005
<211> 21
<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3005

cucaccagga aagacugaua a

21

<210> 3006

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3006

ucaccaggaa agacugauac a

21

<210> 3007

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3007

caccaggaaa gacugauaca a

21

<210> 3008

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3008

accaggaaag acugauacag a

21

<210> 3009

<211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3009
 ccaggaaaga cugauacaga a 21

<210> 3010
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3010
 caggaaagac ugauacagaa a 21

<210> 3011
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3011
 aggaaagacu gauacagaac a 21

<210> 3012
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3012
 ggaaagacug auacagaacg a 21

<210> 3013
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3013
gaaagacuga uacagaacga a 21

<210> 3014
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3014
aaagacugau acagaacgau a 21

<210> 3015
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3015
aagacugaua cagaacgauc a 21

<210> 3016
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3016

agacugauac agaacgaucg a 21

<210> 3017
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3017
gacugauaca gaacgaucga a 21

<210> 3018
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3018
acugauacag aacgaucgau a 21

<210> 3019
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3019
cugauacaga acgaucgaua a 21

<210> 3020
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3020
ugauacagaa cgaucgauac a 21

<210> 3021
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3021
gauacagaac gaucgauaca a 21

<210> 3022
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3022
auacagaacg aucgauacag a 21

<210> 3023
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3023
uacagaacga ucgauacaga a 21

<210> 3024
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3024

acagaacgau cgauacagaa a

21

<210> 3025

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3025

cagaacgauc gauacagaaa a

21

<210> 3026

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3026

agaacgaucg auacagaaac a

21

<210> 3027

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3027

gaacgaucga uacagaaacc a

21

<210> 3028

<211> 21

<212> RNA

<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3028
 aacgaucgau acagaaacca a 21

<210> 3029
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3029
 acgaucgaua cagaaaccac a 21

<210> 3030
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3030
 cgaucgauac agaaaccacg a 21

<210> 3031
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3031
 caccaucacc aucgacagaa a 21

<210> 3032
 <211> 21
 <212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3032

caucaccauc gacagaacag a

21

<210> 3033

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3033

ucaccaucga cagaacaguc a

21

<210> 3034

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3034

caccaucgac agaacagucc a

21

<210> 3035

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3035

accaucgaca gaacaguccu a

21

<210> 3036

<211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3036
 ccaucgacag aacaguccuu a 21

<210> 3037
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3037
 caucgacaga acaguccuua a 21

<210> 3038
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3038
 aucgacagaa caguccuuaa a 21

<210> 3039
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3039
 ucgacagaac aguccuuaau a 21

<210> 3040
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3040
cgacagaaca guccuuaauc a 21

<210> 3041
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3041
gacagaacag uccuuaaucc a 21

<210> 3042
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3042
acagaacagu ccuuaaucca a 21

<210> 3043
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3043

agaacagucc uuaauccaga a 21

<210> 3044
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3044
gaacaguccu uauccagaa a 21

<210> 3045
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3045
aacaguccuu aaucagaaa a 21

<210> 3046
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3046
acaguccua auccagaaac a 21

<210> 3047
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3047
caguccuuaa uccagaaacc a 21

<210> 3048
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3048
aguccuuaau ccagaaaccu a 21

<210> 3049
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3049
guccuuaauc cagaaaccug a 21

<210> 3050
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3050
uccuuaaucc agaaaccuga a 21

<210> 3051
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3051

ccuuaaucca gaaaccugaa a

21

<210> 3052

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3052

cuuaauccag aaaccugaaa a

21

<210> 3053

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3053

uuaauccaga aaccugaaau a

21

<210> 3054

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3054

cagaaaccug aaaugaagga a

21

<210> 3055

<211> 21

<212> RNA

<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3055
 agaaaccuga aaugaaggaa a 21

<210> 3056
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3056
 gaaaccugaa augaaggaag a 21

<210> 3057
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3057
 aaaccugaaa ugaaggaaga a 21

<210> 3058
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3058
 aaccugaaau gaaggaagag a 21

<210> 3059
 <211> 21
 <212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3059

ccugaaauga aggaagagga a

21

<210> 3060

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3060

augaaggaag aggagacucu a

21

<210> 3061

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3061

ucccucuugg aauggauuc a

21

<210> 3062

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3062

ccucuuggaa uuggauucgc a

21

<210> 3063

<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3063
cucuuggaau uggauucgcc a 21

<210> 3064
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3064
uuggaauugg auucgccauu a 21

<210> 3065
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3065
uggaauugga uucgccauuu a 21

<210> 3066
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3066
ggaauuggau ucgccauuuu a 21

<210> 3067
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3067
gaauuggauu cgccauuuua a 21

<210> 3068
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3068
aauggauuc gccauuuuau a 21

<210> 3069
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3069
auuggauucg ccauuuuauu a 21

<210> 3070
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3070

uuggauucgc cauuuuauuu a 21

<210> 3071
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3071
uggauucgcc auuuuauuuu a 21

<210> 3072
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3072
ggauucgcca uuuuauuuuu a 21

<210> 3073
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3073
gauucgccau uuuaauuuuc a 21

<210> 3074
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3074
ucgccauuuu auuuuucug a 21

<210> 3075
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3075
cgccauuuua uuuuucugc a 21

<210> 3076
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3076
gccauuuuau uuuucugcu a 21

<210> 3077
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3077
ccauuuuauu uuucugcug a 21

<210> 3078
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3078

cauuuuauuu uucuugcugc a

21

<210> 3079

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3079

auuuuauuuu ucuugcugcu a

21

<210> 3080

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3080

uuuuuauuuu cuugcugcua a

21

<210> 3081

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3081

uuucuugcug cuaaucacc a

21

<210> 3082

<211> 21

<212> RNA

<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3082
ucaccgagcc cggaagaua a 21

<210> 3083
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3083
gcccggaaga uuagagaguu a 21

<210> 3084
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3084
cccggaagau uagagaguuu a 21

<210> 3085
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3085
cggaagaua gagaguuuuu a 21

<210> 3086
<211> 21
<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3086

ggaagauuag agaguuuuau a

21

<210> 3087

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3087

gaagauuaga gaguuuuauu a

21

<210> 3088

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3088

aagauuagag aguuuuauuu a

21

<210> 3089

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3089

agauuagaga guuuuauuuc a

21

<210> 3090

<211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3090
 auuagagagu uuauuuucug a 21

<210> 3091
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3091
 uuagagaguu uuauuuucugg a 21

<210> 3092
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3092
 uagagaguuu uauuucuggg a 21

<210> 3093
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3093
 agagaguuuu auuucuggga a 21

<210> 3094
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3094
gagaguuuuu uuucugggau a 21

<210> 3095
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3095
agaguuuuau uucugggau a 21

<210> 3096
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3096
gaguuuuau ucugggauuc a 21

<210> 3097
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3097

aguuuuuuuuu cugggauucc a 21

<210> 3098
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3098
guuuuuuuuuc ugggauuccu a 21

<210> 3099
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3099
uuuuuuuuucu gggauuccug a 21

<210> 3100
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3100
uuuauuucug ggauuccugu a 21

<210> 3101
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3101
uuauuucugg gauuccugua a 21

<210> 3102
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3102
uauuucuggg auuccuguag a 21

<210> 3103
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3103
auuucuggga uuccuguaga a 21

<210> 3104
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3104
uuucugggau uccuguagac a 21

<210> 3105
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3105
ucugggauuc cuguagacac a 21

<210> 3106
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3106
cugggauucc uguagacaca a 21

<210> 3107
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3107
ugggauuccu guagacacac a 21

<210> 3108
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3108
gggauuccug uagacacacc a 21

<210> 3109
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3109
acacaccac ccacauacau a 21

<210> 3110
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3110
accacccac auacauacau a 21

<210> 3111
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3111
cccaccaca uacauacau a 21

<210> 3112
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3112
ccaccacau acauacauu a 21

<210> 3113
<211> 21
<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3113

caccacaua cauacauua a

21

<210> 3114

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3114

ccacauacu acauuuauau a

21

<210> 3115

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3115

cacauacau cauuuauaua a

21

<210> 3116

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3116

uuaaaauaac agugcuaug a

21

<210> 3117

<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3117
uaaaauaaca gugcuaaugu a 21

<210> 3118
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3118
aaaauaacag ugcuaauguu a 21

<210> 3119
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3119
aaauaacagu gcuaauguua a 21

<210> 3120
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3120
auuaacagug cuaauguuau a 21

<210> 3121
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3121
uuaacagugc uaauguuauu a 21

<210> 3122
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3122
uaacagugcu aauguuauug a 21

<210> 3123
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3123
aacagugcua auguuauugg a 21

<210> 3124
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3124

acagugcuaa uguuauuggu a 21

<210> 3125
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3125
cagugcuaau guuauuggug a 21

<210> 3126
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3126
gugcuaaugu uauugguguc a 21

<210> 3127
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3127
ugcuaauguu auuggugucu a 21

<210> 3128
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3128
gcuaauguua uggugucuu a 21

<210> 3129
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3129
cuaauguuau uggugucuuc a 21

<210> 3130
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3130
uaauguuauu ggugucuuca a 21

<210> 3131
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3131
aauguuauug gugucuucac a 21

<210> 3132
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3132

auguuauugg ugucuucacu a

21

<210> 3133

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3133

uguuauuggu gucuucacug a

21

<210> 3134

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3134

guuauuggug ucuucacugg a

21

<210> 3135

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3135

uuauuggugu cuucacugga a

21

<210> 3136

<211> 21

<212> RNA

<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3136
 uggugucuuc acuggaugua a 21

<210> 3137
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3137
 ugucuucacu ggauguauuu a 21

<210> 3138
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3138
 cacuggaugu auuugacugc a 21

<210> 3139
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3139
 acuggaugua uuugacugcu a 21

<210> 3140
 <211> 21
 <212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3140

uggauguauu ugacugcugu a

21

<210> 3141

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3141

uauuugacug cuguggacuu a

21

<210> 3142

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3142

uuugacugcu guggacuuga a

21

<210> 3143

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3143

gcuguggacu ugaguuggga a

21

<210> 3144

<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3144
ucccacucag auccugacag a 21

<210> 3145
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3145
cccacucaga uccugacagg a 21

<210> 3146
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3146
ggaggagaug agagacucug a 21

<210> 3147
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3147
gaggagauga gagacucugg a 21

<210> 3148
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3148
ggagaugaga gacucuggca a 21

<210> 3149
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3149
gagacucugg caugaucuuu a 21

<210> 3150
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3150
agacucuggc augaucuuuu a 21

<210> 3151
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3151

uuuugggaac accgacaaac a 21

<210> 3152
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 3152
 gagcuucagg acauugcugu a 21

<210> 3153
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 3153
 gcuucaggac auugcugugc a 21

<210> 3154
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 3154
 cuucaggaca uugcugugcu a 21

<210> 3155
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 3155
uucaggacau ugcugugcuu a 21

<210> 3156
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3156
ucaggacauu gcugugcuuu a 21

<210> 3157
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3157
caggacauug cugugcuuug a 21

<210> 3158
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3158
cgcuuacucu caccugcuuc a 21

<210> 3159
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3159

gcuuacucuc accugcuucu a

21

<210> 3160

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3160

uuacucucac cugcuucuga a

21

<210> 3161

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3161

cucucaccug cuucugaguu a

21

<210> 3162

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3162

ucucaccugc uucugaguug a

21

<210> 3163

<211> 21

<212> RNA

<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3163
 cucaccugcu ucugaguugc a 21

<210> 3164
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3164
 ucaccugcuu cugaguugcc a 21

<210> 3165
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3165
 caccugcuuc ugaguugccc a 21

<210> 3166
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3166
 accugcuucu gaguugccca a 21

<210> 3167
 <211> 21
 <212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3167

ccugcuucug aguugcccag a

21

<210> 3168

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3168

cggcgaagag aagagacaca a

21

<210> 3169

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3169

ggcgaagaga agagacacau a

21

<210> 3170

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3170

gcgaagagaa gagacacauu a

21

<210> 3171

<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3171
cgaagagaag agacacauug a 21

<210> 3172
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3172
gaagagaaga gacacauugu a 21

<210> 3173
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3173
aagagaagag acacauuguu a 21

<210> 3174
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3174
agagaagaga cacauuguug a 21

<210> 3175
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3175
gagaagagac acauuguugg a 21

<210> 3176
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3176
agaagagaca cauuguugga a 21

<210> 3177
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3177
gaagagacac auuguuggaa a 21

<210> 3178
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3178

aagagacaca uuguuggaag a 21

<210> 3179
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3179
agagacacau uguuggaaga a 21

<210> 3180
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3180
gagacacauu guuggaagaa a 21

<210> 3181
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3181
agacacauug uuggaagaag a 21

<210> 3182
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3182
gacacauugu uggaagaagc a 21

<210> 3183
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3183
acacauuguu ggaagaagca a 21

<210> 3184
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3184
cacauuguug gaagaagcag a 21

<210> 3185
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3185
uauuccuca caccaugaa a 21

<210> 3186
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3186

uccucacacc auugaaacca a

21

<210> 3187

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3187

ccucacacca uugaaaccac a

21

<210> 3188

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3188

cucacaccau ugaaaccacu a

21

<210> 3189

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3189

ucacaccau gaaaccacua a

21

<210> 3190

<211> 21

<212> RNA

<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3190
 cacaccauug aaaccacuag a 21

<210> 3191
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3191
 ccauugaaac cacuaguucu a 21

<210> 3192
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3192
 caugaaacc acuaguucug a 21

<210> 3193
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3193
 auugaaacca cuaguucugu a 21

<210> 3194
 <211> 21
 <212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3194

uugaaaccac uaguucuguc a

21

<210> 3195

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3195

ugaaaccacu aguucugucc a

21

<210> 3196

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3196

gaccugguug ugugugugug a

21

<210> 3197

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3197

accugguugu guguguguga a

21

<210> 3198

<211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3198
 ccugguugug ugugugugag a 21

<210> 3199
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3199
 cugguugugu gugugugagu a 21

<210> 3200
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3200
 uggguugugug ugugugagug a 21

<210> 3201
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3201
 gguugugugu gugugagugg a 21

<210> 3202
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3202
gugugugugu gagugguuga a 21

<210> 3203
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3203
ugugugugug agugguugac a 21

<210> 3204
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3204
ugugugugag ugguugaccu a 21

<210> 3205
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3205

ugugugagug guugaccuuc a 21

<210> 3206
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3206
gugugagugg uugaccuucc a 21

<210> 3207
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3207
ugugaguggu ugaccuuccu a 21

<210> 3208
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3208
ugagugguug accuuccucc a 21

<210> 3209
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3209
gugguugacc uuccuccauc a 21

<210> 3210
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3210
uuguggaggc agagaaaaga a 21

<210> 3211
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3211
uguggaggca gagaaaagag a 21

<210> 3212
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3212
guggaggcag agaaaagaga a 21

<210> 3213
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3213

uggaggcaga gaaaagagaa a

21

<210> 3214

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3214

ggaggcagag aaaagagaaa a

21

<210> 3215

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3215

gaggcagaga aaagagaaag a

21

<210> 3216

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3216

aggcagagaa aagagaaagu a

21

<210> 3217

<211> 21

<212> RNA

<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3217
 ggcagagaaa agagaaagug a 21

<210> 3218
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3218
 gcagagaaaa gagaaagugu a 21

<210> 3219
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3219
 cagagaaaag agaaaguguu a 21

<210> 3220
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3220
 agagaaaaga gaaaguguuu a 21

<210> 3221
 <211> 21
 <212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3221

gagaaaagag aaaguguuuu a

21

<210> 3222

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3222

agaaaagaga aaguguuuuu a

21

<210> 3223

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3223

gaaaagagaa aguguuuuau a

21

<210> 3224

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3224

aaaagagaaa guguuuuaua a

21

<210> 3225

<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3225
aaagagaaag uguuuuauau a 21

<210> 3226
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3226
aagagaaagu guuuuauaua a 21

<210> 3227
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3227
agagaaagug uuuuauauac a 21

<210> 3228
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3228
gagaaagugu uuuuauauacg a 21

<210> 3229
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3229
agaaaguguu uuauauacgg a 21

<210> 3230
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3230
aaaguguuuu auauacggua a 21

<210> 3231
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3231
aaguguuuuu uauacggua c a 21

<210> 3232
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3232

aguguuuuau auacgguacu a 21

<210> 3233
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3233
guguuuuaua uacgguacuu a 21

<210> 3234
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3234
uguuuuauau acgguacuua a 21

<210> 3235
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3235
guuuuuauaua cgguacuau a 21

<210> 3236
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3236
uuuuauauac gguacuuauu a 21

<210> 3237
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3237
uuuauauacg guacuuauuu a 21

<210> 3238
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3238
uuauauacgg uacuuauuuu a 21

<210> 3239
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3239
uauauacggg acuuauuuua a 21

<210> 3240
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3240

guacuuuuu aaaucccuu a

21

<210> 3241

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3241

uacuuuuua aaaucccuu a

21

<210> 3242

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3242

uuauagauug uauuuuugc a

21

<210> 3243

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3243

uauagauugu auuuuuugcu a

21

<210> 3244

<211> 21

<212> RNA

<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3244
 augagaugua uuuuuugcuc a 21

<210> 3245
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3245
 ugagauguau cuuuugcucu a 21

<210> 3246
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3246
 gagauguau uuuugcucuc a 21

<210> 3247
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3247
 agauguau uuuugcucucu a 21

<210> 3248
 <211> 21
 <212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3248

gauguaucuu uugcucucuc a

21

<210> 3249

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3249

auguaucuuu ugcucucucu a

21

<210> 3250

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3250

gcucucucuu gcucucuau a

21

<210> 3251

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3251

cucucucuug cucucuauu a

21

<210> 3252

<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3252
ucucucuugc ucucuauuuu a 21

<210> 3253
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3253
cucucuugcu cucuuauuug a 21

<210> 3254
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3254
ucucuugcuc ucuauuuugu a 21

<210> 3255
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3255
cucuugcucu cuuauuuugua a 21

<210> 3256
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3256
ucuugcucuc uuauuuguac a 21

<210> 3257
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3257
cuugcucucu uauuuguacc a 21

<210> 3258
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3258
uugcucucuu auuuguaccg a 21

<210> 3259
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3259

ugcucucuua uuuguaccgg a	21
<210> 3260 <211> 21 <212> RNA <213> Artificial Sequence <220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 3260 cucucuuaau uguaccgguu a	21
<210> 3261 <211> 21 <212> RNA <213> Artificial Sequence <220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 3261 ucucuuaauu guaccgguu a	21
<210> 3262 <211> 21 <212> RNA <213> Artificial Sequence <220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
<400> 3262 cucuuaauug uaccgguuu a	21
<210> 3263 <211> 21 <212> RNA <213> Artificial Sequence <220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	

<400> 3263
ucuuuuuugu accgguuuuu a 21

<210> 3264
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3264
cuuauuuugua ccgguuuuug a 21

<210> 3265
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3265
uuauuuuguac cgguuuuuugu a 21

<210> 3266
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3266
uauuuuguacc gguuuuuugua a 21

<210> 3267
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3267

auuuguaccg guuuuugau a

21

<210> 3268

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3268

uuuguaccgg uuuuuguaua a

21

<210> 3269

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3269

uuguaccggu uuuuguauau a

21

<210> 3270

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3270

uguaccgguu uuuguauaua a

21

<210> 3271

<211> 21

<212> RNA

<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3271
 guaccgguuu uuguauauaa a 21

<210> 3272
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3272
 uaccgguuuu uguauauaaa a 21

<210> 3273
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3273
 accgguuuuu guauauaaaa a 21

<210> 3274
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3274
 auucauguuu ccaaucucuc a 21

<210> 3275
 <211> 21
 <212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3275

uucauguuuc caaucucucu a

21

<210> 3276

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3276

ucauguuucc aaucucucuc a

21

<210> 3277

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3277

cauguuuucca aucucucucu a

21

<210> 3278

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3278

auguuuccaa ucucucucuc a

21

<210> 3279

<211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3279
 uguuuccaau cucucucucc a 21

<210> 3280
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3280
 uuuccaau cu cucucuccu a 21

<210> 3281
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3281
 uccaau cu cu cuccuga a 21

<210> 3282
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3282
 cggugacagu cacuagcuu a 21

<210> 3283
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3283
ggugacaguc acuagcuuau a 21

<210> 3284
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3284
agucacuagc uuaucuugaa a 21

<210> 3285
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3285
gucacuagcu uaucuugaac a 21

<210> 3286
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3286

ucacuagcuu aucuugaaca a 21

<210> 3287
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3287
acuagcuuau cuugaacaga a 21

<210> 3288
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3288
cuagcuuau uugaacagau a 21

<210> 3289
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3289
uagcuuau ugaacagau a 21

<210> 3290
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3290
agcuuauuu gaacagauau a 21

<210> 3291
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3291
gcuuauuug aacagauuu a 21

<210> 3292
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3292
cagcacauu uccuuugaaa a 21

<210> 3293
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3293
agcacauu ccuuugaaau a 21

<210> 3294
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3294

gcacacauuc cuuugaaa a

21

<210> 3295

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3295

cacacauucc uuugaaa a

21

<210> 3296

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3296

cacauuccuu ugaaa aagg a

21

<210> 3297

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3297

uccuuugaaa uaagguuca a

21

<210> 3298

<211> 21

<212> RNA

<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3298
 cuuugaaaau agguuucuu a 21

<210> 3299
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3299
 uuugaaaaua gguuucuu a 21

<210> 3300
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3300
 agguuucuu auacaucau a 21

<210> 3301
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3301
 gguuucuuu uacaucau a 21

<210> 3302
 <211> 21
 <212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3302

guuucaauau acaucuacau a

21

<210> 3303

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3303

uuucaauaua caucuacau a

21

<210> 3304

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3304

uucaauauac aucuacauac a

21

<210> 3305

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3305

uauuuggcaa cuuguauuug a

21

<210> 3306

<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3306
uuuggcaacu uguauuugug a 21

<210> 3307
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3307
uggcaacuug uauuugugug a 21

<210> 3308
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3308
ggcaacuugu auuugugugu a 21

<210> 3309
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3309
gcaacuugua uuugugugua a 21

<210> 3310
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3310
caacuuguau uuguguguau a 21

<210> 3311
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3311
aacuuguauu uguguguaua a 21

<210> 3312
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3312
acuuguauuu guguguauau a 21

<210> 3313
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3313

uucugauaaa auagacauug a 21

<210> 3314
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3314
ugauaaaaua gacauugcua a 21

<210> 3315
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3315
gauaaaauag acauugcuau a 21

<210> 3316
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3316
uaaaaauagac auugcuauuc a 21

<210> 3317
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3317
uagacauugc uauucuguuu a 21

<210> 3318
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3318
agacauugcu auucuguuuu a 21

<210> 3319
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3319
ucuacauacu aaaucucucu a 21

<210> 3320
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3320
cuacauacua aaucucucuc a 21

<210> 3321
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3321

uacauacuaa aucucucucc a

21

<210> 3322

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3322

acauacuaaa ucucucuccu a

21

<210> 3323

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3323

cauacuaaauc cucucuccuu a

21

<210> 3324

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3324

auacuaaauc ucucuccuuu a

21

<210> 3325

<211> 21

<212> RNA

<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3325
 uacuaaaucu cucuccuuuu a 21

<210> 3326
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3326
 cauuuauuuu uuggugcuac a 21

<210> 3327
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3327
 auuuauuuau uggugcuacu a 21

<210> 3328
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3328
 uuuauuuauu ggugcuacug a 21

<210> 3329
 <211> 21
 <212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3329

uuauuuauug gugcuacugu a

21

<210> 3330

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3330

uauuuauugg ugcuaacuguu a

21

<210> 3331

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3331

auuuauuggu gcuacuguuu a

21

<210> 3332

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3332

uuauuggugc uacuguuuau a

21

<210> 3333

<211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3333
 auuggugcua cuguuuaucc a 21

<210> 3334
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3334
 gaaaagauau uaacaucacg a 21

<210> 3335
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3335
 aacaucacgu cuuugucucu a 21

<210> 3336
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3336
 acaucacguc uuugucucua a 21

<210> 3337
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3337
gucuuugucu cuagugcagu a 21

<210> 3338
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3338
ucuuugucuc uagugcaguu a 21

<210> 3339
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3339
cuuugucucu agugcaguuu a 21

<210> 3340
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3340

gagauauucc guaguacaua a 21

<210> 3341
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3341
agauauuccg uaguacauau a 21

<210> 3342
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3342
gauauuccgu aguacauauu a 21

<210> 3343
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3343
cgacaaagaa auacagauau a 21

<210> 3344
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3344
gacaaagaaa uacagauaua a 21

<210> 3345
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3345
acaaagaaau acagauauau a 21

<210> 3346
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3346
caaagaaaua cagauauauc a 21

<210> 3347
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3347
uaauaucaaa uuccagcacc gag 23

<210> 3348
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3348

ugaauaucaa auuccagcac cga

23

<210> 3349

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3349

uaugaauauc aaauccagc acc

23

<210> 3350

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3350

uaaugaauau caauuccag cac

23

<210> 3351

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3351

uucaugaau aucaauucc agc

23

<210> 3352

<211> 23

<212> RNA

<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3352
 uaucaaugaa uaucaaaauuc cag 23

<210> 3353
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3353
 ugaucaauga auaucaaaau cca 23

<210> 3354
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3354
 uggaucaaug aaaucaaaau ucc 23

<210> 3355
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3355
 ucggaucaau gaauaucaaa uuc 23

<210> 3356
 <211> 23
 <212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3356

uccggaucaa ugaauaucaa auu

23

<210> 3357

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3357

ugaauaggcaa gcaaaaauaa auu

23

<210> 3358

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3358

uggaauggca agcaaaaaua aa

23

<210> 3359

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3359

uccaaaaucc acagugauuu ggg

23

<210> 3360

<211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3360
 uuccaaaauc cacagugauu ugg 23

<210> 3361
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3361
 uuuccaaaau ccacagugau uug 23

<210> 3362
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3362
 uuuuccaaaa uccacaguga uuu 23

<210> 3363
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3363
 uguuuccaaa auccacagug auu 23

<210> 3364
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3364
ugguuuccaa aauccacagu gau 23

<210> 3365
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3365
uugguuucca aaauccacag uga 23

<210> 3366
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3366
ucugguuucc aaaauccaca gug 23

<210> 3367
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3367

ugcugguuuc caaaauccac agu 23

<210> 3368
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3368
uugcugguuu ccaaaaucca cag 23

<210> 3369
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3369
uuucugcugg uuuccaaaau cca 23

<210> 3370
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3370
uuuucugcug guuuccaaaa ucc 23

<210> 3371
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3371
ucuuucugcu gguuuccaaa auc 23

<210> 3372
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3372
uucuuucugc ugguuuccaa aa 23

<210> 3373
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3373
uuccucuuuc ugugguuuc caa 23

<210> 3374
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3374
uuuuccucuu ucugcugguu ucc 23

<210> 3375
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3375

ucuuuccucu uucugcuggu uuc

23

<210> 3376

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3376

uucuuuccuc uuucugcugg uuu

23

<210> 3377

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3377

ucucuuuccu cuuucugcug guu

23

<210> 3378

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3378

uccucuuucc ucuuucugcu ggu

23

<210> 3379

<211> 23

<212> RNA

<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3379
 uaccucuuuc cucuuucugc ugg 23

<210> 3380
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3380
 uuaccucuuu ccucuuucug cug 23

<210> 3381
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3381
 ucuaccucuu uccucuuucu gcu 23

<210> 3382
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3382
 uuugcuaccu cuuuccucuu ucu 23

<210> 3383
 <211> 23
 <212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3383

ucuugcuacc ucuuuccucu uuc

23

<210> 3384

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3384

uucuugcuac cucuuuccuc uuu

23

<210> 3385

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3385

ucucuugcua ccucuuccu cuu

23

<210> 3386

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3386

uagcucuugc uaccucuuc cuc

23

<210> 3387

<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3387
ucucuggagc ucuugcuacc ucu 23

<210> 3388
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3388
uuuccucgac uucucucugg agc 23

<210> 3389
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3389
ucuuccucga cuucucucug gag 23

<210> 3390
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3390
uucuuccucg acuucucucu gga 23

<210> 3391
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3391
ucucucuucc ucgacuucuc ucu

23

<210> 3392
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3392
uucucucuuc cugacuucu cuc

23

<210> 3393
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3393
uucucucucu uccugacuu cuc

23

<210> 3394
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3394

uccaaaagca ggucacucac uuu 23

<210> 3395
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 3395
 uaaaaguuuc agugcgacgc cgc 23

<210> 3396
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 3396
 uacgaaaagu uucagugcga cgc 23

<210> 3397
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 3397
 ugacgaaaag uuucagugcg acg 23

<210> 3398
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 3398
uuuggacgaa aaguuucagu gcg 23

<210> 3399
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3399
uguuggacga aaaguuucag ugc 23

<210> 3400
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3400
uaaguuggac gaaaaguuuc agu 23

<210> 3401
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3401
ucagaaguug gacgaaaagu uuc 23

<210> 3402
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3402

uccgaagcga gaacagccca gaa

23

<210> 3403

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3403

uuccgaagcg agaacagccc aga

23

<210> 3404

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3404

ucuccgaagc gagaacagcc cag

23

<210> 3405

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3405

uuccuccgaa gcgagaacag ccc

23

<210> 3406

<211> 23

<212> RNA

<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3406
 ugagcuagca cuucucgcgg cuc 23

 <210> 3407
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3407
 ucgagcuagc acuucucgcg gcu 23

 <210> 3408
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3408
 uaaguucaug guuucggagg ccc 23

 <210> 3409
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3409
 uaugauucug cccuccuccu ucu 23

 <210> 3410
 <211> 23
 <212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3410

ucacuucgug augauucugc ccu

23

<210> 3411

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3411

uuucaccacu ucgugaugau ucu

23

<210> 3412

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3412

ucuucaccac uucgugauga uuc

23

<210> 3413

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3413

uacuucacca cuucgugaug auu

23

<210> 3414

<211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3414
 uaacuucacc acuucgugau gau 23

<210> 3415
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3415
 uugaacuuca ccacuucgug aug 23

<210> 3416
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3416
 uauccaugaa cuucaccacu ucg 23

<210> 3417
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3417
 ucauccauga acuucaccac uuc 23

<210> 3418
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3418
uacaucaug aacuucacca cuu

23

<210> 3419
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3419
uagacaucca ugaacuucac cac

23

<210> 3420
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3420
uuagacaucc augaacuuca cca

23

<210> 3421
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3421

uauagacauc caugaacuuc acc 23

<210> 3422
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 3422
 uugauagaca uccaugaacu uca 23

<210> 3423
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 3423
 ucugauagac auccaugaac uuc 23

<210> 3424
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 3424
 ucgcugauag acauccauga acu 23

<210> 3425
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 3425
uuacuccugg aagaugucca cca 23

<210> 3426
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3426
uuggcuugaa gauguacug auc 23

<210> 3427
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3427
uauggcuuga agauguacuc gau 23

<210> 3428
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3428
ugauggcuug aagauguacu cga 23

<210> 3429
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3429

uaggauggcu ugaagaugua cuc

23

<210> 3430

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3430

uaaucugcau ggugauguug gac

23

<210> 3431

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3431

uuaaucugca uggugauguu gga

23

<210> 3432

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3432

ucauaaucug cauggugaug uug

23

<210> 3433

<211> 23

<212> RNA

<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3433
 ugcauaaucu gcauggugau guu 23

 <210> 3434
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3434
 uauccgcaua aucugcaugg uga 23

 <210> 3435
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3435
 uuugauccgc auaaucugca ugg 23

 <210> 3436
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3436
 uuuugauccg cauaaucugc aug 23

 <210> 3437
 <211> 23
 <212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3437

uguuugaucc gcauaaucug cau

23

<210> 3438

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3438

ugagguuuga uccgcauaau cug

23

<210> 3439

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3439

uugagguuug auccgcauaa ucu

23

<210> 3440

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3440

uccuugguga gguuugaucc gca

23

<210> 3441

<211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3441
 uuguaggaag cucaucucuc cua 23

<210> 3442
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3442
 uugcuguagg aagcucaucu cuc 23

<210> 3443
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3443
 uuugucugua ggaagcucau cuc 23

<210> 3444
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3444
 uuugucugu aggaagcuca ucu 23

<210> 3445
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3445
uuguugugcu guaggaagcu cau 23

<210> 3446
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3446
uuuguugugc uguaggaagc uca 23

<210> 3447
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3447
uuuuguugug cuguaggaag cuc 23

<210> 3448
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3448

uauuuuguugu gcuguaggaa gcu

23

<210> 3449
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3449
uacauuuuguu gugcuguagg aag

23

<210> 3450
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3450
uucacauuug uugugcugua gga

23

<210> 3451
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3451
uuucacauuu guugugcugu agg

23

<210> 3452
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3452
ugcauucaca uuuguugugc ugu 23

<210> 3453
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3453
uugcauucac auuguugug cug 23

<210> 3454
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3454
uuaucaugucu uuuccugguga gag 23

<210> 3455
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3455
uguaucauguc uuuccuggug aga 23

<210> 3456
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3456

uuguaucagu cuuuccuggu gag

23

<210> 3457

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3457

ucuguaucag ucuuuccugg uga

23

<210> 3458

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3458

uucuguauca gucuuccug gug

23

<210> 3459

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3459

uuucuguauc agucuuccu ggu

23

<210> 3460

<211> 23

<212> RNA

<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3460
uguucuguau cagucuuucc ugg 23

<210> 3461
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3461
ucguucugua ucagucuuuc cug 23

<210> 3462
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3462
uucguucugu aucagucuuu ccu 23

<210> 3463
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3463
uaucguucug uaucagucuu ucc 23

<210> 3464
<211> 23
<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3464

ugaucguucu guaucagucu uuc

23

<210> 3465

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3465

ucgaucguuc ugaucaguc uuu

23

<210> 3466

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3466

uucgaucguu cuguaucagu cuu

23

<210> 3467

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3467

uaucaucgu ucuguaucag ucu

23

<210> 3468

<211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3468
 uuaucaugcgu uucuguauc guc 23

<210> 3469
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3469
 uguaucaugc guucuguauc agu 23

<210> 3470
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3470
 uuuguaucaugc cguucuguauc cag 23

<210> 3471
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3471
 ucuguaucaugc ucguucugua uca 23

<210> 3472
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3472
uucuguaucg aucguucugu auc

23

<210> 3473
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3473
uuucuguauc gaucguucug uau

23

<210> 3474
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3474
uuuucuguau cgaucguucu gua

23

<210> 3475
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3475

uguuucugua ucgaucguuc ugu

23

<210> 3476
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3476
ugguuucugu aucgaucguu cug

23

<210> 3477
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3477
uugguuucug uaucgaucgu ucu

23

<210> 3478
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3478
ugugguuucu guaucgaucg uuc

23

<210> 3479
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3479
ucgugguuuc uguaucgauc guu 23

<210> 3480
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3480
uuucugucga uggugauggu gug 23

<210> 3481
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3481
ucuguucugu cgauggugau ggu 23

<210> 3482
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3482
ugacuguucu gucgauggug aug 23

<210> 3483
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3483

uggacuguuc ugucgauggu gau

23

<210> 3484

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3484

uaggacuguu cugucgaugg uga

23

<210> 3485

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3485

uaaggacugu ucugucgaug gug

23

<210> 3486

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3486

uuaggacug uucugucgau ggu

23

<210> 3487

<211> 23

<212> RNA

<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 3487
 uuuaaggacu guucugucga ugg 23

<210> 3488
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 3488
 uauuaaggac uguucugucg aug 23

<210> 3489
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 3489
 ugauuaagga cuguucuguc gau 23

<210> 3490
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 3490
 uggauuaagg acuguucugu cga 23

<210> 3491
 <211> 23
 <212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3491

uuggauuaag gacuguucug ucg

23

<210> 3492

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3492

uucuggauua aggacuguuc ugu

23

<210> 3493

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3493

uuucuggauu aaggacuguu cug

23

<210> 3494

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3494

uuuucuggau uaaggacugu ucu

23

<210> 3495

<211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3495
 uguuucugga uuaaggacug uuc 23

<210> 3496
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3496
 ugguuucugg auuaaggacu guu 23

<210> 3497
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3497
 uagguuucug gauuaaggac ugu 23

<210> 3498
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3498
 ucagguuucu ggauuaagga cug 23

<210> 3499
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3499
uucagguuuc uggauuaagg acu 23

<210> 3500
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3500
uuucagguuu cuggauuaag gac 23

<210> 3501
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3501
uuuucagguu ucuggauuaa gga 23

<210> 3502
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3502

uauuucaggu uucuggauua agg

23

<210> 3503
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3503
uuccuucuu ucagguuucu gga

23

<210> 3504
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3504
uuuccuucuu uucagguuuc ugg

23

<210> 3505
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3505
ucuuccuucuu uuucagguuu cug

23

<210> 3506
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3506
uucuuccuuc auuucagguu ucu 23

<210> 3507
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3507
ucucuuccuu cauucaggu uuc 23

<210> 3508
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3508
uuccucuucc uucauuucag guu 23

<210> 3509
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3509
uagagucucc ucuuccuuc uuu 23

<210> 3510
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3510

ugaauccaau uccaagaggg acc

23

<210> 3511

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3511

ugcgaucca auuccaagag gga

23

<210> 3512

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3512

uggcgaucc aaauccaaga ggg

23

<210> 3513

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3513

uaauggcgaa uccaauucca aga

23

<210> 3514

<211> 23

<212> RNA

<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 3514
 uaaauggcga auccaauucc aag 23

<210> 3515
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 3515
 uaaaauggcg aauccaauuc caa 23

<210> 3516
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 3516
 uuaaaauggc gaauccaauu cca 23

<210> 3517
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 3517
 uauaaaaugg cgauccaau ucc 23

<210> 3518
 <211> 23
 <212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3518

uaauaaaug gcgaauccaa uuc

23

<210> 3519

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3519

uaauaaaau ggcgaaucca auu

23

<210> 3520

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3520

uaaaauaaaa uggcgaucc aa

23

<210> 3521

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3521

uaaaauaaa auggcgauc caa

23

<210> 3522

<211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3522
 ugaaaaauaa aauggcgaau cca 23

<210> 3523
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3523
 ucaagaaaaa uaaauggcg aa 23

<210> 3524
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3524
 ugcaagaaaa auaaauggc gaa 23

<210> 3525
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3525
 uagcaagaaa aaaaaaugg cga 23

<210> 3526
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3526
ucagcaagaa aaauaaaaug gcg 23

<210> 3527
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3527
ugcagcaaga aaaauaaaau ggc 23

<210> 3528
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3528
uagcagcaag aaaaauaaaa ugg 23

<210> 3529
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3529

uuagcagcaa gaaaaaauaaa aug 23

<210> 3530
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3530
uggugauuuu gcagcaagaa aaa 23

<210> 3531
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3531
uuaaucuucc gggcucggug auu 23

<210> 3532
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3532
uaacucucua aucuuccggg cuc 23

<210> 3533
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3533
uaaacucucu aaucuuccgg gcu 23

<210> 3534
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3534
uuaaaacucu cuaaucuucc ggg 23

<210> 3535
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3535
uauaaaacuc ucuaaucuuc cgg 23

<210> 3536
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3536
uaauaaaacu cucuaaucuu ccg 23

<210> 3537
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3537

uaauuaaaac ucucuaaucu ucc

23

<210> 3538

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3538

ugaaauaaaa cucucuaauc uuc

23

<210> 3539

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3539

ucagaaauaa aacucucuaa ucu

23

<210> 3540

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3540

uccagaaaua aaacucucua auc

23

<210> 3541

<211> 23

<212> RNA

<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3541
 uccagaaau aaaacucucu aaau
 23

<210> 3542
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3542
 uuccagaaa uaaaacucuc uaa
 23

<210> 3543
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3543
 uauccagaa auaaaacucu cua
 23

<210> 3544
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3544
 uauccaga aaauaacuc ucu
 23

<210> 3545
 <211> 23
 <212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3545

ugaauccag aaauaaaacu cuc

23

<210> 3546

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3546

uggaaucca gaaauaaaac ucu

23

<210> 3547

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3547

uaggaauccc agaaauaaaa cuc

23

<210> 3548

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3548

ucaggaaucc cagaaauaaa acu

23

<210> 3549

<211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3549
 uacaggauc ccagaaaua aac 23

<210> 3550
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3550
 uuacaggaau cccagaaaua aaa 23

<210> 3551
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3551
 ucuacaggaa ucccagaaau aaa 23

<210> 3552
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3552
 uucuacagga aucccagaaa uaa 23

<210> 3553
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3553
ugucuacagg aauc ccagaa aua 23

<210> 3554
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3554
ugugucuaca ggaauccag aaa 23

<210> 3555
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3555
uugugucuac aggaauccca gaa 23

<210> 3556
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3556

ugugugucua caggaauccc aga 23

<210> 3557
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3557
uggugugucu acaggaaucc cag 23

<210> 3558
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3558
uauguaugug ggugggugug ucu 23

<210> 3559
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3559
uauguaugua uguggguggg ugu 23

<210> 3560
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3560
uaauguaugu augugggugg gug 23

<210> 3561
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3561
uaaauaugaug uaugugggug ggu 23

<210> 3562
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3562
uuaaauguaug uaugugggu ggg 23

<210> 3563
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3563
uauauaaaug uauguaugug ggu 23

<210> 3564
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3564

uuauauaaaau guauguaugu ggg

23

<210> 3565

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3565

ucauuagcac uguuaauua aaa

23

<210> 3566

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3566

uacauuagca cuguuaauuu aaa

23

<210> 3567

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3567

uaacauuagc acuguuaauu uaa

23

<210> 3568

<211> 23

<212> RNA

<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3568
 uuaacauuag cacuguuaau uua 23

<210> 3569
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3569
 uauaacauua gcacuguuaa uuu 23

<210> 3570
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3570
 uaauaacauu agcacuguua auu 23

<210> 3571
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3571
 ucaauaacau uagcacuguu aaU 23

<210> 3572
 <211> 23
 <212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3572

uccaauaaca uuagcacugu uaa

23

<210> 3573

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3573

uaccaauaac auuagcacug uua

23

<210> 3574

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3574

ucaccaauaa cauuagcacu guu

23

<210> 3575

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3575

ugacaccaau aacauuagca cug

23

<210> 3576

<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3576
uagacaccaa uaacauuagc acu 23

<210> 3577
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3577
uaagacacca auaacauuag cac 23

<210> 3578
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3578
ugaagacacc aaauacauua gca 23

<210> 3579
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3579
uugaagacac caauacauu agc 23

<210> 3580
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3580
ugugaagaca ccaauaacau uag 23

<210> 3581
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3581
uagugaagac accaauaaca uua 23

<210> 3582
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3582
ucagugaaga caccauaaac auu 23

<210> 3583
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3583

uccagugaag acaccaauaa cau 23

<210> 3584
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 3584
 uuccagugaa gacaccaua aca 23

<210> 3585
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 3585
 uuacauccag ugaagacacc aaU 23

<210> 3586
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 3586
 uaaauacauC cagugaagac acc 23

<210> 3587
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 3587
ugcagucaaa uacauccagu gaa 23

<210> 3588
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3588
uagcagucaa auacauccag uga 23

<210> 3589
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3589
uacagcaguc aaauacaucc agu 23

<210> 3590
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3590
uaaguccaca gcagucaaaau aca 23

<210> 3591
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3591
uucaagucca cagcagucca aua 23

<210> 3592
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3592
uucccaacuc aaguccacag cag 23

<210> 3593
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3593
ucugucagga ucugaguggg aac 23

<210> 3594
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3594
uccugucagg aucugagugg gaa 23

<210> 3595
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3595
 ucagagucuc ucauccucuc cuc 23

 <210> 3596
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3596
 uccagagucu cucaucccu ccu 23

 <210> 3597
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3597
 uugccagagu cucucaucuc cuc 23

 <210> 3598
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3598
 uaaagaucau gccagagucu cuc 23

 <210> 3599
 <211> 23
 <212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3599

uaaaagauca ugccagaguc ucu

23

<210> 3600

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3600

uguuuugucgg uguucccaaa acu

23

<210> 3601

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3601

uacagcaaug uccugaagcu ccc

23

<210> 3602

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3602

ugcacagcaa uguccugaag cuc

23

<210> 3603

<211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3603
 uagcacagca auguccugaa gcu 23

<210> 3604
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3604
 uaagcacagc aauguccuga agc 23

<210> 3605
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3605
 uaaagcacag caauguccug aag 23

<210> 3606
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3606
 ucaaagcaca gcaauguccu gaa 23

<210> 3607
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3607
ugaagcaggu gagaguaagc gaa

23

<210> 3608
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3608
uagaagcagg ugagaguaag cga

23

<210> 3609
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3609
uucagaagca ggugagagua agc

23

<210> 3610
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3610

uaacucagaa gcaggugaga gua 23

<210> 3611
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3611
ucaacucaga agcaggugag agu 23

<210> 3612
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3612
ugcaacucag aagcagguga gag 23

<210> 3613
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3613
uggcaacuca gaagcaggug aga 23

<210> 3614
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3614
ugggcaacuc agaagcaggu gag 23

<210> 3615
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3615
uugggcaacu cagaagcagg uga 23

<210> 3616
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3616
ucugggcaac ucagaagcag gug 23

<210> 3617
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3617
uugugucucu ucucuucgcc ggg 23

<210> 3618
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3618

uauugugucuc uucucuucgc cgg

23

<210> 3619

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3619

uauugugucu cuucucuucg ccg

23

<210> 3620

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3620

ucaauguguc ucuucucuuc gcc

23

<210> 3621

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3621

uacaaugugu cucuucucu cgc

23

<210> 3622

<211> 23

<212> RNA

<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3622
 uaacaaugug ucucuucucu ucg 23

 <210> 3623
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3623
 ucaacaaugu gucucuucuc uuc 23

 <210> 3624
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3624
 uccaacaug ugucucuucu cuu 23

 <210> 3625
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3625
 uuccaacaau gugucucuuc ucu 23

 <210> 3626
 <211> 23
 <212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3626

uuuccaaca ugugucucu cuc

23

<210> 3627

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3627

ucuuccaaca augugucucu ucu

23

<210> 3628

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3628

uucuuccaac aaugugucuc uuc

23

<210> 3629

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3629

uuucuuccaa caaugugucu cuu

23

<210> 3630

<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3630
ucuucuucca acaauguguc ucu 23

<210> 3631
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3631
ugcuucuucc aacaugugu cuc 23

<210> 3632
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3632
uugcuucuuc caacaugug ucu 23

<210> 3633
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3633
ucugcuucuu ccaacaugu guc 23

<210> 3634
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3634
uuucaauggu gugaggacau agg 23

<210> 3635
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3635
uugguucaa uggugugagg aca 23

<210> 3636
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3636
ugugguuua auggugugag gac 23

<210> 3637
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3637

uagugguuuc aaugguguga gga

23

<210> 3638
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3638
uuagugguuu caauggugug agg

23

<210> 3639
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3639
ucuagugguu ucaauggugu gag

23

<210> 3640
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3640
uagaacuagu gguucaaug gug

23

<210> 3641
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3641
ucagaacuag ugguuucuu ggu 23

<210> 3642
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3642
uacagaacua gugguuucaa ugg 23

<210> 3643
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3643
ugacagaacu agugguuuca aug 23

<210> 3644
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3644
uggacagaac uagugguuuc aa 23

<210> 3645
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3645
ucacacacac acaaccaggu cuc 23

<210> 3646
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3646
uucacacaca cacaaccagg ucu 23

<210> 3647
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3647
ucucacacac acacaaccag guc 23

<210> 3648
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3648
uacucacaca cacacaacca ggu 23

<210> 3649
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3649
 ucacucacac acacacaacc agg 23

<210> 3650
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3650
 uccacucaca cacacacaac cag 23

<210> 3651
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3651
 uucaaccacu cacacacaca caa 23

<210> 3652
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3652
 ugucaaccac ucacacacac aca 23

<210> 3653
 <211> 23
 <212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3653

uaggucaacc acucacacac aca

23

<210> 3654

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3654

ugaaggucaa ccacucacac aca

23

<210> 3655

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3655

uggaagguca accacucaca cac

23

<210> 3656

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3656

uaggaagguc aaccacucac aca

23

<210> 3657

<211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3657
 uggaggaagg ucaaccacuc aca 23

<210> 3658
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3658
 ugauggagga aggucaacca cuc 23

<210> 3659
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3659
 uucuuuuucuc ugccuccaca aug 23

<210> 3660
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3660
 ucucuuuuucu cugccuccac aa 23

<210> 3661
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3661
uucucuuuuc ucugccucca caa

23

<210> 3662
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3662
uuucucuuuu cucugccucc aca

23

<210> 3663
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3663
uuuucucuuu ucucugccuc cac

23

<210> 3664
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3664

ucuuuucucu uucucugccu cca

23

<210> 3665
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3665
uacuuuucucu uuucucugcc ucc

23

<210> 3666
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3666
ucacuuuucuc uuuucucugc cuc

23

<210> 3667
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3667
uacacuuucu cuuuucucug ccu

23

<210> 3668
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3668
uaacacuuuc uuuuuucucu gcc 23

<210> 3669
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3669
uaaacacuuu cucuuuucuc ugc 23

<210> 3670
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3670
uaaaacacuu ucucuuuucu cug 23

<210> 3671
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3671
uuaaaacacu uucucuuuuc ucu 23

<210> 3672
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3672

uauaaaacac uuucucuuuu cuc

23

<210> 3673

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3673

uuauaaaaca cuuucucuuu ucu

23

<210> 3674

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3674

uauauaaaac acuuucucuu uuc

23

<210> 3675

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3675

uuauauaaaa cacuuucucu uuu

23

<210> 3676

<211> 23

<212> RNA

<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 3676
 uguauauaaa acacuuucuc uuu 23

<210> 3677
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 3677
 ucguauauaa aacacuuucu cuu 23

<210> 3678
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 3678
 uccguauaua aaacacuuuc ucu 23

<210> 3679
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 3679
 uuaccguaua uaaaacacuu ucu 23

<210> 3680
 <211> 23
 <212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3680

uguaccguau auaaaacacu uuc

23

<210> 3681

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3681

uaguaccgua uauaaaacac uuu

23

<210> 3682

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3682

uaaguaccgu auauaaaaca cuu

23

<210> 3683

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3683

uuaaguaccg uauauaaaac acu

23

<210> 3684

<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3684
uauaaguacc guauauaaaa cac 23

<210> 3685
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3685
uaauaaguac cguauauaaa aca 23

<210> 3686
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3686
uaauaagua ccguauauaa aac 23

<210> 3687
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3687
uuauaagu accguauaua aaa 23

<210> 3688
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3688
uuuaaauaag uaccguauau aaa

23

<210> 3689
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3689
uaagggauau uaaauaagua ccg

23

<210> 3690
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3690
uaaagggaug uaaaauaagu acc

23

<210> 3691
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3691

ugcaaaagau acaucucaua aaau 23

<210> 3692
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 3692
 uagcaaaaga uacaucucau aaa 23

<210> 3693
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 3693
 ugagcaaaag auacaucuca uaa 23

<210> 3694
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 3694
 uagagcaaaa gauacaucuc aua 23

<210> 3695
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 3695
ugagagcaaa agauacaucau cau 23

<210> 3696
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3696
uagagagcaa aagauacaucau uca 23

<210> 3697
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3697
ugagagagca aaagauacau cuc 23

<210> 3698
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3698
uagagagagc aaaagauaca ucu 23

<210> 3699
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3699
uauaagagag caagagagag caa 23

<210> 3700
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3700
uaauaagaga gcaagagaga gca 23

<210> 3701
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3701
uaaauaagag agcaagagag agc 23

<210> 3702
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3702
ucaaaauaaga gagcaagaga gag 23

<210> 3703
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3703
 uacaaauaag agagcaagag aga 23

 <210> 3704
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3704
 uuacaaauaa gagagcaaga gag 23

 <210> 3705
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3705
 uguacaaaua agagagcaag aga 23

 <210> 3706
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3706
 ugguacaaau aagagagcaa gag 23

 <210> 3707
 <211> 23
 <212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3707

ucgguacaaa uaagagagca aga

23

<210> 3708

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3708

uccgguacaa auaagagagc aag

23

<210> 3709

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3709

uaaccgguac aaauaagaga gca

23

<210> 3710

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3710

uaaaccggua caaauaagag agc

23

<210> 3711

<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3711
uaaaaccggu acaaauaaga gag 23

<210> 3712
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3712
uaaaaaccgg uacaaauaag aga 23

<210> 3713
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3713
ucaaaaaccg guacaaauaa gag 23

<210> 3714
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3714
uacaaaaacc gguacaaaua aga 23

<210> 3715
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3715
uuacaaaaac cgguacaaau aag 23

<210> 3716
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3716
uauacaaaaa ccgguacaaa uaa 23

<210> 3717
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3717
uuauacaaaa accgguacaa aua 23

<210> 3718
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3718

uauauacaaa aaccgguaca aa

23

<210> 3719
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3719
uuauauacaa aaaccgguac aaa

23

<210> 3720
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3720
uuuauauaca aaaaccggu caa

23

<210> 3721
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3721
uuuuauauac aaaaaccggu aca

23

<210> 3722
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3722
uuuuuuauaua caaaaaccgg uac 23

<210> 3723
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3723
ugagagauug gaaacaugaa uuu 23

<210> 3724
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3724
uagagagauu ggaaacauga auu 23

<210> 3725
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3725
ugagagagau uggaacaug aaU 23

<210> 3726
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3726

uagagagaga uuggaaacau gaa

23

<210> 3727

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3727

ugagagagag auuggaaaca uga

23

<210> 3728

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3728

uggagagaga gauuggaaac aug

23

<210> 3729

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3729

uagggagaga gagauuggaa aca

23

<210> 3730

<211> 23

<212> RNA

<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3730
 uucagggaga gagagauugg aaa 23

<210> 3731
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3731
 uuaagcuagu gacugucacc gau 23

<210> 3732
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3732
 uauaagcuag ugacugucac cga 23

<210> 3733
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3733
 uuucaagaua agcuagugac ugu 23

<210> 3734
 <211> 23
 <212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3734

uguucaagau aagcuaguga cug

23

<210> 3735

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3735

uuguucaaga uaagcuagug acu

23

<210> 3736

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3736

uucuguucaa gauaagcuag uga

23

<210> 3737

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3737

uaucuguuca agauaagcua gug

23

<210> 3738

<211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3738
 uuaucuguuc aagauaagcu agu 23

<210> 3739
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3739
 uauaucuguu caagauaagc uag 23

<210> 3740
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3740
 uaauaucugu ucaagauaag cua 23

<210> 3741
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3741
 uuuucaaagg aaugugugcu ggg 23

<210> 3742
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3742
uauuucaaag gaaugugugc ugg 23

<210> 3743
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3743
uuauuucaaa ggaaugugug cug 23

<210> 3744
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3744
uuuauuucaa aggaugugu gcu 23

<210> 3745
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3745

uccuuauuuc aaaggaaugu gug 23

<210> 3746
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3746
uugaaaccuu auuucaaagg aaau 23

<210> 3747
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3747
uauugaaacc uuauuucaaa gga 23

<210> 3748
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3748
uuauugaaac cuuauuucaa agg 23

<210> 3749
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3749
uguagaugua uauugaaacc uua 23

<210> 3750
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3750
uuguagaugu auauugaaac cuu 23

<210> 3751
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3751
uauguagaug uauauugaaa ccu 23

<210> 3752
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3752
uuauaguagau guauauugaa acc 23

<210> 3753
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3753
uguauuguaga uguauauuga aac 23

<210> 3754
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3754
ucaaauacaa guugccaaau aua 23

<210> 3755
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3755
ucacaaauac aaguugccaa aua 23

<210> 3756
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3756
ucacacaaau acaaguugcc aaa 23

<210> 3757
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3757
 uacacacaaa uacaaguugc caa 23

<210> 3758
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3758
 uuacacacaa auacaaguug cca 23

<210> 3759
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3759
 uauacacaca aaauacaagu gcc 23

<210> 3760
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3760
 uuauacacac aaauacaagu ugc 23

<210> 3761
 <211> 23
 <212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3761

uauauacaca caauacaag uug

23

<210> 3762

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3762

ucaaugucua uuuuaucauga auc

23

<210> 3763

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3763

uuagcaaugu cuuuuuaucau aga

23

<210> 3764

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3764

uauagcaaug ucuuuuuau cag

23

<210> 3765

<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3765
ugaauagcaa ugucuauuuu auc 23

<210> 3766
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3766
uaaacagaau agcaaugucu auu 23

<210> 3767
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3767
uaaaacagaa uagcaauguc uau 23

<210> 3768
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3768
uagagagauu uaguauguag aaau 23

<210> 3769
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3769
ugagagagau uuaguaugua gaa 23

<210> 3770
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3770
uggagagaga uuuaguaugu aga 23

<210> 3771
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3771
uaggagagag auuuaguaug uag 23

<210> 3772
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3772

uaaggagaga gauuuaguau gua 23

<210> 3773
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3773
uaaaggagag agauuuagua ugu 23

<210> 3774
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3774
uaaaaggaga gagauuuagu aug 23

<210> 3775
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3775
uguagcacca auaaaauaaau gau 23

<210> 3776
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3776
uaguagcacc aaauaaauaaa uga 23

<210> 3777
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3777
ucaguagcac caauaaauaa aug 23

<210> 3778
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3778
uacaguagca ccaauaaaua aau 23

<210> 3779
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3779
uaacaguagc accaauaaau aaa 23

<210> 3780
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3780

uaaacaguag caccauaaa uaa

23

<210> 3781

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3781

uauaaacagu agcaccaua aa

23

<210> 3782

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3782

uggauaaaca guagcaccaa uaa

23

<210> 3783

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3783

ucgugauguu aaauuuuuu ccc

23

<210> 3784

<211> 23

<212> RNA

<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 3784
 uagagacaaa gacgugaugu uaa 23

<210> 3785
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 3785
 uuagagacaa agacgugaug uua 23

<210> 3786
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 3786
 uacugcacua gagacaaaga cgu 23

<210> 3787
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 3787
 uaacugcacu agagacaaag acg 23

<210> 3788
 <211> 23
 <212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3788

uaaacugcac uagagacaaa gac

23

<210> 3789

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3789

uuauguacua cggaauaucu cga

23

<210> 3790

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3790

uauauguacu acggaauauc ucg

23

<210> 3791

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3791

uaauauguac uacggaauau cuc

23

<210> 3792

<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3792
uauaucugua uuucuuuguc guu 23

<210> 3793
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3793
uuauaucugu auuucuuugu cgu 23

<210> 3794
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3794
uauauaucug uauuucuuug ucg 23

<210> 3795
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3795
ugauauaucu guauuucuuu guc 23

<210> 3796
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3796
aaaagagaaa guguuuuaua a 21

<210> 3797
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3797
aaaagagaaa guguuuuaua a 21

<210> 3798
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3798
aaaagagaaa guguuuuaua a 21

<210> 3799
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3799

aaagacugau acagaacgau a 21

<210> 3800
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3800
aaagacugau acagaacgau a 21

<210> 3801
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3801
aaagacugau acagaacgau a 21

<210> 3802
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 3802
aaagagaaag tguuuuauau a 21

<210> 3803
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3803
aaagagaaag uguuuuauau a

21

<210> 3804
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3804
aaagagaaag uguuuuauau a

21

<210> 3805
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 3805
aacagugcta auguuauugg a

21

<210> 3806
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3806

aacagugcua auguuauugg a 21

<210> 3807
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3807
aacagugcua auguuauugg a 21

<210> 3808
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3808
aacgaucgau acagaaacca a 21

<210> 3809
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3809
aacgaucgau acagaaacca a 21

<210> 3810
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3810
aacgaucgau acagaaacca a 21

<210> 3811
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 3811
aagacugata cagaacgauc a 21

<210> 3812
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3812
aagacugaua cagaacgauc a 21

<210> 3813
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3813
aagacugaua cagaacgauc a 21

<210> 3814
<211> 21

<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3814
aagagaaagu guuuuauaua a 21

<210> 3815
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3815
aagagaaagu guuuuauaua a 21

<210> 3816
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3816
aagagaaagu guuuuauaua a 21

<210> 3817
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 3817
aauggautc gccauuuuau a 21

<210> 3818
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3818
aauggauuc gccauuuuau a 21

<210> 3819
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3819
aauggauuc gccauuuuau a 21

<210> 3820
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3820
acagaacagu ccuaaucca a 21

<210> 3821
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3821

acagaacagu ccuuaaucca a

21

<210> 3822

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3822

acagaacagu ccuuaaucca a

21

<210> 3823

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 3823

acaguccuta auccagaaac a

21

<210> 3824

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3824

acaguccuua auccagaaac a

21

<210> 3825
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3825
 acaguccuua auccagaaac a 21

<210> 3826
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3826
 accaggaaag acugauacag a 21

<210> 3827
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3827
 accaggaaag acugauacag a 21

<210> 3828
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3828
 accaggaaag acugauacag a 21

<210> 3829
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 3829
accaugcaga tuaugcggau a 21

<210> 3830
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3830
accaugcaga uuaugcggau a 21

<210> 3831
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3831
accaugcaga uuaugcggau a 21

<210> 3832
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

<400> 3832
 agaacagucc tuaauccaga a 21

<210> 3833
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 3833
 agaacagucc uuaauccaga a 21

<210> 3834
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 3834
 agaacagucc uuaauccaga a 21

<210> 3835
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<220>
 <221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 3835
agauguaucu tuugcucucu a 21

<210> 3836
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3836
agauguaucu uuugcucucu a 21

<210> 3837
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3837
agauguaucu uuugcucucu a 21

<210> 3838
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3838
agauuagaga guuuuauuuc a 21

<210> 3839
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3839
 agauuagaga guuuuauuuc a 21

<210> 3840
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3840
 agauuagaga guuuuauuuc a 21

<210> 3841
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3841
 auacagaacg aucgauacag a 21

<210> 3842
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 3842
 auacagaacg aucgauacag a 21

<210> 3843
 <211> 21
 <212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3843

auacagaacg aucgauacag a

21

<210> 3844

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 3844

augcagauta tgcggauc aa a

21

<210> 3845

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3845

augcagauua ugcggauc aa a

21

<210> 3846

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3846
augcagauua ugcggauc aa 21

<210> 3847
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3847
auuggauucg ccuuuuuuuu a 21

<210> 3848
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3848
auuggauucg ccuuuuuuuu a 21

<210> 3849
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3849
auuggauucg ccuuuuuuuu a 21

<210> 3850
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<400> 3850
caacaucacc augcagauua a 21

<210> 3851
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3851
caacaucacc augcagauua a 21

<210> 3852
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3852
caacaucacc augcagauua a 21

<210> 3853
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 3853
cagaacagtc cuuaauccag a 21

<210> 3854

<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3854
cagaacaguc cuuaauccag a 21

<210> 3855
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3855
cagaacaguc cuuaauccag a 21

<210> 3856
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 3856
caucaccatg cagauuauagc a 21

<210> 3857
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<400> 3857
caucaccaug cagauuauagc a 21

<210> 3858
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3858
caucaccaug cagauuauagc a 21

<210> 3859
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 3859
ccucuuggaa tuggauucgc a 21

<210> 3860
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3860
ccucuuggaa uuggauucgc a 21

<210> 3861

<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3861
ccucuuggaa uuggauucgc a 21

<210> 3862
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3862
cuacagcaca aaaauguga a 21

<210> 3863
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3863
cuacagcaca aaaauguga a 21

<210> 3864
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3864
cuacagcaca aaaauguga a 21

<210> 3865
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3865
cugauacaga acgaucgaua a 21

<210> 3866
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3866
cugauacaga acgaucgaua a 21

<210> 3867
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3867
cugauacaga acgaucgaua a 21

<210> 3868
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

<400> 3868
 gaaagugutu tauauacggu a 21

<210> 3869
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 3869
 gaaaguguuu uauauacggu a 21

<210> 3870
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 3870
 gaaaguguuu uauauacggu a 21

<210> 3871
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

<400> 3871
 gagaaagugu tuuauauacg a 21

<210> 3872
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3872
gagaaagugu uuuaauuacg a 21

<210> 3873
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3873
gagaaagugu uuuaauuacg a 21

<210> 3874
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 3874
gauucgccau tuauuuuuuc a 21

<210> 3875
<211> 21
<212> RNA
<213> Artificial Sequence

<220>

<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3875
gauucgccau uuuaauuuuuc a 21

<210> 3876
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3876
gauucgccau uuuaauuuuuc a 21

<210> 3877
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 3877
guccuuaatc cagaaaccug a 21

<210> 3878
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3878
guccuuaauc cagaaaccug a 21

<210> 3879
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3879
guccuuaauc cagaaaccug a 21

<210> 3880
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 3880
guguuuuata tacgguacuu a 21

<210> 3881
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3881
guguuuuuaua uacgguacuu a 21

<210> 3882
<211> 21
<212> RNA
<213> Artificial Sequence

<220>

<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3882
guguuuuaua uacgguacuu a 21

<210> 3883
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 3883
uagacauugc tauucuguuu a 21

<210> 3884
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3884
uagacauugc uauucuguuu a 21

<210> 3885
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3885
uagacauugc uauucuguuu a 21

<210> 3886
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 3886
utauaaaaca ctutctcuu ucu 23

<210> 3887
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 3887
utauaaaaca ctuucucu ucu 23

<210> 3888
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3888
uuauaaaaca cuuucucu ucu 23

<210> 3889

<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 3889
uauugutcuu uauagucuu ucc 23

<210> 3890
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 3890
uauugutcuu uauagucuu ucc 23

<210> 3891
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3891
uauuguucuu uauagucuu ucc 23

<210> 3892
<211> 23
<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 3892

uauataaaac acutucucuu uuc

23

<210> 3893

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 3893

uauataaaac acuuucucuu uuc

23

<210> 3894

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3894

uauauaaaac acuuucucuu uuc

23

<210> 3895

<211> 23

<212> DNA

<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 3895
uccaauaaca utagcacugu ugg 23

<210> 3896
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 3896
uccaauaaca utagcacugu ugg 23

<210> 3897
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3897
uccaauaaca uuagcacugu ugg 23

<210> 3898
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 3898

utggtuucug uaucgaucgu ucu

23

<210> 3899

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 3899

utggtuucug uaucgaucgu ucu

23

<210> 3900

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 3900

uuggtuucug uaucgaucgu ucu

23

<210> 3901

<211> 23

<212> DNA

<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 3901
ugaucguucu gtatcagucu uuc 23

<210> 3902
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 3902
ugaucguucu gtaucagucu uuc 23

<210> 3903
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3903
ugaucguucu guaucagucu uuc 23

<210> 3904
<211> 23
<212> DNA
<213> Artificial Sequence

<220>

<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 3904
utauauaaaa cactutcucu uuu 23

<210> 3905
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 3905
utauauaaaa cacuuucucu uuu 23

<210> 3906
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3906
uuauauaaaa cacuuucucu uuu 23

<210> 3907
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<400> 3907
uauaaaaugg cgaauccaau ucc 23

<210> 3908
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3908
uauaaaaugg cgaauccaau ucc 23

<210> 3909
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3909
uauaaaaugg cgaauccaau ucc 23

<210> 3910
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 3910
utggautaag gactgtucug ucg 23

<210> 3911

<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 3911
utggautaaag gacuguucug ucg 23

<210> 3912
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3912
uuggauuaag gacuguucug ucg 23

<210> 3913
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 3913
uguutcugga utaaggacug uuc 23

<210> 3914
<211> 23
<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 3914

uguutcugga utaaggacug uuc

23

<210> 3915

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 3915

uguutcugga uuaaggacug uuc

23

<210> 3916

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 3916

ucugtatcag ucutuccugg ugc

23

<210> 3917
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 3917
ucugtattcag ucuuuccugg ugc 23

<210> 3918
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3918
ucuguaucaag ucuuuccugg ugc 23

<210> 3919
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 3919
uauccgcaua atctgcaugg ugc 23

<210> 3920
<211> 23

<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 3920
uauccgcaua atcugcaugg ugc 23

<210> 3921
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3921
uauccgcaua aucugcaugg ugc 23

<210> 3922
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 3922
utcuggauua aggactguuc ugu 23

<210> 3923
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 3923
utcuggauua aggacuguuc ugu 23

<210> 3924
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 3924
uucuggauua aggacuguuc ugu 23

<210> 3925
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3925
uagagagcaa aagauacauc ucg 23

<210> 3926
<211> 23
<212> RNA
<213> Artificial Sequence

<220>

<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3926
uagagagcaa aagauacauc ucg 23

<210> 3927
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3927
uagagagcaa aagauacauc ucg 23

<210> 3928
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 3928
ugaaauaaaa ctctctaac uuc 23

<210> 3929
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic

oligonucleotide"

<400> 3929
ugaaauaaaa ctcucuaauc uuc 23

<210> 3930
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3930
ugaaauaaaa cucucuaauc uuc 23

<210> 3931
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 3931
ucugtaucga ucgtucugua ucg 23

<210> 3932
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 3932
ucugtaucga ucguucugua ucg 23

<210> 3933
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 3933
ucugtaucga ucguucugua ucg 23

<210> 3934
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 3934
utugaucgc ataucugca ugg 23

<210> 3935
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 3935
utugauccgc ataaucugca ugg

23

<210> 3936
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 3936
uuugauccgc auaaucugca ugg

23

<210> 3937
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 3937
uaauaaaug gcgaatccaa uuc

23

<210> 3938
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 3938
uaauaaaaug gcgaauccaa uuc 23

<210> 3939
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3939
uaauaaaaug gcgaauccaa uuc 23

<210> 3940
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 3940
utaatcugca uggtgauguu ggc 23

<210> 3941
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 3941
utaatcugca uggugauguu ggc 23

<210> 3942
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 3942
uuaatcugca uggugauguu ggc 23

<210> 3943
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3943
ucuggauuaa ggacuguucu guc 23

<210> 3944
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic

oligonucleotide"

<400> 3944
ucuggauuaa ggacuguucu guc 23

<210> 3945
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3945
ucuggauuaa ggacuguucu guc 23

<210> 3946
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 3946
ugcataaucu gcatggugau guu 23

<210> 3947
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 3947
ugcataaucu gcauggugau guu 23

<210> 3948
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3948
ugcauaaucu gcauggugau guu 23

<210> 3949
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 3949
ugcgaatcca atuccaagag ggc 23

<210> 3950
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 3950
ugcgaatcca atuccaagag ggc 23

<210> 3951
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3951
ugcgaaucca auuccaagag ggc

23

<210> 3952
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 3952
utcacatuug utgtgcugua ggg

23

<210> 3953
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 3953
utcacatuug utgugcugua ggg

23

<210> 3954
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3954
uucacauuug uugugcugua ggg

23

<210> 3955
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 3955
utaucgaucg utctgtauca guc

23

<210> 3956
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 3956
utaucgaucg utcugauca guc

23

<210> 3957
<211> 23

<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 3957
uuaucaugc uucugauca guc 23

<210> 3958
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3958
uaccguauau aaaacacuuu cuc 23

<210> 3959
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3959
uaccguauau aaaacacuuu cuc 23

<210> 3960
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3960
uaccguauau aaaacacuuu cuc 23

<210> 3961
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 3961
ucguauauaa aacactuucu cuu 23

<210> 3962
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 3962
ucguauauaa aacacuuucu cuu 23

<210> 3963
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3963

ucguauauaa aacacuuucu cuu	23
<p><210> 3964 <211> 23 <212> RNA <213> Artificial Sequence</p> <p><220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"</p>	
<p><400> 3964 ugaaaaauaa aauggcgaau ccg</p>	23
<p><210> 3965 <211> 23 <212> DNA <213> Artificial Sequence</p> <p><220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"</p>	
<p><220> <221> source <223> /note="Description of Combined DNA/RNA Molecule: Synthetic oligonucleotide"</p>	
<p><400> 3965 ugaaaaauaa aauggcgaau ccg</p>	23
<p><210> 3966 <211> 23 <212> RNA <213> Artificial Sequence</p> <p><220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"</p>	
<p><400> 3966 ugaaaaauaa aauggcgaau ccg</p>	23
<p><210> 3967 <211> 23 <212> DNA <213> Artificial Sequence</p>	

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 3967
ucaggutucu ggatuaagga cug 23

<210> 3968
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 3968
ucaggutucu ggauuaagga cug 23

<210> 3969
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3969
ucagguuucu ggauuaagga cug 23

<210> 3970
<211> 23
<212> DNA
<213> Artificial Sequence

<220>

<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 3970
uaagtaccgu atataaaaca cuu 23

<210> 3971
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 3971
uaagtaccgu atauaaaaca cuu 23

<210> 3972
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3972
uaaguaccgu auauaaaaca cuu 23

<210> 3973
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 3973

uaaacagaau agcaatgucu auu

23

<210> 3974

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3974

uaaacagaau agcaaugucu auu

23

<210> 3975

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3975

uaaacagaau agcaaugucu auu

23

<210> 3976

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3976

aaaagagaaa guguuuuaua a

21

<210> 3977

<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3977
aaaagagaaa guguuuuaua a 21

<210> 3978
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3978
aaaagagaaa guguuuuaua a 21

<210> 3979
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3979
aaagacugau acagaacgau a 21

<210> 3980
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3980
aaagacugau acagaacgau a 21

<210> 3981
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3981
aaagacugau acagaacgau a 21

<210> 3982
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 3982
aaagagaaag tguuuuauau a 21

<210> 3983
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3983
aaagagaaag uguuuuauau a 21

<210> 3984
<211> 21
<212> RNA
<213> Artificial Sequence

<220>

<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3984
aaagagaaag uguuuuauau a 21

<210> 3985
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 3985
aacagugcta auguuauugg a 21

<210> 3986
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3986
aacagugcua auguuauugg a 21

<210> 3987
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3987
aacagugcua auguuauugg a 21

<210> 3988
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3988
aacgaucgau acagaaacca a 21

<210> 3989
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3989
aacgaucgau acagaaacca a 21

<210> 3990
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3990
aacgaucgau acagaaacca a 21

<210> 3991
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

<400> 3991
 aagacugata cagaacgauc a 21

<210> 3992
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 3992
 aagacugaua cagaacgauc a 21

<210> 3993
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 3993
 aagacugaua cagaacgauc a 21

<210> 3994
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 3994
 aagagaaagu guuuuauaua a 21

<210> 3995
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3995
aagagaaagu guuuuauaua a 21

<210> 3996
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3996
aagagaaagu guuuuauaua a 21

<210> 3997
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 3997
aauggautc gccauuuuau a 21

<210> 3998
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3998

aauggauuc gccauuuuau a 21

<210> 3999
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 3999
aauggauuc gccauuuuau a 21

<210> 4000
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4000
acagaacagu ccuaaucca a 21

<210> 4001
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4001
acagaacagu ccuaaucca a 21

<210> 4002
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4002
acagaacagu ccuaaucca a 21

<210> 4003
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 4003
acaguccuta auccagaaac a 21

<210> 4004
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4004
acaguccuua auccagaaac a 21

<210> 4005
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4005
acaguccuua auccagaaac a 21

<210> 4006
<211> 21

<212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 4006
 accaggaaag acugauacag a 21

<210> 4007
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 4007
 accaggaaag acugauacag a 21

<210> 4008
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 4008
 accaggaaag acugauacag a 21

<210> 4009
 <211> 21
 <212> DNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

<400> 4009
accaugcaga tuaugcggau a 21

<210> 4010
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4010
accaugcaga uuaugcggau a 21

<210> 4011
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4011
accaugcaga uuaugcggau a 21

<210> 4012
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 4012
agaacagucc tuaauccaga a 21

<210> 4013
<211> 21

<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4013
agaacagucc uaaauccaga a 21

<210> 4014
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4014
agaacagucc uaaauccaga a 21

<210> 4015
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 4015
agaugauucu tuugcucucu a 21

<210> 4016
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4016
agauguaucu uuugcucucu a 21

<210> 4017
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4017
agauguaucu uuugcucucu a 21

<210> 4018
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4018
agauuagaga guuuuauuuc a 21

<210> 4019
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4019
agauuagaga guuuuauuuc a 21

<210> 4020
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4020

agauuagaga guuuuauuuc a

21

<210> 4021

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4021

auacagaacg aucgauacag a

21

<210> 4022

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4022

auacagaacg aucgauacag a

21

<210> 4023

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4023

auacagaacg aucgauacag a

21

<210> 4024

<211> 21

<212> DNA

<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

<400> 4024
 augcagauta tgcggauc aa 21

<210> 4025
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 4025
 augcagauua ugcggauc aa 21

<210> 4026
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 4026
 augcagauua ugcggauc aa 21

<210> 4027
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 4027
 auuggauucg ccuuuuuuu a 21

<210> 4028
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4028
auuggauucg ccuuuuuuuu a 21

<210> 4029
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4029
auuggauucg ccuuuuuuuu a 21

<210> 4030
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4030
caacaucc accaugcaguuu a 21

<210> 4031
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4031
caacaucacc augcagauua a 21

<210> 4032
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4032
caacaucacc augcagauua a 21

<210> 4033
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 4033
cagaacagtc cuuaauccag a 21

<210> 4034
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4034
cagaacaguc cuuaauccag a 21

<210> 4035
<211> 21
<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4035

cagaacaguc cuuaauccag a

21

<210> 4036

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 4036

caucaccatg cagauuauagc a

21

<210> 4037

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4037

caucaccaug cagauuauagc a

21

<210> 4038

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4038
caucaccaug cagauuaugc a 21

<210> 4039
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 4039
ccucuuggaa tuggauucgc a 21

<210> 4040
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4040
ccucuuggaa uuggauucgc a 21

<210> 4041
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4041
ccucuuggaa uuggauucgc a 21

<210> 4042
<211> 21
<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4042

cuacagcaca acaaauguga a

21

<210> 4043

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4043

cuacagcaca acaaauguga a

21

<210> 4044

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4044

cuacagcaca acaaauguga a

21

<210> 4045

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4045

cugauacaga acgaucgaua a

21

<210> 4046

<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4046
cugauacaga acgaucgaua a 21

<210> 4047
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4047
cugauacaga acgaucgaua a 21

<210> 4048
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 4048
gaaagugutu tauauacggu a 21

<210> 4049
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<400> 4049
gaaaguguuu uauauacggu a 21

<210> 4050
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4050
gaaaguguuu uauauacggu a 21

<210> 4051
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 4051
gagaaagugu tuuauauacg a 21

<210> 4052
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4052
gagaaagugu uuuauauacg a 21

<210> 4053

<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4053
gagaaagugu uuuaauuacg a 21

<210> 4054
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 4054
gauucgccau tuuauuuuuc a 21

<210> 4055
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4055
gauucgccau uuuaauuuuuc a 21

<210> 4056
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<400> 4056
gauucgccau uuuauuuuuc a 21

<210> 4057
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 4057
guccuuaatc cagaaaccug a 21

<210> 4058
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4058
guccuuaauc cagaaaccug a 21

<210> 4059
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4059
guccuuaauc cagaaaccug a 21

<210> 4060

<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 4060
guguuuuata tacgguacuu a 21

<210> 4061
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4061
guguuuuuaua uacgguacuu a 21

<210> 4062
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4062
guguuuuuaua uacgguacuu a 21

<210> 4063
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 4063

uagacauugc tauucuguuu a

21

<210> 4064

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4064

uagacauugc uauucuguuu a

21

<210> 4065

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4065

uagacauugc uauucuguuu a

21

<210> 4066

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 4066
utauaaaaca ctutctcuu ucu 23

<210> 4067
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 4067
utauaaaaca ctuucucu ucu 23

<210> 4068
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4068
uuauaaaaca cuuucucu ucu 23

<210> 4069
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 4069
uauugutcu uauagucu ucc 23

<210> 4070
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 4070
uauugutug uauagucuu ucc 23

<210> 4071
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4071
uauugucug uauagucuu ucc 23

<210> 4072
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 4072
uauataaaac acutucucuu uuc 23

<210> 4073
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 4073
uauataaaac acuuucucuu uuc 23

<210> 4074
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4074
uauauaaaac acuuucucuu uuc 23

<210> 4075
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 4075
uccaauaaca utagcacugu ugg 23

<210> 4076
<211> 23

<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 4076
uccaauaaca utagcacugu ugg 23

<210> 4077
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4077
uccaauaaca uuagcacugu ugg 23

<210> 4078
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 4078
utggtuucug uaucgaucgu ucu 23

<210> 4079
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 4079
utggtuucug uaucgaucgu ucu 23

<210> 4080
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 4080
uuggtuucug uaucgaucgu ucu 23

<210> 4081
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 4081
ugaucguucu gtatcagucu uuc 23

<210> 4082

<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 4082
ugaucguucu gtaucagucu uuc 23

<210> 4083
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4083
ugaucguucu guaucagucu uuc 23

<210> 4084
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 4084
utauauaaaa cactuttcucu uuu 23

<210> 4085
<211> 23
<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 4085

utauauaaaa cacuuucucu uuu

23

<210> 4086

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4086

uuauauaaaa cacuuucucu uuu

23

<210> 4087

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4087

uauaaaaugg cgaauc caau ucc

23

<210> 4088

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4088
uauaaaaugg cgaauccaau ucc 23

<210> 4089
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4089
uauaaaaugg cgaauccaau ucc 23

<210> 4090
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 4090
utggautaag gactgtucug ucg 23

<210> 4091
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 4091
utggautaag gacuguucug ucg 23

<210> 4092
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4092
uuggauuaag gacuguucug ucg

23

<210> 4093
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 4093
uguutcugga utaaggacug uuc

23

<210> 4094
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 4094
uguutcugga utaaggacug uuc

23

<210> 4095
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 4095
uguutcugga uuaaggacug uuc

23

<210> 4096
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 4096
ucugtatacag ucutuccugg ugc

23

<210> 4097
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 4097

ucugtatacag ucuuuccugg ugc 23

<210> 4098
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4098
ucuguauacag ucuuuccugg ugc 23

<210> 4099
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 4099
uaucgcgauc atctgcaugg ugc 23

<210> 4100
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 4100
uaucgcgauc atcugcaugg ugc 23

<210> 4101
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4101
uauccgcaua aucugcaugg ugc

23

<210> 4102
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 4102
utcuggauua aggactguuc ugu

23

<210> 4103
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 4103
utcuggauua aggacuguuc ugu

23

<210> 4104

<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4104
uucuggauua aggacuguuc ugu 23

<210> 4105
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4105
uagagagcaa aagauacauc ucg 23

<210> 4106
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4106
uagagagcaa aagauacauc ucg 23

<210> 4107
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4107
uagagagcaa aagauacauc ucg 23

<210> 4108
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 4108
ugaaauaaaa ctctctaauc uuc 23

<210> 4109
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 4109
ugaaauaaaa ctcucuaauc uuc 23

<210> 4110
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4110
ugaaauaaaa cucucuaauc uuc 23

<210> 4111

<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 4111
ucugtaucga ucgtucugua ucg 23

<210> 4112
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 4112
ucugtaucga ucguucugua ucg 23

<210> 4113
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 4113
ucugtaucga ucguucugua ucg 23

<210> 4114
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 4114
utugaucgcg ataaucugca ugg 23

<210> 4115
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 4115
utugaucgcg ataaucugca ugg 23

<210> 4116
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4116
uuugaucgcg auaaucugca ugg 23

<210> 4117
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 4117
uaauaaaug gcgaatccaa uuc 23

<210> 4118
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4118
uaauaaaug gcgaauccaa uuc 23

<210> 4119
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4119
uaauaaaug gcgaauccaa uuc 23

<210> 4120
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 4120

utaatcugca uggtgauguu ggc

23

<210> 4121

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 4121

utaatcugca ugguagauguu ggc

23

<210> 4122

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 4122

uuaatcugca ugguagauguu ggc

23

<210> 4123

<211> 23

<212> RNA

<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4123
ucuggauuaa ggacuguucu guc 23

<210> 4124
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4124
ucuggauuaa ggacuguucu guc 23

<210> 4125
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4125
ucuggauuaa ggacuguucu guc 23

<210> 4126
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 4126

ugcataaucu gcatggugau guu 23

<210> 4127
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 4127
ugcataaucu gcauggugau guu 23

<210> 4128
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4128
ugcauaaucu gcauggugau guu 23

<210> 4129
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 4129
ugcgaatcca atuccaagag ggc 23

<210> 4130
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 4130
ugcgaatcca atuccaagag ggc 23

<210> 4131
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4131
ugcgaaucca auuccaagag ggc 23

<210> 4132
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 4132
utcacatuug utgtgcugua ggc 23

<210> 4133

<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 4133
utcacatuug utgugcugua ggg 23

<210> 4134
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4134
uucacauuug uugugcugua ggg 23

<210> 4135
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 4135
utaucgaucg utctgtauca guc 23

<210> 4136
<211> 23
<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 4136

utaucgaucg utcugauca guc

23

<210> 4137

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4137

uuaucgaucg uucugauca guc

23

<210> 4138

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4138

uaccguauau aaaacacuuu cuc

23

<210> 4139

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4139
uaccguauau aaaacacuuu cuc 23

<210> 4140
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4140
uaccguauau aaaacacuuu cuc 23

<210> 4141
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 4141
ucguauauaa aacactuucu cuu 23

<210> 4142
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4142
ucguauauaa aacacuuucu cuu 23

<210> 4143
<211> 23
<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4143

ucguauauaa aacacuuucu cuu

23

<210> 4144

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4144

ugaaaaauaa aauggcgaau ccg

23

<210> 4145

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4145

ugaaaaauaa aauggcgaau ccg

23

<210> 4146

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4146

ugaaaaauaa aauggcgaau ccg

23

<210> 4147

<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 4147
ucaggutucu ggatuaagga cug 23

<210> 4148
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 4148
ucaggutucu ggauuaagga cug 23

<210> 4149
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4149
ucagguuucu ggauuaagga cug 23

<210> 4150
<211> 23
<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 4150

uaagtaccgu atataaaaca cuu

23

<210> 4151

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 4151

uaagtaccgu atauaaaaca cuu

23

<210> 4152

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4152

uaaguaccgu auauaaaaca cuu

23

<210> 4153

<211> 23

<212> DNA

<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <220>
 <221> source
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide"

 <400> 4153
 uaaacagaau agcaatgucu auu 23

 <210> 4154
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 4154
 uaaacagaau agcaaugucu auu 23

 <210> 4155
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 4155
 uaaacagaau agcaaugucu auu 23

 <210> 4156
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 4156
 aagacugaua cagaacgauc a 21

<210> 4157
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4157
acgguacuua uuuaauaucc a

21

<210> 4158
<211> 16
<212> PRT
<213> Unknown

<220>
<221> source
<223> /note="Description of Unknown:
RFGF peptide"

<400> 4158
Ala Ala Val Ala Leu Leu Pro Ala Val Leu Leu Ala Leu Leu Ala Pro
1 5 10 15

<210> 4159
<211> 11
<212> PRT
<213> Unknown

<220>
<221> source
<223> /note="Description of Unknown:
RFGF analogue peptide"

<400> 4159
Ala Ala Leu Leu Pro Val Leu Leu Ala Ala Pro
1 5 10

<210> 4160
<211> 13
<212> PRT
<213> Human immunodeficiency virus

<400> 4160
Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Pro Pro Gln
1 5 10

<210> 4161
<211> 16
<212> PRT
<213> Drosophila sp.

<400> 4161
Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp Lys Lys
1 5 10 15

<210> 4162
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 4162
aacaguguuc uugcucuaua a 21

<210> 4163
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 4163
uuauagagca agaacacugu uuu 23

<210> 4164
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 4164
cgacagaaca guccuuaauc a 21

<210> 4165
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4165
cagaacaguc cuuaauccag a 21

<210> 4166
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4166
cagaacaguc cuuaauccag a 21

<210> 4167
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4167
aacagugcua auguuauugg a 21

<210> 4168
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4168
agugcuaaug uuauuggugu a 21

<210> 4169
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4169
gagaaagugu uuuaauacg a 21

<210> 4170
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4170
aaaauagaca uugcuauucu a 21

<210> 4171
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4171
aaauagacau ugcuaucug a 21

<210> 4172
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4172
gaaaguguuu uauauacggu a 21

<210> 4173
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4173
guuuuauaua cggacuau a 21

<210> 4174
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 4174
agugcuaatg tuauuggugu a 21

<210> 4175
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 4175
aaaauagaca tugcuauucu a 21

<210> 4176
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4176
ugauuaagga cuguucuguc gau

23

<210> 4177
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4177
ucuggauuaa ggacuguucu guc

23

<210> 4178
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 4178
ucuggatuaa ggacuguucu guc

23

<210> 4179
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 4179
 uccaauaaca uuagcacugu uaa 23

<210> 4180
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 4180
 uacaccaua acauuagcac ugu 23

<210> 4181
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 4181
 ucguauauaa aacacuuucu cuu 23

<210> 4182
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

<400> 4182
 uagaauagca augucuauuu uau 23

<210> 4183
 <211> 23
 <212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4183

ucagaauagc aaugucuauu uua

23

<210> 4184

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4184

uaccguauau aaaacacuuu cuc

23

<210> 4185

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4185

uauaaguacc guauauaaaa cac

23

<210> 4186

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>

<221> source

<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 4186
uacaccaua acatuagcac ugu 23

<210> 4187
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 4187
uagaauagca atgtctauuu uau 23

<210> 4188
<211> 23
<212> RNA
<213> Homo sapiens

<400> 4188
aucgacagaa caguccuuaa ucc 23

<210> 4189
<211> 23
<212> RNA
<213> Homo sapiens

<400> 4189
gacagaacag uccuuaaucc aga 23

<210> 4190
<211> 23
<212> RNA
<213> Homo sapiens

<400> 4190
gacagaacag uccuuaaucc aga 23

<210> 4191
<211> 23
<212> RNA
<213> Homo sapiens

<400> 4191
uuaacagugc uaauguuauu ggu 23

<210> 4192
<211> 23
<212> RNA
<213> Homo sapiens

<400> 4192
acagugcuaa uguuauuggu guc 23

<210> 4193
<211> 23
<212> RNA
<213> Homo sapiens

<400> 4193
aagagaaagu guuuuauaua cgg 23

<210> 4194
<211> 23
<212> RNA
<213> Homo sapiens

<400> 4194
auaaaauaga cauugcuauu cug 23

<210> 4195
<211> 23
<212> RNA
<213> Homo sapiens

<400> 4195
uaaaaauagac auugcuauuc ugu 23

<210> 4196
<211> 23
<212> RNA
<213> Homo sapiens

<400> 4196
gagaaagugu uuuauauacg gua 23

<210> 4197
<211> 23
<212> RNA
<213> Homo sapiens

<400> 4197
guguuuuaua uacgguacuu auu 23

<210> 4198
<211> 23
<212> RNA
<213> Homo sapiens

<400> 4198
acagugcuaa uguuauuggu guc 23

<210> 4199
<211> 23
<212> RNA
<213> Homo sapiens

<400> 4199
auaaaauaga cauugcuauu cug 23

<210> 4200
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4200
cgacagaaca guccuuaauc a 21

<210> 4201
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4201
cagaacaguc cuuaauccag a 21

<210> 4202
<211> 21
<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4202

cagaacaguc cuuaauccag a

21

<210> 4203

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4203

aacagugcua auguuauugg a

21

<210> 4204

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4204

agugcuaaug uuauuggugu a

21

<210> 4205

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4205

gagaaagugu uuuaauacg a

21

<210> 4206

<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4206
aaaauagaca uugcuauucu a 21

<210> 4207
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4207
aaaauagacau ugcuaauucug a 21

<210> 4208
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4208
gaaaguguuu uauauacggu a 21

<210> 4209
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4209
guuuuuauaua cgguacuuau a 21

<210> 4210
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 4210
agugcuaatg tuauuggugu a 21

<210> 4211
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 4211
aaaauagaca tugcuauucu a 21

<210> 4212
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4212
ugauuaagga cuguucuguc gau 23

<210> 4213

<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4213
ucuggauuaa ggacuguucu guc 23

<210> 4214
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 4214
ucuggatuaa ggacuguucu guc 23

<210> 4215
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4215
uccaauaaca uuagcacugu uaa 23

<210> 4216
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<400> 4216
uacaccaaua acauuagcac ugu 23

<210> 4217
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4217
ucguauauaa aacacuuucu cuu 23

<210> 4218
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4218
uagaauagca augucuauuu uau 23

<210> 4219
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4219
ucagaauagc aaugucuauu uua 23

<210> 4220
<211> 23
<212> RNA
<213> Artificial Sequence

<220>

<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4220
uaccguauau aaaacacuuu cuc 23

<210> 4221
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 4221
uauaaguacc guauauaaaa cac 23

<210> 4222
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 4222
uacaccaua acatuagcac ugu 23

<210> 4223
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic

oligonucleotide"

<400> 4223
uagaauagca atgtctauuu uau 23

<210> 4224
<211> 23
<212> RNA
<213> Homo sapiens

<400> 4224
gaaagacuga uacagaacga ucg 23

<210> 4225
<211> 23
<212> RNA
<213> Homo sapiens

<400> 4225
auacgguacu uauuuauau ccc 23

<210> 4226
<211> 23
<212> RNA
<213> Homo sapiens

<400> 4226
gacagaacag uccuuaaucc aga 23

<210> 4227
<211> 23
<212> RNA
<213> Homo sapiens

<400> 4227
aucgacagaa caguccuuaa ucc 23

<210> 4228
<211> 23
<212> RNA
<213> Homo sapiens

<400> 4228
aagcauuugu uuguacaaga ucc 23

<210> 4229
<211> 23
<212> RNA

<213> Homo sapiens	
<400> 4229	
guuauuggug ucuucacugg aug	23
<210> 4230	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4230	
agacugauac agaacgaucg aua	23
<210> 4231	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4231	
ggaaagacug auacagaacg auc	23
<210> 4232	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4232	
ugauacagaa cgaucgauac aga	23
<210> 4233	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4233	
gacugauaca gaacgaucga uac	23
<210> 4234	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4234	
aagagaaagu guuuuauaua cgg	23
<210> 4235	
<211> 23	
<212> RNA	

<213> Homo sapiens	
<400> 4235	
aaacgaacgu acuugcagau gug	23
<210> 4236	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4236	
cucuuggaau uggauucgcc auu	23
<210> 4237	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4237	
gaggcagcuu gaguuaaacg aac	23
<210> 4238	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4238	
gagggcagaa ucaucacgaa gug	23
<210> 4239	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4239	
aguuaaacga acguacuugc aga	23
<210> 4240	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4240	
auguuauugg ugucuucacu gga	23
<210> 4241	
<211> 23	
<212> RNA	

<213> Homo sapiens

<400> 4241

gcagcuugag uuaaacgaac gua

23

<210> 4242

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4242

aggcagcuug aguuaaacga acg

23

<210> 4243

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4243

cacgaagugg ugaagucau gga

23

<210> 4244

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4244

ggcagaauca ucacgaagug gug

23

<210> 4245

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4245

auaaaauaga cauugcuauu cug

23

<210> 4246

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4246

ggcagcuuga guuaaacgaa cgu

23

<210> 4247

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4247

gucgcacuga aacuuuucgu cca

23

<210> 4248

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4248

gcagauuaug cggaucuaac cuc

23

<210> 4249

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4249

uugcucucuu auuuguaccg guu

23

<210> 4250

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4250

ggugacaguc acuagcuuau cuu

23

<210> 4251

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4251

agcuugaguu aaacgaacgu acu

23

<210> 4252

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4252

acagugcuaa uguuauuggu guc

23

<210> 4253

<211> 23

<212> RNA

<213> Homo sapiens	
<400> 4253	
agauccgcag acguguaau guu	23
<210> 4254	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4254	
aaagacugau acagaacgau cga	23
<210> 4255	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4255	
aauguuauug gugucuucac ugg	23
<210> 4256	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4256	
cggugcugga auuugauauu cau	23
<210> 4257	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4257	
ucuugcugcu aaauccacga gcc	23
<210> 4258	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4258	
aucaccaugc agauuaugcg gau	23
<210> 4259	
<211> 23	
<212> RNA	

<213> Homo sapiens

<400> 4259

gagaaagcau uuguuuguac aag

23

<210> 4260

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4260

cagcuugagu uaaacgaacg uac

23

<210> 4261

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4261

gaucggugac agucacuagc uua

23

<210> 4262

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4262

cgaggcagcu ugaguuaaac gaa

23

<210> 4263

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4263

uccugcaaaa acacagacuc gcg

23

<210> 4264

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4264

uucuugcugc uaaaucaccg agc

23

<210> 4265

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4265
uuuucuugcu gcuaaaucac cga 23

<210> 4266
<211> 23
<212> RNA
<213> Homo sapiens

<400> 4266
agaaagcauu uguuuguaca aga 23

<210> 4267
<211> 23
<212> RNA
<213> Homo sapiens

<400> 4267
gauccgcaga cguguaaaug uuc 23

<210> 4268
<211> 23
<212> RNA
<213> Homo sapiens

<400> 4268
uacgguacuu auuuauauc ccu 23

<210> 4269
<211> 23
<212> RNA
<213> Homo sapiens

<400> 4269
aagacugaua cagaacgauc gau 23

<210> 4270
<211> 23
<212> RNA
<213> Homo sapiens

<400> 4270
caaaaacaca gacucgcguu gca 23

<210> 4271
<211> 23
<212> RNA

<213> Homo sapiens

<400> 4271

uugaguuaaa cgaacguacu ugc

23

<210> 4272

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4272

cuucacugga uguauuugac ugc

23

<210> 4273

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4273

ggccuccgaa accaugaacu uuc

23

<210> 4274

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4274

gcuugaguua aacgaacgua cuu

23

<210> 4275

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4275

ggugcuacug uuuauccgua aua

23

<210> 4276

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4276

auccgcagac guguaaangu ucc

23

<210> 4277

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4277

uccgcagacg uguaaauguu ccu

23

<210> 4278

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4278

gaagagaaga gacacauugu ugg

23

<210> 4279

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4279

cuacagcaca acaaauauga aug

23

<210> 4280

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4280

uuucuugcug cuaaucacc gag

23

<210> 4281

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4281

ucacaccuu gaaaccacua guu

23

<210> 4282

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4282

gcgaggcagc uugaguuaaa cga

23

<210> 4283

<211> 23

<212> RNA

<213> Homo sapiens	
<400> 4283 ucgcacugaa acuuuucguc caa	23
<210> 4284 <211> 23 <212> RNA <213> Homo sapiens	
<400> 4284 guguuuuaua uacgguacuu auu	23
<210> 4285 <211> 23 <212> RNA <213> Homo sapiens	
<400> 4285 cacaccauug aaaccacuag uuc	23
<210> 4286 <211> 23 <212> RNA <213> Homo sapiens	
<400> 4286 acaucaccau gcagauuaug cgg	23
<210> 4287 <211> 23 <212> RNA <213> Homo sapiens	
<400> 4287 cuugaguuaa acgaacguac uug	23
<210> 4288 <211> 23 <212> RNA <213> Homo sapiens	
<400> 4288 gagaaagugu uuuauauacg gua	23
<210> 4289 <211> 23 <212> RNA	

<213> Homo sapiens	
<400> 4289	
ugacagucac uagcuuauucu uga	23
<210> 4290	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4290	
uggugcuacu guuuauccgu aa	23
<210> 4291	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4291	
uuccugcaaa aacacagacu cgc	23
<210> 4292	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4292	
ugcaaaaaca cagacucgcg uug	23
<210> 4293	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4293	
acugcugugg acuugaguug gga	23
<210> 4294	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4294	
cagugcuaau guuauuggug ucu	23
<210> 4295	
<211> 23	
<212> RNA	

<213> Homo sapiens	
<400> 4295	
auuggugcua cuguuuaucc gua	23
<210> 4296	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4296	
agagaaagug uuuuauauac ggu	23
<210> 4297	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4297	
ucaacuauuu augagaugua ucu	23
<210> 4298	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4298	
ugaguuaaac gaacguacuu gca	23
<210> 4299	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4299	
uacaucuuca agccauccug ugu	23
<210> 4300	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4300	
gguuuuuuuu caguauucuu ggu	23
<210> 4301	
<211> 23	
<212> RNA	

<213> Homo sapiens

<400> 4301

guuuauccgu aaauuugug ggg

23

<210> 4302

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4302

acgguacua uuuaauaucc cuu

23

<210> 4303

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4303

aucacgucu ugucucuagu gca

23

<210> 4304

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4304

ccugcaaaaa cacagacucg cgu

23

<210> 4305

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4305

caacuauua ugagauguau cuu

23

<210> 4306

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4306

aaaggggcaa aaacgaaagc gca

23

<210> 4307

<211> 23

<212> RNA

<213> Homo sapiens	
<400> 4307	
ucuugcucuc uuauuuguac cgg	23
<210> 4308	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4308	
gcuuuuguuu guacaagauc cgc	23
<210> 4309	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4309	
acuugcagau gugacaagcc gag	23
<210> 4310	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4310	
uucaacuauu uaugagaugu auc	23
<210> 4311	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4311	
agaauucuaac auacuaaauc ucu	23
<210> 4312	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4312	
cuauguccuc acaccauuga aac	23
<210> 4313	
<211> 23	
<212> RNA	

<213> Homo sapiens	
<400> 4313 auuuguuugu acaagaucg cag	23
<210> 4314 <211> 23 <212> RNA <213> Homo sapiens	
<400> 4314 cuuaauccag aaaccugaaa uga	23
<210> 4315 <211> 23 <212> RNA <213> Homo sapiens	
<400> 4315 aagaaaaaaa aucaguucga gga	23
<210> 4316 <211> 23 <212> RNA <213> Homo sapiens	
<400> 4316 aggggcaaaa acgaaagcgc aag	23
<210> 4317 <211> 23 <212> RNA <213> Homo sapiens	
<400> 4317 ggugaaguuc auggaugucu auc	23
<210> 4318 <211> 23 <212> RNA <213> Homo sapiens	
<400> 4318 aucacgaagu ggugaaguuc aug	23
<210> 4319 <211> 23 <212> RNA	

<213> Homo sapiens

<400> 4319

ucacgucuuu gucucuagug cag

23

<210> 4320

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4320

ccaacauac caugcagauu aug

23

<210> 4321

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4321

uuggugcuac uguuuauccg uaa

23

<210> 4322

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4322

uaaaauagac auugcuauuc ugu

23

<210> 4323

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4323

acuucccaa aucacugugg auu

23

<210> 4324

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4324

aagaucgca gacguguaaa ugu

23

<210> 4325

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4325

uauuaacauc acgucuuugu cuc

23

<210> 4326

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4326

gcaaagugag ugaccugcuu uug

23

<210> 4327

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4327

gcaaaaacac agacucgcgu ugc

23

<210> 4328

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4328

ggcgucgcac ugaaacuuuu cgu

23

<210> 4329

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4329

uuaacagugc uaauguuauu ggu

23

<210> 4330

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4330

uuuucgucca acuucugggc ugu

23

<210> 4331

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4331
uuauuggugu cuucacugga ugu 23

<210> 4332
<211> 23
<212> RNA
<213> Homo sapiens

<400> 4332
cugcaaaaac acagacucgc guu 23

<210> 4333
<211> 23
<212> RNA
<213> Homo sapiens

<400> 4333
aaaaaaaauca guucgaggaa agg 23

<210> 4334
<211> 23
<212> RNA
<213> Homo sapiens

<400> 4334
cgcagacgug uaaauguucc ugc 23

<210> 4335
<211> 23
<212> RNA
<213> Homo sapiens

<400> 4335
uauuccuca caccauugaa acc 23

<210> 4336
<211> 23
<212> RNA
<213> Homo sapiens

<400> 4336
guuuuuuuuc aguauucuug guu 23

<210> 4337
<211> 23
<212> RNA

<213> Homo sapiens	
<400> 4337	
caagauccgc agacguguaa aug	23
<210> 4338	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4338	
gucccucuug gaauuggauu cgc	23
<210> 4339	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4339	
aagauauuaa caucacgucu uug	23
<210> 4340	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4340	
uauuggugcu acuguuuau cgu	23
<210> 4341	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4341	
gaaaggggca aaaacgaaag cgc	23
<210> 4342	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4342	
uacuugcaga ugugacaagc cga	23
<210> 4343	
<211> 23	
<212> RNA	

<213> Homo sapiens

<400> 4343

aaaaaucagu ucgaggaaag gga

23

<210> 4344

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4344

aaacuuuucg uccaacuucu ggg

23

<210> 4345

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4345

auauuaacau cacgucuuug ucu

23

<210> 4346

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4346

cacgucuuug ucucuagugc agu

23

<210> 4347

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4347

aaaacacaga cucgcuugc aag

23

<210> 4348

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4348

agauauuaac aucacgucuu ugu

23

<210> 4349

<211> 23

<212> RNA

<213> Homo sapiens	
<400> 4349	
cuguuuaucc gaaauuuug ugg	23
<210> 4350	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4350	
aaaaaauccg uucgaggaaa ggg	23
<210> 4351	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4351	
uguuuauccg uauuuuuuuu ggg	23
<210> 4352	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4352	
ucaggacauu gcugugcuuu ggg	23
<210> 4353	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4353	
agacugauac agaaggaucg aua	23
<210> 4354	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4354	
ggaaagacug auacagaacg auc	23
<210> 4355	
<211> 23	
<212> RNA	

<213> Homo sapiens	
<400> 4355	
aagagaaagu guuuuauaua cgg	23
<210> 4356	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4356	
aaagacugau acagaacgau cga	23
<210> 4357	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4357	
uucaacuauu uaugagaugu auc	23
<210> 4358	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4358	
gaaagacuga uacagaacga ucg	23
<210> 4359	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4359	
ugauacagaa cgaucgauac aga	23
<210> 4360	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4360	
uuaacagugc uaauguuauu ggu	23
<210> 4361	
<211> 23	
<212> RNA	

<213> Homo sapiens

<400> 4361
cagugcuaau guuauuggug ucu 23

<210> 4362
<211> 23
<212> RNA
<213> Homo sapiens

<400> 4362
ucaacuauuu augagaugua ucu 23

<210> 4363
<211> 23
<212> RNA
<213> Homo sapiens

<400> 4363
gacagaacag uccuuaaucc aga 23

<210> 4364
<211> 23
<212> RNA
<213> Homo sapiens

<400> 4364
aagacugaua cagaacgauc gau 23

<210> 4365
<211> 23
<212> RNA
<213> Homo sapiens

<400> 4365
cuacagcaca acaaauauga aug 23

<210> 4366
<211> 23
<212> RNA
<213> Homo sapiens

<400> 4366
uaaaauagac auugcuauuc ugu 23

<210> 4367
<211> 23
<212> RNA

<213> Homo sapiens

<400> 4367

guuauuggug ucuucacugg aug

23

<210> 4368

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4368

gacugauaca gaacgaucga uac

23

<210> 4369

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4369

uugcucucuu auuuguaccg guu

23

<210> 4370

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4370

cacaccauug aaaccacuag uuc

23

<210> 4371

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4371

gaggcagcuu gaguuaaacg aac

23

<210> 4372

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4372

aguuaaacga acguacuugc aga

23

<210> 4373

<211> 23

<212> RNA

<213> Homo sapiens	
<400> 4373	
gaucggugac agucacuagc uua	23
<210> 4374	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4374	
ugaguuaaac gaacguacuu gca	23
<210> 4375	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4375	
aggcagcuug aguuaaacga acg	23
<210> 4376	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4376	
acagugcuaa uguuauuggu guc	23
<210> 4377	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4377	
cacgaagugg ugaagucau gga	23
<210> 4378	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4378	
agaaagcauu uguuuguaca aga	23
<210> 4379	
<211> 23	
<212> RNA	

<213> Homo sapiens	
<400> 4379	
cuauguccuc acaccauuga aac	23
<210> 4380	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4380	
cuugaguuaa acgaacguac uug	23
<210> 4381	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4381	
ucacaccauu gaaaccacua guu	23
<210> 4382	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4382	
ugcaaaaaca cagacucgcg uug	23
<210> 4383	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4383	
uauguccuca caccauugaa acc	23
<210> 4384	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4384	
ggcagcuuga guuaaacgaa cgu	23
<210> 4385	
<211> 23	
<212> RNA	

<213> Homo sapiens

<400> 4385

uuggugcuac uguuuauccg uaa

23

<210> 4386

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4386

ucuugcucuc uuauuuguac cgg

23

<210> 4387

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4387

uuucuugcug cuaaucacc gag

23

<210> 4388

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4388

uacgguacuu auuuauauc ccu

23

<210> 4389

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4389

auaaaauaga cauugcuauu cug

23

<210> 4390

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4390

aaacuuuucg uccaacuucu ggg

23

<210> 4391

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4391

uauuggugcu acuguuuauac cgu

23

<210> 4392

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4392

auguuauugg ugucuucacu gga

23

<210> 4393

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4393

uuuucgucca acuucugggc ugu

23

<210> 4394

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4394

uuuucuugcu gcuaaaucac cga

23

<210> 4395

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4395

acgguacuua uuuaauaucc cuu

23

<210> 4396

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4396

agauauuaac aucacgucuu ugu

23

<210> 4397

<211> 23

<212> RNA

<213> Homo sapiens	
<400> 4397	
gcgaggcagc uugaguuaaa cga	23
<210> 4398	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4398	
uggugcuacu guuuauccgu aa	23
<210> 4399	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4399	
cgaggcagcu ugaguuaaac gaa	23
<210> 4400	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4400	
auuggugcua cuguuaucc gua	23
<210> 4401	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4401	
gaaaggggca aaaacgaaag cgc	23
<210> 4402	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4402	
ugacagucac uagcuuau cu uga	23
<210> 4403	
<211> 23	
<212> RNA	

<213> Homo sapiens

<400> 4403

auacgguacu uauuuauau ccc

23

<210> 4404

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4404

uugaguuaaa cgaacguacu ugc

23

<210> 4405

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4405

aauguuauug gugucuucac ugg

23

<210> 4406

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4406

aucgacagaa caguccuuaa ucc

23

<210> 4407

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4407

aaaaaauag uucgaggaaa ggg

23

<210> 4408

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4408

cucuuggaau uggauucgcc auu

23

<210> 4409

<211> 23

<212> RNA

<213> Homo sapiens	
<400> 4409	
gaagagaaga gacacauugu ugg	23
<210> 4410	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4410	
ucacgucuuu gucucuagug cag	23
<210> 4411	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4411	
ggugacaguc acuagcuuau cuu	23
<210> 4412	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4412	
gcuugaguua aacgaacgua cuu	23
<210> 4413	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4413	
gagaaagcau uuguuuguac aag	23
<210> 4414	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4414	
acaucaccau gcagauuaug cgg	23
<210> 4415	
<211> 23	
<212> RNA	

<213> Homo sapiens	
<400> 4415 aucaccaugc agauuaugcg gau	23
<210> 4416 <211> 23 <212> RNA <213> Homo sapiens	
<400> 4416 agcuugaguu aaacgaacgu acu	23
<210> 4417 <211> 23 <212> RNA <213> Homo sapiens	
<400> 4417 acuugcagau gugacaagcc gag	23
<210> 4418 <211> 23 <212> RNA <213> Homo sapiens	
<400> 4418 caacuauuuu ugagauguau cuu	23
<210> 4419 <211> 23 <212> RNA <213> Homo sapiens	
<400> 4419 gguuuuuuuu cagauucuu ggu	23
<210> 4420 <211> 23 <212> RNA <213> Homo sapiens	
<400> 4420 guguuuuaua uacgguacuu auu	23
<210> 4421 <211> 23 <212> RNA	

<213> Homo sapiens

<400> 4421

gagaaagugu uuauauacg gua

23

<210> 4422

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4422

cuucacugga uguauuugac ugc

23

<210> 4423

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4423

cagcuugagu uaaacgaacg uac

23

<210> 4424

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4424

ggccuccgaa accaugaacu uuc

23

<210> 4425

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4425

aaaaaaauca guucgaggaa agg

23

<210> 4426

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4426

uagagaauuc uacauacuaa auc

23

<210> 4427

<211> 23

<212> RNA

<213> Homo sapiens	
<400> 4427	
gcagauuaug cggaucaaac cuc	23
<210> 4428	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4428	
aaaaaucagu ucgaggaaag gga	23
<210> 4429	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4429	
aagcauuugu uuguacaaga ucc	23
<210> 4430	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4430	
aucacgaagu ggugaaguuc aug	23
<210> 4431	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4431	
cuuaauccag aaaccugaaa uga	23
<210> 4432	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4432	
uacaucuuca agccauccug ugu	23
<210> 4433	
<211> 23	
<212> RNA	

<213> Homo sapiens

<400> 4433

ggugcuacug uuuaucCGua aua

23

<210> 4434

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4434

ucuugcugcu aaauCaccga gcc

23

<210> 4435

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4435

aagauauuaa caucacgucu uug

23

<210> 4436

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4436

uccugcaaaa acacagacuc gcg

23

<210> 4437

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4437

uucuugcugc uaaauCaccg agc

23

<210> 4438

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4438

agagaaagug uuuuauauac ggu

23

<210> 4439

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4439
ccaacauac caugcagauu aug 23

<210> 4440
<211> 23
<212> RNA
<213> Homo sapiens

<400> 4440
uccgcagacg uguaaauguu ccu 23

<210> 4441
<211> 23
<212> RNA
<213> Homo sapiens

<400> 4441
gcagcuugag uuaaacgaac gua 23

<210> 4442
<211> 23
<212> RNA
<213> Homo sapiens

<400> 4442
ucgcacugaa acuuuucguc caa 23

<210> 4443
<211> 23
<212> RNA
<213> Homo sapiens

<400> 4443
agaauucua acuaaaauc ucu 23

<210> 4444
<211> 23
<212> RNA
<213> Homo sapiens

<400> 4444
auccgcagac guguaaangu ucc 23

<210> 4445
<211> 23
<212> RNA

<213> Homo sapiens	
<400> 4445	
gauccgcaga cguguaaaug uuc	23
<210> 4446	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4446	
gucgcacuga aacuuuucgu cca	23
<210> 4447	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4447	
gucccucuug gaauuggauu cgc	23
<210> 4448	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4448	
cgcagacgug uaaauguucc ugc	23
<210> 4449	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4449	
aaacgaacgu acuugcagau gug	23
<210> 4450	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4450	
agauccgcag acguguaaaau guu	23
<210> 4451	
<211> 23	
<212> RNA	

<213> Homo sapiens

<400> 4451

ggcagaauca ucacgaagug gug

23

<210> 4452

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4452

uuccugcaaa aacacagacu cgc

23

<210> 4453

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4453

ucaggacauu gcugugcuuu ggg

23

<210> 4454

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4454

gagggcagaa ucaucacgaa gug

23

<210> 4455

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4455

ggugaaguuc auggaugucu auc

23

<210> 4456

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4456

ggcgucgcac ugaaacuuuu cgu

23

<210> 4457

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4457

aagaaaaaaa aucaguucga gga

23

<210> 4458

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4458

uuauuggugu cuucacugga ugu

23

<210> 4459

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4459

caagauccgc agacguguaa aug

23

<210> 4460

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4460

aagauccgca gacguguaaa ugu

23

<210> 4461

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4461

auuuguuugu acaagauccg cag

23

<210> 4462

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4462

acugcugugg acuugaguug gga

23

<210> 4463

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4463

aucacgucuu ugucucuagu gca

23

<210> 4464

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4464

guuuuuuuuc aguuuucuug guu

23

<210> 4465

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4465

cggugcugga auuugauauu cau

23

<210> 4466

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4466

uauuaacauc acgucuuugu cuc

23

<210> 4467

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4467

aaaggggcaa aaacgaaagc gca

23

<210> 4468

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4468

gcaaagugag ugaccugcuu uug

23

<210> 4469

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4469

gcaaaaacac agacucgcgu ugc

23

<210> 4470

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4470

gcuuuuguuu guacaagauc cgc

23

<210> 4471

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4471

acuuccccaa aucacugugg auu

23

<210> 4472

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4472

auauuaacau cacgucuuug ucu

23

<210> 4473

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4473

cacgucuuug ucucuagugc agu

23

<210> 4474

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4474

caaaaacaca gacucgcguu gca

23

<210> 4475

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4475

ccugcaaaaa cacagacucg cgu

23

<210> 4476

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4476

aaaacacaga cucgcguugc aag

23

<210> 4477

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4477

uacuugcaga ugugacaagc cga

23

<210> 4478

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4478

uguuuauccg uaauaaugu ggg

23

<210> 4479

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4479

cugcaaaaac acagacucgc guu

23

<210> 4480

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4480

cuguuuaucc guaauaaug ugg

23

<210> 4481

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4481

aggggcaaaa acgaaagcgc aag

23

<210> 4482

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4482

guuuauccgu aaauauugug ggg

23

<210> 4483

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4483

auaaaauaga cauugcuauu cug

23

<210> 4484

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4484

acagugcuaa uguuauuggu guc

23

<210> 4485

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4485

ugauacagaa cgaucgauac aga

23

<210> 4486

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4486

cuacagcaca acaaauguga aug

23

<210> 4487

<211> 23

<212> RNA

<213> Homo sapiens	
<400> 4487	
gacugauaca gaacgaucga uac	23
<210> 4488	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4488	
aagagaaagu guuuuauaua cgg	23
<210> 4489	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4489	
ucaacuauuu augagaugua ucu	23
<210> 4490	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4490	
gaaagacuga uacagaacga ucg	23
<210> 4491	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4491	
uagagaauuc uacauacuaa auc	23
<210> 4492	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4492	
ggaaagacug auacagaacg auc	23
<210> 4493	
<211> 23	
<212> RNA	

<213> Homo sapiens

<400> 4493

auacgguacu uauuuauau ccc

23

<210> 4494

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4494

agacugauac agaacgaucg aua

23

<210> 4495

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4495

aucgacagaa caguccuuaa ucc

23

<210> 4496

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4496

gacagaacag uccuuaaucc aga

23

<210> 4497

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4497

uuaacagugc uaauguuauu ggu

23

<210> 4498

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4498

ugacagucac uagcuuau cu uga

23

<210> 4499

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4499

uucuugcugc uaaaucaccg agc

23

<210> 4500

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4500

gagaaagugu uuuaauuacg gua

23

<210> 4501

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4501

uugcucucuu auuuguaccg guu

23

<210> 4502

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4502

uuuucuugcu gcuaaaucac cga

23

<210> 4503

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4503

cacaccaug aaaccacuag uuc

23

<210> 4504

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4504

uacgguacuu auuuauauc ccu

23

<210> 4505

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4505

uucaacuauu uaugagaugu auc

23

<210> 4506

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4506

cuuaauccag aaaccugaaa uga

23

<210> 4507

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4507

uaaaaauagac auugcuauuc ugu

23

<210> 4508

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4508

agaaagcauu uguuuguaca aga

23

<210> 4509

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4509

cucuuggaau uggauucgcc auu

23

<210> 4510

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4510

ucacaccauu gaaaccacua guu

23

<210> 4511

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4511
ccaacaucaac caugcagauu aug 23

<210> 4512
<211> 23
<212> RNA
<213> Homo sapiens

<400> 4512
ggugacaguc acuagcuuau cuu 23

<210> 4513
<211> 23
<212> RNA
<213> Homo sapiens

<400> 4513
ugaguuaaac gaacguacuu gca 23

<210> 4514
<211> 23
<212> RNA
<213> Homo sapiens

<400> 4514
caacuauuuu ugagauguau cuu 23

<210> 4515
<211> 23
<212> RNA
<213> Homo sapiens

<400> 4515
aguuaaacga acguacuugc aga 23

<210> 4516
<211> 23
<212> RNA
<213> Homo sapiens

<400> 4516
acgguacuua uuuaauaucc cuu 23

<210> 4517
<211> 23
<212> RNA

<213> Homo sapiens

<400> 4517

cacgaagugg ugaagucau gga

23

<210> 4518

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4518

aauguuauug gugucuucac ugg

23

<210> 4519

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4519

ucuugcucuc uuauuuguac cgg

23

<210> 4520

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4520

guguuuuaua uacgguacuu auu

23

<210> 4521

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4521

cuucacugga uguauuugac ugc

23

<210> 4522

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4522

ggccuccgaa accaugaacu uuc

23

<210> 4523

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4523

guuauuggug ucuucacugg aug

23

<210> 4524

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4524

aaagacugau acagaacgau cga

23

<210> 4525

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4525

gauccgcaga cguguaaaug uuc

23

<210> 4526

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4526

uugaguuaaa cgaacguacu ugc

23

<210> 4527

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4527

agagaaagug uuuuauauac ggu

23

<210> 4528

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4528

auguuauugg ugucuucacu gga

23

<210> 4529

<211> 23

<212> RNA

<213> Homo sapiens	
<400> 4529	
agcuugaguu aaacgaacgu acu	23
<210> 4530	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4530	
cuugaguuaa acgaacguac uug	23
<210> 4531	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4531	
acaucaccau gcagauuaug cgg	23
<210> 4532	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4532	
gcuugaguua aacgaacgua cuu	23
<210> 4533	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4533	
aggcagcuug aguuaaacga acg	23
<210> 4534	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4534	
gucgcacuga aacuuuucgu cca	23
<210> 4535	
<211> 23	
<212> RNA	

<213> Homo sapiens

<400> 4535

gaucggugac agucacuagc uua

23

<210> 4536

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4536

cagugcuaau guuauuggug ucu

23

<210> 4537

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4537

uccgcagacg uguaaauguu ccu

23

<210> 4538

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4538

gaagagaaga gacacauugu ugg

23

<210> 4539

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4539

ggugaaguuc auggaugucu auc

23

<210> 4540

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4540

agaauucuac auacuaaauc ucu

23

<210> 4541

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4541

cgcagacgug uaaauguucc ugc

23

<210> 4542

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4542

aucacgaagu ggugaaguuc aug

23

<210> 4543

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4543

cagcuugagu uaaacgaacg uac

23

<210> 4544

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4544

uacaucuuca agccauccug ugu

23

<210> 4545

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4545

aucaccaugc agauuaugcg gau

23

<210> 4546

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4546

gaggcagcuu gaguuaaacg aac

23

<210> 4547

<211> 23

<212> RNA

<213> Homo sapiens	
<400> 4547	
cuauguccuc acaccauuga aac	23
<210> 4548	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4548	
auccgcagac guguaaangu ucc	23
<210> 4549	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4549	
ggcagaauca ucacgaagug gug	23
<210> 4550	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4550	
uggugcuacu guuuauccgu aaU	23
<210> 4551	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4551	
uauguccuca caccauugaa acc	23
<210> 4552	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4552	
uccugcaaaa acacagacuc gcg	23
<210> 4553	
<211> 23	
<212> RNA	

<213> Homo sapiens	
<400> 4553	
gcgaggcagc uugaguuaaa cga	23
<210> 4554	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4554	
agauccgcag acguguaaa guu	23
<210> 4555	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4555	
aagcauuugu uuguacaaga ucc	23
<210> 4556	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4556	
gagaaagcau uuguuuguac aag	23
<210> 4557	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4557	
auuggugcua cuguuuaucc gua	23
<210> 4558	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4558	
cgaggcagcu ugaguuaaac gaa	23
<210> 4559	
<211> 23	
<212> RNA	

<213> Homo sapiens	
<400> 4559	
ucgcacugaa acuuuucguc caa	23
<210> 4560	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4560	
aagacugaua cagaacgauc gau	23
<210> 4561	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4561	
aaacgaacgu acuugcagau gug	23
<210> 4562	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4562	
ggcagcuuga guuaaacgaa cgu	23
<210> 4563	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4563	
gcagcuugag uuaaacgaac gua	23
<210> 4564	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4564	
aagauauuaa caucacgucu uug	23
<210> 4565	
<211> 23	
<212> RNA	

<213> Homo sapiens	
<400> 4565	
uuccugcaaa aacacagacu cgc	23
<210> 4566	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4566	
cggugcugga auuugauau cau	23
<210> 4567	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4567	
uauuggugcu acuguuuau cgu	23
<210> 4568	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4568	
uuauuggugu cuucacugga ugu	23
<210> 4569	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4569	
uuucuugcug cuaaucacc gag	23
<210> 4570	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4570	
ucuugcugcu aaucaccga gcc	23
<210> 4571	
<211> 23	
<212> RNA	

<213> Homo sapiens

<400> 4571

gcagauuaug cggaucacaaac cuc

23

<210> 4572

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4572

gagggcagaa ucaucacgaa gug

23

<210> 4573

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4573

gcuuuuuuuu guacaagauc cgc

23

<210> 4574

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4574

ugcaaaaaca cagacucgcg uug

23

<210> 4575

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4575

ggugcuacug uuuaucgua aua

23

<210> 4576

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4576

aaacuuuucg uccaacuucu ggg

23

<210> 4577

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4577

uuggugcuac uguuuauccg uaa

23

<210> 4578

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4578

cugcaaaaac acagacucgc guu

23

<210> 4579

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4579

ggcgucgcac ugaaacuuuu cg

23

<210> 4580

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4580

agauauuaac aucacgucuu ugu

23

<210> 4581

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4581

caaaaacaca gacucgcguu gca

23

<210> 4582

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4582

uacuugcaga ugugacaagc cga

23

<210> 4583

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4583

gguuuuuuuu caguauucuu ggu

23

<210> 4584

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4584

gcaaagugag ugaccugcuu uug

23

<210> 4585

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4585

uuuucgucca acuucugggc ugu

23

<210> 4586

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4586

ucaggacauu gcugugcuuu ggg

23

<210> 4587

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4587

aaaaaucagu ucaggaaaag gga

23

<210> 4588

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4588

acuuccccaa aucacugugg auu

23

<210> 4589

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4589

gucccucuug gaauuggauu cgc

23

<210> 4590

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4590

acuugcagau gugacaagcc gag

23

<210> 4591

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4591

aucacgucuu ugucucuagu gca

23

<210> 4592

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4592

aagaucgcga gacguguaaa ugu

23

<210> 4593

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4593

aaaaaaaauca guucgaggaa agg

23

<210> 4594

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4594

acugcugugg acuugaguug gga

23

<210> 4595

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4595

gaaaggggca aaaacgaaag cgc

23

<210> 4596

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4596

ccugcaaaaa cacagacucg cgu

23

<210> 4597

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4597

ucacgucuuu gucucuagug cag

23

<210> 4598

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4598

aggggcaaaa acgaaagcgc aag

23

<210> 4599

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4599

aaaggggcaa aaacgaaagc gca

23

<210> 4600

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4600

aagaaaaaaa aucaguucga gga

23

<210> 4601

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4601
aaaaaaucaag uucgaggaaa ggg 23

<210> 4602
<211> 23
<212> RNA
<213> Homo sapiens

<400> 4602
gcaaaaacac agacucgcgu ugc 23

<210> 4603
<211> 23
<212> RNA
<213> Homo sapiens

<400> 4603
uguuuauccg uaauaaugu ggg 23

<210> 4604
<211> 23
<212> RNA
<213> Homo sapiens

<400> 4604
caagaucgc agacguguaa aug 23

<210> 4605
<211> 23
<212> RNA
<213> Homo sapiens

<400> 4605
uauuaacau acgucuuugu cuc 23

<210> 4606
<211> 23
<212> RNA
<213> Homo sapiens

<400> 4606
cacgucuuug ucucuagugc agu 23

<210> 4607
<211> 23
<212> RNA

<213> Homo sapiens

<400> 4607

cuguuuaucc guaauauug ugg

23

<210> 4608

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4608

auuuguuugu acaagaucg cag

23

<210> 4609

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4609

guuuauccgu aaauauugug ggg

23

<210> 4610

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4610

aaaacacaga cucgcguugc aag

23

<210> 4611

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4611

guuuuuuuuc aguauucuug guu

23

<210> 4612

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4612

auauuaacau cacgucuug ucu

23

<210> 4613

<211> 23

<212> RNA

<213> Rattus norvegicus

<400> 4613

cacggaaacu uuucguccaa cuu

23

<210> 4614

<211> 23

<212> RNA

<213> Rattus norvegicus

<400> 4614

acggaaacuu uucguccaac uuc

23

<210> 4615

<211> 23

<212> RNA

<213> Rattus norvegicus

<400> 4615

gucgacagaa caguccuuaa ucc

23

<210> 4616

<211> 23

<212> RNA

<213> Rattus norvegicus

<400> 4616

cucugcuaau guuauuggug ucu

23

<210> 4617

<211> 23

<212> RNA

<213> Rattus norvegicus

<400> 4617

uuuccgagau auuccguagu aca

23

<210> 4618

<211> 23

<212> RNA

<213> Rattus norvegicus

<400> 4618

uccgagauau uccguaguac aua

23

<210> 4619

<211> 23

<212> RNA

<213> Rattus norvegicus

<400> 4619
uugcacggaa acuuuucguc caa 23

<210> 4620
<211> 23
<212> RNA
<213> Rattus norvegicus

<400> 4620
ugcacggaaa cuuuucgucc aac 23

<210> 4621
<211> 23
<212> RNA
<213> Rattus norvegicus

<400> 4621
ccgagauauu ccguaguaca uau 23

<210> 4622
<211> 23
<212> RNA
<213> Rattus norvegicus

<400> 4622
auuuguuuugu ccaagaucg cag 23

<210> 4623
<211> 23
<212> RNA
<213> Rattus norvegicus

<400> 4623
gcacggaaac uuuucgucca acu 23

<210> 4624
<211> 23
<212> RNA
<213> Rattus norvegicus

<400> 4624
agaucaugcg gaucaaaccu cac 23

<210> 4625
<211> 23
<212> RNA

<213> Rattus norvegicus

<400> 4625
ucaugcggau caaaccucac caa 23

<210> 4626
<211> 23
<212> RNA
<213> Rattus norvegicus

<400> 4626
cagaucaugc ggaucaaacc uca 23

<210> 4627
<211> 23
<212> RNA
<213> Rattus norvegicus

<400> 4627
cauuuguuug uccaagauc gca 23

<210> 4628
<211> 23
<212> RNA
<213> Rattus norvegicus

<400> 4628
cagaucggug acagucacua gcu 23

<210> 4629
<211> 23
<212> RNA
<213> Rattus norvegicus

<400> 4629
ccaagaucg cagacgugua aa 23

<210> 4630
<211> 23
<212> RNA
<213> Rattus norvegicus

<400> 4630
uuuguccaag auccgcagac gug 23

<210> 4631
<211> 23
<212> RNA

<213> Rattus norvegicus

<400> 4631
acaucacguc uuugucucua gag 23

<210> 4632
<211> 23
<212> RNA
<213> Rattus norvegicus

<400> 4632
ucugaaacca ugaacuuucu gcu 23

<210> 4633
<211> 23
<212> RNA
<213> Rattus norvegicus

<400> 4633
cuuugucucu agagcaguuu ucc 23

<210> 4634
<211> 23
<212> RNA
<213> Rattus norvegicus

<400> 4634
cucacuucca gaaacacgac aaa 23

<210> 4635
<211> 23
<212> RNA
<213> Rattus norvegicus

<400> 4635
uaugaaaucu guguuuccaa ucu 23

<210> 4636
<211> 23
<212> RNA
<213> Rattus norvegicus

<400> 4636
augaaaucug uguuuccaau cuc 23

<210> 4637
<211> 23
<212> RNA

<213> Rattus norvegicus

<400> 4637

ucuuugucuc uagagcaguu uuc

23

<210> 4638

<211> 23

<212> RNA

<213> Rattus norvegicus

<400> 4638

uuugucucua gagcaguuuu ccg

23

<210> 4639

<211> 23

<212> RNA

<213> Rattus norvegicus

<400> 4639

uaaacuguau uguuuuacgc uuu

23

<210> 4640

<211> 23

<212> RNA

<213> Rattus norvegicus

<400> 4640

aaacuguauu guuuuacgcu uua

23

<210> 4641

<211> 23

<212> RNA

<213> Rattus norvegicus

<400> 4641

aacuguauug uuuuacgcuu uaa

23

<210> 4642

<211> 23

<212> RNA

<213> Rattus norvegicus

<400> 4642

acuguauugu uuuacgcuu aau

23

<210> 4643

<211> 23

<212> RNA

<213> Rattus norvegicus

<400> 4643
ccauugaaac cacuaauucu guc 23

<210> 4644
<211> 23
<212> RNA
<213> Rattus norvegicus

<400> 4644
guacuuauuu aaagcccuu uuu 23

<210> 4645
<211> 23
<212> RNA
<213> Rattus norvegicus

<400> 4645
ugucucuaga gcaguuuucc gag 23

<210> 4646
<211> 23
<212> RNA
<213> Rattus norvegicus

<400> 4646
uuccgagaua uuccguagua cau 23

<210> 4647
<211> 23
<212> RNA
<213> Rattus norvegicus

<400> 4647
gcucugggau uugauauuca aac 23

<210> 4648
<211> 23
<212> RNA
<213> Rattus norvegicus

<400> 4648
ucuucacugg auauguuuga cug 23

<210> 4649
<211> 23
<212> RNA

<213> Rattus norvegicus

<400> 4649
uuggcucacu uccagaaaca cga 23

<210> 4650
<211> 23
<212> RNA
<213> Rattus norvegicus

<400> 4650
cacuuccaga aacacgacaa acc 23

<210> 4651
<211> 23
<212> RNA
<213> Rattus norvegicus

<400> 4651
cagaccauug aaaccacuaa uuc 23

<210> 4652
<211> 23
<212> RNA
<213> Rattus norvegicus

<400> 4652
acagucacua gcuuguccug aga 23

<210> 4653
<211> 23
<212> RNA
<213> Rattus norvegicus

<400> 4653
ccaccacaca uuccuuugaa aua 23

<210> 4654
<211> 23
<212> RNA
<213> Rattus norvegicus

<400> 4654
ucaccggaaa gaccgauuaa cca 23

<210> 4655
<211> 23
<212> RNA

<213> Rattus norvegicus

<400> 4655

aaagaccgau uaaccauguc acc

23

<210> 4656

<211> 23

<212> RNA

<213> Rattus norvegicus

<400> 4656

gucuucacug gauauguuug acu

23

<210> 4657

<211> 23

<212> RNA

<213> Rattus norvegicus

<400> 4657

cguuggcuca cuuccagaaa cac

23

<210> 4658

<211> 23

<212> RNA

<213> Rattus norvegicus

<400> 4658

ggcucacuuc cagaaacacg aca

23

<210> 4659

<211> 23

<212> RNA

<213> Rattus norvegicus

<400> 4659

cggugacagu cacuagcuug ucc

23

<210> 4660

<211> 23

<212> RNA

<213> Rattus norvegicus

<400> 4660

uugucucuag agcaguuuuc cga

23

<210> 4661

<211> 23

<212> RNA

<213> Rattus norvegicus	
<400> 4661	
gucucuagag caguuuuccg aga	23
<210> 4662	
<211> 23	
<212> RNA	
<213> Rattus norvegicus	
<400> 4662	
caguuuuccg agauauuccg uag	23
<210> 4663	
<211> 23	
<212> RNA	
<213> Rattus norvegicus	
<400> 4663	
uuuuccgaga uauuccguag uac	23
<210> 4664	
<211> 23	
<212> RNA	
<213> Rattus norvegicus	
<400> 4664	
ucuuaaacug uauuguuuua cgc	23
<210> 4665	
<211> 23	
<212> RNA	
<213> Rattus norvegicus	
<400> 4665	
uuaaacugua uuguuuuacg cuu	23
<210> 4666	
<211> 23	
<212> RNA	
<213> Rattus norvegicus	
<400> 4666	
uggauucgcc auuuucuau auu	23
<210> 4667	
<211> 23	
<212> RNA	

<213> Rattus norvegicus

<400> 4667

cuucacugga uauguuugac ugc

23

<210> 4668

<211> 23

<212> RNA

<213> Rattus norvegicus

<400> 4668

acguuggcuc acuuccagaa aca

23

<210> 4669

<211> 23

<212> RNA

<213> Rattus norvegicus

<400> 4669

ucacuuccag aaacacgaca aac

23

<210> 4670

<211> 23

<212> RNA

<213> Rattus norvegicus

<400> 4670

gguacuuauu uaauagcccu uuu

23

<210> 4671

<211> 23

<212> RNA

<213> Rattus norvegicus

<400> 4671

cuagagcagu uuuccgagau auu

23

<210> 4672

<211> 23

<212> RNA

<213> Rattus norvegicus

<400> 4672

ucugggauuu gauauucaaa ccu

23

<210> 4673

<211> 23

<212> RNA

<213> Rattus norvegicus

<400> 4673

cugggauuug auaucaaac cuc

23

<210> 4674

<211> 23

<212> RNA

<213> Rattus norvegicus

<400> 4674

gggauuugau auucaaaccu cuu

23

<210> 4675

<211> 23

<212> RNA

<213> Rattus norvegicus

<400> 4675

cuuaaacugu auuguuuuac gcu

23

<210> 4676

<211> 23

<212> RNA

<213> Rattus norvegicus

<400> 4676

ucucaccgga aagaccgauu aac

23

<210> 4677

<211> 23

<212> RNA

<213> Rattus norvegicus

<400> 4677

cucaccggaa agaccgauua acc

23

<210> 4678

<211> 23

<212> RNA

<213> Rattus norvegicus

<400> 4678

caccggaaag accgauuaac cau

23

<210> 4679

<211> 23

<212> RNA

<213> Rattus norvegicus

<400> 4679

uggaacugga uucgccauuu ucu

23

<210> 4680

<211> 23

<212> RNA

<213> Rattus norvegicus

<400> 4680

uucacuggau auguuugacu gcu

23

<210> 4681

<211> 23

<212> RNA

<213> Rattus norvegicus

<400> 4681

gaggaccuug ugugaucaga cca

23

<210> 4682

<211> 23

<212> RNA

<213> Rattus norvegicus

<400> 4682

gaucagacca uugaaaccac uaa

23

<210> 4683

<211> 23

<212> RNA

<213> Rattus norvegicus

<400> 4683

accauugaaa ccacuaauuc ugu

23

<210> 4684

<211> 23

<212> RNA

<213> Rattus norvegicus

<400> 4684

cucuagagca guuuuccgag aua

23

<210> 4685

<211> 23

<212> RNA

<213> Rattus norvegicus

<400> 4685

ucuagagcag uuuuccgaga uau

23

<210> 4686

<211> 23

<212> RNA

<213> Rattus norvegicus

<400> 4686

gcaguuuucc gagauauucc gua

23

<210> 4687

<211> 23

<212> RNA

<213> Rattus norvegicus

<400> 4687

augcggauc aaccucacca aag

23

<210> 4688

<211> 23

<212> RNA

<213> Rattus norvegicus

<400> 4688

aaagcauuug uuuguccaag auc

23

<210> 4689

<211> 23

<212> RNA

<213> Rattus norvegicus

<400> 4689

ccucucaccg gaaagaccga uua

23

<210> 4690

<211> 23

<212> RNA

<213> Rattus norvegicus

<400> 4690

ucucuagagc aguuuuccga gau

23

<210> 4691

<211> 23

<212> RNA

<213> Rattus norvegicus

<400> 4691
ggauugcacg gaaacuuuuc guc 23

<210> 4692
<211> 23
<212> RNA
<213> Rattus norvegicus

<400> 4692
gugcucuggg auuugauau caa 23

<210> 4693
<211> 23
<212> RNA
<213> Rattus norvegicus

<400> 4693
ugugagccuu guucagagcg gag 23

<210> 4694
<211> 23
<212> RNA
<213> Rattus norvegicus

<400> 4694
ugagccuugu ucagagcgga gaa 23

<210> 4695
<211> 23
<212> RNA
<213> Rattus norvegicus

<400> 4695
agcauuuguu uguccaagau ccg 23

<210> 4696
<211> 23
<212> RNA
<213> Rattus norvegicus

<400> 4696
ccggaaagac cgauuaacca ugu 23

<210> 4697
<211> 23
<212> RNA

<213> Rattus norvegicus

<400> 4697

cggaagacc gauuacgau guc

23

<210> 4698

<211> 23

<212> RNA

<213> Rattus norvegicus

<400> 4698

gaaagaccga uuaacgaug cac

23

<210> 4699

<211> 23

<212> RNA

<213> Rattus norvegicus

<400> 4699

aagaccgauu aacgaugca cca

23

<210> 4700

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4700

cucggugcug gaauugaua uuc

23

<210> 4701

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4701

ucggugcugg aaauugauau uca

23

<210> 4702

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4702

ggugcuggaa uuugauauuc auu

23

<210> 4703

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4703

gugcuggaau uugauauuca uug

23

<210> 4704

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4704

gcuggaauuu gauauucauu gau

23

<210> 4705

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4705

cuggaauuug auauucauug auc

23

<210> 4706

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4706

uggaauuuga uauucauuga ucc

23

<210> 4707

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4707

ggaauuugau auucauugau ccg

23

<210> 4708

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4708

gaauuugaua uucauugauc cgg

23

<210> 4709

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4709

aaauugauau ucauugaucc ggg

23

<210> 4710

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4710

aaauuuuuuu ugcuugccau ucc

23

<210> 4711

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4711

auuuuuuuuu gcuugccauu ccc

23

<210> 4712

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4712

cccaaaucac uguggauuuu gga

23

<210> 4713

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4713

ccaaucacu guggauuuug gaa

23

<210> 4714

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4714

caaaucacug uggauuuugg aaa

23

<210> 4715

<211> 23

<212> RNA

<213> Homo sapiens	
<400> 4715	
aaaucacugu ggauuuugga aac	23
<210> 4716	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4716	
aaucacugug gauuuuggaa acc	23
<210> 4717	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4717	
aucacugugg auuuuggaaa cca	23
<210> 4718	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4718	
ucacugugga uuuuggaaac cag	23
<210> 4719	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4719	
cacuguggau uuuggaaacc agc	23
<210> 4720	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4720	
acuguggauu uuggaaacca gca	23
<210> 4721	
<211> 23	
<212> RNA	

<213> Homo sapiens

<400> 4721

cuguggauuu uggaaccag cag

23

<210> 4722

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4722

uggauuuugg aaaccagcag aaa

23

<210> 4723

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4723

ggauuuugga aaccagcaga aag

23

<210> 4724

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4724

gauuuuggaa accagcagaa aga

23

<210> 4725

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4725

auuuuggaaa ccagcagaaa gag

23

<210> 4726

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4726

uuggaaacca gcagaaagag gaa

23

<210> 4727

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4727

ggaaaccagc agaaagagga aag

23

<210> 4728

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4728

gaaaccagca gaaagaggaa aga

23

<210> 4729

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4729

aaaccagcag aaagaggaaa gag

23

<210> 4730

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4730

aaccagcaga aagaggaaag agg

23

<210> 4731

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4731

accagcagaa agaggaaaga ggu

23

<210> 4732

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4732

ccagcagaaa gaggaaagag gua

23

<210> 4733

<211> 23

<212> RNA

<213> Homo sapiens	
<400> 4733	
cagcagaaag aggaaagagg uag	23
<210> 4734	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4734	
agcagaaaga ggaaagaggu agc	23
<210> 4735	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4735	
agaaagagga aagagguagc aag	23
<210> 4736	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4736	
gaaagaggaa agagguagca aga	23
<210> 4737	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4737	
aaagaggaaa gagguagcaa gag	23
<210> 4738	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4738	
aagaggaaag agguagcaag agc	23
<210> 4739	
<211> 23	
<212> RNA	

<213> Homo sapiens

<400> 4739

gaggaaagag guagcaagag cuc

23

<210> 4740

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4740

agagguagca agagcuccag aga

23

<210> 4741

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4741

gcuccagaga gaagucgagg aag

23

<210> 4742

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4742

cuccagagag aagucgagga aga

23

<210> 4743

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4743

uccagagaga agucgaggaa gag

23

<210> 4744

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4744

agagagaagu cgaggaagag aga

23

<210> 4745

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4745

gagagaaguc gaggaagaga gag

23

<210> 4746

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4746

gagaagucga ggaagagaga gac

23

<210> 4747

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4747

aaagugagug accugcuuuu ggg

23

<210> 4748

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4748

gcggcgucgc acugaaacuu uuc

23

<210> 4749

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4749

gcgucgcacu gaaacuuuuc guc

23

<210> 4750

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4750

cgucgcacug aaacuuuucg ucc

23

<210> 4751

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4751

cgcacugaaa cuuuucgucc aac

23

<210> 4752

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4752

gcacugaaac uuuucgucca acu

23

<210> 4753

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4753

acugaaacuu uucguccaac uuc

23

<210> 4754

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4754

gaaacuuuuc guccaacuuc ugg

23

<210> 4755

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4755

uucugggcug uucucguuc gga

23

<210> 4756

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4756

ucugggcugu ucucgcuucg gag

23

<210> 4757

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4757

cugggcuguu cucgcuucgg agg

23

<210> 4758

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4758

gggcuguucu cgcuucggag gag

23

<210> 4759

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4759

gagccgcgag aagugcuagc ucg

23

<210> 4760

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4760

agccgcgaga agugcuagcu cgg

23

<210> 4761

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4761

gggccuccga aaccaugaac uuu

23

<210> 4762

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4762

agaaggagga gggcagaauc auc

23

<210> 4763

<211> 23

<212> RNA

<213> Homo sapiens	
<400> 4763	
agggcagaau caucacgaag ugg	23
<210> 4764	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4764	
agaaucauca cgaaguggug aag	23
<210> 4765	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4765	
gaaucaucac gaagugguga agu	23
<210> 4766	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4766	
aaucaucacg aaguggugaa guu	23
<210> 4767	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4767	
aucaucacga aguggugaag uuc	23
<210> 4768	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4768	
caucacgaag uggugaaguu cau	23
<210> 4769	
<211> 23	
<212> RNA	

<213> Homo sapiens	
<400> 4769	
cgaaguggug aagucaugg aug	23
<210> 4770	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4770	
gaagugguga aguucaugga ugu	23
<210> 4771	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4771	
aaguggugaa guucauggau guc	23
<210> 4772	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4772	
guggugaagu ucauggaugu cua	23
<210> 4773	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4773	
uggugaaguu cauggauguc uau	23
<210> 4774	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4774	
ggugaaguuc auggaugucu auc	23
<210> 4775	
<211> 23	
<212> RNA	

<213> Homo sapiens

<400> 4775

ugaaguucau ggaugucuau cag

23

<210> 4776

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4776

gaaguucaug gaugucuauc agc

23

<210> 4777

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4777

aguucaugga ugucuaucag cgc

23

<210> 4778

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4778

ugguggacau cuuccaggag uac

23

<210> 4779

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4779

gaucgaguac aucucaagc cau

23

<210> 4780

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4780

aucgaguaca ucuucaagcc auc

23

<210> 4781

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4781

ucgaguacau cuucaagcca ucc

23

<210> 4782

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4782

gaguacau cuucaagccaug cug

23

<210> 4783

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4783

guccaacau accaugcaga uua

23

<210> 4784

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4784

uccaacauc ccaugcagau uau

23

<210> 4785

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4785

caacauacc augcagauua ugc

23

<210> 4786

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4786

aacauacca ugcagauuau gcg

23

<210> 4787

<211> 23

<212> RNA

<213> Homo sapiens	
<400> 4787	
ucaccaugca gauuauugcgg auc	23
<210> 4788	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4788	
ccaugcagau uaugcggauc aaa	23
<210> 4789	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4789	
caugcagauu augcggauc aac	23
<210> 4790	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4790	
augcagauua ugcggauc aa acc	23
<210> 4791	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4791	
cagauuauugc ggaucaaacc uca	23
<210> 4792	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4792	
agauuauugc gaucaaaccu cac	23
<210> 4793	
<211> 23	
<212> RNA	

<213> Homo sapiens

<400> 4793

ugcggaucaa accucaccaa ggc

23

<210> 4794

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4794

uaggagagau gagcuuccua cag

23

<210> 4795

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4795

gagagaugag cuuccuacag cac

23

<210> 4796

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4796

gagaugagcu uccuacagca caa

23

<210> 4797

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4797

agaugagcuu ccuacagcac aac

23

<210> 4798

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4798

augagcuucc uacagcacao caa

23

<210> 4799

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4799

ugagcuuccu acagcacaac aaa

23

<210> 4800

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4800

gagcuuccua cagcacaaca aa

23

<210> 4801

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4801

agcuuccuac agcacaaca aug

23

<210> 4802

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4802

cuuccuacag cacaacaaau gug

23

<210> 4803

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4803

uccuacagca caacaaugu gaa

23

<210> 4804

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4804

ccuacagcac aacaaugug aa

23

<210> 4805

<211> 23

<212> RNA

<213> Homo sapiens	
<400> 4805	
acagcacaac aaaugugaau gca	23
<210> 4806	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4806	
cagcacaaca aaugugaaug cag	23
<210> 4807	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4807	
cucucaccag gaaagacuga uac	23
<210> 4808	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4808	
ucucaccagg aaagacugau aca	23
<210> 4809	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4809	
cucaccagga aagacugaua cag	23
<210> 4810	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4810	
ucaccaggaa agacugauac aga	23
<210> 4811	
<211> 23	
<212> RNA	

<213> Homo sapiens	
<400> 4811	
caccaggaaa gacugauaca gaa	23
<210> 4812	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4812	
accaggaaag acugauacag aac	23
<210> 4813	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4813	
ccaggaaaga cugauacaga acg	23
<210> 4814	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4814	
caggaaagac ugauacagaa cga	23
<210> 4815	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4815	
aggaaagacu gauacagaac gau	23
<210> 4816	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4816	
ggaaagacug auacagaacg auc	23
<210> 4817	
<211> 23	
<212> RNA	

<213> Homo sapiens

<400> 4817

gaaagacuga uacagaacga ucg

23

<210> 4818

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4818

aaagacugau acagaacgau cga

23

<210> 4819

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4819

aagacugaua cagaacgauc gau

23

<210> 4820

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4820

agacugauac agaacgaucg aua

23

<210> 4821

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4821

gacugauaca gaacgaucga uac

23

<210> 4822

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4822

acugauacag aacgaucgau aca

23

<210> 4823

<211> 23

<212> RNA

<213> Homo sapiens	
<400> 4823	
cugauacaga acgaucgaua cag	23
<210> 4824	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4824	
ugauacagaa cgaucgauac aga	23
<210> 4825	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4825	
gauacagaac gaucgauaca gaa	23
<210> 4826	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4826	
auacagaacg aucgauacag aaa	23
<210> 4827	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4827	
uacagaacga ucgauacaga aac	23
<210> 4828	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4828	
acagaacgau cgauacagaa acc	23
<210> 4829	
<211> 23	
<212> RNA	

<213> Homo sapiens	
<400> 4829	
cagaacgauc gauacagaaa cca	23
<210> 4830	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4830	
agaacgaucg auacagaaac cac	23
<210> 4831	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4831	
gaacgaucga uacagaaacc acg	23
<210> 4832	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4832	
aacgaucgau acagaaacca cgc	23
<210> 4833	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4833	
cacaccauca ccaucgacag aac	23
<210> 4834	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4834	
accaucacca ucgacagaac agu	23
<210> 4835	
<211> 23	
<212> RNA	

<213> Homo sapiens	
<400> 4835	
caucaccauc gacagaacag ucc	23
<210> 4836	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4836	
aucaccaucg acagaacagu ccu	23
<210> 4837	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4837	
ucaccaucga cagaacaguc cuu	23
<210> 4838	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4838	
caccaucgac agaacagucc uua	23
<210> 4839	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4839	
accaucgaca gaacaguccu uaa	23
<210> 4840	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4840	
ccaucgacag aacaguccuu aaU	23
<210> 4841	
<211> 23	
<212> RNA	

<213> Homo sapiens

<400> 4841
caucgacaga acaguccuua auc 23

<210> 4842
<211> 23
<212> RNA
<213> Homo sapiens

<400> 4842
aucgacagaa caguccuuaa ucc 23

<210> 4843
<211> 23
<212> RNA
<213> Homo sapiens

<400> 4843
ucgacagaac aguccuuaau cca 23

<210> 4844
<211> 23
<212> RNA
<213> Homo sapiens

<400> 4844
cgacagaaca guccuuaauc cag 23

<210> 4845
<211> 23
<212> RNA
<213> Homo sapiens

<400> 4845
acagaacagu ccuaaucca gaa 23

<210> 4846
<211> 23
<212> RNA
<213> Homo sapiens

<400> 4846
cagaacaguc cuuaauccag aaa 23

<210> 4847
<211> 23
<212> RNA

<213> Homo sapiens

<400> 4847

agaacagucc uuaauccaga aac

23

<210> 4848

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4848

gaacaguccu uaauccagaa acc

23

<210> 4849

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4849

aacaguccuu aauccagaaa ccu

23

<210> 4850

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4850

acaguccuua auccagaaac cug

23

<210> 4851

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4851

caguccuuaa uccagaaacc uga

23

<210> 4852

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4852

aguccuuaau ccagaaaccu gaa

23

<210> 4853

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4853

guccuuaauc cagaaaccug aaa

23

<210> 4854

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4854

uccuuaaucc agaaaccuga aa

23

<210> 4855

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4855

ccuuaaucca gaaaccugaa aug

23

<210> 4856

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4856

uccagaaacc ugaaugaag gaa

23

<210> 4857

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4857

ccagaaaccu gaaugaagg aag

23

<210> 4858

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4858

cagaaaccug aaaugaagga aga

23

<210> 4859

<211> 23

<212> RNA

<213> Homo sapiens	
<400> 4859	
agaaaccuga aaugaaggaa gag	23
<210> 4860	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4860	
gaaaccugaa augaaggaag agg	23
<210> 4861	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4861	
aaccugaaau gaaggaagag gag	23
<210> 4862	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4862	
aaaugaagga agaggagacu cug	23
<210> 4863	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4863	
ggucccucuu ggaauuggau ucg	23
<210> 4864	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4864	
ucccucuugg aauggauuc gcc	23
<210> 4865	
<211> 23	
<212> RNA	

<213> Homo sapiens

<400> 4865

cccucuugga auuggauucg cca

23

<210> 4866

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4866

ucuuggaauu ggauucgcca uuu

23

<210> 4867

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4867

cuuggaauug gauucgccau uuu

23

<210> 4868

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4868

uuggaauugg auucgccauu uua

23

<210> 4869

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4869

uggaauugga uucgccauuu uau

23

<210> 4870

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4870

ggaauuggau ucgccauuuu auu

23

<210> 4871

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4871

gaauuggauu cgccauuuua uuu

23

<210> 4872

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4872

aauggauuc gccauuuuau uuu

23

<210> 4873

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4873

auuggauucg ccauuuuauu uuu

23

<210> 4874

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4874

uuggauucgc cauuuuauuu uuc

23

<210> 4875

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4875

uggauucgcc auuuuauuuu ucu

23

<210> 4876

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4876

auucgccauu uuauuuuucu ugc

23

<210> 4877

<211> 23

<212> RNA

<213> Homo sapiens	
<400> 4877	
uucgccauuu uauuuuucuu gcu	23
<210> 4878	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4878	
ucgccauuuu auuuuucug cug	23
<210> 4879	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4879	
cgccauuuua uuuuucugc ugc	23
<210> 4880	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4880	
gccauuuuau uuuucugcu gcu	23
<210> 4881	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4881	
ccauuuuauu uuucugcug cua	23
<210> 4882	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4882	
cauuuuauuu uucugcugc uaa	23
<210> 4883	
<211> 23	
<212> RNA	

<213> Homo sapiens

<400> 4883

uuuuucuugc ugcuaaauca ccg

23

<210> 4884

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4884

aaucaccgag cccggaagau uag

23

<210> 4885

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4885

gagcccggaa gauuagagag uuu

23

<210> 4886

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4886

agcccggaag auuagagagu uuu

23

<210> 4887

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4887

cccggaagau uagagaguuu uau

23

<210> 4888

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4888

ccggaagauu agagaguuuu auu

23

<210> 4889

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4889

cggaagauua gagaguuuuu uuu

23

<210> 4890

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4890

ggaagauuag agaguuuuau uuc

23

<210> 4891

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4891

gaagauuaga gaguuuuauu ucu

23

<210> 4892

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4892

agauuagaga guuuuuuuuc ugg

23

<210> 4893

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4893

gauuagagag uuuuuuuucu ggg

23

<210> 4894

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4894

auuagagagu uuuuuuucug gga

23

<210> 4895

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4895

uuagagaguu uuauuucugg gau

23

<210> 4896

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4896

uagagaguuu uauuucuggg auu

23

<210> 4897

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4897

agagaguuuu auuucuggga uuc

23

<210> 4898

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4898

gagaguuuuu uuucugggau ucc

23

<210> 4899

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4899

agaguuuuau uucugggauu ccu

23

<210> 4900

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4900

gaguuuuauu ucugggauuc cug

23

<210> 4901

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4901

aguuuuuuuu cugggauucc ugu

23

<210> 4902

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4902

guuuuuuuuc uggaauuccu gua

23

<210> 4903

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4903

uuuuuuuuuc gggauuccug uag

23

<210> 4904

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4904

uuuauuuucug ggauuccugu aga

23

<210> 4905

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4905

uuauuucugg gauuccugua gac

23

<210> 4906

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4906

uauuucuggg auuccuguag aca

23

<210> 4907

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4907

uuucugggau uccuguagac aca

23

<210> 4908

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4908

uucugggauu ccuguagaca cac

23

<210> 4909

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4909

ucugggauuc cuguagacac acc

23

<210> 4910

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4910

cugggauucc uguagacaca ccc

23

<210> 4911

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4911

agacacacc acccacauac aua

23

<210> 4912

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4912

acaccaccc acauacauac auu

23

<210> 4913

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4913

cacccaccca cauacauaca uuu

23

<210> 4914

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4914

accacccac auacauacau uua

23

<210> 4915

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4915

cccaccaca uacauacau uau

23

<210> 4916

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4916

accacauac auacauuuau aua

23

<210> 4917

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4917

cccacauaca uacauuuaua uau

23

<210> 4918

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4918

uuuuaaaaua acagugcuaa ugu

23

<210> 4919

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4919
uuuaauuaa cagugcuaau guu 23

<210> 4920
<211> 23
<212> RNA
<213> Homo sapiens

<400> 4920
uuaaauaac agugcuaaug uua 23

<210> 4921
<211> 23
<212> RNA
<213> Homo sapiens

<400> 4921
uaaaauaaca gugcuaaugu uau 23

<210> 4922
<211> 23
<212> RNA
<213> Homo sapiens

<400> 4922
aaaauaacag ugcuaauguu auu 23

<210> 4923
<211> 23
<212> RNA
<213> Homo sapiens

<400> 4923
aaauaacagu gcuaauguua uug 23

<210> 4924
<211> 23
<212> RNA
<213> Homo sapiens

<400> 4924
auuaacagug cuaauguuau ugg 23

<210> 4925
<211> 23
<212> RNA

<213> Homo sapiens	
<400> 4925 uuaacagugc uaauguuauu ggu	23
<210> 4926 <211> 23 <212> RNA <213> Homo sapiens	
<400> 4926 uaacagugcu aauguuauug gug	23
<210> 4927 <211> 23 <212> RNA <213> Homo sapiens	
<400> 4927 aacagugcua auguuauugg ugu	23
<210> 4928 <211> 23 <212> RNA <213> Homo sapiens	
<400> 4928 cagugcuaau guuauuggug ucu	23
<210> 4929 <211> 23 <212> RNA <213> Homo sapiens	
<400> 4929 agugcuaaug uuauuggugu cuu	23
<210> 4930 <211> 23 <212> RNA <213> Homo sapiens	
<400> 4930 gugcuaaugu uauugguguc uuc	23
<210> 4931 <211> 23 <212> RNA	

<213> Homo sapiens

<400> 4931

ugcuaauguu auuggugucu uca

23

<210> 4932

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4932

gcuaauguua uuggugucu cac

23

<210> 4933

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4933

cuaauguuau uggugucuuc acu

23

<210> 4934

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4934

uaauguuauu ggugucuuca cug

23

<210> 4935

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4935

aauguuauug gugucuucac ugg

23

<210> 4936

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4936

auguuauugg ugucuucacu gga

23

<210> 4937

<211> 23

<212> RNA

<213> Homo sapiens	
<400> 4937	
uguuauuggu gucuucacug gau	23
<210> 4938	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4938	
auuggugucu ucacuggaug uau	23
<210> 4939	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4939	
ggugucuuca cuggauguau uug	23
<210> 4940	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4940	
uucacuggau guauuugacu gcu	23
<210> 4941	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4941	
ucacuggaug uauuugacug cug	23
<210> 4942	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4942	
acuggaugua uuugacugcu gug	23
<210> 4943	
<211> 23	
<212> RNA	

<213> Homo sapiens

<400> 4943

uguauuugac ugcuguggac uug

23

<210> 4944

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4944

uauuugacug cuguggacuu gag

23

<210> 4945

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4945

cugcugugga cuugaguugg gag

23

<210> 4946

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4946

guucccacuc agauccugac agg

23

<210> 4947

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4947

uucccacuca gauccugaca ggg

23

<210> 4948

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4948

gaggaggaga ugagagacuc ugg

23

<210> 4949

<211> 23

<212> RNA

<213> Homo sapiens	
<400> 4949	
aggaggagau gagagacucu ggc	23
<210> 4950	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4950	
gaggagauga gagacucugg cau	23
<210> 4951	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4951	
gagagacucu ggcaugaucu uuu	23
<210> 4952	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4952	
agagacucug gcaugaucuu uuu	23
<210> 4953	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4953	
aguuuuggga acaccgacaa acc	23
<210> 4954	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4954	
gggagcuuca ggacauugcu gug	23
<210> 4955	
<211> 23	
<212> RNA	

<213> Homo sapiens	
<400> 4955 gagcuucagg acauugcugu gcu	23
<210> 4956 <211> 23 <212> RNA <213> Homo sapiens	
<400> 4956 agcuucagga cauugcugug cuu	23
<210> 4957 <211> 23 <212> RNA <213> Homo sapiens	
<400> 4957 gcuucaggac auugcugugc uuu	23
<210> 4958 <211> 23 <212> RNA <213> Homo sapiens	
<400> 4958 cuucaggaca uugcugugcu uug	23
<210> 4959 <211> 23 <212> RNA <213> Homo sapiens	
<400> 4959 uucaggacau ugcugugcu ugg	23
<210> 4960 <211> 23 <212> RNA <213> Homo sapiens	
<400> 4960 uucgcuacu cucaccugcu ucu	23
<210> 4961 <211> 23 <212> RNA	

<213> Homo sapiens

<400> 4961
ucgcuuacuc ucaccugcuu cug 23

<210> 4962
<211> 23
<212> RNA
<213> Homo sapiens

<400> 4962
gcuuacucuc accugcuucu gag 23

<210> 4963
<211> 23
<212> RNA
<213> Homo sapiens

<400> 4963
uacucucacc ugcucugag uug 23

<210> 4964
<211> 23
<212> RNA
<213> Homo sapiens

<400> 4964
acucucaccu gcuucugagu ugc 23

<210> 4965
<211> 23
<212> RNA
<213> Homo sapiens

<400> 4965
cucucaccug cuucugaguu gcc 23

<210> 4966
<211> 23
<212> RNA
<213> Homo sapiens

<400> 4966
ucucaccugc uucugaguug ccc 23

<210> 4967
<211> 23
<212> RNA

<213> Homo sapiens	
<400> 4967	
cucaccugcu ucugaguugc cca	23
<210> 4968	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4968	
ucaccugcuu cugaguugcc cag	23
<210> 4969	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4969	
caccugcuuc ugaguugccc agg	23
<210> 4970	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4970	
cccggcgaag agaagagaca cau	23
<210> 4971	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4971	
ccggcgaaga gaagagacac auu	23
<210> 4972	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4972	
cggcgaagag aagagacaca uug	23
<210> 4973	
<211> 23	
<212> RNA	

<213> Homo sapiens	
<400> 4973	
ggcgaagaga agagacacau ugu	23
<210> 4974	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4974	
gcgaagagaa gagacacauu guu	23
<210> 4975	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4975	
cgaagagaag agacacauug uug	23
<210> 4976	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4976	
gaagagaaga gacacauugu ugg	23
<210> 4977	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4977	
aagagaagag acacauuguu gga	23
<210> 4978	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4978	
agagaagaga cacauuguug gaa	23
<210> 4979	
<211> 23	
<212> RNA	

<213> Homo sapiens	
<400> 4979	
gagaagagac acauuguugg aag	23
<210> 4980	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4980	
agaagagaca cauuguugga aga	23
<210> 4981	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4981	
gaagagacac auuguuggaa gaa	23
<210> 4982	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4982	
aagagacaca uuguuggaag aag	23
<210> 4983	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4983	
agagacacau uguuggaaga agc	23
<210> 4984	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4984	
gagacacauu guuggaagaa gca	23
<210> 4985	
<211> 23	
<212> RNA	

<213> Homo sapiens

<400> 4985

agacacauug uuggaagaag cag

23

<210> 4986

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4986

gacacauugu uggaagaagc agc

23

<210> 4987

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4987

ccuauguccu cacaccauug aaa

23

<210> 4988

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4988

uguccucaca ccuugaaac cac

23

<210> 4989

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4989

guccucacac cauugaaacc acu

23

<210> 4990

<211> 23

<212> RNA

<213> Homo sapiens

<400> 4990

uccucacacc auugaaacca cua

23

<210> 4991

<211> 23

<212> RNA

<213> Homo sapiens	
<400> 4991	
ccucacacca uugaaaccac uag	23
<210> 4992	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4992	
cucacaccau ugaaaccacu agu	23
<210> 4993	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4993	
caccauugaa accacuaguu cug	23
<210> 4994	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4994	
accauugaaa ccacuaguuc ugu	23
<210> 4995	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4995	
ccauugaaac cacuaguucu guc	23
<210> 4996	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4996	
cauugaaacc acuaguucug ucc	23
<210> 4997	
<211> 23	
<212> RNA	

<213> Homo sapiens	
<400> 4997	
auugaaacca cuaguucugu ccc	23
<210> 4998	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4998	
gagaccuggu ugugugugug uga	23
<210> 4999	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 4999	
agaccugguu gugugugugu gag	23
<210> 5000	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5000	
gaccugguug ugugugugug agu	23
<210> 5001	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5001	
accugguugu guguguguga gug	23
<210> 5002	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5002	
ccugguugug ugugugugag ugg	23
<210> 5003	
<211> 21	
<212> RNA	

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 5003

aacaguguuc uugcucuaua a

21

<210> 5004

<211> 23

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 5004

uuauagagca agaacacugu uuu

23

<210> 5005

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 5005

augcagauua ugcggaucaa a

21

<210> 5006

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 5006

accaggaaag acugauacag a

21

<210> 5007

<211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 5007
 agaacagucc uuaauccaga a 21

<210> 5008
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 5008
 agauuagaga guuuuauuuc a 21

<210> 5009
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 5009
 aaaagagaaa guguuuaua a 21

<210> 5010
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 5010
 aaagagaaag uguuuuauau a 21

<210> 5011
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 5011
cuacagcaca acaaauguga a 21

<210> 5012
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 5012
aaagacugau acagaacgau a 21

<210> 5013
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 5013
aagacugaua cagaacgauc a 21

<210> 5014
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 5014

auacagaacg aucgauacag a 21

<210> 5015
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 5015
cagaacaguc cuuaauccag a 21

<210> 5016
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 5016
auuggauucg ccuuuuuauu a 21

<210> 5017
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 5017
gauucgccau uuuauiuuuuc a 21

<210> 5018
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 5018
gagaaagugu uuuauauacg a 21

<210> 5019
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 5019
guguuuuaua uacgguacuu a 21

<210> 5020
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<220>
<221> source
<223> /note="Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide"

<400> 5020
agauuagaga guuuuauuuc a 21

<210> 5021
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 5021
aacaguguuc uugcucuaua a 21

<210> 5022
<211> 23

<212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 5022
 uuauagagca agaacacugu uuu 23

<210> 5023
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 5023
 augcagauua ugcggaucaa a 21

<210> 5024
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 5024
 accaggaaag acugauacag a 21

<210> 5025
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic
 oligonucleotide"

 <400> 5025
 agaacagucc uuaauccaga a 21

<210> 5026
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 5026
agauuagaga guuuuauuuc a 21

<210> 5027
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 5027
aaaagagaaa guguuuaua a 21

<210> 5028
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 5028
aaagagaaag uguuuuauau a 21

<210> 5029
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 5029
cuacagcaca aaaauguga a 21

<210> 5030
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 5030
aaagacugau acagaacgau a

21

<210> 5031
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 5031
aagacugaua cagaacgauc a

21

<210> 5032
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 5032
auacagaacg aucgauacag a

21

<210> 5033
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 5033
cagaacaguc cuuaauccag a 21

<210> 5034
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 5034
auuggauucg ccuuuuuuuu a 21

<210> 5035
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 5035
gauucgccau uuuuuuuuuu a 21

<210> 5036
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 5036
gagaaagugu uuuaauuacg a 21

<210> 5037
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<400> 5037
guguuuuaua uacgguacuu a 21

<210> 5038
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 5038
agauuagaga guuuuauuuc a 21

<210> 5039
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"

<400> 5039
ugaucguucu gtaucagucu uuc 23

<210> 5040
<211> 23
<212> RNA
<213> Homo sapiens

<400> 5040
uuuuauauac gguacuuauu uaa 23

<210> 5041
<211> 23
<212> RNA
<213> Homo sapiens

<400> 5041
uuuauauacg guacuuauu aa 23

<210> 5042
<211> 23

<212> RNA	
<213> Homo sapiens	
<400> 5042	
cgguacuuau uuaauauccc uuu	23
<210> 5043	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5043	
gguacuuauu uaauaucccu uuu	23
<210> 5044	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5044	
auuuauagaga ugaucuuuu gcu	23
<210> 5045	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5045	
uuuauagagau guaucuuuug cuc	23
<210> 5046	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5046	
uuauagagau uaucuuuugc ucu	23
<210> 5047	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5047	
uauagagau aucuuuugcu cuc	23
<210> 5048	
<211> 23	

<212> RNA	
<213> Homo sapiens	
<400> 5048	
augagaugua uuuuugcuc ucu	23
<210> 5049	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5049	
ugagaugau cuuuugcucu cuc	23
<210> 5050	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5050	
gagaugauc uuuugcucuc ucu	23
<210> 5051	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5051	
agaugaucu uuugcucucu cuu	23
<210> 5052	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5052	
uugcucucuc uugcucucu auu	23
<210> 5053	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5053	
ugcucucucu ugcucucuua uuu	23
<210> 5054	
<211> 23	

<212> RNA	
<213> Homo sapiens	
<400> 5054	
gcucucucuu gcucucuau uug	23
<210> 5055	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5055	
cucucucuug cucucuauu ugu	23
<210> 5056	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5056	
ucucucuugc ucucuauuu gua	23
<210> 5057	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5057	
cucucuugcu cucuauuuug uac	23
<210> 5058	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5058	
ucucuugcuc ucuauuuugu acc	23
<210> 5059	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5059	
cucuugcucu cuuauuuugua ccg	23
<210> 5060	
<211> 23	

<212> RNA	
<213> Homo sapiens	
<400> 5060	
ucuugcucuc uuauuuguac cgg	23
<210> 5061	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5061	
cuugcucucu uauuuguacc ggu	23
<210> 5062	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5062	
ugcucucuua uuuguaccgg uuu	23
<210> 5063	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5063	
gcucucuau uuguaccggu uuu	23
<210> 5064	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5064	
cucucuauu uguaccgguu uuu	23
<210> 5065	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5065	
ucucuauuu guaccgguu uug	23
<210> 5066	
<211> 23	

<212> RNA	
<213> Homo sapiens	
<400> 5066	
cucuuauuug uaccgguuuu ugu	23
<210> 5067	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5067	
ucuuauuugu accgguuuuu gua	23
<210> 5068	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5068	
cuaauuuugua ccgguuuuug uau	23
<210> 5069	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5069	
uuauuuuguac cgguuuuugu aua	23
<210> 5070	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5070	
uauuuuguacc gguuuuugua uau	23
<210> 5071	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5071	
auuuuguaccg guuuuuguau aua	23
<210> 5072	
<211> 23	

<212> RNA	
<213> Homo sapiens	
<400> 5072	
uuuguaccgg uuuuuguaua uaa	23
<210> 5073	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5073	
uuguaccggu uuuuguauau aaa	23
<210> 5074	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5074	
uguaccgguu uuuguauaua aaa	23
<210> 5075	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5075	
guaccgguuu uuguauauaa aa	23
<210> 5076	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5076	
aaaucaugu uuccaucuc ucu	23
<210> 5077	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5077	
aaaucaugu uuccaucuc cuc	23
<210> 5078	
<211> 23	

<212> RNA	
<213> Homo sapiens	
<400> 5078	
auucauguuu ccaaucucuc ucu	23
<210> 5079	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5079	
uucauguuuc caaucucucu cuc	23
<210> 5080	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5080	
ucauguuucc aaucucucuc ucc	23
<210> 5081	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5081	
cauguuucca aucucucucu ccc	23
<210> 5082	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5082	
uguuuccaau cucucucucc cug	23
<210> 5083	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5083	
uuuccaau cu cucucuccu gau	23
<210> 5084	
<211> 23	

<212> RNA	
<213> Homo sapiens	
<400> 5084	
aucggugaca gucacuagcu uau	23
<210> 5085	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5085	
ucggugacag ucacuagcuu auc	23
<210> 5086	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5086	
acagucacua gcuuauucuug aac	23
<210> 5087	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5087	
cagucacuag cuuauucuuga aca	23
<210> 5088	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5088	
agucacuagc uuaucuugaa cag	23
<210> 5089	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5089	
ucacuagcuu aucuugaaca gau	23
<210> 5090	
<211> 23	

<212> RNA	
<213> Homo sapiens	
<400> 5090	
cacuagcuua ucuugaacag aua	23
<210> 5091	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5091	
acuagcuuau cuugaacaga uau	23
<210> 5092	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5092	
cuagcuuau uugaacagau auu	23
<210> 5093	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5093	
uagcuuau ugaacagau uuu	23
<210> 5094	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5094	
cccagcacac auuccuuuga aau	23
<210> 5095	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5095	
ccagcacaca uuccuuugaa aua	23
<210> 5096	
<211> 23	

<212> RNA	
<213> Homo sapiens	
<400> 5096	
cagcacacau uccuuugaaa uaa	23
<210> 5097	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5097	
agcacacauu ccuuugaaau aag	23
<210> 5098	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5098	
cacacauucc uuugaaauaa ggu	23
<210> 5099	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5099	
auuccuuuga aaauagguuu caa	23
<210> 5100	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5100	
uccuuugaaa uaagguuua aua	23
<210> 5101	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5101	
ccuuugaaau aagguuucua uau	23
<210> 5102	
<211> 23	

<212> RNA	
<213> Homo sapiens	
<400> 5102	
uaagguuuca auauacaucu aca	23
<210> 5103	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5103	
aagguuucaa uauacaucua cau	23
<210> 5104	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5104	
agguuucaau auacaucuac aua	23
<210> 5105	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5105	
gguuucaaua uacaucuaca uac	23
<210> 5106	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5106	
guuucaauau acaucuacau acu	23
<210> 5107	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5107	
uauauuuggc aacuuguauu ugu	23
<210> 5108	
<211> 23	

<212> RNA	
<213> Homo sapiens	
<400> 5108	
uauuuggcaa cuuguauuug ugu	23
<210> 5109	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5109	
uuuggcaacu uguauuugug ugu	23
<210> 5110	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5110	
uuggcaacuu guauuugugu gua	23
<210> 5111	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5111	
uggcaacuug uauuugugug uau	23
<210> 5112	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5112	
ggcaacuugu auuugugugu aua	23
<210> 5113	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5113	
gcaacuugua uuugugugua uau	23
<210> 5114	
<211> 23	

<212> RNA	
<213> Homo sapiens	
<400> 5114	
caacuuguau uuguguguau aua	23
<210> 5115	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5115	
gauucugaua aaauagacau ugc	23
<210> 5116	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5116	
ucugauaaaa uagacauugc uau	23
<210> 5117	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5117	
cugauaaaau agacauugcu auu	23
<210> 5118	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5118	
gauaaaauag acauugcuau ucu	23
<210> 5119	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5119	
aaauagacauu gcuaauucugu uuu	23
<210> 5120	
<211> 23	

<212> RNA	
<213> Homo sapiens	
<400> 5120	
auagacauug cuauucuguu uuu	23
<210> 5121	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5121	
auucuacaua cuaaucucu cuc	23
<210> 5122	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5122	
uucuacauac uaaaucucuc ucc	23
<210> 5123	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5123	
ucuacauacu aaaucucucu ccu	23
<210> 5124	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5124	
cuacauacua aaucucucuc cuu	23
<210> 5125	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5125	
uacauacuaa aucucucucc uuu	23
<210> 5126	
<211> 23	

<212> RNA	
<213> Homo sapiens	
<400> 5126	
acauacuaaa ucucucuccu uuu	23
<210> 5127	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5127	
cauacuaaau cucucuccu uuu	23
<210> 5128	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5128	
aucauuuuuu uauuggugcu acu	23
<210> 5129	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5129	
ucauuuuuuu auuggugcua cug	23
<210> 5130	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5130	
cauuuuuuua uuggugcuac ugu	23
<210> 5131	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5131	
auuuuuuuau uggugcuacu guu	23
<210> 5132	
<211> 23	

<212> RNA	
<213> Homo sapiens	
<400> 5132	
uuuauuuauu ggugcuacug uuu	23
<210> 5133	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5133	
uuauuuauug gugcuacugu uua	23
<210> 5134	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5134	
auuuauuggu gcuacuguuu auc	23
<210> 5135	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5135	
uuauuggugc uacuguuuau ccg	23
<210> 5136	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5136	
gggaaaagau auuaacauca cgu	23
<210> 5137	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5137	
uuaacaucac gucuuugucu cua	23
<210> 5138	
<211> 23	

<212> RNA	
<213> Homo sapiens	
<400> 5138	
uaacaucacg ucuuugucuc uag	23
<210> 5139	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5139	
acgucuuugu cucuagugca guu	23
<210> 5140	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5140	
cgucuuuguc ucuagugcag uuu	23
<210> 5141	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5141	
gucuuugucu cuagugcagu uuu	23
<210> 5142	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5142	
ucgagauauu ccguaguaca uau	23
<210> 5143	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5143	
cgagauauuc cguaguacau auu	23
<210> 5144	
<211> 23	

<212> RNA	
<213> Homo sapiens	
<400> 5144	
gagauauucc guaguacaua uuu	23
<210> 5145	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5145	
aacgacaaag aaauacagau aua	23
<210> 5146	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5146	
acgacaaaga aaauacagaua uau	23
<210> 5147	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5147	
cgacaaagaa auacagauau auc	23
<210> 5148	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5148	
gacaaagaaa uacagauaua ucu	23
<210> 5149	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5149	
agaaaagaga aaguguuuua uau	23
<210> 5150	
<211> 23	

<212> RNA	
<213> Homo sapiens	
<400> 5150	
agaaaagaga aaguguuua uau	23
<210> 5151	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5151	
agaaaagaga aaguguuua uau	23
<210> 5152	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5152	
ggaaagacug auacagaacg auc	23
<210> 5153	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5153	
ggaaagacug auacagaacg auc	23
<210> 5154	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5154	
ggaaagacug auacagaacg auc	23
<210> 5155	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5155	
gaaaagagaa aguguuuau aua	23
<210> 5156	
<211> 23	

<212> RNA	
<213> Homo sapiens	
<400> 5156	
gaaaagagaa aguguuuuau aua	23
<210> 5157	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5157	
gaaaagagaa aguguuuuau aua	23
<210> 5158	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5158	
uuaacagugc uaauguuuau ggu	23
<210> 5159	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5159	
uuaacagugc uaauguuuau ggu	23
<210> 5160	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5160	
uuaacagugc uaauguuuau ggu	23
<210> 5161	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5161	
agaacgaucg auacagaaac cac	23
<210> 5162	
<211> 23	

<212> RNA	
<213> Homo sapiens	
<400> 5162	
agaacgaucg auacagaaac cac	23
<210> 5163	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5163	
agaacgaucg auacagaaac cac	23
<210> 5164	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5164	
gaaagacuga uacagaacga ucg	23
<210> 5165	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5165	
gaaagacuga uacagaacga ucg	23
<210> 5166	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5166	
gaaagacuga uacagaacga ucg	23
<210> 5167	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5167	
aaaagagaaa guguuuuaa uac	23
<210> 5168	
<211> 23	

<212> RNA	
<213> Homo sapiens	
<400> 5168	
aaaagagaaa guguuuaua uac	23
<210> 5169	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5169	
aaaagagaaa guguuuaua uac	23
<210> 5170	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5170	
ggaauuggau ucgccauuuu auu	23
<210> 5171	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5171	
ggaauuggau ucgccauuuu auu	23
<210> 5172	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5172	
ggaauuggau ucgccauuuu auu	23
<210> 5173	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5173	
cgacagaaca guccuuaauc cag	23
<210> 5174	
<211> 23	

<212> RNA	
<213> Homo sapiens	
<400> 5174	
cgacagaaca guccuuaauc cag	23
<210> 5175	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5175	
cgacagaaca guccuuaauc cag	23
<210> 5176	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5176	
gaacaguccu uauccagaa acc	23
<210> 5177	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5177	
gaacaguccu uauccagaa acc	23
<210> 5178	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5178	
gaacaguccu uauccagaa acc	23
<210> 5179	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5179	
ucaccaggaa agacugauac aga	23
<210> 5180	
<211> 23	

<212> RNA	
<213> Homo sapiens	
<400> 5180	
ucaccaggaa agacugauac aga	23
<210> 5181	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5181	
ucaccaggaa agacugauac aga	23
<210> 5182	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5182	
ucaccaugca gauuauugcgg auc	23
<210> 5183	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5183	
ucaccaugca gauuauugcgg auc	23
<210> 5184	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5184	
ucaccaugca gauuauugcgg auc	23
<210> 5185	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5185	
acagaacagu ccuuaaucca gaa	23
<210> 5186	
<211> 23	

<212> RNA	
<213> Homo sapiens	
<400> 5186	
acagaacagu ccuuaaucca gaa	23
<210> 5187	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5187	
acagaacagu ccuuaaucca gaa	23
<210> 5188	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5188	
ugagauguau cuuuugcucu cuc	23
<210> 5189	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5189	
ugagauguau cuuuugcucu cuc	23
<210> 5190	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5190	
ugagauguau cuuuugcucu cuc	23
<210> 5191	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5191	
gaagauuaga gaguuuuauu ucu	23
<210> 5192	
<211> 23	

<212> RNA	
<213> Homo sapiens	
<400> 5192	
gaagauuaga gaguuuuauu ucu	23
<210> 5193	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5193	
gaagauuaga gaguuuuauu ucu	23
<210> 5194	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5194	
ugauacagaa cgaucgauac aga	23
<210> 5195	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5195	
ugauacagaa cgaucgauac aga	23
<210> 5196	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5196	
ugauacagaa cgaucgauac aga	23
<210> 5197	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5197	
ccaugcagau uaugcggauc aaa	23
<210> 5198	
<211> 23	

<212> RNA	
<213> Homo sapiens	
<400> 5198	
ccaugcagau uaugcggauc aaa	23
<210> 5199	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5199	
ccaugcagau uaugcggauc aaa	23
<210> 5200	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5200	
gaauuggauu cgccauuuua uuu	23
<210> 5201	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5201	
gaauuggauu cgccauuuua uuu	23
<210> 5202	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5202	
gaauuggauu cgccauuuua uuu	23
<210> 5203	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5203	
uccaacauc ccaugcagau uau	23
<210> 5204	
<211> 23	

<212> RNA	
<213> Homo sapiens	
<400> 5204	
uccaacaucac ccaugcagau uau	23
<210> 5205	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5205	
uccaacaucac ccaugcagau uau	23
<210> 5206	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5206	
gacagaacag uccuuaaucc aga	23
<210> 5207	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5207	
gacagaacag uccuuaaucc aga	23
<210> 5208	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5208	
gacagaacag uccuuaaucc aga	23
<210> 5209	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5209	
aacaucacca ugcagauuau gcg	23
<210> 5210	
<211> 23	

<212> RNA	
<213> Homo sapiens	
<400> 5210	
aacaucacca ugcagauuau gcg	23
<210> 5211	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5211	
aacaucacca ugcagauuau gcg	23
<210> 5212	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5212	
ucccucuugg aauggauuc gcc	23
<210> 5213	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5213	
ucccucuugg aauggauuc gcc	23
<210> 5214	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5214	
ucccucuugg aauggauuc gcc	23
<210> 5215	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5215	
uccuacagca caacaaaugu gaa	23
<210> 5216	
<211> 23	

<212> RNA	
<213> Homo sapiens	
<400> 5216	
uccuacagca caacaaaugu gaa	23
<210> 5217	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5217	
uccuacagca caacaaaugu gaa	23
<210> 5218	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5218	
gacugauaca gaacgaucga uac	23
<210> 5219	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5219	
gacugauaca gaacgaucga uac	23
<210> 5220	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5220	
gacugauaca gaacgaucga uac	23
<210> 5221	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5221	
gagaaagugu uuuauauacg gua	23
<210> 5222	
<211> 23	

<212> RNA	
<213> Homo sapiens	
<400> 5222	
gagaaagugu uuuauauacg gua	23
<210> 5223	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5223	
gagaaagugu uuuauauacg gua	23
<210> 5224	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5224	
aagagaaagu guuuuauaua cgg	23
<210> 5225	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5225	
aagagaaagu guuuuauaua cgg	23
<210> 5226	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5226	
aagagaaagu guuuuauaua cgg	23
<210> 5227	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5227	
uggauucgcc auuuuauuuu ucu	23
<210> 5228	
<211> 23	

<212> RNA	
<213> Homo sapiens	
<400> 5228	
uggauucgcc auuuuauuuu ucu	23
<210> 5229	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5229	
uggauucgcc auuuuauuuu ucu	23
<210> 5230	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5230	
caguccuuaa uccagaaacc uga	23
<210> 5231	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5231	
caguccuuaa uccagaaacc uga	23
<210> 5232	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5232	
caguccuuaa uccagaaacc uga	23
<210> 5233	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5233	
aaguguuuaa uauacgguac uua	23
<210> 5234	
<211> 23	

<212> RNA	
<213> Homo sapiens	
<400> 5234	
aaguguuuuu uauacgguac uua	23
<210> 5235	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5235	
aaguguuuuu uauacgguac uua	23
<210> 5236	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5236	
aaauagacauu gcuaauucugu uuu	23
<210> 5237	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5237	
aaauagacauu gcuaauucugu uuu	23
<210> 5238	
<211> 23	
<212> RNA	
<213> Homo sapiens	
<400> 5238	
aaauagacauu gcuaauucugu uuu	23